<SEC-DOCUMENT>0001299130-25-000102.txt : 20250512
<SEC-HEADER>0001299130-25-000102.hdr.sgml : 20250512
<ACCEPTANCE-DATETIME>20250512160853
ACCESSION NUMBER:		0001299130-25-000102
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250512
DATE AS OF CHANGE:		20250512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		25934842

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pacb-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1b1d8431-b0de-47a8-b616-b49433c1f17c,g:bee9e017-2ca3-4a3e-a5bb-871b7f56db6b,d:8ceeb5c9aa84416fb9d34124a1b6c447-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:pacb="http://www.pacificbiosciences.com/20250331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pacb-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001299130</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-70" name="pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition" id="f-368">P20D</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-462">http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-105" decimals="8" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-621">0.02045157</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-139" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-622">0.0229885</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-120" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-623">0.0465116</ix:nonFraction><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-628">http://fasb.org/us-gaap/2024#CostOfRevenue</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-654">http://fasb.org/us-gaap/2024#CostOfRevenue</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pacb-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:unit id="customer"><xbrli:measure>pacb:customer</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:A2020PlanInducementPlanAndTheOmniomePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2025</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-34899</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><img src="pacb-20250331_g1.jpg" alt="Logo 1.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:260px" id="i-1"/></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Pacific Biosciences of California, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">16-1590339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">1305 O&#8217;Brien Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94025</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">521-8000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:37.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">PACB</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of shares outstanding of the issuer&#8217;s common stock as of April&#160;30, 2025: <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">300,084,685</ix:nonFraction>. </span></div><div style="margin-bottom:1pt;margin-top:2pt;text-indent:25.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_13">Item 1. Financial Statements (unaudited):</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16">March</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16"> 3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16">1</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16"> and December 31, 20</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16">24</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_16">3</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19"> </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">March</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19"> 3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">1</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19"> and 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_19">4</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22"> Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22">March</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22"> 3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22">1</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22"> and 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_22">5</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">Three</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25"> Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">March</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25"> 3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">1</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">, 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25"> and 202</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_25">6</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_28">Notes to Condensed Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_28">7</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_70">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_70">29</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_91">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_91">38</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_94">Item 4. Controls and Procedures</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_94">38</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_100">Item 1. Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_100">39</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_446">Item 1A. Risk Factors </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_446">41</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_106">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_106">82</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_109">Item 3. Defaults Upon Senior Securities </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_109">82</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_112">Item 4. Mine Safety Disclosures </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_112">82</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_115">Item 5. Other Information</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_115">83</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_121">Item 6. Exhibits</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_121">84</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_124">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_124">85</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-2"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_13"></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1.  FINANCIAL STATEMENTS</span></td></tr></table></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_16"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except par value)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current assets </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">58,507</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">55,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-32">284,603</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-33">334,561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">31,645</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">27,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-36">54,007</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-37">58,755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">15,471</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">18,781</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-40">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-41">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current assets </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">444,923</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">495,681</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">24,794</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-45">30,505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">44,408</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">16,091</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-50">18,182</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-51">389,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-52">317,761</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-53">317,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other long-term assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">9,189</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">9,305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">860,789</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-57">1,260,447</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities and Stockholders&#8217; Equity </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">14,037</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">16,590</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">29,337</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">22,595</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenue, current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">15,241</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">13,864</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">10,026</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities, current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">5,570</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">3,224</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">66,602</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">66,299</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenue, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">5,855</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">5,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration liability, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">18,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">50,480</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">14,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Convertible senior notes, net, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-76">646,214</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-77">647,494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-79">546</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-80">769,151</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-81">753,853</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-82"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-83"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-84"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-85">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-87">50,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-89"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-91">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-94"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-95">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-97">1,000,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-99">300,041</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-101">294,418</ix:nonFraction></ix:nonFraction> shares at March&#160;31, 2025 and December&#160;31, 2024, respectively </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-102">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-103">294</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional paid-in capital </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-104">2,665,958</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-105">2,654,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive income</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-106">381</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-107">422</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated deficit </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-108">2,575,001</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-109">2,148,926</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">91,638</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">506,594</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">860,789</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">1,260,447</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-3"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.234%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-114">31,113</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-115">35,009</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-116">6,040</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-117">3,801</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-118">37,153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-119">38,810</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of product revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-120">26,333</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-121">22,447</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-122">3,778</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-123">3,738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-124">4,345</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-125">1,343</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on purchase commitment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:LossOnPurchaseCommitment" format="ixt:num-dot-decimal" scale="3" id="f-126">4,068</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="pacb:LossOnPurchaseCommitment" format="ixt:fixed-zero" scale="3" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cost of revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-128">38,524</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-129">27,528</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross (loss) profit</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-130">1,371</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-131">11,282</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating Expense:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">29,053</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">43,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">40,168</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">43,753</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-136">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-137">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-138">362,042</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-139">5,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-140">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-141">70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expense </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-142">427,563</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-143">92,644</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">428,934</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">81,362</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-146">1,737</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-147">3,575</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-149">6,759</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before benefit from income taxes</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-150">426,377</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">78,178</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-152">302</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">426,075</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">78,178</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized loss on investments </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-156">41</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-157">525</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-158">426,116</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-159">78,703</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-160">1.44</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-161">0.29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted </span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-162">1.44</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-163">0.29</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in calculating net loss per share:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-164">296,858</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-165">269,578</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted </span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-166">296,858</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-167">269,578</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-4"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.769%"><tr><td style="width:1.0%"/><td style="width:26.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Comprehensive Income</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-168">294,418</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">294</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">2,654,804</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-171">422</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">2,148,926</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">506,594</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">426,075</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">426,075</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-176">41</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-177">41</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-178">5,623</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-179">6</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-180">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-181">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-182">9,201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-183">9,201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-184">300,041</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-185">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">2,665,958</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-187">381</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">2,575,001</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-189">91,638</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.769%"><tr><td style="width:1.0%"/><td style="width:26.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2024</span></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-190">267,744</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-191">268</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">2,539,892</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-193">219</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">1,839,075</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">701,304</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">78,178</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">78,178</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-198">525</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-199">525</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-200">4,536</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-201">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-202">6,887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-203">6,891</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-204">19,525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-205">19,525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at March 31, 2024</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-206">272,280</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-207">272</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">2,566,304</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-209">306</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">1,917,253</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-211">649,017</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.461%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.820%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-5"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_25"></div><hr style="page-break-after:always"/><div style="min-height:22.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span id="i621938aabdfd4171831aa7e62a3b61b2_3-1-1-1-154987"></span><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-212">426,075</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-213">78,178</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-214">5,131</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-215">3,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-216">366,390</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-217">6,853</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-218">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-219">1,921</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-220">9,201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-221">19,525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-222">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-223">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accretion of discount and amortization of premium on marketable securities, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-224">1,706</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-225">4,031</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in the estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-226">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-227">70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory provision</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-228">7,659</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="f-229">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-230">546</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:fixed-zero" scale="3" id="f-231">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-232">719</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-233">403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in assets and liabilities </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-234">4,121</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-235">6,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-236">2,538</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-237">11,655</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-238">3,426</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-239">3,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-240">1,525</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-241">6,644</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-242">311</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-243">23,753</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-244">1,332</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-245">1,601</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-246">1,618</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-247">2,376</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-248">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-249">5,152</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in operating activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-250">44,056</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-251">75,682</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of property and equipment </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-252">1,389</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-253">3,879</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-254">5,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-256">61,820</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-257">191,907</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Maturities of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-258">113,443</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-259">161,650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-260">45,234</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-261">34,136</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock from equity plans</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-262">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-263">6,891</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes payable principal payoff</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-265">338</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-266">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-267">6,553</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-268">3,137</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-269">103,265</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at beginning of period </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-270">57,592</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-271">182,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-272">60,729</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-273">79,368</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of period </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-274">58,507</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-275">76,646</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash at end of period </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-276">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-277">2,722</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-278">60,729</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-279">79,368</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use asset and lease liability recognized due to lease extension</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-280">29,575</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-6"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_31"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-282" continuedAt="f-282-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-283" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 ("2024 Annual Report").</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-284" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2025. Actual results could differ materially from these estimates.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-7"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-282-1" continuedAt="f-282-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-285" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025 and 2024, no customer accounted for 10% or more of total revenue during the period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, <ix:nonFraction unitRef="number" contextRef="c-36" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-286">36</ix:nonFraction>% of our accounts receivable were from domestic customers, compared to <ix:nonFraction unitRef="number" contextRef="c-37" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-287">36</ix:nonFraction>% as of December&#160;31, 2024. As of March&#160;31, 2025, one customer exceeded <ix:nonFraction unitRef="number" contextRef="c-38" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-288">10</ix:nonFraction>% of our net accounts receivable, while no customer represented 10% or more of our net accounts receivable as of December&#160;31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-289" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-8"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-282-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.</span></div></ix:continuation><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_37"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-290" continuedAt="f-290-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 2.  FINANCIAL INSTRUMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-291" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-9"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-290-1" continuedAt="f-290-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-292" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-293">42,952</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-294">15,555</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-296">58,507</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-297">55,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-300">55,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-302">38,790</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-304">38,790</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-305">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-306">46,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-307">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-308">46,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-310">245,813</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-312">245,813</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-314">287,656</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-316">287,656</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-318">284,603</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-320">284,603</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-322">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-324">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-325">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-328">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-329">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-332">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-333">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-336">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-337">1,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-340">1,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-341">45,174</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-342">300,158</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-344">345,332</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-345">57,592</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-346">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-348">392,153</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-355">18,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-356">18,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-363">18,700</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-364">18,700</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the August 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apton Biosystems, Inc. (&#8220;Apton&#8221;)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acquisition, contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-365">25.0</ix:nonFraction>&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" format="ixt:num-dot-decimal" scale="6" id="f-366">50.0</ix:nonFraction>&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the <ix:nonNumeric contextRef="c-71" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:durwordsen" id="f-367">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the <span style="-sec-ix-hidden:f-368">twenty</span> trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed <ix:nonFraction unitRef="number" contextRef="c-72" decimals="3" name="pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" scale="-2" id="f-369">19.9</ix:nonFraction>% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our condensed consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability was calculated using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-10"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-290-2" continuedAt="f-290-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the <ix:nonNumeric contextRef="c-73" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:durwordsen" id="f-370">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition. The key input used in the determination of the fair value included projected revenues of the high-throughput short-read products and services leveraging Apton's technology. As of March&#160;31, 2025, primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the <ix:nonNumeric contextRef="c-73" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:durwordsen" id="f-371">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition, the estimated fair value of the contingent consideration liability was $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="f-372">0</ix:nonFraction>. An acceleration in the timing of projected revenues or an increase in the projected revenues may result in an increase in the fair value of the liability. A decrease in the discount rates, which include the risk-free rate and estimated subordinated credit spread for CCC credit rating, may result in an increase in the fair value of the liability.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-373" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-374">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-375">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of March 31, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statement of operations and comprehensive loss.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-11"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-290-3"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-377" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-378">58,507</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-379">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-380">1</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-381">58,507</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-382">38,635</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-383">169</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-384">14</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-385">38,790</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-386">245,587</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-387">283</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-388">57</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-389">245,813</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-390">284,222</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-391">452</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-392">71</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-393">284,603</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-394">342,729</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-395">453</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-396">72</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-397">343,110</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-398">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-399">690</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-400">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-401">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-402">55,370</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-405">55,370</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-406">46,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-407">184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-408">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-409">46,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-410">287,393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-411">418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-412">155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-413">287,656</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-414">334,139</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-415">602</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-416">180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-417">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-418">389,509</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-419">602</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-420">180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-421">389,931</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-422">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-423">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-424">1,532</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-425">1,532</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-426">227,680</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:num-dot-decimal" scale="3" id="f-427">72,478</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-428">300,158</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated statements of operations and comprehensive loss </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-429">3.9</ix:nonFraction> million for the three months ended March&#160;31, 2025 and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-430">7.2</ix:nonFraction> million for the three months ended March&#160;31, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-12"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-431" continuedAt="f-431-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 3.  BALANCE SHEET COMPONENTS </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory, Net</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-432" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-433">44,479</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-434">45,270</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-435">24,914</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-436">22,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-437">13,429</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-438">14,081</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-439">82,822</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-440">81,523</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-441">28,815</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-442">22,768</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-443">54,007</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-444">58,755</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2024, as of the beginning of April 2024, noting <ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-445">no</ix:nonFraction> impairment. We recognized a $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-446">93.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-447">51.3</ix:nonFraction>&#160;million impairment charge in the second and fourth quarter of 2024, respectively, as a result of quantitative interim impairment tests.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based primarily on the decline in our stock price and overall market capitalization during the first quarter of 2025, driven in part by macroeconomic uncertainties, as well as our updated strategic plans and restructuring initiatives that prioritize accelerating adoption of HiFi sequencing and ceasing development of our high-throughput short-read platform, we concluded that changes to the timing and amount of expected future cash flows, among other factors, indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount, requiring an interim goodwill impairment assessment. As a result of the quantitative interim impairment test performed as of March 31, 2025, we concluded that there was no impairment, as the estimated fair value of the entity-level reporting unit exceeded the carrying value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value of the entity-level reporting unit as of March 31, 2025, we performed our impairment test using a combination of an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-448">12.0</ix:nonFraction>%. The discount rate was based on the weighted average cost of capital, determined using market, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="pacb:GoodwillImpairmentIncreaseInBasisPointDiscountRate" scale="-4" id="f-449">100</ix:nonFraction> basis points to the discount rate used in our assessment would have resulted in a change in the fair value of the reporting unit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="pacb:AdditionalGoodwillImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-450">75</ix:nonFraction>&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation and a supportable control premium.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairment tests could affect the implied fair value of goodwill and may result in additional impairment charges in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technology, customer relationships, and acquired in-process research and development ("IPR&amp;D"). In connection with the Apton acquisition in August 2023, we allocated $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="f-451">55.0</ix:nonFraction> million of the purchase price to IPR&amp;D. This asset is considered indefinite-lived until the associated research and development activities are either completed or abandoned, and is tested for impairment annually and more </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-13"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-431-1" continuedAt="f-431-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-452">40.0</ix:nonFraction>&#160;million impairment charge in the fourth quarter of 2024 as a result of a quantitative interim impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our decision to cease development of the high-throughput short-read sequencing platform, which would utilize the IPR&amp;D, and the resulting changes to the expected future cash flows, among other factors, we concluded  that it was more likely than not that the fair value of the IPR&amp;D was less than its carrying amount, requiring an interim impairment assessment. Using a discounted cash flow model under the income approach, we determined the fair value was below carrying value and recorded a $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-453">15.0</ix:nonFraction>&#160;million impairment charge. The decline in the fair value of the IPR&amp;D below its carrying amount as of March 31, 2025 resulted primarily from changes in the timing of expected future cash flows as compared to the fair value as of December 31, 2024, driven by the restructuring initiatives that prioritize accelerating adoption of HiFi sequencing and resulted in ceasing development of our high-throughput short-read sequencing platform. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions used in the income approach include timing of future cash flows, revenue growth assumptions, a selected discount rate of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-454">14.0</ix:nonFraction>%, and a selected obsolescence factor of <ix:nonNumeric contextRef="c-3" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm" format="ixt-sec:duryear" id="f-455">11</ix:nonNumeric> years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. A decrease of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" scale="0" id="f-456">200</ix:nonFraction> basis points to the discount rate used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-457">3</ix:nonFraction>&#160;million, and an increase of <ix:nonNumeric contextRef="c-3" name="pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" format="ixt-sec:durwordsen" id="f-458">one year</ix:nonNumeric> to the obsolescence factor used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInTerm" format="ixt:num-dot-decimal" scale="6" id="f-459">3</ix:nonFraction>&#160;million. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock" id="f-460" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-461">15,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-462">Impairment charge</span></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-463">15,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of March&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-465" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-87" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-466">3</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="c-88" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-467">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-468">421,179</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-469">402,997</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-470">18,182</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-471">411,179</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-472">36,607</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-473">374,572</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-91" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-474">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-475">360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-476">360</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-478">360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-479">360</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-481">421,539</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-482">403,357</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-483">18,182</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-484">411,539</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-485">36,967</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-486">374,572</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-14"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-431-2" continuedAt="f-431-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-487" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-488">3,059</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-489">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-490">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-491">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-492">745</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-493">4,921</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-494">18,182</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review finite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, we revised the estimated useful life of the developed technology acquired in the 2021 Omniome, Inc. ("Omniome") acquisition. This change reflects updated strategic plans and restructuring initiatives focused on accelerating HiFi sequencing adoption, leading to ceased development of our high-throughput short-read platform and revised expectations for the timing and amount of future cash flows from short-read sequencing products and services. As a result of the change in estimate, during the three months ended March 31, 2025 we recognized accelerated amortization of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="pacb:RestructuringAndRelatedCostAcceleratedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-495">359.3</ix:nonFraction>&#160;million within amortization of acquired intangible assets in operating expenses, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. This expense reduced basic and diluted net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="c-94" decimals="2" name="pacb:ChangeInEarningsPerShare" scale="0" id="f-496">1.21</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2025, the Company entered into an agreement to acquire certain developed technology and related intellectual property from The Chinese University of Hong Kong for total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-497">9.7</ix:nonFraction>&#160;million. In addition, the Company entered into a license agreement for complementary developed technology during the three months ended March 31, 2025. Both the acquired technology and license are classified as intangible assets and are being amortized over an estimated useful life of <ix:nonNumeric contextRef="c-96" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-498"><ix:nonNumeric contextRef="c-97" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-499">three years</ix:nonNumeric></ix:nonNumeric>. As of March 31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-500">5.0</ix:nonFraction>&#160;million of intangible assets acquired during the first quarter of 2025 remained unpaid, is included in accrued liabilities on the condensed consolidated balance sheets, and is expected to be paid in 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, as part of our interim goodwill impairment test, we also performed a recoverability test for the definite-lived asset group noting <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-501">no</ix:nonFraction> impairment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Deferred Revenue</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had a total of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-502">21.1</ix:nonFraction>&#160;million of deferred revenue, $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-503">15.2</ix:nonFraction>&#160;million of which was recorded as deferred revenue, current, and $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-504">5.9</ix:nonFraction>&#160;million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next <ix:nonNumeric contextRef="c-100" name="pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" format="ixt-sec:durwordsen" id="f-505">five years</ix:nonNumeric>. Revenue recorded in the three months ended March&#160;31, 2025 includes $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-506">4.6</ix:nonFraction>&#160;million that was included in deferred revenue as of December&#160;31, 2024. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-15"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-431-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of March&#160;31, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-507">58.7</ix:nonFraction>&#160;million, of which approximately <ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="f-508">70</ix:nonFraction>% is expected to be converted to revenue over the next <ix:nonNumeric contextRef="c-101" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-509">twelve months</ix:nonNumeric>, approximately <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="f-510">23</ix:nonFraction>% in the following <ix:nonNumeric contextRef="c-102" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-511">twelve months</ix:nonNumeric>, and the remainder thereafter.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Warranties</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a <ix:nonNumeric contextRef="c-1" name="pacb:StandardProductWarrantyPeriod" format="ixt-sec:durwordsen" id="f-512">one-year</ix:nonNumeric> warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on the condensed consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="f-513" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-514">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-515">4,681</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-516">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-517">1,600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-518">1,552</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-519">2,161</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-520">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-521">4,120</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_43"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-522" continuedAt="f-522-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 4.  CONVERTIBLE SENIOR NOTES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2029 Convertible Senior Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#8220;SBN&#8221;), a subsidiary of SoftBank Group Corp., pursuant to which we agreed to exchange the remaining approximately $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-523">459.0</ix:nonFraction>&#160;million in aggregate principal amount of our previously held <ix:nonFraction unitRef="number" contextRef="c-103" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-524">1.50</ix:nonFraction>% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) outstanding for (i) $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-525">200.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-104" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-526">1.50</ix:nonFraction>% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;), (ii) <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-527">20,451,570</ix:nonFraction> shares of common stock (the &#8220;Exchange Shares&#8221;) and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-528">50.0</ix:nonFraction>&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The Exchange Shares were issued on November 21, 2024 (the &#8220;Closing Date&#8221;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes are subject to certain lock-up restrictions for a <ix:nonNumeric contextRef="c-107" name="pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" format="ixt-sec:durwordsen" id="f-529">six-month</ix:nonNumeric> period (the &#8220;Lock-Up Period&#8221;) beginning on the Closing Date of the 2024 Exchange Transaction; the lock-up restrictions will terminate immediately prior to the consummation of any change in control of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#8217;s common stock which would cause SBN's beneficial ownership of common stock to exceed either <ix:nonFraction unitRef="number" contextRef="c-106" decimals="4" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-530">9.9</ix:nonFraction>% of the total number of issued and outstanding shares of common stock or <ix:nonFraction unitRef="number" contextRef="c-106" decimals="4" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-531">9.9</ix:nonFraction>% of the combined voting power of all of the securities of the Company, in each case, following such conversion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are governed by an indenture (the &#8220;2029 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-104" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-532">1.50</ix:nonFraction>% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15, commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-16"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-522-1" continuedAt="f-522-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-104" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-533">4.89</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-534">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="d" contextRef="c-105" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-535">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="c-105" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-536">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-537">100</ix:nonFraction>% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-105" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-538">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-539">0.25</ix:nonFraction>% per annum of the principal amount of the 2029 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-108" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-540">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-105" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-541">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-109" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-542">0.50</ix:nonFraction>% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-110" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-543">181</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the <ix:nonNumeric contextRef="c-111" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-544">360</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the <ix:nonNumeric contextRef="c-109" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-545">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-109" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-546">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-17"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-522-2" continuedAt="f-522-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange qualified as a troubled debt restructuring under ASC 470-60 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings by Debtors</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-547">154.4</ix:nonFraction>&#160;million, which resulted in a decrease of basic net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-112" decimals="2" name="pacb:RestructuringOfDebtPricePerShare" scale="0" id="f-548">0.56</ix:nonFraction>, during the year ended December 31, 2024 on our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2029 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-549">3.1</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="pacb:DebtIssuanceCostLenderFees" format="ixt:num-dot-decimal" scale="6" id="f-550">0.2</ix:nonFraction>&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring on our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-551">1.8</ix:nonFraction>&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-552">50.0</ix:nonFraction>&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, <ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-553">no</ix:nonFraction> amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the liability for the 2029 Notes as of March&#160;31, 2025 is $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-554">213.5</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-555">210.5</ix:nonFraction>&#160;million is included as convertible senior notes, net, non-current, and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-556">3.0</ix:nonFraction>&#160;million is included as accrued expenses on our consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="pacb:ScheduleOfInterestExpenseTableTextBlock" id="f-557" continuedAt="f-557-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the 2029 Notes during the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of December 31, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-558">214,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="f-559">700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of March 31, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-560">213,500</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the estimated fair value (Level 2) of the 2029 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-561">154.0</ix:nonFraction>&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2030 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 2028 Notes, pursuant to which we issued $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-562">441.0</ix:nonFraction>&#160;million in aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="c-119" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-563">1.375</ix:nonFraction>% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;) in exchange for $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-564">441.0</ix:nonFraction>&#160;million principal amount of the 2028 Notes (the &#8220;2023 Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-119" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-565">1.375</ix:nonFraction>% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-566">21.50</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice" scale="-2" id="f-567">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="c-120" name="pacb:DebtInstrumentRedemptionPriceTradingDays" format="ixt-sec:durday" id="f-568">20</ix:nonNumeric> trading days (whether or not </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-18"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-522-3" continuedAt="f-522-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consecutive) during any <ix:nonNumeric contextRef="c-120" name="pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays" format="ixt-sec:durday" id="f-569">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-570">100</ix:nonFraction>% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-571">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-120" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-572">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-120" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-573">0.25</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-121" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-574">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-120" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-575">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-120" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-576">0.50</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-122" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-577">181</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the <ix:nonNumeric contextRef="c-123" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-578">360</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the <ix:nonNumeric contextRef="c-124" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-579">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-124" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-580">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-581">2.0</ix:nonFraction>&#160;million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-582">1.5</ix:nonFraction>&#160;million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-583">7.3</ix:nonFraction>&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our condensed consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-119" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-584">1.6</ix:nonFraction>%. We also paid accrued but unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-585">2.5</ix:nonFraction>&#160;million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-19"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-522-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the 2023 Exchange Transaction, $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-586">459.0</ix:nonFraction>&#160;million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-587" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-588">441,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-589">441,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="f-590">434</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="f-591">453</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-592">5,720</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-593">5,959</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-594">435,714</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-595">435,494</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-557-1" continuedAt="f-557-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-596">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-597">1,533</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-598">239</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-599">239</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-600">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-601">1,772</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the estimated fair value (Level 2) of the 2030 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-602">276.6</ix:nonFraction> million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2028 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-603">900.0</ix:nonFraction>&#160;million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February 16, 2021 and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-135" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-604">1.50</ix:nonFraction>% per annum. As discussed above, in June 2023 we completed an exchange of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-605">441.0</ix:nonFraction>&#160;million in aggregate principal amount of our 2028 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-606">441.0</ix:nonFraction>&#160;million aggregate principal amount of the 2030 Notes, leaving approximately $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-607">459.0</ix:nonFraction>&#160;million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-608">459.0</ix:nonFraction>&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-609">200.0</ix:nonFraction>&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-610">50.0</ix:nonFraction>&#160;million of cash. As of December 31, 2024 <ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-611">no</ix:nonFraction> amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-612">4.5</ix:nonFraction>&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-613">1.6</ix:nonFraction>%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-614">1.1</ix:nonFraction>&#160;million were extinguished by offsetting the carrying amount of the convertible senior notes. </span></div><ix:continuation id="f-557-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-616">1,721</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-618">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-620">1,802</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-20"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-624" continuedAt="f-624-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 5.  RESTRUCTURING</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we implemented an expense reduction initiative aimed at lowering our annualized run-rate operating expenses. These actions, which included workforce reductions and other cost-saving measures, were part of a broader strategic shift to prioritize the adoption of HiFi sequencing.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-625" continuedAt="f-625-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-626">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-627">4,649</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-628">Total restructuring charges</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-629">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-630">4,649</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-631">2.5</ix:nonFraction>&#160;million was recorded in sales, general and administrative expense and $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-632">2.1</ix:nonFraction>&#160;million in research and development expense.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges included employee separation costs comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="f-633">2.4</ix:nonFraction>&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-634">2.2</ix:nonFraction>&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the restructuring and strategic shift, we incurred an additional $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="pacb:RestructuringChargesAdditionalCostsIncurred" format="ixt:num-dot-decimal" scale="6" id="f-635">388.2</ix:nonFraction>&#160;million in costs. These include $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="pacb:RestructuringAndRelatedCostAcceleratedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-636">359.3</ix:nonFraction>&#160;million of accelerated amortization of certain intangible assets, $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-637">15.0</ix:nonFraction>&#160;million of IPR&amp;D impairment charges, $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-638">7.7</ix:nonFraction>&#160;million related to excess inventory due to decreased external demand and $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="pacb:GainLossOnPurchaseCommitments" format="ixt:num-dot-decimal" scale="6" id="f-639">3.8</ix:nonFraction>&#160;million for estimated losses on purchase commitments tied to anticipated future excess inventory included in cost of revenue, and $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-640">2.4</ix:nonFraction>&#160;million of accelerated depreciation of fixed assets. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">Note 3. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the IPR&amp;D impairment assessment and the change in estimated useful life of the intangible asset and accelerated amortization.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-641" continuedAt="f-641-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, excluding non-cash activities)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recorded in Q1 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-642">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-643">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid in Q1 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities</span></div><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-646">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="f-647">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-21"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-624-1"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.</span></div><ix:continuation id="f-625-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-651">10,008</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-652">975</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-653">16,189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-654"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-655">975</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-656">26,197</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For the three months ended March&#160;31, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="pacb:RestructuringChargesExcludingAdjustments" scale="6" id="f-657">1.0</ix:nonFraction> million was recorded in sales, general and administrative expense.</span></div><div style="margin-top:3pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-658">15.9</ix:nonFraction> million in sales, general and administrative expense; $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-659">5.9</ix:nonFraction> million in research and development expense; and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-660">4.4</ix:nonFraction> million in cost of revenue.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include employee separation costs comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="f-661">5.5</ix:nonFraction>&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-662">4.5</ix:nonFraction>&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs in the three months ended March&#160;31, 2025 are primarily related to a lease termination fee and other costs related to our exit of the San Diego office. Other costs in cumulative charges incurred to date are primarily related to accelerated amortization and depreciation of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-663">8.1</ix:nonFraction>&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-664">3.6</ix:nonFraction>&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the three months ended June 30, 2024 resulting in a reduction in the operating lease liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-665">4.4</ix:nonFraction>&#160;million, which was offset against the right-of-use asset on the condensed consolidated balance sheets. We fully exited our San Diego office in September 2024.</span></div><ix:continuation id="f-641-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-666">170</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-667">170</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional expense recorded</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-668">975</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-669">975</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="f-670">581</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="f-671">581</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of March&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-672">564</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-673">564</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability as of March&#160;31, 2025 is $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-676">1.8</ix:nonFraction>&#160;million, and is included in operating lease liabilities, current on the condensed consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-22"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-677" continuedAt="f-677-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 6.  COMMITMENTS AND CONTINGENCIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, we amended our existing lease covering our corporate headquarters, as well as our research and development, manufacturing, and distribution facilities in Menlo Park, California. The lease amendment extends the term to April 30, 2034. We will pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="pacb:OperatingLeaseExpectedBaseRentExpense" format="ixt:num-dot-decimal" scale="6" id="f-678">97.7</ix:nonFraction>&#160;million in base rent over the life of the amended lease and receive base rent abatement of approximately $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="pacb:LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" format="ixt:num-dot-decimal" scale="6" id="f-679">11.6</ix:nonFraction>&#160;million for the period beginning on March 1, 2025 and ending on July 31, 2026. We are also entitled to a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="f-680">7.2</ix:nonFraction>&#160;million. The lease amendment increased our operating lease right-of-use assets and operating lease liabilities by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-681">29.6</ix:nonFraction>&#160;million on our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="pacb:LesseeOperatingLeaseDescriptionTableTextBlock" id="f-682" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-683">2,327</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-684">3,941</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-685">9,165</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-686">12,389</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-687">12,761</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-688">59,897</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-689">100,480</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-690">47,583</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of operating lease liabilities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-691">52,897</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-692">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-693">50,480</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-694">52,897</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-695">10.1</ix:nonFraction>%. The weighted-average remaining lease term for our operating leases as of March&#160;31, 2025 was <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-696">9.0</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="f-697">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:PaymentsForRent" format="ixt:num-dot-decimal" scale="6" id="f-698">3.0</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively, and were included in operating cash flows.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-23"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-677-1"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-699">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-700">2.6</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contingencies</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_100">Legal Proceedings, in Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnification</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations" format="ixt:fixed-zero" scale="0" id="f-701"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations" format="ixt:fixed-zero" scale="0" id="f-702">No</ix:nonFraction></ix:nonFraction> additional liability associated with such indemnification obligations has been recorded as of March&#160;31, 2025 and December&#160;31, 2024.</span></div></ix:continuation><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_55"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-703" continuedAt="f-703-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 7.  EQUITY PLANS AND SHARE-BASED COMPENSATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Equity Plans</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-704">11.3</ix:nonFraction>&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of our 2024 Annual Report for more information on the Company's equity plans</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-24"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-703-1" continuedAt="f-703-2"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Options</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-705" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-706">10,509</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-707">11.09</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-708">7,562</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-709">1.24</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-164" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-710">1,287</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-711">9.20</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-164" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-712">236</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-713">6.91</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-165" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-714">16,548</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-165" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-715">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We issue PSUs for which the number of shares issuable is based on performance relative to specified revenue targets and continued employment through the vesting period. The PSUs are issuable following the third year of the performance period. Maximum achievement of the revenue goal under the PSUs will result in up to <ix:nonFraction unitRef="number" contextRef="c-166" decimals="2" name="pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" scale="-2" id="f-716">200</ix:nonFraction>% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under the PSUs will result in no shares subject to the PSUs becoming eligible to vest. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-717" continuedAt="f-717-1" escape="true">The following table summarizes the time-based RSUs and PSUs activity: </ix:nonNumeric></span></div><ix:continuation id="f-717-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-718">14,211</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-719">392</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-167" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-720">7.41</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-721">9.43</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-722">11,618</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-724">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-169" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-726">3,870</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-728">9.51</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-169" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-730">552</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-732">5.79</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-734">21,407</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-735">392</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-736">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-737">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan ("ESPP")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under our ESPP wer</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-738">1,752,417</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-739">1,194,436</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> durin</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g the three months ended March&#160;31, 2025 and 2024, respectively. In the first quarter of 2025, an additional <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="f-740">4.0</ix:nonFraction>&#160;million shares were reserved under the ESPP. As of March&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-741">16.5</ix:nonFraction>&#160;million shares of our common stock remain avai</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lable for issuance under our ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-742" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-743">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-744">2,106</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-745">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-746">5,788</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-747">5,429</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-748">11,631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-749">9,201</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-750">19,525</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-25"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-703-2"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Determining Fair Value</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-751"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-752">zero</ix:nonFraction></ix:nonFraction> for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-753" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-183" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-754">4.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-184" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-755">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-756">95</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-757">96</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-758">81</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="number" contextRef="c-183" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-759">3.92</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-183" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-760">4.29</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-184" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-761">4.32</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-183" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-762">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-184" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-763">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-183" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-764">0.91</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-765">2.45</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="f-766" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-185" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-767">0.5</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="c-186" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-768">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-769">0.5</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="c-188" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-770">2.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-771">113</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-190" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-772">81</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-773">3.96</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-189" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-774">4.31</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-190" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-775">4.54</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-190" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-776">5.27</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-189" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-777">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-190" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-778">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-779">0.93</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-190" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-780">2.78</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_58"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-781" continuedAt="f-781-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 8.  NET LOSS PER SHARE</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the Notes, using the if-converted method, and outstanding equity awards using the treasury stock method.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-26"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-781-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-782" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-783">426,075</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-784">78,178</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-785">296,858</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-786">269,578</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-787">1.44</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-788">0.29</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-789">296,858</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-790">269,578</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-791">1.44</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-792">0.29</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-793" escape="true"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-794">61,415</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-795">31,063</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-796">47,133</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-797">36,924</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55">7</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55">Equity Plans and Sha</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55">re-Based Compensation</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on equity awards.</span></div></ix:continuation><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_61"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-798" continuedAt="f-798-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, <ix:nonFraction unitRef="customer" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-799">one</ix:nonFraction> reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker (CODM) is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a regular basis, our CODM reviews:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total revenues by category</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">net loss per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-27"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><ix:continuation id="f-798-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-800" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-801">37,153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-802">38,810</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-803">38,524</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-804">27,528</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-805">29,053</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-806">43,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-807">20,076</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-808">22,537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-809">20,092</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-810">21,216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-811">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-813">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-814">70</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-815">362,042</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-816">5,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-817">2,557</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-818">3,184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-819">302</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-820">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-821">426,075</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-822">78,178</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-823" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-824">16,303</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-825">17,678</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-826">9,240</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-827">8,356</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-828">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-829">12,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-830">37,153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-831">38,810</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-832" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows: </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-833">11,016</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-834">19,025</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-835">20,097</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-836">15,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-837">31,113</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-838">35,009</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-839">6,040</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-840">3,801</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-841">37,153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-842">38,810</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-28"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with (i) our unaudited condensed consolidated financial statements and related notes that are included elsewhere in this Quarterly Report on Form 10-Q and (ii) our 2024 Annual Report filed with the U.S. Securities and Exchange Commission, or the SEC, on March 17, 2025. This discussion contains forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q, and you should not place undue reliance on our forward-looking statements. We do not assume any obligation to update any forward-looking statements. In preparing this Management's Discussion and Analysis ("MD&amp;A"), we presume that readers have access to and have read the MD&amp;A in our 2024 Annual Report on Form 10-K, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MD&amp;A is organized into the following sections:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Overview and Outlook </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Results of Operations </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Liquidity and Capital Resources </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Critical Accounting Policies and Estimates</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Recent Accounting Pronouncements</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Off Balance Sheet Arrangements</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_73"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OVERVIEW AND OUTLOOK</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About PacBio</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its &#8220;method of the year&#8221; for 2022 for its contributions to biological understanding and future potential. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-read sequencing</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus on creating some of the world&#8217;s most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-29"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Objectives</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2025 strategic objectives are to grow revenue and expand gross margins through the following four activities: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Enabling the full-scale release of the Vega benchtop platform to broaden our market reach.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe this platform broadens the long-read market opportunity.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Accelerating samples onto the Revio platform via SPRQ chemistry and application kits.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SPRQ chemistry enables the sub-$500 HiFi genome, improves methylation detection capabilities, and achieves a 75% reduction in DNA input requirements for human whole genome sequencing.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These features can drive more samples onto HiFi sequencing than ever before. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Investing in future product launches to diversify our offerings.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to develop sequencing systems designed to increase throughput and lower the cost to sequence a genome, which we believe will allow us to address an even larger part of the market. Additionally, we continue to develop kitted-solutions, like our Kinnex Full-length RNA kits and PureTarget, and enhance our on-market sequencers with products like SPRQ chemistry to drive more sequencing volume. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Progressing our clinical strategy to improve outcomes and create durability.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revio is increasingly being used in laboratory developed tests ("LDT") and clinical research settings to consolidate multiple tests and address complex genetic challenges. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that with the capabilities of our HiFi chemistry and SMRT</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, we can be a market leader in whole-genome clinical sequencing. Leading institutions have adopted our products to study rare and inherited disease. We believe the market opportunity for clinical sequencing is significant and could drive substantial revenue growth for the Company. We plan to continue to pursue partner collaborations where the technologies being developed or applications being considered extend beyond whole-genome clinical sequencing. Collaborative arrangements add to the awareness of our products and service offerings and may drive new applications for use of our technology.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Overview</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key highlights of the three months ended March 31, 2025 consolidated financial results include the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.865%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross loss of</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss of</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investments of</span></div></td></tr><tr><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$37.2 M</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$1.4 M</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$428.9 M</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$343.1 M</span></div></td></tr><tr><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $38.8 M during the same period of 2024</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to gross profit of $11.3 M during the same period of 2024</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $81.4 M during the same period of 2024</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $389.9 M at December&#160;31, 2024</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.14pt">Revenue was comprised of $11.0 million in instrument revenue, $20.1 million in consumables revenue and $6.0 million in service and other revenue for the first quarter of 2025. Revenue was comprised of $19.0 million in instrument revenue, $16.0 million in consumables revenue and $3.8 million in service and other revenue for the first quarter of 2024. The decrease was primarily due to lower Revio unit sales, which was partially offset by higher Vega unit sales, consumable sales, and service and other revenue.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.91pt">We recorded a gross loss for the first quarter of 2025 primarily due to $12.0&#160;million of restructuring charges, which include $7.7 million in inventory adjustments and $3.8 million of losses on purchase commitments, and an increase of $3.0 million in amortization of acquired intangible assets, partially offset by lower per unit costs to manufacture our products. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information. Gross margins may be affected by product mix, manufacturing efficiencies, warranty cost improvements, average selling price fluctuations, future product launches, changes to inventory reserves, costs of raw materials, and tariffs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-30"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.91pt">Loss from operations increased $347.6 million for the first quarter of 2025 compared with the same quarter of 2024. Operating expenses increased $334.9 million primarily due to $381.8&#160;million of costs incurred in connection with the restructuring and strategic shift, which include $359.3 million of accelerated amortization of acquired intangible assets, $15.0 million of impairment charges, and $4.6&#160;million of employee separation costs. The increase was partially offset by an $18.7 million decrease in the change in the fair value of the contingent consideration and a decrease in research and development expenses.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.91pt">Cash, cash equivalents, and short-term investments were $343.1 million at March&#160;31, 2025, which represents a 12% decrease compared to the balance at December&#160;31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales cycle for Revio instrument purchases continues to be elongated. We believe this has been caused by, among other reasons, the uncertainty surrounding the funding for new capital equipment, in particular, uncertainty in the United States related to the National Institutes of Health ("NIH") and academic funding; procurement delays; small-to-mid-size existing customers yet to increase their sample volumes to drive an upgrade to Revio; new customers, which have shown they have longer sales cycles compared to existing PacBio customers; and sample volumes materializing slower than expected for some potential Revio customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic dynamics impacting the Company in the future may include rising inflation, geopolitical tensions, volatile capital markets, tariffs, uncertainty in the United States related to NIH and academic funding, and fluctuating exchange rates. These factors could continue to impact our revenues and results of operations in future periods; however, the magnitude and duration of these impacts is highly uncertain and inherently unpredictable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, we evaluate our significant estimates, including those related to the valuation of goodwill and finite-lived assets. However, these estimates could change in future periods based on events or changes in circumstances, which could result in material future impairment charges. We recorded $15.0 million of impairment charges for the first quarter of 2025. See additional discussion below in Results of Operations, as well as </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">B</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">alance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information. Additionally, refer to the Critical Accounting Policies and Estimates section of our 2024 Annual Report for further discussion on the Company's asset impairment assessments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_446">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section for further discussion.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-31"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2025 and 2024</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,113&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,009&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,896)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,040&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,153&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,810&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,657)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of product revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,333&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,778&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,345&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,343&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,002&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on purchase commitment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,068&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,068&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cost of revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,524&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,528&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,996&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 68.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross (loss) profit</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,371)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,282&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,653)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating Expense:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,053&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14,402)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,168&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">362,042&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">356,536&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6475&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,630)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expense </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">427,563&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92,644&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,919&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">362&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(428,934)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(81,362)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(347,572)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,737)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,575)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,838&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,294&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,465)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before benefit from income taxes</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426,377)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(78,178)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(348,199)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax benefit</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(302)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(302)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426,075)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(78,178)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(347,897)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-32"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20250331_g3.jpg" alt="1099511633646" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-33"/></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased $1.7 million, or 4%, for the first quarter of 2025 compared with the same quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue decreased $3.9 million, or 11%, primarily due to a decrease of $8.0 million, or 42%, in instrument revenue, partially offset by an increase of $4.1 million, or 26%, in consumable revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue increased $2.2 million, or 59%, primarily driven by an increase in Revio service contracts.</span></div></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instrument Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20250331_g4.jpg" alt="1099511636005" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-34"/></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instrument revenue decreased primarily due to the sale of 12 Revio systems in the first quarter of 2025 compared to 28 Revio systems in the first quarter of 2024, partially offset by the sale of 28 Vega systems in the first quarter of 2025.</span></div></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumables Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:12pt;text-align:justify"><img src="pacb-20250331_g5.jpg" alt="1099511636036" style="height:163px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-35"/></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumables revenue increased primarily due to higher Revio consumables sales attributable to the growth in the Revio instrument installed base, partially offset by a decline in Sequel</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> II and IIe consumables as customers transition to Revio. We expect Revio consumable sales to increase as the installed base grows. While we expect to see a decline in Sequel II and IIe consumable sales resulting from the product transition, there is uncertainty as to the rate at which these sales will decline.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-36"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:21pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue and Gross (Loss) Profit</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of revenue increased $11.0 million, or 40% due to an increase in cost of product revenue, $3.8 million of restructuring costs relating to loss on purchase commitments which is based on an estimate of future excess inventory related to supply agreements for which we do not expect to have related sales, and an increase of $3.0 million in amortization attributable to acquired intangible assets that are related to sales generating activities. Cost of product revenue increased $3.9 million, or 17%, for the first quarter of 2025 compared with the same quarter of 2024 primarily due to $7.7 million of charges for excess inventory due to our updated strategy to prioritize long-read technology and decrease in demand for short-read related inventory partially offset by lower per unit costs to manufacture our products. Total cost of revenue included share-based compensation expense of $1.2 million and $2.1 million during the first quarter of 2025 and 2024, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a gross loss of $1.4 million for the first quarter of 2025, compared to a gross profit of $11.3 million in the same quarter of 2024, primarily driven by the increase in cost of revenue from restructuring activities and the decrease in revenue described above. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information about restructuring activities. Gross margins may be affected by product mix, manufacturing efficiencies, warranty cost improvements, average selling price fluctuations, future product launches, changes to inventory reserves, costs of raw materials and tariffs.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $14.4 million, or 33%, for the first quarter of 2025, compared to the same quarter of 2024. The decrease was primarily driven by a decrease in personnel and related expenses due to prior year restructuring activities, as well as the transition of launched products from development to commercialization. Research and development expense included share-based compensation expense of $2.6 million and $5.8 million during the first quarter of 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sales, General, and Administrative Expense</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative expense decreased by $3.6 million, or 8%, for the first quarter of 2025, compared to the same quarter of 2024. The decrease was primarily due to a net decrease in personnel and related expenses due to restructuring activities. Sales, general, and administrative expense included share-based compensation expense of $5.4 million and $11.6 million during the first quarter of 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Impairment Charges</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified indicators of impairment during the first quarter of 2025 and performed an interim impairment assessment. Impairment testing demonstrated that the carrying value of our in-process research and development ("IPR&amp;D") exceeded its estimated fair value. As a result, we recorded $15.0 million of impairment charges for the first quarter of 2025. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">. </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for the first quarter of 2025 included $362.0 million of amortization expense, primarily driven by $359.3 million of accelerated amortization related to developed technology from the 2021 Omniome acquisition, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. We expect significantly lower amortization expense for the remainder of 2025.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration during the first quarter of 2025 and 2024 represents the remeasurement impact of the contingent consideration due upon the achievement of the milestone. As of March&#160;31, 2025, primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the five-year anniversary of the closing date of the acquisition, the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-37"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated fair value of the contingent consideration liability was $0, resulting in a change in fair value for the first quarter of 2025 of $18.7 million.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the first quarter of 2025, was $1.7 million compared to $3.6 million for the first quarter of 2024 and was primarily comprised of interest on the Notes.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Income, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the first quarter of 2025, was $4.3 million compared to $6.8 million for the first quarter of 2024. The decrease was primarily driven by lower investment income due to lower cash and investment balances.</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_82"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had cash, cash equivalents and investments of $343.1 million compared to $389.9 million as of December&#160;31, 2024. We believe that our existing cash, cash equivalents and investments will be sufficient to fund our projected operating requirements beyond the next 12 months from the date of filing of this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity, other than our holdings of cash, cash equivalents, and investments, have primarily been through the issuance of debt or equity securities, together with cash flow from operating activities. We have historically incurred, and expect to continue to incur, operating losses and generate negative cash flows from operations on an annual basis, and as a result, we may require additional capital resources to execute our strategic initiatives to grow our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began implementing expense reduction initiatives in the second quarter of 2024, including workforce reductions, facility downsizing, and a streamlined development pipeline, with the goal of lowering annualized run-rate operating expenses by year-end. In the first quarter of 2025, we implemented additional actions, including further workforce reductions, to support continued cost savings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may affect our capital needs include, but are not limited to, the pace of adoption of our products, which affects the sales of our products and services; our ability to efficiently manage our operations; the effectiveness of our expense reduction initiatives; our ability to obtain new collaboration and customer arrangements and maintain existing collaborations and arrangements; the progress of our research and development programs; initiation, expansion, or funding of research programs and collaborations; the purchase of patent licenses; the impact of product quality; litigation costs, including the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; costs of developing new and enhanced products; acquisitions of complementary businesses, technologies or assets; achievement of milestones in connection with acquisitions; and other factors. There can be no assurance that funds will be available on favorable terms, or at all.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contingent Consideration</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2023 Apton acquisition, we entered into an arrangement where we are obligated to pay former holders of Apton's outstanding equity interests $25.0 million upon the achievement of $50.0 million in revenue associated with a high throughput sequencer using Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock. As of March&#160;31, 2025, primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the five-year anniversary of the closing date of the acquisition, the estimated fair value of the contingent consideration liability was $0.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-38"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in operating activities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(44,056)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(75,682)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,234&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34,136)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,959&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,137&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(103,265)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash in operating activities include the development of future products and product enhancements, manufacturing, and support functions related to our sales, general and administrative activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the first quarter of 2025 of $44.1 million was due primarily to a $426.1 million net loss that included non-cash items such as amortization of acquired intangible assets of $366.4&#160;million, an impairment charge of $15.0 million, share-based compensation of $9.2&#160;million,$7.7&#160;million of inventory adjustments, depreciation expense of $5.1&#160;million, and $2.4&#160;million in net changes to operating assets and liabilities, partially offset by an $18.7 million decrease in the change in the fair value of the contingent consideration. Cash flow impact from changes in net operating assets and liabilities was primarily driven by an increase in accrued expenses partially offset by an increase in accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the first quarter of 2024 of $75.7 million was due primarily to a $78.2 million net loss that included non-cash items such as share-based compensation of $19.5&#160;million, amortization of intangible assets of $6.9&#160;million, depreciation expense of $3.2&#160;million, and amortization of right-of-use assets of $1.9&#160;million. This was offset by the accretion of discount and amortization of premium on marketable securities, net of $4.0&#160;million, and $25.3&#160;million in net changes to operating assets and liabilities. Cash flow impact from changes in net operating assets and liabilities was primarily driven by an increase in inventory, as well as decreases in accrued expenses, other liabilities, and operating lease liabilities. These uses of cash were partially offset by decreases in accounts receivable and prepaid expenses and other assets and increases in accounts payable and deferred revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities consist primarily of capital expenditures and investment purchases, sales, and maturities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the first quarter of 2025, was primarily from $113.4&#160;million of maturities of investments partially offset by $61.8&#160;million of purchases of investments and $5.0&#160;million in purchases of intangible assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the first quarter of 2024, was primarily due to $191.9&#160;million in purchases of investments and $3.9&#160;million in purchases of property and equipment partially offset by $161.7&#160;million of maturities of investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the first quarter of 2025 resulted from $2.0&#160;million from the issuance of common stock through our equity compensation plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the first quarter of 2024 resulted from $6.9&#160;million from the issuance of common stock through our equity compensation plans.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-39"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented our contractual obligations at December&#160;31, 2024 in our 2024 Annual Report. There were no material changes outside the ordinary course of business to our contractual obligations during the first quarter of 2025.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with the rules and regulations of the SEC. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_88"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_31">Note 1. Organization and Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Recent Accounting Pronouncements&#8221;, in Part I, Item 1 of this Quarterly Report on Form 10-Q for information regarding applicable recent accounting pronouncements. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we did not have any off-balance sheet arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into standard indemnification arrangements. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology, or from claims relating to our performance or non-performance under a contract, any defective products supplied by us, or any acts or omissions, or willful misconduct, committed by us or any of our employees, agents or representatives. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in future periods but have not yet been made. To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between us and such third parties in connection with such fundraising efforts. To the extent that such indemnification obligations apply to the lawsuits described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_52">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_52">6</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_52">. Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification agreements has been recorded as of March&#160;31, 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-40"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:15pt;padding-left:55.44pt;text-align:justify;text-indent:-55.44pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes and 2029 Notes have fixed annual interest rates of 1.375% and 1.50%, respectively, and accordingly we do not have any economic interest rate exposure or financial statement risk associated with changes in interest rates. The fair value of the notes, however, may fluctuate when interest rates and the market price of our stock changes. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_43">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_43">4</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_43">. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, we invested in cash equivalents, U.S. government and agency securities, and corporate debt securities which were designated as cash equivalents and available-for-sale investments. Our cash equivalents and available-for-sale securities as of March&#160;31, 2025 was $343.1 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio comprised of marketable securities. We invest in a number of securities including U.S. government and agency securities, U.S. Treasury securities, and corporate debt securities and money market funds. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in high grade investment securities. The fair market value of our fixed rate securities may be adversely impacted by increases in interest rates while income earned may decline as a result of decreases in interest rates. A hypothetical 100 basis-point (one percentage point) increase or decrease in interest rates compared to rates at March&#160;31, 2025 would have affected the fair value of our investment portfolio by approximately $1.8&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes in market risk from the information provided in our 2024 Annual Report.</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_94"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4.  CONTROLS AND PROCEDURES</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer, our Chief Financial Officer and our Chief Accounting Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer to determine whether any change in our internal control over financial reporting occurred during the quarter ended March 31, 2025 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no material changes in our internal control over financial reporting during the quarter ended March 31, 2025, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-41"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_100"></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1.  LEGAL PROCEEDINGS</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">U.S. District Court Proceedings</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#8220;PGI District Court matter&#8221;). The matter from this complaint is based on PGI&#8217;s U.S. Patent No. 7,767,441 (the &#8220;&#8216;441 Patent&#8221;). The complaint alleges that our Sequel systems and Sequel II systems infringe the &#8216;441 Patent. The complaint seeks unspecified monetary damages and an order enjoining us from infringing the &#8217;441 Patent. On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking declaratory judgments of non-infringement and invalidity of the &#8216;441 Patent.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, we filed a petition requesting institution of an inter-partes review ("IPR") to the Patent Trial and Appeals Board (the &#8220;Board&#8221;) at the United States Patent Office (IPR2020-01163) requesting the Board to find a set of claims in the &#8216;441 Patent invalid. On June 27, 2020, we filed a second petition (IPR2020-01200) requesting institution of an IPR requesting the Board to find another set of claims in the &#8216;441 Patent invalid. The two petitions (the &#8220;PacBio IPR Petitions&#8221;) together asserted that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions be instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs. In one IPR, all challenged claims were found unpatentable, including PGI&#8217;s core device claims. In the second IPR, the Board did not find the disputed claims unpatentable. PGI and PacBio each appealed to the U.S. Court of Appeals for the Federal Circuit, which affirmed both IPR decisions on January 9, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final written decisions on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. However, in a subsequent order dated September 15, 2022, the judge stayed the PGI District Court matter pending a final decision by the U.S. Court of Appeals for the Federal Circuit regarding the appeal described above. On February 26, 2024, we moved to transfer the case from the District of Delaware to the Northern District of California and that motion was granted on June 18, 2024. On March 18, 2024, the parties filed a joint status report in which PGI requested the Court set a revised scheduling order and we requested grant of our motion to transfer and proposed an alternate scheduling order. A case management conference was held on October 10, 2024 and the Court set a trial date of October 5, 2026. We plan to vigorously defend against the remaining claims.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2022, Take2 Technologies, Ltd. ("Take2") and the Chinese University of Hong Kong (&#8220;CUHK&#8221;) filed a complaint in the U.S. District Court for Delaware against us alleging infringement of U.S. Patent No. 11,091,794 (the &#8220;&#8217;794 Patent&#8221;) (C.A. No. 22- cv-01595) (the "Take2 District Court matter"). The complaint alleges that our Sequel II systems, Sequel IIe systems, and Revio systems that operate version 11.0 or later of the SMRT Link software, infringe the &#8216;794 Patent. The complaint seeks unspecified monetary damages and an order enjoining us from infringing the &#8217;794 Patent. We filed a motion to dismiss on February 14, 2023, which was denied on March 25, 2024. We also filed a motion to transfer the case from the District of Delaware to the Northern District of California which was granted on August 2, 2023. The case was transferred on August 16, 2023 (C.A. No. 5:23-cv-04166). Take2 filed a motion to disqualify our in-house legal department from representing PacBio in the district court action on September 20, 2023. We opposed Take2&#8217;s disqualification motion on October 4, 2023. An oral hearing on the disqualification motion was held on October 26, 2023 and the court issued orders on November 6 and December 4 of 2023 partially granting the motion. While some members of the in-house legal department were disqualified, General Counsel for PacBio was not disqualified and continues to represent PacBio in the Take2 District Court matter. We filed a petition for inter partes review at the Board (IPR2024-00028) challenging the validity of all claims of the &#8217;794 patent on October 17, 2023. The CUHK filed a preliminary response to the petition on January 26, 2024. On April 22, 2024, we filed our answer to the complaint, denying infringement and seeking declaratory judgments of non-infringement and invalidity of the &#8216;794 Patent. On April 24, 2024, the Board granted institution of IPR2024-00028 on the validity of all claims of the &#8217;794 patent. On May 2, 2024, the parties filed a joint stipulation and proposed order to stay the Take2 District Court matter pending inter partes review. On May 3, 2024, the Court granted the motion to stay. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Briefing is complete in IPR2024-00028 and an oral hearing took place on January 23, 2025. On March 7, 2025, we entered into a purchase agreement with CUHK to purchase the &#8216;794 patent. In connection with our purchase of the &#8216;794 Patent, each of Take2 and CUHK, on the one hand, and PacBio, on the other hand, agreed to waive and seek the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-42"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discharge of all outstanding litigation claims and patent-related challenges, including with respect to the Take2 District Court matter and IPR2024-00028. The agreement to discharge the litigation claims and the patent challenge has been granted by the Northern District of California and the Board, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Proceedings in China</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2020, PGI filed a complaint in the Wuhan Intermediate People&#8217;s Court in China alleging infringement of one or more claims of China patent No. CN101743321B (the &#8220;CN321 Patent&#8221;), which is related to the &#8216;441 Patent. On November 23, 2020 we filed an Invalidation Petition at the China National Intellectual Property Administration (CNIPA) demonstrating the invalidity of the claims in the CN321 Patent on grounds of insufficient disclosure, and the lack of support, essential technical features, clarity, novelty, and inventiveness. A hearing in the invalidation proceeding at the CNIPA was held on April 29, 2021. On September 2, 2021, the CNIPA issued its decision on the Invalidation Petition and determined that all claims (1-61) of the CN321 patent were invalid. On December 1, 2021, PGI filed an appeal with the Beijing IP Court, contesting the CNIPA decision. We filed a petition with the Wuhan Intermediate People&#8217;s court requesting dismissal of the infringement action based on the CNIPA invalidation decision, and PGI filed a petition to withdraw its complaint. The Wuhan Intermediate People&#8217;s court granted PGI&#8217;s petition and dismissed the infringement action in May 2022.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Proceedings</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also be involved in a variety of other claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment, and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-43"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_446"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below, together with all of the other information in our public filings with the SEC, which could materially affect our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations and prospects. In addition, any worsening of the economic environment may exacerbate the risks described below, any of which could have a material impact on us. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, operations, and financial results. Such risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully market, commercialize, and sell current and future products and related maintenance services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to achieve profitability for our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to implement required expense reduction initiatives;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to repay our debt and fund our long-term operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully leverage and integrate our acquisitions and future acquisitions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully research, develop and timely manufacture our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">management of new product introductions and transitions, resultant costs, and ability of new products to generate promised performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">recent significant changes to our leadership team and resultant disruptions to our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">retention, recruitment, and training of senior management, key personnel, scientists and engineers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to further penetrate nucleic acid sequencing applications, as well as grow product demand;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our reliance on outsourcing to other companies for manufacturing certain components and sub-assemblies, some of which are sole-sourced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of tariffs recently imposed by the U.S. government and its trading partners in response, other possible tariffs or trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to consistently manufacture our instruments and consumables to meet customers&#8217; specifications, quantity, cost, or performance requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the high amount of competition we face in our industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract customers and increase sales of current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our reliance on a limited number of customers for a significant portion of our revenues, including academic, research and government institutions, which may be impacted by reductions in funding or targeted cancellations of certain grants or contracts by the U.S. federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the complexity of our products giving rise to defects or errors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our unpredictable and lengthy sales cycles;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the possibility that our goodwill or intangible assets could become impaired;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse effects resulting from political and economic tensions between the United States and other countries, including China and Russia, and other geopolitical uncertainties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">securing and maintaining patent or other intellectual property protection for our products and related improvements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">current and future legal proceedings filed against us claiming intellectual property infringement;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-44"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the potential adverse impact of health epidemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential cybersecurity incidents and security breaches;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">governmental regulations that burden operations or narrow the market for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse effects resulting from enhanced trade tariffs, import restrictions, export restrictions, or other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">evolving ethical, legal, privacy, social, and regulatory concerns regarding genetic testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">volatility of the price of our common stock; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our stock price falling as a result of future offerings or sales of securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are not guarantees that no such conditions exist as of the date hereof and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span id="i8f6c895010734eacbbfa7762111ecdf4_193035"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expanding into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made and expect to continue making substantial investments to develop new products and enhance our existing products through our acquisitions and research and development efforts. For example, we commenced commercial shipments of Revio, our new long-read sequencing system in the first quarter of 2023, and commenced commercial shipments of Onso, our SBB short-read platform, in the third quarter of 2023. We also began taking orders and shipping our new Vega benchtop long-read sequencing system in the fourth quarter of 2024. Our future success is substantially dependent on our ability to successfully develop and commercialize our products, including in particular the Revio and Vega systems, as well as acquired technologies, which are anticipated to be used in demanding scientific research that requires substantial levels of accuracy and precision. In addition, we may not be successful in transitioning the customers of our prior generation products to our Revio and Vega products, or transitioning users of other third-party sequencing platforms to our portfolio of products, and have incurred and could continue to incur related obsolete inventory charges and losses on firm purchase commitments. Customers may also be slower than we anticipate in making new capital equipment acquisitions, especially in the current economic environment. Due to challenges we may experience in developing and marketing our existing products and launching new products, we may not be able to effectively:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">manage the timeliness of our new product introductions and the rate at which sales of our new products may cannibalize sales of our existing products or manage sales and marketing of multiple sequencing platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">drive adoption of our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">maintain our competitive position by continuing to attract and retain customers for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide appropriate levels of customer training and support for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">implement an effective marketing strategy to promote awareness of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">develop and implement an effective sales and distribution strategy for our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">develop, manufacture and commercialize new products or achieve an acceptable return on our manufacturing or research and development efforts and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">comply with regulatory requirements applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">anticipate and adapt to changes in our market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">accommodate customer expectations and demands with respect to our products, increase product adoption by our existing customers or develop new customer relationships;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deliver our early access systems to our external early access testing sites or complete our external early access testing program on our currently expected timelines;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-45"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">overcome unexpected challenges discovered during early access testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">complete the scientific and technical validation of new products on our currently expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deliver our future products in a timely manner to our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">grow our market share by marketing and selling our products for new and additional applications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">manage the significant burdens that expanding our existing or future products into current and new markets may impose on marketing, compliance, and other administrative and managerial resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">maintain and develop strategic relationships with vendors, manufacturers, and other industry partners to acquire necessary materials for the production of, and to develop, manufacture and commercialize, our existing or future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adapt or scale our manufacturing activities to meet performance specifications and potential demand at a reasonable cost;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">avoid infringement and misappropriation of third-party intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">obtain and maintain any necessary licenses to third-party intellectual property on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">obtain valid and enforceable patents that give us a competitive advantage or enforce existing patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">protect our proprietary technology; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks noted above, especially with respect to the marketing, sales, and commercialization of our products, may be heightened by the impact of current uncertain market and other conditions. In addition, a high percentage of our expenses is and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, we could suffer a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and other intangible assets with indefinite useful lives for impairment annually and whenever events or changes in circumstances indicate that the fair value of such assets may be less than the carrying value. We also perform regular reviews to determine if any event has occurred that may indicate that the carrying values of our intangible assets with finite lives and other finite-lived assets are impaired. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy, and acts by governments or courts. The occurrence of any of these events, may require us to record future impairment charges. For example, we recorded $184.5 million of impairment charges during the year ended December 31, 2024 as described in additional detail in Note 4. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Components</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of our 2024 Annual Report, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million of impairment charges during the three months ended March 31, 2025, as described in additional detail in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">3</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40">. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q. Additionally, amortization of acquired intangible assets during the three months ended March 31, 2025 included $359.3 million of accelerated amortization pertaining to the Company's change in estimate of its remaining useful life of the developed technology acquired in connection with the 2021 Omniome acquisition as described in additional detail in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">5</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49">. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q. Any such charges may adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses to date, and we expect to continue to incur significant losses as we develop our business and we may never achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generally incurred net losses each quarter since inception, and we cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Even if profitability is achieved in the future, we may not be able to sustain profitability on a consistent basis. We expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Although we initiated expense reduction plans during the second quarter of 2024, and further expense reduction plans during the first quarter of 2025, we do not expect to be profitable in 2025, and there can be no assurance that these expense reduction initiatives will be successful in helping us achieve profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-46"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses since inception and our expectation of incurring substantial losses and negative cash flow for the foreseeable future could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">make it more difficult for us to satisfy our obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our ability to fund future working capital, capital expenditures, research and development and other business opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increase the volatility of the price of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our flexibility to react to changes in our business and the industry in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">place us at a disadvantage to other companies that offer nucleic acid sequencing equipment or consumables; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our ability to borrow additional funds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, inflationary pressure, including as a result of supply shortages, has adversely impacted and could continue to adversely impact our financial results, and our operating costs may increase. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our customers may choose to reduce their business with us if we increase our pricing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of the foregoing may have a material adverse effect on our business, operations, financial condition, and prospects. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on impairment considerations, see &#8220;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193035">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expand</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193035">ing</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193035"> into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expense reduction initiatives could be disruptive to our operations and adversely affect our results of operations and financial condition, and we may not realize some or all of the anticipated benefits of these initiatives, whether in the time frame anticipated or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expense reduction initiatives comprise, among other things, workforce reductions, facilities downsizing and a refined pipeline of development activities. For example, during the second quarter of 2024 we initiated plans to reduce certain of our annualized run-rate operating expenses by the end of the year, with the intent of better aligning our organizational structure and resources with our strategic initiatives, and during the first quarter of 2025 we initiated further plans to reduce certain of our annualized run-rate operating expenses by the end of the year, given persistent uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs. The implementation of these expense reduction initiatives, including the impact of workforce reductions, could impair our ability to invest in developing, marketing and selling new and existing products, be disruptive to our operations, make it difficult to attract or retain employees, result in higher than anticipated charges, divert the attention of management, result in a loss of accumulated knowledge, impact our customer and supplier relationships, and otherwise adversely affect our results of operations and financial condition. In addition, our ability to complete our expense reduction initiatives and achieve the anticipated benefits within the expected time frame is subject to estimates and assumptions and may vary materially from our expectations, including as a result of factors that are beyond our control. Furthermore, our efforts to stabilize our business may not be successful.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-47"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Additional funds may not be available on terms acceptable to us or at all. We have incurred significant debt, and we may incur additional debt in the future. As of December 31, 2024, we had outstanding approximately $200.0&#160;million aggregate principal amount of our 1.50% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;) and $441.0&#160;million aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;). As discussed in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_43">Note </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_43">4</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_43">. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part I, Item 1 of this Quarterly Report on Form 10-Q, we exchanged the remaining approximately $459.0&#160;million in aggregate principal amount of our 1.50% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) 20,451,570 shares of common stock and (iii) $50.0&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The 2024 Exchange Transaction closed on November 21, 2024. We may not have sufficient cash to make required payments under the terms of this debt, and should this occur, debt holders have rights senior to common stockholders to make claims on our assets. In addition, if we do not have sufficient cash to make the required payments at maturity, we may need to raise additional capital, which could result in dilution of our existing investors, or refinance or restructure our debt, which will depend on, among other things, the condition of the capital markets and our financial condition at such time, and which may be at higher interest rates. We may not be able to issue equity securities due to unacceptable terms and conditions to us in the capital markets. To the extent that we intend to raise additional funds through the sale of our common stock, downward fluctuations in our stock price could adversely affect such fundraising efforts. Furthermore, equity financings normally involve shares sold at a discount to the current market price and fundraising through sales of additional shares of common stock or other equity securities will have a dilutive effect on our existing investors. We may be required to seek equity financing at a time when the market price for our common stock is low, which would further dilute ownership for existing common stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our growth will depend, in part, on our ability to fund our commercialization efforts and our efforts to develop new products and improve our existing products. To the extent our existing resources are not sufficient, it may require us to delay, or even not allow us to conduct any or all of these activities that we believe would be beneficial for our future growth. We may need to raise additional funds through public or private debt or equity financing or alternative financing arrangements, which may include collaborations or licensing arrangements. If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts, launching of new products, or operations, or to increase or maintain the level of our research and development activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of, or eliminating some or all of, our development programs. We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products, or we may need to cease operations. Any of these actions could materially impede our ability to achieve our business objectives and could materially harm our operating results, and there can be no assurance that any of these actions would be successful. If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements and we are unable to raise capital, it could have a material adverse effect on our business, financial condition and results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have made acquisitions and, in the future, may continue to acquire businesses, technologies or assets, form joint ventures or make other strategic investments with companies that could adversely affect our operating results, dilute our stockholders&#8217; ownership, or cause us to incur debt or significant expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we have acquired and expect to continue to pursue acquisitions of complementary businesses, technologies, or assets. We may also pursue technology license arrangements, strategic alliances or investments that complement our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions and strategic transactions involve numerous risks, any of which could harm our business and negatively affect our financial condition and results of operations, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">intense competition for suitable acquisition targets, which could increase prices and adversely affect our ability to consummate deals on favorable or acceptable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure or material delay in closing a transaction;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-48"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">transaction-related lawsuits or claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in integrating the technologies, operations, existing contracts, and personnel of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in retaining key employees or business partners of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in retaining suppliers, partners, or customers of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">challenges with integrating the brand identity of an acquired company with our own;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">diversion of financial and management resources from existing operations or alternative acquisition opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure to realize the anticipated benefits or synergies of a transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in developing technology post-acquisition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure to identify the problems, liabilities, or other shortcomings or challenges of an acquired company or technology, including issues related to intellectual property, regulatory compliance practices, litigation, revenue recognition or other accounting practices, or employee or user issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risks that regulatory bodies may enact new laws or promulgate new regulations that are adverse to an acquired company or business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risks that regulatory bodies do not approve our acquisitions or business combinations or delay such approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">theft of our trade secrets or confidential information that we share with potential acquisition candidates or other potential strategic partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risk that an acquired company or investment in new services cannibalizes a portion of our existing business; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse market reaction to an acquisition or other strategic transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or other strategic investments, we may raise additional funds, which could adversely affect our existing stockholders and our business. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. In addition, our stockholders may experience substantial dilution as a result of additional securities we may issue for acquisitions. Open market sales of substantial amounts of our common stock issued to stockholders of companies we acquire could also depress our stock price. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to address the foregoing risks or other problems encountered in connection with past or future acquisitions of businesses, new technologies, services, and other assets and strategic investments, or if we fail to successfully integrate such acquisitions or investments, our business, financial condition, and results of operations could be adversely affected, including potential impairments of goodwill and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-49"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and timely manufacture our current and future products our business may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considering the highly complex technologies involved in our products, there can be no assurance that we will be able to manufacture and commercialize our current and future products on a timely basis or continue providing adequate support for our existing products. The commercial success of our products, including the Sequel, Sequel II/IIe, Revio, Onso and Vega systems, and the products under development, including acquired technologies, depends on a number of factors, including performance and reliability of the systems, our anticipating and effectively addressing customer preferences and demands, the success of our sales and marketing efforts, effective forecasting and management of product demand, purchase commitments and inventory levels, effective management of manufacturing and supply costs, and the quality of our products, including consumables such as SMRT Cells and reagents. Should we face delays in or discover unexpected defects during the further development or manufacturing process of instruments or consumables related to our products, including any delays or defects in software development or product functionality, the timing and success of the continued rollout and scaling of our products may be significantly impacted, which may materially and negatively impact our revenue and gross margin. The ability of our customers to successfully utilize our products will also depend on our ability to deliver high quality SMRT Cells and reagents. We have designed SMRT Cells and other consumables specifically for the Sequel, Sequel II/IIe, Revio and Vega systems, and may need to develop in the future, other customized SMRT Cells and consumables for our future products. Our production of the SMRT Cells for the Sequel and Sequel II/IIe systems has been and may in the future, including with respect to the Revio system, be below desired levels and yields, and we have experienced and may experience in the future manufacturing delays, product or quality defects, SMRT Cell variability, and other issues. The performance of our consumables is critical to our customers&#8217; successful utilization of our products, and any defects or performance issues with our consumables would adversely affect our business. All of the foregoing could have a material adverse effect on our ability to sell our products or result in other material adverse effects on our business, operations, financial condition, operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of our products is complex and costly. Problems in the design or quality of our products may have a material and adverse effect on our brand, business, financial condition, and operating results, and could result in us losing our certifications from the International Organization for Standardization (&#8220;ISO&#8221;). If we were to lose ISO certification, then our customers might choose not to purchase products from us and this could adversely impact our ability to develop products approved for clinical uses. Unanticipated problems with our products could divert substantial resources, which may impair our ability to support our new and existing products and could substantially increase our costs. If we encounter development challenges or discover errors in our products late in our development cycle, including during external beta testing, we may be forced to undertake design and/or production changes, delay product shipments or the scaling of manufacturing or supply. The completion of the production and external testing of our beta systems may also take longer than currently planned, cost more than currently expected and the scientific and technical validation may not be completed on our currently expected timelines or at all. Such testing may also expose fundamental flaws in our products that may cause us to abandon the further development of such products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the continued rollout of our current and future products, including with respect to the SMRT Cell, the Sequel, Sequel II/IIe, Revio, Onso and Vega systems, is delayed or is not successful or less successful than anticipated, then we may not be able to achieve an acceptable return, if any, on our substantial research and development efforts, and our business may be materially and adversely affected. The expenses or losses associated with delayed or unsuccessful product development or lack of market acceptance of our existing and new products, including the SMRT Cell and the Sequel, Sequel II/IIe, Revio, Onso and Vega systems could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-50"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development efforts may not result in the benefits that we anticipate, and our failure to successfully market, sell, and commercialize our current and future products could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dedicated significant resources to developing our current products. We are also engaged in substantial and complex research and development efforts, which, if successful, may result in the introduction of new products in the future, including in connection with the SMRT Cell and the Sequel II/IIe, Revio, Onso and Vega systems, in addition to other products currently under development, including acquired technologies. Our research and development efforts are complex and require us to incur substantial expenses and we may not be able to develop, manufacture and commercialize new products or obtain regulatory approval if necessary. We may divert significant resources to research and development initiatives that do not result in commercialized products, and even if these efforts do result in commercialized products, there can be no assurance that such products will compete successfully in the market or achieve an acceptable return, if any, on our research and development efforts and expenses. Moreover, our joint research and development efforts with partners require significant management attention and operational resources. If we are unable to successfully manage such joint research and development efforts, our future results may be adversely impacted. Furthermore, we will need to continue to expand our internal capabilities or seek new partnerships or collaborations, or both, in order to successfully develop, market, sell and commercialize our products for and in the markets we seek to reach. If we are unable to do so or are delayed, then this could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must successfully manage new product introductions and transitions and the development of acquired technologies, for which we may incur significant costs during these transitions and development, and these efforts may not result in the benefits we anticipate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products and services fail to deliver the performance, scalability or results expected by our current and future customers, or are not delivered on a timely basis, our reputation and credibility may suffer, our current and future sales and revenue may be materially harmed and our business may not succeed. For instance, if we are not able to successfully execute on the commercialization plan for our Revio HiFi long-read sequencing system and the Vega benchtop long-read sequencing system, and each of their related consumables, and any future products that may be developed for research, medical and clinical uses, including acquired technologies, it could have a material adverse effect on our business, financial condition and results of operations. In addition, the introduction of future products, including with respect to future long-read products, and related consumables, has and may in the future lead to our limiting or ceasing development of further enhancements to our existing products as we focus our resources on new products, and has resulted and could in the future result in reduced marketplace acceptance and loss of sales of our existing products, materially adversely affecting our revenue and operating results. The introduction of new products, including the recent commercialization of our Revio and Vega systems, has had and may in the future also have a negative impact on our revenue in the near-term as our current and future customers have delayed or cancelled and may in the future delay or cancel orders of existing products in anticipation of new products and we may also be pressured to decrease prices for our existing products. Our experience in managing product transitions is limited, and we have experienced, and may in the future experience, difficulty in managing or forecasting customer reactions, purchasing decisions or transition requirements with respect to newly launched products. We have incurred and may continue to incur significant costs in completing these transitions, including costs of write-downs of our products, as current or future customers transition to new products. If we do not successfully manage these product transitions, including with respect to the Revio, Onso and Vega systems and each of their related consumables, and any future long-read products, our business, operations, financial condition, and prospects may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected by epidemics or other public health emergencies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of epidemics or other public health emergencies. These impacts could include, but are not necessarily limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">shutdowns or business disruptions experienced by manufacturers, suppliers and other third parties with whom we conduct business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruptions or interruptions to our supply chains;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in applicable public health regulations that require us to modify our business practices and operations; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-51"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruption to customer demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which any epidemic or other public health emergency impacts our business and financial results inherently depends on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of a particular public health matter and the actions to contain it or treat its impact, among others. Even after an epidemic or public health emergency has subsided, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may continue to experience an adverse impact to our business as a result of economic aftershocks, including recessionary effects and inflationary pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant changes to our leadership team and the resulting management transitions might harm our future operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in recent years experienced significant changes to our leadership team, and although we believe these leadership transitions are in the best interest of our stakeholders, these transitions may result in the loss of personnel with deep institutional or technical knowledge. Further, the transition could potentially disrupt our operations and relationships with employees, suppliers, partners, and customers due to added costs, operational inefficiencies, decreased employee morale and productivity and increased turnover. We must successfully recruit and integrate our new leadership team members within our organization to achieve our operating objectives; as such, the leadership </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transition</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may temporarily affect our business performance and results of operations while the new members of our leadership team become familiar with our business. In addition, our competitors may seek to use this transition and the related potential disruptions to gain a competitive advantage over us. Furthermore, these changes may increase our dependency on the other members of our leadership team that remain with us, who are not contractually obligated to remain employed with us and may leave at any time. Any such departure could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional management turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. Our future operating results depend substantially upon the continued service of our key personnel and in significant part upon our ability to attract and retain qualified management personnel. If we are unable to mitigate these or other similar risks, our business, results of operations and financial condition may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified scientists, engineers, sales personnel and other employees, our ability to maintain, develop and commercialize our products could be harmed and we may be unable to achieve our goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. In particular, our scientists and engineers are critical to our technological and product innovations, and we will need to hire additional qualified personnel from time to time. Our industry, is characterized by high demand and intense competition for talent, and the turnover rate has been and may continue to be high. Our employees can leave our company with little to no prior notice and would be free to work for a competitor. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics. We also compete for qualified sales personnel to support the commercialization of our existing and new products. Workforce reductions, such as the workforce reduction we implemented in 2024 and 2025, and other expense reduction efforts may be negatively received by potential or current employees, and accordingly result in attrition or difficulty in recruiting desirable candidates. Additionally, we may face challenges in retaining and recruiting key personnel due to sustained declines in our stock price that could reduce the retentive value of stock options, restricted stock units and other equity awards we issue as compensation. We may not be able to provide adequate cash or other incentives to adequately counterbalance any negative perceptions about the value of our equity awards. Moreover, the value of any equity awards that we do grant to our personnel may be significantly affected by movements in our stock price that are beyond our control. The loss of qualified employees, or an inability to attract, retain, and motivate employees, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and launches, business growth prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, changes to U.S. immigration policies, such as the implementation of more restrictive interpretations by the U.S. Citizenship and Immigration Services of regulatory requirements for H-1B and other visa programs, could restrain the flow of technical and professional talent into the U.S. and may inhibit our ability to hire qualified personnel. If some of our employees&#8217; temporary work permits expire and are not renewed, we may face increased turnover rates and labor shortages, which could result in higher labor costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-52"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have &#8220;key person&#8221; life insurance policies covering any member of our management team or other key personnel. The loss of any of these individuals or any inability to attract or retain qualified personnel, including scientists, engineers, sales personnel and others, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and introductions, business growth prospects, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to further penetrate nucleic acid sequencing applications as well as on the growth and expansion of the demand for our products. If our products fail to achieve and sustain sufficient market acceptance, we will not generate expected revenue and our business may not succeed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although nucleic acid sequencing technology is well-established, our SMRT Sequencing technology is relatively new and evolving. We cannot be sure that our current or future products will gain acceptance in the marketplace at levels sufficient to support our costs. Our success depends, in part, on our ability to expand overall demand for nucleic acid sequencing to include new applications that are not practicable with other current technologies and to introduce new products that capture a larger share of growing overall demand for sequencing. To accomplish this, we must successfully commercialize, and continue development of, our proprietary SMRT Sequencing technology for use in a variety of life science and other research applications, including uses by academic, government and clinical laboratories, as well as pharmaceutical, diagnostic, biotechnology, and agriculture companies, among others. However, we may be unsuccessful in these efforts and the sale and commercialization of our products may not grow sufficiently to cover our costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be successful in adding new products or securing additional customers for our current and future products. If we are unable to successfully develop acquired technologies and sell acquired technology products, we may fail to achieve our strategic commercial initiatives in connection with the planned release of new products and anticipated entry into new markets. Our ability to further penetrate existing applications and any new applications depends on a number of factors, including the cost, performance and perceived value associated with our products, as well as customers&#8217; willingness to adopt a different approach to nucleic acid sequencing. Potential customers may have already made significant investments in other sequencing technologies and may be unwilling to invest in new technologies. We are experiencing pricing pressures caused by industry competition and increased demand for lower-priced instruments and lower operational costs. We have limited experience commercializing and selling products outside of the academic and research settings, and we cannot guarantee success in acquiring additional customers. Furthermore, we cannot guarantee that our products will be satisfactory to potential customers or that our products will perform in accordance with customer expectations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nucleic acid sequencing applications are new and dynamic, and there can be no assurance that they will develop as quickly as we anticipate, that they will reach their full potential or that our products will be appropriate or competitive for these applications. As a result, we may be required to refocus our marketing efforts, and we may have to make changes to the specifications of our products to enhance our ability to enter particular applications more quickly. We may also need to delay full-scale commercial deployment of new products as we develop them in order to perform quality control and early access user testing. We also need to maintain reliable supply chains for the various components in our new products and consumables to support large-scale commercial production. Even if we are able to implement our technology successfully, we and/or our sales and distribution partners may fail to achieve or sustain market acceptance of our current or future products across the full range of our intended life science and other applications. We need to continue to expand and update our internal capabilities or to collaborate with other partners, or both, in order to successfully expand sales of our products in the applications that we seek to reach, which we may be unable to do at the scale required to support our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the demand for our products grows more slowly than anticipated, if we are unable to successfully scale or otherwise ensure sufficient manufacturing capacity for new products to meet demand, if we are not able to successfully market and sell our products, if competitors develop better or more cost-effective products, if our product launches and commercialization are not successful, or if we are unable to further grow our customer base or do not realize the growth with existing customers that we are expecting, our current and future sales and revenue may be materially and adversely harmed, or we may recognize an impairment loss, and our business may not succeed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-53"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on other companies for the manufacture of certain components and sub-assemblies and intend to outsource additional sub-assemblies in the future, some of which are sole sources. We may not be able to successfully scale the manufacturing process necessary to build and test multiple products on a full commercial basis, which could materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are complex and involve a large number of unique components, many of which require precise manufacturing. The nature of our products requires customized components that are currently available only from a limited number of sources, and in some cases, single sources. We have chosen to source certain critical components from a single source, including suppliers for our SMRT Cells, reagents, and instruments. We cannot assure you that product supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply collaborators, or that product supplies will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. We may be unable to negotiate binding agreements with our current and future sole source third-party manufacturing and supply collaborators or, in the event that such collaborators&#8217; services become interrupted for any reason, find replacement manufacturers to support our development and commercial activities at commercially reasonable terms. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or fail to provide sufficient quantities in a timely manner. If we are required to purchase these components from alternative sources, it could take several months or longer to qualify the alternative sources. If we are unable to source these product components from sole-source third-party manufacturing and supply collaborators for any reason, including in connection with acts of terrorism, hostilities, military conflict and acts of war, including between China and Taiwan, or secure a sufficient supply of these product components on a timely basis and at an acceptable cost, or if these components do not meet our expectations or specifications for quality and functionality, our operations and manufacturing would be materially and adversely affected, we could be unable to meet customer demand and our business and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of our third-party manufacturing partners and suppliers have had and may in the future be disrupted by conditions unrelated to our business or operations or that are beyond our control, including but not limited to changing international trade policies, inflation, supply chain disruptions, and conditions&#160;&#160;&#160;&#160;related to epidemics or pandemics. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. We have and may continue to face challenges in our supply chain, which has and may continue to adversely impact margins. During periods of shortage or delay, the price of components may increase or the components may not be available at all. Our suppliers have raised prices and may continue to raise prices that we may not be able to pass on to our customers, which could adversely affect our business, including our competitive position, market share, revenues, and profit margins in material ways. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products in a timely manner in the quantities or configurations needed. Various government policies have had, and may continue to have in the future, a negative impact on manufacturing and/or supply chains, in addition to customer demand for our products and demand through certain distributors. As a result of global economic or political instability, such as the uncertainty in the Middle East, an escalation of the war in Ukraine, potential uncertainty related to Taiwan and its relationship with China, changing international trade policies, other disease outbreaks, or supply issues, we or our contractors could experience shortages, business disruptions or delays for materials sourced or manufactured in the affected countries, and their ability to supply us with instruments or product components may be affected. Occasionally, system components and reagents reach the end of their life cycles or become obsolete, requiring us to source alternatives. If we encounter delays or difficulties in securing the quality and quantity of materials we require for our products, our supply chain would be interrupted, which would adversely affect sales. If any of these events occur, our business and operating results could be harmed. Accordingly, if any of the foregoing occurs, our ability to commercialize our products, revenue and gross margins could suffer until lockdowns related to epidemics or pandemics are lifted, supply issues or business disruptions are resolved and/or other sources can be developed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-54"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current manufacturing process is also characterized by long lead times between the placement of orders for and delivery of our products. If we do not accurately anticipate our needs or if we receive insufficient components to manufacture our products on a timely basis to meet customer demand, our sales and our gross margin may be adversely affected, and our business could be materially harmed. If we are unable to reduce our manufacturing costs and establish and maintain reliable, high-volume manufacturing suppliers as we scale our operations and expand our product offerings, our business, operations, financial condition, and prospects could be materially and adversely harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to consistently manufacture our instruments and consumables, including SMRT Cells and reagents, to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully generate revenue from our products, we need to supply our customers with products that meet their expectations for quality and functionality in accordance with established specifications. Our customers have experienced variability in the performance of our products. We have experienced and may continue to experience delays, quality issues or other difficulties leading to customer dissatisfaction with our products. Our production of SMRT Cells, flow cells and of reagents for both our long- and short-read technologies, involve a long and complex manufacturing process and has been and may in the future be below desired yields and resulting output levels. We have experienced and may experience in the future manufacturing delays, product defects, variability in the performance of SMRT Cells, flow cells and other products, inadequate reserves for inventory, or other issues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be able to manufacture our products so that they consistently achieve the product specifications and quality that our customers expect, including any products developed for clinical uses. Problems in the design or quality of our products, including low manufacturing yields of SMRT Cells, flow cells, or sub-performing reagent lots may have a material adverse </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our brand, business, financial condition, and operating results, and could result in us losing our ISO certifications. If we were to lose our ISO certifications, then our customers might choose not to purchase products from us. There is also no assurance that we will be able to increase manufacturing yields and decrease costs, particularly if high rates of inflation continue, or that we will be successful in forecasting customer demand or manufacturing and supply costs, or that product supplies, including reagents or integrated chips, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. Furthermore, while we are undertaking efforts to increase our manufacturing scale and capability, we may not be able to increase manufacturing to meet anticipated demand or may experience downtime in our manufacturing facilities, including, for example, if our suppliers are unable to meet our increased demand at a time when the supply chain is under duress due to potential dislocations and disruptions in product and employee availability (whether due to pandemics, government policy or otherwise). An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs, will have a negative impact, and may have a material adverse effect on our business, product development timelines, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rapidly changing technology in life sciences and research diagnostics could make our products obsolete unless we continue to develop, manufacture and commercialize new and improved products and pursue new opportunities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. These new and evolving technologies may be superior to, impair, or render obsolete the products we currently offer or the technologies currently underlying our products. Our future success depends on our ability to continually improve our products, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis and to pursue new opportunities. These new opportunities may be outside the scope of our proven expertise or in areas where demand is unproven, and new products and services developed by us may not gain market acceptance or may not adequately perform to capture market share. Our inability to develop and introduce new products and to gain market acceptance of our existing and new products could harm our future operating results. Unanticipated difficulties or delays in replacing existing products with new products or in commercializing our existing or new products in sufficient quantities and of acceptable quality to meet customer demand, including with respect to the SMRT Cell and the Sequel, Sequel II/IIe, Revio, Onso and Vega systems, could diminish future demand for our products and may materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-55"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of the markets for our products, including our Revio, Onso and Vega instruments, may be smaller than estimated, and new market opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for sequencing systems and consumables products is evolving, making it difficult to accurately predict the size of the markets for our current and future products, including our Revio, Onso and Vega instruments. Our estimates of the total addressable market for our current and future products are based on a number of internal and third-party estimates and assumptions that may be incorrect, including the assumptions that academic, governmental, corporate, or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our products. In addition, sales of new products may take time to develop and mature and we cannot be certain that these market opportunities will develop as we expect. While we believe our assumptions and the data underlying our estimates of the total addressable market for our products are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates, or those underlying the third-party data we have used, may change at any time, thereby reducing the accuracy of our estimates. As a result, our estimates of the total addressable market and growth opportunities for our products may be incorrect.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future growth of the market for our current and future products depends on many factors beyond our control, including recognition and acceptance of our products by the research and scientific communities, the growth, prevalence and costs of competing products and solutions and the development of robust ecosystems supporting our products and their methodologies. For example, the market acceptance and growth of long-read sequencing technologies, like our Revio and Vega systems, depends on a variety of factors, including the availability and cost-effectiveness of related tools for high quality sample collection and preparation and advanced bioinformatic tools to process results; as well as the perceived advantages and disadvantages of long-read sequencing compared to short-read or other sequencing technologies: consequently, if potential customers conclude the costs of adopting long-read sequencing technologies outweigh the benefits, the market for our Revio and Vega systems may be negatively impaired. There can be no assurance that our current or future products will gain traction in the market. If the markets for our current and future products are smaller than estimated or do not develop as we expect, our growth may be limited, and it could materially and adversely affect our business, operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased market adoption of our products by customers may depend on the availability of sample preparation and informatics tools, some of which may be developed by third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part upon the development of sample preparation and software and informatics tools by third parties for use with our products. We cannot guarantee that product supplies, including reagents, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices, or that third parties will develop tools that our current and future customers will find useful with our products, or that customers will adopt such third-party tools on a timely basis or at all. A lack of complementary sample preparation and informatics tools, or delayed updates of such tools, may impede the adoption of our products and may materially and adversely impact our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a significant number of companies offering nucleic acid sequencing products and/or services, including Illumina, BGI Genomics (also known as MGI or Complete Genomics), Thermo, ONT Ltd., Roche, Bionano, and Qiagen. Other companies recently entering the market include Ultima, Element and Singular. Many of these companies currently have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater financial, technical, research and/or other resources, more experience in new product development, larger and more established manufacturing capabilities and marketing, sales, and support functions, and/or more established distribution channels to deliver products to customers than we do. These companies may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-56"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also several companies that are in the process of developing or have already developed and commercialized new, competing or potentially competing technologies, products and/or services, including ONT Ltd. and its subsidiaries, against whom we have filed complaints for patent infringement in the U.S. District Court for the District of Delaware and, previously, with the U.S. International Trade Commission, in the High Court of England and Wales and in the District Court of Mannheim, Germany. ONT Ltd. previously filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany, also for patent infringement. Roche is developing potentially competing sequencing products. Increased competition may result in pricing pressures, which could harm our sales, profitability or market share. Our failure to further enhance our existing products and to introduce new products to compete effectively could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully increase sales of our current products or market and sell our future products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve profitability depends, in part, on our ability to attract customers for our current and future products including Revio and Onso, and we may be unable to effectively market or sell our products or find appropriate partners to do so. To perform sales, marketing, distribution, and customer support functions successfully, we face a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract, retain and manage qualified sales, marketing, and service personnel necessary to expand market acceptance for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the performance and commercial availability expectations of our existing and potential customers with respect to new and existing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">availability of potential sales and distribution partners to sell our technologies, and our ability to attract and retain such sales and distribution partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the time and cost of maintaining and growing a specialized sales, marketing and service force for a particular application, which may be difficult to justify in light of the revenue generated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our sales, marketing and service force may be unable to execute successful commercial activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may in the future, use promotional pricing and similar measures to attract purchases of our products. These measures may not be successful in attracting purchases and, even if successful, may negatively impact our gross margins. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have enlisted and may continue to enlist third parties to assist with sales, equipment leasing, distribution and customer support. There is no guarantee that we will be successful in attracting desirable sales and distribution partners, that we will be able to enter into arrangements with such partners on terms favorable to us or that we will be able to retain such partners on a going-forward basis. If our sales and marketing efforts, or those of any of our third-party sales and distribution partners, are not successful, or our products do not perform in accordance with customer expectations, our technologies and products may not gain market acceptance, which could materially and adversely impact our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large purchases by a limited number of customers represent a significant portion of our revenue, and any loss or delay of expected purchases has resulted, and in the future could result, in material quarter-to-quarter fluctuations of our revenue or otherwise adversely affect our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a significant portion of our revenue from a limited number of customers. While for the three months ended March&#160;31, 2025, and 2024, no customer accounted for 10% or more of our total revenue, many of our customers make large purchases on a purchase-order basis rather than pursuant to long-term contracts. As a consequence of the concentrated nature of our customer base and their purchasing behavior, our quarterly revenue and results of operations have fluctuated, and may fluctuate in the future, from quarter to quarter and are difficult to forecast. For example, the cancellation of orders or acceleration or delay in anticipated product purchases or the acceptance of shipped products by our larger customers has materially affected, and in the future could materially affect, our revenue and results of operations in any quarterly period. We have been, and may in the future be, unable to sustain or increase our revenue from our larger customers, or offset any discontinuation or decrease of purchases by our larger customers with purchases by new or other existing customers. To the extent one or more of our larger customers experience significant financial difficulty, bankruptcy or insolvency, this could have a material adverse effect on our sales and our ability to collect on receivables, which could materially and adversely harm our financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-57"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our customers, including some of our larger customers, have negotiated, or may in the future negotiate, volume-based discounts or other more favorable terms from us or our sales and distribution partners, which can and have had a negative effect on our gross margins or revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that such concentrated purchases will continue to contribute materially to our revenue for the foreseeable future and that our results of operations may fluctuate materially as a result of such larger customers&#8217; buying patterns. In addition, we may see consolidation of our customer base. The loss of one of our larger customers, a significant delay or reduction in its purchases, or any volume-based discount or other more favorable terms that we or our sales and distribution partner(s) may agree to provide, in light of the aggregated purchase volume or buying power resulting from such consolidation, has harmed, and in the future could harm, our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are highly complex, have recurring support requirements and could have unknown defects or errors, which may give rise to claims against us or divert application of our resources from other purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are highly complex and may develop or contain undetected defects or errors. Our customers have previously experienced reliability issues with our existing products, including the Sequel and Sequel II/IIe systems. In addition, it is possible our customers could experience reliability issues with current or future products, including the Sequel II/IIe, Revio, Onso and Vega systems. Despite internal and external testing, defects, or errors may arise in our products, which could result in a failure to obtain, maintain, or increase market acceptance of our products, diversion of development resources, injury to our reputation and increased warranty, service, and maintenance costs. New products, including the Revio, Onso and Vega systems, or enhancements to our existing products, including the SMRT Cell and the Sequel II/IIe systems, in particular may contain undetected errors or performance problems that are discovered only after delivery to customers. If our products have reliability or other quality issues or require unexpected levels of support in the future, the market acceptance and utilization of our products may not grow to levels sufficient to support our costs and our reputation and business could be harmed. Low utilization rates of our products has and could in the future cause our revenue and gross margins to be adversely affected. We provide a warranty for our sequencing instruments and consumables, which is generally limited to replacing, repairing, or at our option, giving credit for any sequencing instrument or consumable with defects in material or workmanship. Service contracts for our sequencing instruments may be separately purchased. Defects or errors in our products may also discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may be substantial and could materially and adversely affect our operating margins. If our service and support costs increase, our business and operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, such defects or errors could lead to the filing of product liability claims against us or against third parties whom we may have an obligation to indemnify against such claims, which could be costly and time-consuming to defend and result in substantial damages. Although we have product liability insurance, any product liability insurance that we have or procure in the future may not protect our business from the financial impact of a product liability claim. Moreover, we may not be able to obtain adequate insurance coverage on acceptable terms. Any insurance that we have or obtain will be subject to deductibles and coverage limits. A product liability claim could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our sales depends on customers&#8217; spending budgets that may be subject to significant and unexpected variation which could have a negative effect on the demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments represent significant capital expenditures for our customers in research applications. Current and potential customers for our current or future products include academic and government institutions, genome centers, medical research institutions, clinical laboratories, pharmaceutical, agricultural, biotechnology, diagnostic and chemical companies. Their spending budgets can have a significant effect on the demand for our products. Spending budgets are based on a wide variety of factors, including the allocation of available resources to make purchases, funding from government sources which is highly uncertain and subject to change, including the persistent uncertainty surrounding NIH and academic funding, the spending priorities among various types of research equipment, policies regarding capital expenditures during economically uncertain periods and the potential impacts from health epidemics or pandemics. Any decrease in capital spending or change in spending priorities of our current and potential customers could significantly reduce the demand for our products. Any delay or reduction in purchases by current or potential customers or our inability to forecast fluctuations in demand could materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-58"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to convert our orders in backlog into revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our backlog represents product orders from our customers that we have confirmed but have not been able to fulfill, and, accordingly, for which we have not yet recognized revenue. We may not receive revenue from these orders, and any order backlog we report may not be indicative of our future revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many events can cause an order to be delayed or not completed at all, some of which may be out of our control, including the potential impacts from health epidemics or pandemics and our suppliers, especially our sole source suppliers, not being able to provide us with products or components. If we delay fulfilling customer orders or if customers reconsider their orders, those customers may seek to cancel or modify their orders with us. Customers may otherwise seek to cancel or delay their orders even if we are prepared to fulfill them. If our orders in backlog do not result in sales, our operating results may suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales cycles are unpredictable and lengthy, which makes it difficult to forecast revenue and may increase the magnitude of quarterly or annual fluctuations in our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales cycles for our sequencing instruments are lengthy because they represent a major capital expenditure and generally require the approval of our customers&#8217; senior management. This may contribute to substantial fluctuations in our quarterly or annual operating results, particularly during periods in which our sales volume is low. Because of these fluctuations, it is likely that in some future quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely decrease. Past fluctuations in our quarterly and annual operating results have resulted in decreases in our stock price. Such fluctuations also mean that investors may not be able to rely on our operating results in any particular period as an indication of future performance. Sales to existing customers and the establishment of a business relationship with other potential customers is a lengthy process, generally taking several months and sometimes longer. Following the establishment of the relationship, the negotiation of purchase terms can be time-consuming, including as a result of seasonal factors, as discussed below, and a potential customer may require an extended evaluation and testing period. Our sales cycles may also lengthen, and those sales cycles may result in lower units sold per cycle, as we continue to introduce our Revio and Vega instruments and their associated consumables to the market, as our customers may have additional administrative, technical or other requirements associated with transitioning to new products and technologies. In anticipation of product orders, we may incur substantial costs before the sales cycle is complete and before we receive any customer payments. As a result, if a sale is not completed or is canceled or delayed, we may have incurred substantial expenses, making it more difficult for us to become profitable or otherwise negatively impacting our financial results. Even if our selling efforts are successful, the realization of revenue may be substantially delayed, our ability to forecast our future revenue may be more limited and our revenue may fluctuate significantly from quarter to quarter and year over year. For more information on the impact of these fluctuations on our results and stock price, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193518">&#8212;</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193518">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because some of our customers and suppliers are based in China, our business, financial condition and results of operations could be adversely affected by the political and economic tensions between the United States and China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with political conflicts between the U.S. and China. While for the three months ended March&#160;31, 2025 and 2024, no customer accounted for 10% or more of our total revenue, a portion of our revenue is generated from China. In addition, certain components, some of which are critical components, of our products are manufactured in China. These components are either sourced directly from companies in China or indirectly from third parties that source from companies in China.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-59"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. Tariffs imposed by the U.S. and China have increased, and may continue to increase, our costs. Additionally, export restrictions imposed by the U.S. may impact our ability to export certain products to customers or distributors in China and restrict our ability to use certain integrated circuits in our products, and it is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. Moreover, the Chinese government may continue to retaliate against U.S. trade restrictions in ways that could impact our business, including through the imposition of additional tariffs on imports from the U.S. and/or the imposition of additional export controls affecting the export of certain items from China. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional import, export, tax, or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations. For more information, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193832">&#8212;</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193832">Enhanced trade tariffs, import restrictions, export restrictions or other trade barriers may materially harm our business</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193832">.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks could include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">interruptions to operations in China as a result of potential disease outbreaks or natural catastrophic events, which have in the past and can result in the future in business closures, transportation restrictions, import and export complications and cause shortages in the supply of raw materials or disruptions in manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">product supply disruptions and increased costs as a result of heightened exposure to changes in the policies of the Chinese government, political unrest or unstable economic conditions in China; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the nationalization or other expropriation of private enterprises or intellectual property by the Chinese government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Difficulties in this relationship may require us to take actions adverse to our business to comply with governmental restrictions on business and trade with China.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant risks associated with doing business with Taiwanese suppliers and manufacturers due to the tense relationship between Taiwan and mainland China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our consumable chips are partly manufactured by a company based in Taiwan. Our supply of consumables chips and other critical components may be materially and adversely affected by diplomatic, geopolitical, military and other developments affecting the relationship between China and Taiwan. Recent military exercises in the Taiwan Strait have contributed to geopolitical uncertainty regarding the future of the relationship between China and Taiwan. Current or future diplomatic, geopolitical, military or other tensions between China and Taiwan, including trade disputes, may lead to circumstances that negatively affect the availability of such consumable chips and other critical components to us, which could limit or prohibit our ability to manufacture consumable chips and other critical components or lead to an increase in our supply costs if we cannot find a similar cost alternative supplier, which could materially and adversely impact our business, operations, prospects, financial condition and results, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span id="i8f6c895010734eacbbfa7762111ecdf4_193518"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products, particularly our sequencing instruments, are subject to significant seasonality due to several factors, including the procurement and budgeting cycles of many of our customers, especially government-funded customers, which often coincide with government fiscal year ends and significant holidays disrupting business and sales activities in key markets. These factors have contributed, and in the future may contribute, to substantial fluctuations in our quarterly operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any given period can also be impacted by numerous other factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">market acceptance for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract new customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the length of our sales cycles, as discussed above;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to achieve economies of scale and other manufacturing efficiencies at the rate we anticipate;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-60"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">publications of studies by us, our competitors or third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the timing and success of new product introductions by us or our competitors or other changes in the competitive dynamics of our industry, such as consolidation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the amount and timing of our costs and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in our pricing policies or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">general economic, industry and market conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the regulatory environment in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">expenses associated with warranty obligations or unforeseen product quality issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the hiring, training, and retention of key employees, including our ability to grow our sales organization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">litigation or other claims against us for intellectual property infringement or otherwise;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to obtain additional financing as necessary; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes or trends in new technologies and industry standards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, it is possible that in some quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our common stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance. Additionally, any bankruptcy of a customer or other party with whom we do business, or the failure of any such party to make payments when due, or any breach or default by any such party, or the loss of any significant partnerships, could impact our revenue recognition or result in material losses to us, which may have a material adverse impact on our business. Seasonal or cyclical variations in our sales have in the past, and may in the future, become more or less pronounced over time, and have in the past materially affected, and may in the future materially affect, our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to substantial limitations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (&#8220;NOLs&#8221;) and other pre-change tax attributes, such as research and development credits, to offset its post-change taxable income or tax liability. An &#8220;ownership change&#8221; is generally defined as a greater than 50% change (by value) in a corporation&#8217;s equity ownership by &#8220;5 percent shareholders&#8221; over a rolling three-year period. We believe that we have had one or more ownership changes, and as a result our existing NOLs are currently subject to limitation. Future changes in our stock ownership could result in additional ownership changes, including potentially material changes, under Sections 382 and 383. Further, California has enacted legislation that limits the use of state NOLs for tax years beginning on or after January 1, 2024 and before January 1, 2027. Other limitations may also apply under state tax law. As a result of this legislation or other unforeseen reasons, we may not be able to utilize some or all of our NOLs even if we attain profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law and differences in interpretation of tax laws and regulations could adversely impact our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in multiple jurisdictions and are subject to tax laws and regulations of the U.S. federal, state and local and non-U.S. governments. Tax laws, regulations and administrative practices in these jurisdictions may be subject to significant changes, with or without advance notice.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws, regulations or rulings, changes in interpretations of existing laws and regulations or changes in accounting principles could negatively and materially affect our financial position, cash flows, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-61"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our facilities in California are located near earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in California are located near earthquake fault zones and are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to secure patent or other intellectual property protection for our products and improvements to our products may reduce our ability to maintain any technological or competitive advantage over our current and potential competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to protect and enforce our intellectual property rights is uncertain and depends on complex legal and factual questions. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our licensors might not have been the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">it is possible that neither our pending patent applications nor the pending patent applications of our licensors will result in issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the scope of the patent protection we or our licensors obtain may not be sufficiently broad to prevent others from practicing our technologies, developing competing products, designing around our patented technologies or independently developing similar or alternative technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our and our licensors&#8217; patent applications or patents have been, are and may in the future be, subject to interference, opposition or similar administrative proceedings, which could result in those patent applications failing to issue as patents, those patents being held invalid or the scope of those patents being substantially reduced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our enforcement of patents and proprietary rights in other countries may be problematic or unpredictable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our partners may not adequately protect our trade secrets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we may not develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the patents of others may limit our freedom to operate and prevent us from commercializing our technology in accordance with our plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events could impair our ability to operate without infringing upon the proprietary rights of others or prevent us from establishing or maintaining a competitive advantage over our competitors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-62"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variability in intellectual property laws may adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property laws, and patent laws and regulations in particular, have been subject to significant variability either through administrative or legislative changes to such laws or regulations or changes or differences in judicial interpretation, and it is expected that such variability will continue to occur. Additionally, intellectual property laws and regulations differ by country. Variations in the patent laws and regulations or in interpretations of patent laws and regulations in the United States and other countries may diminish the value of our intellectual property and may change the impact of third-party intellectual property on us. Accordingly, we cannot predict the scope of the patents that may be granted to us with certainty, the extent to which we will be able to enforce our patents against third parties or the extent to which third parties may be able to enforce their patents against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and changes to the rights we have licensed may adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license from third parties some of the intellectual property that is important to our business. If the third parties who license intellectual property to us fail to maintain the intellectual property that we have licensed, or lose rights to that intellectual property, the rights we have licensed may be reduced or eliminated, which would eliminate barriers against our competition. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, or could subject us to claims of intellectual property infringement or contract breach in litigation or other administrative proceedings that could result in damage awards against us and injunctions that could prohibit us from selling our products. In addition, some of our licenses from third parties limit the field in which we can use the licensed technology. Therefore, for us to use such licensed technology in potential future applications that are outside the licensed field of use, we may be required to negotiate new licenses with our licensors or expand our rights under our existing licenses. We cannot be certain that we will be able to obtain such licenses or expanded rights on reasonable terms or at all. In the event a dispute with our licensors were to occur, our licensors may seek to renegotiate the terms of our licenses, increase the royalty rates that we pay to obtain and maintain those licenses, limit the field or scope of the licenses, or terminate the license agreements. In addition, we have limited rights to participate in the prosecution and enforcement of the patents and patent applications that we have licensed. If we fail to meet our obligations under these licenses, or if we have a dispute regarding the terms of the licenses, these third parties could terminate the licenses, which could subject us to claims of intellectual property infringement. As a result, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. Further, because of the rapid pace of technological change in our industry, we may need to rely on key technologies developed or licensed by third parties, and we may not be able to obtain licenses and technologies from these third parties at all or on reasonable terms. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-63"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The measures that we use to protect the security of and enforce our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we also rely upon trademarks, trade secrets, copyrights, and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented, or misappropriated. In addition, we attempt to protect our intellectual property and proprietary information by requiring our employees and consultants to enter into confidentiality and assignment of inventions agreements, and by entering into confidentiality agreements with our third-party development, manufacturing, sales, and distribution partners, who may also acquire, develop and/or commercialize alternative or competing products or provide services to our competitors. For example, Roche had certain access to our trade secrets and other proprietary information pursuant to an agreement we had entered into with Roche, subject to the confidentiality provisions thereof (certain of which provisions survive the termination of the agreement); however, Roche is developing potentially competing sequencing products. There can be no assurance that our measures have provided or will provide adequate protection for our intellectual property and proprietary information. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and other proprietary information may be disclosed to others, or others may gain access to or disclose our trade secrets and other proprietary information. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. Additionally, others may independently develop proprietary information and techniques that are substantially equivalent to ours. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property may be subject to challenges in the United States or foreign jurisdictions that could adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending, issued and granted U.S. and foreign patents and patent applications have been, are and may in the future be, subject to challenges by ONT Ltd., Oxford Nanopore Technologies, Inc. ("ONT Inc.") and Metrichor, Ltd. (&#8220;Metrichor&#8221; and, together with ONT Ltd. and ONT Inc., &#8220;ONT&#8221;) in addition to other parties asserting prior invention by others or invalidity on various grounds, through proceedings, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interferences</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, reexaminations, or opposition proceedings. Addressing these challenges to our intellectual property has been, and any future challenges can be, costly and distract management&#8217;s attention and resources. For example, we previously incurred significant legal expenses to litigate and settle a complaint seeking review of a patent interference decision of the U.S. Patent and Trademark Office. Additionally, ONT previously requested that the U.S. Patent and Trademark Office institute </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews of certain patents that we have asserted against ONT Inc. and ONT Ltd. in litigation proceedings for patent infringement. While none of the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews requested by ONT were instituted by the U.S. Patent and Trademark Office, challenges of this nature before the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) in the future could result in determinations that our patents or pending patent applications are unpatentable to us, or are invalidated or unenforceable in whole or in part and could require us to expend significant time, funds, and other resources in litigating such challenges. Accordingly, adverse rulings in such proceedings could negatively impact the scope of our intellectual property protection for our products and technology and could materially and adversely affect our business. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we hold now or in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such products. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-64"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our technology is subject to &#8220;march-in&#8221; rights by the U.S. government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patented technology was developed with U.S. federal government funding. When new technologies are </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that such action is necessary to (i) achieve practical application of the U.S. government-funded technology, (ii) alleviate health or safety needs, (iii) meet requirements of federal regulations, or (iv) give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and such government funding must be disclosed in any resulting patent applications. Furthermore, our rights in such inventions are subject to government license rights and foreign manufacturing restrictions. The U.S. government has generally denied requests to exercise its march-in rights, even to provide access to potentially life-saving medications; however, if the U.S. government were to exercise its march-in rights to our patent technologies funded by the U.S. government, particularly for the benefit of one of more of our competitors, that may have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings to enforce our intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property rights involve complex factual, scientific, and legal questions. We operate in an industry characterized by significant intellectual property litigation. Even though we may believe that we have a valid patent on a particular technology, other companies have from time to time taken, and may in the future take, actions that we believe violate our patent rights. For example, we were previously involved in legal proceedings with ONT and Harvard University in several United States and European jurisdictions. We have in the past received adverse rulings against us with respect to our complaint with the United States International Trade Commission for one of these proceedings. Legal actions to enforce our patent rights have been, and will continue to be, expensive, and may divert significant management time and resources. Adverse parties from previous legal actions have brought, and they and others may in the future bring, claims against us and/or our intellectual property. Litigation is a significant ongoing expense, recognized in sales, general and administrative expense, with an uncertain outcome, and has been, and may in the future be, a material expense for us. Our enforcement actions may not be successful, have given rise to legal claims against us and could result in some of our intellectual property rights being determined to be invalid or not enforceable. Furthermore, an adverse determination or judgement could lead to an award of damages against us, or the issuance of an injunction against us or our products that could prevent us from selling any products found to be infringing the intellectual property rights of another party.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-65"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or misappropriate their intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are based on complex, rapidly developing technologies. We may not be aware of issued or previously filed patent applications that belong to third parties that mature into issued patents that cover some aspect of our products or their use. In addition, because patent litigation is complex and the outcome inherently uncertain, our belief that our products do not </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringe</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third-party patents of which we are aware or that such third-party patents are invalid and unenforceable may be determined to be incorrect. As a result, third parties have claimed, and may in the future claim, that we infringe their patent rights and have filed, and may in the future file lawsuits or engage in other proceedings against us to enforce their patent rights. For example, we are involved in legal proceedings for alleged patent infringement and related matters in the United States with Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;), Take2 Technologies, Ltd., and the Chinese University of Hong Kong. In addition, ONT Ltd. and Harvard University have, in the past, filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany for patent infringement, and PGI has filed claims against us in the U.S. District Court for the District of Delaware and in the Wuhan People&#8217;s Court in China. We are aware of other issued patents and patent applications owned by third parties that could be construed to read on our products, and related maintenance and support services. Although we do not believe that our products or services infringe any valid issued patents, the third-party owners of these patents and applications may in the future claim that we infringe their patent rights and file lawsuits against us. In addition, as we enter new markets, our competitors and other third parties may claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to further develop or commercialize products or services and could result in the award of substantial damages against us. Patent litigation between competitors in our industry is common. Additionally, we have certain obligations to many of our customers and suppliers to indemnify and defend them against claims by third parties that our products or their use infringe any intellectual property of these third parties. In defending ourselves against any of these claims, we have in the past incurred, and could in the future incur, to defend ourselves or our customers, substantial costs, and the attention of our management and technical personnel could be diverted. For example, we previously incurred significant legal expenses to litigate and settle a complaint alleging patent infringement. Even if we have an agreement that indemnifies us against such costs, the indemnifying party may be unable to uphold its contractual obligations. To avoid or settle legal claims, it may be necessary or desirable in the future to obtain licenses relating to one or more products or relating to current or future technologies, which could negatively affect our gross margins. We may not be able to obtain these licenses on commercially reasonable terms, or at all. We may be unable to modify our products so that they do not infringe the intellectual property rights of third parties. In some situations, the results of litigation or settlement of claims may require us to cease allegedly infringing activities which could prevent us from selling some or all of our products. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may from time to time have access or be alleged to have access to confidential or proprietary information of others, which, though not patented, may be protected as trade secrets. Others could bring claims against us asserting that we improperly used their confidential or proprietary information, or that we misappropriated their technologies and incorporated those technologies into our products. A determination that we illegally used the confidential or proprietary information or misappropriated technologies of others in our products could result in us paying substantial damage awards or being prevented from further developing or selling some or all of our products, which could materially and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-66"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of &#8220;open source&#8221; software could adversely affect our ability to sell our products and subject us to possible litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the products or technologies developed and/or distributed by us incorporate &#8220;open source&#8221; software, and we may incorporate open source software into other products or technologies in the future. Some open source software licenses require that we disclose the source code for any modifications to such open source software that we make and distribute to one or more third parties, and that we license the source code for such modifications to third parties, including our competitors, at no cost. We monitor the use of open source software in our products to avoid uses in a manner that would require us to disclose or grant licenses under our source code that we wish to maintain as proprietary; however, there can be no assurance that such efforts have been or will be successful. In some circumstances, distribution of our software that includes or is linked with open source software could require that we disclose and license some or all of our proprietary source code in that software, which could include permitting the use of such software and source code at no cost to the user. Open source license terms are often ambiguous and there is little legal precedent governing the interpretation of these licenses. Successful claims made by the licensors of open source software that we have violated the terms of these licenses could result in unanticipated obligations, including being subject to significant damages, being enjoined from distributing products that incorporate open source software and being required to make available our proprietary source code pursuant to an open source license, which could substantially help our competitors develop products that are similar to or better than ours or otherwise materially and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Regulation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are, and may become, subject to governmental regulations that may impose burdens on our operations, and the markets for our products may be narrowed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject, both directly and indirectly, to the adverse impact of government regulation of our operations and markets. For example, export of our instruments may be subject to strict regulatory control in a number of jurisdictions, and we could experience disruption in our supply chain as a result of certain geopolitical events and conflicts and any related political or economic responses and counter-responses or otherwise by various global actors. On January 15, 2025, the United States Department of Commerce&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) issued an Interim Final Rule (&#8220;IFR&#8221;) implementing targeted export controls on certain analytical instruments that are highly suitable for generating large, detailed biological datasets based upon the potential to exploit these techniques for asymmetric military advantage. While the Company&#8217;s products would not be included under the current IFR, future BIS or other government regulations could potentially apply to our products and/or negatively impact our ability to export those products to certain countries and markets. Additionally, restrictions on the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing to China continue to increase in both product and country scope and may impact our ability to provide products to customers or distributors worldwide. We have expanded and are continuing to expand the international jurisdictions into which we supply products, which increases the risks surrounding governmental regulations relating to our business. The need to or failure to satisfy export control criteria or to obtain necessary clearances could delay or prevent shipment of products, which could materially and adversely affect our revenue and profitability. Moreover, the life sciences industry, which is expected to continue to be one of the primary markets for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which may narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulations that may adversely affect our market opportunities. Additionally, if ethical and other concerns surrounding the use of genetic information, diagnostics or therapies become widespread, there may be less demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life science industry in particular. Failure to comply with government regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenue and the cost of operating our business. In addition, changes to laws and government regulations could cause a material adverse effect on our business as we will need to adapt our business to comply with such changes. For example, a governmental prohibition on the use of human </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostics or other regulations that negatively impact the research and development activities of our customers would adversely impact our commercialization of products on which we have expended significant research and development resources, which would in turn have a material adverse impact on our business and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-67"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products could become subject to government regulation as medical devices by the U.S. Food and Drug Administration or other domestic and international regulatory agencies even if we do not elect to seek regulatory clearance or approval to market our products for diagnostic purposes, which could increase our costs and impede or delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are currently labeled and promoted as research use only (&#8220;RUO&#8221;) products and are not currently designed, or intended to be used, for clinical diagnostic tests or as medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject to regulation by the FDA, or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products. Also, even if our products are labeled, promoted, and intended as RUO, the FDA or comparable agencies of other countries could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with the FDA&#8217;s guidance on RUO products. For example, our customers may independently elect to use our RUO labeled products in their own LDTs for clinical diagnostic use, which could subject our products to government regulation, and the regulatory clearance or approval and maintenance process for such products may be uncertain, expensive, and time-consuming.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, in 2013, the FDA issued Final Guidance &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only.&#8221; The guidance emphasizes that the FDA will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly labeled as RUO. The final guidance states that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, and other regulatory requirements if the circumstances surrounding the distribution, marketing and promotional practices indicate that the manufacturer knows its products are, or intends for its products to be, used for clinical diagnostic purposes. These circumstances may include written or verbal sales and marketing claims or links to articles regarding a product&#8217;s performance in clinical applications and a manufacturer&#8217;s provision of technical support for clinical applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against laboratories developing and offering LDTs. In May 2024, the FDA issued a final rule that phases out its enforcement discretion for LDTs, unless exempt, and amends the FDA&#8217;s regulations to make explicit that in vitro diagnostics are medical devices under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), including when the manufacturer of the diagnostic product is a laboratory. On March 31, 2025, U.S. District Court in Texas ruled that FDA exceeded its authority and vacated and set aside this LDT final rule in its entirety. We will continue to monitor this case, as well as any future lawsuits brought against the FDA, and future legislative and administration actions on our business. Additionally, in June 2024, the U.S. Supreme Court overruled the Chevron doctrine, which gave deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions of the FDA, which could undermine the FDA&#8217;s authority and lead to uncertainties in the industry. We cannot predict the full impact of this decision on our business or that of our customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the new leadership at the Department of Health and Human Services under the Trump administration, agency reorganization, departure of high-profile regulators at the FDA, layoffs due to the reduction in force initiative may impact the normal operations of federal agencies, including FDA. NIH funding cuts can impact the business operations of our customers and decrease the demand for our products. It is unclear how our industry and the businesses of our customers will be impacted by executive orders, policies and regulations implemented under the Trump administration. There is significant uncertainty in the industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future legislative or administrative actions can impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with applicable laws. Changes to the current regulatory framework could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation and enforcement by the applicable government agencies. Such laws include, without limitation, state and federal anti-kickback or anti-referral laws, healthcare fraud and abuse laws, false claims laws, privacy and security laws, Physician Payments Sunshine Act and related transparency and manufacturer reporting laws, and other laws and regulations applicable to medical device manufacturers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines our products or related applications should be subject to additional regulation as in vitro diagnostic devices based upon customers&#8217; use of our products for clinical diagnostic or therapeutic decision-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-68"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">making purposes, our ability to market and sell our products could be impeded and our business, prospects, results of operations and financial condition may be adversely affected. In addition, the FDA could consider our products to be misbranded or adulterated under the FDCA and subject to recall and/or other enforcement action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To the extent we elect to label and promote any of our products as medical devices, we would be required to obtain prior approval or clearance by the FDA or comparable foreign regulatory authority, which could take significant time and expense and could fail to result in a marketing authorization for the intended uses we believe are commercially attractive. Obtaining marketing authorization in one jurisdiction does not mean that we will be successful in obtaining marketing authorization in other jurisdictions where we conduct business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we elect to label and market our products for use as, or in the performance of, clinical diagnostics in the United States, thereby subjecting them to FDA regulation as medical devices, we would be required to obtain pre-market 510(k) clearance or pre-market approval from the FDA, unless an exception applies. It is possible, in the event we elect to submit 510(k) applications for certain of our products, that the FDA would take the position that a more burdensome pre-market application, such as a PMA or a </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> application is required for some of our products. If such applications were required, greater time and investment would be required to obtain FDA approval. Even if the FDA agreed that a 510(k) was appropriate, FDA clearance can be expensive and time consuming. It generally takes a significant amount of time to prepare a 510(k), including conducting appropriate testing on our products, and several months to years for the FDA to review a submission. Notwithstanding the effort and expense, FDA clearance or approval could be denied for some or all of our products for which we choose to market as a medical device or a clinical diagnostic device. Even if we were to seek and obtain regulatory approval or clearance, it may not be for the intended uses we request or that we believe are important or commercially attractive. There can be no assurance that future products for which we may seek pre-market clearance or approval will be approved or cleared by FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of such products. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our products. The lengthy and unpredictable pre-market clearance or approval process, as well as the unpredictability of the results of any required clinical studies, may result in our failing to obtain regulatory clearance or approval to market such products, which would significantly harm our business, results of operations, reputation, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we sought and received regulatory clearance or approval for certain of our products, we would be subject to ongoing FDA obligations and continued regulatory oversight and review, including the general controls listed above and the FDA&#8217;s Quality System Regulations for our development and manufacturing operations. In addition, we would be required to obtain a new 510(k) clearance before we could introduce subsequent material modifications or improvements to such products. We could also be subject to additional FDA post-marketing obligations for such products, any or all of which would increase our costs and divert resources away from other projects. If we sought and received regulatory clearance or approval and are not able to maintain regulatory compliance with applicable laws, we could be prohibited from marketing our products for use as, or in the performance of, clinical diagnostics and/or could be subject to enforcement actions, including warning letters and adverse publicity, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we decide to seek regulatory clearance or approval for certain of our products in countries outside of the United States or if a foreign regulatory authority determines that our products are regulated as medical devices, we would be subject to extensive medical device laws and regulations outside of the United States. Sales of such products outside the United States will likely be subject to foreign regulatory requirements, which can vary greatly from country to country. As a result, the time required to obtain clearances or approvals outside the United States may differ from that required to obtain FDA clearance or approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. In Europe, we would need to comply with the Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, which could make obtaining regulatory approvals in Europe more challenging. In addition, the FDA regulates exports of medical devices. The number and scope of these requirements are increasing. Unlike many of the other companies offering nucleic acid sequencing equipment or consumables, this is an area where we do not have expertise. We, or our other third-party sales and distribution partners, may not be able to obtain regulatory approvals in such countries or may incur significant costs in obtaining or maintaining our foreign regulatory approvals. In addition, the export by us of certain of our products, which have not yet been cleared for domestic commercial distribution, may be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-69"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to FDA or other export restrictions. Failure to comply with these regulatory requirements or obtain and maintain required approvals, clearances and certifications could impair our ability to commercialize our products for diagnostic use outside of the United States. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-top:9pt;text-align:justify"><span id="i8f6c895010734eacbbfa7762111ecdf4_193832"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced trade tariffs, import restrictions, export restrictions, or other trade barriers may materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to expand our international operations as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the United States, especially the Asia-Pacific region, as discussed above. There is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, government regulations and tariffs. Starting in September 2018, the U.S. Trade Representative (the &#8220;USTR&#8221;) enacted various tariffs ranging from 7.5% to 25% on the import of Chinese products, including non-U.S. components and materials that may be used in our products. Since that time, USTR has enacted further tariff increases on certain Chinese products, in some instances raising this additional tariff on these products to up to 100%. In February 2025, the U.S. government also enacted an additional 10% ad valorem tariff on almost all imports of Chinese-origin goods, and in March 2025, this tariff was further escalated to 20% ad valorem. An additional reciprocal 125% ad valorem tariff has been imposed by the U.S. on many Chinese-origin goods since April 2025&#8212;alongside an 10% ad valorem tariff on almost all imports from trading partners other than China, Canada, Mexico, and countries with which the U.S. does not have normal trade relations&#8212;with limited exceptions for pharmaceuticals, semiconductors, computers, and certain other imports. Additionally, China also has imposed tariffs on imports into China from the United States. These tariffs have and could continue to raise our costs. Furthermore, tariffs, trade restrictions, or trade barriers that have been, and may in the future be, placed on products such as ours by foreign governments, especially China, have raised, and could further raise, amounts paid for some or all of our products, which may result in the loss of customers and our business, and our financial condition and results of operations may be harmed. In February 2025, the Trump Administration also announced new 25% tariffs on imports from Canada and Mexico, which were temporarily suspended subject to further negotiations, and partially implemented with respect to goods not eligible for duty-free import under the U.S.-Mexico-Canada Agreement as of March 2025. U.S. tariffs of 25% have also been implemented on a wider array of imported steel and aluminum items as of March 2025, on automobiles as of April 2025 and on automobile components as of May 2025. Additional reciprocal tariffs on a wide range of U.S. trading partners were briefly implemented in April 2025 and have been temporarily suspended through July 2025. Additional tariffs may be forthcoming, including tariffs on items that have been the subject of recent U.S. executive orders and U.S. government tariff investigations, including (i) critical minerals and derivative products thereof (e.g., semiconductor wafers, semiconductors, and semiconductor manufacturing equipment) and (ii) pharmaceuticals and pharmaceutical products. Further tariffs may be imposed that could cover imports of additional components and materials used in our products and our business may be adversely impacted by these measures or by retaliatory trade measures taken by China, Canada, the EU, or other countries, including restricted access to components or materials used in our products or increased amounts that must be paid for our products, which could materially harm our business, financial condition, and results of operations. We may be unable to make changes in our supply chain quickly enough to avoid the impact of new or potential tariffs, or to do so on commercially reasonable terms. Uncertainty regarding the scope and amount of potential additional tariffs may also result in disruptions in our supply chain, particularly if such changes in applicable or potential tariffs makes current or planned production unprofitable. In addition, these tariff actions may also indirectly affect our business through impacts on our customers, who may be directly affected by some or all of these tariff actions, or indirectly affected by macroeconomic effects resulting from these or other tariff related actions, including potential risks associated with inflation or economic recession.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-70"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to U.S. export control laws and regulations, including the Export Administration Regulations administered by the U.S. Department of Commerce&#8217;s Bureau of Industry and Security. Under these laws and regulations, exports of our products as well as the underlying technology may require export authorization, including by license, a license exception, or other appropriate government authorizations. Furthermore, our products and services are subject to U.S. economic and trade sanctions laws and regulations administered by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control that prohibit the provision of services and the export of hardware, software, and technology to embargoed jurisdictions or sanctioned parties without the required export authorizations. The U.S. government has continued to increase controls imposed in 2022 restricting the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing. In 2023 and 2024, the U.S. government expanded the list of advanced integrated circuits subject to heightened export controls, including certain hardware containing these specified integrated circuits, expanded the list of destinations requiring export authorization for such items, and added new restrictions based on the headquarters location of the parties involved. Regulations further expanding the controls to impose a worldwide licensing requirement on certain integrated circuits and computing resources that are used for training of AI models are currently in effect and have a scheduled compliance date of May 15, 2025, after which time companies may be subject to further enforcement. In many cases, these licenses are subject to a policy of denial and will not be issued. The U.S. government also continues to add additional entities in China and other countries to restricted party lists impacting the ability of U.S. companies to provide items to these entities. These existing and future laws and regulations may impact our ability to export certain products to customers or distributors in China or other locations and restrict our ability to use certain integrated circuits in our products. Should we violate such existing or similar laws or regulations, we may be subject to substantial monetary fines or suffer reputational damage and other penalties that could negatively impact our business. If we need to obtain any necessary export licenses or other authorizations for a particular sale, the process may be time-consuming and may result in the delay or loss of opportunities to sell our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in November 2018, the U.S. Commerce Department&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) released an advance notice of proposed rulemaking to control the export of emerging technologies. This notice included &#8220;[b]iotechnology, including nanobiology; synthetic biology; genomic and genetic engineering; or neurotech&#8221; as possible areas of increased export controls. Since 2018, the U.S. government has continued to provide updated lists of emerging technologies subject to national security consents. These lists continue to include biotechnologies including &#8220;[g]enome and protein engineering including design tools&#8221; and &#8220;[b]iomanufacturing and bioprocessing technologies.&#8221; Therefore, it is possible that our ability to export our products to customers or distributors may be further restricted in the future. For example, on January 15, 2025, BIS issued an IFR implementing targeted export controls on certain analytical instruments that are highly suitable for generating large, detailed biological datasets based upon the potential to exploit these techniques for asymmetric military advantage. While the Company&#8217;s products would not be included under the current IFR, future BIS or other government regulations could potentially apply to our products and/or negatively impact our ability to export those products to certain countries and markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chinese government has introduced retaliatory measures in response to existing or future U.S. export controls, tariffs and other trade restrictions and it is possible that the Chinese or U.S. governments will implement additional retaliatory measures which could impact our business. For example, in December 2024, China announced a new export control regime that includes stringent export controls on exports of germanium and gallium, and in February 2025 implemented additional export controls regulating the export of resources including tungsten, tellurium, bismuth, indium, and molybdenum. Export controls on these and other rare earth materials further increased in retaliation to the increase in U.S. tariffs on products of Chinese origin in April 2025, which has resulted in a pause of the export of these materials from China. It also is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. The continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional tax or other regulatory changes in the future. Any such changes could, directly or indirectly, adversely impact our financial results and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-71"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international business could expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engaging in international business inherently involves a number of difficulties and risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">required compliance with existing and changing foreign regulatory requirements and laws that are or may be applicable to our business in the future, such as the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), the UK General Data Protection Regulation and other data privacy requirements, labor and employment regulations, anti-competition regulations, the U.K. Bribery Act of 2010 and other anti-corruption laws, regulations relating to the use of certain hazardous substances or chemicals in commercial products, and require the collection, reuse, and recycling of waste from products we manufacture;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and trade and economic sanctions and other regulations established by the Office of Foreign Asset Control;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">export requirements and import or trade restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">laws and business practices favoring local companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">restrictions on both inbound and outbound cross-border investment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">foreign currency exchange, longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, manufacturing, research and development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we may sell our products including as a result of ongoing geopolitical tensions related to the political uncertainty and military actions associated with the war in Ukraine, resulting sanctions imposed by the U.S. and other countries, and retaliatory actions taken by Russia in response to such sanctions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties and costs of staffing and managing foreign operations; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties protecting, maintaining, enforcing, or procuring intellectual property rights and defending against intellectual property claims under the law and judicial systems of other countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of these risks occurs, it could require us to dedicate significant resources to remedy such occurrence, and if we are unsuccessful in finding a solution, our financial results will suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations involve the use of hazardous materials, and we must comply with environmental, health and safety laws, which can be expensive and may adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities involve the use of hazardous materials, including chemicals and biological materials, and some of our products include hazardous materials. Accordingly, we are subject to federal, state, local and foreign laws, regulations, and permits relating to environmental, health and safety matters, including, among others, those governing the use, storage, handling, exposure to and disposal of hazardous materials and wastes, the health and safety of our employees, and the shipment, labeling, collection, recycling, treatment, and disposal of products containing hazardous materials. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. For example, under certain circumstances and under certain environmental laws, we could be held liable for costs relating to contamination at our or our predecessors&#8217; past or present facilities and at third-party waste disposal sites. We could also be held liable for damages arising out of human exposure to hazardous materials. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure or other causes. The failure to comply with past, present or future laws could result in the imposition of substantial fines and penalties, remediation costs, property damage and personal injury claims, investigations, the suspension of production or product sales, loss of permits or a cessation of operations. Any of these events could harm our business, operating results, and financial condition. We also expect that our operations will be affected by new environmental, health and safety laws and regulations on an ongoing basis, or more stringent enforcement of existing laws and regulations. New laws or changes to existing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-72"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laws may result in additional costs and may increase penalties associated with violations or require us to change the content of our products or how we manufacture them, which could have a material adverse effect on our business, operating results, and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal, privacy, data protection and social concerns or governmental restrictions surrounding the use of genetic information could reduce demand for our technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may be used to provide genetic information about humans, agricultural crops and other living organisms. The information obtained from our products could be used in a variety of applications which may have underlying ethical, legal, privacy, data protection and social concerns, including the genetic engineering or modification of agricultural products or testing for genetic predisposition for certain medical conditions. Governmental authorities could, for safety, social or other purposes, call for limits on or regulation of the use of genetic testing, and may consider or adopt such regulations or other restrictions. Such concerns or governmental restrictions could limit the use of our products or be costly and burdensome to comply with, and actual or perceived violations of any such restrictions may lead to the imposition of substantial fines and penalties, remediation costs, claims and litigation, regulatory investigations and proceedings, and other liability, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations related to conflict minerals has caused us to incur, and will continue to cause us to incur, additional expenses and could limit the supply and increase the costs of certain materials used in the manufacture of our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 that require us to conduct diligence and report on whether or not our products contain conflict minerals. These requirements could adversely affect the sourcing, availability and pricing of the materials used in the manufacture of components used in our products. Furthermore, the complex nature of our products requires components and materials that may be available only from a limited number of sources and, in some cases, from only a single source. We have incurred, and will continue to incur, additional costs to comply with the disclosure requirements, including costs related to conducting diligence procedures to determine the sources of conflict minerals that may be used or necessary to the production of our products and, if applicable, potential changes to components, processes, or sources of supply as a consequence of such verification activities. We may face reputational harm if we determine that certain of our products contain minerals that are not determined to be conflict free or if we are unable to alter our processes or sources of supply to avoid using such materials. In such circumstances, the reputational harm could materially and adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Owning Our Common Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been, is, and may continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is highly volatile, and we expect it to continue to be volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">actual or anticipated fluctuations in our financial condition and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements of new products, technological innovations or strategic partnerships by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements by us, our customers, partners, or suppliers relating directly or indirectly to our products, services or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">overall conditions in our industry and market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">addition or loss of significant customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in laws or regulations applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-73"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">competition from existing products or new products that may emerge;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">issuance of new or updated research or reports by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">sales of our common stock by us or our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">reports, guidance and ratings issued by securities or industry analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">operating results below the expectations of securities analysts or investors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">general economic and market conditions, which could be impacted by various events including health epidemics or pandemics, interest rate fluctuations, increases in fuel prices, foreign currency fluctuations, changing international trade policies, acts of terrorism, hostilities or the perception that hostilities may be imminent, military conflict and acts of war, including further political uncertainty and military actions associated with the war in Ukraine and the related response, including sanctions or other restrictive actions, by the United States and/or other countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the forgoing occurs, it would cause our stock price or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations; these fluctuations have been, and may continue to be, exacerbated by current macroeconomic trends and geopolitical events. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been a party to this type of litigation in the past and may be the target of this type of litigation again in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could reduce the market price that our common stock might otherwise attain and may dilute your voting power and your ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price of our common stock and may make it more difficult for existing stockholders to sell their common stock at a time and price that they deem appropriate and may dilute their voting power and ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our stockholders sell, or indicate an intent to sell, a large number of shares of our common stock in the public market, it could cause our stock price to fall, particularly if such sales occur over a short period of time (for example, following delivery of shares upon achievement of milestones in our acquisition agreements). We may also issue shares of common stock or securities convertible into our common stock in connection with a financing, acquisition, our equity incentive plans, or otherwise. Any such issuances would result in dilution to our existing stockholders and the market price of our common stock may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership by our principal stockholders may result in control by such stockholders of the composition of our board of directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing principal stockholders, holders of Notes, executive officers, directors, and their affiliates beneficially own, or following conversion of the Notes could own, a significant number of our outstanding shares of common stock. In addition, such parties may acquire additional control by purchasing stock that we issue in connection with our future fundraising efforts. These parties may now and in the future be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors. This control could have the effect of delaying or preventing a change of control of our company or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-74"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of undesignated preferred stock and up to approximately 1,000,000,000 shares of authorized but unissued shares of common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">specify that special meetings of our stockholders can be called only by our board of directors, the Chair of the Board, the Chief Executive Officer or the President;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">establish advance notice procedures for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms (until our board of directors is fully declassified beginning with the 2027 annual meeting of stockholders);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide that our directors may be removed only for cause; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain stockholder litigation matters, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, each of which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, stockholders, or employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf&#894; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, stockholders, officers, or other employees to us or our stockholders&#894; (iii) any action arising pursuant to any provision of the Delaware General Corporation Law; (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws&#894; or (v) any action asserting a claim governed by the internal affairs doctrine, except as to each of (i) through (v) above, for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws also provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-75"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Act including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing, holding or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to the foregoing bylaw provisions. Although we believe these exclusive forum provisions benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, stockholders, officers or other employees, which may discourage lawsuits with respect to such claims against us and our current and former directors, stockholders, officers or other employees. In addition, a stockholder that is unable to bring a claim in the judicial forum of its choosing may be required to incur additional costs in the pursuit of actions which are subject to the exclusive forum provisions described above. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds either exclusive forum provision contained in our bylaws to be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our large number of authorized but unissued shares of common stock may potentially dilute existing stockholders&#8217; stockholdings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of authorized but unissued shares of common stock. Our board of directors may issue shares of common stock from this authorized but unissued pool from time to time without stockholder approval, resulting in the dilution of our existing stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash or to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had outstanding approximately $200.0&#160;million aggregate principal amount of our 2029 Notes and $441.0&#160;million aggregate principal amount of our 2030 Notes. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2029 Notes and the 2030 Notes are collectively referred to as the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of each series of Notes will have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a fundamental change before the maturity date at a repurchase price equal to 100% of the principal amount of the Notes of the applicable series to be repurchased, plus unpaid interest to, but excluding, the applicable maturity date. In addition, upon conversion of the Notes of a series, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to settle a portion or all of our conversion obligation in cash in respect of the Notes being converted. Moreover, we will be required to repay the Notes of the applicable series in cash at the applicable maturity unless earlier converted, redeemed, or repurchased. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or pay cash with respect to Notes being converted or at their maturity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-76"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to repurchase the Notes or to pay cash upon conversions of Notes or at the applicable maturity may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase Notes of a series at a time when the repurchase is required by the applicable indenture or to pay cash upon conversions such Notes or at the applicable maturity as required by the applicable indenture would constitute a default under such indenture. A default under either indenture or the occurrence of a fundamental change under either indenture itself could also lead to a default under agreements governing our future indebtedness. Moreover, the occurrence of a fundamental change under either indenture could constitute an event of default under any such agreement. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness or to pay cash amounts due upon conversion, upon required repurchase or at maturity of the applicable series of Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Side Letter to our 2029 Notes imposes operating restrictions on us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2024, in connection with the issuance of the 2029 Notes, the Company and SB Northstar LP (&#8220;SBN&#8221;) entered into a letter agreement (the &#8220;Letter Agreement&#8221;) pursuant to which the Company and SBN agreed that, for so long as SBN and its affiliates hold at least $180 million aggregate principal amount of the 2029 Notes, the Company and its subsidiaries are subject to certain negative covenants that restrict the Company&#8217;s and its subsidiaries&#8217; ability to incur additional indebtedness and create liens, in each case, subject to the exceptions set forth in the Letter Agreement, including exceptions which permit the Company to incur up to $75 million in aggregate principal amount of secured indebtedness pursuant to Credit Facilities (as defined in the Letter Agreement).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Letter Agreement restricts the ability of the Company and its subsidiaries from guaranteeing any indebtedness or incurring certain indebtedness outside of the ordinary course of business unless, in each case, the Company and its subsidiaries concurrently provide a guarantee of the Company&#8217;s obligations under the 2029 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These covenants may adversely affect our ability to finance our operations, meet or otherwise address our capital needs, pursue business opportunities or react to market conditions, or otherwise restrict our activities or business plans. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A breach of any of the covenants under the Letter Agreement could result in an event of default under the 2029 Notes. As of March&#160;31, 2025, we were in compliance with all covenants under the Letter Agreement. However, if an event of default occurs, SBN could accelerate our obligations under the 2029 Notes. Any such acceleration could result in an event of default under our other indebtedness, including the 2030 Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the Notes are converted, it may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of either series of Notes are entitled to convert their respective series of Notes at any time at their option. If one or more holders elect to convert the Notes of the applicable series, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. In addition, issuances of shares of common stock upon conversion of our Notes could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. The existence of the Notes may encourage short selling by market participants because the conversion of the Notes could depress the price of our common stock. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-77"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General Risk Factors</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General conditions in the global economy and in the global financial markets could adversely affect our results of operations, and the overall demand for nucleic acid sequencing products may be particularly vulnerable to unfavorable economic conditions. A global financial crisis, inflation or a global or regional political disruption, as well as acts of terrorism, hostilities, military conflict and acts of war, including any further escalation of the conflict in the Middle East and the war in Ukraine, as well as the related responses, could cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our product and services. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business. For more information on impairment considerations, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193035">&#8212;The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expand</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193035">ing</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i8f6c895010734eacbbfa7762111ecdf4_193035"> into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control. Any failure to deliver products to our customers in a safe and timely manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these carriers are unable to deliver our products, the delivery of our products by our customers may be delayed, which could harm our business and financial results. The failure to deliver our products in a safe and timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Doing business internationally creates operational and financial risks for our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently conduct operations in various countries and jurisdictions, and continue to expand to new international jurisdictions as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the U.S. We sell directly and through distribution partners throughout Europe, the Asia-Pacific region, Mexico, Brazil, and South Africa and have a significant portion of our sales and customer support personnel in Europe and the Asia-Pacific region. As a result, we or our distribution partners may be subject to additional regulations and increased diversion of management time and efforts. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be materially and adversely affected and failure to comply with laws and regulations applicable to business operations in foreign jurisdictions may also subject us to significant liabilities and other penalties. International operations entail a variety of other risks, including, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">challenges in staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potentially longer sales cycles and more time required to engage and educate customers on the benefits of our platform outside of the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the potential need for localized software and documentation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property and contract rights abroad;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">defending against intellectual property claims in other countries;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-78"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">restrictions on both inbound and outbound cross-border investment, including enhanced oversight by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) and substantial restrictions on investment from China;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">U.S. and foreign government trade restrictions, including those which may impose restrictions on the importation, exportation, re-exportation, sale, shipment or other transfer of programming, technology, components, and/or services to foreign persons;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes, sanctions, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, which may be imposed on products such as ours, the scope and duration of which, if implemented, remains uncertain;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deterioration of political relations among, between, and within the U.S., Russia, China, Japan, Korea, Mexico, Canada, the United Kingdom (&#8220;U.K.&#8221;), and the European Union ("E.U."), which could have a material adverse effect on our sales and operations in these countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in social, political, and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions into which we sell our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">fluctuations in currency exchange rates and the related effect on our results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increased financial accounting and reporting burdens and complexities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential limits to travel as a result of epidemics or pandemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruptions to global trade due to disease outbreaks or conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential increases on tariffs or restrictions on trade generally; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">significant taxes or other burdens of complying with a variety of foreign laws and regulations, including laws and regulations relating to privacy and data protection such as the E.U. General Data Protection Regulation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conducting our international operations, we are subject to U.S. laws relating to our international activities, such as the Foreign Corrupt Practices Act of 1977, as well as foreign laws relating to our activities in other countries, such as the United Kingdom Bribery Act of 2010. Additionally, the inclusion of one of our foreign customers on any applicable U.S. Government sanctioned persons list, including but not limited to the U.S. Department of Commerce&#8217;s List of Denied Persons and the U.S. Department of Treasury&#8217;s List of Specially Designated Nationals and Blocked Persons List, could be material to our earnings. Failure to comply with these laws may subject us to claims or financial and/or other penalties in the United States and/or foreign countries that could materially and adversely impact our operations or financial condition. These risks have become increasingly prevalent as we have expanded our sales into countries that are generally recognized as having a higher risk of corruption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to the current global economic environment, which could delay or prevent our customers from purchasing our products, which could in turn harm our business, financial condition, and results of operations. The state of the global economy continues to be uncertain. The current global economic conditions and uncertain credit markets and concerns regarding the availability of credit pose a risk that could impact customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers, and creditors, including financial institutions. If the current global economic environment deteriorates, our business could be negatively affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-79"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers&#8217; local currencies could make our products more expensive, impacting our ability to compete or as a result of financial or other instability in such locations which could result in decreased sales of our products. Our costs of materials from international suppliers may also increase as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Such actions may materially and adversely impact our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of complex foreign and U.S. laws and regulations could result in fines and penalties, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially affect our brand, our international growth efforts, our ability to attract and retain employees, our business, and our operating results. Even if we implement policies or procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our distribution partners, our employees, contractors, or agents will not violate our policies and subject us to potential claims or penalties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business and our stock price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Operating as a public company requires sufficient resources within the accounting and finance functions in order to produce timely financial information, ensure the level of segregation of duties, and maintain adequate internal control over financial reporting customary for a U.S. public company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, we perform periodic evaluations of our internal control over financial reporting. While we have in the past performed this evaluation and concluded that our internal control over financial reporting was operating effectively, there can be no assurance that in the future material weaknesses or significant deficiencies will not exist or otherwise be discovered. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by changes in the United States political environment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products depend on the availability of genetic data and its utilization in clinical research by academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, CROs, pharmaceutical companies, and agricultural companies. As a result, changes in the regulatory environment affecting such institutions could adversely affect our business or results of operations. For example, reduced allocations to government agencies that fund research and development activities, such as the recent announcements regarding NIH funding involving a cap on the institute&#8217;s indirect funding rates, or targeted cancellations by the U.S. federal government of certain grants or contracts may significantly impact the markets in which we compete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-80"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant ongoing uncertainty with respect to potential legislation, regulation and government policy at the federal level, as well as the state and local levels. Specific legislative and regulatory proposals discussed or implemented that might materially impact us include, but are not limited to, changes to spending priorities and potential reductions in research funding. Uncertainty about U.S. government funding has posed, and may continue to pose, a risk as customers may choose to postpone or reduce spending in response to actual or anticipated restraints on funding. To the extent changes in the political environment have a negative impact on us or on our markets, our business, results of operation and financial condition could be materially and adversely impacted in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruption of critical information technology systems or material breaches in the security of our systems could harm our business, customer relations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information technology (&#8220;IT&#8221;) helps us to operate efficiently, interface with customers, maintain financial accuracy and efficiently and accurately produce our financial statements. IT systems are used extensively in virtually all aspects of our business, including in our products, sales forecast, order fulfillment and billing, customer service, logistics, and management of data from running samples on our products. Our success depends, in part, on the continued and uninterrupted performance of our IT systems. Our IT systems, including those used in our products, may be vulnerable to damage from a variety of sources, including telecommunications or network failures, power loss, natural disasters, human acts, computer viruses, ransomware, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Furthermore, there may be a heightened risk of potential cybersecurity incidents and security breaches to which we could be vulnerable by state-sponsored or affiliated actors or others in connection with political uncertainty and conflict in the Middle East and the war in Ukraine. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, disruption of our operations, which could harm our reputation and financial results. Some of our IT infrastructure still utilizes outdated legacy systems, software and hardware, some of which may be approaching end-of-life or end of support, and that may be particularly susceptible to cybersecurity breaches, errors and operational failures. Upgrading, replacing and enhancing such infrastructure may be expensive and put the continuity of our operations at risk while a failure to do so may make us more susceptible to the risks discussed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not allocate and effectively manage the resources necessary to build and sustain the proper IT infrastructure, including those used in our products, we could be subject to transaction errors, processing inefficiencies, loss of customers, business disruptions or loss of or damage to intellectual property. If our data management systems do not effectively collect, store, process and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies or human error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our reputation, financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-81"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, and personal information of our customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our IT infrastructure may be vulnerable to attacks by hackers, computer viruses, malicious codes, ransomware, unauthorized access attempts, and cyber- or phishing-attacks, or breached or otherwise disrupted due to employee error, malfeasance, faulty password management or other disruptions. Third parties may attempt to fraudulently induce employees or other persons into disclosing usernames, passwords or other sensitive information, which may in turn be used to access our IT systems, commit identity theft or carry out other unauthorized or illegal activities. Any such breach or incident could compromise our systems and networks and the information stored or otherwise processed there could be accessed, publicly disclosed, lost, stolen or otherwise processed in an unauthorized manner. We engage third-party vendors and service providers to store and otherwise process some of our data, including sensitive and personal information. Our vendors and service providers may also be the targets of the risks described above, including cyber-attacks, malicious software, ransomware, phishing schemes, and fraud. Our ability to monitor our vendors and service providers&#8217; data security is limited, and, in any event, third parties may be able to circumvent those security measures, resulting in the unauthorized access to, misuse, disclosure, loss or destruction of our data, including sensitive and personal information, and disruption of our or our third-party service providers&#8217; systems. We and our third-party service providers may face difficulties in identifying, or promptly responding to, potential security breaches and other instances of unauthorized access to, or disclosure, other processing, or loss or unavailability of, information. Any hacking or other attack on our or our third-party service providers&#8217; or vendors&#8217; systems, and any unauthorized access to, or disclosure, other processing, or loss or unavailability of, information suffered by us or our third-party service providers or vendors, or the perception that any of these have occurred, could result in legal claims or proceedings, loss of intellectual property, liability under laws that protect the privacy of personal information, negative publicity, disruption of our operations and damage to our reputation, and data integrity issues, which could divert our management&#8217;s attention from the operation of our business and materially and adversely affect our business, revenues and competitive position. Moreover, we may need to increase our efforts to train our personnel to detect and defend against cyber- or phishing-attacks, which are becoming more sophisticated and frequent, and we may need to implement additional protective measures to reduce the risk of potential security breaches and security incidents, which could cause us to incur significant additional expenses. Retaliatory acts by Russia in response to Western sanctions or otherwise in connection with the war in Ukraine could include cyber-attacks that could disrupt the economy generally or that may either directly or indirectly impact our operations specifically.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our insurance may be insufficient to cover our losses resulting from cyber-attacks, breaches, or other interruptions, and any incidents may result in loss of, or increased costs of, such insurance. The successful assertion of one or more large claims against us that exceed available insurance coverage, the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, or denials of coverage, could have a material adverse effect on our business, including our financial condition, results of operations and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-82"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of artificial intelligence and machine learning technologies may result in reputational harm or liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incorporated and may continue to incorporate additional artificial intelligence and machine learning, or AIML, technologies into our sequencing platforms, marketing programs, and analysis software, and these solutions and features are advantageous to describing, enhancing, and maximizing the capabilities of our differentiated technologies and to our future growth over time. We rely and expect to rely on AIML technologies such as basecalling, variant calling, epigenetic analysis and tertiary analysis, but there can be no assurance that we will realize the desired or anticipated benefits from AIML or any at all. We may also fail to properly implement or utilize AIML technologies. Our competitors or other third parties may incorporate AIML into their products, platforms, software and services or otherwise within their business more quickly or more successfully than us, which could impair our ability to compete effectively and adversely affect our results of operations. Additionally, our use of AIML technologies may expose us to additional claims, demands and proceedings by private parties and regulatory authorities and subject us to legal liability as well as brand and reputational harm. For example, if output from AIML technologies or that they assist in producing are or are alleged to be deficient, inaccurate, or biased, or for such output, or such technologies or their development or deployment, including the collection, use, or other processing of data used to train or create such AIML technologies, to alleged to infringe upon or to have misappropriated third-party intellectual property rights or to violate applicable laws, regulations, or other actual or asserted legal obligations to which we are or may become subject, then our business, financial condition, and results of operations may be adversely affected. The legal, regulatory, and policy environments around AIML are evolving rapidly, and we may become subject to new and evolving legal and other obligations. These and other developments may require us to make significant changes to our use of AIML, including by limiting or restricting our use of AIML, and may require us to make significant changes to our policies and practices, which may necessitate expenditure of significant time, expense, and other resources. AIML also presents emerging ethical issues, and if our use of AIML becomes controversial, we may experience brand or reputational harm.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our future customer base, and thereby decrease our revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we currently, and in the future will, collect, store, transfer, use or process sensitive data, including personal information of employees, and intellectual property and proprietary business information owned or controlled by ourselves and other parties. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-83"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bureau</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Federal Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In November 2020, California also passed the California Privacy Rights Act, or (&#8220;CPRA&#8221;), which significantly expanded the CCPA as of January 1, 2023, including by introducing additional obligations such as data minimization and storage limitations and granting additional rights to consumers, among others. The enactment of the CCPA has prompted similar legislative developments in other states, and numerous other states have proposed, and in certain cases enacted, legislation relating to privacy and data security, many of which are similar to the CCPA and CPRA. Similar laws are being considered by other state legislatures. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. State laws are changing rapidly and there has been discussion in the U.S. Congress of a new comprehensive federal data privacy law. These and future laws and regulations may increase our compliance costs and potential liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), establish privacy and security standards that limit the use and disclosure of individually identifiable health information (known as &#8220;protected health information&#8221;) and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing interpretation. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or disrupted, breached or otherwise compromised due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or disruption could compromise our networks and the information stored there could be accessed, manipulated, publicly disclosed, lost, stolen, made unavailable, or otherwise processed without authorization. Any such disruption, access, breach, unavailability, theft, loss or other unauthorized processing of information, or the perception that any of these has occurred could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as the HIPAA, the Health Information Technology for Economic and Clinical Health Act, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, notice may need to be made to the media or state attorneys general. Such a notice could harm our reputation and our ability to compete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-84"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have in place formal policies and procedures related to the storage, collection, and processing of information, and have conducted data privacy audits, we continue to evaluate our compliance needs, including the need to conduct additional internal and external data privacy audits or adopt additional policies and procedures, to ensure our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our third-party vendors&#8217; compliance with applicable data protection laws and regulations. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security, could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased scrutiny of our environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investor advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and customers are increasingly focused on environmental, social, and governance (&#8220;ESG&#8221;) practices of companies. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continues to grow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices fail to meet regulatory requirements or investor or other industry stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, board and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted and customers and suppliers may be unwilling to do business with us and potential or current investors may elect to invest in other companies with ESG practices that are perceived to be better than ours. In addition, ESG reporting and disclosure may result in additional costs and require additional resources to monitor, report, and comply with our various ESG practices as well as additional attention from our board of directors and management. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the expectations of stakeholders, or comply with applicable regulatory requirements, our reputation, business, financial performance, and growth may be adversely impacted.</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_106"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_109"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.  DEFAULTS UPON SENIOR SECURITIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_112"></div><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-85"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 5.  OTHER INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities Trading Plans of Directors and Executive Officers</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-843"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-844">adopted</ix:nonNumeric></ix:nonNumeric> and/or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-845"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-846">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-86"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 6.  EXHIBITS</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incorporated by reference herein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Filing Date</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm">3.1</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm">Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 23, 2011</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit31-certificateofame.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit31-certificateofame.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to declassify the Board</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 20, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit32-certificateofame.htm">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit32-certificateofame.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to limit the liability of officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 20, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103xex3_1.htm">3.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103xex3_1.htm">Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 7, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913025000061/pacb-exx1021xpacbiox1305ob.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913025000061/pacb-exx1021xpacbiox1305ob.htm">Third Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated March 7, 2025</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 17, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a102jamesgibsonofferletter.htm">10.2+</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a102jamesgibsonofferletter.htm">Letter Relating to Employment Terms by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a102jamesgibsonofferletter.htm">the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a102jamesgibsonofferletter.htm"> and James R. Gibson effective March 24, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a103pacbiooutsidedirectorc.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a103pacbiooutsidedirectorc.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a103pacbiooutsidedirectorc.htm">+</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a103pacbiooutsidedirectorc.htm">O</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a103pacbiooutsidedirectorc.htm">utside Director Comp</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a103pacbiooutsidedirectorc.htm">ensation Pol</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="a103pacbiooutsidedirectorc.htm">icy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx311xq1x25.htm">31</a>.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx311xq1x25.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx312xq1x25.htm">31</a>.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx312xq1x25.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx321xq1x25.htm">32.1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx321xq1x25.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx322xq1x25.htm">32.2</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx322xq1x25.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">______________________________________________________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The certification</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s att</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-87"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></td></tr></table></div></div></div><div id="i8ceeb5c9aa84416fb9d34124a1b6c447_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8ceeb5c9aa84416fb9d34124a1b6c447_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;12, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Christian O. Henry </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;12, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Jim R. Gibson</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jim R. Gibson</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;12, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Michele Farmer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michele Farmer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President and Chief Accounting Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:4.5pt"><img src="pacb-20250331_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-88"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q1 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>a102jamesgibsonofferletter.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2d279318adcb44de87ee0b258d459833_1"></div><div style="min-height:100.08pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div><div><font><br></font></div><div style="text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:182px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">James R. Gibson</font></div><div style="margin-bottom:1.7pt;margin-top:1.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:11.00pt">&#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear James,</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On behalf of Pacific Biosciences of California, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), I am pleased to offer you a position at the Company as Chief Financial Officer (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CFO</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). You will be reporting to the Chief Executive Officer.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:13.35pt">You will receive a salary of $500,000 annually, paid twice monthly according to the Company&#8217;s</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:13.35pt">payroll schedule, subject to applicable withholdings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You will be eligible to receive an annual cash bonus with a target gross amount of 55% of your base salary (subject to the achievement of certain performance goals and objectives that may be established by our Board of Directors or a committee thereof (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as applicable, from time to time). Further details regarding this bonus opportunity will be made available to you.  Any such bonus will be paid in accordance with the Company&#8217;s standard practices, less applicable withholdings, and subject to your continuous service on the date of payment.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to approval of our Board or its delegates, as applicable, as a material inducement to you accepting employment with the Company, the Company will grant you equity awards under the Company&#8217;s current equity incentive plans (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Plans</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as follows&#58; (i) a nonstatutory stock option (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to purchase a total of 2,000,000 shares of the Company&#8217;s common stock (each a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and, collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), having an exercise price per Share equal to the fair market value of a Share on the date of grant, and (ii) an award of restricted stock units covering 1,000,000 Shares (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), subject to adjustment for any stock splits, reverse splits, combinations, dividends, and the like after the date hereof. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The RSU award will be scheduled to vest as to one fourth (1&#47;4th) of the underlying Shares on each of the one (1), two (2), three (3) and four (4) year anniversaries of the vesting commencement date, provided that you remain in continuous service with the Company through the applicable vesting dates. Any portion of the RSUs that have not vested as of the date of cessation of your continuous service with the Company will terminate as of the date of such cessation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Option will be scheduled to vest as to one-fourth (1&#47;4th) of the Shares subject at grant to the Option on the one-year anniversary of the vesting commencement date and as to one forty-eighth (1&#47;48th) of the Shares subject at grant to the Option each month thereafter on the same day of the month as the vesting commencement date, provided that you remain in continuous service with the Company through the applicable vesting date.  Any portion of the Option that has not vested as of the date of cessation of your continuous service with the Company will terminate as of the date of such cessation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Option and the RSU award will each be effective as of and subject to your commencing employment with the Company. The speci&#64257;c terms of the Option the RSU awards each will be determined when granted by the Board or its delegates, as applicable, and will be subject to the terms and conditions of </font></div><div style="height:94.86pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center;text-indent:-76.5pt"><font style="color:#df1995;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">pacb.com     </font><font style="color:#bfbfbf;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#124;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#df1995;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">650.521.8000</font><font style="color:#df1995;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">     </font><font style="color:#bfbfbf;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#124;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font><font style="color:#df1995;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">   </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1305 O&#8217;Brien Dr. Menlo Park, CA 94025</font></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center;text-indent:-76.5pt"><font><br></font></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center;text-indent:-76.5pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:25px;margin-bottom:5pt;vertical-align:text-bottom;width:114px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Plan and the applicable RSU and Option award agreements thereunder, which will be provided to you after the grant is made.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You will be eligible to receive equity awards covering Shares pursuant to any plans or arrangements the Company may have in effect from time to time, including but not limited to any focal grants.  The Board will determine in its discretion whether you will be granted any such equity awards and the terms of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You will also be offered certain benefits pursuant to our standard executive Change in Control Severance Agreement, subject to approval by the Compensation Committee of the Board, and our standard director&#47;officer Indemnification Agreement, copies of which are attached.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We will be offering you our standard benefits package and a phone allowance under our Mobile Device Policy of $100 per month. You will receive designated Company holidays, and the terms of our time off with pay policies are outlined in our employee handbook. The Company reserves the right to modify or terminate the benefit plans, policies, allowances, and programs it offers to its employees at any time.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Your employment with the Company is for no specified period of time. Your employment with the Company will be &#8220;at will,&#8221; meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Any contrary representations that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation, benefits and allowances, as well as the Company&#8217;s personnel policies and procedures, may change from time to time in the Company&#8217;s sole discretion, the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).</font></div><div style="margin-top:0.6pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You represent that the performance of your duties in the position described above will not violate the terms of any agreements you may have with others, including your former employer. You also understand that you are not to bring to or use at the Company any confidential information of your prior employers.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Your employment is also conditioned upon your agreement and execution of the attached Pacific Biosciences At Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon your acceptance of this offer (as evidenced by your return of a signed copy of this letter and the attached agreements to the Company), this letter agreement, the Pacific Biosciences At Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement, the Change in Control Severance Agreement (if signed by you) and the Indemnification Agreement (if signed by you) together constitute the complete agreement between you and the Company, contain all of the terms of </font></div><div style="height:94.86pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 2 of 3</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:25px;margin-bottom:5pt;vertical-align:text-bottom;width:114px"></div></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As required by law, your employment with the Company is contingent upon your providing legal proof of identity and authorization to work within the United States on your first day of employment. In addition, to the extent permitted by applicable law, this offer and your employment with the Company is contingent upon completing a Director and Officer Questionnaire that will be subject to review and approval by the Company, and your submitting to, and passing, a background check. Additionally, any employee authorized to drive a Company vehicle, or who is receiving a vehicle allowance, must provide a valid and current driver&#8217;s license and consent to a DMV check.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To accept our offer, please sign and date this letter in the space provided below. If you accept our offer, your first day of employment will be March 31, 2025, subject to your satisfaction of the above conditions.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This offer of employment will terminate if it is not accepted, signed, and returned by midnight Pacific Time, March 26, 2025.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is committed to hiring employees like you that have the courage, creativity, and experience to develop new ideas for new markets.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We look forward to having you on our team!</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Christian O. Henry</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">___________________________________________________________________________________</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc. By&#58; Christian O. Henry, President, Chief Executive Officer and Interim Chief Financial Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I have read and accept this employment offer&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; James R. Gibson      3&#47;24&#47;2025</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">___________________________________________________________________________________</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">James R. Gibson</font></div><div style="height:94.86pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page 3 of 3</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>a103pacbiooutsidedirectorc.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i062301b2a2a4449c9532aae74fd2ff77_1"></div><div style="min-height:69.12pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-top:3pt;padding-left:80.97pt;padding-right:80.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY</font></div><div style="padding-left:81pt;padding-right:81pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective as of April 22, 2025</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pacific Biosciences of California, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) believes that providing cash and equity compensation to its members of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and members of the Board, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) represents an effective tool to attract, retain and reward Directors who are not Employees of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Outside Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). This Outside Director Compensation Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is intended to formalize the Company&#8217;s policy regarding cash compensation and grants of equity awards to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy will be effective as of April 22, 2025 (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">Cash Compensation</font></div><div style="margin-top:1.1pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Annual Cash Retainer</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Outside Director will be paid an annual cash retainer of $40,000. There are no per- meeting attendance fees for attending Board meetings. This cash compensation will be paid quarterly in equal installments in advance.</font></div><div style="margin-top:12pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Committee Annual Cash Retainer</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of the Effective Date, each Outside Director who serves as the lead Outside Director or Board chair, or the chair or a member of a committee of the Board, will be eligible to earn additional annual fees (paid quarterly in equal installments in advance) as follows&#58;</font></div><div style="margin-top:7pt"><font><br></font></div><div style="padding-left:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.895%"><tr><td style="width:1.0%"></td><td style="width:82.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.30pt">Lead Independent Director&#47;Board Chair&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.30pt">$40,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair of Audit Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$20,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Member of Audit Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair of Compensation Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$14,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Member of Compensation Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$7,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair of Corporate Governance and Nominating Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$10,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Member of Corporate Governance and Nominating Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$5,000</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.80pt">Chair of Science and Technology Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.75pt;padding-right:-0.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.80pt">$10,000</font></div></td></tr></table></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i062301b2a2a4449c9532aae74fd2ff77_4"></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.895%"><tr><td style="width:1.0%"></td><td style="width:74.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.30pt">Member of Science and Technology Committee&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:59.47pt;padding-right:-2.63pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.30pt">$5,000</font></div></td></tr></table></div><div style="margin-top:12pt;padding-left:5.75pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, each Outside Director who serves as the chair of a committee will not receive both the additional annual fee as the chair of the committee and the additional annual fee as a member of the committee.</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">Equity Compensation</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options) under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to Section 2 of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions&#58;</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">No Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.07pt;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to adjustment pursuant to the applicable terms of the Plan, each individual who first becomes an Outside Director following the Effective Date automatically will be granted an Award of Nonstatutory Stock Options (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Option Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and an Award of Restricted Stock Units (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and together with the Initial Option Award, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that have an aggregate Value (as defined below) as of such Initial Awards&#8217; grant date equal to $450,000, with the Initial Option Award having a Value equal to fifty percent (50%) of such dollar amount and the Initial RSU Award having a Value equal to fifty percent (50%) of such dollar amount&#59; provided that in no event will the aggregate number of Shares subject to the Initial Awards granted to an Outside Director exceed 127,000 Shares. The Initial Awards will be made on the first date on which such individual first becomes an Outside Director (the first date as an Outside Director, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy. If an individual was a member of the Board and also an Employee, becoming an Outside Director due to termination of employment will not entitle the Outside Director to any Initial Awards. Each Initial Option Award will be scheduled to vest as to one-third (1&#47;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) of the Shares subject to the Initial Option Award on the one (1) year anniversary of the Outside Director&#8217;s Initial Start Date, and thereafter, in equal installments on a monthly basis for the next twenty-four (24) months on the same day of the month as the Outside Director&#8217;s Initial Start Date (or if a particular month does not have a corresponding day within that month, then the last day of that month), in each case subject to the Outside Director continuing to be a Director through the applicable vesting date. Each Initial RSU Award will be scheduled to vest as to one-third (1&#47;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) of the Shares subject to the Initial RSU Award on the one (1), two (2), and three (3) year anniversaries of the Outside Director&#8217;s Initial Start Date, in each case subject to the Outside Director continuing to be a Director through the applicable vesting date.</font></div><div style="margin-top:11.95pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.7pt;text-decoration:underline">Annual Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to adjustment pursuant to the applicable terms of the Plan, effective as of the date of each Annual Meeting (as defined below) occurring after the Effective Date (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Meeting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each individual who is an Outside Director as of such date</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:7.038%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 2 -</font></div></td></tr></table></div></div></div><div id="i062301b2a2a4449c9532aae74fd2ff77_7"></div><hr style="page-break-after:always"><div style="min-height:60.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3pt;padding-left:5.95pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will be automatically granted an Award of Nonstatutory Stock Options (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with an aggregate Value as of such Annual Award&#8217;s grant date equal to $200,000&#59; provided that in no event will the aggregate number of Shares subject to the Annual Award granted to an Outside Director as of an Annual Meeting Date exceed 65,000 Shares. Further, the Value of the first Annual Award to be granted to an Outside Director will be prorated based on the number of months of continuous service such Outside Director provided as a member of the Board during the twelve (12) month period immediately preceding such Annual Meeting Date (with any partial month of service provided rounded up to a whole month) to the extent such individual&#8217;s service as a member of the Board commenced after the date of the immediately preceding Annual Meeting. For purposes of clarity, an individual who is an Outside Director as of an Annual Meeting Date who resigns from such Outside Director role or otherwise ceases to be an Outside Director as of such date, will not be granted an Annual Award on such date, and an individual who first becomes an Outside Director as of an Annual Meeting Date will be eligible to receive Initial Awards pursuant to subsection (b) above but not an Annual Award with respect to such Annual Meeting Date. The Annual Award will be scheduled to vest monthly over one (1) year, on the same day of the month as the Annual Award&#8217;s date of grant (or if a particular month does not have a corresponding day within that month, then the last day of that month) or if earlier, on the date of the next annual meeting of the Company&#8217;s stockholders occurring after the Annual Award&#8217;s date of grant, provided such Outside Director continues to serve as a Director through the applicable vesting dates.</font></div><div style="margin-top:11.95pt;padding-left:6pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.02pt;text-decoration:underline">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to an Award of Options or Restricted Stock Units, its grant date fair value (determined in accordance with U.S. generally accepted accounting principles), or such other methodology the Board or Compensation Committee may determine prior to the grant of the Award becoming effective, as applicable&#59; provided, however, that any Award of Options or Restricted Stock Units will cover only a whole number of Shares, such that any fractional Share that otherwise would result from a given Value will be rounded down and will not become subject to such Award. For purposes of clarity, in the event that the Share limit set forth in subsection (b) or (c) above is exceeded, then the aggregate Value of the Initial Awards or Annual Awards, as applicable, will be reduced (while the 50&#47;50 mix of Options and Restricted Stock Units for the Initial Award based on Value is maintained) until the aggregate number of Shares subject to such Awards ceases to exceed such Share limit.</font></div><div style="margin-top:3pt;padding-left:5.95pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.75pt;text-decoration:underline">Other Terms of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an annual meeting of the Company&#8217;s stockholders (after giving effect to any postponements and adjournments with respect thereto). Each Award granted under this Policy will be evidenced by the applicable form of Award agreement as approved by the Board or the Compensation Committee of the Board, as applicable, for use thereunder. The per Share exercise price of an Option granted under this Policy will be one hundred percent (100%) of the Fair Market Value on the Option&#8217;s date of grant. The maximum term to expiration of an Option granted under this Policy will be ten (10) years, subject to earlier termination as provided in the Plan and the Award agreement governing the terms of the Option. Awards granted pursuant to this Policy are subject to the terms and conditions of the Plan, including for clarity, and without limitation, that the number of Shares to be covered by an Award is subject to the number of Shares available for issuance under the Plan as of the grant date of such Award (and accordingly, will be subject to reduction on a prorated basis to the extent Awards to be granted pursuant to the Policy as of a given date would cover a number of Shares that exceeds the number of Shares available for issuance under the Plan).</font></div><div style="height:39.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:6.908%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 3 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:60.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">Additional Provisions</font></div><div style="margin-top:1.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">Adjustments</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, reclassification, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs (other than any ordinary dividends or other ordinary distributions), the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under this Policy, will adjust the number of Shares issuable pursuant to Awards granted under this Policy.</font></div><div style="margin-top:12.05pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">Limitations</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Outside Director may be granted, in any Fiscal Year, Awards (the value of which will be based on their grant date fair value determined in accordance with U.S. generally accepted accounting principles) and any other compensation (including without limitation any cash retainers or fees) that, in the aggregate, exceed $500,000, provided that such amount is increased to $1,000,000 in the Fiscal Year of his or her initial service as an Outside Director. Any Awards or other compensation provided to an individual for his or her services as an Employee, or for his or her services as a Consultant other than as an Outside Director, will be excluded for purposes of this Section.</font></div><div style="margin-top:11.95pt;padding-left:42pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">ECTION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">409A</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In no event will cash payments under this Policy be paid after the later of (i) the 15th day of the 3rd month following the end of the Company&#8217;s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (ii) the 15th day of the 3rd month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#8220;short-term deferral&#8221; exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply. In no event will the Company or any of its Parent or Subsidiaries have any responsibility, obligation, or liability to reimburse, indemnify, or hold harmless an Outside Director for any taxes imposed, or other costs incurred, as a result of Section 409A.</font></div><div style="margin-top:12pt;padding-left:40.1pt;text-indent:-16.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:7.1pt;text-decoration:underline">Revisions</font></div><div style="margin-top:1.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board may amend, alter, suspend or terminate this Policy at any time and for any reason. Further, the Board may provide for cash, equity-based or other compensation to Outside Directors in addition to the compensation provided under this Policy. No amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director </font></div><div style="height:39.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:6.908%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 4 -</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:60.12pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company. Termination of this Policy will not affect the Board&#8217;s or the Compensation Committee&#8217;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="height:39.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:6.908%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 5 -</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>pacb-10qxexx311xq1x25.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0971baca57d3445f8fee9802a1b31e27_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christian Henry, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">I have reviewed this quarterly report on Form 10-Q of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:20pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:44.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry<br>&#160;President and Chief Executive Officer <br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>pacb-10qxexx312xq1x25.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i025e8f4ea6e44fff932b7675ce27c7ac_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jim Gibson, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">I have reviewed this quarterly report on Form 10-Q of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:43.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jim R. Gibson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jim R. Gibson<br>Chief Financial Officer <br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:9pt;padding-left:72pt;text-indent:24.5pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>pacb-10qxexx321xq1x25.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i271285efe3d04b37b98aa6aefcb8a581_1"></div><div style="min-height:45pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2025, as filed with the Securities and Exchange Commission on the date hereof, I, Christian Henry, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Quarterly Report of the Company on Form 10-Q for the period ended March&#160;31, 2025 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:42.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry<br>&#160;President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>pacb-10qxexx322xq1x25.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9ae55fd0dba84b13b40331646aedb30b_1"></div><div style="min-height:45pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2025, as filed with the Securities and Exchange Commission on the date hereof, I, Jim Gibson, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Quarterly Report of the Company on Form 10-Q for the period ended March&#160;31, 2025 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;12, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jim R. Gibson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jim R. Gibson </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pacb-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1b1d8431-b0de-47a8-b616-b49433c1f17c,g:bee9e017-2ca3-4a3e-a5bb-871b7f56db6b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pacb="http://www.pacificbiosciences.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacificbiosciences.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pacificbiosciences.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS">
        <link:definition>9952157 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTS" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS">
        <link:definition>9952158 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTES" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES">
        <link:definition>9952159 - Disclosure - CONVERTIBLE SENIOR NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURING" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURING">
        <link:definition>9952160 - Disclosure - RESTRUCTURING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952161 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATION" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION">
        <link:definition>9952162 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE">
        <link:definition>9952163 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATION" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION">
        <link:definition>9952164 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>9955512 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSTables" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables">
        <link:definition>9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESTables" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables">
        <link:definition>9955514 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGTables" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables">
        <link:definition>9955515 - Disclosure - RESTRUCTURING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>9955516 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables" roleURI="http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables">
        <link:definition>9955517 - Disclosure - SEQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables">
        <link:definition>9955518 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONTables" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables">
        <link:definition>9955519 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>9955520 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955521 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>9955522 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails">
        <link:definition>9955523 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails">
        <link:definition>9955524 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails">
        <link:definition>9955525 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofInventoryDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails">
        <link:definition>9955526 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails">
        <link:definition>9955527 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails_1" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1">
        <link:definition>9955527 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails">
        <link:definition>9955528 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails">
        <link:definition>9955529 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails">
        <link:definition>9955530 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails">
        <link:definition>9955531 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails">
        <link:definition>9955532 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails">
        <link:definition>9955533 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails">
        <link:definition>9955534 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails">
        <link:definition>9955535 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails">
        <link:definition>9955536 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails">
        <link:definition>9955537 - Disclosure - RESTRUCTURING - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails">
        <link:definition>9955538 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>9955539 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails">
        <link:definition>9955540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities of our Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9955540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities of our Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9955541 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails">
        <link:definition>9955542 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails">
        <link:definition>9955543 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955544 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails">
        <link:definition>9955545 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails">
        <link:definition>9955546 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955547 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails">
        <link:definition>9955548 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails">
        <link:definition>9955549 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails">
        <link:definition>9955550 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails">
        <link:definition>9955551 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails">
        <link:definition>9955552 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pacb_ServiceAndOtherMember" abstract="false" name="ServiceAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_LossOnPurchaseCommitment" abstract="false" name="LossOnPurchaseCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AmortizationOfAcquiredIntangibleAssets" abstract="false" name="AmortizationOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IncomeLossPerShareAbstract" abstract="true" name="IncomeLossPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" abstract="true" name="SupplementalBalanceSheetComponentsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_LesseeOperatingLeaseDescriptionTableTextBlock" abstract="false" name="LesseeOperatingLeaseDescriptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DomesticCustomersMember" abstract="false" name="DomesticCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_CustomerOneMember" abstract="false" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ShortTermRestrictedCashFairValueDisclosure" abstract="false" name="ShortTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_LongTermRestrictedCashFairValueDisclosure" abstract="false" name="LongTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AptonMember" abstract="true" name="AptonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_AchievementOfMilestoneMember" abstract="false" name="AchievementOfMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" abstract="false" name="BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" abstract="false" name="StockIssuedDuringPeriodAverageTradingPeriodAcquisition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" abstract="false" name="PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_ScheduleOfBalanceSheetComponentsTable" abstract="true" name="ScheduleOfBalanceSheetComponentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_A2025RestructuringMember" abstract="true" name="A2025RestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DevelopedTechnologyAndIntellectualPropertyMember" abstract="true" name="DevelopedTechnologyAndIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ScheduleOfBalanceSheetComponentsLineItems" abstract="true" name="ScheduleOfBalanceSheetComponentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" abstract="false" name="GoodwillImpairmentDiscountedCashFlowModelDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" abstract="false" name="GoodwillImpairmentIncreaseInBasisPointDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" abstract="false" name="AdditionalGoodwillImpairmentChangeInDiscountRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" abstract="false" name="IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" abstract="false" name="IntangibleAssetImpairmentDiscountedCashFlowModelTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" abstract="false" name="IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" abstract="false" name="AdditionalIntangibleAssetImpairmentChangeInDiscountRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" abstract="false" name="IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" abstract="false" name="AdditionalIntangibleAssetImpairmentChangeInTerm" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_RestructuringAndRelatedCostAcceleratedAmortization" abstract="false" name="RestructuringAndRelatedCostAcceleratedAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ChangeInEarningsPerShare" abstract="false" name="ChangeInEarningsPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" abstract="false" name="ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_StandardProductWarrantyPeriod" abstract="false" name="StandardProductWarrantyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_A2028ConvertibleSeniorNotesMember" abstract="false" name="A2028ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_A2030ConvertibleSeniorNotesMember" abstract="true" name="A2030ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_A2029NotesMember" abstract="true" name="A2029NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ExchangeTransactionMember" abstract="true" name="ExchangeTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_PaymentsInConjunctionWithNotesExchange" abstract="false" name="PaymentsInConjunctionWithNotesExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" abstract="false" name="HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentDebtDefaultCalendarDays" abstract="false" name="DebtInstrumentDebtDefaultCalendarDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentInterestInTheEventOfDefault" abstract="false" name="DebtInstrumentInterestInTheEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" abstract="false" name="DebtInstrumentAdditionalInterestInEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_RestructuringOfDebtPricePerShare" abstract="false" name="RestructuringOfDebtPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pacb_DebtIssuanceCostLenderFees" abstract="false" name="DebtIssuanceCostLenderFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" abstract="false" name="DebtInstrumentRedemptionPricePercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_EmployeeSeparationCostsMember" abstract="true" name="EmployeeSeparationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_A2024RestructuringMember" abstract="true" name="A2024RestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_RestructuringChargesExcludingAdjustments" abstract="false" name="RestructuringChargesExcludingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" abstract="false" name="InProcessResearchAndDevelopmentIndefiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" abstract="false" name="RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_RestructuringChargesAdditionalCostsIncurred" abstract="false" name="RestructuringChargesAdditionalCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_GainLossOnPurchaseCommitments" abstract="false" name="GainLossOnPurchaseCommitments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_OperatingLeaseExpectedBaseRentExpense" abstract="false" name="OperatingLeaseExpectedBaseRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" abstract="false" name="LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" abstract="false" name="AdditionalLiabilityAssociatedWithIndemnificationObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BalanceSheetClassificationAbstract" abstract="true" name="BalanceSheetClassificationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_EmployeeStockPurchasePlanMember" abstract="false" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" abstract="true" name="A2020PlanInducementPlanAndTheOmniomePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsPSUMember" abstract="true" name="TimeBasedRestrictedStockUnitsPSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_TimeBasedStockOptionMember" abstract="false" name="TimeBasedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsRsusMember" abstract="false" name="TimeBasedRestrictedStockUnitsRsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_StockBasedCompensationMember" abstract="false" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_OptionsToPurchaseCommonStockMember" abstract="false" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InstrumentMember" abstract="false" name="InstrumentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="pacb_ConsumableMember" abstract="false" name="ConsumableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>pacb-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1b1d8431-b0de-47a8-b616-b49433c1f17c,g:bee9e017-2ca3-4a3e-a5bb-871b7f56db6b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1fad330b-fd18-4f2e-91c4-dd81a8335853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b36afcb1-760c-4a6a-be49-80cad288b0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1fad330b-fd18-4f2e-91c4-dd81a8335853" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b36afcb1-760c-4a6a-be49-80cad288b0dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f37f37c5-0065-44bc-a715-1b2183958e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1fad330b-fd18-4f2e-91c4-dd81a8335853" xlink:to="loc_us-gaap_ShortTermInvestments_f37f37c5-0065-44bc-a715-1b2183958e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6bba430e-076f-4e30-9f1a-b488306e0257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1fad330b-fd18-4f2e-91c4-dd81a8335853" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6bba430e-076f-4e30-9f1a-b488306e0257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_01559de1-9c36-43c1-9b04-dbd8dacc3e67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1fad330b-fd18-4f2e-91c4-dd81a8335853" xlink:to="loc_us-gaap_InventoryNet_01559de1-9c36-43c1-9b04-dbd8dacc3e67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0e571fec-d77a-4016-9e15-386e3735a15f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1fad330b-fd18-4f2e-91c4-dd81a8335853" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0e571fec-d77a-4016-9e15-386e3735a15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_6e3c1e2a-6ae6-48b6-946d-9b906037723f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1fad330b-fd18-4f2e-91c4-dd81a8335853" xlink:to="loc_us-gaap_RestrictedCashCurrent_6e3c1e2a-6ae6-48b6-946d-9b906037723f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e85d6f0d-0342-497e-9967-c62e058d71ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f3256814-e1f6-4f18-944d-2bcca9a4c118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e85d6f0d-0342-497e-9967-c62e058d71ba" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f3256814-e1f6-4f18-944d-2bcca9a4c118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f7243a13-c9ac-4cfe-b6a3-c45be7dafb06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e85d6f0d-0342-497e-9967-c62e058d71ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f7243a13-c9ac-4cfe-b6a3-c45be7dafb06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6cf3cbf1-ebf4-419a-a1a2-5c975401aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e85d6f0d-0342-497e-9967-c62e058d71ba" xlink:to="loc_us-gaap_LiabilitiesCurrent_6cf3cbf1-ebf4-419a-a1a2-5c975401aa67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fd480bc-d5d8-48f5-bb70-1805835de639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e85d6f0d-0342-497e-9967-c62e058d71ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fd480bc-d5d8-48f5-bb70-1805835de639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_e4e7a13d-cd54-4b77-9fd2-24e4257a926a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e85d6f0d-0342-497e-9967-c62e058d71ba" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_e4e7a13d-cd54-4b77-9fd2-24e4257a926a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8e8d65ba-2baf-42a2-bf42-2f1d93aecd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e85d6f0d-0342-497e-9967-c62e058d71ba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8e8d65ba-2baf-42a2-bf42-2f1d93aecd8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_182366e4-cc0e-428b-a21d-c98d96f235d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:to="loc_us-gaap_AssetsCurrent_182366e4-cc0e-428b-a21d-c98d96f235d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0c4ab4cc-5912-4f44-91dc-90acac0c4430" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0c4ab4cc-5912-4f44-91dc-90acac0c4430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_23614d6d-57fc-42fc-b936-ac39f695ac08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_23614d6d-57fc-42fc-b936-ac39f695ac08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_df4213e5-5502-43ed-8748-02887d0b0ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_df4213e5-5502-43ed-8748-02887d0b0ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_540ced86-50f4-4fec-8284-ebd2dc1411df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_540ced86-50f4-4fec-8284-ebd2dc1411df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_08efb5ed-0316-42c9-abd4-44c602567af7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_08efb5ed-0316-42c9-abd4-44c602567af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e8c72718-5590-406f-941f-3e68f57a707a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4194972d-4d72-4714-ba49-5c182d1db7df" xlink:to="loc_us-gaap_Goodwill_e8c72718-5590-406f-941f-3e68f57a707a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d9ab9b2-8401-41e9-a423-50aa62c00304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_46b2d836-01f2-419e-ac89-c8cea19530f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d9ab9b2-8401-41e9-a423-50aa62c00304" xlink:to="loc_us-gaap_Liabilities_46b2d836-01f2-419e-ac89-c8cea19530f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d554efd-f808-45da-ad15-b038ed585390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d9ab9b2-8401-41e9-a423-50aa62c00304" xlink:to="loc_us-gaap_StockholdersEquity_3d554efd-f808-45da-ad15-b038ed585390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cc34159f-ca35-41e8-b2da-9040da564383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0d9ab9b2-8401-41e9-a423-50aa62c00304" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cc34159f-ca35-41e8-b2da-9040da564383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb052bfd-aa44-489b-9eb2-4d4d4c4312ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0b70d55c-de67-4802-b410-7724c30e4764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb052bfd-aa44-489b-9eb2-4d4d4c4312ab" xlink:to="loc_us-gaap_AccountsPayableCurrent_0b70d55c-de67-4802-b410-7724c30e4764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4afca8f7-7fe8-4eac-8afe-98ef3f316125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb052bfd-aa44-489b-9eb2-4d4d4c4312ab" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4afca8f7-7fe8-4eac-8afe-98ef3f316125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd430801-0851-4cb2-b579-6bd014f66c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb052bfd-aa44-489b-9eb2-4d4d4c4312ab" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cd430801-0851-4cb2-b579-6bd014f66c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d80007a-ac07-4f4b-8de4-79adbb1790c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb052bfd-aa44-489b-9eb2-4d4d4c4312ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d80007a-ac07-4f4b-8de4-79adbb1790c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c0d1dfd7-9395-4d92-8fba-7f8df023d94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb052bfd-aa44-489b-9eb2-4d4d4c4312ab" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c0d1dfd7-9395-4d92-8fba-7f8df023d94d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_754feb51-591f-4d42-9a26-76f2a8b0fac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_763b3412-94d8-449f-8937-9dd7cf450560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_754feb51-591f-4d42-9a26-76f2a8b0fac1" xlink:to="loc_us-gaap_PreferredStockValue_763b3412-94d8-449f-8937-9dd7cf450560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bcd4c3be-fc74-4e83-bab7-3b436261f2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_754feb51-591f-4d42-9a26-76f2a8b0fac1" xlink:to="loc_us-gaap_CommonStockValue_bcd4c3be-fc74-4e83-bab7-3b436261f2d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cb6314bb-76be-4c35-94c4-d74b933158fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_754feb51-591f-4d42-9a26-76f2a8b0fac1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cb6314bb-76be-4c35-94c4-d74b933158fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ee63e7b-de04-44ec-9d61-99e3bbb302b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_754feb51-591f-4d42-9a26-76f2a8b0fac1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ee63e7b-de04-44ec-9d61-99e3bbb302b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d703d5b4-9c63-4771-95df-325e1e0aae66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_754feb51-591f-4d42-9a26-76f2a8b0fac1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d703d5b4-9c63-4771-95df-325e1e0aae66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8035794-619d-4b47-bcda-bf9eeb7136a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bbfe4ec4-c532-414e-91ff-d1f728129273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a8035794-619d-4b47-bcda-bf9eeb7136a3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bbfe4ec4-c532-414e-91ff-d1f728129273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66a05336-e392-4960-9d14-00d379fb8850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a8035794-619d-4b47-bcda-bf9eeb7136a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_66a05336-e392-4960-9d14-00d379fb8850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_bb73e66b-eff0-4647-99a9-df8f6663e016" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f2ae1b33-fac4-47a3-a170-cc9f61d35fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_bb73e66b-eff0-4647-99a9-df8f6663e016" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f2ae1b33-fac4-47a3-a170-cc9f61d35fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_b3c4ee9d-a810-456b-a437-2b69b5e3846b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_bb73e66b-eff0-4647-99a9-df8f6663e016" xlink:to="loc_us-gaap_CostOfRevenue_b3c4ee9d-a810-456b-a437-2b69b5e3846b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e20fb69-1534-40dd-9d57-ac61e31ffdae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_ddac05a1-48e2-4d53-ab2e-fb7ab5d3e7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e20fb69-1534-40dd-9d57-ac61e31ffdae" xlink:to="loc_us-gaap_InterestExpenseNonoperating_ddac05a1-48e2-4d53-ab2e-fb7ab5d3e7a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_abc8183b-3c2b-4395-8747-8d6f1cad0dea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e20fb69-1534-40dd-9d57-ac61e31ffdae" xlink:to="loc_us-gaap_OperatingIncomeLoss_abc8183b-3c2b-4395-8747-8d6f1cad0dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d75f3819-d321-4737-8b7e-67c4cf78eb65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e20fb69-1534-40dd-9d57-ac61e31ffdae" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d75f3819-d321-4737-8b7e-67c4cf78eb65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aebd3742-ddc0-4e8e-888e-50e2aa295213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7c4bbd83-9322-4f75-9a44-527f216db072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_aebd3742-ddc0-4e8e-888e-50e2aa295213" xlink:to="loc_us-gaap_GrossProfit_7c4bbd83-9322-4f75-9a44-527f216db072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_750f10d0-bc7b-4d9a-8a68-e7b226383759" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_aebd3742-ddc0-4e8e-888e-50e2aa295213" xlink:to="loc_us-gaap_OperatingExpenses_750f10d0-bc7b-4d9a-8a68-e7b226383759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d73a4564-f0dc-48ba-bcd1-873e4ddac380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d64032e-47d2-443b-96f5-c975be47b9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d73a4564-f0dc-48ba-bcd1-873e4ddac380" xlink:to="loc_us-gaap_NetIncomeLoss_3d64032e-47d2-443b-96f5-c975be47b9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_45e24472-ba34-4d7e-ac9c-2f4131b19d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d73a4564-f0dc-48ba-bcd1-873e4ddac380" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_45e24472-ba34-4d7e-ac9c-2f4131b19d7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cd201b60-4209-49b5-af02-755a8d0ec368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_fcf9b1a8-8986-4265-b25b-34685aa93e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd201b60-4209-49b5-af02-755a8d0ec368" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_fcf9b1a8-8986-4265-b25b-34685aa93e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_50e1616f-e3e9-42f8-8485-fb772f83a189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd201b60-4209-49b5-af02-755a8d0ec368" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_50e1616f-e3e9-42f8-8485-fb772f83a189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_66a9c5c3-da7a-4851-b013-8cf4867408c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd201b60-4209-49b5-af02-755a8d0ec368" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_66a9c5c3-da7a-4851-b013-8cf4867408c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_b95c21e8-38fb-485e-bc4b-8bdf89bc9675" xlink:href="pacb-20250331.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd201b60-4209-49b5-af02-755a8d0ec368" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_b95c21e8-38fb-485e-bc4b-8bdf89bc9675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_30d2b16f-66cf-47db-bb58-5ab5e2aa148d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd201b60-4209-49b5-af02-755a8d0ec368" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_30d2b16f-66cf-47db-bb58-5ab5e2aa148d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_3a5ab32b-8146-439a-a99d-fd8a070339ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_b8cdf230-5be5-475c-bda2-4a5b58c16e1f" xlink:href="pacb-20250331.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_3a5ab32b-8146-439a-a99d-fd8a070339ed" xlink:to="loc_pacb_LossOnPurchaseCommitment_b8cdf230-5be5-475c-bda2-4a5b58c16e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_07d7ca7d-003f-4da8-9e85-390b59864051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_3a5ab32b-8146-439a-a99d-fd8a070339ed" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_07d7ca7d-003f-4da8-9e85-390b59864051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_86a51735-dc26-42d4-b80d-a6f6c0eacbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_3a5ab32b-8146-439a-a99d-fd8a070339ed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_86a51735-dc26-42d4-b80d-a6f6c0eacbc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109b8092-bcd4-42fb-93b5-a4e23ed3ac46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1612d29e-61e6-47d5-8806-9bb9e459cb92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109b8092-bcd4-42fb-93b5-a4e23ed3ac46" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1612d29e-61e6-47d5-8806-9bb9e459cb92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e73623c0-b878-4649-b341-fb5f673c3e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_109b8092-bcd4-42fb-93b5-a4e23ed3ac46" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e73623c0-b878-4649-b341-fb5f673c3e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c818446-dc95-4124-8b5f-d33b80514072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_403aa0f9-bb24-444d-8553-371f6d4a70d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c818446-dc95-4124-8b5f-d33b80514072" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_403aa0f9-bb24-444d-8553-371f6d4a70d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_536d7a05-0ad6-45e5-8584-f88043610cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c818446-dc95-4124-8b5f-d33b80514072" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_536d7a05-0ad6-45e5-8584-f88043610cc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c49cdbad-33a1-4189-8c11-42f3b6f58922" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ee90f996-1fdb-4c81-8d72-b2fe54dd6e55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c49cdbad-33a1-4189-8c11-42f3b6f58922" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ee90f996-1fdb-4c81-8d72-b2fe54dd6e55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2b17656a-15e9-46a6-ad69-001db6da92ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c49cdbad-33a1-4189-8c11-42f3b6f58922" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2b17656a-15e9-46a6-ad69-001db6da92ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5274cbcf-b7ee-44b2-a279-857bcedb9aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c49cdbad-33a1-4189-8c11-42f3b6f58922" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5274cbcf-b7ee-44b2-a279-857bcedb9aca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1bfb3e18-b28c-4c07-9514-f7fd3e494454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c49cdbad-33a1-4189-8c11-42f3b6f58922" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1bfb3e18-b28c-4c07-9514-f7fd3e494454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_39e0306f-4508-400c-affc-877bb974677a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_39e0306f-4508-400c-affc-877bb974677a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_16324bb1-c8ef-4fdc-9018-09fffa9e6604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_16324bb1-c8ef-4fdc-9018-09fffa9e6604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_add9e138-14bc-4b25-a59c-45d36d09b7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_add9e138-14bc-4b25-a59c-45d36d09b7d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30105ea5-b0ea-46f6-beeb-78f999e4261f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30105ea5-b0ea-46f6-beeb-78f999e4261f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5eac272f-d269-4853-8478-ca03146d76b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_NetIncomeLoss_5eac272f-d269-4853-8478-ca03146d76b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01606a3e-905e-40aa-bc34-520abeb89a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01606a3e-905e-40aa-bc34-520abeb89a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4749cf55-e034-4e5c-b1f8-34265ab6410d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4749cf55-e034-4e5c-b1f8-34265ab6410d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_28bedfa3-670d-4a80-a9ce-2d23c19c6efc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_Depreciation_28bedfa3-670d-4a80-a9ce-2d23c19c6efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d8322f6f-f390-4792-bb73-6e962226320f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d8322f6f-f390-4792-bb73-6e962226320f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_359989b3-f283-4096-b209-046fd84fa401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_359989b3-f283-4096-b209-046fd84fa401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e5af477b-d7a4-4fb2-8a59-9a78095cfd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e5af477b-d7a4-4fb2-8a59-9a78095cfd1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2df41812-d3cb-4412-92d4-82853bc91e07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2df41812-d3cb-4412-92d4-82853bc91e07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_362c5a4f-7ce3-4452-b700-d3adc92b125f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_362c5a4f-7ce3-4452-b700-d3adc92b125f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_50f11266-2e5b-4a4d-8e17-9b290ae56b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_ShareBasedCompensation_50f11266-2e5b-4a4d-8e17-9b290ae56b0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_19c4b7f2-b6f1-4643-a5e3-ce784ca0e572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_19c4b7f2-b6f1-4643-a5e3-ce784ca0e572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4f029e23-148a-473d-a864-8de37575944b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4f029e23-148a-473d-a864-8de37575944b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9a88d4f0-b03e-4d76-b6ca-dfe032fd6a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9a88d4f0-b03e-4d76-b6ca-dfe032fd6a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d19b12b7-11f4-432f-b644-914f1c7e222f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_InventoryWriteDown_d19b12b7-11f4-432f-b644-914f1c7e222f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_997b6dd5-8472-49d2-9226-08aef90b42d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5326046-82fb-4ea3-9117-7b5880e737b0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_997b6dd5-8472-49d2-9226-08aef90b42d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a58e44b1-450a-4539-97ad-b67643a58cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc6cbde1-fb1f-4208-8fb5-99ea718e28af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a58e44b1-450a-4539-97ad-b67643a58cd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cc6cbde1-fb1f-4208-8fb5-99ea718e28af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697d30a-68d8-4576-bcb9-2de70ecbdc85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a58e44b1-450a-4539-97ad-b67643a58cd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7697d30a-68d8-4576-bcb9-2de70ecbdc85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee089969-44ac-4766-a23d-c0775161f5af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a58e44b1-450a-4539-97ad-b67643a58cd0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee089969-44ac-4766-a23d-c0775161f5af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9d957240-c093-48d7-9826-9bef9b9f5bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_0c273462-d3f1-4eed-a8c4-91b014963b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9d957240-c093-48d7-9826-9bef9b9f5bd5" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_0c273462-d3f1-4eed-a8c4-91b014963b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_1c5c9a29-5521-414c-bbaf-7efc7b5ec680" xlink:href="pacb-20250331.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9d957240-c093-48d7-9826-9bef9b9f5bd5" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_1c5c9a29-5521-414c-bbaf-7efc7b5ec680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_735f1f46-4ec8-4a9f-8369-24316e57a499" xlink:href="pacb-20250331.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9d957240-c093-48d7-9826-9bef9b9f5bd5" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_735f1f46-4ec8-4a9f-8369-24316e57a499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12564d06-5221-4bc2-a4da-32fa0be2b739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9d957240-c093-48d7-9826-9bef9b9f5bd5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12564d06-5221-4bc2-a4da-32fa0be2b739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ca4c59dc-d7ed-43ab-8c37-93119f011c19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_db291cd1-ced3-4c86-9f51-48c808596cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_ca4c59dc-d7ed-43ab-8c37-93119f011c19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_db291cd1-ced3-4c86-9f51-48c808596cbd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba1b2f78-71c7-435d-8cf3-b461b545e65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da77beb3-0835-4cef-9dc2-4ec82e2c26f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba1b2f78-71c7-435d-8cf3-b461b545e65b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da77beb3-0835-4cef-9dc2-4ec82e2c26f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_54f17e19-246a-40a5-9feb-ea0842597b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba1b2f78-71c7-435d-8cf3-b461b545e65b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_54f17e19-246a-40a5-9feb-ea0842597b0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_42ceae02-4ed0-4879-ac2b-f3cc44c9dab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ba1b2f78-71c7-435d-8cf3-b461b545e65b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_42ceae02-4ed0-4879-ac2b-f3cc44c9dab2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_70bb49cf-2ccc-493f-9c75-69a37a557fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_e25ee913-d730-43fe-8d37-77f524418254" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_70bb49cf-2ccc-493f-9c75-69a37a557fa1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_e25ee913-d730-43fe-8d37-77f524418254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_10068b55-58f9-4578-b488-527247bdad04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_70bb49cf-2ccc-493f-9c75-69a37a557fa1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_10068b55-58f9-4578-b488-527247bdad04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d0304219-2016-4805-909d-04152c13c517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_af391594-682f-48d7-9229-079bb80428d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d0304219-2016-4805-909d-04152c13c517" xlink:to="loc_us-gaap_InventoryFinishedGoods_af391594-682f-48d7-9229-079bb80428d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_cde33556-14fd-4c4b-9cdb-db07bae1020f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d0304219-2016-4805-909d-04152c13c517" xlink:to="loc_us-gaap_InventoryRawMaterials_cde33556-14fd-4c4b-9cdb-db07bae1020f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_1ba25e3e-94d1-4b32-9cf6-b32b22ca7f88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d0304219-2016-4805-909d-04152c13c517" xlink:to="loc_us-gaap_InventoryWorkInProcess_1ba25e3e-94d1-4b32-9cf6-b32b22ca7f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9f4e8c56-8c14-4f87-8739-012e44a37bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_f24b3b51-dd4a-4d3b-8a19-f4a2d2b87e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9f4e8c56-8c14-4f87-8739-012e44a37bdf" xlink:to="loc_us-gaap_InventoryGross_f24b3b51-dd4a-4d3b-8a19-f4a2d2b87e83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_608b6ffc-6c5c-4b89-af3f-5714ab33bb50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9f4e8c56-8c14-4f87-8739-012e44a37bdf" xlink:to="loc_us-gaap_InventoryValuationReserves_608b6ffc-6c5c-4b89-af3f-5714ab33bb50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_975b294d-0e61-4a31-9917-f8b8a25c1919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_53d8ff9d-07f2-42fd-97e2-9c52bf21aadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_975b294d-0e61-4a31-9917-f8b8a25c1919" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_53d8ff9d-07f2-42fd-97e2-9c52bf21aadb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1fcb7c55-f73d-4a41-87df-762d98b401bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_975b294d-0e61-4a31-9917-f8b8a25c1919" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1fcb7c55-f73d-4a41-87df-762d98b401bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4645cfe-727d-470a-b58b-09823d02a1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f79752d9-5741-4dcc-8941-176fee0466d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4645cfe-727d-470a-b58b-09823d02a1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f79752d9-5741-4dcc-8941-176fee0466d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_08d34423-c985-4c00-8a48-da840c29f53c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4645cfe-727d-470a-b58b-09823d02a1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_08d34423-c985-4c00-8a48-da840c29f53c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e30810fc-7a4c-47d6-a537-3f7b1f3077b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4645cfe-727d-470a-b58b-09823d02a1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e30810fc-7a4c-47d6-a537-3f7b1f3077b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0975a75-343d-4bcf-8eef-b7eb01928e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4645cfe-727d-470a-b58b-09823d02a1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0975a75-343d-4bcf-8eef-b7eb01928e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_14ce1d35-849a-452b-9100-6acb71d7c1c1" xlink:href="pacb-20250331.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4645cfe-727d-470a-b58b-09823d02a1cc" xlink:to="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_14ce1d35-849a-452b-9100-6acb71d7c1c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_18fbe83a-2b52-4e5e-8c2d-9033c70a9845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a4645cfe-727d-470a-b58b-09823d02a1cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_18fbe83a-2b52-4e5e-8c2d-9033c70a9845" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a30dd0f8-3d03-4ca2-80e5-8d3aca7e2baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_8bdd5c2a-8f1c-4e81-af01-eb35bfc02078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a30dd0f8-3d03-4ca2-80e5-8d3aca7e2baa" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_8bdd5c2a-8f1c-4e81-af01-eb35bfc02078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5156c167-4998-463a-a107-a4e7244eee55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a30dd0f8-3d03-4ca2-80e5-8d3aca7e2baa" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5156c167-4998-463a-a107-a4e7244eee55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_65b6a99a-e668-49ea-88ed-a6133faa28e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a30dd0f8-3d03-4ca2-80e5-8d3aca7e2baa" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_65b6a99a-e668-49ea-88ed-a6133faa28e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_29aaf5c2-5654-4fab-a45b-04f178ce3f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4dea1f6c-b136-4864-8e1e-0ddcb3ce0e42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_29aaf5c2-5654-4fab-a45b-04f178ce3f2c" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4dea1f6c-b136-4864-8e1e-0ddcb3ce0e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b4afe528-63cb-4943-a191-90b9fbc1c98f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_29aaf5c2-5654-4fab-a45b-04f178ce3f2c" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_b4afe528-63cb-4943-a191-90b9fbc1c98f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5add9810-2807-476b-9a8e-a115f69019b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_41ffdf25-86ad-48f0-bfb6-70f4ae968636" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5add9810-2807-476b-9a8e-a115f69019b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_41ffdf25-86ad-48f0-bfb6-70f4ae968636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cdcf99c2-0498-44e2-b5ae-17ec69a9f96c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5add9810-2807-476b-9a8e-a115f69019b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cdcf99c2-0498-44e2-b5ae-17ec69a9f96c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e0d9eb4-8021-4351-a9c2-c411cc91e7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bdfdcd7e-9749-4243-9900-67349280010e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e0d9eb4-8021-4351-a9c2-c411cc91e7f7" xlink:to="loc_us-gaap_OperatingLeaseLiability_bdfdcd7e-9749-4243-9900-67349280010e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9907ec98-034d-469f-bede-2707226eb0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e0d9eb4-8021-4351-a9c2-c411cc91e7f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9907ec98-034d-469f-bede-2707226eb0b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="pacb-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a3afc15-9d19-476e-a9b0-73d1da3c4f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0f4b0e31-b4e1-401a-8993-cf35347f29c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a3afc15-9d19-476e-a9b0-73d1da3c4f2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0f4b0e31-b4e1-401a-8993-cf35347f29c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20e6cf5f-c8c1-4916-aff8-7416a3299cac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a3afc15-9d19-476e-a9b0-73d1da3c4f2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20e6cf5f-c8c1-4916-aff8-7416a3299cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f19947c-89c7-4b4b-b8b4-7b7e307e9e92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a3afc15-9d19-476e-a9b0-73d1da3c4f2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7f19947c-89c7-4b4b-b8b4-7b7e307e9e92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e5588a66-b713-4606-94e6-0d3212acf7db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a3afc15-9d19-476e-a9b0-73d1da3c4f2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e5588a66-b713-4606-94e6-0d3212acf7db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_abc05ca0-a176-43b0-92a5-f7597c1229eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a3afc15-9d19-476e-a9b0-73d1da3c4f2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_abc05ca0-a176-43b0-92a5-f7597c1229eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_86649f8d-13b4-40bc-82dc-ba2706d5e168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1a3afc15-9d19-476e-a9b0-73d1da3c4f2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_86649f8d-13b4-40bc-82dc-ba2706d5e168" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>pacb-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1b1d8431-b0de-47a8-b616-b49433c1f17c,g:bee9e017-2ca3-4a3e-a5bb-871b7f56db6b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_508cd720-6bfc-47d6-b23e-c044695217e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_StatementTable_508cd720-6bfc-47d6-b23e-c044695217e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c1a0290-2fca-46fd-9bb8-29fcfab41144" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_508cd720-6bfc-47d6-b23e-c044695217e5" xlink:to="loc_srt_ProductOrServiceAxis_5c1a0290-2fca-46fd-9bb8-29fcfab41144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c1a0290-2fca-46fd-9bb8-29fcfab41144_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5c1a0290-2fca-46fd-9bb8-29fcfab41144" xlink:to="loc_srt_ProductsAndServicesDomain_5c1a0290-2fca-46fd-9bb8-29fcfab41144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5c1a0290-2fca-46fd-9bb8-29fcfab41144" xlink:to="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a9b7269b-217e-4ff4-aed5-33ef04955b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:to="loc_us-gaap_ProductMember_a9b7269b-217e-4ff4-aed5-33ef04955b1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_d4a76c6c-05be-4155-a8d5-4e2e4ad3de3e" xlink:href="pacb-20250331.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:to="loc_pacb_ServiceAndOtherMember_d4a76c6c-05be-4155-a8d5-4e2e4ad3de3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bb9ce19c-dc80-4a36-8f6f-b4c841611459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_RevenuesAbstract_bb9ce19c-dc80-4a36-8f6f-b4c841611459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_688a34c6-9339-4839-93f7-7e4f631f4ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_bb9ce19c-dc80-4a36-8f6f-b4c841611459" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_688a34c6-9339-4839-93f7-7e4f631f4ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_514d5cc0-4b23-41cb-8707-04ef24546417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_514d5cc0-4b23-41cb-8707-04ef24546417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_0b52177e-5ee4-4f0a-9bad-11258850286a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_0b52177e-5ee4-4f0a-9bad-11258850286a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_89d26b6c-033f-4b49-a7ab-1ee41fa504aa" xlink:href="pacb-20250331.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_pacb_LossOnPurchaseCommitment_89d26b6c-033f-4b49-a7ab-1ee41fa504aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_98f32297-e67f-482b-9ccd-2ee0782c776d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_us-gaap_CostOfRevenue_98f32297-e67f-482b-9ccd-2ee0782c776d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_912cdba1-12a1-4627-a50b-2d4ba254f814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_GrossProfit_912cdba1-12a1-4627-a50b-2d4ba254f814" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_27d5d61e-880d-4722-b34f-6b57a0d59a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_27d5d61e-880d-4722-b34f-6b57a0d59a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08f8fe08-c9eb-4c49-b9a9-9bd6acd67971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08f8fe08-c9eb-4c49-b9a9-9bd6acd67971" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ba845ac1-0daf-4811-b4a9-8fcccc7a0f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ba845ac1-0daf-4811-b4a9-8fcccc7a0f14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_66fbe1f2-3531-478a-acf9-9d0bbd5e939f" xlink:href="pacb-20250331.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_66fbe1f2-3531-478a-acf9-9d0bbd5e939f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c9e06e40-d9b5-4dd1-91ea-8ebad2236ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c9e06e40-d9b5-4dd1-91ea-8ebad2236ca6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1dc8908b-dd93-4df6-8736-1c901c23958e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_OperatingExpenses_1dc8908b-dd93-4df6-8736-1c901c23958e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3310f78c-b473-4164-a4ef-f100d25452b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OperatingIncomeLoss_3310f78c-b473-4164-a4ef-f100d25452b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_69810c80-97a1-49ef-9feb-23c0b50bce9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_InterestExpenseNonoperating_69810c80-97a1-49ef-9feb-23c0b50bce9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5cdf8b9d-35e2-4f88-9e8d-efb411991af9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5cdf8b9d-35e2-4f88-9e8d-efb411991af9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5790b743-5a30-4f15-a65a-98a603f830a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5790b743-5a30-4f15-a65a-98a603f830a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae4d531e-0767-43df-9036-ce10102a5c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ae4d531e-0767-43df-9036-ce10102a5c4b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_353090ce-3bee-4ef1-8f58-db58042fed78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_NetIncomeLoss_353090ce-3bee-4ef1-8f58-db58042fed78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_86bf2d28-97e6-450e-a634-69d0cae698a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_86bf2d28-97e6-450e-a634-69d0cae698a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dbfa8196-5141-4408-8749-d38a59339ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_86bf2d28-97e6-450e-a634-69d0cae698a8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dbfa8196-5141-4408-8749-d38a59339ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_30f552de-ab71-4b78-b946-9afe8ac9f01f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_30f552de-ab71-4b78-b946-9afe8ac9f01f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:href="pacb-20250331.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_09145fe9-bdf9-4f26-a584-dadd7de851d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:to="loc_us-gaap_EarningsPerShareBasic_09145fe9-bdf9-4f26-a584-dadd7de851d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bb66f0c1-4807-4a6d-beb9-72e908bafeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bb66f0c1-4807-4a6d-beb9-72e908bafeaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2e07251-8d0d-4cde-92bd-5e17e4a544f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2e07251-8d0d-4cde-92bd-5e17e4a544f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7738b15-a54e-438c-8712-2c70b38f106e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7738b15-a54e-438c-8712-2c70b38f106e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7899933-fca9-4824-9567-19b65a8fe05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b0825318-5773-4055-95a5-ced03874f459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a7899933-fca9-4824-9567-19b65a8fe05b" xlink:to="loc_us-gaap_StatementTable_b0825318-5773-4055-95a5-ced03874f459" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3423ed0-dc5c-4210-bc67-ddb6a51b707e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b0825318-5773-4055-95a5-ced03874f459" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3423ed0-dc5c-4210-bc67-ddb6a51b707e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3423ed0-dc5c-4210-bc67-ddb6a51b707e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3423ed0-dc5c-4210-bc67-ddb6a51b707e" xlink:to="loc_us-gaap_EquityComponentDomain_a3423ed0-dc5c-4210-bc67-ddb6a51b707e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3423ed0-dc5c-4210-bc67-ddb6a51b707e" xlink:to="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b072f440-1d28-40e6-bc3f-fa8de11d4639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_CommonStockMember_b072f440-1d28-40e6-bc3f-fa8de11d4639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ea6d50cb-c721-4104-8772-73f470187f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ea6d50cb-c721-4104-8772-73f470187f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b25bb33-5272-4f0b-9464-515a8cdc2697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b25bb33-5272-4f0b-9464-515a8cdc2697" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c4ba66f0-bea3-4a2a-b97d-3fffbe949e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_RetainedEarningsMember_c4ba66f0-bea3-4a2a-b97d-3fffbe949e6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a7899933-fca9-4824-9567-19b65a8fe05b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b3de5813-7dad-4c2e-a07e-d49f83aa4f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b3de5813-7dad-4c2e-a07e-d49f83aa4f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27de2fee-b02e-4ef3-bc3a-7b2817023542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_StockholdersEquity_27de2fee-b02e-4ef3-bc3a-7b2817023542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f4472b1-9f0b-48c0-b4fb-32ec4ab90672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_NetIncomeLoss_5f4472b1-9f0b-48c0-b4fb-32ec4ab90672" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9b9580f-cfa3-4f22-b00b-4a669db6845b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9b9580f-cfa3-4f22-b00b-4a669db6845b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b88c08b-6323-4ead-be2d-dfbdca43411f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b88c08b-6323-4ead-be2d-dfbdca43411f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_41ca1d53-4129-4af1-9316-b25ff3844bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_41ca1d53-4129-4af1-9316-b25ff3844bc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd28c7c2-5519-4f11-9ddb-20ff002b3fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd28c7c2-5519-4f11-9ddb-20ff002b3fb5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e7626023-5a25-4f27-9e49-ff707b2bee8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd991201-9930-4e4f-8cd8-901709cddad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f8410b2b-4b2c-4359-9861-911e8da4bb85" xlink:href="pacb-20250331.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:href="pacb-20250331.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f8410b2b-4b2c-4359-9861-911e8da4bb85" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_523ae250-94e1-4ce3-b201-0efb366ee1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_523ae250-94e1-4ce3-b201-0efb366ee1b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_523ae250-94e1-4ce3-b201-0efb366ee1b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_523ae250-94e1-4ce3-b201-0efb366ee1b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_523ae250-94e1-4ce3-b201-0efb366ee1b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba287cdd-c64a-4c76-8a05-f4b94b83540c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_523ae250-94e1-4ce3-b201-0efb366ee1b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba287cdd-c64a-4c76-8a05-f4b94b83540c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8bca2093-81ad-48d0-9d48-25f171fcc451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba287cdd-c64a-4c76-8a05-f4b94b83540c" xlink:to="loc_us-gaap_AccountsReceivableMember_8bca2093-81ad-48d0-9d48-25f171fcc451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_98c5a0a2-0fd4-4176-9bb5-42950146c87b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:to="loc_srt_MajorCustomersAxis_98c5a0a2-0fd4-4176-9bb5-42950146c87b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_98c5a0a2-0fd4-4176-9bb5-42950146c87b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_98c5a0a2-0fd4-4176-9bb5-42950146c87b" xlink:to="loc_srt_NameOfMajorCustomerDomain_98c5a0a2-0fd4-4176-9bb5-42950146c87b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_98c5a0a2-0fd4-4176-9bb5-42950146c87b" xlink:to="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_7d4030b4-126a-4e56-a311-abc7d5e519f7" xlink:href="pacb-20250331.xsd#pacb_DomesticCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:to="loc_pacb_DomesticCustomersMember_7d4030b4-126a-4e56-a311-abc7d5e519f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_5d703af0-8a2f-4b2a-8cfd-874899ddc1d2" xlink:href="pacb-20250331.xsd#pacb_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:to="loc_pacb_CustomerOneMember_5d703af0-8a2f-4b2a-8cfd-874899ddc1d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_06aaef9b-3f4e-4416-9312-c63d315494a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_06aaef9b-3f4e-4416-9312-c63d315494a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e79cf893-c4f2-42fe-ace1-b250232e8c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_06aaef9b-3f4e-4416-9312-c63d315494a8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e79cf893-c4f2-42fe-ace1-b250232e8c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1bdc681a-845e-4464-b5f2-0f94ab7e2b49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f8410b2b-4b2c-4359-9861-911e8da4bb85" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1bdc681a-845e-4464-b5f2-0f94ab7e2b49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2f9fe89b-08d4-4204-a1f6-8d5edf32f6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2f9fe89b-08d4-4204-a1f6-8d5edf32f6e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f02438a2-37b2-4e10-9c85-666102090821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f02438a2-37b2-4e10-9c85-666102090821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fefebe60-5ac9-40cb-8995-d65aed0a3b86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fefebe60-5ac9-40cb-8995-d65aed0a3b86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_600c12d9-79cf-40ec-929d-d62e5cf0e48f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_600c12d9-79cf-40ec-929d-d62e5cf0e48f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_600c12d9-79cf-40ec-929d-d62e5cf0e48f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_600c12d9-79cf-40ec-929d-d62e5cf0e48f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_600c12d9-79cf-40ec-929d-d62e5cf0e48f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_aaf3301f-31bc-4102-8705-f7f98127f70c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_600c12d9-79cf-40ec-929d-d62e5cf0e48f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_aaf3301f-31bc-4102-8705-f7f98127f70c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_aaf3301f-31bc-4102-8705-f7f98127f70c" xlink:to="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3426c702-3a3f-44a8-8f93-dd8193dd1f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3426c702-3a3f-44a8-8f93-dd8193dd1f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_135c3404-3a3d-4372-ba5e-aa355806b509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_135c3404-3a3d-4372-ba5e-aa355806b509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c1e7630-243f-4732-a3e3-262dcbbf5843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c1e7630-243f-4732-a3e3-262dcbbf5843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_c2db903a-7aa7-42ff-9668-2401355e73a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c1e7630-243f-4732-a3e3-262dcbbf5843" xlink:to="loc_us-gaap_InvestmentsMember_c2db903a-7aa7-42ff-9668-2401355e73a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:to="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7b401562-ec30-49cd-a583-03c655b11742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7b401562-ec30-49cd-a583-03c655b11742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_883abe21-14ca-4563-8357-ea13369b4d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_883abe21-14ca-4563-8357-ea13369b4d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_66297d56-12f3-4078-8de7-226a5273fd3f" xlink:href="pacb-20250331.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_66297d56-12f3-4078-8de7-226a5273fd3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_31985cb0-042a-4e98-a965-8b50f7941e69" xlink:href="pacb-20250331.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_31985cb0-042a-4e98-a965-8b50f7941e69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9ad682b8-19a1-4289-98ed-352b58ea5734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9ad682b8-19a1-4289-98ed-352b58ea5734" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:to="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_265a6325-6ba2-4c83-a855-196039da220e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_265a6325-6ba2-4c83-a855-196039da220e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_92ba66e1-f501-40cd-bf04-abe61a631fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_92ba66e1-f501-40cd-bf04-abe61a631fbb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f24624e-129d-44a5-b08a-95ed91cc02bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f24624e-129d-44a5-b08a-95ed91cc02bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f24624e-129d-44a5-b08a-95ed91cc02bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f24624e-129d-44a5-b08a-95ed91cc02bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f24624e-129d-44a5-b08a-95ed91cc02bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31e6560b-f7b9-4257-ba78-4f4bd71f188f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f24624e-129d-44a5-b08a-95ed91cc02bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31e6560b-f7b9-4257-ba78-4f4bd71f188f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_6c4c7a19-7be2-4a14-98ce-bc313957ef8f" xlink:href="pacb-20250331.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31e6560b-f7b9-4257-ba78-4f4bd71f188f" xlink:to="loc_pacb_AptonMember_6c4c7a19-7be2-4a14-98ce-bc313957ef8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_2e688d6f-fd70-40be-ac3d-e1ca86510f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_2e688d6f-fd70-40be-ac3d-e1ca86510f75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2e688d6f-fd70-40be-ac3d-e1ca86510f75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2e688d6f-fd70-40be-ac3d-e1ca86510f75" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2e688d6f-fd70-40be-ac3d-e1ca86510f75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a01c5b8a-0862-401f-9975-e420d7fa1d12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2e688d6f-fd70-40be-ac3d-e1ca86510f75" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a01c5b8a-0862-401f-9975-e420d7fa1d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_9cf671fd-0e7e-4563-bccb-6fdcfd5f3741" xlink:href="pacb-20250331.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a01c5b8a-0862-401f-9975-e420d7fa1d12" xlink:to="loc_pacb_AchievementOfMilestoneMember_9cf671fd-0e7e-4563-bccb-6fdcfd5f3741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9ba313a-2b80-416a-b8ba-9d026017bde9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:to="loc_srt_RangeAxis_c9ba313a-2b80-416a-b8ba-9d026017bde9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c9ba313a-2b80-416a-b8ba-9d026017bde9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c9ba313a-2b80-416a-b8ba-9d026017bde9" xlink:to="loc_srt_RangeMember_c9ba313a-2b80-416a-b8ba-9d026017bde9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e7a035b-9562-4381-8196-57bc7667a83b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c9ba313a-2b80-416a-b8ba-9d026017bde9" xlink:to="loc_srt_RangeMember_3e7a035b-9562-4381-8196-57bc7667a83b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_04a8d1de-f12b-4e0f-800b-d19cc9aaed71" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3e7a035b-9562-4381-8196-57bc7667a83b" xlink:to="loc_srt_MaximumMember_04a8d1de-f12b-4e0f-800b-d19cc9aaed71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02f6b7f2-6849-4a24-8702-6c999bfabc31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02f6b7f2-6849-4a24-8702-6c999bfabc31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_229127c5-5471-4982-9d23-929de5a200a4" xlink:href="pacb-20250331.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_229127c5-5471-4982-9d23-929de5a200a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_cbf998f2-37b2-4ee1-b690-fc33deb8cdb7" xlink:href="pacb-20250331.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_cbf998f2-37b2-4ee1-b690-fc33deb8cdb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_2daf20d0-c89c-4e0c-9b74-43ad51b5206b" xlink:href="pacb-20250331.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_2daf20d0-c89c-4e0c-9b74-43ad51b5206b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_f551f00f-5e4b-42a5-bc7f-ecc0006e72cb" xlink:href="pacb-20250331.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_f551f00f-5e4b-42a5-bc7f-ecc0006e72cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_4e43c363-3ff9-4bc0-b882-91568fbd9c41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_us-gaap_InvestmentIncomeNet_4e43c363-3ff9-4bc0-b882-91568fbd9c41" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e2ea15e0-c501-4dea-ae43-f55f40853313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bed5a2c-5dbb-44d1-9c41-a71186f48536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e2ea15e0-c501-4dea-ae43-f55f40853313" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bed5a2c-5dbb-44d1-9c41-a71186f48536" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_808dd2aa-9fb9-459d-af60-a6b00b7c0a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bed5a2c-5dbb-44d1-9c41-a71186f48536" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_808dd2aa-9fb9-459d-af60-a6b00b7c0a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_808dd2aa-9fb9-459d-af60-a6b00b7c0a68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_808dd2aa-9fb9-459d-af60-a6b00b7c0a68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_808dd2aa-9fb9-459d-af60-a6b00b7c0a68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2a035c3-890d-401f-9826-fcbdf655ba5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_808dd2aa-9fb9-459d-af60-a6b00b7c0a68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2a035c3-890d-401f-9826-fcbdf655ba5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1b11e35d-3aa9-4237-b7a8-7c3eea6ca99a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2a035c3-890d-401f-9826-fcbdf655ba5a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1b11e35d-3aa9-4237-b7a8-7c3eea6ca99a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e2ea15e0-c501-4dea-ae43-f55f40853313" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_989badcd-0fff-45e2-9c1c-a73bac6ee33c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_989badcd-0fff-45e2-9c1c-a73bac6ee33c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_61576f0b-2011-49fa-a25f-494ccb198b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_61576f0b-2011-49fa-a25f-494ccb198b38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_564dc0e5-926a-4be9-9d46-fb5fbf67188b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_81e8745d-6c62-4546-b93b-4e360451716e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_81e8745d-6c62-4546-b93b-4e360451716e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_799c449c-c80c-48df-a944-c3a84ab6d04e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_81e8745d-6c62-4546-b93b-4e360451716e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_799c449c-c80c-48df-a944-c3a84ab6d04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799c449c-c80c-48df-a944-c3a84ab6d04e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_799c449c-c80c-48df-a944-c3a84ab6d04e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_799c449c-c80c-48df-a944-c3a84ab6d04e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_799c449c-c80c-48df-a944-c3a84ab6d04e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_673dc02a-cb0c-4c48-8139-6815021e4286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_673dc02a-cb0c-4c48-8139-6815021e4286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:to="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_44ca285a-e789-4d0b-a1d9-9b1f647b59b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_44ca285a-e789-4d0b-a1d9-9b1f647b59b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a861e999-49df-455f-9e9f-5b2f472451bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a861e999-49df-455f-9e9f-5b2f472451bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4fa12890-4258-4b5e-b8de-352c4db7590f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4fa12890-4258-4b5e-b8de-352c4db7590f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b5bd901-d537-4893-8e03-bfdb6c2b2632" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b5bd901-d537-4893-8e03-bfdb6c2b2632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfbf54bd-fc3c-4f80-b37b-b76db4497618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfbf54bd-fc3c-4f80-b37b-b76db4497618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19f2b6f7-7f5d-4e24-bbf7-2659173b8747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19f2b6f7-7f5d-4e24-bbf7-2659173b8747" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1a8f7e6e-d229-4920-8f54-a5bb0b724399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_RestrictedCashCurrent_1a8f7e6e-d229-4920-8f54-a5bb0b724399" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1ae14d73-1e90-4fca-8a03-d07bb9675737" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1ae14d73-1e90-4fca-8a03-d07bb9675737" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec2384b4-52aa-44a5-96d5-6cee868d1029_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec2384b4-52aa-44a5-96d5-6cee868d1029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_0971d718-f662-4c46-9162-1bff8b8514d7" xlink:href="pacb-20250331.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:to="loc_pacb_AptonMember_0971d718-f662-4c46-9162-1bff8b8514d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68f28069-2a54-4718-b954-b32703b67e4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68f28069-2a54-4718-b954-b32703b67e4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3e87c91-9564-4591-88d9-4fe57620a681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3e87c91-9564-4591-88d9-4fe57620a681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3c9397f-eca9-4377-907c-ea790ad25b33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3c9397f-eca9-4377-907c-ea790ad25b33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6099d97c-175d-470f-99ba-319e5ca596cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6099d97c-175d-470f-99ba-319e5ca596cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7d9b40c5-5326-45eb-a220-67f64bd9e077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7d9b40c5-5326-45eb-a220-67f64bd9e077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_8e5eb95c-61a2-451d-96a8-bbc0faeef88a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_LicenseMember_8e5eb95c-61a2-451d-96a8-bbc0faeef88a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2bac561-3394-4ed0-a243-9ea0e5c567ca_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:to="loc_srt_ProductsAndServicesDomain_e2bac561-3394-4ed0-a243-9ea0e5c567ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:to="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_17ddcbe5-7a43-44e0-8713-4b78eb254797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:to="loc_us-gaap_ServiceMember_17ddcbe5-7a43-44e0-8713-4b78eb254797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_52b594e7-1a80-40e8-a893-5c26b18d9e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_52b594e7-1a80-40e8-a893-5c26b18d9e75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_61c3f454-a829-4464-80e2-14fd783bb4b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:to="loc_us-gaap_RestructuringPlanDomain_61c3f454-a829-4464-80e2-14fd783bb4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:to="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_4d241236-7349-4319-aece-7845a352d5fc" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:to="loc_pacb_A2025RestructuringMember_4d241236-7349-4319-aece-7845a352d5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_582b2436-7bda-447e-8060-a1b0ccebfe3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_582b2436-7bda-447e-8060-a1b0ccebfe3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_90b4197c-8291-48a5-8a68-b431c3c25106" xlink:href="pacb-20250331.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:to="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_90b4197c-8291-48a5-8a68-b431c3c25106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_628680b0-17f0-46fe-893c-7068e0cb0ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_628680b0-17f0-46fe-893c-7068e0cb0ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_d8a4cb5f-b279-456a-8019-d9416bfa0de9" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_d8a4cb5f-b279-456a-8019-d9416bfa0de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_7e08607e-edf6-4bdb-9b51-04ab9f75e350" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_7e08607e-edf6-4bdb-9b51-04ab9f75e350" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_c93a68cf-30d1-458f-97f3-64d5c98a1b4e" xlink:href="pacb-20250331.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_c93a68cf-30d1-458f-97f3-64d5c98a1b4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c0432cf5-fe87-4387-9f72-dacb0bf2c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c0432cf5-fe87-4387-9f72-dacb0bf2c5ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6062e0b1-2d4c-4fd8-b135-271152d3ecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6062e0b1-2d4c-4fd8-b135-271152d3ecd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c872884e-70ee-42d7-9838-e0e84fb10b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c872884e-70ee-42d7-9838-e0e84fb10b42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_fa2e9b4b-3e79-47be-bbd7-e5013f0a1569" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_fa2e9b4b-3e79-47be-bbd7-e5013f0a1569" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_e519c97b-23fa-42a2-acf7-5906b3a0ebad" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_e519c97b-23fa-42a2-acf7-5906b3a0ebad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_9b0f9a24-0d64-488f-8565-c94d7b7f4b1a" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_9b0f9a24-0d64-488f-8565-c94d7b7f4b1a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_5b0cd747-d987-45d7-8b83-7b24c42414d8" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_5b0cd747-d987-45d7-8b83-7b24c42414d8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_b27348de-c464-4638-aeeb-db26a6f1aa4c" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_b27348de-c464-4638-aeeb-db26a6f1aa4c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_21a57ee2-6d98-4607-8cd6-bccc30d57167" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_21a57ee2-6d98-4607-8cd6-bccc30d57167" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_cedb7653-792e-4001-bef4-ad7c227514c1" xlink:href="pacb-20250331.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_cedb7653-792e-4001-bef4-ad7c227514c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare_a9066e55-75fc-45c8-b54d-12241eb09d5d" xlink:href="pacb-20250331.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ChangeInEarningsPerShare_a9066e55-75fc-45c8-b54d-12241eb09d5d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9d023feb-1b29-46b5-be23-2dd81416c462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9d023feb-1b29-46b5-be23-2dd81416c462" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ea5c56c4-0d5e-45a1-a43f-2a019bb57a51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ea5c56c4-0d5e-45a1-a43f-2a019bb57a51" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_c8411fc2-67db-478e-a67b-7ebd5bb0a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_c8411fc2-67db-478e-a67b-7ebd5bb0a0b6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43940ccb-f403-44cc-9697-266c094bee46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43940ccb-f403-44cc-9697-266c094bee46" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_513a440e-e982-4f3a-98f3-4b802108fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_513a440e-e982-4f3a-98f3-4b802108fb87" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9f57e1a2-9cbf-4eb8-b6d3-f5dde7e082d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9f57e1a2-9cbf-4eb8-b6d3-f5dde7e082d5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_b0480c50-9868-42b2-9a4e-4956c55e374c" xlink:href="pacb-20250331.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_b0480c50-9868-42b2-9a4e-4956c55e374c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8f14a05a-684f-4007-b701-32d7ec7b1432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8f14a05a-684f-4007-b701-32d7ec7b1432" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7415eb4f-9cee-4755-bba9-71772e607247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7415eb4f-9cee-4755-bba9-71772e607247" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_4be4533c-1ed0-4b34-ae4f-928326088754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_4be4533c-1ed0-4b34-ae4f-928326088754" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a527820c-efa6-49d1-83c8-02007613a689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a527820c-efa6-49d1-83c8-02007613a689" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_da8ee32d-c43c-4a96-a102-95888d9504d2" xlink:href="pacb-20250331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_StandardProductWarrantyPeriod_da8ee32d-c43c-4a96-a102-95888d9504d2" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec2384b4-52aa-44a5-96d5-6cee868d1029_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ec2384b4-52aa-44a5-96d5-6cee868d1029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_0971d718-f662-4c46-9162-1bff8b8514d7" xlink:href="pacb-20250331.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:to="loc_pacb_AptonMember_0971d718-f662-4c46-9162-1bff8b8514d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68f28069-2a54-4718-b954-b32703b67e4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_68f28069-2a54-4718-b954-b32703b67e4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3e87c91-9564-4591-88d9-4fe57620a681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3e87c91-9564-4591-88d9-4fe57620a681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3c9397f-eca9-4377-907c-ea790ad25b33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c3c9397f-eca9-4377-907c-ea790ad25b33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6099d97c-175d-470f-99ba-319e5ca596cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6099d97c-175d-470f-99ba-319e5ca596cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7d9b40c5-5326-45eb-a220-67f64bd9e077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7d9b40c5-5326-45eb-a220-67f64bd9e077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_8e5eb95c-61a2-451d-96a8-bbc0faeef88a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_LicenseMember_8e5eb95c-61a2-451d-96a8-bbc0faeef88a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2bac561-3394-4ed0-a243-9ea0e5c567ca_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:to="loc_srt_ProductsAndServicesDomain_e2bac561-3394-4ed0-a243-9ea0e5c567ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:to="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_17ddcbe5-7a43-44e0-8713-4b78eb254797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:to="loc_us-gaap_ServiceMember_17ddcbe5-7a43-44e0-8713-4b78eb254797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_61c3f454-a829-4464-80e2-14fd783bb4b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:to="loc_us-gaap_RestructuringPlanDomain_61c3f454-a829-4464-80e2-14fd783bb4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:to="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_4d241236-7349-4319-aece-7845a352d5fc" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:to="loc_pacb_A2025RestructuringMember_4d241236-7349-4319-aece-7845a352d5fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_582b2436-7bda-447e-8060-a1b0ccebfe3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_582b2436-7bda-447e-8060-a1b0ccebfe3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_90b4197c-8291-48a5-8a68-b431c3c25106" xlink:href="pacb-20250331.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:to="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_90b4197c-8291-48a5-8a68-b431c3c25106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_628680b0-17f0-46fe-893c-7068e0cb0ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_628680b0-17f0-46fe-893c-7068e0cb0ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_d8a4cb5f-b279-456a-8019-d9416bfa0de9" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_d8a4cb5f-b279-456a-8019-d9416bfa0de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_7e08607e-edf6-4bdb-9b51-04ab9f75e350" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_7e08607e-edf6-4bdb-9b51-04ab9f75e350" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_c93a68cf-30d1-458f-97f3-64d5c98a1b4e" xlink:href="pacb-20250331.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_c93a68cf-30d1-458f-97f3-64d5c98a1b4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c0432cf5-fe87-4387-9f72-dacb0bf2c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c0432cf5-fe87-4387-9f72-dacb0bf2c5ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6062e0b1-2d4c-4fd8-b135-271152d3ecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6062e0b1-2d4c-4fd8-b135-271152d3ecd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c872884e-70ee-42d7-9838-e0e84fb10b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c872884e-70ee-42d7-9838-e0e84fb10b42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_fa2e9b4b-3e79-47be-bbd7-e5013f0a1569" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_fa2e9b4b-3e79-47be-bbd7-e5013f0a1569" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_e519c97b-23fa-42a2-acf7-5906b3a0ebad" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_e519c97b-23fa-42a2-acf7-5906b3a0ebad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_9b0f9a24-0d64-488f-8565-c94d7b7f4b1a" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_9b0f9a24-0d64-488f-8565-c94d7b7f4b1a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_5b0cd747-d987-45d7-8b83-7b24c42414d8" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_5b0cd747-d987-45d7-8b83-7b24c42414d8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_b27348de-c464-4638-aeeb-db26a6f1aa4c" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_b27348de-c464-4638-aeeb-db26a6f1aa4c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_21a57ee2-6d98-4607-8cd6-bccc30d57167" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_21a57ee2-6d98-4607-8cd6-bccc30d57167" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_cedb7653-792e-4001-bef4-ad7c227514c1" xlink:href="pacb-20250331.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_cedb7653-792e-4001-bef4-ad7c227514c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare_a9066e55-75fc-45c8-b54d-12241eb09d5d" xlink:href="pacb-20250331.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ChangeInEarningsPerShare_a9066e55-75fc-45c8-b54d-12241eb09d5d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9d023feb-1b29-46b5-be23-2dd81416c462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9d023feb-1b29-46b5-be23-2dd81416c462" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ea5c56c4-0d5e-45a1-a43f-2a019bb57a51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ea5c56c4-0d5e-45a1-a43f-2a019bb57a51" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_c8411fc2-67db-478e-a67b-7ebd5bb0a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_c8411fc2-67db-478e-a67b-7ebd5bb0a0b6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43940ccb-f403-44cc-9697-266c094bee46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43940ccb-f403-44cc-9697-266c094bee46" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_513a440e-e982-4f3a-98f3-4b802108fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_513a440e-e982-4f3a-98f3-4b802108fb87" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9f57e1a2-9cbf-4eb8-b6d3-f5dde7e082d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9f57e1a2-9cbf-4eb8-b6d3-f5dde7e082d5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_b0480c50-9868-42b2-9a4e-4956c55e374c" xlink:href="pacb-20250331.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_b0480c50-9868-42b2-9a4e-4956c55e374c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8f14a05a-684f-4007-b701-32d7ec7b1432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8f14a05a-684f-4007-b701-32d7ec7b1432" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7415eb4f-9cee-4755-bba9-71772e607247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7415eb4f-9cee-4755-bba9-71772e607247" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_4be4533c-1ed0-4b34-ae4f-928326088754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_4be4533c-1ed0-4b34-ae4f-928326088754" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a527820c-efa6-49d1-83c8-02007613a689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a527820c-efa6-49d1-83c8-02007613a689" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_da8ee32d-c43c-4a96-a102-95888d9504d2" xlink:href="pacb-20250331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_StandardProductWarrantyPeriod_da8ee32d-c43c-4a96-a102-95888d9504d2" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b208e9a0-1d98-4569-92f6-54bcaeea5d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_32c91490-1e92-4691-a48a-d3a6544902d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b208e9a0-1d98-4569-92f6-54bcaeea5d25" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_32c91490-1e92-4691-a48a-d3a6544902d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e9f13983-1068-4b7a-884c-b04fc4791699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_32c91490-1e92-4691-a48a-d3a6544902d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e9f13983-1068-4b7a-884c-b04fc4791699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e9f13983-1068-4b7a-884c-b04fc4791699_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e9f13983-1068-4b7a-884c-b04fc4791699" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e9f13983-1068-4b7a-884c-b04fc4791699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_956a2704-e6c0-45a3-85d6-ef3780be2185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e9f13983-1068-4b7a-884c-b04fc4791699" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_956a2704-e6c0-45a3-85d6-ef3780be2185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c0d4a26d-3ada-4aac-82ac-7b5925154120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_956a2704-e6c0-45a3-85d6-ef3780be2185" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c0d4a26d-3ada-4aac-82ac-7b5925154120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b208e9a0-1d98-4569-92f6-54bcaeea5d25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02d74fb2-7e10-4cc8-8e08-aafb497f66c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02d74fb2-7e10-4cc8-8e08-aafb497f66c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c74bb5a8-7303-4c22-acf1-a7fb81ec3685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c74bb5a8-7303-4c22-acf1-a7fb81ec3685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_40a5dbf6-b63b-4ece-9a28-fb3fdf13f525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8c360633-0f72-40df-8828-bae97329b0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8c360633-0f72-40df-8828-bae97329b0d0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ee02c02-f548-42b6-b553-3b71f00af6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ee02c02-f548-42b6-b553-3b71f00af6d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ee02c02-f548-42b6-b553-3b71f00af6d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ee02c02-f548-42b6-b553-3b71f00af6d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ee02c02-f548-42b6-b553-3b71f00af6d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ee02c02-f548-42b6-b553-3b71f00af6d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f7226c53-82d1-4047-9a09-9087708fc945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f7226c53-82d1-4047-9a09-9087708fc945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_691aa99f-d64f-44e2-a07b-d418749a1ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:to="loc_us-gaap_CustomerRelationshipsMember_691aa99f-d64f-44e2-a07b-d418749a1ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:to="loc_srt_RangeAxis_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8" xlink:to="loc_srt_RangeMember_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8" xlink:to="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a498e5d9-540e-4c54-9b12-d0e64ab52aff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:to="loc_srt_MinimumMember_a498e5d9-540e-4c54-9b12-d0e64ab52aff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c708b7c5-ae3d-4005-a3b7-a08dcf84459b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:to="loc_srt_MaximumMember_c708b7c5-ae3d-4005-a3b7-a08dcf84459b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7509eb3c-a934-446a-86d7-fc560ff310d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7509eb3c-a934-446a-86d7-fc560ff310d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3aa50323-7580-4453-baee-ec359e594586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3aa50323-7580-4453-baee-ec359e594586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d86a8e98-2aea-4780-acd5-c234941e8455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d86a8e98-2aea-4780-acd5-c234941e8455" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df4c9e2a-d76a-4527-a840-08ee5f8e986a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df4c9e2a-d76a-4527-a840-08ee5f8e986a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d6861e4f-c842-4fef-adc3-2ec18453747a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_us-gaap_DebtInstrumentAxis_d6861e4f-c842-4fef-adc3-2ec18453747a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d6861e4f-c842-4fef-adc3-2ec18453747a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6861e4f-c842-4fef-adc3-2ec18453747a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d6861e4f-c842-4fef-adc3-2ec18453747a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6861e4f-c842-4fef-adc3-2ec18453747a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_b6b7d1d3-afd0-485f-a9c9-97f387e037f9" xlink:href="pacb-20250331.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_b6b7d1d3-afd0-485f-a9c9-97f387e037f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_34fae1bb-2530-4862-954d-6c6405213ef1" xlink:href="pacb-20250331.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_34fae1bb-2530-4862-954d-6c6405213ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_888e306a-5f24-411b-91c3-d282ec4c754c" xlink:href="pacb-20250331.xsd#pacb_A2029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_A2029NotesMember_888e306a-5f24-411b-91c3-d282ec4c754c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_2677f1e1-1145-4247-aba0-fee240b02190" xlink:href="pacb-20250331.xsd#pacb_ExchangeTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_ExchangeTransactionMember_2677f1e1-1145-4247-aba0-fee240b02190" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_87f75f38-1812-45c5-8c18-e2b730fc7782" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_87f75f38-1812-45c5-8c18-e2b730fc7782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87f75f38-1812-45c5-8c18-e2b730fc7782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_87f75f38-1812-45c5-8c18-e2b730fc7782" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87f75f38-1812-45c5-8c18-e2b730fc7782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c6fbb3d-b4d3-4704-8216-a2e3d33f9fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_87f75f38-1812-45c5-8c18-e2b730fc7782" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c6fbb3d-b4d3-4704-8216-a2e3d33f9fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_add2ffca-37bb-4efe-a14a-a66170131a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c6fbb3d-b4d3-4704-8216-a2e3d33f9fbc" xlink:to="loc_us-gaap_ConvertibleDebtMember_add2ffca-37bb-4efe-a14a-a66170131a3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_405050b6-7bc7-4647-ae5f-13f059d41c53" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_405050b6-7bc7-4647-ae5f-13f059d41c53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_405050b6-7bc7-4647-ae5f-13f059d41c53_default" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_405050b6-7bc7-4647-ae5f-13f059d41c53" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_405050b6-7bc7-4647-ae5f-13f059d41c53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_405050b6-7bc7-4647-ae5f-13f059d41c53" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_3d4768c5-35c2-472b-b19c-827e916024d3" xlink:href="pacb-20250331.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:to="loc_pacb_DebtConversionTermsOneMember_3d4768c5-35c2-472b-b19c-827e916024d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_1881b716-f27a-4505-9b38-ec92d48b2768" xlink:href="pacb-20250331.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:to="loc_pacb_DebtConversionTermsTwoMember_1881b716-f27a-4505-9b38-ec92d48b2768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_srt_RangeAxis_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2" xlink:to="loc_srt_RangeMember_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2" xlink:to="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_407c8ec5-58b0-4b6a-8fed-52346ecd8d21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:to="loc_srt_MinimumMember_407c8ec5-58b0-4b6a-8fed-52346ecd8d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f49e1773-facb-4f37-9dd9-9c88c9d1f1bc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:to="loc_srt_MaximumMember_f49e1773-facb-4f37-9dd9-9c88c9d1f1bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ca8dcf60-ad05-46b5-a0ae-4b0f1f13e52f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ca8dcf60-ad05-46b5-a0ae-4b0f1f13e52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0b3135-f8ab-4b6c-87d5-b5ca2032606d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0b3135-f8ab-4b6c-87d5-b5ca2032606d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c1696524-35d4-4e3f-bee2-ebeb42fc0c73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c1696524-35d4-4e3f-bee2-ebeb42fc0c73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5afba514-c6d9-4bf8-8914-165ee023e9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5afba514-c6d9-4bf8-8914-165ee023e9c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_a3546ee7-5194-4906-b2f0-f4e9f11a0021" xlink:href="pacb-20250331.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_a3546ee7-5194-4906-b2f0-f4e9f11a0021" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_564f3b11-6550-47de-9684-08afa09573a2" xlink:href="pacb-20250331.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_564f3b11-6550-47de-9684-08afa09573a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f88c7a20-91e6-4b5c-9163-5f7384d07243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f88c7a20-91e6-4b5c-9163-5f7384d07243" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9c8e81bc-bc33-4133-b4bc-bd74427a4cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9c8e81bc-bc33-4133-b4bc-bd74427a4cbe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b03c2b2-d35f-4ea0-877c-ead783643888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b03c2b2-d35f-4ea0-877c-ead783643888" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_fce9742c-be1b-4e29-9049-b08bb34c9a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_fce9742c-be1b-4e29-9049-b08bb34c9a78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_208a1837-4d4d-4033-a9ab-2acb49e0b570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_208a1837-4d4d-4033-a9ab-2acb49e0b570" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b1602321-838b-4639-807f-7a3d42428ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b1602321-838b-4639-807f-7a3d42428ac6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_4026932a-b1c3-45ff-975b-816762e1d626" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_4026932a-b1c3-45ff-975b-816762e1d626" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_93ef604c-535a-4981-ad4b-ce7fac535ed2" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_93ef604c-535a-4981-ad4b-ce7fac535ed2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_e4ed1ad6-115f-4c24-a4e2-8e1aa0f27133" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_e4ed1ad6-115f-4c24-a4e2-8e1aa0f27133" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_9f883e1c-af02-4cdf-adaa-0a33eac82c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_9f883e1c-af02-4cdf-adaa-0a33eac82c04" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare_d104d355-752f-4a99-af03-f965d366b2de" xlink:href="pacb-20250331.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_RestructuringOfDebtPricePerShare_d104d355-752f-4a99-af03-f965d366b2de" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_a09ee7da-af9a-45b5-ac28-37609faf2c47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_a09ee7da-af9a-45b5-ac28-37609faf2c47" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees_ced6204e-eb44-4a56-a3cc-1b6e69936221" xlink:href="pacb-20250331.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtIssuanceCostLenderFees_ced6204e-eb44-4a56-a3cc-1b6e69936221" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_441a3607-f4ff-4839-80a5-998dad82e41f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_441a3607-f4ff-4839-80a5-998dad82e41f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8cd50b4a-92de-466b-a231-c4ed2458e579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_LongTermDebt_8cd50b4a-92de-466b-a231-c4ed2458e579" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_ee6ac72d-8185-4c44-a77f-eb9fec1f1c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_ConvertibleNotesPayable_ee6ac72d-8185-4c44-a77f-eb9fec1f1c9e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_1d34a385-a176-46fa-aff8-28e28dfb220d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_1d34a385-a176-46fa-aff8-28e28dfb220d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b60fa16b-748f-448a-b00f-6665059dab66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b60fa16b-748f-448a-b00f-6665059dab66" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_1de941e9-63d2-4a9f-99b7-edd11ac2c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_1de941e9-63d2-4a9f-99b7-edd11ac2c5ce" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_f74c6f92-d692-4ab1-a602-b9da15a8ffb5" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_f74c6f92-d692-4ab1-a602-b9da15a8ffb5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0532d90e-ae89-4b54-9e57-4ce42c71d9af" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0532d90e-ae89-4b54-9e57-4ce42c71d9af" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_caa78d88-47d3-474e-bb7a-76940fc4cf44" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_caa78d88-47d3-474e-bb7a-76940fc4cf44" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9d5fd5b3-923d-45a7-8bf2-5fff6c2b8b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9d5fd5b3-923d-45a7-8bf2-5fff6c2b8b05" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fdab3e5-d50b-48b5-80c3-f8523700c356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fdab3e5-d50b-48b5-80c3-f8523700c356" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ad4d0c4e-61c6-4c13-847c-eff631dd23db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ad4d0c4e-61c6-4c13-847c-eff631dd23db" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1b28977b-2b24-4ca4-83d7-e9832a43152c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:to="loc_us-gaap_DebtInstrumentTable_1b28977b-2b24-4ca4-83d7-e9832a43152c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_473700f0-1a98-43cc-8140-95fd1a5724f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1b28977b-2b24-4ca4-83d7-e9832a43152c" xlink:to="loc_us-gaap_DebtInstrumentAxis_473700f0-1a98-43cc-8140-95fd1a5724f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_473700f0-1a98-43cc-8140-95fd1a5724f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_473700f0-1a98-43cc-8140-95fd1a5724f2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_473700f0-1a98-43cc-8140-95fd1a5724f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ea883d0-a9a2-4224-b51b-f9c715f9376c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_473700f0-1a98-43cc-8140-95fd1a5724f2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ea883d0-a9a2-4224-b51b-f9c715f9376c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_651c03ab-d087-4c7c-8784-20ee353af939" xlink:href="pacb-20250331.xsd#pacb_A2029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ea883d0-a9a2-4224-b51b-f9c715f9376c" xlink:to="loc_pacb_A2029NotesMember_651c03ab-d087-4c7c-8784-20ee353af939" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_1a7ee5dd-e915-4485-a864-29f989ddf905" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:to="loc_us-gaap_ConvertibleNotesPayable_1a7ee5dd-e915-4485-a864-29f989ddf905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_3eec72ba-dc71-477d-9073-003c0c40b778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_3eec72ba-dc71-477d-9073-003c0c40b778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_4923f3dc-4f48-4a1c-814d-f4d24180782d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2fc5e2a1-b3a6-4575-b8db-407e6a9c8013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_DebtInstrumentTable_2fc5e2a1-b3a6-4575-b8db-407e6a9c8013" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aee8c7d6-123a-4fdd-8641-ff611e7a590a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2fc5e2a1-b3a6-4575-b8db-407e6a9c8013" xlink:to="loc_us-gaap_DebtInstrumentAxis_aee8c7d6-123a-4fdd-8641-ff611e7a590a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aee8c7d6-123a-4fdd-8641-ff611e7a590a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_aee8c7d6-123a-4fdd-8641-ff611e7a590a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aee8c7d6-123a-4fdd-8641-ff611e7a590a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_92e4e4b0-3268-40b3-a975-50dd54c98881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_aee8c7d6-123a-4fdd-8641-ff611e7a590a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_92e4e4b0-3268-40b3-a975-50dd54c98881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_a245a928-320e-4d58-9d68-ec20c23fcc5b" xlink:href="pacb-20250331.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92e4e4b0-3268-40b3-a975-50dd54c98881" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_a245a928-320e-4d58-9d68-ec20c23fcc5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_784f94af-c9d6-4b57-80f8-1a4f58f2dd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_784f94af-c9d6-4b57-80f8-1a4f58f2dd3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_298865f1-4e7c-4e55-98de-e489bdab6a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_298865f1-4e7c-4e55-98de-e489bdab6a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_f6249dd1-f5b0-4b7b-9855-cf9900723a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_f6249dd1-f5b0-4b7b-9855-cf9900723a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_472d5b72-8789-4ebe-842c-4241725ea394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_LongTermDebt_472d5b72-8789-4ebe-842c-4241725ea394" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fc0196db-493f-4986-ae8a-7df54690db8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:to="loc_us-gaap_DebtInstrumentTable_fc0196db-493f-4986-ae8a-7df54690db8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fc0196db-493f-4986-ae8a-7df54690db8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_ed299382-9de5-4e03-bfe7-40eebbfd63c0" xlink:href="pacb-20250331.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_ed299382-9de5-4e03-bfe7-40eebbfd63c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_4e59e174-7f3d-485a-a563-3e5751d287b6" xlink:href="pacb-20250331.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_4e59e174-7f3d-485a-a563-3e5751d287b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_44a2f379-67a7-45b5-bcb2-a2e57c837133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_44a2f379-67a7-45b5-bcb2-a2e57c837133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_53590924-a927-430e-80c2-626937aeac01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_53590924-a927-430e-80c2-626937aeac01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_400617c1-46a7-4018-b3f2-6f02f45507b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:to="loc_us-gaap_InterestExpenseDebt_400617c1-46a7-4018-b3f2-6f02f45507b7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d714e3c7-347b-4a3b-ae2a-2fc07badb557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d714e3c7-347b-4a3b-ae2a-2fc07badb557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d714e3c7-347b-4a3b-ae2a-2fc07badb557_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d714e3c7-347b-4a3b-ae2a-2fc07badb557" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d714e3c7-347b-4a3b-ae2a-2fc07badb557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d714e3c7-347b-4a3b-ae2a-2fc07badb557" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_46c5facf-fa26-4e52-a0b1-86a5b86aae26" xlink:href="pacb-20250331.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:to="loc_pacb_EmployeeSeparationCostsMember_46c5facf-fa26-4e52-a0b1-86a5b86aae26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_64f0b5b4-bd26-4321-9268-5276efb7fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:to="loc_us-gaap_OtherRestructuringMember_64f0b5b4-bd26-4321-9268-5276efb7fdc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5f2ba26f-78ae-4b08-93c2-85f469016224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5f2ba26f-78ae-4b08-93c2-85f469016224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f2ba26f-78ae-4b08-93c2-85f469016224_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5f2ba26f-78ae-4b08-93c2-85f469016224" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f2ba26f-78ae-4b08-93c2-85f469016224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5f2ba26f-78ae-4b08-93c2-85f469016224" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea4035ac-f54b-48b2-8947-0d72ce23ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea4035ac-f54b-48b2-8947-0d72ce23ccb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_48cfa2d1-6194-46b0-9452-c35f6187f944" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_48cfa2d1-6194-46b0-9452-c35f6187f944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f2e2a52a-92c3-4fa8-b919-e4ea71ed9240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:to="loc_us-gaap_CostOfSalesMember_f2e2a52a-92c3-4fa8-b919-e4ea71ed9240" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_d7e99c71-a48f-4287-a152-f351c909cc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:to="loc_us-gaap_RestructuringPlanAxis_d7e99c71-a48f-4287-a152-f351c909cc9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d7e99c71-a48f-4287-a152-f351c909cc9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_d7e99c71-a48f-4287-a152-f351c909cc9c" xlink:to="loc_us-gaap_RestructuringPlanDomain_d7e99c71-a48f-4287-a152-f351c909cc9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_d7e99c71-a48f-4287-a152-f351c909cc9c" xlink:to="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_22ccfb5f-9ddb-42b7-9442-27a403bda6f5" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:to="loc_pacb_A2025RestructuringMember_22ccfb5f-9ddb-42b7-9442-27a403bda6f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_c3381f97-3eb9-4967-8fe8-3424fed09949" xlink:href="pacb-20250331.xsd#pacb_A2024RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:to="loc_pacb_A2024RestructuringMember_c3381f97-3eb9-4967-8fe8-3424fed09949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fcb1815e-f577-46b6-91d1-c09233227f16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_us-gaap_RestructuringCharges_fcb1815e-f577-46b6-91d1-c09233227f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c5597314-61cf-4c31-9c45-aaf5ebb45ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c5597314-61cf-4c31-9c45-aaf5ebb45ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_883dfbae-f845-48eb-8eca-ce3bdea93ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_883dfbae-f845-48eb-8eca-ce3bdea93ff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesExcludingAdjustments_1aa2b2cf-707e-4146-a9b8-26a5b489da80" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesExcludingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_pacb_RestructuringChargesExcludingAdjustments_1aa2b2cf-707e-4146-a9b8-26a5b489da80" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURINGNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6de88448-5ae4-4961-b05f-ba2237a11843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:to="loc_us-gaap_RestructuringPlanAxis_6de88448-5ae4-4961-b05f-ba2237a11843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6de88448-5ae4-4961-b05f-ba2237a11843_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_6de88448-5ae4-4961-b05f-ba2237a11843" xlink:to="loc_us-gaap_RestructuringPlanDomain_6de88448-5ae4-4961-b05f-ba2237a11843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_6de88448-5ae4-4961-b05f-ba2237a11843" xlink:to="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_5fa3dce9-1e88-4495-a5b3-67651ad01b9c" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:to="loc_pacb_A2025RestructuringMember_5fa3dce9-1e88-4495-a5b3-67651ad01b9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_6ba23e57-df27-4cdc-8f27-5abd60ad6c7f" xlink:href="pacb-20250331.xsd#pacb_A2024RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:to="loc_pacb_A2024RestructuringMember_6ba23e57-df27-4cdc-8f27-5abd60ad6c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_e9399f2c-679a-4c29-a053-5df3f9d8a836" xlink:href="pacb-20250331.xsd#pacb_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:to="loc_pacb_SanDiegoOfficeMember_e9399f2c-679a-4c29-a053-5df3f9d8a836" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ec2dda85-4df4-44e4-bdae-940feea19b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ec2dda85-4df4-44e4-bdae-940feea19b29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ec2dda85-4df4-44e4-bdae-940feea19b29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ec2dda85-4df4-44e4-bdae-940feea19b29" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ec2dda85-4df4-44e4-bdae-940feea19b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5141a984-1e60-4951-bd4a-3f571fcc825e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ec2dda85-4df4-44e4-bdae-940feea19b29" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5141a984-1e60-4951-bd4a-3f571fcc825e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_c7d0b469-b59d-42ff-9f5b-fd3fe01998eb" xlink:href="pacb-20250331.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5141a984-1e60-4951-bd4a-3f571fcc825e" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_c7d0b469-b59d-42ff-9f5b-fd3fe01998eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_535fadb7-db6c-4acf-9352-5a848ab3d492" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_535fadb7-db6c-4acf-9352-5a848ab3d492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_117b077e-19fe-4fb5-a933-217280c22a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_SeveranceCosts1_117b077e-19fe-4fb5-a933-217280c22a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesAdditionalCostsIncurred_d2474fdd-c6ec-41ab-bcac-98bd4a3d49bc" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesAdditionalCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_RestructuringChargesAdditionalCostsIncurred_d2474fdd-c6ec-41ab-bcac-98bd4a3d49bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ac02bf71-e12c-4b0f-853b-5989a0928354" xlink:href="pacb-20250331.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ac02bf71-e12c-4b0f-853b-5989a0928354" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2d3ac3b3-a575-4357-aed4-872fe13d49a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2d3ac3b3-a575-4357-aed4-872fe13d49a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_036003a9-cd22-481b-a302-121ca2091826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_InventoryWriteDown_036003a9-cd22-481b-a302-121ca2091826" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GainLossOnPurchaseCommitments_18938a8b-4af7-4d33-a844-b7691f7a01fc" xlink:href="pacb-20250331.xsd#pacb_GainLossOnPurchaseCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_GainLossOnPurchaseCommitments_18938a8b-4af7-4d33-a844-b7691f7a01fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_90105685-d86a-40bc-9028-797a35d63940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_90105685-d86a-40bc-9028-797a35d63940" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_10fb9bce-9fe4-48ef-970e-f8d92b14a176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_10fb9bce-9fe4-48ef-970e-f8d92b14a176" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0246cff2-06c7-472a-a22a-11981ac3018d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_OperatingLeaseLiability_0246cff2-06c7-472a-a22a-11981ac3018d" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_292b60e6-5d4d-4da5-9bc3-23a0059acef8" xlink:href="pacb-20250331.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:to="loc_pacb_EmployeeSeparationCostsMember_292b60e6-5d4d-4da5-9bc3-23a0059acef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_6135ef15-5741-4ab4-9117-79ec148f7309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:to="loc_us-gaap_OtherRestructuringMember_6135ef15-5741-4ab4-9117-79ec148f7309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_028d9a6e-8a53-4fe9-9697-726132ed1b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:to="loc_us-gaap_RestructuringPlanAxis_028d9a6e-8a53-4fe9-9697-726132ed1b19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_028d9a6e-8a53-4fe9-9697-726132ed1b19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_028d9a6e-8a53-4fe9-9697-726132ed1b19" xlink:to="loc_us-gaap_RestructuringPlanDomain_028d9a6e-8a53-4fe9-9697-726132ed1b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_028d9a6e-8a53-4fe9-9697-726132ed1b19" xlink:to="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_cf5fcaa2-2f4f-45c7-8c78-71c3ef37d56a" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:to="loc_pacb_A2025RestructuringMember_cf5fcaa2-2f4f-45c7-8c78-71c3ef37d56a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_f2cfe2cf-24c7-410d-bd09-2910e7233dc1" xlink:href="pacb-20250331.xsd#pacb_A2024RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:to="loc_pacb_A2024RestructuringMember_f2cfe2cf-24c7-410d-bd09-2910e7233dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_9a1dfe52-901f-4775-8c94-a34b8e18149b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_RestructuringReserve_9a1dfe52-901f-4775-8c94-a34b8e18149b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f4bf8369-1b55-4861-aa0b-d8ccb4f41272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_RestructuringCharges_f4bf8369-1b55-4861-aa0b-d8ccb4f41272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_c0060599-cfe0-4f2f-abaf-c722bda7c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_PaymentsForRestructuring_c0060599-cfe0-4f2f-abaf-c722bda7c4a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f56476c0-2c95-4b2c-942a-66db6dba09d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_3ab69e37-931b-4d83-94c3-b9a1eb76a950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_3ab69e37-931b-4d83-94c3-b9a1eb76a950" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_a90b34db-5e78-4406-8cec-4386202c190d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_a90b34db-5e78-4406-8cec-4386202c190d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_a990bf4b-a707-4d73-a67a-ad452c2fe0e9" xlink:href="pacb-20250331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_a90b34db-5e78-4406-8cec-4386202c190d" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_a990bf4b-a707-4d73-a67a-ad452c2fe0e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_265401e4-c56b-4bed-92d2-5f4828d08ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:to="loc_us-gaap_PlanNameAxis_265401e4-c56b-4bed-92d2-5f4828d08ffa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_265401e4-c56b-4bed-92d2-5f4828d08ffa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_265401e4-c56b-4bed-92d2-5f4828d08ffa" xlink:to="loc_us-gaap_PlanNameDomain_265401e4-c56b-4bed-92d2-5f4828d08ffa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_17d141df-a2b4-470e-acf2-ab7222b7c52d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_265401e4-c56b-4bed-92d2-5f4828d08ffa" xlink:to="loc_us-gaap_PlanNameDomain_17d141df-a2b4-470e-acf2-ab7222b7c52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_78d06124-6e3e-4dc7-8578-832371db2b4e" xlink:href="pacb-20250331.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_17d141df-a2b4-470e-acf2-ab7222b7c52d" xlink:to="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_78d06124-6e3e-4dc7-8578-832371db2b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_827b4e9d-69d0-41a8-9520-a8846eefc313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:to="loc_us-gaap_AwardTypeAxis_827b4e9d-69d0-41a8-9520-a8846eefc313" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827b4e9d-69d0-41a8-9520-a8846eefc313_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_827b4e9d-69d0-41a8-9520-a8846eefc313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_827b4e9d-69d0-41a8-9520-a8846eefc313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed29baa1-33f5-4d55-ad8b-6d421d966746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_827b4e9d-69d0-41a8-9520-a8846eefc313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed29baa1-33f5-4d55-ad8b-6d421d966746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_19ef1ffa-3394-4396-aa1e-220c9d11dda7" xlink:href="pacb-20250331.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed29baa1-33f5-4d55-ad8b-6d421d966746" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_19ef1ffa-3394-4396-aa1e-220c9d11dda7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f8b605d6-0e40-4289-877e-50625f2ac382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f8b605d6-0e40-4289-877e-50625f2ac382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_4cbaefcd-d04d-4d02-aea5-07ee2528a8b4" xlink:href="pacb-20250331.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_4cbaefcd-d04d-4d02-aea5-07ee2528a8b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_58997985-1af0-4b85-8b5a-251f4efff0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_58997985-1af0-4b85-8b5a-251f4efff0a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c73b9deb-6037-43f9-9192-7f084a24c70b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c73b9deb-6037-43f9-9192-7f084a24c70b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40f4dac5-7881-4591-ae1e-ee790e34dda7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40f4dac5-7881-4591-ae1e-ee790e34dda7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00324306-1472-4ddf-b119-772cbfabcb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00324306-1472-4ddf-b119-772cbfabcb9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_70625e60-d5d7-4714-98da-496404fe4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00324306-1472-4ddf-b119-772cbfabcb9a" xlink:to="loc_us-gaap_AwardTypeAxis_70625e60-d5d7-4714-98da-496404fe4e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70625e60-d5d7-4714-98da-496404fe4e20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_70625e60-d5d7-4714-98da-496404fe4e20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70625e60-d5d7-4714-98da-496404fe4e20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7279ac-f302-4c88-bda0-3db098bfb72f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_70625e60-d5d7-4714-98da-496404fe4e20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7279ac-f302-4c88-bda0-3db098bfb72f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_f02327db-1f8e-44c6-b4f0-f2c6f1ea7740" xlink:href="pacb-20250331.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7279ac-f302-4c88-bda0-3db098bfb72f" xlink:to="loc_pacb_TimeBasedStockOptionMember_f02327db-1f8e-44c6-b4f0-f2c6f1ea7740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb88978b-3fc1-444e-a05c-2a9e356affe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb88978b-3fc1-444e-a05c-2a9e356affe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8e825444-e38f-48de-8b99-73dafaae4a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8e825444-e38f-48de-8b99-73dafaae4a42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54a84e09-2821-44c7-a0cb-c6b4ecf51067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54a84e09-2821-44c7-a0cb-c6b4ecf51067" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c250dd04-86d9-429f-bf14-c5766d756ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c250dd04-86d9-429f-bf14-c5766d756ff6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c47c872e-34e6-452e-9515-72c65993d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9c0f2ca6-ab6c-4c11-9cd2-d12cdb1a6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9c0f2ca6-ab6c-4c11-9cd2-d12cdb1a6b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e2b21a7a-a478-4b76-80a2-9610c0bb25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e2b21a7a-a478-4b76-80a2-9610c0bb25bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_42ca0ce1-eccf-40d8-8228-a7b5bb7e2b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_42ca0ce1-eccf-40d8-8228-a7b5bb7e2b72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b6e3ef13-eb93-421a-a87b-f7be9b7c2b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b6e3ef13-eb93-421a-a87b-f7be9b7c2b5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_713db03e-95e1-4e95-84d2-1904bb613db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa0bb0e2-4950-436b-b5a3-711369811666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa0bb0e2-4950-436b-b5a3-711369811666" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_573bee45-f720-4c0b-8459-ec21e7d3e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa0bb0e2-4950-436b-b5a3-711369811666" xlink:to="loc_us-gaap_AwardTypeAxis_573bee45-f720-4c0b-8459-ec21e7d3e25d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_573bee45-f720-4c0b-8459-ec21e7d3e25d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_573bee45-f720-4c0b-8459-ec21e7d3e25d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_573bee45-f720-4c0b-8459-ec21e7d3e25d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_573bee45-f720-4c0b-8459-ec21e7d3e25d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_d0785239-9d28-40cb-8b6b-8d79b10ce609" xlink:href="pacb-20250331.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_d0785239-9d28-40cb-8b6b-8d79b10ce609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e1998cb6-18de-4a0b-8d8c-bee66de33b86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:to="loc_us-gaap_PerformanceSharesMember_e1998cb6-18de-4a0b-8d8c-bee66de33b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc9d3977-dd43-4ad7-8251-c8566ec81403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc9d3977-dd43-4ad7-8251-c8566ec81403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70382d7f-008e-45fb-b3a2-b91f34f8479e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70382d7f-008e-45fb-b3a2-b91f34f8479e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5fdd6b8b-9ad5-473d-a4e7-cc9eda02a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5fdd6b8b-9ad5-473d-a4e7-cc9eda02a93a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8037cb6-b932-4945-8944-0561da49e5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8037cb6-b932-4945-8944-0561da49e5ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_308a3bfb-286d-48d8-8a98-381086112781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3bfd9f1-b103-4c97-9e12-850119e4bf90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3bfd9f1-b103-4c97-9e12-850119e4bf90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34cff6fa-56c9-4655-a545-a122e58e78aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34cff6fa-56c9-4655-a545-a122e58e78aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_546d695b-49a8-4acc-9b93-86346e91d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_546d695b-49a8-4acc-9b93-86346e91d9eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3aeb46ee-6af9-4abf-a376-95814cb32968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3aeb46ee-6af9-4abf-a376-95814cb32968" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_516f24d8-36b3-4608-a2ea-77ca19c6c388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7a49d9b5-45fb-412a-98f6-72f3409396aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c9ce86e-d0be-4b51-b290-c9ed0975be84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7a49d9b5-45fb-412a-98f6-72f3409396aa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c9ce86e-d0be-4b51-b290-c9ed0975be84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70fa01f8-e00e-4faf-bec5-00628914df32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c9ce86e-d0be-4b51-b290-c9ed0975be84" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70fa01f8-e00e-4faf-bec5-00628914df32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_70fa01f8-e00e-4faf-bec5-00628914df32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70fa01f8-e00e-4faf-bec5-00628914df32" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_70fa01f8-e00e-4faf-bec5-00628914df32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70fa01f8-e00e-4faf-bec5-00628914df32" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6de19cd1-5f77-404f-845d-1b463905ff48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_us-gaap_CostOfSalesMember_6de19cd1-5f77-404f-845d-1b463905ff48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d69f075-120a-4c78-a934-8c8efba7d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d69f075-120a-4c78-a934-8c8efba7d20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_26acee8e-0723-4624-a486-94118198f243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_26acee8e-0723-4624-a486-94118198f243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_c1bc37d6-2855-4c6b-ab0e-87e4602548f9" xlink:href="pacb-20250331.xsd#pacb_StockBasedCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_pacb_StockBasedCompensationMember_c1bc37d6-2855-4c6b-ab0e-87e4602548f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ce0d5c5-eb21-4ec8-b60a-df8114946fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7a49d9b5-45fb-412a-98f6-72f3409396aa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ce0d5c5-eb21-4ec8-b60a-df8114946fe8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576ec89b-8689-44a7-8b36-4921a239da88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576ec89b-8689-44a7-8b36-4921a239da88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_65b78164-a29d-4094-b9f1-04344f3a09ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576ec89b-8689-44a7-8b36-4921a239da88" xlink:to="loc_us-gaap_AwardTypeAxis_65b78164-a29d-4094-b9f1-04344f3a09ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65b78164-a29d-4094-b9f1-04344f3a09ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_65b78164-a29d-4094-b9f1-04344f3a09ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65b78164-a29d-4094-b9f1-04344f3a09ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f43d75bd-4029-4220-8b01-875f1f0bdb02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_65b78164-a29d-4094-b9f1-04344f3a09ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f43d75bd-4029-4220-8b01-875f1f0bdb02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_a4b6af6e-a4c0-4f6c-bced-9534c49d8dd8" xlink:href="pacb-20250331.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f43d75bd-4029-4220-8b01-875f1f0bdb02" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_a4b6af6e-a4c0-4f6c-bced-9534c49d8dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d95993c-525f-43ec-b51e-328df8021250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d95993c-525f-43ec-b51e-328df8021250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c46da047-f8b2-439b-936d-80cf10a94564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c46da047-f8b2-439b-936d-80cf10a94564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0fdbee0e-720f-4a0b-abf7-8ee334068f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0fdbee0e-720f-4a0b-abf7-8ee334068f33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_57613446-f8a5-4a66-b9d7-fc35a349dd78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_57613446-f8a5-4a66-b9d7-fc35a349dd78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b4007f0f-6a54-4a84-b152-1ec5f437f559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b4007f0f-6a54-4a84-b152-1ec5f437f559" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d638476e-dcf2-4874-9eca-a39493b52494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d638476e-dcf2-4874-9eca-a39493b52494" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eca9e1bb-8aee-4003-83fe-87a0382709a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eca9e1bb-8aee-4003-83fe-87a0382709a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_686780a2-8a17-4f39-8ea7-32c4d2597fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_686780a2-8a17-4f39-8ea7-32c4d2597fb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09b152e3-661f-4a74-a9a9-8419b37381db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09b152e3-661f-4a74-a9a9-8419b37381db" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d0b3fce6-1d18-408c-8b5d-585c23a028ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:to="loc_srt_RangeAxis_d0b3fce6-1d18-408c-8b5d-585c23a028ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0b3fce6-1d18-408c-8b5d-585c23a028ab_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d0b3fce6-1d18-408c-8b5d-585c23a028ab" xlink:to="loc_srt_RangeMember_d0b3fce6-1d18-408c-8b5d-585c23a028ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d0b3fce6-1d18-408c-8b5d-585c23a028ab" xlink:to="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a95e9f6-39a0-4d28-a392-766a7d9ef34e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:to="loc_srt_MinimumMember_6a95e9f6-39a0-4d28-a392-766a7d9ef34e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e681632-e302-4878-8ebd-f783b207bf15" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:to="loc_srt_MaximumMember_5e681632-e302-4878-8ebd-f783b207bf15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4bce424e-694f-464d-92c0-5a04cb15b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:to="loc_us-gaap_PlanNameAxis_4bce424e-694f-464d-92c0-5a04cb15b1d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4bce424e-694f-464d-92c0-5a04cb15b1d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4bce424e-694f-464d-92c0-5a04cb15b1d2" xlink:to="loc_us-gaap_PlanNameDomain_4bce424e-694f-464d-92c0-5a04cb15b1d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9426d2a5-bc4a-48e6-bce3-23e159ecedbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4bce424e-694f-464d-92c0-5a04cb15b1d2" xlink:to="loc_us-gaap_PlanNameDomain_9426d2a5-bc4a-48e6-bce3-23e159ecedbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_403b1af7-6dd5-401f-ad7d-85220a426f6a" xlink:href="pacb-20250331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9426d2a5-bc4a-48e6-bce3-23e159ecedbe" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_403b1af7-6dd5-401f-ad7d-85220a426f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f454db8f-426e-4511-926b-892ae06111ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f454db8f-426e-4511-926b-892ae06111ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e4f60ad-30c9-4539-9b1e-41c98b452de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e4f60ad-30c9-4539-9b1e-41c98b452de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2643ba87-8e9c-4a67-9980-62dd0f572945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2643ba87-8e9c-4a67-9980-62dd0f572945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8439bab8-4e39-403a-99fb-be418b2b1d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8439bab8-4e39-403a-99fb-be418b2b1d09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6672cc3b-2f59-4adc-85ba-150585bcfa49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6672cc3b-2f59-4adc-85ba-150585bcfa49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d8035e8-5e18-4dae-94ed-a39f6340f393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d8035e8-5e18-4dae-94ed-a39f6340f393" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3fe5c64c-1193-400e-8b4b-b810c7021835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8687e1bd-75f9-4fa8-82fd-25bf668f918c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3fe5c64c-1193-400e-8b4b-b810c7021835" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8687e1bd-75f9-4fa8-82fd-25bf668f918c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44bb8bfa-b62b-4905-806b-fc90cbed27c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8687e1bd-75f9-4fa8-82fd-25bf668f918c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44bb8bfa-b62b-4905-806b-fc90cbed27c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_44bb8bfa-b62b-4905-806b-fc90cbed27c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44bb8bfa-b62b-4905-806b-fc90cbed27c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_44bb8bfa-b62b-4905-806b-fc90cbed27c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44bb8bfa-b62b-4905-806b-fc90cbed27c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_6b8fef22-99f3-4ffc-8c28-e93707251afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_6b8fef22-99f3-4ffc-8c28-e93707251afa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1f787b04-35fa-4af5-98bf-7dcbfdfdf1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:to="loc_us-gaap_StockCompensationPlanMember_1f787b04-35fa-4af5-98bf-7dcbfdfdf1bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70db83c7-ccb0-4c69-80b0-4556f7092708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3fe5c64c-1193-400e-8b4b-b810c7021835" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70db83c7-ccb0-4c69-80b0-4556f7092708" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_baad6cb3-f054-4b37-8dc7-2edc9f4827d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_baad6cb3-f054-4b37-8dc7-2edc9f4827d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7689fdb5-4e49-4ac5-9be2-30c7c0f77747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_baad6cb3-f054-4b37-8dc7-2edc9f4827d4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7689fdb5-4e49-4ac5-9be2-30c7c0f77747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7689fdb5-4e49-4ac5-9be2-30c7c0f77747_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7689fdb5-4e49-4ac5-9be2-30c7c0f77747" xlink:to="loc_us-gaap_SegmentDomain_7689fdb5-4e49-4ac5-9be2-30c7c0f77747_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93ad3ce4-c393-4e53-82a6-b118efe95f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7689fdb5-4e49-4ac5-9be2-30c7c0f77747" xlink:to="loc_us-gaap_SegmentDomain_93ad3ce4-c393-4e53-82a6-b118efe95f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember_3f8c0ae1-2f90-49e1-bbf8-74dd1a5adb9c" xlink:href="pacb-20250331.xsd#pacb_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_93ad3ce4-c393-4e53-82a6-b118efe95f51" xlink:to="loc_pacb_ReportableSegmentMember_3f8c0ae1-2f90-49e1-bbf8-74dd1a5adb9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e0e47bbe-feef-4008-afe7-57e2aa8e6dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e0e47bbe-feef-4008-afe7-57e2aa8e6dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_44e7445a-5824-4627-82a6-af44a7070eee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_CostOfRevenue_44e7445a-5824-4627-82a6-af44a7070eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_72322e7d-26ef-4100-9eb0-3e99fcdae43e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_72322e7d-26ef-4100-9eb0-3e99fcdae43e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_fe9a7cd5-e864-4a87-a6e0-6cacf56123de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_SellingAndMarketingExpense_fe9a7cd5-e864-4a87-a6e0-6cacf56123de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca78fed5-ec8b-41fb-a943-8f94c5ed4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca78fed5-ec8b-41fb-a943-8f94c5ed4c82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a015fa8b-0995-4b25-b7e7-ec8d9ca5f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a015fa8b-0995-4b25-b7e7-ec8d9ca5f5e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e8ab9b82-3f27-4333-8677-96ae6c975620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e8ab9b82-3f27-4333-8677-96ae6c975620" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2791de26-943b-4ac3-9397-e8c179cbdcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2791de26-943b-4ac3-9397-e8c179cbdcf3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_060dc37d-90e3-4250-b9cd-66c5b7bc43d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_060dc37d-90e3-4250-b9cd-66c5b7bc43d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec2dde48-19c9-4a03-8cc9-e8eb95134f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec2dde48-19c9-4a03-8cc9-e8eb95134f36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e22d54f-0fc6-47f4-a0e9-fe7553822174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_NetIncomeLoss_9e22d54f-0fc6-47f4-a0e9-fe7553822174" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1a71c54d-52c9-445d-a4b0-83c32735c053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a1dbbedc-5cb0-4931-a473-75adbc0178c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1a71c54d-52c9-445d-a4b0-83c32735c053" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a1dbbedc-5cb0-4931-a473-75adbc0178c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79d30d40-efe4-411e-bced-3128ec3ba5cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a1dbbedc-5cb0-4931-a473-75adbc0178c0" xlink:to="loc_srt_StatementGeographicalAxis_79d30d40-efe4-411e-bced-3128ec3ba5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_79d30d40-efe4-411e-bced-3128ec3ba5cd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_79d30d40-efe4-411e-bced-3128ec3ba5cd" xlink:to="loc_srt_SegmentGeographicalDomain_79d30d40-efe4-411e-bced-3128ec3ba5cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_79d30d40-efe4-411e-bced-3128ec3ba5cd" xlink:to="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_223c04e7-eb7e-4a6b-8dda-a5db173ef240" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:to="loc_srt_AmericasMember_223c04e7-eb7e-4a6b-8dda-a5db173ef240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_4981643e-0eba-4028-9dd2-f3499bdc5a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:to="loc_us-gaap_EMEAMember_4981643e-0eba-4028-9dd2-f3499bdc5a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_43c27f5c-2b31-4758-8acb-17b01816bf97" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:to="loc_srt_AsiaPacificMember_43c27f5c-2b31-4758-8acb-17b01816bf97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8dcacfa9-2ea9-4595-bc6f-ce7277bc1407" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1a71c54d-52c9-445d-a4b0-83c32735c053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8dcacfa9-2ea9-4595-bc6f-ce7277bc1407" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ea897dc5-142b-4b1e-8268-b91f82d593d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_705ae16b-4db1-4039-9c80-02ae6c5c5c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ea897dc5-142b-4b1e-8268-b91f82d593d7" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_705ae16b-4db1-4039-9c80-02ae6c5c5c90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7973b87e-f184-4662-8d3a-e70f6c776a55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_705ae16b-4db1-4039-9c80-02ae6c5c5c90" xlink:to="loc_srt_ProductOrServiceAxis_7973b87e-f184-4662-8d3a-e70f6c776a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7973b87e-f184-4662-8d3a-e70f6c776a55_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7973b87e-f184-4662-8d3a-e70f6c776a55" xlink:to="loc_srt_ProductsAndServicesDomain_7973b87e-f184-4662-8d3a-e70f6c776a55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7973b87e-f184-4662-8d3a-e70f6c776a55" xlink:to="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:to="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_79e945c3-0394-4e49-b880-5065da3859dd" xlink:href="pacb-20250331.xsd#pacb_InstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:to="loc_pacb_InstrumentMember_79e945c3-0394-4e49-b880-5065da3859dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_77504213-5a69-4b1a-8ffd-06e5c4f0062a" xlink:href="pacb-20250331.xsd#pacb_ConsumableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:to="loc_pacb_ConsumableMember_77504213-5a69-4b1a-8ffd-06e5c4f0062a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_d7b3f7f9-ae22-4e5c-8c89-3d96906329fc" xlink:href="pacb-20250331.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:to="loc_pacb_ServiceAndOtherMember_d7b3f7f9-ae22-4e5c-8c89-3d96906329fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e34bd5e1-3358-40e1-85b4-edcc76eefb15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ea897dc5-142b-4b1e-8268-b91f82d593d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e34bd5e1-3358-40e1-85b4-edcc76eefb15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>pacb-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1b1d8431-b0de-47a8-b616-b49433c1f17c,g:bee9e017-2ca3-4a3e-a5bb-871b7f56db6b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_27a4d33c-75e6-458b-9174-7b01889687d4_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government &amp; agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d969b52b-80b9-4ac1-8ca1-904725f2d552_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_eb510e9e-7919-4df8-a64e-6c953fbae448_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units Rsus [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time-Based Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:href="pacb-20250331.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9eb172e7-b6d2-4e61-aba6-6d767c35fc35_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_0db6325f-d9a8-4515-a7e9-82cb32eb4243_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_29a9ffaa-908c-408e-bbd1-986a5f37506f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0c9fbbe9-cb17-49aa-beba-3da4b91a5f9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_52dafc2b-b10b-4504-9cca-63ee0c437606_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash, Cash Equivalents, Restricted Cash and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_dbb91d56-a789-498a-b490-b39ee70203bb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_979be490-02f4-4ea9-be1c-b0bf8c6403ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aca39a15-4c56-4475-a9d6-8680052725a2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_6df74d3b-712c-43be-bfa0-202b036149ba_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_9b3784c1-1da8-432a-9216-066bf151eddd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_be651892-d9ae-4c49-bc2e-22c2a1a2b0ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_f51cf255-68e9-4932-9f6c-680acc001cd5_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, debt default, calendar days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:to="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fa98d9f4-5b94-43a4-b164-3f76c1b700e3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_e3347943-5e71-452e-9713-e67975799680_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_fd6d9f97-0efb-4751-87d8-ae9f2a8dd33d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_f6c9b19b-9d5b-4e9e-b6f2-1248a748c936_terseLabel_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:href="pacb-20250331.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_d8b828c8-be3e-44bd-8519-07a1f9246924_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:href="pacb-20250331.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_7bf527be-1d66-414d-8547-44fd92a6d141_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_fd0f378e-a061-4cd4-8c94-cdc39928d591_terseLabel_en-US" xlink:label="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in basis point discount rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_label_en-US" xlink:label="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_documentation_en-US" xlink:label="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:to="lab_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_e277cbdd-dab0-4dab-b02b-6dcfc4166f0e_terseLabel_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_label_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_documentation_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Components Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_7ab1f801-314d-4938-b4a5-caedd2531863_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a69f8975-3590-46b7-936f-7ccc7baa1dc1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_79942af4-6f84-4a73-9cdf-420569b68ed4_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1539860f-c1b0-4dd9-95bd-c9b0d2c6511e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2758d5ab-b384-4e39-8680-11c04313db13_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_22bdd742-bccc-4754-b869-20fd9243463b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ExchangeTransactionMember_75e58e58-a3d8-4e94-b6aa-41d42c1baab2_terseLabel_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange Transaction</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_label_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Transaction [Member]</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_documentation_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember" xlink:href="pacb-20250331.xsd#pacb_ExchangeTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ExchangeTransactionMember" xlink:to="lab_pacb_ExchangeTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3c7b6961-5f23-4abd-96b2-0e1594e47ae9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d9c133be-6e0a-4000-b5b5-24f020fdf7e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a735ba75-18f0-407e-bb47-755833cdc494_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3dbdc980-d03a-4373-95de-bd30db3b318b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a6104bf8-2715-425b-8590-41433301331d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2025RestructuringMember_1f60558f-9cf2-4ad0-97c3-e542200e672c_terseLabel_en-US" xlink:label="lab_pacb_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Restructuring</link:label>
    <link:label id="lab_pacb_A2025RestructuringMember_label_en-US" xlink:label="lab_pacb_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Restructuring [Member]</link:label>
    <link:label id="lab_pacb_A2025RestructuringMember_documentation_en-US" xlink:label="lab_pacb_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2025RestructuringMember" xlink:to="lab_pacb_A2025RestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4a5391a4-e558-4be2-a718-2bc5e560a8d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock remain available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_aeebf80f-9279-4b56-a0f3-e45b3af0ef43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_38576263-d9db-4bcd-9805-dd57afda386f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_27a0066f-3ec7-429d-ba81-4b50716e9af5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_60d2a094-6f15-42c5-bfb1-c8cb60118d95_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4401c303-ec9a-4d83-a806-1f88ea68d855_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_479883ae-7325-4625-b70a-26b47cbc4b1f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c56030fa-1a3e-43f1-97a1-b22e01df40df_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fc0e8fc3-4484-4ea6-8ab3-4740069fe4c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_ba9ea794-5cde-4cb8-b4bd-0b42ea88d3a1_terseLabel_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Acquired Intangible Assets</link:label>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:href="pacb-20250331.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:to="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_442a03b7-a955-48e5-8e6c-4dedb802102b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockBasedCompensationMember_19472cbb-faa0-46b7-9209-a93858fa98c0_terseLabel_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_label_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_documentation_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember" xlink:href="pacb-20250331.xsd#pacb_StockBasedCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockBasedCompensationMember" xlink:to="lab_pacb_StockBasedCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_62bfd532-c694-4f2d-bb3a-5b6e9735b323_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount and amortization of premium on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c06a492c-ec40-4d45-af66-d2eea1c65334_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_922d910b-2552-465f-a2b8-4f3c71396365_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_08cff618-796c-4a02-aabf-4066081811f4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_ae528ef6-4b63-4d45-b9d7-7b9e34cc0fe4_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, discounted cash flow model, term (in years)</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Term</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:to="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d0c2782d-1f5b-4ad4-a625-bf19ea625574_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3456449c-3703-4f2f-b0cf-50a32edb6a73_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_42c0b8b2-d85e-4ba1-b3af-4514d35769e6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_3ef57a35-8b5a-4a95-84a2-8901e340b673_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_6de58592-078e-429f-82e7-d86106c6125f_terseLabel_en-US" xlink:label="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional goodwill impairment</link:label>
    <link:label id="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_label_en-US" xlink:label="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Goodwill Impairment, Change In Discount Rate</link:label>
    <link:label id="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_documentation_en-US" xlink:label="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Goodwill Impairment, Change In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:href="pacb-20250331.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:to="lab_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e5436f67-496f-4e68-bbae-54226b9241cf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_2631834e-26a8-48a4-afc3-cbcb46d48c38_terseLabel_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard product warranty, period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_label_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_documentation_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod" xlink:href="pacb-20250331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StandardProductWarrantyPeriod" xlink:to="lab_pacb_StandardProductWarrantyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_227bab8c-c6e8-42e0-b460-7f2000bdefad_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_06a87c10-f566-4124-bf2b-9566f98ddc2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_779bfa6c-5b32-4e7b-a429-377881f25a49_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_1823c689-ebe1-41c1-8eb7-2e2285db0999_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f1db20bc-2f9f-483c-9cc3-e2ef7587945c_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d031c9eb-4320-4884-97de-dbefed173b98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1b07c270-d012-4155-912f-cead0d1b52b2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8c5c54bb-df9e-48fd-948d-fad0e0d9b9e4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_0c637a81-0e5b-4254-8a08-3938fdc93337_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_9138f181-329b-41c7-8890-ba78714d3404_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7bf981b8-ff1f-4113-a1eb-43d4b5a2a596_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_baa925d8-b4c4-4260-9efc-d51549040f68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pre-Tax Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9349218d-cbb5-4866-b522-7cbe3cb2cf5b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d4da68bf-82f6-4918-8f8e-dd6301c3739c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac04ed13-4cac-498b-aec7-689a665a14e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_fea7a3a7-5b2f-41ee-baad-95f77f5d93bd_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_8d75dfec-d2f9-4838-92df-92d738807b99_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, consecutive trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_88968907-c820-4573-b9ff-57c93c882194_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional common stock purchased under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3d2524fd-e004-4569-a2f1-df24e0f18265_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2c528f41-8bca-4e6a-bae6-da7d00bcddb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eab9d9d6-67b1-4365-9c6a-27732e358818_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6b23c461-4e42-4d45-b63d-bc246903cd65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_74fdfe07-3784-4267-970d-44d002d85ba3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68b5bccc-36ec-4116-981e-318bdf68c8f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ceb1491-0aed-47c4-8b4f-eb83b75fc910_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e9bec071-1273-4278-958a-b251ce7504e0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_GainLossOnPurchaseCommitments_5aa11805-53cd-4a37-830c-1942d48a2855_terseLabel_en-US" xlink:label="lab_pacb_GainLossOnPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on purchase commitments</link:label>
    <link:label id="lab_pacb_GainLossOnPurchaseCommitments_label_en-US" xlink:label="lab_pacb_GainLossOnPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss On Purchase Commitments</link:label>
    <link:label id="lab_pacb_GainLossOnPurchaseCommitments_documentation_en-US" xlink:label="lab_pacb_GainLossOnPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Loss On Purchase Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GainLossOnPurchaseCommitments" xlink:href="pacb-20250331.xsd#pacb_GainLossOnPurchaseCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_GainLossOnPurchaseCommitments" xlink:to="lab_pacb_GainLossOnPurchaseCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ccedd113-3ee6-4a67-b07f-f16abc1c4b48_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_93ca8fb4-f126-415b-b234-fb39126f8e65_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9832bdcf-9d00-4530-8153-dc0d5ef0f39c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_3912e06a-e0c5-498c-869e-fc5e6dccd0ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_2ca7ee86-11f4-4d2d-9a08-8caa47b02f3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repairs and replacements</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_37954fc2-aaa4-4f1b-94ea-128004e70826_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8055f535-af9a-42de-8539-300505c0bf9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a924a095-772f-4517-9f3a-ffa18e757cf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bd4a41cf-ab31-4a1d-a62c-5da4a81afd9b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_903bb03f-d160-4608-a4de-dadadf864ab9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_b78d7d78-98e1-47fd-8921-697033f79a36_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53acb2b3-ba59-4fb6-a602-fe3feabb8f2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6aa13f36-ee75-4b0d-a686-c2624a9b755b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_63ca09e8-91d5-4e1f-a4f3-744e1a9c3341_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_916efa5b-5f2f-42f2-a397-3d5778fa9e55_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_8b3e977a-7fa2-4c71-962f-e806898b95e4_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1b9aa971-f8d2-4caf-866d-269c71ad2e7d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_21e12992-6e25-49c4-8dbf-b94e6141653b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_c6433e82-f822-469a-a2dd-2a99b64706a6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_bdca0706-4254-4ecf-be04-173444e86e2f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1b0ec600-42ec-4e58-aa4f-06d55e9d6b54_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3f7225a5-9bfc-4a57-ab4b-0c3684905df2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_5bf85d62-1549-4ee0-a62b-b6e9d4540364_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c80edad0-15d8-474c-a0ed-e8c7a4b002f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0a492823-3935-4337-be98-d31c552d6647_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b56e24e0-7775-4668-b4fe-93828a8269be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_36c26a13-fdab-4882-90fa-6ad38c98de64_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_a098861d-7e9a-489d-872f-ca56ed2d0469_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_2e63046a-315c-455d-9380-1da713ed92db_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_7300a07d-fcb6-488b-9a31-0f10eec3cf3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f4b724fd-5bfb-4627-b4ce-f4933d06a834_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_1c4d5420-e914-44e2-8c00-91375b18d6c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f696b3e7-0e41-4da2-8856-6a11ec3ac1c9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ServiceAndOtherMember_9c9d32a9-a560-4d70-bd24-e798fe350402_terseLabel_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_label_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service And Other [Member]</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_documentation_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember" xlink:href="pacb-20250331.xsd#pacb_ServiceAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ServiceAndOtherMember" xlink:to="lab_pacb_ServiceAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_ecaf6174-9a9d-4ace-8bc4-16de6e72afaa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition amount unpaid</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_c40d5283-f245-4cd1-8e5b-90e970cdd422_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchased under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_a75fdd42-1dce-47e8-991f-b4f53f2c7e75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_a90eb9a1-fd19-4042-b970-b89ddfb6bcbf_terseLabel_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on purchase commitment</link:label>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_label_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Purchase Commitment</link:label>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_documentation_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Purchase Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment" xlink:href="pacb-20250331.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LossOnPurchaseCommitment" xlink:to="lab_pacb_LossOnPurchaseCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_05657a7d-75d3-42f4-b4e4-539ee830a2b8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_f425f4b6-8368-45cc-9d17-b383cb796f9a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3ebf2791-af43-4fd0-9aa9-7e8bfaa10c32_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3bbe1d8b-1e48-4771-8514-1af18fbc04c1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d32da5db-3d65-453b-9616-ebaf8d61f13d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_459de5c4-bd15-4064-a1de-50f6087fe755_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used in computing diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1865d1c5-463e-4916-ab9c-ba9e566cda60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ReportableSegmentMember_f8cae96f-b8db-4663-b353-62455179cbf4_terseLabel_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_pacb_ReportableSegmentMember_label_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_pacb_ReportableSegmentMember_documentation_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember" xlink:href="pacb-20250331.xsd#pacb_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ReportableSegmentMember" xlink:to="lab_pacb_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_b0b1fe99-0c19-47c4-8eac-2f4797fba8e7_terseLabel_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lock-up period restriction (in months)</link:label>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_label_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Holding Period For Transfer, Assignment Or Sale Of Founder Shares</link:label>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_documentation_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Holding Period For Transfer, Assignment Or Sale Of Founder Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:href="pacb-20250331.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:to="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b06e2de0-24c8-424a-922b-c171e477f54d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_17e44912-e9e3-49fe-80c8-8fbb77f72bcc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4fda0f4e-ca6c-450f-b405-3b478d18d9d6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8c371ed6-f9fc-4d02-9b4d-f8df19757b0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d5beba6d-d8d7-494c-98fe-58180a7e8de2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_899ead2c-a70f-4bef-b0ae-dcd29f8df85e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_12237266-88f9-4563-b4f1-bf7cfef9c1c6_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_01441b10-25f4-496b-9e88-32db05a582a3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_dd9ebbf2-3d93-4d38-baf9-e88ea7d3435d_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt restructuring</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_b30eb828-fbac-493c-923c-6197f09a3028_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_8f8dc3c7-ff22-4d82-a0d0-fdd06e0efe4a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_99399c2e-5358-4617-927a-44e4fe171956_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Rate of Time Deposits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:to="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b91cdfa3-1f6a-4ec7-b756-159a0fe0542c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2dfe95df-91ad-4484-be16-354118300110_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12cdeffa-6a2d-4fe6-94a8-470a349e6663_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_c3d91905-98a8-4ebe-8b78-496deeef30b8_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_5e989439-e0c4-47bf-9b83-5c402d34cb65_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3d538f6c-e58a-4f04-93a7-428d18c6a958_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_26212138-1433-4a19-92e3-60d109d6bd0e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_bbc32f46-ed22-42ce-945e-2977a508ae5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_11532ec5-6f9b-439b-b0fd-63076ccf2c95_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate outstanding balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_47c0d379-2bb6-4fd2-a01c-9b5b6493241f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a4d7f60d-90e4-44cc-91f4-f288a21a59b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_733b5884-b7ea-402f-bb10-776585b73147_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_f2a2fa84-35f4-4a5e-9425-9ab9c1e3dcbe_terseLabel_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research And Development Indefinite Lived</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_label_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development Indefinite Lived [Member]</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_documentation_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development indefinite lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:href="pacb-20250331.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:to="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_6288b8fa-534b-4bce-b025-b644e8a9845a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon conversion of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_2844875c-4f96-401b-90b8-8f987ae1feab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bea2ea1b-e240-4f0c-bc06-82b0f6ca3d23_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_08904a2e-b6d1-44aa-b6fa-d3f66b0fb20d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_78a9106f-4c2e-456e-ae75-b4846a6f7e06_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest in the event of default (as a percent)</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:to="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b3724293-6103-4ddd-a5f0-ade6b28bc5ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringChargesExcludingAdjustments_676f2a36-bd72-49cf-922a-6ec889ae7c2e_terseLabel_en-US" xlink:label="lab_pacb_RestructuringChargesExcludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges, excluding adjustments</link:label>
    <link:label id="lab_pacb_RestructuringChargesExcludingAdjustments_label_en-US" xlink:label="lab_pacb_RestructuringChargesExcludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Excluding Adjustments</link:label>
    <link:label id="lab_pacb_RestructuringChargesExcludingAdjustments_documentation_en-US" xlink:label="lab_pacb_RestructuringChargesExcludingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Excluding Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesExcludingAdjustments" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesExcludingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringChargesExcludingAdjustments" xlink:to="lab_pacb_RestructuringChargesExcludingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_80144f47-b99c-406a-8b95-5f0f3ed092ad_terseLabel_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee separation costs</link:label>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_label_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Separation Costs [Member]</link:label>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_documentation_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Separation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember" xlink:href="pacb-20250331.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeSeparationCostsMember" xlink:to="lab_pacb_EmployeeSeparationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_c6a2f7e5-82bc-4476-bf13-8d8a079f9fc1_terseLabel_en-US" xlink:label="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment, discount rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_label_en-US" xlink:label="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:label id="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_documentation_en-US" xlink:label="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:to="lab_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_c6d92d60-2ea7-42b5-8481-a1a80f25d5cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e2a43abf-4cc0-4016-ac2f-6218e10cea51_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_76f9a564-29ac-422e-ad40-4a88ab654e78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_3361f19a-7623-4c4c-a42e-968e4dfcb526_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember" xlink:href="pacb-20250331.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsTwoMember" xlink:to="lab_pacb_DebtConversionTermsTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d233b348-805d-4efb-8a60-82f3dcd38281_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Profit or Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_e47bdc41-2cff-4140-a913-eb5b56f28994_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_1855cabf-f980-4c2e-82d9-81fdb6f10986_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b49f7124-79bb-415c-be8d-abf6f8c2a878_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability, non-current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ceca77c-5c3c-4532-8c13-2c063bfa68e0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8ac25e24-e825-4463-aa34-5a29c6fba0d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_67fc8216-a0b3-4b41-bbc8-e17f8717f243_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0621dc5c-4e8a-4fd3-90ba-01665409fd36_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_048df4b3-d6fc-4ce3-93ec-634ee109219d_terseLabel_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Liabilities</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_label_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_documentation_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Description [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:href="pacb-20250331.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:to="lab_pacb_LesseeOperatingLeaseDescriptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1673ecfc-a217-470f-918e-0b2218b3d3e6_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_88bd3ac4-6919-4dc3-9c7c-502c2996993b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_a8ab38cf-ad28-4847-9bc0-4735228a6a99_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="pacb-20250331.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_71da2b79-d22e-4c00-8ce9-bccf5c3380b2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b05ece4e-d3be-4708-842e-2d2c6a44b6a4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2adcb9f2-ac8b-4f72-a4cd-b108bb16392a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_97a47cf3-42c6-457f-ba09-d10824c26a2e_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, discounted cash flow model, discount rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:to="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_38819029-8b87-4e59-b94c-33d9adeb03b0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a9a06848-dc49-4af3-9d83-5552b3dd6d8f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_cbc9e154-c046-47a0-833c-aaab74ae9723_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1e6ff4ad-256b-4e9c-b00a-1efca351c84b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6c739ea8-be74-4b90-a690-34c4483c7384_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4daa70ca-0a01-4706-899d-8dd811286c56_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_1c8b66db-2abe-4590-a129-b7544a6f8b2e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_c323f9f5-95cb-4b97-9509-4cd2baf664f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_00654908-204f-4cec-bf38-57feca381250_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23e91872-95af-47fe-bf89-1d34efc5f55d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99c176b2-f8c9-4c0f-b3cf-0bc7095cfebb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_b8db89f4-db6c-488b-b8ad-b7d313ba7ed6_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, increase in term (in years)</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Obsolescence Factor, Term</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Obsolescence Factor, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:to="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_b8f8ba3a-4aac-4c88-9289-9c4ce8327ddb_terseLabel_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional liability associated with indemnification obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_label_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_documentation_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:href="pacb-20250331.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:to="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ae248221-490f-4e7f-b27e-4bf0c47a3318_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d90c985b-e096-426d-b92c-5835ee9d829f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0eec88cd-2573-4381-bf5c-f0c08508af5e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_35f1347c-e285-4dde-bc67-54392edb9094_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets From Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7d981b2c-06dc-471e-8d36-84ad49800712_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_a96c3d60-7ff0-4525-ac0f-bfbcdb8e9d34_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0bcdd5fa-4b4c-4bb9-96a1-ba08d7f4af2e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_6f1511ac-9c0b-40ca-9f0f-4b9550de7903_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_958933aa-9c68-462b-9ee3-333b9e1e5b9b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_fd62d486-1cde-4a54-9448-28e2af5562d7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_bf9985aa-53fa-4c0b-8207-3041194484d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_fc40d01c-474c-48bf-b47b-1094efe50c95_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9c5eb5ed-3a37-4d07-b4d5-59119a6c3964_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f366dd0c-d16a-47b9-868e-85cfcb416e9f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6199b3d4-d19b-4920-8eef-233e3a57856a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc84598a-7b4f-4123-91a0-0b332b4ff7d0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_363d4070-f94e-454c-8f06-797c47dfd96a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_71c36846-ee19-40a6-bd0f-6d0ea4a30116_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ef15c403-d2a2-4b94-9f7f-02b4b21222b4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_03886158-4c40-4ea8-9616-352e1714947b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a1d6c96a-9ab1-490c-834d-f11f07a74cce_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_69d7b468-4025-4d69-a29e-2155676bd17b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_9573c8dd-605b-4c83-8eba-3addff67ee0a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_27d62090-ced1-4542-9880-510f8c1d90fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_416a0794-ce27-4686-8409-eb49e852bc84_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_label_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue Achievement Milestone</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:href="pacb-20250331.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:to="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_466985f2-e976-47fa-bfb5-ca59d6ede748_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESTRUCTURING</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_2970fc1b-db09-44eb-a89b-00c95b5b79c9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fe26b20e-cf12-44f5-9d0d-9b41d13a84b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_3abf665f-660e-4c3a-9263-0eee01181ff0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_38765d2a-395f-4f68-8ec9-dd076cbc255c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_116ce7e0-b249-4b01-a394-4a0ee6d23d52_terseLabel_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount eligible to vest upon achievement of goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_label_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_documentation_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:href="pacb-20250331.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:to="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_ea9a425e-6a5b-47a0-a3c1-965c950d3fa4_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_ca093a52-913a-47ce-8641-085ecde84321_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_62dfb83a-8e41-4b80-a62d-3e379d8a9c26_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1e97a0a6-1fdd-4068-a386-c1a07bbf217b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember_c61049d4-586f-402d-913c-0916ca40ed00_terseLabel_en-US" xlink:label="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Technology and Intellectual Property</link:label>
    <link:label id="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember_label_en-US" xlink:label="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology and Intellectual Property [Member]</link:label>
    <link:label id="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember_documentation_en-US" xlink:label="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Technology and Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:href="pacb-20250331.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:to="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DomesticCustomersMember_977ec251-1018-44e8-b44d-448468a62bbe_terseLabel_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Customers</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_label_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:label id="lab_pacb_DomesticCustomersMember_documentation_en-US" xlink:label="lab_pacb_DomesticCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember" xlink:href="pacb-20250331.xsd#pacb_DomesticCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DomesticCustomersMember" xlink:to="lab_pacb_DomesticCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3497e503-bfd2-426a-8459-50e9d84a47ec_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_dd6e5295-bf22-4879-80b2-d2e531ff9d72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_1e176ab4-0006-403e-b5c7-42d2df5cf8bf_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b6fe324f-c3aa-4da3-854e-4db33dbfb132_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_d20cca5a-7b1a-4ba7-bc3d-9533a6903f6e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory provision</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f5b9dff1-e271-4c32-a6f1-e599079ebbc7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8512d9d2-94b0-488f-b71a-6036f02865c2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_953540e7-906f-456a-926c-137cb2444b9d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b4bc4606-1179-4493-a440-09e2ddde0964_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b6d0e5e1-0932-4e91-ba5b-b9579f50f505_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringChargesAdditionalCostsIncurred_3026553c-a108-4a98-9c79-45913c38c2e0_terseLabel_en-US" xlink:label="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional costs incurred</link:label>
    <link:label id="lab_pacb_RestructuringChargesAdditionalCostsIncurred_label_en-US" xlink:label="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Additional Costs Incurred</link:label>
    <link:label id="lab_pacb_RestructuringChargesAdditionalCostsIncurred_documentation_en-US" xlink:label="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Additional Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesAdditionalCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:to="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74ef42ef-8d77-4796-99cb-2cf999e7dc84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization_9d53d35a-f511-4a48-bb9c-d3b45fd9ca2f_terseLabel_en-US" xlink:label="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, accelerated amortization</link:label>
    <link:label id="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization_label_en-US" xlink:label="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Amortization</link:label>
    <link:label id="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization_documentation_en-US" xlink:label="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:href="pacb-20250331.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:to="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1838648c-6197-444a-963f-272aa1464922_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_603fca38-33d8-42db-a196-a66a88ec50cc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_4e1dcc70-c52e-4bc5-ac2a-cafbdd47f044_terseLabel_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments made in conjunction with convertible notes exchange</link:label>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_label_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments In Conjunction With Notes Exchange</link:label>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_documentation_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments In Conjunction With Notes Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange" xlink:href="pacb-20250331.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PaymentsInConjunctionWithNotesExchange" xlink:to="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_05d7c625-13d9-4da0-96e0-fcf5de91ded4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional expense recorded</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2914b1e9-8e0b-4c4a-a7ee-cee3ad199ef9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems_31ca2985-5f7f-4e5a-89af-ed49fa034d41_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems_label_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a3f4f557-4eef-42cd-91a6-01c4534e012d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_ebc8c25c-d181-4373-b081-50e6dddaaeb8_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7d0230d4-5047-4d35-b33a-08f44b494773_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset and lease liability recognized due to lease extension</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b684a2fa-364b-4d79-864e-755884e8e790_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_0f37fea3-2b72-4182-8deb-55fa748bed0b_terseLabel_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan</link:label>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_label_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan [Member]</link:label>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_documentation_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:href="pacb-20250331.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:to="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_accfcc4c-7dc5-4359-8227-b1621b4fd029_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_366c7379-518c-4615-9674-bd93deefb59e_terseLabel_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WARN act and other employee benefits</link:label>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_label_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</link:label>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_documentation_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:to="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e38d9896-c0e1-4552-abb1-94c8e55147ea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4b4988f5-0433-487c-9cde-2bbad17b2c96_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1fb45687-f873-4772-a40a-24bf700c95d8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c0297534-0c48-4c06-b092-eff2bc4e6c04_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e99b89cd-3a18-45fc-9839-ee1def7cb0c9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d5400eb3-05ea-4537-b0d9-0a413116e862_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_657d27e9-8718-4299-8b41-a21580f27626_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d1bd6c15-f15b-4762-9052-4814170fa57c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_8e0ca9b7-3dfd-4053-af3e-7c64f0ca64c5_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-based stock option</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_label_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Stock Option [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time-based stock option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember" xlink:href="pacb-20250331.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedStockOptionMember" xlink:to="lab_pacb_TimeBasedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_4c5280c4-fda8-4968-8004-41fbc8314641_terseLabel_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20250331.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_92bbdff0-7dcc-4a69-bc36-f96a72d89f0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae166ddf-5037-4045-8bab-457c4e7829fd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Eligible Item or Group [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_628be2ad-cfb1-43be-9771-3a8c74285962_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_648fa30f-c784-48ef-aa47-d90995e24c6b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_09256fb0-d9a6-4761-9c03-c3199c06a32c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_042358be-8a4b-470f-ac50-192ee7d13da9_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia-Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_3978f7fe-8953-4cb7-beeb-628e99bbca2c_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_label_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_0aecf1ef-5942-42c3-81c2-d221e21b6843_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative amount incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fd57e750-820a-4109-9b8e-ced76fa9875e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_c04845ec-e4b9-4b43-8975-6a424465f4ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_108a1695-4516-4ed0-9897-e26d3dff0056_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e4fa49e-91eb-4846-8534-6ccd5f81543a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_24a86ee8-1e7d-4b57-b507-77a158312b66_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c49f1263-cbfd-4567-85a3-2a433ac3e485_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e1563cd8-953d-4a9f-8e9f-7ecf3c164fec_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4eeb2522-7973-45ab-933d-59a12d10cd67_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c22d92be-a176-40b0-baf9-2fae82166895_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_912af858-62bd-4acd-9857-90d230339984_terseLabel_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification</link:label>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_label_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification [Abstract]</link:label>
    <link:label id="lab_pacb_BalanceSheetClassificationAbstract_documentation_en-US" xlink:label="lab_pacb_BalanceSheetClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetClassificationAbstract" xlink:href="pacb-20250331.xsd#pacb_BalanceSheetClassificationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BalanceSheetClassificationAbstract" xlink:to="lab_pacb_BalanceSheetClassificationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2f427bc3-e197-4bf9-8a1e-8c4d6afca9ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e494ccf4-8e97-4625-9dee-31a16b499aae_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f63f4f69-a1b1-46ef-89b7-60f087853c4b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_b97287f6-c9c4-466a-9661-ae8234d120b3_terseLabel_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of milestone</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_label_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Milestone [Member]</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_documentation_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon achievement of a milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember" xlink:href="pacb-20250331.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AchievementOfMilestoneMember" xlink:to="lab_pacb_AchievementOfMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_fc654583-42f2-4cce-9d63-bb692366f433_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a8244dea-5550-4099-9ced-d91b25c4ce66_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f451f898-e148-459e-8d3e-fb04ad55eb64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6efb6793-e3c1-4fb7-b3a6-d0f8a1c46ee4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value per share (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OperatingLeaseExpectedBaseRentExpense_e29bca6a-c5c7-45a8-8633-8305116d91e3_terseLabel_en-US" xlink:label="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, base rent expense</link:label>
    <link:label id="lab_pacb_OperatingLeaseExpectedBaseRentExpense_label_en-US" xlink:label="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expected Base Rent, Expense</link:label>
    <link:label id="lab_pacb_OperatingLeaseExpectedBaseRentExpense_documentation_en-US" xlink:label="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Expected Base Rent, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:href="pacb-20250331.xsd#pacb_OperatingLeaseExpectedBaseRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:to="lab_pacb_OperatingLeaseExpectedBaseRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_acfbd10d-e07c-48e8-a8d1-016210396926_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding used in calculating net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_9a936fd3-f764-4941-9ecd-6d68e09187e6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_6ed2b624-711f-4cc2-93b4-267377592f03_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_181d8688-5e73-433e-813e-d59bd87f5dea_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_17b24de2-89fd-4e95-b796-8b5d3c33f921_terseLabel_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional intangible asset impairment, change in discount rate</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_label_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Discount Rate</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_documentation_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:to="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_02c50c78-a802-4232-bf44-390e0017ac44_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_2474d3ee-c870-464b-907e-fe63290b277d_terseLabel_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember" xlink:href="pacb-20250331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeStockPurchasePlanMember" xlink:to="lab_pacb_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_eedb5da8-1d01-44a7-b711-265b44c6284d_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, anniversary</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_label_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:href="pacb-20250331.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:to="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4f27cf96-2164-4275-8086-5eccadfb320b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ca1c2585-aa71-4283-9596-aadb4d9b60a3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_36b63eab-9f23-493b-8a6b-1861b9fc9bb7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9b31762b-182b-4271-93f4-c6fa25fdbf72_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d935904-7966-45a7-b52f-6c4a88c093c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8a40c86-29e5-4292-a5e9-227b25721929_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_8b83b5fc-b706-49c4-bb16-2985789871d0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_d8569feb-5dcf-473d-95cf-69c719297fc9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_99a2bfc2-4b04-4727-a2f1-4c24a055f55d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c3405bf-bc09-4e6a-b0e3-908629f6eeb8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dbc8211f-b977-41d9-b71d-ed96714007ee_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock from equity plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_14adb39a-4c7c-44c5-8ce7-828df158eeba_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6daf8ed0-05ef-40ad-99cd-a37681d489f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_072a51df-5908-4c56-a58f-47282c538891_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_81ecbf1c-f194-4d98-ac9a-9a4159cda72d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_82a6f50b-03e0-42de-9427-a5830249d8a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_5ee4a41b-4908-4c0b-bd77-a9266eda4a87_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a0f8c614-cd06-4eaf-b072-8919090c96d2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_127bf32c-1ce0-480a-8866-9f05cfcee78e_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average trading period</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:href="pacb-20250331.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:to="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_cca0f51f-1b77-4e15-8e75-119fb35ada35_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_6d91d6f6-f70f-4842-82a5-161d81bb8dde_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_ebe18226-6cd4-48a8-bca5-95de9d64060d_terseLabel_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_pacb_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:href="pacb-20250331.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_pacb_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_484a0c70-7ccb-4623-a557-c5cc7e9ad83e_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8a146c41-d075-4fbf-bdb8-b5edadf2fcf9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_157b2b05-920d-4c88-9273-6c1ec384498b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_b396c8a6-5a7b-4f64-9808-2ee70161200c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Time-Based RSUs and PSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_f2efbc3b-cd33-41d2-be53-722261ad114d_terseLabel_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance cost, lender fees</link:label>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_label_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost, Lender Fees</link:label>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_documentation_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost, Lender Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees" xlink:href="pacb-20250331.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtIssuanceCostLenderFees" xlink:to="lab_pacb_DebtIssuanceCostLenderFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e3727fcd-b340-40bb-8dcc-2f5ab1f9a6f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ff4dfbaf-fc6f-4b64-b275-c97d67f79140_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_42a0120f-df2b-4dbd-a2f9-083464f8126c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_34bbb2e4-7454-4450-aac1-ea3b3a2f544a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c41b5716-b759-478b-8c12-e78a6bee6078_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8dd61559-654f-49cd-9b65-b580572cc889_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d7a19c9c-239b-445d-99a7-7f670f345d12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_007063b5-4514-42cc-bebb-f2fe95ab2307_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9821e1b0-3023-48d5-a710-38f0e1980f6a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_c75076bc-c695-4c3b-8c87-971cbfedfbf5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2add6f15-658a-4743-a402-3b37057cfc54_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_30cb5174-fbbe-48d9-9103-4d331300d354_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d257e3fd-18fc-4818-bed6-4aff7718dc9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b5471955-f0b4-4163-8803-11d3fcda05d0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bb4c24fc-d102-4c2a-9e16-ce3e750e138b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d4596124-e59c-4e49-a8f8-63660f0a942c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ca41dc75-7f07-4812-8666-910ebe9deaa6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d85d036d-c32b-49a0-87ad-4f1043ba0b6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3e011d6f-7c80-4943-bfa2-9d3172d94c94_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_68d33933-38a6-4cf5-953f-6ab9d5801620_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_f0b17531-7788-4384-8c36-5a7a9fc4bf93_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions charged to cost of product revenue</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_93b4b344-eb8f-4151-bc87-9b782d0bb28d_terseLabel_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 and thereafter</link:label>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="pacb-20250331.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_595676d1-1aee-4fa5-9d05-e15c158b3dd4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUITY PLANS AND SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_82039d90-9b54-4f2c-88c1-4fedd495dd1d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9c8a484f-aa24-4928-b517-f8e68b85065c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1bdf1df5-461c-42db-b4b1-760666b2662a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_7816c289-da04-4070-8f2f-a7b7ad6331e7_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT AND GEOGRAPHIC INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_fea49647-f0de-4b7e-ba52-533dcef23e96_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid accrued but unpaid interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e86f6db3-156a-44f3-bdc0-f391e0d66c29_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_059c8249-1571-4b04-b027-5381af64fa09_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_eb0624fd-9738-4406-b6b5-ad2fd89de4ba_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in the estimated fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2eb682a8-06d5-46bc-8458-d9f93997646b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_59781fb4-1012-4d15-a719-acc0fd304643_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c368b0a9-c277-47fb-a3ca-87fb6873e770_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_ccc79032-590b-4ced-9290-e4acae50dc38_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8381e3fc-fdf5-4c19-bcc2-fdf1aa3dc40c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0f84ef5e-e054-427c-9524-787a454ddadf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_27585798-f155-4b06-8f02-05e04a21e165_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_78a87ec4-f186-4c84-b3c2-6fee63cdf834_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_1a7ae7be-e338-4909-9bdc-d14f5d1b46a3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6ffe65b5-42b5-4945-b4d0-f5d75d36fc63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_129c12be-0567-46fe-a132-38e19a78f989_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_c77914ce-b987-413b-a311-8c0b5127c21e_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_6f9a8226-422d-4e35-8d59-0db05875ddee_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated total restructuring costs to still be incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f1e8bd25-cf74-4599-bfa2-bec841314e71_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_7e118de7-7697-4558-b9e3-f02057ee3c06_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ad1d0930-2f90-44da-a971-0a683fee0b00_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_94e9e8e3-7af4-4025-8310-c2471454fcc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2029NotesMember_8d73cec0-b18c-4d97-9a9e-22d7f216c2f9_terseLabel_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2029NotesMember_label_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2029 Notes [Member]</link:label>
    <link:label id="lab_pacb_A2029NotesMember_documentation_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2029 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember" xlink:href="pacb-20250331.xsd#pacb_A2029NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2029NotesMember" xlink:to="lab_pacb_A2029NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ef229df6-70c0-4964-92ff-cc926595a217_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_cdbbf80d-655b-4cd6-a2c6-4c0995c2ecb8_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember" xlink:href="pacb-20250331.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsOneMember" xlink:to="lab_pacb_DebtConversionTermsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_593c4fb1-f460-4f27-a28f-79b1e059c6d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_ef2fa505-bd9e-4bc7-8d0a-6d0fada68ebd_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional interest in the event of default (as a percent)</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:to="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_93b8660a-af04-4034-97fc-06c419f8095f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3204d2fe-3165-452c-88b4-0c8642b85c65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_711c8645-b504-4b4a-b096-32d38eaeccfa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f77d44df-3306-4532-846d-35de536a75fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_070d9478-165c-4bb2-86da-54c141ca8471_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, increase in basis point discount rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:to="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_3ba3d2e4-634d-430e-a43e-f5dd790c2f11_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9b8c7443-e207-4821-a32e-41b9ba309db3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d4bbfee5-9951-4b27-98a7-545adde7fb8a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_a4b37ffc-7e41-461d-b66e-a54237f23928_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_9a006fc1-9f97-405c-a5ec-a77e79ff12dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f551e6eb-1a46-4456-a477-f237a8d8772c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1d1eae2a-45fe-4d56-862b-2887b33bc30e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4b2cfb48-ad92-4e4e-a222-6510fdf9e8be_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_5261cdba-f1a6-487d-8ab3-8e180e4f5083_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_6e8cd307-c170-4dcd-9f70-4d00e6429e85_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9fad31b-b070-459a-ad95-c5246af42e79_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_CustomerOneMember_945711a5-b22b-486d-932f-3cf15fa864d8_terseLabel_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_pacb_CustomerOneMember_label_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_pacb_CustomerOneMember_documentation_en-US" xlink:label="lab_pacb_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember" xlink:href="pacb-20250331.xsd#pacb_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_CustomerOneMember" xlink:to="lab_pacb_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ec27932d-3902-429f-a02d-e8cf407b153c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6cf5f4a9-331a-422f-925c-8ef2db90dfdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_36e1eb8d-2b4d-4974-95c6-d69d80882126_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_32bb74fd-44fe-4290-bd8e-5667b51f2a9a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_685894ad-56a9-4e50-b640-a36500eadb6d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_1dd1887f-b0b4-416f-ab43-6742d3860d97_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Units (PSU)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_453f9d15-e229-4e46-bd77-47970f8fd99d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8c744253-7373-4736-a908-b8a0377706ec_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4bf7ed64-ac44-4407-a52a-4d35911dd7b0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_d3c7fa27-f462-4c77-a0ba-23a769ef09a7_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross (loss) profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_5352238b-4c34-4078-b2fb-4ebf674b29bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Reserve for Product Warranties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_dde7c20b-5608-43e3-805a-00209b69ae27_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_801974c7-4bdc-466c-930b-085dcea63863_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e177e34c-ee45-45e7-a328-82c871af9e5d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONVERTIBLE SENIOR NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c190790-a4f7-479d-b5e4-aa4c148a7627_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0d3d7cab-cb0e-42f7-a65b-5abd5cd13158_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_970e1cfd-7de9-45d2-b616-893cecdec0ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AptonMember_895fbc62-80e8-4650-b8a9-5490617f422d_terseLabel_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apton</link:label>
    <link:label id="lab_pacb_AptonMember_label_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apton [Member]</link:label>
    <link:label id="lab_pacb_AptonMember_documentation_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember" xlink:href="pacb-20250331.xsd#pacb_AptonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AptonMember" xlink:to="lab_pacb_AptonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_61badfd6-1e3b-4fda-a766-e08b55a7013a_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_9114feaa-86bd-47d9-b307-3501ec2c7e89_periodStartLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_0cacc830-71c1-4fad-8961-233375872afd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrual" xlink:to="lab_us-gaap_ProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0ad5cc50-1b70-4b86-bcbc-783e44b68a41_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_deab9fa0-108e-4b73-80f1-3890c40d9240_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82066f08-30a7-499f-a004-8ff376295c6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_d3db0075-3c9a-4543-be06-237f85e1ad25_terseLabel_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional intangible asset impairment, change in term</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_label_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Term</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_documentation_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:to="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f6c6aab0-7c4f-495f-adec-5032ea0ec9bb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ConsumableMember_6e51f29b-b047-4f58-95ac-7693e41b2d93_terseLabel_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumable revenue</link:label>
    <link:label id="lab_pacb_ConsumableMember_label_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumable [Member]</link:label>
    <link:label id="lab_pacb_ConsumableMember_documentation_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember" xlink:href="pacb-20250331.xsd#pacb_ConsumableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ConsumableMember" xlink:to="lab_pacb_ConsumableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_a4d67058-dffc-4ef4-8540-267988cc5303_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d115949e-72de-426a-a0cf-2c234926327f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4f52287a-d6db-4a5f-96c1-5db77bb61d43_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SanDiegoOfficeMember_0aa3409d-3659-4867-ad35-374db6b853cc_terseLabel_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego Office</link:label>
    <link:label id="lab_pacb_SanDiegoOfficeMember_label_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_pacb_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember" xlink:href="pacb-20250331.xsd#pacb_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SanDiegoOfficeMember" xlink:to="lab_pacb_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_2dfd3049-a193-423a-8a4e-ff68144592ab_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_808c72ee-cbd2-4991-be8c-bcde894aa932_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_label_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Outstanding Shares Of Common To Be Issued In Merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_documentation_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:href="pacb-20250331.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:to="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c34d3181-7fd8-4dd7-a67a-275e45af95ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_d5637dd7-7e06-4fd8-94e3-e57558d8452e_terseLabel_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease base rent abatement</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_label_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Base Rent Abatement, Amount</link:label>
    <link:label id="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_documentation_en-US" xlink:label="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Base Rent Abatement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:href="pacb-20250331.xsd#pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:to="lab_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_923fac87-ca5d-4ff9-ad01-65a8097e1038_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3aba0b6-a5da-4303-ae65-7fe06740c6d4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc7b0af5-c992-4a21-9c64-b23caa5e2149_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d17ce600-c0d9-41a8-9402-35cac4ef85a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_29d3ddbb-2b7e-4330-bc41-45f0e59c657e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9d58076c-0437-4996-84ee-06f59a679324_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_db4531ea-c7a6-4f27-bd1e-ef0b021103e8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_25a8a733-731d-4e23-ae3c-18660a1baa96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a1ed15e8-0a48-4552-923d-c018c32c347c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_290324a6-90d2-496e-a7fa-b4735d528546_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bd2d1f0f-81a7-4e08-b754-61b2da149ea3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3376ea10-33ee-43f9-b30b-d6fb941d6f0b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cc5b3fef-58cd-4328-b1f8-05f2f65a23ff_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_1a0bfd55-4c6d-4312-b82a-0d2b81e818c6_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_9382cb89-f9bc-4b3a-a94a-fb4b65fc87d2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_0c5723e7-5856-464c-8ffa-190c355c05a6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, net, non-current</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bcf8be41-1f80-4ee9-a1a1-cb32fbc38a58_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_889d75ad-2f95-4480-8a3e-0f74e1432261_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_72e897ae-2e2d-4315-a3c1-287063671e01_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_a6a54593-3137-47de-8eb3-3baecdcf9171_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_539f31ad-f4a7-4951-8fd5-2e3e4e467e70_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:to="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_d9d711c6-2be4-4757-a9fd-e30f8ed5b9e0_terseLabel_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:href="pacb-20250331.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_85ee9a08-3be4-41f9-94e7-700f6cf65c2a_terseLabel_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring of debt (in dollar per share)</link:label>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_label_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Of Debt Price Per Share</link:label>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_documentation_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Of Debt Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare" xlink:href="pacb-20250331.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringOfDebtPricePerShare" xlink:to="lab_pacb_RestructuringOfDebtPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_ed806403-6ca7-4b5b-98e8-a1dc5aea490a_terseLabel_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_label_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss per Share Abstrct</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_documentation_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Loss per Share Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract" xlink:href="pacb-20250331.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeLossPerShareAbstract" xlink:to="lab_pacb_IncomeLossPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1b8f2356-9374-4a86-be2b-564116a22739_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_486be601-29c8-40c0-b350-9e0239b12307_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ac740a77-9a22-42f6-a3ac-a9890d0b0a0a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_04fbd29a-00d4-4934-bdae-7a1e3f8ed327_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2c926bbe-bdeb-4867-b8f2-52fac0f57cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRent_7aa259e8-4c0e-47d2-927e-04bdb065f341_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRent_label_en-US" xlink:label="lab_us-gaap_PaymentsForRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRent" xlink:to="lab_us-gaap_PaymentsForRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_d83fac29-ee3b-4adb-ab48-77f13c86162e_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Notes payable principal payoff</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d2c3aeba-44c2-417a-b133-15178caff625_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7476f2c2-57ad-475d-9089-f03703a9adb3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_e734cc11-371f-4e24-8ae4-f36ca33fa93d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9d1075b3-0172-4546-b192-b4837f851da0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_de3b16c7-ab7d-4cae-b1c4-2614b63315ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_287dc0a3-64b7-4787-bff2-f102c43b9355_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff252506-03f0-4b54-8c38-9d6857a4f7e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e1d700a7-7876-4717-83aa-0fef0b17959d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d8d43f84-8e53-4992-bf6c-b095235ed348_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2024RestructuringMember_3501169a-664e-465f-b73c-8dbe1e3b7724_terseLabel_en-US" xlink:label="lab_pacb_A2024RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Restructuring</link:label>
    <link:label id="lab_pacb_A2024RestructuringMember_label_en-US" xlink:label="lab_pacb_A2024RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Restructuring [Member]</link:label>
    <link:label id="lab_pacb_A2024RestructuringMember_documentation_en-US" xlink:label="lab_pacb_A2024RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember" xlink:href="pacb-20250331.xsd#pacb_A2024RestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2024RestructuringMember" xlink:to="lab_pacb_A2024RestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_462b582e-bd32-42e4-814a-2d7293c347ec_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, consideration transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_4274ab05-154d-4f06-aa9e-31672fcd57a8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Geographic Location</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3a014f98-ac63-46d2-8dfb-5479e1295f1a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0db9e23d-b790-4d99-a3df-b505336a41c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_598f7f53-4974-4844-a129-eafea4ce052b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_82aeb332-8e2c-48c0-a9d0-cf286202144c_terseLabel_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_label_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options To Purchase Common Stock [Member]</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_documentation_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:href="pacb-20250331.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:to="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4c1a0756-0015-4350-817c-be12b8436865_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_2350adf1-3045-4f45-9e96-c7a54f131ef9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_dceb3136-1059-4e44-8af6-940cabdc5f35_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_67c223a9-9b01-4ba9-810c-6e8ef39c5f6d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb57568d-8560-4cbe-8fd1-6f239b43b853_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_9ff22cec-a8da-49b1-8d92-9a9abbeace9b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e28b07f8-245f-4c90-adae-ccf50d206c52_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_676c4efd-8b6e-444f-ad9e-00aec4786749_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_41566770-c08e-4bcf-89a3-2480875e1b01_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ChangeInEarningsPerShare_c09bc2fa-776c-4e22-b858-d25a364407a4_terseLabel_en-US" xlink:label="lab_pacb_ChangeInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in net loss, basic (in dollars per share)</link:label>
    <link:label id="lab_pacb_ChangeInEarningsPerShare_label_en-US" xlink:label="lab_pacb_ChangeInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Earnings Per Share</link:label>
    <link:label id="lab_pacb_ChangeInEarningsPerShare_documentation_en-US" xlink:label="lab_pacb_ChangeInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare" xlink:href="pacb-20250331.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ChangeInEarningsPerShare" xlink:to="lab_pacb_ChangeInEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_60bc9e48-65e7-4082-9f31-2631e7999e88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_418c10d7-6e46-4e66-b1d2-946b244a2946_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_6cb6c514-6f6c-45e2-8b20-ddd96f4dcc5f_terseLabel_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20250331.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_75ec94af-27c8-4677-8dae-c9448aee961c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e2cf6203-416f-4a75-89ed-3d5083974e97_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_64f6455c-6865-45da-a63b-0c58093353ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cd65f495-217e-4d67-9c16-d3ad98452fd8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_58ac05fc-0ceb-4d0c-956f-c27b57c5758f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_d8d7b820-d449-416a-8ec7-f659a4514244_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_a3ab25d7-ab4d-4db5-9225-169027996f72_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_86f4d44a-ebc5-443d-9497-d650ea25cd11_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d72e0589-651e-4cff-b2de-ebe41de460e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a5596540-2830-46a1-9d5e-283f185688c7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_9456236e-2aee-48c8-acc0-76de625bbcbb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_92481e31-0ed8-4b3e-94ea-0e9c09be77fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InstrumentMember_235cc234-b168-497c-b457-1d3f883a6b75_terseLabel_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instrument revenue</link:label>
    <link:label id="lab_pacb_InstrumentMember_label_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Instrument [Member]</link:label>
    <link:label id="lab_pacb_InstrumentMember_documentation_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember" xlink:href="pacb-20250331.xsd#pacb_InstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InstrumentMember" xlink:to="lab_pacb_InstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_a7031184-83a0-4db9-a027-96b5c14c0601_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d718ece8-9c6b-4d43-a2ad-ae4c317ad58b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_75354dfa-0be4-4a71-a825-7f6e24f143f7_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, percentage of conversion price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:to="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_386f8ce7-b45d-4caf-bfa2-c27f88a3023b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4e2685bc-e3b9-4aa4-b1f5-9869da3220fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2ff7967a-f8ba-4763-aa32-fa82ecd426fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_998cc5ca-7a27-4162-807c-bc5a46078074_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_642ab7f8-cc91-4b33-ba2c-7433ff1b2456_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BALANCE SHEET COMPONENTS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a4d9af07-64f7-496f-8164-8b1cf1cbb953_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_960ce36a-9652-4d01-8850-e6da5a74b196_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_1f0d85e8-6335-435c-8566-4c0a4a0941b2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_bd24f6b4-b0f8-4b5e-bb0a-30a453de2292_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b39f499d-a58a-4d46-bd46-dc572aafdbfb_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_91c4b9e4-4eea-4742-b824-d683020cc0a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f0e25721-75ff-49e4-a5ed-16045d0d0f45_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7a70aef1-57b9-4031-8633-d696245f8ec3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c52fcea3-f3ca-4917-812c-2dca1ffaad26_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d968fa61-c30a-4efd-b061-d167f850a0a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_89e79b02-97ab-483d-9297-d64c08c4a439_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d92218c7-2732-455f-9737-0bae0252e6c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_26e3da7e-8646-4fe3-ac79-3ad7642ea3b9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_75adca7d-64fc-402b-a364-b4cb48fd632c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_9dc17a66-a7f8-4997-9dbd-cd97dda7369a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_e225e4f5-b1a7-4578-b463-f44423b3b5c2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_6f92f048-9b8c-47fd-a6de-60a4755607e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3faa8fb7-5653-46a5-b0b4-0fbf0ef030ca_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ded26f70-f776-4e9f-8fa6-46ef7889e51a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used in computing basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0f02252a-9205-4a3c-bbf8-1149b662f4aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_42a47a0e-404c-4217-ad03-4c489480d4d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_441959cd-c2bc-4d32-9c24-61e9b10f2e80_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_6a2ba789-97c1-4cde-bcf7-048d7748b889_terseLabel_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, noncurrent, recognition (in years)</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_label_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_documentation_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:href="pacb-20250331.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:to="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_b3e00ee6-1adb-4211-9661-2049f38d0de4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_898dacbb-8c8e-4691-bc07-0cdc4c14fc29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_72e065e4-6acd-47a0-989b-7ed34a8a17f1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_fbef0836-afc4-4288-ab6d-2803e522b09e_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_b0cb407c-22ca-4dd3-98b0-8384e388d130_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_d5230e5f-e598-4f3f-9e9a-250951578791_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ca419474-e7cb-475b-8a97-1864a1d6fe64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_27e0c4f9-1575-49bd-9943-a0459e390102_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>pacb-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:1b1d8431-b0de-47a8-b616-b49433c1f17c,g:bee9e017-2ca3-4a3e-a5bb-871b7f56db6b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CoverPage" xlink:type="simple" xlink:href="pacb-20250331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b31c2eec-3df5-4327-8a8f-2714f5ac4e5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_DocumentType_b31c2eec-3df5-4327-8a8f-2714f5ac4e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d29bef2e-7729-46ec-9af6-0a05331df8fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_DocumentQuarterlyReport_d29bef2e-7729-46ec-9af6-0a05331df8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c3bc207f-b05f-4eeb-8417-aa1bec0289ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_DocumentPeriodEndDate_c3bc207f-b05f-4eeb-8417-aa1bec0289ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7c7c995e-bcb6-41c3-930a-7e1e8a0b53ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_DocumentTransitionReport_7c7c995e-bcb6-41c3-930a-7e1e8a0b53ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_38b8a483-2d2e-4082-80fd-847d29e97043" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityFileNumber_38b8a483-2d2e-4082-80fd-847d29e97043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ed694986-4746-4067-921d-27ff4adf48e4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityRegistrantName_ed694986-4746-4067-921d-27ff4adf48e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_26d0beec-21f3-4d47-a192-040f589cbc43" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityIncorporationStateCountryCode_26d0beec-21f3-4d47-a192-040f589cbc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_2ba995f2-301c-49f7-99bc-d3ab55b740bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityTaxIdentificationNumber_2ba995f2-301c-49f7-99bc-d3ab55b740bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a739aa85-b695-406b-91b9-d5abebdf9246" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityAddressAddressLine1_a739aa85-b695-406b-91b9-d5abebdf9246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_819acbac-774b-44f0-aaab-1a216fdb6f93" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityAddressCityOrTown_819acbac-774b-44f0-aaab-1a216fdb6f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_245bb6b2-9118-4ad7-983d-bad11a452b31" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityAddressStateOrProvince_245bb6b2-9118-4ad7-983d-bad11a452b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b5ddf6a7-5d99-4058-9e09-e372bc4ad918" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityAddressPostalZipCode_b5ddf6a7-5d99-4058-9e09-e372bc4ad918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_03a2b4b9-fe40-45cf-b138-806e038d1591" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_CityAreaCode_03a2b4b9-fe40-45cf-b138-806e038d1591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e7426a21-17dd-4f93-9661-535597d5e568" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_LocalPhoneNumber_e7426a21-17dd-4f93-9661-535597d5e568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ff65f5a6-ca76-455a-9311-8af3e1bc680a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_Security12bTitle_ff65f5a6-ca76-455a-9311-8af3e1bc680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c0badcc0-fb01-4062-89f5-d0103d6bb6f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_TradingSymbol_c0badcc0-fb01-4062-89f5-d0103d6bb6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_94073941-5b09-4f02-8591-9cf8fbe79f6c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_SecurityExchangeName_94073941-5b09-4f02-8591-9cf8fbe79f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_04f1a6d1-8cfe-4872-8e3b-bb8ee750efd0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityCurrentReportingStatus_04f1a6d1-8cfe-4872-8e3b-bb8ee750efd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a7c2ff6e-6340-44c6-920e-a072799fb98b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityInteractiveDataCurrent_a7c2ff6e-6340-44c6-920e-a072799fb98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0384e7eb-2096-4ec5-835a-59fa6ab4b045" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityFilerCategory_0384e7eb-2096-4ec5-835a-59fa6ab4b045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_db0146c9-0eea-49f5-b293-5737b312d019" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntitySmallBusiness_db0146c9-0eea-49f5-b293-5737b312d019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bc555ce4-0a84-4b9e-afe9-cd3c7416e400" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityEmergingGrowthCompany_bc555ce4-0a84-4b9e-afe9-cd3c7416e400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c52e51e3-ae8c-4e9f-be10-62ac05bb0740" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityShellCompany_c52e51e3-ae8c-4e9f-be10-62ac05bb0740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_de59fd69-1f64-4416-9da8-b75f292c2f76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_de59fd69-1f64-4416-9da8-b75f292c2f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1f89a4b9-829c-48d7-9fdb-d2fa364dd4e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_EntityCentralIndexKey_1f89a4b9-829c-48d7-9fdb-d2fa364dd4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1d0d2789-00df-497d-8628-84fec777279e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_CurrentFiscalYearEndDate_1d0d2789-00df-497d-8628-84fec777279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2c70d619-1ec7-4389-9867-9d2020f34ade" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_DocumentFiscalYearFocus_2c70d619-1ec7-4389-9867-9d2020f34ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_907bdb77-90a4-4df4-a692-65d3a1b95d02" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_DocumentFiscalPeriodFocus_907bdb77-90a4-4df4-a692-65d3a1b95d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_de77e578-e602-49a2-b937-779261aad443" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f338cc6b-b6a4-4c41-913e-20eac65a4d35" xlink:to="loc_dei_AmendmentFlag_de77e578-e602-49a2-b937-779261aad443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ade65822-6ab8-4248-b63b-b945719ed783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ade65822-6ab8-4248-b63b-b945719ed783" xlink:to="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6632e4c8-7161-443d-9ef8-112e617119ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6632e4c8-7161-443d-9ef8-112e617119ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_b760c081-333b-4f0c-9a04-3c1793fca970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:to="loc_us-gaap_ShortTermInvestments_b760c081-333b-4f0c-9a04-3c1793fca970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_405ce42e-6c7a-40f9-9ea6-28c25b60fbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_405ce42e-6c7a-40f9-9ea6-28c25b60fbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_047d9ad1-a9f1-41a4-a12b-63c7a3637864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:to="loc_us-gaap_InventoryNet_047d9ad1-a9f1-41a4-a12b-63c7a3637864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_74136c9c-b6d0-4713-8023-503c286d39c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_74136c9c-b6d0-4713-8023-503c286d39c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_31453b55-7d77-43cb-9afb-180ea921f4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:to="loc_us-gaap_RestrictedCashCurrent_31453b55-7d77-43cb-9afb-180ea921f4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f49df898-49e8-40c9-853a-a1c04d4374f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_90b0d4cf-e80a-43a4-b76e-6efc78adcc67" xlink:to="loc_us-gaap_AssetsCurrent_f49df898-49e8-40c9-853a-a1c04d4374f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_05865334-34ea-4bfc-b8dd-6f9b7a8c0a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_05865334-34ea-4bfc-b8dd-6f9b7a8c0a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9cfc7c6f-c149-4005-ac06-1db17ef936bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9cfc7c6f-c149-4005-ac06-1db17ef936bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d35388f8-d552-4ded-bb22-8d89b4e55bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d35388f8-d552-4ded-bb22-8d89b4e55bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a2d110e-3560-4556-88d9-5873ded213ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3a2d110e-3560-4556-88d9-5873ded213ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_23e2d5fd-b32c-4cf8-9dce-6593159c9798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_Goodwill_23e2d5fd-b32c-4cf8-9dce-6593159c9798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_60bf6908-15a2-4d8e-9ca3-dbf736ea6a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_60bf6908-15a2-4d8e-9ca3-dbf736ea6a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dec95aff-cb2a-4046-8e3d-18b71857d00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d6859955-9d2c-4630-b4d6-0a4d8824c119" xlink:to="loc_us-gaap_Assets_dec95aff-cb2a-4046-8e3d-18b71857d00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ade65822-6ab8-4248-b63b-b945719ed783" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_af9ebc8f-8272-4f2a-97fa-c2b74153384f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:to="loc_us-gaap_AccountsPayableCurrent_af9ebc8f-8272-4f2a-97fa-c2b74153384f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eff4c22c-6fc7-45e3-8527-0fe45e4709df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_eff4c22c-6fc7-45e3-8527-0fe45e4709df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_96dfb695-e844-481a-a314-a7a18cd4ae74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_96dfb695-e844-481a-a314-a7a18cd4ae74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ee766282-8f6e-48d2-8a8b-3313f3655abc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ee766282-8f6e-48d2-8a8b-3313f3655abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8cc06642-ea63-4712-9e8a-c9d23a86500a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8cc06642-ea63-4712-9e8a-c9d23a86500a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_76e6f1fb-dece-41bc-913f-9a2e03b11947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9ea48a7f-2ab9-449a-8993-a2e14f1ce6f6" xlink:to="loc_us-gaap_LiabilitiesCurrent_76e6f1fb-dece-41bc-913f-9a2e03b11947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2a960bde-103d-4d5c-b880-2926caf35510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2a960bde-103d-4d5c-b880-2926caf35510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eff04e95-546b-474d-9c06-236aa59dce72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eff04e95-546b-474d-9c06-236aa59dce72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc48770d-50ed-46ba-97d2-c8d69fc7b735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc48770d-50ed-46ba-97d2-c8d69fc7b735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_d9eb8b5b-78ed-4463-8eff-07646600efbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_d9eb8b5b-78ed-4463-8eff-07646600efbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_360860bc-51cb-4e50-ae46-a4b2e4cecb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_360860bc-51cb-4e50-ae46-a4b2e4cecb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cb08256f-6d05-4142-a728-eb9d57c01982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_Liabilities_cb08256f-6d05-4142-a728-eb9d57c01982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f881e4b2-2006-42d2-9753-c9b86c240d50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f881e4b2-2006-42d2-9753-c9b86c240d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8398c765-53cc-4e2a-9120-20bccb116a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:to="loc_us-gaap_PreferredStockValue_8398c765-53cc-4e2a-9120-20bccb116a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bfa8d334-6ac5-4376-bfef-672f2b08832e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:to="loc_us-gaap_CommonStockValue_bfa8d334-6ac5-4376-bfef-672f2b08832e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7ca0dda5-4f09-4f0a-8f49-9ed00adecf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7ca0dda5-4f09-4f0a-8f49-9ed00adecf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5512109d-e259-40a8-b3db-ac70787c8e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5512109d-e259-40a8-b3db-ac70787c8e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f008c72d-6b82-4f6b-a89b-b9243be8c9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f008c72d-6b82-4f6b-a89b-b9243be8c9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42d66351-9313-40a1-83cd-39255026c867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ba28fe82-fd1c-41d2-83b9-7b688d9b5e66" xlink:to="loc_us-gaap_StockholdersEquity_42d66351-9313-40a1-83cd-39255026c867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b98196f-8325-450d-bdc3-338d25922476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f615e0e0-69d9-4a79-a78f-a147b12f3824" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b98196f-8325-450d-bdc3-338d25922476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6c99cbc9-12d1-427c-9dbd-d37d1101ff21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6c99cbc9-12d1-427c-9dbd-d37d1101ff21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ff88c697-0fb3-454a-ab5e-69556245cedc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ff88c697-0fb3-454a-ab5e-69556245cedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_45a88468-c59f-4efb-88e9-366b18284e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_PreferredStockSharesIssued_45a88468-c59f-4efb-88e9-366b18284e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_acd3dbb2-251c-42cf-8325-9f2652e833b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_acd3dbb2-251c-42cf-8325-9f2652e833b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_941520ae-99ee-4715-8946-f54b28b336f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_941520ae-99ee-4715-8946-f54b28b336f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f36a690a-2e39-4cc6-8c69-0e585d385754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f36a690a-2e39-4cc6-8c69-0e585d385754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7a9d4319-b5a3-4323-8119-05dfb57b07ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_CommonStockSharesIssued_7a9d4319-b5a3-4323-8119-05dfb57b07ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ff7c6eb2-4959-4042-9448-da12bd3b2d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cf722686-b777-4ac5-b066-ea2bece19598" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ff7c6eb2-4959-4042-9448-da12bd3b2d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8718b396-6f4e-4ed2-b998-249ffec58c09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_508cd720-6bfc-47d6-b23e-c044695217e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8718b396-6f4e-4ed2-b998-249ffec58c09" xlink:to="loc_us-gaap_StatementTable_508cd720-6bfc-47d6-b23e-c044695217e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c1a0290-2fca-46fd-9bb8-29fcfab41144" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_508cd720-6bfc-47d6-b23e-c044695217e5" xlink:to="loc_srt_ProductOrServiceAxis_5c1a0290-2fca-46fd-9bb8-29fcfab41144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5c1a0290-2fca-46fd-9bb8-29fcfab41144" xlink:to="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a9b7269b-217e-4ff4-aed5-33ef04955b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:to="loc_us-gaap_ProductMember_a9b7269b-217e-4ff4-aed5-33ef04955b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_d4a76c6c-05be-4155-a8d5-4e2e4ad3de3e" xlink:href="pacb-20250331.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1dce213-4093-403e-8f1c-659ecce95b5e" xlink:to="loc_pacb_ServiceAndOtherMember_d4a76c6c-05be-4155-a8d5-4e2e4ad3de3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_508cd720-6bfc-47d6-b23e-c044695217e5" xlink:to="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bb9ce19c-dc80-4a36-8f6f-b4c841611459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_RevenuesAbstract_bb9ce19c-dc80-4a36-8f6f-b4c841611459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_688a34c6-9339-4839-93f7-7e4f631f4ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bb9ce19c-dc80-4a36-8f6f-b4c841611459" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_688a34c6-9339-4839-93f7-7e4f631f4ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_514d5cc0-4b23-41cb-8707-04ef24546417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_514d5cc0-4b23-41cb-8707-04ef24546417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_0b52177e-5ee4-4f0a-9bad-11258850286a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_0b52177e-5ee4-4f0a-9bad-11258850286a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_89d26b6c-033f-4b49-a7ab-1ee41fa504aa" xlink:href="pacb-20250331.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_pacb_LossOnPurchaseCommitment_89d26b6c-033f-4b49-a7ab-1ee41fa504aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_98f32297-e67f-482b-9ccd-2ee0782c776d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_935c9cd1-b446-4dcd-aa23-d719e63d4262" xlink:to="loc_us-gaap_CostOfRevenue_98f32297-e67f-482b-9ccd-2ee0782c776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_912cdba1-12a1-4627-a50b-2d4ba254f814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_GrossProfit_912cdba1-12a1-4627-a50b-2d4ba254f814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_27d5d61e-880d-4722-b34f-6b57a0d59a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_27d5d61e-880d-4722-b34f-6b57a0d59a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08f8fe08-c9eb-4c49-b9a9-9bd6acd67971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08f8fe08-c9eb-4c49-b9a9-9bd6acd67971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ba845ac1-0daf-4811-b4a9-8fcccc7a0f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ba845ac1-0daf-4811-b4a9-8fcccc7a0f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_66fbe1f2-3531-478a-acf9-9d0bbd5e939f" xlink:href="pacb-20250331.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_66fbe1f2-3531-478a-acf9-9d0bbd5e939f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c9e06e40-d9b5-4dd1-91ea-8ebad2236ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c9e06e40-d9b5-4dd1-91ea-8ebad2236ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1dc8908b-dd93-4df6-8736-1c901c23958e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_394bcec6-0309-4885-a494-4b17b57d7eb0" xlink:to="loc_us-gaap_OperatingExpenses_1dc8908b-dd93-4df6-8736-1c901c23958e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3310f78c-b473-4164-a4ef-f100d25452b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OperatingIncomeLoss_3310f78c-b473-4164-a4ef-f100d25452b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_69810c80-97a1-49ef-9feb-23c0b50bce9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_InterestExpenseNonoperating_69810c80-97a1-49ef-9feb-23c0b50bce9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5cdf8b9d-35e2-4f88-9e8d-efb411991af9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5cdf8b9d-35e2-4f88-9e8d-efb411991af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5790b743-5a30-4f15-a65a-98a603f830a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5790b743-5a30-4f15-a65a-98a603f830a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae4d531e-0767-43df-9036-ce10102a5c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ae4d531e-0767-43df-9036-ce10102a5c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_353090ce-3bee-4ef1-8f58-db58042fed78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_NetIncomeLoss_353090ce-3bee-4ef1-8f58-db58042fed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_86bf2d28-97e6-450e-a634-69d0cae698a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_86bf2d28-97e6-450e-a634-69d0cae698a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dbfa8196-5141-4408-8749-d38a59339ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_86bf2d28-97e6-450e-a634-69d0cae698a8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dbfa8196-5141-4408-8749-d38a59339ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_30f552de-ab71-4b78-b946-9afe8ac9f01f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_30f552de-ab71-4b78-b946-9afe8ac9f01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:href="pacb-20250331.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_09145fe9-bdf9-4f26-a584-dadd7de851d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:to="loc_us-gaap_EarningsPerShareBasic_09145fe9-bdf9-4f26-a584-dadd7de851d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bb66f0c1-4807-4a6d-beb9-72e908bafeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_01ba7c62-0d5a-4e7f-9192-b06f33aaf404" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bb66f0c1-4807-4a6d-beb9-72e908bafeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8d4889fb-7e71-4782-a897-e93956aff62a" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2e07251-8d0d-4cde-92bd-5e17e4a544f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f2e07251-8d0d-4cde-92bd-5e17e4a544f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7738b15-a54e-438c-8712-2c70b38f106e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_85544424-1c3d-4553-a3ed-3876e18f4a0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b7738b15-a54e-438c-8712-2c70b38f106e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1519b2b6-6d6c-46b9-b63d-5ea11a28e786" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b0825318-5773-4055-95a5-ced03874f459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1519b2b6-6d6c-46b9-b63d-5ea11a28e786" xlink:to="loc_us-gaap_StatementTable_b0825318-5773-4055-95a5-ced03874f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3423ed0-dc5c-4210-bc67-ddb6a51b707e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b0825318-5773-4055-95a5-ced03874f459" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3423ed0-dc5c-4210-bc67-ddb6a51b707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3423ed0-dc5c-4210-bc67-ddb6a51b707e" xlink:to="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b072f440-1d28-40e6-bc3f-fa8de11d4639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_CommonStockMember_b072f440-1d28-40e6-bc3f-fa8de11d4639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ea6d50cb-c721-4104-8772-73f470187f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ea6d50cb-c721-4104-8772-73f470187f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b25bb33-5272-4f0b-9464-515a8cdc2697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b25bb33-5272-4f0b-9464-515a8cdc2697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c4ba66f0-bea3-4a2a-b97d-3fffbe949e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aea837f9-9a59-4eca-bc1b-aafc1b883fe3" xlink:to="loc_us-gaap_RetainedEarningsMember_c4ba66f0-bea3-4a2a-b97d-3fffbe949e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a7899933-fca9-4824-9567-19b65a8fe05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b0825318-5773-4055-95a5-ced03874f459" xlink:to="loc_us-gaap_StatementLineItems_a7899933-fca9-4824-9567-19b65a8fe05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a7899933-fca9-4824-9567-19b65a8fe05b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b3de5813-7dad-4c2e-a07e-d49f83aa4f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b3de5813-7dad-4c2e-a07e-d49f83aa4f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27de2fee-b02e-4ef3-bc3a-7b2817023542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_StockholdersEquity_27de2fee-b02e-4ef3-bc3a-7b2817023542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f4472b1-9f0b-48c0-b4fb-32ec4ab90672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_NetIncomeLoss_5f4472b1-9f0b-48c0-b4fb-32ec4ab90672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9b9580f-cfa3-4f22-b00b-4a669db6845b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9b9580f-cfa3-4f22-b00b-4a669db6845b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b88c08b-6323-4ead-be2d-dfbdca43411f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0b88c08b-6323-4ead-be2d-dfbdca43411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_41ca1d53-4129-4af1-9316-b25ff3844bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_41ca1d53-4129-4af1-9316-b25ff3844bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd28c7c2-5519-4f11-9ddb-20ff002b3fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd28c7c2-5519-4f11-9ddb-20ff002b3fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e7626023-5a25-4f27-9e49-ff707b2bee8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e7626023-5a25-4f27-9e49-ff707b2bee8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd991201-9930-4e4f-8cd8-901709cddad0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ea99faa-18e2-4a59-85a4-c145480ba915" xlink:to="loc_us-gaap_StockholdersEquity_cd991201-9930-4e4f-8cd8-901709cddad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a466e5d9-b5b0-4bd8-8308-607723cd8b56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a466e5d9-b5b0-4bd8-8308-607723cd8b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1698bf4c-ee9a-410a-adc9-e1e547434c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a466e5d9-b5b0-4bd8-8308-607723cd8b56" xlink:to="loc_us-gaap_NetIncomeLoss_1698bf4c-ee9a-410a-adc9-e1e547434c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a466e5d9-b5b0-4bd8-8308-607723cd8b56" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_242b2c3c-07be-4e2b-98fa-538098f17362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_Depreciation_242b2c3c-07be-4e2b-98fa-538098f17362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_34027561-2741-420d-93bf-33da4dd6a464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_34027561-2741-420d-93bf-33da4dd6a464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d1284973-feaf-4487-80df-1bad942a3ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d1284973-feaf-4487-80df-1bad942a3ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5e55d5d5-fc77-47ce-ad1c-b9c86f81b8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_ShareBasedCompensation_5e55d5d5-fc77-47ce-ad1c-b9c86f81b8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_64127967-54cf-492e-ac3e-5f313425a4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_64127967-54cf-492e-ac3e-5f313425a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_544f7ca5-58cd-49ee-afc3-367c6113f94a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_544f7ca5-58cd-49ee-afc3-367c6113f94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3b348b6e-4d95-4ac2-a14f-26b252f7cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3b348b6e-4d95-4ac2-a14f-26b252f7cec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_60d44362-dd54-4a07-98a9-2ac9e3adc044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_InventoryWriteDown_60d44362-dd54-4a07-98a9-2ac9e3adc044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cae3c046-68df-4439-bbfe-27d144301087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_cae3c046-68df-4439-bbfe-27d144301087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_2194ae57-2467-44e0-91b1-43a020e72b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_2194ae57-2467-44e0-91b1-43a020e72b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ff894e45-6d78-4c5b-a410-5e6a307e51c5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9a91e756-5679-40d4-acb9-ed9024f16a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9a91e756-5679-40d4-acb9-ed9024f16a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_17d9b323-d3c4-4c42-ab09-8b6f13ba1631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_17d9b323-d3c4-4c42-ab09-8b6f13ba1631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eab2eb1e-4d8c-4fe4-83f1-36c026163aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_eab2eb1e-4d8c-4fe4-83f1-36c026163aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b8250768-7430-4bd7-bcbb-0294486d2d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b8250768-7430-4bd7-bcbb-0294486d2d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_62c82243-3860-46b3-9fa1-8b1c3bd255d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_62c82243-3860-46b3-9fa1-8b1c3bd255d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7111cffa-2f43-4b9b-a150-5ae1c5e11ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7111cffa-2f43-4b9b-a150-5ae1c5e11ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_239ee211-d05a-4d4d-9072-02e25ef26f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_239ee211-d05a-4d4d-9072-02e25ef26f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ed944e68-8ef0-47d6-94cc-8e5ce6e69c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_276b519b-fa3d-4d85-ac7e-ac5c8592f8fb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ed944e68-8ef0-47d6-94cc-8e5ce6e69c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0051324a-1c70-4223-ad48-e77ddae74cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a466e5d9-b5b0-4bd8-8308-607723cd8b56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0051324a-1c70-4223-ad48-e77ddae74cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ccfc25-26e7-49b9-8ed2-0671ec9a48cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ccfc25-26e7-49b9-8ed2-0671ec9a48cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d99ab646-c74d-4d56-846f-baa88a4664f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ccfc25-26e7-49b9-8ed2-0671ec9a48cf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d99ab646-c74d-4d56-846f-baa88a4664f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_93abbf7d-92b6-4828-99ca-d0b553cacbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ccfc25-26e7-49b9-8ed2-0671ec9a48cf" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_93abbf7d-92b6-4828-99ca-d0b553cacbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2bc27add-32bc-4731-8485-98c9aaa38abc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ccfc25-26e7-49b9-8ed2-0671ec9a48cf" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2bc27add-32bc-4731-8485-98c9aaa38abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3de19ac2-170c-426f-b01f-33318263bd28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ccfc25-26e7-49b9-8ed2-0671ec9a48cf" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3de19ac2-170c-426f-b01f-33318263bd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b08a651-c089-47ed-8bf7-f0608baa78ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88ccfc25-26e7-49b9-8ed2-0671ec9a48cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b08a651-c089-47ed-8bf7-f0608baa78ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c3ea478-a2ec-4b3c-8ec5-fd363c0a0ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c3ea478-a2ec-4b3c-8ec5-fd363c0a0ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2f01af0a-6c71-4bc1-a27c-a50a28ff30ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c3ea478-a2ec-4b3c-8ec5-fd363c0a0ce1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2f01af0a-6c71-4bc1-a27c-a50a28ff30ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_c054feb0-8bfc-4876-98a4-5ed33a0ad404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c3ea478-a2ec-4b3c-8ec5-fd363c0a0ce1" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_c054feb0-8bfc-4876-98a4-5ed33a0ad404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_817f0ffc-ac3d-4481-8bef-b4149b0f4000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5c3ea478-a2ec-4b3c-8ec5-fd363c0a0ce1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_817f0ffc-ac3d-4481-8bef-b4149b0f4000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90001955-71a9-41eb-abd0-07a2f4084bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90001955-71a9-41eb-abd0-07a2f4084bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fd11654-b25a-40f3-8a08-d26dd75069e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5fd11654-b25a-40f3-8a08-d26dd75069e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6322793-6c0f-47ce-846a-1e036d1bdbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6322793-6c0f-47ce-846a-1e036d1bdbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6563d6a-2058-4a73-88c9-d19d1ef91032" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6563d6a-2058-4a73-88c9-d19d1ef91032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_18e1329e-eb23-45ce-8857-2c58803ff3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_18e1329e-eb23-45ce-8857-2c58803ff3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efd7b837-1e32-45ed-95f6-bf80cd730291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efd7b837-1e32-45ed-95f6-bf80cd730291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_552b1d1c-a156-4539-9382-15d331328984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_150581dd-eb53-48b8-8c8f-e2fe4814eafa" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_552b1d1c-a156-4539-9382-15d331328984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ffd21c2d-42ce-4aba-bc78-1aa447b9e5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_552b1d1c-a156-4539-9382-15d331328984" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ffd21c2d-42ce-4aba-bc78-1aa447b9e5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="pacb-20250331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dea7e387-a682-4ffd-ab98-ef0f9c744820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_48127886-2366-4dc0-b6c7-1939b2e7768a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dea7e387-a682-4ffd-ab98-ef0f9c744820" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_48127886-2366-4dc0-b6c7-1939b2e7768a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_198e0941-2c1a-4bf9-b60d-75a51ab1f0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_7a6162cb-f2cc-43eb-977a-8a976973a055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_198e0941-2c1a-4bf9-b60d-75a51ab1f0d2" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_7a6162cb-f2cc-43eb-977a-8a976973a055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_0c855e82-348c-4d08-8230-0da26005958a" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_bffb8967-66f9-48a1-aaa2-62ac92ada442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_0c855e82-348c-4d08-8230-0da26005958a" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_bffb8967-66f9-48a1-aaa2-62ac92ada442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6f1588d2-8f39-43a3-8ca2-dcbf72cc114b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fae4441c-80a6-469d-be8d-f51ed6e5598f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6f1588d2-8f39-43a3-8ca2-dcbf72cc114b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fae4441c-80a6-469d-be8d-f51ed6e5598f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURING" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURING"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5ac8d109-c2ee-469b-84eb-119666f65d65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_95c93d6d-1df7-4456-be84-5187202fd562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5ac8d109-c2ee-469b-84eb-119666f65d65" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_95c93d6d-1df7-4456-be84-5187202fd562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="pacb-20250331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3677aa15-e2fe-4867-8cd9-714de6cee73a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_68f03a4d-46de-45dc-af8f-61b9a2cca184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3677aa15-e2fe-4867-8cd9-714de6cee73a" xlink:to="loc_us-gaap_LossContingencyDisclosures_68f03a4d-46de-45dc-af8f-61b9a2cca184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76e71beb-869f-4d88-992b-7a0124a15e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f050f49-7f05-445b-8e24-dc053c87cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76e71beb-869f-4d88-992b-7a0124a15e41" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f050f49-7f05-445b-8e24-dc053c87cf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="pacb-20250331.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_412ab827-a78b-40b7-97df-e0e13b15c3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_05407940-b9cd-4b83-92c1-ab5713cc138b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_412ab827-a78b-40b7-97df-e0e13b15c3bc" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_05407940-b9cd-4b83-92c1-ab5713cc138b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATION"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_11625c50-5b69-46eb-bc11-6c9121847e38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5893b03d-7baf-4c08-84f6-9ee34cf630b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_11625c50-5b69-46eb-bc11-6c9121847e38" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5893b03d-7baf-4c08-84f6-9ee34cf630b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="pacb-20250331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63476fc6-c4fb-49e6-a0f8-0ae17f071e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3674915d-6c52-4a30-8090-5a84d07a9bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63476fc6-c4fb-49e6-a0f8-0ae17f071e2a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3674915d-6c52-4a30-8090-5a84d07a9bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f5991bac-6389-46eb-98c8-20efbfa91fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63476fc6-c4fb-49e6-a0f8-0ae17f071e2a" xlink:to="loc_us-gaap_UseOfEstimates_f5991bac-6389-46eb-98c8-20efbfa91fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_428fdd94-d6d7-40a1-b81a-a227b345ab37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63476fc6-c4fb-49e6-a0f8-0ae17f071e2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_428fdd94-d6d7-40a1-b81a-a227b345ab37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_27ca3511-53d1-492f-b55c-47321062cb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63476fc6-c4fb-49e6-a0f8-0ae17f071e2a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_27ca3511-53d1-492f-b55c-47321062cb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_51efc081-5f3b-43c4-b4eb-f895237e7381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_63476fc6-c4fb-49e6-a0f8-0ae17f071e2a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_51efc081-5f3b-43c4-b4eb-f895237e7381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9d685db8-541b-4068-8203-74a726c7b8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8da5d6fa-5746-423b-8169-72a7499f8b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9d685db8-541b-4068-8203-74a726c7b8ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8da5d6fa-5746-423b-8169-72a7499f8b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d4ac1e8c-8325-4348-83ff-ad8b10a6d7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9d685db8-541b-4068-8203-74a726c7b8ab" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d4ac1e8c-8325-4348-83ff-ad8b10a6d7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2bcc673a-321e-405b-b255-7213eed089c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9d685db8-541b-4068-8203-74a726c7b8ab" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2bcc673a-321e-405b-b255-7213eed089c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c4ee620a-ac2a-4600-a018-119fb3e3e21b" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9d510f4d-bc58-4314-9afe-7affd9d53a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c4ee620a-ac2a-4600-a018-119fb3e3e21b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9d510f4d-bc58-4314-9afe-7affd9d53a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_b40a4b56-630f-4c46-891a-38063419487b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c4ee620a-ac2a-4600-a018-119fb3e3e21b" xlink:to="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_b40a4b56-630f-4c46-891a-38063419487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_eb5d35f7-f687-4b4c-a0ca-f8ee17a65189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c4ee620a-ac2a-4600-a018-119fb3e3e21b" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_eb5d35f7-f687-4b4c-a0ca-f8ee17a65189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_eee55d78-9f5a-4385-a1e4-8457746a728e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c4ee620a-ac2a-4600-a018-119fb3e3e21b" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_eee55d78-9f5a-4385-a1e4-8457746a728e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_37793bd7-fd11-41bf-b6a2-441733cdf927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_c4ee620a-ac2a-4600-a018-119fb3e3e21b" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_37793bd7-fd11-41bf-b6a2-441733cdf927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ce4f9d6b-b356-4f56-86e9-b2fd182efcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_e48e92a2-4dc1-49e0-953a-f578bf214ccc" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce4f9d6b-b356-4f56-86e9-b2fd182efcfc" xlink:to="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_e48e92a2-4dc1-49e0-953a-f578bf214ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d6293c50-566a-4f3d-a51e-d06fea52b7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce4f9d6b-b356-4f56-86e9-b2fd182efcfc" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_d6293c50-566a-4f3d-a51e-d06fea52b7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURINGTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_255ad6cc-2d68-4137-be6e-413fd529f5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_248447ee-6147-4dc2-bfb0-07ab1d988a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_255ad6cc-2d68-4137-be6e-413fd529f5c3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_248447ee-6147-4dc2-bfb0-07ab1d988a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_cfef958a-1ffc-4c41-b878-c53403b8d307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_255ad6cc-2d68-4137-be6e-413fd529f5c3" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_cfef958a-1ffc-4c41-b878-c53403b8d307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="pacb-20250331.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f794cee2-93f7-4caa-803b-d7ff907f6530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_846c9322-fdc4-4655-8f2e-0f6400b12a4a" xlink:href="pacb-20250331.xsd#pacb_LesseeOperatingLeaseDescriptionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f794cee2-93f7-4caa-803b-d7ff907f6530" xlink:to="loc_pacb_LesseeOperatingLeaseDescriptionTableTextBlock_846c9322-fdc4-4655-8f2e-0f6400b12a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b370021d-b39c-4a00-a41c-3037d4bce2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5c043121-98f0-4058-9466-a2c0cd8a1d28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b370021d-b39c-4a00-a41c-3037d4bce2f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5c043121-98f0-4058-9466-a2c0cd8a1d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6f16a36c-9aa4-4865-bdc6-dbe21bcb56ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b370021d-b39c-4a00-a41c-3037d4bce2f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_6f16a36c-9aa4-4865-bdc6-dbe21bcb56ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84853ae1-7112-409d-91f0-008d9f6ea106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b370021d-b39c-4a00-a41c-3037d4bce2f5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84853ae1-7112-409d-91f0-008d9f6ea106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9d264720-2223-4b93-9501-53ddd4506463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b370021d-b39c-4a00-a41c-3037d4bce2f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9d264720-2223-4b93-9501-53ddd4506463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_fed945ab-d11d-443a-bb49-1ce648886533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b370021d-b39c-4a00-a41c-3037d4bce2f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_fed945ab-d11d-443a-bb49-1ce648886533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="pacb-20250331.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_58b7c7c4-f820-4a18-900b-114009377dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a8489ef-529b-4757-a865-853ee477ded4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_58b7c7c4-f820-4a18-900b-114009377dff" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a8489ef-529b-4757-a865-853ee477ded4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6f505fe8-0535-40f1-840d-cf22346616ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_58b7c7c4-f820-4a18-900b-114009377dff" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6f505fe8-0535-40f1-840d-cf22346616ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fef88235-b917-485c-9ea6-dd82790c93f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c8e026cf-ed80-4a16-af33-629a20105916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fef88235-b917-485c-9ea6-dd82790c93f5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c8e026cf-ed80-4a16-af33-629a20105916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_ad00cd92-9b1e-4425-acfb-0a7543435646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fef88235-b917-485c-9ea6-dd82790c93f5" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_ad00cd92-9b1e-4425-acfb-0a7543435646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e3f56ce4-a91b-4f40-a9f9-67429b09308c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fef88235-b917-485c-9ea6-dd82790c93f5" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e3f56ce4-a91b-4f40-a9f9-67429b09308c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_463a37ca-6f06-428f-b6ef-dc8eae9a330d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:href="pacb-20250331.xsd#pacb_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_463a37ca-6f06-428f-b6ef-dc8eae9a330d" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_523ae250-94e1-4ce3-b201-0efb366ee1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_523ae250-94e1-4ce3-b201-0efb366ee1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba287cdd-c64a-4c76-8a05-f4b94b83540c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_523ae250-94e1-4ce3-b201-0efb366ee1b6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba287cdd-c64a-4c76-8a05-f4b94b83540c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8bca2093-81ad-48d0-9d48-25f171fcc451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba287cdd-c64a-4c76-8a05-f4b94b83540c" xlink:to="loc_us-gaap_AccountsReceivableMember_8bca2093-81ad-48d0-9d48-25f171fcc451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_98c5a0a2-0fd4-4176-9bb5-42950146c87b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:to="loc_srt_MajorCustomersAxis_98c5a0a2-0fd4-4176-9bb5-42950146c87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_98c5a0a2-0fd4-4176-9bb5-42950146c87b" xlink:to="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DomesticCustomersMember_7d4030b4-126a-4e56-a311-abc7d5e519f7" xlink:href="pacb-20250331.xsd#pacb_DomesticCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:to="loc_pacb_DomesticCustomersMember_7d4030b4-126a-4e56-a311-abc7d5e519f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_CustomerOneMember_5d703af0-8a2f-4b2a-8cfd-874899ddc1d2" xlink:href="pacb-20250331.xsd#pacb_CustomerOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b4f215f4-ac8b-4a6f-a405-18b7ba01168f" xlink:to="loc_pacb_CustomerOneMember_5d703af0-8a2f-4b2a-8cfd-874899ddc1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_06aaef9b-3f4e-4416-9312-c63d315494a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cda8a1f8-fc05-4c47-9a1a-001cf2af4f41" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_06aaef9b-3f4e-4416-9312-c63d315494a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e79cf893-c4f2-42fe-ace1-b250232e8c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_06aaef9b-3f4e-4416-9312-c63d315494a8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e79cf893-c4f2-42fe-ace1-b250232e8c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f8410b2b-4b2c-4359-9861-911e8da4bb85" xlink:href="pacb-20250331.xsd#pacb_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesTable_6e637c42-6244-4302-bec9-ccc8ce8ec870" xlink:to="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f8410b2b-4b2c-4359-9861-911e8da4bb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1bdc681a-845e-4464-b5f2-0f94ab7e2b49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SummaryOfSignificantAccountingPoliciesLineItems_f8410b2b-4b2c-4359-9861-911e8da4bb85" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1bdc681a-845e-4464-b5f2-0f94ab7e2b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b1d93fac-65b1-4886-826c-152f82eab664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b1d93fac-65b1-4886-826c-152f82eab664" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ec5df93-e55f-4ee3-bfa5-baa03d956fcb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2f9fe89b-08d4-4204-a1f6-8d5edf32f6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2f9fe89b-08d4-4204-a1f6-8d5edf32f6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f02438a2-37b2-4e10-9c85-666102090821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f02438a2-37b2-4e10-9c85-666102090821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fefebe60-5ac9-40cb-8995-d65aed0a3b86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5dc9c122-fe9a-40a1-aa16-6a17361906f1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fefebe60-5ac9-40cb-8995-d65aed0a3b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_600c12d9-79cf-40ec-929d-d62e5cf0e48f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_600c12d9-79cf-40ec-929d-d62e5cf0e48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_aaf3301f-31bc-4102-8705-f7f98127f70c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_600c12d9-79cf-40ec-929d-d62e5cf0e48f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_aaf3301f-31bc-4102-8705-f7f98127f70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_aaf3301f-31bc-4102-8705-f7f98127f70c" xlink:to="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3426c702-3a3f-44a8-8f93-dd8193dd1f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3426c702-3a3f-44a8-8f93-dd8193dd1f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_135c3404-3a3d-4372-ba5e-aa355806b509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_c9b114b9-d0ea-409a-8857-4c997fb3bf1b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_135c3404-3a3d-4372-ba5e-aa355806b509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c1e7630-243f-4732-a3e3-262dcbbf5843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a6ce52f6-20a9-44bf-a0a2-fb80e3eccb7c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c1e7630-243f-4732-a3e3-262dcbbf5843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_c2db903a-7aa7-42ff-9668-2401355e73a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2c1e7630-243f-4732-a3e3-262dcbbf5843" xlink:to="loc_us-gaap_InvestmentsMember_c2db903a-7aa7-42ff-9668-2401355e73a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a1de7740-dcde-41a1-b3fd-db20d63726d6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:to="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7b401562-ec30-49cd-a583-03c655b11742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7b401562-ec30-49cd-a583-03c655b11742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_883abe21-14ca-4563-8357-ea13369b4d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_883abe21-14ca-4563-8357-ea13369b4d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_66297d56-12f3-4078-8de7-226a5273fd3f" xlink:href="pacb-20250331.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_66297d56-12f3-4078-8de7-226a5273fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_31985cb0-042a-4e98-a965-8b50f7941e69" xlink:href="pacb-20250331.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_31985cb0-042a-4e98-a965-8b50f7941e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9ad682b8-19a1-4289-98ed-352b58ea5734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_98b54395-210f-4a1d-9209-d551fcb11b10" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9ad682b8-19a1-4289-98ed-352b58ea5734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5f2fbc69-de67-46ee-aafc-31a20e03a056" xlink:to="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_265a6325-6ba2-4c83-a855-196039da220e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_265a6325-6ba2-4c83-a855-196039da220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_92ba66e1-f501-40cd-bf04-abe61a631fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_17d17f7c-6fe2-4be2-9b96-c90d3307a6c8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_92ba66e1-f501-40cd-bf04-abe61a631fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2ba52b6a-c3a8-425b-bce9-96faf816516b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2ba52b6a-c3a8-425b-bce9-96faf816516b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f24624e-129d-44a5-b08a-95ed91cc02bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f24624e-129d-44a5-b08a-95ed91cc02bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31e6560b-f7b9-4257-ba78-4f4bd71f188f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f24624e-129d-44a5-b08a-95ed91cc02bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31e6560b-f7b9-4257-ba78-4f4bd71f188f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_6c4c7a19-7be2-4a14-98ce-bc313957ef8f" xlink:href="pacb-20250331.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31e6560b-f7b9-4257-ba78-4f4bd71f188f" xlink:to="loc_pacb_AptonMember_6c4c7a19-7be2-4a14-98ce-bc313957ef8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_2e688d6f-fd70-40be-ac3d-e1ca86510f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_2e688d6f-fd70-40be-ac3d-e1ca86510f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a01c5b8a-0862-401f-9975-e420d7fa1d12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2e688d6f-fd70-40be-ac3d-e1ca86510f75" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a01c5b8a-0862-401f-9975-e420d7fa1d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_9cf671fd-0e7e-4563-bccb-6fdcfd5f3741" xlink:href="pacb-20250331.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a01c5b8a-0862-401f-9975-e420d7fa1d12" xlink:to="loc_pacb_AchievementOfMilestoneMember_9cf671fd-0e7e-4563-bccb-6fdcfd5f3741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c9ba313a-2b80-416a-b8ba-9d026017bde9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:to="loc_srt_RangeAxis_c9ba313a-2b80-416a-b8ba-9d026017bde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e7a035b-9562-4381-8196-57bc7667a83b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c9ba313a-2b80-416a-b8ba-9d026017bde9" xlink:to="loc_srt_RangeMember_3e7a035b-9562-4381-8196-57bc7667a83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_04a8d1de-f12b-4e0f-800b-d19cc9aaed71" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3e7a035b-9562-4381-8196-57bc7667a83b" xlink:to="loc_srt_MaximumMember_04a8d1de-f12b-4e0f-800b-d19cc9aaed71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1b8c2f7e-9734-488b-b31d-d39e56603e50" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02f6b7f2-6849-4a24-8702-6c999bfabc31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_02f6b7f2-6849-4a24-8702-6c999bfabc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_229127c5-5471-4982-9d23-929de5a200a4" xlink:href="pacb-20250331.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_229127c5-5471-4982-9d23-929de5a200a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_cbf998f2-37b2-4ee1-b690-fc33deb8cdb7" xlink:href="pacb-20250331.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_cbf998f2-37b2-4ee1-b690-fc33deb8cdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_2daf20d0-c89c-4e0c-9b74-43ad51b5206b" xlink:href="pacb-20250331.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_2daf20d0-c89c-4e0c-9b74-43ad51b5206b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_f551f00f-5e4b-42a5-bc7f-ecc0006e72cb" xlink:href="pacb-20250331.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_f551f00f-5e4b-42a5-bc7f-ecc0006e72cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_4e43c363-3ff9-4bc0-b882-91568fbd9c41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e8a76a25-79f5-43dc-80b2-7817ed905478" xlink:to="loc_us-gaap_InvestmentIncomeNet_4e43c363-3ff9-4bc0-b882-91568fbd9c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e64f4101-19d9-414b-9f76-0b8fe1a1ab07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bed5a2c-5dbb-44d1-9c41-a71186f48536" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_e64f4101-19d9-414b-9f76-0b8fe1a1ab07" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bed5a2c-5dbb-44d1-9c41-a71186f48536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_808dd2aa-9fb9-459d-af60-a6b00b7c0a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bed5a2c-5dbb-44d1-9c41-a71186f48536" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_808dd2aa-9fb9-459d-af60-a6b00b7c0a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2a035c3-890d-401f-9826-fcbdf655ba5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_808dd2aa-9fb9-459d-af60-a6b00b7c0a68" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2a035c3-890d-401f-9826-fcbdf655ba5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1b11e35d-3aa9-4237-b7a8-7c3eea6ca99a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2a035c3-890d-401f-9826-fcbdf655ba5a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1b11e35d-3aa9-4237-b7a8-7c3eea6ca99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e2ea15e0-c501-4dea-ae43-f55f40853313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2bed5a2c-5dbb-44d1-9c41-a71186f48536" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e2ea15e0-c501-4dea-ae43-f55f40853313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e2ea15e0-c501-4dea-ae43-f55f40853313" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_989badcd-0fff-45e2-9c1c-a73bac6ee33c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_989badcd-0fff-45e2-9c1c-a73bac6ee33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_61576f0b-2011-49fa-a25f-494ccb198b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_61576f0b-2011-49fa-a25f-494ccb198b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_564dc0e5-926a-4be9-9d46-fb5fbf67188b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_357e776d-fdaa-447b-83cc-8abafaf03d79" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_564dc0e5-926a-4be9-9d46-fb5fbf67188b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ecf00e7c-6e91-4799-8ec9-8cc39d35ef5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_81e8745d-6c62-4546-b93b-4e360451716e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ecf00e7c-6e91-4799-8ec9-8cc39d35ef5a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_81e8745d-6c62-4546-b93b-4e360451716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_799c449c-c80c-48df-a944-c3a84ab6d04e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_81e8745d-6c62-4546-b93b-4e360451716e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_799c449c-c80c-48df-a944-c3a84ab6d04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_799c449c-c80c-48df-a944-c3a84ab6d04e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_673dc02a-cb0c-4c48-8139-6815021e4286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_673dc02a-cb0c-4c48-8139-6815021e4286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_733867e4-8d88-4f0c-9058-03ba2963e242" xlink:to="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_44ca285a-e789-4d0b-a1d9-9b1f647b59b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_44ca285a-e789-4d0b-a1d9-9b1f647b59b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a861e999-49df-455f-9e9f-5b2f472451bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_86cafede-4af5-40e1-b037-af95ca4fea37" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a861e999-49df-455f-9e9f-5b2f472451bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_81e8745d-6c62-4546-b93b-4e360451716e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4fa12890-4258-4b5e-b8de-352c4db7590f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4fa12890-4258-4b5e-b8de-352c4db7590f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b5bd901-d537-4893-8e03-bfdb6c2b2632" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8b5bd901-d537-4893-8e03-bfdb6c2b2632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfbf54bd-fc3c-4f80-b37b-b76db4497618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfbf54bd-fc3c-4f80-b37b-b76db4497618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19f2b6f7-7f5d-4e24-bbf7-2659173b8747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_19f2b6f7-7f5d-4e24-bbf7-2659173b8747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1a8f7e6e-d229-4920-8f54-a5bb0b724399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_RestrictedCashCurrent_1a8f7e6e-d229-4920-8f54-a5bb0b724399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1ae14d73-1e90-4fca-8a03-d07bb9675737" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a6bc06f2-d7a7-45fd-a75a-629696b835a8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1ae14d73-1e90-4fca-8a03-d07bb9675737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2b935a3a-2f78-45e7-8e9f-1121d7fda555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_30a86ff3-02e4-4da8-b993-ed1af3096c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2b935a3a-2f78-45e7-8e9f-1121d7fda555" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_30a86ff3-02e4-4da8-b993-ed1af3096c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_38fa0fbe-da36-4af6-80eb-f3bd70419343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2b935a3a-2f78-45e7-8e9f-1121d7fda555" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_38fa0fbe-da36-4af6-80eb-f3bd70419343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_63f09e68-5e6b-4cd4-9454-47e71dad394a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2b935a3a-2f78-45e7-8e9f-1121d7fda555" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_63f09e68-5e6b-4cd4-9454-47e71dad394a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d43352c7-c7e1-41dd-8106-56cb64ad54eb" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_7d766784-8db0-4f7b-952a-fe15e4a592b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d43352c7-c7e1-41dd-8106-56cb64ad54eb" xlink:to="loc_us-gaap_InventoryRawMaterials_7d766784-8db0-4f7b-952a-fe15e4a592b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5444a084-f35c-4e6c-a28c-eb60cc5e6770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d43352c7-c7e1-41dd-8106-56cb64ad54eb" xlink:to="loc_us-gaap_InventoryWorkInProcess_5444a084-f35c-4e6c-a28c-eb60cc5e6770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_4d28881b-cb41-4266-ae40-c5aefe8e0701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d43352c7-c7e1-41dd-8106-56cb64ad54eb" xlink:to="loc_us-gaap_InventoryFinishedGoods_4d28881b-cb41-4266-ae40-c5aefe8e0701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_ab86be68-7512-4a18-82f5-093934859cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d43352c7-c7e1-41dd-8106-56cb64ad54eb" xlink:to="loc_us-gaap_InventoryGross_ab86be68-7512-4a18-82f5-093934859cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_70b5b70e-f2c8-4df2-a7a1-775c0d82cdae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d43352c7-c7e1-41dd-8106-56cb64ad54eb" xlink:to="loc_us-gaap_InventoryValuationReserves_70b5b70e-f2c8-4df2-a7a1-775c0d82cdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_16aadc85-b973-4f65-ae52-395dc4c2c928" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d43352c7-c7e1-41dd-8106-56cb64ad54eb" xlink:to="loc_us-gaap_InventoryNet_16aadc85-b973-4f65-ae52-395dc4c2c928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_94afbe75-c654-45b7-9540-365700f0273a" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_94afbe75-c654-45b7-9540-365700f0273a" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ec2384b4-52aa-44a5-96d5-6cee868d1029" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_0971d718-f662-4c46-9162-1bff8b8514d7" xlink:href="pacb-20250331.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02251468-1d02-4f81-8e43-63cfec845739" xlink:to="loc_pacb_AptonMember_0971d718-f662-4c46-9162-1bff8b8514d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_68f28069-2a54-4718-b954-b32703b67e4d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3e87c91-9564-4591-88d9-4fe57620a681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9c5db34b-8e2d-4cfc-8dc8-acb1912abd7a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a3e87c91-9564-4591-88d9-4fe57620a681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c3c9397f-eca9-4377-907c-ea790ad25b33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6099d97c-175d-470f-99ba-319e5ca596cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6099d97c-175d-470f-99ba-319e5ca596cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7d9b40c5-5326-45eb-a220-67f64bd9e077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7d9b40c5-5326-45eb-a220-67f64bd9e077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_8e5eb95c-61a2-451d-96a8-bbc0faeef88a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af94c178-c781-4521-8455-f465a9c98e6c" xlink:to="loc_us-gaap_LicenseMember_8e5eb95c-61a2-451d-96a8-bbc0faeef88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e2bac561-3394-4ed0-a243-9ea0e5c567ca" xlink:to="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_17ddcbe5-7a43-44e0-8713-4b78eb254797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_88a7a07e-5da4-40aa-aa60-1dac0cf13ba0" xlink:to="loc_us-gaap_ServiceMember_17ddcbe5-7a43-44e0-8713-4b78eb254797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_52b594e7-1a80-40e8-a893-5c26b18d9e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_52b594e7-1a80-40e8-a893-5c26b18d9e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_61c3f454-a829-4464-80e2-14fd783bb4b1" xlink:to="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_4d241236-7349-4319-aece-7845a352d5fc" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_f24154bc-a44d-476b-9752-895a1496f1c0" xlink:to="loc_pacb_A2025RestructuringMember_4d241236-7349-4319-aece-7845a352d5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_582b2436-7bda-447e-8060-a1b0ccebfe3e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_90b4197c-8291-48a5-8a68-b431c3c25106" xlink:href="pacb-20250331.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_6895aa59-4cd5-487a-9976-6cac8889cace" xlink:to="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_90b4197c-8291-48a5-8a68-b431c3c25106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:href="pacb-20250331.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_a9a1d394-d582-44f1-b88c-974dd433898c" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_628680b0-17f0-46fe-893c-7068e0cb0ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_628680b0-17f0-46fe-893c-7068e0cb0ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_d8a4cb5f-b279-456a-8019-d9416bfa0de9" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate_d8a4cb5f-b279-456a-8019-d9416bfa0de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_7e08607e-edf6-4bdb-9b51-04ab9f75e350" xlink:href="pacb-20250331.xsd#pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate_7e08607e-edf6-4bdb-9b51-04ab9f75e350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_c93a68cf-30d1-458f-97f3-64d5c98a1b4e" xlink:href="pacb-20250331.xsd#pacb_AdditionalGoodwillImpairmentChangeInDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate_c93a68cf-30d1-458f-97f3-64d5c98a1b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c0432cf5-fe87-4387-9f72-dacb0bf2c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c0432cf5-fe87-4387-9f72-dacb0bf2c5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6062e0b1-2d4c-4fd8-b135-271152d3ecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6062e0b1-2d4c-4fd8-b135-271152d3ecd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c872884e-70ee-42d7-9838-e0e84fb10b42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c872884e-70ee-42d7-9838-e0e84fb10b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_fa2e9b4b-3e79-47be-bbd7-e5013f0a1569" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_fa2e9b4b-3e79-47be-bbd7-e5013f0a1569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_e519c97b-23fa-42a2-acf7-5906b3a0ebad" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_e519c97b-23fa-42a2-acf7-5906b3a0ebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_9b0f9a24-0d64-488f-8565-c94d7b7f4b1a" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_9b0f9a24-0d64-488f-8565-c94d7b7f4b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_5b0cd747-d987-45d7-8b83-7b24c42414d8" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_5b0cd747-d987-45d7-8b83-7b24c42414d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_b27348de-c464-4638-aeeb-db26a6f1aa4c" xlink:href="pacb-20250331.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_b27348de-c464-4638-aeeb-db26a6f1aa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_21a57ee2-6d98-4607-8cd6-bccc30d57167" xlink:href="pacb-20250331.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_21a57ee2-6d98-4607-8cd6-bccc30d57167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_cedb7653-792e-4001-bef4-ad7c227514c1" xlink:href="pacb-20250331.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_cedb7653-792e-4001-bef4-ad7c227514c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare_a9066e55-75fc-45c8-b54d-12241eb09d5d" xlink:href="pacb-20250331.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ChangeInEarningsPerShare_a9066e55-75fc-45c8-b54d-12241eb09d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9d023feb-1b29-46b5-be23-2dd81416c462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9d023feb-1b29-46b5-be23-2dd81416c462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ea5c56c4-0d5e-45a1-a43f-2a019bb57a51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ea5c56c4-0d5e-45a1-a43f-2a019bb57a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_c8411fc2-67db-478e-a67b-7ebd5bb0a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_c8411fc2-67db-478e-a67b-7ebd5bb0a0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43940ccb-f403-44cc-9697-266c094bee46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43940ccb-f403-44cc-9697-266c094bee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_513a440e-e982-4f3a-98f3-4b802108fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_513a440e-e982-4f3a-98f3-4b802108fb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9f57e1a2-9cbf-4eb8-b6d3-f5dde7e082d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9f57e1a2-9cbf-4eb8-b6d3-f5dde7e082d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_b0480c50-9868-42b2-9a4e-4956c55e374c" xlink:href="pacb-20250331.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_b0480c50-9868-42b2-9a4e-4956c55e374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8f14a05a-684f-4007-b701-32d7ec7b1432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8f14a05a-684f-4007-b701-32d7ec7b1432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_7415eb4f-9cee-4755-bba9-71772e607247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_7415eb4f-9cee-4755-bba9-71772e607247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_4be4533c-1ed0-4b34-ae4f-928326088754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_4be4533c-1ed0-4b34-ae4f-928326088754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a527820c-efa6-49d1-83c8-02007613a689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a527820c-efa6-49d1-83c8-02007613a689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_da8ee32d-c43c-4a96-a102-95888d9504d2" xlink:href="pacb-20250331.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_76d6e998-78a7-44f1-ae10-da349b5cd16b" xlink:to="loc_pacb_StandardProductWarrantyPeriod_da8ee32d-c43c-4a96-a102-95888d9504d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f426a3f-5144-4e0c-8923-a8f9f5637067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_32c91490-1e92-4691-a48a-d3a6544902d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6f426a3f-5144-4e0c-8923-a8f9f5637067" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_32c91490-1e92-4691-a48a-d3a6544902d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e9f13983-1068-4b7a-884c-b04fc4791699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_32c91490-1e92-4691-a48a-d3a6544902d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e9f13983-1068-4b7a-884c-b04fc4791699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_956a2704-e6c0-45a3-85d6-ef3780be2185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e9f13983-1068-4b7a-884c-b04fc4791699" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_956a2704-e6c0-45a3-85d6-ef3780be2185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c0d4a26d-3ada-4aac-82ac-7b5925154120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_956a2704-e6c0-45a3-85d6-ef3780be2185" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c0d4a26d-3ada-4aac-82ac-7b5925154120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b208e9a0-1d98-4569-92f6-54bcaeea5d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_32c91490-1e92-4691-a48a-d3a6544902d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b208e9a0-1d98-4569-92f6-54bcaeea5d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_b208e9a0-1d98-4569-92f6-54bcaeea5d25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02d74fb2-7e10-4cc8-8e08-aafb497f66c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_02d74fb2-7e10-4cc8-8e08-aafb497f66c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c74bb5a8-7303-4c22-acf1-a7fb81ec3685" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c74bb5a8-7303-4c22-acf1-a7fb81ec3685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_40a5dbf6-b63b-4ece-9a28-fb3fdf13f525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_40a5dbf6-b63b-4ece-9a28-fb3fdf13f525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8c360633-0f72-40df-8828-bae97329b0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_a5af375b-beca-4634-8432-1ce29d904e81" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8c360633-0f72-40df-8828-bae97329b0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_26200b42-d90b-49e6-9d5c-bf42b89692ba" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_26200b42-d90b-49e6-9d5c-bf42b89692ba" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ee02c02-f548-42b6-b553-3b71f00af6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ee02c02-f548-42b6-b553-3b71f00af6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ee02c02-f548-42b6-b553-3b71f00af6d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f7226c53-82d1-4047-9a09-9087708fc945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f7226c53-82d1-4047-9a09-9087708fc945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_691aa99f-d64f-44e2-a07b-d418749a1ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f8d1bc6-7396-4d94-bc44-a6c539a878c5" xlink:to="loc_us-gaap_CustomerRelationshipsMember_691aa99f-d64f-44e2-a07b-d418749a1ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:to="loc_srt_RangeAxis_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6fa6e5a4-e0fc-4a1f-b3e6-ac8133e5c7b8" xlink:to="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a498e5d9-540e-4c54-9b12-d0e64ab52aff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:to="loc_srt_MinimumMember_a498e5d9-540e-4c54-9b12-d0e64ab52aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c708b7c5-ae3d-4005-a3b7-a08dcf84459b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c3200045-b4df-48da-a11a-1a9c85f2ebd1" xlink:to="loc_srt_MaximumMember_c708b7c5-ae3d-4005-a3b7-a08dcf84459b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_993f632c-6ffd-4cf0-9884-418618a21334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7509eb3c-a934-446a-86d7-fc560ff310d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7509eb3c-a934-446a-86d7-fc560ff310d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3aa50323-7580-4453-baee-ec359e594586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3aa50323-7580-4453-baee-ec359e594586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d86a8e98-2aea-4780-acd5-c234941e8455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d86a8e98-2aea-4780-acd5-c234941e8455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df4c9e2a-d76a-4527-a840-08ee5f8e986a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9b399a6e-7c71-47af-a42a-190460bb6d0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_df4c9e2a-d76a-4527-a840-08ee5f8e986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_8a38c723-9a6a-4181-b5b0-d3a6a0826a30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_8a38c723-9a6a-4181-b5b0-d3a6a0826a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5d3b43f6-f8cc-4617-8f06-d77b9fa540b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5d3b43f6-f8cc-4617-8f06-d77b9fa540b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_eb8b23af-a498-45c9-b7ca-4edd0db22fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_eb8b23af-a498-45c9-b7ca-4edd0db22fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2044afff-1a15-4cff-a67b-e6ea1271e69f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2044afff-1a15-4cff-a67b-e6ea1271e69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_edcf4bb5-80bb-45f3-9f9a-d04f8e7c240f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_edcf4bb5-80bb-45f3-9f9a-d04f8e7c240f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_853d1b60-65b9-4024-807b-a1fefbee1cf5" xlink:href="pacb-20250331.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:to="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_853d1b60-65b9-4024-807b-a1fefbee1cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ac06d49c-d9fc-4956-bcca-799cb1ebfd66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_8a2a6f61-a848-443f-a251-eb5556d9dfc5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ac06d49c-d9fc-4956-bcca-799cb1ebfd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_48f6344f-6ab4-4299-950d-71e8246e1ca3" xlink:href="pacb-20250331.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_b4ceb5b2-2f39-4a69-879d-8c3eae7e7e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_48f6344f-6ab4-4299-950d-71e8246e1ca3" xlink:to="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_b4ceb5b2-2f39-4a69-879d-8c3eae7e7e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_ea1aec51-7d83-4265-8feb-37b529e85876" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_b4ceb5b2-2f39-4a69-879d-8c3eae7e7e2c" xlink:to="loc_us-gaap_ProductWarrantyAccrual_ea1aec51-7d83-4265-8feb-37b529e85876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_20c63b84-f685-4e4b-ba40-59913571c802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_b4ceb5b2-2f39-4a69-879d-8c3eae7e7e2c" xlink:to="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_20c63b84-f685-4e4b-ba40-59913571c802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_540da6f1-86d4-45ea-a275-c941c98927ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_b4ceb5b2-2f39-4a69-879d-8c3eae7e7e2c" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_540da6f1-86d4-45ea-a275-c941c98927ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_b37cb58e-6e05-435a-8024-00e7b41bb381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_b4ceb5b2-2f39-4a69-879d-8c3eae7e7e2c" xlink:to="loc_us-gaap_ProductWarrantyAccrual_b37cb58e-6e05-435a-8024-00e7b41bb381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6ac59a3-1613-48df-97d3-b3bb95595d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6ac59a3-1613-48df-97d3-b3bb95595d6d" xlink:to="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d6861e4f-c842-4fef-adc3-2ec18453747a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_us-gaap_DebtInstrumentAxis_d6861e4f-c842-4fef-adc3-2ec18453747a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d6861e4f-c842-4fef-adc3-2ec18453747a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_b6b7d1d3-afd0-485f-a9c9-97f387e037f9" xlink:href="pacb-20250331.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_b6b7d1d3-afd0-485f-a9c9-97f387e037f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_34fae1bb-2530-4862-954d-6c6405213ef1" xlink:href="pacb-20250331.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_34fae1bb-2530-4862-954d-6c6405213ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_888e306a-5f24-411b-91c3-d282ec4c754c" xlink:href="pacb-20250331.xsd#pacb_A2029NotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_A2029NotesMember_888e306a-5f24-411b-91c3-d282ec4c754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_2677f1e1-1145-4247-aba0-fee240b02190" xlink:href="pacb-20250331.xsd#pacb_ExchangeTransactionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c085fda-e144-4a87-8f79-b05ffb1c20ef" xlink:to="loc_pacb_ExchangeTransactionMember_2677f1e1-1145-4247-aba0-fee240b02190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_87f75f38-1812-45c5-8c18-e2b730fc7782" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_87f75f38-1812-45c5-8c18-e2b730fc7782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c6fbb3d-b4d3-4704-8216-a2e3d33f9fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_87f75f38-1812-45c5-8c18-e2b730fc7782" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c6fbb3d-b4d3-4704-8216-a2e3d33f9fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_add2ffca-37bb-4efe-a14a-a66170131a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c6fbb3d-b4d3-4704-8216-a2e3d33f9fbc" xlink:to="loc_us-gaap_ConvertibleDebtMember_add2ffca-37bb-4efe-a14a-a66170131a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_405050b6-7bc7-4647-ae5f-13f059d41c53" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_405050b6-7bc7-4647-ae5f-13f059d41c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_405050b6-7bc7-4647-ae5f-13f059d41c53" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_3d4768c5-35c2-472b-b19c-827e916024d3" xlink:href="pacb-20250331.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:to="loc_pacb_DebtConversionTermsOneMember_3d4768c5-35c2-472b-b19c-827e916024d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_1881b716-f27a-4505-9b38-ec92d48b2768" xlink:href="pacb-20250331.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3ac3d45d-12ba-4f4d-b6a3-d6d11c9257c1" xlink:to="loc_pacb_DebtConversionTermsTwoMember_1881b716-f27a-4505-9b38-ec92d48b2768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_srt_RangeAxis_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9e8e7c9a-25aa-42ec-91e7-e15ba0dc87c2" xlink:to="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_407c8ec5-58b0-4b6a-8fed-52346ecd8d21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:to="loc_srt_MinimumMember_407c8ec5-58b0-4b6a-8fed-52346ecd8d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f49e1773-facb-4f37-9dd9-9c88c9d1f1bc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_466348b7-7caf-405f-b64f-1c0efef8097c" xlink:to="loc_srt_MaximumMember_f49e1773-facb-4f37-9dd9-9c88c9d1f1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc1eaded-5a45-4891-92f8-99d7af856caf" xlink:to="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ca8dcf60-ad05-46b5-a0ae-4b0f1f13e52f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ca8dcf60-ad05-46b5-a0ae-4b0f1f13e52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0b3135-f8ab-4b6c-87d5-b5ca2032606d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7c0b3135-f8ab-4b6c-87d5-b5ca2032606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c1696524-35d4-4e3f-bee2-ebeb42fc0c73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c1696524-35d4-4e3f-bee2-ebeb42fc0c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5afba514-c6d9-4bf8-8914-165ee023e9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5afba514-c6d9-4bf8-8914-165ee023e9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_a3546ee7-5194-4906-b2f0-f4e9f11a0021" xlink:href="pacb-20250331.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_a3546ee7-5194-4906-b2f0-f4e9f11a0021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_564f3b11-6550-47de-9684-08afa09573a2" xlink:href="pacb-20250331.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_564f3b11-6550-47de-9684-08afa09573a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f88c7a20-91e6-4b5c-9163-5f7384d07243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f88c7a20-91e6-4b5c-9163-5f7384d07243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9c8e81bc-bc33-4133-b4bc-bd74427a4cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9c8e81bc-bc33-4133-b4bc-bd74427a4cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b03c2b2-d35f-4ea0-877c-ead783643888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_3b03c2b2-d35f-4ea0-877c-ead783643888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_fce9742c-be1b-4e29-9049-b08bb34c9a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_fce9742c-be1b-4e29-9049-b08bb34c9a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_208a1837-4d4d-4033-a9ab-2acb49e0b570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_208a1837-4d4d-4033-a9ab-2acb49e0b570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b1602321-838b-4639-807f-7a3d42428ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_b1602321-838b-4639-807f-7a3d42428ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_4026932a-b1c3-45ff-975b-816762e1d626" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_4026932a-b1c3-45ff-975b-816762e1d626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_93ef604c-535a-4981-ad4b-ce7fac535ed2" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_93ef604c-535a-4981-ad4b-ce7fac535ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_e4ed1ad6-115f-4c24-a4e2-8e1aa0f27133" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_e4ed1ad6-115f-4c24-a4e2-8e1aa0f27133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_9f883e1c-af02-4cdf-adaa-0a33eac82c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_9f883e1c-af02-4cdf-adaa-0a33eac82c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare_d104d355-752f-4a99-af03-f965d366b2de" xlink:href="pacb-20250331.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_RestructuringOfDebtPricePerShare_d104d355-752f-4a99-af03-f965d366b2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_a09ee7da-af9a-45b5-ac28-37609faf2c47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_a09ee7da-af9a-45b5-ac28-37609faf2c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees_ced6204e-eb44-4a56-a3cc-1b6e69936221" xlink:href="pacb-20250331.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtIssuanceCostLenderFees_ced6204e-eb44-4a56-a3cc-1b6e69936221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_441a3607-f4ff-4839-80a5-998dad82e41f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_441a3607-f4ff-4839-80a5-998dad82e41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8cd50b4a-92de-466b-a231-c4ed2458e579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_LongTermDebt_8cd50b4a-92de-466b-a231-c4ed2458e579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_ee6ac72d-8185-4c44-a77f-eb9fec1f1c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_ConvertibleNotesPayable_ee6ac72d-8185-4c44-a77f-eb9fec1f1c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_1d34a385-a176-46fa-aff8-28e28dfb220d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_1d34a385-a176-46fa-aff8-28e28dfb220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b60fa16b-748f-448a-b00f-6665059dab66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b60fa16b-748f-448a-b00f-6665059dab66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_1de941e9-63d2-4a9f-99b7-edd11ac2c5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_1de941e9-63d2-4a9f-99b7-edd11ac2c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_f74c6f92-d692-4ab1-a602-b9da15a8ffb5" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_f74c6f92-d692-4ab1-a602-b9da15a8ffb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0532d90e-ae89-4b54-9e57-4ce42c71d9af" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_0532d90e-ae89-4b54-9e57-4ce42c71d9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_caa78d88-47d3-474e-bb7a-76940fc4cf44" xlink:href="pacb-20250331.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_caa78d88-47d3-474e-bb7a-76940fc4cf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9d5fd5b3-923d-45a7-8bf2-5fff6c2b8b05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9d5fd5b3-923d-45a7-8bf2-5fff6c2b8b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fdab3e5-d50b-48b5-80c3-f8523700c356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0fdab3e5-d50b-48b5-80c3-f8523700c356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ad4d0c4e-61c6-4c13-847c-eff631dd23db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64e74cdb-7068-4bcf-a474-327c4fd0e394" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ad4d0c4e-61c6-4c13-847c-eff631dd23db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a43a1127-18fc-4b26-9993-8dddcf3af2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1b28977b-2b24-4ca4-83d7-e9832a43152c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a43a1127-18fc-4b26-9993-8dddcf3af2ff" xlink:to="loc_us-gaap_DebtInstrumentTable_1b28977b-2b24-4ca4-83d7-e9832a43152c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_473700f0-1a98-43cc-8140-95fd1a5724f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b28977b-2b24-4ca4-83d7-e9832a43152c" xlink:to="loc_us-gaap_DebtInstrumentAxis_473700f0-1a98-43cc-8140-95fd1a5724f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ea883d0-a9a2-4224-b51b-f9c715f9376c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_473700f0-1a98-43cc-8140-95fd1a5724f2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ea883d0-a9a2-4224-b51b-f9c715f9376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_651c03ab-d087-4c7c-8784-20ee353af939" xlink:href="pacb-20250331.xsd#pacb_A2029NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8ea883d0-a9a2-4224-b51b-f9c715f9376c" xlink:to="loc_pacb_A2029NotesMember_651c03ab-d087-4c7c-8784-20ee353af939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1b28977b-2b24-4ca4-83d7-e9832a43152c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_1a7ee5dd-e915-4485-a864-29f989ddf905" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:to="loc_us-gaap_ConvertibleNotesPayable_1a7ee5dd-e915-4485-a864-29f989ddf905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_3eec72ba-dc71-477d-9073-003c0c40b778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_3eec72ba-dc71-477d-9073-003c0c40b778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_4923f3dc-4f48-4a1c-814d-f4d24180782d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21a37d6d-62ff-43e4-a15d-7c02284db452" xlink:to="loc_us-gaap_ConvertibleNotesPayable_4923f3dc-4f48-4a1c-814d-f4d24180782d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2c9ac1d7-1370-4a98-b4d4-0b552ab0dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2fc5e2a1-b3a6-4575-b8db-407e6a9c8013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2c9ac1d7-1370-4a98-b4d4-0b552ab0dca8" xlink:to="loc_us-gaap_DebtInstrumentTable_2fc5e2a1-b3a6-4575-b8db-407e6a9c8013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_aee8c7d6-123a-4fdd-8641-ff611e7a590a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2fc5e2a1-b3a6-4575-b8db-407e6a9c8013" xlink:to="loc_us-gaap_DebtInstrumentAxis_aee8c7d6-123a-4fdd-8641-ff611e7a590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_92e4e4b0-3268-40b3-a975-50dd54c98881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_aee8c7d6-123a-4fdd-8641-ff611e7a590a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_92e4e4b0-3268-40b3-a975-50dd54c98881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_a245a928-320e-4d58-9d68-ec20c23fcc5b" xlink:href="pacb-20250331.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_92e4e4b0-3268-40b3-a975-50dd54c98881" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_a245a928-320e-4d58-9d68-ec20c23fcc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2fc5e2a1-b3a6-4575-b8db-407e6a9c8013" xlink:to="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_784f94af-c9d6-4b57-80f8-1a4f58f2dd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_784f94af-c9d6-4b57-80f8-1a4f58f2dd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_298865f1-4e7c-4e55-98de-e489bdab6a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_298865f1-4e7c-4e55-98de-e489bdab6a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_f6249dd1-f5b0-4b7b-9855-cf9900723a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_f6249dd1-f5b0-4b7b-9855-cf9900723a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_472d5b72-8789-4ebe-842c-4241725ea394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_692f70be-8040-4093-aa42-9c32c64c8fd5" xlink:to="loc_us-gaap_LongTermDebt_472d5b72-8789-4ebe-842c-4241725ea394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f0780dad-bda1-4ec8-9625-b793b5726fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fc0196db-493f-4986-ae8a-7df54690db8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f0780dad-bda1-4ec8-9625-b793b5726fe6" xlink:to="loc_us-gaap_DebtInstrumentTable_fc0196db-493f-4986-ae8a-7df54690db8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc0196db-493f-4986-ae8a-7df54690db8d" xlink:to="loc_us-gaap_DebtInstrumentAxis_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf0c507a-6e3f-4e71-89fc-bac6f5a37adb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_ed299382-9de5-4e03-bfe7-40eebbfd63c0" xlink:href="pacb-20250331.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_ed299382-9de5-4e03-bfe7-40eebbfd63c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_4e59e174-7f3d-485a-a563-3e5751d287b6" xlink:href="pacb-20250331.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4ff34b86-7d7c-4d9c-88a0-e5722250b539" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_4e59e174-7f3d-485a-a563-3e5751d287b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fc0196db-493f-4986-ae8a-7df54690db8d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_44a2f379-67a7-45b5-bcb2-a2e57c837133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_44a2f379-67a7-45b5-bcb2-a2e57c837133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_53590924-a927-430e-80c2-626937aeac01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_53590924-a927-430e-80c2-626937aeac01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_400617c1-46a7-4018-b3f2-6f02f45507b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_11ebbcc8-a242-4e69-b3c8-f9bc4fd3dd22" xlink:to="loc_us-gaap_InterestExpenseDebt_400617c1-46a7-4018-b3f2-6f02f45507b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4ff706de-9985-40ed-9097-e9523f1e6c00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4ff706de-9985-40ed-9097-e9523f1e6c00" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d714e3c7-347b-4a3b-ae2a-2fc07badb557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d714e3c7-347b-4a3b-ae2a-2fc07badb557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d714e3c7-347b-4a3b-ae2a-2fc07badb557" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_46c5facf-fa26-4e52-a0b1-86a5b86aae26" xlink:href="pacb-20250331.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:to="loc_pacb_EmployeeSeparationCostsMember_46c5facf-fa26-4e52-a0b1-86a5b86aae26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_64f0b5b4-bd26-4321-9268-5276efb7fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d5469ffb-86dc-4b0a-8a43-ec0512d7fb1b" xlink:to="loc_us-gaap_OtherRestructuringMember_64f0b5b4-bd26-4321-9268-5276efb7fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5f2ba26f-78ae-4b08-93c2-85f469016224" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5f2ba26f-78ae-4b08-93c2-85f469016224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5f2ba26f-78ae-4b08-93c2-85f469016224" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea4035ac-f54b-48b2-8947-0d72ce23ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea4035ac-f54b-48b2-8947-0d72ce23ccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_48cfa2d1-6194-46b0-9452-c35f6187f944" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_48cfa2d1-6194-46b0-9452-c35f6187f944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f2e2a52a-92c3-4fa8-b919-e4ea71ed9240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_baa78aa7-0a44-406b-9c6a-b165ed074ee2" xlink:to="loc_us-gaap_CostOfSalesMember_f2e2a52a-92c3-4fa8-b919-e4ea71ed9240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_d7e99c71-a48f-4287-a152-f351c909cc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:to="loc_us-gaap_RestructuringPlanAxis_d7e99c71-a48f-4287-a152-f351c909cc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_d7e99c71-a48f-4287-a152-f351c909cc9c" xlink:to="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_22ccfb5f-9ddb-42b7-9442-27a403bda6f5" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:to="loc_pacb_A2025RestructuringMember_22ccfb5f-9ddb-42b7-9442-27a403bda6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_c3381f97-3eb9-4967-8fe8-3424fed09949" xlink:href="pacb-20250331.xsd#pacb_A2024RestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d6d211f1-3b57-436b-b2b4-1b14a62e876f" xlink:to="loc_pacb_A2024RestructuringMember_c3381f97-3eb9-4967-8fe8-3424fed09949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bfb63d97-dca2-4f71-bd49-5a751a687bcf" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fcb1815e-f577-46b6-91d1-c09233227f16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_us-gaap_RestructuringCharges_fcb1815e-f577-46b6-91d1-c09233227f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c5597314-61cf-4c31-9c45-aaf5ebb45ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_c5597314-61cf-4c31-9c45-aaf5ebb45ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_883dfbae-f845-48eb-8eca-ce3bdea93ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_883dfbae-f845-48eb-8eca-ce3bdea93ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesExcludingAdjustments_1aa2b2cf-707e-4146-a9b8-26a5b489da80" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesExcludingAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b0330f27-3254-42f3-b780-de7e1579f74e" xlink:to="loc_pacb_RestructuringChargesExcludingAdjustments_1aa2b2cf-707e-4146-a9b8-26a5b489da80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURINGNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a2322043-66c6-4030-bd0c-e5880f823e06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a2322043-66c6-4030-bd0c-e5880f823e06" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_6de88448-5ae4-4961-b05f-ba2237a11843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:to="loc_us-gaap_RestructuringPlanAxis_6de88448-5ae4-4961-b05f-ba2237a11843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_6de88448-5ae4-4961-b05f-ba2237a11843" xlink:to="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_5fa3dce9-1e88-4495-a5b3-67651ad01b9c" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:to="loc_pacb_A2025RestructuringMember_5fa3dce9-1e88-4495-a5b3-67651ad01b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_6ba23e57-df27-4cdc-8f27-5abd60ad6c7f" xlink:href="pacb-20250331.xsd#pacb_A2024RestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:to="loc_pacb_A2024RestructuringMember_6ba23e57-df27-4cdc-8f27-5abd60ad6c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_e9399f2c-679a-4c29-a053-5df3f9d8a836" xlink:href="pacb-20250331.xsd#pacb_SanDiegoOfficeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_424bdb1c-006a-455a-932a-7d20d0b263c8" xlink:to="loc_pacb_SanDiegoOfficeMember_e9399f2c-679a-4c29-a053-5df3f9d8a836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ec2dda85-4df4-44e4-bdae-940feea19b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ec2dda85-4df4-44e4-bdae-940feea19b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5141a984-1e60-4951-bd4a-3f571fcc825e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ec2dda85-4df4-44e4-bdae-940feea19b29" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5141a984-1e60-4951-bd4a-3f571fcc825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_c7d0b469-b59d-42ff-9f5b-fd3fe01998eb" xlink:href="pacb-20250331.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5141a984-1e60-4951-bd4a-3f571fcc825e" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_c7d0b469-b59d-42ff-9f5b-fd3fe01998eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04c61944-ce25-4f45-bb05-2be606a5eab7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_535fadb7-db6c-4acf-9352-5a848ab3d492" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_535fadb7-db6c-4acf-9352-5a848ab3d492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_117b077e-19fe-4fb5-a933-217280c22a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_SeveranceCosts1_117b077e-19fe-4fb5-a933-217280c22a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesAdditionalCostsIncurred_d2474fdd-c6ec-41ab-bcac-98bd4a3d49bc" xlink:href="pacb-20250331.xsd#pacb_RestructuringChargesAdditionalCostsIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_RestructuringChargesAdditionalCostsIncurred_d2474fdd-c6ec-41ab-bcac-98bd4a3d49bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ac02bf71-e12c-4b0f-853b-5989a0928354" xlink:href="pacb-20250331.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ac02bf71-e12c-4b0f-853b-5989a0928354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2d3ac3b3-a575-4357-aed4-872fe13d49a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2d3ac3b3-a575-4357-aed4-872fe13d49a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_036003a9-cd22-481b-a302-121ca2091826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_InventoryWriteDown_036003a9-cd22-481b-a302-121ca2091826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GainLossOnPurchaseCommitments_18938a8b-4af7-4d33-a844-b7691f7a01fc" xlink:href="pacb-20250331.xsd#pacb_GainLossOnPurchaseCommitments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_pacb_GainLossOnPurchaseCommitments_18938a8b-4af7-4d33-a844-b7691f7a01fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_90105685-d86a-40bc-9028-797a35d63940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_90105685-d86a-40bc-9028-797a35d63940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_10fb9bce-9fe4-48ef-970e-f8d92b14a176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_10fb9bce-9fe4-48ef-970e-f8d92b14a176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0246cff2-06c7-472a-a22a-11981ac3018d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_27b4f9d5-dfc5-4c46-9373-5a8cf69fa97d" xlink:to="loc_us-gaap_OperatingLeaseLiability_0246cff2-06c7-472a-a22a-11981ac3018d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9756ee2e-db3a-4778-ae58-a9c056ed8235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9756ee2e-db3a-4778-ae58-a9c056ed8235" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_ce5d15a4-00e5-4087-ad3d-6d7eec67ec19" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_292b60e6-5d4d-4da5-9bc3-23a0059acef8" xlink:href="pacb-20250331.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:to="loc_pacb_EmployeeSeparationCostsMember_292b60e6-5d4d-4da5-9bc3-23a0059acef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_6135ef15-5741-4ab4-9117-79ec148f7309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_120228f0-b9ed-4999-9b8c-7bf71f3e3840" xlink:to="loc_us-gaap_OtherRestructuringMember_6135ef15-5741-4ab4-9117-79ec148f7309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_028d9a6e-8a53-4fe9-9697-726132ed1b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:to="loc_us-gaap_RestructuringPlanAxis_028d9a6e-8a53-4fe9-9697-726132ed1b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_028d9a6e-8a53-4fe9-9697-726132ed1b19" xlink:to="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_cf5fcaa2-2f4f-45c7-8c78-71c3ef37d56a" xlink:href="pacb-20250331.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:to="loc_pacb_A2025RestructuringMember_cf5fcaa2-2f4f-45c7-8c78-71c3ef37d56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_f2cfe2cf-24c7-410d-bd09-2910e7233dc1" xlink:href="pacb-20250331.xsd#pacb_A2024RestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_2c1831f2-f081-42e4-b618-73d45e723db3" xlink:to="loc_pacb_A2024RestructuringMember_f2cfe2cf-24c7-410d-bd09-2910e7233dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2c5c1d02-8aca-49d6-b3c7-f34e8992fab8" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_9a1dfe52-901f-4775-8c94-a34b8e18149b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_RestructuringReserve_9a1dfe52-901f-4775-8c94-a34b8e18149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f4bf8369-1b55-4861-aa0b-d8ccb4f41272" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_RestructuringCharges_f4bf8369-1b55-4861-aa0b-d8ccb4f41272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_c0060599-cfe0-4f2f-abaf-c722bda7c4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_PaymentsForRestructuring_c0060599-cfe0-4f2f-abaf-c722bda7c4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f56476c0-2c95-4b2c-942a-66db6dba09d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_RestructuringReserve_f56476c0-2c95-4b2c-942a-66db6dba09d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_3ab69e37-931b-4d83-94c3-b9a1eb76a950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_595677d2-fcec-4498-916e-14e2a5d22fc0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_3ab69e37-931b-4d83-94c3-b9a1eb76a950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OperatingLeaseExpectedBaseRentExpense_b8712f90-1f7e-40ce-86bf-704de60e9c33" xlink:href="pacb-20250331.xsd#pacb_OperatingLeaseExpectedBaseRentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_pacb_OperatingLeaseExpectedBaseRentExpense_b8712f90-1f7e-40ce-86bf-704de60e9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_a7e9fd97-1bd6-473f-9de5-4ae7fe279623" xlink:href="pacb-20250331.xsd#pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount_a7e9fd97-1bd6-473f-9de5-4ae7fe279623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_300da239-6a14-4acd-a3ba-08b5cd5f6060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_us-gaap_TenantImprovements_300da239-6a14-4acd-a3ba-08b5cd5f6060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_92dbc9b3-5fdf-4514-95c3-645954cbcbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_92dbc9b3-5fdf-4514-95c3-645954cbcbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3d0a7948-32f0-4b6e-b2ed-7cad0b02d40c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3d0a7948-32f0-4b6e-b2ed-7cad0b02d40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_035f696d-4f22-4cc1-a247-a3ca8044c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_035f696d-4f22-4cc1-a247-a3ca8044c1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRent_1ec41021-63b5-446b-a744-bb2df6bbbc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_us-gaap_PaymentsForRent_1ec41021-63b5-446b-a744-bb2df6bbbc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_56fcb15c-6c39-45c0-8f45-19fa071272e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_us-gaap_OperatingLeaseCost_56fcb15c-6c39-45c0-8f45-19fa071272e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_21cf3e26-98be-41d8-b192-33b7a370009e" xlink:href="pacb-20250331.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9879e6da-4caa-499d-8357-a94a814e7132" xlink:to="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_21cf3e26-98be-41d8-b192-33b7a370009e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b651fbb-3b12-45a0-9b6f-ee82c953e557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b651fbb-3b12-45a0-9b6f-ee82c953e557" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20e662e2-dbd0-48f1-8129-e6c12ed4359d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20e662e2-dbd0-48f1-8129-e6c12ed4359d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3772cbf-74b2-49ce-a58c-e9a4b1a2471b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3772cbf-74b2-49ce-a58c-e9a4b1a2471b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_336a5515-1714-4587-9954-29962988e68b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_336a5515-1714-4587-9954-29962988e68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8821a94c-ae74-4e35-9179-5b28ecfa7e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8821a94c-ae74-4e35-9179-5b28ecfa7e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5d74bdf9-52aa-4bc4-90a8-c61e96b5d8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5d74bdf9-52aa-4bc4-90a8-c61e96b5d8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_86947b02-3cc5-4165-a54b-9a8dc14c1072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_86947b02-3cc5-4165-a54b-9a8dc14c1072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dead29de-084c-4e70-94b7-634e49283050" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dead29de-084c-4e70-94b7-634e49283050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a670eafb-e1fa-4069-a7f3-6e3eb5b74f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a670eafb-e1fa-4069-a7f3-6e3eb5b74f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1ea0d1df-926e-4cbd-a6a1-9931d9411926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7932701f-cc0a-4041-823c-1b9e51e8156f" xlink:to="loc_us-gaap_OperatingLeaseLiability_1ea0d1df-926e-4cbd-a6a1-9931d9411926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BalanceSheetClassificationAbstract_22cd21d2-3785-4785-a434-6c490c4f76a4" xlink:href="pacb-20250331.xsd#pacb_BalanceSheetClassificationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b651fbb-3b12-45a0-9b6f-ee82c953e557" xlink:to="loc_pacb_BalanceSheetClassificationAbstract_22cd21d2-3785-4785-a434-6c490c4f76a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4811c0b3-8c01-48d3-a55a-4ad717d451a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_22cd21d2-3785-4785-a434-6c490c4f76a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4811c0b3-8c01-48d3-a55a-4ad717d451a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_753a709c-890e-4bd9-879c-6dc20b42b09f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_22cd21d2-3785-4785-a434-6c490c4f76a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_753a709c-890e-4bd9-879c-6dc20b42b09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_18d23137-9f00-435e-86a3-cbda325987c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_BalanceSheetClassificationAbstract_22cd21d2-3785-4785-a434-6c490c4f76a4" xlink:to="loc_us-gaap_OperatingLeaseLiability_18d23137-9f00-435e-86a3-cbda325987c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e2e726a-618c-4e34-ab87-f134796b7a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e2e726a-618c-4e34-ab87-f134796b7a4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_a90b34db-5e78-4406-8cec-4386202c190d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_f2361dba-63b8-4fe1-8d22-2e69fcbeccc6" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_a90b34db-5e78-4406-8cec-4386202c190d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_a990bf4b-a707-4d73-a67a-ad452c2fe0e9" xlink:href="pacb-20250331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_a90b34db-5e78-4406-8cec-4386202c190d" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_a990bf4b-a707-4d73-a67a-ad452c2fe0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_265401e4-c56b-4bed-92d2-5f4828d08ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:to="loc_us-gaap_PlanNameAxis_265401e4-c56b-4bed-92d2-5f4828d08ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_17d141df-a2b4-470e-acf2-ab7222b7c52d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_265401e4-c56b-4bed-92d2-5f4828d08ffa" xlink:to="loc_us-gaap_PlanNameDomain_17d141df-a2b4-470e-acf2-ab7222b7c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_78d06124-6e3e-4dc7-8578-832371db2b4e" xlink:href="pacb-20250331.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_17d141df-a2b4-470e-acf2-ab7222b7c52d" xlink:to="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_78d06124-6e3e-4dc7-8578-832371db2b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_827b4e9d-69d0-41a8-9520-a8846eefc313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:to="loc_us-gaap_AwardTypeAxis_827b4e9d-69d0-41a8-9520-a8846eefc313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed29baa1-33f5-4d55-ad8b-6d421d966746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_827b4e9d-69d0-41a8-9520-a8846eefc313" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed29baa1-33f5-4d55-ad8b-6d421d966746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_19ef1ffa-3394-4396-aa1e-220c9d11dda7" xlink:href="pacb-20250331.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed29baa1-33f5-4d55-ad8b-6d421d966746" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_19ef1ffa-3394-4396-aa1e-220c9d11dda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0ef945f3-6bf6-4aa5-b32f-1fb6e273156c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f8b605d6-0e40-4289-877e-50625f2ac382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f8b605d6-0e40-4289-877e-50625f2ac382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_4cbaefcd-d04d-4d02-aea5-07ee2528a8b4" xlink:href="pacb-20250331.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_4cbaefcd-d04d-4d02-aea5-07ee2528a8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_58997985-1af0-4b85-8b5a-251f4efff0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_58997985-1af0-4b85-8b5a-251f4efff0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c73b9deb-6037-43f9-9192-7f084a24c70b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c73b9deb-6037-43f9-9192-7f084a24c70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40f4dac5-7881-4591-ae1e-ee790e34dda7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e9abf9e4-c74a-4e5e-9f88-fc4e6a7b5a9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40f4dac5-7881-4591-ae1e-ee790e34dda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d883740-e3c0-45cc-8d43-0ce2ec0d991f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00324306-1472-4ddf-b119-772cbfabcb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d883740-e3c0-45cc-8d43-0ce2ec0d991f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00324306-1472-4ddf-b119-772cbfabcb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_70625e60-d5d7-4714-98da-496404fe4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00324306-1472-4ddf-b119-772cbfabcb9a" xlink:to="loc_us-gaap_AwardTypeAxis_70625e60-d5d7-4714-98da-496404fe4e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7279ac-f302-4c88-bda0-3db098bfb72f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_70625e60-d5d7-4714-98da-496404fe4e20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7279ac-f302-4c88-bda0-3db098bfb72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_f02327db-1f8e-44c6-b4f0-f2c6f1ea7740" xlink:href="pacb-20250331.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be7279ac-f302-4c88-bda0-3db098bfb72f" xlink:to="loc_pacb_TimeBasedStockOptionMember_f02327db-1f8e-44c6-b4f0-f2c6f1ea7740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00324306-1472-4ddf-b119-772cbfabcb9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb88978b-3fc1-444e-a05c-2a9e356affe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eb88978b-3fc1-444e-a05c-2a9e356affe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8e825444-e38f-48de-8b99-73dafaae4a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8e825444-e38f-48de-8b99-73dafaae4a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54a84e09-2821-44c7-a0cb-c6b4ecf51067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54a84e09-2821-44c7-a0cb-c6b4ecf51067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c250dd04-86d9-429f-bf14-c5766d756ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c250dd04-86d9-429f-bf14-c5766d756ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c47c872e-34e6-452e-9515-72c65993d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e989064b-3606-4e48-9165-8bd95100cc70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c47c872e-34e6-452e-9515-72c65993d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3bdd1ea0-b46a-4bb9-87d0-86aec25c88a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9c0f2ca6-ab6c-4c11-9cd2-d12cdb1a6b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9c0f2ca6-ab6c-4c11-9cd2-d12cdb1a6b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e2b21a7a-a478-4b76-80a2-9610c0bb25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e2b21a7a-a478-4b76-80a2-9610c0bb25bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_42ca0ce1-eccf-40d8-8228-a7b5bb7e2b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_42ca0ce1-eccf-40d8-8228-a7b5bb7e2b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b6e3ef13-eb93-421a-a87b-f7be9b7c2b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b6e3ef13-eb93-421a-a87b-f7be9b7c2b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_713db03e-95e1-4e95-84d2-1904bb613db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f85fcf5-f57e-4432-8054-cc8e9cf37482" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_713db03e-95e1-4e95-84d2-1904bb613db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d1c8a32-80d2-4b3d-84a7-558de38d94a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa0bb0e2-4950-436b-b5a3-711369811666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d1c8a32-80d2-4b3d-84a7-558de38d94a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa0bb0e2-4950-436b-b5a3-711369811666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_573bee45-f720-4c0b-8459-ec21e7d3e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa0bb0e2-4950-436b-b5a3-711369811666" xlink:to="loc_us-gaap_AwardTypeAxis_573bee45-f720-4c0b-8459-ec21e7d3e25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_573bee45-f720-4c0b-8459-ec21e7d3e25d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_d0785239-9d28-40cb-8b6b-8d79b10ce609" xlink:href="pacb-20250331.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_d0785239-9d28-40cb-8b6b-8d79b10ce609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e1998cb6-18de-4a0b-8d8c-bee66de33b86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c730dd3-123d-4624-849e-178ce9b2d4ff" xlink:to="loc_us-gaap_PerformanceSharesMember_e1998cb6-18de-4a0b-8d8c-bee66de33b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa0bb0e2-4950-436b-b5a3-711369811666" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc9d3977-dd43-4ad7-8251-c8566ec81403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc9d3977-dd43-4ad7-8251-c8566ec81403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70382d7f-008e-45fb-b3a2-b91f34f8479e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70382d7f-008e-45fb-b3a2-b91f34f8479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5fdd6b8b-9ad5-473d-a4e7-cc9eda02a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5fdd6b8b-9ad5-473d-a4e7-cc9eda02a93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8037cb6-b932-4945-8944-0561da49e5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e8037cb6-b932-4945-8944-0561da49e5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_308a3bfb-286d-48d8-8a98-381086112781" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c8cff4d-d707-417e-b717-e8a0ef1f3635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_308a3bfb-286d-48d8-8a98-381086112781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b44f52f-4c1a-40df-90eb-1f8471ceab0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3bfd9f1-b103-4c97-9e12-850119e4bf90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3bfd9f1-b103-4c97-9e12-850119e4bf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34cff6fa-56c9-4655-a545-a122e58e78aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34cff6fa-56c9-4655-a545-a122e58e78aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_546d695b-49a8-4acc-9b93-86346e91d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_546d695b-49a8-4acc-9b93-86346e91d9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3aeb46ee-6af9-4abf-a376-95814cb32968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3aeb46ee-6af9-4abf-a376-95814cb32968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_516f24d8-36b3-4608-a2ea-77ca19c6c388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d0b97d8e-1bfc-47d3-b708-011b40efda6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_516f24d8-36b3-4608-a2ea-77ca19c6c388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d82fa39-8003-4196-8893-18085c407ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c9ce86e-d0be-4b51-b290-c9ed0975be84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d82fa39-8003-4196-8893-18085c407ce1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c9ce86e-d0be-4b51-b290-c9ed0975be84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_70fa01f8-e00e-4faf-bec5-00628914df32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c9ce86e-d0be-4b51-b290-c9ed0975be84" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_70fa01f8-e00e-4faf-bec5-00628914df32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_70fa01f8-e00e-4faf-bec5-00628914df32" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6de19cd1-5f77-404f-845d-1b463905ff48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_us-gaap_CostOfSalesMember_6de19cd1-5f77-404f-845d-1b463905ff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d69f075-120a-4c78-a934-8c8efba7d20c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d69f075-120a-4c78-a934-8c8efba7d20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_26acee8e-0723-4624-a486-94118198f243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_26acee8e-0723-4624-a486-94118198f243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_c1bc37d6-2855-4c6b-ab0e-87e4602548f9" xlink:href="pacb-20250331.xsd#pacb_StockBasedCompensationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9d64411f-bef5-4980-a614-0d6097f98883" xlink:to="loc_pacb_StockBasedCompensationMember_c1bc37d6-2855-4c6b-ab0e-87e4602548f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7a49d9b5-45fb-412a-98f6-72f3409396aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4c9ce86e-d0be-4b51-b290-c9ed0975be84" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7a49d9b5-45fb-412a-98f6-72f3409396aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ce0d5c5-eb21-4ec8-b60a-df8114946fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7a49d9b5-45fb-412a-98f6-72f3409396aa" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6ce0d5c5-eb21-4ec8-b60a-df8114946fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cc816a6-46a8-4b29-a93f-12d89f4e71ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576ec89b-8689-44a7-8b36-4921a239da88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6cc816a6-46a8-4b29-a93f-12d89f4e71ae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576ec89b-8689-44a7-8b36-4921a239da88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_65b78164-a29d-4094-b9f1-04344f3a09ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576ec89b-8689-44a7-8b36-4921a239da88" xlink:to="loc_us-gaap_AwardTypeAxis_65b78164-a29d-4094-b9f1-04344f3a09ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f43d75bd-4029-4220-8b01-875f1f0bdb02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_65b78164-a29d-4094-b9f1-04344f3a09ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f43d75bd-4029-4220-8b01-875f1f0bdb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_a4b6af6e-a4c0-4f6c-bced-9534c49d8dd8" xlink:href="pacb-20250331.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f43d75bd-4029-4220-8b01-875f1f0bdb02" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_a4b6af6e-a4c0-4f6c-bced-9534c49d8dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_576ec89b-8689-44a7-8b36-4921a239da88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d95993c-525f-43ec-b51e-328df8021250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d95993c-525f-43ec-b51e-328df8021250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c46da047-f8b2-439b-936d-80cf10a94564" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c46da047-f8b2-439b-936d-80cf10a94564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0fdbee0e-720f-4a0b-abf7-8ee334068f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0fdbee0e-720f-4a0b-abf7-8ee334068f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_57613446-f8a5-4a66-b9d7-fc35a349dd78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_57613446-f8a5-4a66-b9d7-fc35a349dd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b4007f0f-6a54-4a84-b152-1ec5f437f559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b4007f0f-6a54-4a84-b152-1ec5f437f559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d638476e-dcf2-4874-9eca-a39493b52494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d638476e-dcf2-4874-9eca-a39493b52494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eca9e1bb-8aee-4003-83fe-87a0382709a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eca9e1bb-8aee-4003-83fe-87a0382709a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_686780a2-8a17-4f39-8ea7-32c4d2597fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_686780a2-8a17-4f39-8ea7-32c4d2597fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09b152e3-661f-4a74-a9a9-8419b37381db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58530e05-360e-4740-9c5a-2cbe8e2ec2d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09b152e3-661f-4a74-a9a9-8419b37381db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90858ad5-8e39-4f96-9363-fccd33eb19c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90858ad5-8e39-4f96-9363-fccd33eb19c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d0b3fce6-1d18-408c-8b5d-585c23a028ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:to="loc_srt_RangeAxis_d0b3fce6-1d18-408c-8b5d-585c23a028ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d0b3fce6-1d18-408c-8b5d-585c23a028ab" xlink:to="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a95e9f6-39a0-4d28-a392-766a7d9ef34e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:to="loc_srt_MinimumMember_6a95e9f6-39a0-4d28-a392-766a7d9ef34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e681632-e302-4878-8ebd-f783b207bf15" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44ec2426-3715-4074-9092-667c4a9de432" xlink:to="loc_srt_MaximumMember_5e681632-e302-4878-8ebd-f783b207bf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4bce424e-694f-464d-92c0-5a04cb15b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:to="loc_us-gaap_PlanNameAxis_4bce424e-694f-464d-92c0-5a04cb15b1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9426d2a5-bc4a-48e6-bce3-23e159ecedbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4bce424e-694f-464d-92c0-5a04cb15b1d2" xlink:to="loc_us-gaap_PlanNameDomain_9426d2a5-bc4a-48e6-bce3-23e159ecedbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_403b1af7-6dd5-401f-ad7d-85220a426f6a" xlink:href="pacb-20250331.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9426d2a5-bc4a-48e6-bce3-23e159ecedbe" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_403b1af7-6dd5-401f-ad7d-85220a426f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e7cb4ac-4cf4-47ad-aab5-b80d82acf825" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f454db8f-426e-4511-926b-892ae06111ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f454db8f-426e-4511-926b-892ae06111ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e4f60ad-30c9-4539-9b1e-41c98b452de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e4f60ad-30c9-4539-9b1e-41c98b452de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2643ba87-8e9c-4a67-9980-62dd0f572945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2643ba87-8e9c-4a67-9980-62dd0f572945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8439bab8-4e39-403a-99fb-be418b2b1d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8439bab8-4e39-403a-99fb-be418b2b1d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6672cc3b-2f59-4adc-85ba-150585bcfa49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6672cc3b-2f59-4adc-85ba-150585bcfa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d8035e8-5e18-4dae-94ed-a39f6340f393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ffe61c5a-e320-4386-a22c-b206119b8c7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5d8035e8-5e18-4dae-94ed-a39f6340f393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e4ee0a90-eb87-49e6-be64-e7d1c3182ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_f68d3587-c282-4486-92cf-93f20ed8e871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e4ee0a90-eb87-49e6-be64-e7d1c3182ef8" xlink:to="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_f68d3587-c282-4486-92cf-93f20ed8e871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_e0dc1a63-a8aa-4421-870a-6c28a6344243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_f68d3587-c282-4486-92cf-93f20ed8e871" xlink:to="loc_us-gaap_NetIncomeLossAbstract_e0dc1a63-a8aa-4421-870a-6c28a6344243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3447ba49-55c5-46ce-b0c4-e510cc0a3bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_e0dc1a63-a8aa-4421-870a-6c28a6344243" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3447ba49-55c5-46ce-b0c4-e510cc0a3bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_9e96b0c8-cd85-428c-a862-384bf716db13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_f68d3587-c282-4486-92cf-93f20ed8e871" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_9e96b0c8-cd85-428c-a862-384bf716db13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_1654ce40-df27-47f4-b669-1492edf7373b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_9e96b0c8-cd85-428c-a862-384bf716db13" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_1654ce40-df27-47f4-b669-1492edf7373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dc5186d0-b9b8-4d95-9802-1c34ad173170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1654ce40-df27-47f4-b669-1492edf7373b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dc5186d0-b9b8-4d95-9802-1c34ad173170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a25e7295-0cb0-4c51-8f38-e892fb864ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_9e96b0c8-cd85-428c-a862-384bf716db13" xlink:to="loc_us-gaap_EarningsPerShareBasic_a25e7295-0cb0-4c51-8f38-e892fb864ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_c32a8da2-d5a0-4a1d-90f9-493fac16e2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_9e96b0c8-cd85-428c-a862-384bf716db13" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_c32a8da2-d5a0-4a1d-90f9-493fac16e2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0790a644-012f-4398-abcf-9c05efcde30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c32a8da2-d5a0-4a1d-90f9-493fac16e2d1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0790a644-012f-4398-abcf-9c05efcde30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7a0a5795-6a38-423a-9e5f-c509c67c81f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_9e96b0c8-cd85-428c-a862-384bf716db13" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7a0a5795-6a38-423a-9e5f-c509c67c81f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ff887cf0-0b65-4c77-9b82-1a9bf535f1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8687e1bd-75f9-4fa8-82fd-25bf668f918c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff887cf0-0b65-4c77-9b82-1a9bf535f1de" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8687e1bd-75f9-4fa8-82fd-25bf668f918c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44bb8bfa-b62b-4905-806b-fc90cbed27c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8687e1bd-75f9-4fa8-82fd-25bf668f918c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44bb8bfa-b62b-4905-806b-fc90cbed27c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_44bb8bfa-b62b-4905-806b-fc90cbed27c4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_6b8fef22-99f3-4ffc-8c28-e93707251afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_6b8fef22-99f3-4ffc-8c28-e93707251afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_1f787b04-35fa-4af5-98bf-7dcbfdfdf1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a929c0e-6774-43e0-a39f-ce32a2933f0f" xlink:to="loc_us-gaap_StockCompensationPlanMember_1f787b04-35fa-4af5-98bf-7dcbfdfdf1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3fe5c64c-1193-400e-8b4b-b810c7021835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8687e1bd-75f9-4fa8-82fd-25bf668f918c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3fe5c64c-1193-400e-8b4b-b810c7021835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70db83c7-ccb0-4c69-80b0-4556f7092708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3fe5c64c-1193-400e-8b4b-b810c7021835" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70db83c7-ccb0-4c69-80b0-4556f7092708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_852b42ee-bfc9-49a6-8446-fc8937696968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_642a13f6-f577-4eae-94eb-340dd5e28fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_852b42ee-bfc9-49a6-8446-fc8937696968" xlink:to="loc_us-gaap_NumberOfReportableSegments_642a13f6-f577-4eae-94eb-340dd5e28fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f5edf828-340c-4d43-9935-042872ee7965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_baad6cb3-f054-4b37-8dc7-2edc9f4827d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f5edf828-340c-4d43-9935-042872ee7965" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_baad6cb3-f054-4b37-8dc7-2edc9f4827d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7689fdb5-4e49-4ac5-9be2-30c7c0f77747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_baad6cb3-f054-4b37-8dc7-2edc9f4827d4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7689fdb5-4e49-4ac5-9be2-30c7c0f77747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_93ad3ce4-c393-4e53-82a6-b118efe95f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7689fdb5-4e49-4ac5-9be2-30c7c0f77747" xlink:to="loc_us-gaap_SegmentDomain_93ad3ce4-c393-4e53-82a6-b118efe95f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember_3f8c0ae1-2f90-49e1-bbf8-74dd1a5adb9c" xlink:href="pacb-20250331.xsd#pacb_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_93ad3ce4-c393-4e53-82a6-b118efe95f51" xlink:to="loc_pacb_ReportableSegmentMember_3f8c0ae1-2f90-49e1-bbf8-74dd1a5adb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_baad6cb3-f054-4b37-8dc7-2edc9f4827d4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e0e47bbe-feef-4008-afe7-57e2aa8e6dec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e0e47bbe-feef-4008-afe7-57e2aa8e6dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_44e7445a-5824-4627-82a6-af44a7070eee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_CostOfRevenue_44e7445a-5824-4627-82a6-af44a7070eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_72322e7d-26ef-4100-9eb0-3e99fcdae43e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_72322e7d-26ef-4100-9eb0-3e99fcdae43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_fe9a7cd5-e864-4a87-a6e0-6cacf56123de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_SellingAndMarketingExpense_fe9a7cd5-e864-4a87-a6e0-6cacf56123de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca78fed5-ec8b-41fb-a943-8f94c5ed4c82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca78fed5-ec8b-41fb-a943-8f94c5ed4c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a015fa8b-0995-4b25-b7e7-ec8d9ca5f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a015fa8b-0995-4b25-b7e7-ec8d9ca5f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e8ab9b82-3f27-4333-8677-96ae6c975620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e8ab9b82-3f27-4333-8677-96ae6c975620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2791de26-943b-4ac3-9397-e8c179cbdcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_c687a586-c80d-4504-9370-2bc3861c3cc8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2791de26-943b-4ac3-9397-e8c179cbdcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_060dc37d-90e3-4250-b9cd-66c5b7bc43d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_060dc37d-90e3-4250-b9cd-66c5b7bc43d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec2dde48-19c9-4a03-8cc9-e8eb95134f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec2dde48-19c9-4a03-8cc9-e8eb95134f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e22d54f-0fc6-47f4-a0e9-fe7553822174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0f6ddbfe-173f-44cc-8b52-5d84f0573f64" xlink:to="loc_us-gaap_NetIncomeLoss_9e22d54f-0fc6-47f4-a0e9-fe7553822174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fd811e89-0d7f-4908-97b1-6c29b57002e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a1dbbedc-5cb0-4931-a473-75adbc0178c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fd811e89-0d7f-4908-97b1-6c29b57002e3" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a1dbbedc-5cb0-4931-a473-75adbc0178c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79d30d40-efe4-411e-bced-3128ec3ba5cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a1dbbedc-5cb0-4931-a473-75adbc0178c0" xlink:to="loc_srt_StatementGeographicalAxis_79d30d40-efe4-411e-bced-3128ec3ba5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_79d30d40-efe4-411e-bced-3128ec3ba5cd" xlink:to="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_223c04e7-eb7e-4a6b-8dda-a5db173ef240" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:to="loc_srt_AmericasMember_223c04e7-eb7e-4a6b-8dda-a5db173ef240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_4981643e-0eba-4028-9dd2-f3499bdc5a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:to="loc_us-gaap_EMEAMember_4981643e-0eba-4028-9dd2-f3499bdc5a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_43c27f5c-2b31-4758-8acb-17b01816bf97" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ab69814e-1eb0-4ca8-9854-4529709afc19" xlink:to="loc_srt_AsiaPacificMember_43c27f5c-2b31-4758-8acb-17b01816bf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1a71c54d-52c9-445d-a4b0-83c32735c053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a1dbbedc-5cb0-4931-a473-75adbc0178c0" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1a71c54d-52c9-445d-a4b0-83c32735c053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8dcacfa9-2ea9-4595-bc6f-ce7277bc1407" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1a71c54d-52c9-445d-a4b0-83c32735c053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8dcacfa9-2ea9-4595-bc6f-ce7277bc1407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20250331.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4c2a4a08-512b-42f5-b606-3665b933ecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_705ae16b-4db1-4039-9c80-02ae6c5c5c90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4c2a4a08-512b-42f5-b606-3665b933ecbb" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_705ae16b-4db1-4039-9c80-02ae6c5c5c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7973b87e-f184-4662-8d3a-e70f6c776a55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_705ae16b-4db1-4039-9c80-02ae6c5c5c90" xlink:to="loc_srt_ProductOrServiceAxis_7973b87e-f184-4662-8d3a-e70f6c776a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7973b87e-f184-4662-8d3a-e70f6c776a55" xlink:to="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:to="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_79e945c3-0394-4e49-b880-5065da3859dd" xlink:href="pacb-20250331.xsd#pacb_InstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:to="loc_pacb_InstrumentMember_79e945c3-0394-4e49-b880-5065da3859dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_77504213-5a69-4b1a-8ffd-06e5c4f0062a" xlink:href="pacb-20250331.xsd#pacb_ConsumableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_a01749a1-1195-41b1-b384-2264ca9cdc58" xlink:to="loc_pacb_ConsumableMember_77504213-5a69-4b1a-8ffd-06e5c4f0062a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_d7b3f7f9-ae22-4e5c-8c89-3d96906329fc" xlink:href="pacb-20250331.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d5d09b68-cd0a-4f68-9d99-c765be0a793b" xlink:to="loc_pacb_ServiceAndOtherMember_d7b3f7f9-ae22-4e5c-8c89-3d96906329fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ea897dc5-142b-4b1e-8268-b91f82d593d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_705ae16b-4db1-4039-9c80-02ae6c5c5c90" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ea897dc5-142b-4b1e-8268-b91f82d593d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e34bd5e1-3358-40e1-85b4-edcc76eefb15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ea897dc5-142b-4b1e-8268-b91f82d593d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e34bd5e1-3358-40e1-85b4-edcc76eefb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0 !2@%*  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      %*     0   4H    !  .@ 0 #     0 !  "@ @ $     0  "D^@
M P $     0   D(     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ *7_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA%-O=V5V?NY^TM_P4*_9=_9;\W3O'VO)?:W'P/#FA!;S4 W/$JJP2 >\KK[
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M^C1Q-X>8U4<XI<]&;M3K0NZ<_*]KQG;>$K/JN9:G9T445X)_/84444 %%%%
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M6_\ Q#G)?^@;_P FE_F>O_Q)AX9?]"2/_@RM_P#+#^JG_B**^(?_ $1[1O\
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M:'_DQ[A129%+7B'Y>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"G_H0Q_\&U__ ):?T.?\/_\ Q?\ ]$RTW_P<R_\ R-1_P_\ _%__ $3+3?\
MP<R__(U?SQT4?ZE99_SX_&7^8?\ $BWA3_T(8_\ @VO_ /+3^AS_ (?_ /B_
M_HF6F_\ @YE_^1J/^'__ (O_ .B9:;_X.9?_ )&K^>.BC_4K+/\ GQ^,O\P_
MXD6\*?\ H0Q_\&U__EI_0Y_P_P#_ !?_ -$RTW_P<R__ "-1_P /_P#Q?_T3
M+3?_  <R_P#R-7\\=%'^I66?\^/QE_F'_$BWA3_T(8_^#:__ ,M/Z'/^'_\
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MZ*/]2LL_Y\?C+_,/^)%O"G_H0Q_\&U__ ):?T.?\/_\ Q?\ ]$RTW_P<R_\
MR-1_P_\ _%__ $3+3?\ P<R__(U?SQT4?ZE99_SX_&7^8?\ $BWA3_T(8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^K7N?]?=3XF%%%%(@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBCV*BH8IXKA1) Z.IZ,A##\Q4U<1\2TUHPHHHH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]/\L_VI?^3G?B+_
M -CYX@_].$]>%U[I^U+_ ,G._$7_ +'SQ!_Z<)Z\+K^W\'_!I^B_(_ZF^%_^
M1;A/\$/_ $E!11172>Z%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5R'Q!_Y$+7/^P1>?^B7KKZY#X@_\B%KG
M_8(O/_1+UI1^./J>AE/^]4?\4?S1_G36G_'K%_US7^56*KVG_'K%_P!<U_E5
MBOZM>Y_U]U/B84444B HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV(IOX:,:;]:3=)_^D!1117T!_2 4444 %%%% !1110 4444 %%%% !7Z.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_K[J?$PHHHI$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_C!2J8+'\$XJ=IPDZU&_6,K*I%?X9*,K=>:3V1\?T445^HG^M84444 %%%%
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ME:,K0 M%)E:,K0 M%)E:,K0 M%)E:,K0 M%)E:,K0 M%)E:,K0 M%)E:,K0
MM%)E:,K0 M%)D4N10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^XG_!$'_@HI<_L??'R/X/_ !'ORGP[\=WL=I?>>?W6E:M)MCMK\?W4
M8A8;CH-A#G_5U_?BA#*&&"#R".A]Z_R2&Z5_>U_P0<_;UG_:H_9M/P4^(%WY
MWC/X<06^G22RL#+J&B$;+*Y]2\(7R)3S]U&)R]?AGBOPJK+,Z"\I_I+]'\C_
M "F_:#> 4>6/'.5T[-6CB$EO?2%7UVA+_MU]),_>"BBBOPH_R@"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;UR.*_.^(> *->]7!>Y+MT?IV_+T/\SOI'_LZ\HSQ5<UX)Y<)B=6Z+THS?\
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M4\9,^X+R/ X[(*JISJ5N23<8R]WDD]I)]4C^;C_B&!_:'_Z*7X+_ / 6^_\
MB*/^(8']H?\ Z*7X+_\  6^_^(K^T>BOQW_B*.<?\_5_X"C_ #<_XGR\2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?O#/_@)=_P"%'_#@KXR?]#]X9_\  2[_ ,*_J-HH_P"(@9G_ ,_%_P" H/\
MBHAXI_\ 0QA_X)I?_(G\N7_#@KXR?]#]X9_\!+O_  H_X<%?&3_H?O#/_@)=
M_P"%?U&T4?\ $0,S_P"?B_\  4'_ !40\4_^AC#_ ,$TO_D3^7+_ (<%?&3_
M *'[PS_X"7?^%'_#@KXR?]#]X9_\!+O_  K^HVBC_B(&9_\ /Q?^ H/^*B'B
MG_T,8?\ @FE_\B?RY?\ #@KXR?\ 0_>&?_ 2[_PH_P"'!7QD_P"A^\,_^ EW
M_A7]1M%'_$0,S_Y^+_P%!_Q40\4_^AC#_P $TO\ Y$_ER_X<%?&3_H?O#/\
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MZEHNBOX?\/RD,_B+Q$CVL!3/)@B(\Z<^FQ=GJPK^KWX+?L#?LD_ -HKSX?\
M@O2OM\2@#5M44ZA>Y'\0EN=^PGOY84>U?80 '3Z5\GF?B6[..#I6\Y?Y+_/Y
M'\?>*W[4:<Z<\-P9EC@WHJM>S:\U2BVK]G*;7>+/@#]CC_@G/\"OV/+0:QH4
M3Z]XJEB\NZ\3ZK&GGJ#]Y+2,96WC/HI+GHSFOT  QQ117YEC,=5Q%1U:\G*3
MZL_ROXVXZSCB/,:F:YYBY5ZT]Y2=WY)+:,5TC%)+H@HHHKE/DPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBHIYHK>%[B=E1$4N[N0%55&223
MP !U- TKZ(E)Q7XY_M_?\%7?!'[-KW?PK^#'V3Q%XX5?+N9B1)INCL>#]H9&
M_>W '(A4_*?OD?=/Q]_P4;_X*Y279O\ X%?LG7^(</::YXUMB0S'.UX--;C
MZAKCOTC_ +Y_G0DEEED:65F9W8L[,=Q9F.223R23R2:_5.%.!.=1Q./5ETCW
M]?\ +\NO^M/T1_V?TL=&CQ+Q[1<:;M*GAG=2EU4JW6,>U/23^W9>[+L_B-\2
M?'7Q<\97WQ!^).IW>L:QJ,IENKZ\<NYR>$0=$C7HJ* JC@ "N(HHK];C%)*,
M59(_V6P>#HX>C##X>FH0@DHQBDDDM$DEHDEHDM$%%%%,Z HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^CQG_AYFOU#-Z?-3G?V5:*?)4BNW:2^U!ZQ\XM2>G1117B'X.%%%% !1110
M4444 %%%% '_U_RS_:E_Y.=^(O\ V/GB#_TX3UX77NG[4O\ R<[\1?\ L?/$
M'_IPGKPNO[?P?\&GZ+\C_J;X7_Y%N$_P0_\ 24%%%%=)[H4444 %%%% !111
M0 4444 1R=J_TO/^"5?_ "CI^#W_ &)-E_[-7^:')VK_ $O/^"5?_*.GX/?]
MB39?^S5^0>,?^XT/\?Z,_P W_P!I3_R2^5_]A'_N.9^@%%%%?SL?XSA1110
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MO]I-X;QA/+.*Z$?BO1J/S5YTW]W.K^44?==%%%?AI_E6%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKG\#AGUQ'Y43I****_(S_&\**** "BBB@ HHHH **** "BBB@ HHHH ****
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MH)SS]V\F(XY'K[5YY=?\'0GP<2X=+'X4>)Y(@?D>75K2-R/=1$X'_?1K^-C
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M/^/6+_KFO\JL5_5KW/\ K[J?$PHHHI$!1110 4444 %%%% !1110!:L?^/\
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MU.HE:-2FW[LU^4E]F2:UT;6BBBO'/QD**** "BBB@#__T?RS_:E_Y.=^(O\
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M/^$M\5_]!34?_ F7_&C_ (2WQ7_T%-1_\"9?\:Y^BBR[!]4H_P#/M?<CH/\
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M\?Z,_P W_P!I3_R2^5_]A'_N.9^@%%%%?SL?XSA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %(>:6B@#^+[_@YU^%L&C?'G
MX<_&"TB*MKOAB\T.[F_A9]*N!+&,>NV[/Y"OYB*_M!_X.?/"\=Y^SW\,_&9Q
MNT[QC>:<.>U_9&0\?6U%?Q>CI7]7>&^)=7)Z%^EU]S=OP/\ H)^A)G<L;X;9
M4YN[I^TA\HU)<O\ Y+86BBBONC^KPHHHH **** "BBB@ HHHH *:WK3J:U G
ML?Z0O_!&[7O^$B_X)H?">Z+[V@T&>P<^AM;V>$#\%45^FM?C?_P01U&34/\
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M/X0M7B\7_$%X\VWA+3IPJVA(^634KA0XMEZ$1X,KCHH7YA_$#^V%^WK^TO\
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M-]*'_DWN?_\ 7B9_>'1117\@'_. %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)V&?)O+8DM&W7##*/C*,PYK^<.*N",7E<N:2YJ?22V^?9_TF?XI^/OT6^(>
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M*** "BBB@ HHHH **** "BBB@ HHHH ***0]* /YJO\ @X U7.N?#'0QM/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%WG_ &3K6?\ TJL:^6XV_P"13BO\+/P;Z4/_ ";W/_\ KQ,_O#HHHK^0#_G
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M>!M0N])UC2KJ.]TW4;"1H;BWGB;*/&Z\@C]>AXK^Y;_@D3_P65\/?M>V-G\
M/VA[FUTOXG6\7EV%[A8+3Q)'&N2T0X6.\"@F2$ !P"\8QN1/YWXZ\.)83FQF
M!5Z>[CUC_FOQ7IJ?XT?2M^A=6X=5;B+A:#J81:SIZN5'NUUE377[4%O>-VOZ
M :* <\T5^1G^=H4444 %%%% !1110 4444 %%%% !7(?$'_D0M<_[!%Y_P"B
M7KKZY#X@_P#(A:Y_V"+S_P!$O6E'XX^IZ&4_[U1_Q1_-'^=-:?\ 'K%_US7^
M56*KVG_'K%_US7^56*_JU[G_ %]U/B84444B HHHH **** "BBB@ HHHH M6
M/_'_  ?]=X__ $(5_HI>#?\ D4-*_P"P;;?^BEK_ #K;'_C_ (/^N\?_ *$*
M_P!%+P;_ ,BAI7_8-MO_ $4M?E?BA\.&_P"WOT/\A_VKG\#AGUQ'Y43I****
M_(S_ !O"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *CEDCAB::9E1$4L[,< *.223T J2OS1_X*J_M.6O[.G[+.J:=I=QY7
MB+QBDOAS1$0_.J3+B[N![10,0#_?=/4D=F7X*>)KPH4]Y.W]>A]IX=<#8WB;
M/<#D&7QO4Q$XP7E=ZR?E&-Y2[)-G\I'[9?QA3X]?M0^-?BG:N9+/4-;EBTUC
M_P ^-H!;VQ&>1NCC5L=B:^9* ,#:.@&/RHK^H*-"-*$:4-HI)?(_ZO.'<AP^
M59?A<LPBM3H0C3BNT8145^""BBBM#V HHHH **** "BBB@ HHHH *_2C_@DG
MX ;Q[^W9X2D9<PZ%#?>(I\CC%K T<7/8^=+&1]*_->OZ(_\ @@;\*Y+CQ)X\
M^-5TG[NVM+3PQ92$=9)F^U7&/=52'/\ O5X/%.+5'+L1/NK??I^I_.GTMN,8
MY'X;Y_C>:TI472C_ (JUJ2MYKGO\C^EM:=117\VG_,$%%%% !1110 4444 %
M%%% !7G_ ,6?^25^)O\ L7]1_P#2:2O0*\_^+/\ R2OQ-_V+^H_^DTE:T/CC
MZGK9!_OV&_QQ_P#2D?YW-O\ \>\?^XO\JFJ&W_X]X_\ <7^535_5CW/^O6I\
M3"BBBD0%%%% !1110 4444 %-?[A^AIU-?[A^AIK<:W/[]?V/_\ DU7X=?\
M8F:1_P"DL=?1M?.7['__ ":K\.O^Q,TC_P!)8Z^C:_EC'?QZGJ_S/^2?Q$_Y
M*#,_^OU7_P!+D%%%%<I\<%%%% !1110 4444 %%%% $<LJ01M-*RJB*69F.
MH')))Z 5_$#_ ,%(/VK+K]J_]I'4==TJ=G\,Z \FA^&(@?D:WB;$MT!_>N9
M7S_<"#MS_0W_ ,%?_P!J1_@-^S9)X"\,736_B/QT9-'M6A;$D&GJ ;Z;/4;D
M80K[R$C[IK^.; ' X%?K_AQDO+&6/J+?2/ZO]/O/]F?V97@6J.&Q/'N/I^]4
MO2P]^D5I5J+_ !/]VGNE&:VD%%%%?J)_K>%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]/?L>_
MM(Z]^RK\?]"^+NE-(UG;3BTURSC_ .7K2[@A;F+'0L!ATST=5-?,-*N,\UE7
MH0JPE2J*\9*S/&XCX>P>;9?B<KS"FIT:\90G%]8R5FON>CZ/4_T9?#?B'1O%
MOAZQ\4^';A+O3]2M(;ZRN8CE)8)T#QNI]&4@UM5^$G_!$']J'_A._A/J/[-?
MB:XW:EX0/V[1/,;YI=(N7.Z-<\G[/,2/9)$':OW;%?S1G.62P>)J8>?1_>NC
M^X_Y9?&WPLQ7!?%&/X<Q=W[&7NR_GIOWH3_[>BTWV=UT"BBBO+/RH__4_+/]
MJ7_DYWXB_P#8^>(/_3A/7A=>Z?M2_P#)SOQ%_P"Q\\0?^G">O"Z_M_!_P:?H
MOR/^IOA?_D6X3_!#_P!)04445TGNA1110 4444 %%%% !1110!')VK_2\_X)
M5_\ *.GX/?\ 8DV7_LU?YH<G:O\ 2\_X)5_\HZ?@]_V)-E_[-7Y!XQ_[C0_Q
M_HS_ #?_ &E/_)+Y7_V$?^XYGZ 4445_.Q_C.%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4AI:0T ?QE_\'//Q.@U7XU_#
M7X06TVXZ-X<OM>NX?[C:G<+#$3]5M&K^7L=*_23_ (*Y_'=?VAO^"@_Q%\8V
M<RS:?IFK#PMI3(Q9/LVBH+3<F<<22I)(1ZN:_-RO[#X.R]X7+,/1>_+=^KU?
MYG_21]&S@^61<"Y-EM16DJ2E)=I5+U)+Y.37R"BBBOI3]P"BBB@ HHHH ***
M* "BBB@ IC]*?3'Z4"EL?Z0G_!&S0?\ A'O^":'PGM638T^A3W[CU-U>W$H/
M4]58'^@Z5^F]?-O[&_@9OAI^R7\-/ <L9AETOP+HEI<QD8*SK91&;CM^\+5]
M)5_%.<UU5QE>HOM2D_O;/^7_ ,3,U6/XCS7'1>E6O5DO24Y-?F%%%%>:?$!1
M110 4444 %9.NZYH_AG1;SQ'XBNK>QT^PMI;R^O;N18H8((5+R2R.QVJB*"6
M). .:ULBOXR/^"\G_!5%OB5KM[^Q+^SYJ>[P[IER8/'NL63<:C?0/SIT4@ZV
M]NZ_OB.))!MSM0[OH>&>'*V9XJ.'I:+J^R_K9=3]D\#/!?,N.<^I91@?=@O>
MJ5+75.%]6^[>T8]7V5VOC+_@L'_P56UK]N;Q^WPJ^%%S<V?PM\/7C-81#="^
MNW<?R_;[I,\QJ<_9HV&54[V =B%_$H# Q2T5_6V5950P5"&&P\;1C_5WYL_Z
M'_#WP_ROAC*:&2Y12Y*5)67=OK*3ZRD]6_R5D%%%%>B?:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#] SZ)E;A+#/BOB*ERXVO&U.#WHTWOS=JD^JWA'W7K*224445^@'^D84444
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MU/5_F?\ )/XB?\E!F?\ U^J_^ER"BBBN4^."BBB@ HHHH **** "FL0JEF.
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M?^XYGZ 4445_.Q_C.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\0?\%&?VHK3]D#]CGQI\:5E2/5+?36TSPZC\F35[_,%
MIA?XO+=O-8?W$:OM^OX:?^#A7]N"#XZ?M VG[+_@&^\_PU\.Y7;5V@)\JY\1
MR I.#V?[)$?)4_PNTP!YY^MX)R!YCF%.DU[L=9>BZ?/8_HCZ+OA%4XRXOP>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\DCL2S,S$EF)R35.BBOZ=1_NM""BE&*L@HHHH*"BBB@ HHHH **** "BBB@
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MWBW_ ,%/_P!LH_X?>?L2_P![Q;_X*?\ [91_JQF/_0/+[@_XE1\2?^B;Q/\
MX+D?K]17Y _\/O/V)?[WBW_P4_\ VRC_ (?>?L2_WO%O_@I_^V4?ZL9C_P!
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M"G_[91_JQF/_ $#R^X/^)4?$G_HF\3_X+D?K]17Y _\ #[S]B7^]XM_\%/\
M]LH_X?>?L2_WO%O_ (*?_ME'^K&8_P#0/+[@_P")4?$G_HF\3_X+D?K]17Y
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M =2*BI5C"+G-V2U9Y^;YMAL!A*V.QM10I4HRG*3VC&*;;?DDKG[_ '_!"O\
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MCU/5_F?\D_B)_P E!F?_ %^J_P#I<@HHHKE/C@HHHH **** "BBB@ K^2_\
MX+@?'C_A/OVB].^#&D7'F:?X)TT-=HIRO]J:B%ED_%(!$OL2PXY%?U3>./%^
MC^ /!FK>.O$$BPV&C:;<ZI>2MP%AM8FE<_\ ?*FO\^/XG?$#7?BM\1==^)GB
M9VDO]?U6YU6Y+=FN)"^WZ*"%'TXK])\-LL]IB:F)EM!:>K_X%_O/]._V8GA>
MLPXGQW%&(C[F"ARP_P"OE6ZNO\--33_QHX6BBBOV<_W-"BBB@ HHHH ****
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M44?_ "2"E_Z6?YM/A_\ X)#_ /!27Q.D<NG_  C\31)(1M>^-M9X!QR1/,A
MY[C^5>G6/_!#+_@IW>H[K\.?+V'I/K&EH3_NYNN:_P!$W'>EKP)^,68?9I07
MRE_F?D6+_:1\8R?[G+\-%><:C_\ <B_(_P XO5?^"+7_  4VTF$3R?"S4YP<
M_+:7VG3,,>JK<D\]J^?O'G_!/?\ ;C^&2E_&GPH\=VJ("7EATFXNXE"C))DM
MEE4  =2<>]?Z>M%:T?&/&I_O*$7Z77ZL[\M_:4<40DGB\KH37]WVD7][E/\
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MIW/[.X=XHR[-\+'&Y7BH5Z<MI0DI+[TVK^6X^BBBNH]X**** "BBB@ HHHH
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MC3[A1116AW!1110 4444 %%%% !1110 4444 %%%% !7[Z_\&W__ "D+O/\
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M_5KW/^ONI\3"BBBD0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVY2DW=RDW=MMZMMZM]0HHHJ#D"BBB@ HHHH **** "BBB@ HHHH *\_^+/\
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MU/AJ"I4X4H[127W:'_6]PMP_1RG+,'E6'^##TX4X^D(J*_!!1116Q[H4444
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M *))JO\ X.X?_D:OX_-BT;%H_P"(9Y-_SX?_ (%+_,/^)&O#3_H5/_P=6_\
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M'*-3*\FHTYQVER*4UZ3E>7XB,&8EF)))R2>I)H'2EHKWC]94;!1110,****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 4'%?UX?\ !#[QPOB7]CJ;PJ[EI/#GBF_L<-_#'<B.[0#V_>G'
MXU_(=7]'O_! +Q<RM\2O 4C<-_9.L0)Z$>?!*?QS'^5?&\>T.?+)O^5I_C;]
M3^(?VAW#OU_POQU:UWAJE*HO_ U3?_DM1G__T?RS_:E_Y.=^(O\ V/GB#_TX
M3UX77NG[4O\ R<[\1?\ L?/$'_IPGKPNO[?P?\&GZ+\C_J;X7_Y%N$_P0_\
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M=:S_ .E5C7X%5^^O_!M__P I"[S_ +)UK/\ Z56-?+<;?\BG%?X6?@WTH?\
MDWN?_P#7B9_>'1117\@'_. %%%% !1110 4444 %?R!_\'./[0GVKQ#\/OV6
M]'N#MM+:?QGKD*M\I><M:6 8=-RJEPV#R P/>OZ_*_S2?^"IOQT3]HC]OOXD
M_$.SD,EC#KSZ!IC9!4VFC*MBC+@D;7,)<$'D-GO7Z=X496J^9>VEM33?S>B_
M7[C^Z?V?? :S7C=YG5C>&"IRGY<\O<@ON<I+SB?GX,XYI:**_IH_W/"BBB@
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MQ#OT*O(EW*=)TYF'4+;6C>;M/</<-7[-?!S]F3]GK]GS2UT?X)>"_#?AB)0
M7TFPAAGD(&,RSA?-D;'&YV8^]>Z45^>9GQ%CL8W]9KREY7T^Y:?@?QGQOXS<
M5<1RD\[S2K63^RY-0^4(V@OE$****\4_,PHHHH **** "BBB@ KD/B#_ ,B%
MKG_8(O/_ $2]=?7(?$'_ )$+7/\ L$7G_HEZTH_''U/0RG_>J/\ BC^:/\Z:
MT_X]8O\ KFO\JL57M/\ CUB_ZYK_ "JQ7]6O<_Z^ZGQ,****1 4444 %%%%
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M<V__ ![Q_P"XO\JFJ&W_ ./>/_<7^535_5CW/^O6I\3"BBBD0%%%% !1110
M4444 %-?[A^AIU-?[A^AIK<:W/[]?V/_ /DU7X=?]B9I'_I+'7T;7SE^Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!115[2M*U37]4M]"T.VGO+V[G2VM;2UC:6::60[4CC1069F)P !DFDW;5DSF
MHIRD[)%WPQX7\1^-_$EAX.\'V5UJ6JZK>16&G:?91F6>YN9V"1Q1HN2S,Q
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MGW;;?XG\FYYQ#C\SKO%9EB9UJCWE.3E+[Y-L****YSQPHHHH **** "BBB@
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M*2ZMO1'BO@GP3XP^)7BW3_ 7@#3+S6-9U6Z2RT[3-/B::XN)I#A41%R2?4]
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M;\ 87V.3X:/=7^]M_J?]$GT0,A_L_P .,DI6UG!U'_W$G*:_"2"BBBOL3^E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444AZ4 Q:;GG %?=W['O\
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M!\*1>$_^"G'Q)BA&%U"32M6/^]=Z;;.WYG-?L'@YBG'&UZ/\T;_<U_F?Z/\
M[-;/)4N)LTRZ^E6@I_.G.*7X5&?D[1117]$'^S(4444 %%%% !1110 4444
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M_;_PZ\1\EXKRFCG60XE5J-3JMXOK&2>L9+JGKL]FFTHHHKK/N HHHH ****
M"BBB@ HHHH **** /K7]B3]IG5/V3_VB-%^*D#2-I9D_LSQ%:1G_ (^-+N6
MF&#QNC(65/\ :0#H37]W>DZKIVNZ5;:WI$T=Q:7D$=U:W$1W))%*H='4]PRD
M$5_G'U_79_P1;_:4D^+7[.,OP@\0W EUCP'.EC '.9)-(N,M:-R<D1,'A]@J
MCTK\R\1\F4Z4,;!:QTEZ='\GI\_(_P I?VFO@E'%Y9A>.<%3_>8>U*M;K3D_
MW<G_ ()OE[M36MHH_92BBBOQP_Q1"BBB@ HHHH **** "O/_ (L_\DK\3?\
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MO%/+:;?\6%:'_E*<O_;3^<6BBBOWYG_1@PHHHH **** "BBB@ HHHH ****
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M9?H?W3^SRJRCX@-+K0JI_?!_FC\!****_IL_W/"BBB@ HHHH **** "BBB@
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MVS(!]2*_T)QTK^ #_@WOFBB_X*5:"DC*ID\,Z\D88X+-]EW8'J< G'H*_O\
MQTK^:O%Z5\TAY07YR/\ $#]HS5<N/,/%],-37_E2J_U%HHHK\L/X&"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0^(/_ "(6N?\
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M*#X^_LW^#OBU&^Z75M%A:]Y!*WD&8+I21W$R.*^B:_ERO1E3G*G-:IV?R/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% !1110 4444 %%%% !1110 5_G_ /\ P<(:XFK?\%*M=L%
M!TSPQH-B<#KNM1<<\G)_?8[?U/\ H 'I7^;W_P %CO&7_"<?\%*_BKJ2R"2.
MTUJ#2(V7IBPLX+<C\&0BOU;P@HWS*I/M!_BT?Z!_LX<N=3C;&8CI3PT_OE4I
MI?A<_,NBBBOZ2/\ ;4**** "BBB@ HHHH **** "OWU_X-O_ /E(7>?]DZUG
M_P!*K&OP*K]]?^#;_P#Y2%WG_9.M9_\ 2JQKY;C;_D4XK_"S\&^E#_R;W/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "%MJDGICFO[[/V./AQ_P *E_97\ _#^1!'-8>%[$W: 8 NKB,3
MW'_D61Z_A_\ V;OAI<_&/X_>#?AA;+G^V?$=C:3<9"P>:K3,1Z+&K$^V:_T$
M(8HX(5@A 5$4(BCH%' 'X"ORKQ.Q?NT*"\V_R7ZG^0O[53C%*CD/#\):MU*T
MEZ6A!_C4/__7_+/]J7_DYWXB_P#8^>(/_3A/7A=>Z?M2_P#)SOQ%_P"Q\\0?
M^G">O"Z_M_!_P:?HOR/^IOA?_D6X3_!#_P!)04445TGNA1110 4444 %%%%
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MYM[^%'/_  &.5R?8&OI.#J_L\TPLO[R7WZ?J?MOT;LV6"X]R&NW9>WIQ_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0^(/_(A:Y_V"+S_T
M2]=?7(?$'_D0M<_[!%Y_Z)>M*/QQ]3T,I_WJC_BC^:/\Z:T_X]8O^N:_RJQ5
M>T_X]8O^N:_RJQ7]6O<_Z^ZGQ,****1 4444 %%%% !1110 4444 6K'_C_@
M_P"N\?\ Z$*_T4O!O_(H:5_V#;;_ -%+7^=;8_\ '_!_UWC_ /0A7^BEX-_Y
M%#2O^P;;?^BEK\K\4/APW_;WZ'^0_P"U<_@<,^N(_*B=)1117Y&?XWA1110
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M\?Z,_P W_P!I3_R2^5_]A'_N.9^@%%%%?SL?XSA1110 4444 %%%% !1110
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M5ZO[MC_I$^C;X</A7@O+<HJQM54>>I_U\G[TD_\ #?E](H****^F/W,****
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M]=X__0A7^BEX-_Y%#2O^P;;?^BEK_.ML?^/^#_KO'_Z$*_T4O!O_ "*&E?\
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M_P#Y-5^'7_8F:1_Z2QU]&U\Y?L?_ /)JOPZ_[$S2/_26.OHVOY8QW\>IZO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/4P]574E8^5XWX/P?$&48O)<PC>E7@X2[JZT:\XNS3Z-)G^MK'*DJB2-@RL
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MC!R!YD+*V,CIG%?K5^S_ /\ !>'_ (*%_!!H-/U[Q':^.]+B*AK+QA;+<3E
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M]AG. J8>7]^$HW]&U9^JN;5% HK@/D@HHHH **** "BBB@ HHHH *Y#X@_\
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MIQ<VJT7!J,4V_?CS)V2_EB?WW4445^-'^: 4444 %%%% !7(?$'_ )$+7/\
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MOX]3U?YG_)/XB?\ )09G_P!?JO\ Z7(****Y3XX**** "BBB@ HHHH ****
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M'_N-#_'^C/\ -_\ :4_\DOE?_81_[CF?H!1117\['^,X4444 %%%% !1110
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M0<9+H_Z_$_Q2XLX/S3(L=4RW.,-*C5AO&2L_5=&GTDFT]TV%%%%<9\V%%%%
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M22^UG7]3MM(TRTB&6EN;J18XU]AN89)X R3@#-?Z>G[('[.?AW]DW]FSPA\
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MT9^WI^S%^S#9S+\1?$EK-JL:MY?AW2&6]U*1U_A,,9_=?69D7W[5_,M^V?\
M\%6/C=^U&ESX+\'^;X.\&R@Q/I=E+F]OHS_S^W*X)4]XH\)V;?UKZC(^$<7C
MFI1CRP_F>WR[_+[T?U;X#_0ZXPXZK4ZM##/#81[UZJ:C;_IW'251]N7W;Z2E
M$_1?_@I!_P %:[#0;6_^!/[*>H175_*KVFM^,K1]\5H""LD&GN.'F[-.,JG(
M3+?,O\S<DDDTC33,SN[%W=R69F8Y))/))/))ZTP<# X Z45^Y9-DM# TO94%
MZOJWY_Y=#_?7P/\  C(. ,H659)3UE9U*DK<]62^U)]E]F*]V*V5VVRBBBO6
M/V8**** "BBB@ HHHH **** "BBB@ I"0HW$X Y)I:^A?V4O@K>_M#_M$>$O
MA!:*QBU;5HAJ#J,^780'SKMSU^["C8SU; [UG6JQIPE4F[**;?HCRL]SO#9;
M@<1F.,GRTJ,)3F^T8IRD_DDS^OO_ ()A?!J3X)_L7^$-%OH6@U#6;=_$VIHX
M*L)M2;S45@>04@\I#[J:_0"JUG9VVGVD5A9(L<,$:PPQJ,*B( JJ/8 8%6:_
MEW'8N5>M4KRWDV_O/^3GCWB[$9_G>/SO%?'B:DZC\N>3E;T5[+R04445RGR0
M4444 %%%% !7G_Q9_P"25^)O^Q?U'_TFDKT"O/\ XL_\DK\3?]B_J/\ Z325
MK0^./J>MD'^_8;_''_TI'^=S;_\ 'O'_ +B_RJ:H;?\ X]X_]Q?Y5-7]6/<_
MZ]:GQ,****1 4444 %%%% !1110 4U_N'Z&G4U_N'Z&FMQK<_OU_8_\ ^35?
MAU_V)FD?^DL=?1M?.7['_P#R:K\.O^Q,TC_TECKZ-K^6,=_'J>K_ #/^2?Q$
M_P"2@S/_ *_5?_2Y!1117*?'!1110 4444 %%%% !1110 5\J?MG?LQZ#^UI
M\ =8^$NJ&.&]D47^A7[KDVFI6X)@D]=K9,<F.J,U?5=%;X;$3HU(U:;LXNZ/
M=X8XEQN39CALVRVJZ=:A*,X27247=>OFMFM'H?YT'BSPKX@\#>)]1\&>*[:2
MRU32;V;3M0M)AAX;B!BDB'Z$=>A'(X-<]7])'_!:O]BA[B-/VO/AM99:-4M/
M&]M;KR4&$M]0VC^[Q',?38QZ,:_FWP1UK^E,CS:GCL+'$0^:[/K_ ,#R/^H7
MP"\9L#QYPQA>(,%92DN6I#K3JKXX^GVHOK!Q>EPHHHKU3]F"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC!
MH LVEI<WUS'96,<DT\TBPP0Q*6DDD<A515')9B0 !U-?VZ?\$WOV0[7]D?\
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MB39?^S5^0>,?^XT/\?Z,_P W_P!I3_R2^5_]A'_N.9^@%%%%?SL?XSA1110
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M']ZT?W(_S2\2_P!F[CJ4YU^$\P52.ZIUO=DO)3BG&7SC#S9_H:T5_+O\%_\
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MT:XRJ37OAB[AU*W/'S/Y-Q]FD09Z*&D/^U7Y5F7A=FM"[IP51?W7^CL_S/X
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MHW\+&TLQ*\B^WGQFOQ:_:%_X+5_\%"?VAEN-,N_&DOA/29RP.E>"XQI0V-_
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MJ=^6E%_9IQORKU>LI?WI/H%%%%?-GXJ%%%% !1110 5R'Q!_Y$+7/^P1>?\
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MS_LS?]"KXV_[]6?_ ,D4?\/Y_P!F;_H5?&W_ 'ZL_P#Y(K^4BBC_ (A_EO\
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M/.NAZS1117X:?X)A1110 4444 %%%% !7G_Q9_Y)7XF_[%_4?_2:2O0*\_\
MBS_R2OQ-_P!B_J/_ *325K0^./J>MD'^_8;_ !Q_]*1_G<V__'O'_N+_ "J:
MH;?_ (]X_P#<7^535_5CW/\ KUJ?$PHHHI$!1110 4444 %%%% !37^X?H:=
M37^X?H::W&MS^_7]C_\ Y-5^'7_8F:1_Z2QU]&U\Y?L?_P#)JOPZ_P"Q,TC_
M -)8Z^C:_EC'?QZGJ_S/^2?Q$_Y*#,_^OU7_ -+D%%%%<I\<%%%% !1110 4
M444 %%%% !1110!D:_H>C^)]#O/#?B&VBO+#4+:6RO;2==T<T$RE)$<=U920
M17\0/_!0+]C?7/V.OC?<>'(5DE\+ZRTNH>%+]LL&M=WS6SM_SVMB0K=RI5OX
MJ_N5KY>_:\_9<\$_M<?!C4?A5XM5(;EE-UH>J[<RZ?J"*?*F4]2I/RR+_$A(
MZX(^KX2XB> Q'O\ P2TE_G\OR/Z[^AY]).KX>\1*6+;E@<3:-:*UY?Y:L5_-
M"[NOM1<EO9K^""BO2?B[\)_&_P #_B1JWPK^(MHUEJ^C736UU%U1AU26)OXX
MI%(=&'52*\VK^A(24HJ47=/9G_2%E^/H8NA2Q6%J*=.HE*,D[J46KIIK=-:I
M]0HHHIG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5]/\ [(?[+WC#]K?XV:=\)O"X>&W<_;-;U0(6CL-.C(\V9NVX
MY"1J<;G8#IFO O"?A/Q'XZ\3V'@SP?93ZCJNJ74=EI]C; M+-/*VU%4#WZGH
M!R>!7]M__!/[]B[P]^QM\&HO#\RPW/BK6%CO?%6J1\^9< '9;Q-_SQMPQ5/[
MQW.>6P/F.*^(HY?A[Q_B2^'_ #^7YG\D?2_^DKA_#WAV3PLT\?B4XT(Z/E[U
M9+^6'2_Q2LMN9KZT^&?PW\(?"'P#I/PT\ VB66CZ+91V-C;+SMCC'WF/\3L<
ML['EF))ZUW=%%?SQ.;DW*3NV?\W&.QU;$UJF)Q$W.<VY2DW=MMW;;>[;U;"B
MBBI.4**** /_U?RS_:E_Y.=^(O\ V/GB#_TX3UX77NG[4O\ R<[\1?\ L?/$
M'_IPGKPNO[?P?\&GZ+\C_J;X7_Y%N$_P0_\ 24%%%%=)[H4444 %%%% !111
M0 4444 1R=J_TO/^"5?_ "CI^#W_ &)-E_[-7^:')VK_ $O/^"5?_*.GX/?]
MB39?^S5^0>,?^XT/\?Z,_P W_P!I3_R2^5_]A'_N.9^@%%%%?SL?XSA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &OY9/^#B
MO]@1O%_A*U_;F^&EF#J6A0Q:5X[A@4EKC3=P2TOB!U:V8^5(>IB92<".OZFZ
MQ?$GA[0_%OA^^\+>)K2"_P!.U*TEL;^RN4$D,]O.I22-U/#*RD@@]J]SAS/*
MF78NGBJ?3==UU7]=;'ZEX,^*>,X-XBPF?8/7V;M.-[<]-_'!^JV[22ET/\E]
M>E.K](_^"HW[!'B']@7]I*]\%6T<\_@[76EU;P3JDF6$EB6^:UD<]9[1F$<F
M>6&U\ .*_-RO[ R_'TL51AB*+O&2NC_I"X0XKP.>99ALWRRKST:T5*+\GT?9
MIW36Z::>J"BBBNP^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,"C /
M6EHH 3:I["DV+Z"G44K(5D-V+Z"G8%%%.P6$P*,"EHH&%%%% !1110 4444
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M"@J#U I:* &[%]!1L3T'Y4ZBE9"LA  .E&!2T4QB8%+@#I110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%'2@!K9) &?PK^\;_@A-_P3H?\ 94^"
M1_:!^*=AY7CWQY9131P7"D3:3H;8E@MB& *33G$LXZC$:'!1L_B)_P $*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD]?==X_RP44]T=&9) 5920RL""".""#R"*97[))6/]O HHHI %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %*H9F"*"Q) 55&22>@
M[DTG &3T'6OZ+O\ @DS_ ,$V)+R?3OVJOC]8,L,;+=^#?#]VH_>GJFHW*'G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***UM"T+6?$V
MM6OASP[:7%]J%_<1VEE9VJ&2:>:5@J1QHO)9B0 /Z4TNK)J5(PBYS=DM6WLD
MMVSH?AO\.O&7Q;\<Z9\-_A]8RZEK.KW2VEC:0CEG;JS'HJ(H+.YX502>!7]Q
M'[$O[)'A']COX*V?PZT7R[K5KG;?>)-85<->W[+\Q'<11?<B4]%&>I:OF?\
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MXK];E&Q_LAZ!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=I0OLN\GO*3UD^R22****\4_#0HHHH **** "BBB@#__U_RS_:E_Y.=^(O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OWU_X-O\ _E(7>?\
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M_P "8_*@9B!7??L3?L*?'C]O#XHQ_#KX/V)6SMWC?7_$EVK#3=)MG/\ K)Y
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?\<YO/.,_K\\MHQ6D*<>D81N[+N]92>LFWJ%%%%>6?E(4444 %%%% !1110
M4444 ?_0_+/]J7_DYWXB_P#8^>(/_3A/7A=>Z?M2_P#)SOQ%_P"Q\\0?^G">
MO"Z_M_!_P:?HOR/^IOA?_D6X3_!#_P!)04445TGNA1110 4444 %%%% !111
M0!')VK_2\_X)5_\ *.GX/?\ 8DV7_LU?YH<G:O\ 2\_X)5_\HZ?@]_V)-E_[
M-7Y!XQ_[C0_Q_HS_ #?_ &E/_)+Y7_V$?^XYGZ 4445_.Q_C.%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '\WG_!6;_@A_H'[1*ZC^T1^R9:6FD>/#NO-:\-)MM[#7VZO+$>$@O3U)P(
MYC]_:Y+G^*;Q3X6\2^!?$=[X/\9Z?>:5JNG7#VE_IVH0O!<V\T9PT<D;@,K
M]B*_UG#7Y3_\%&O^"37P$_;]T.3Q#<K'X7^(%O (].\8V,(9IEC!"0:A""OV
MF'L&)$D8QM;:"A_7N"?$J>%4<+CVY0Z2W<?)]U^*\S_1?Z+OTW<1D$:60\6S
ME5PJLH5=93I+HI=9TUTWE%:+F5HK_.?HKZH_:T_8O_:$_8H^(C_#OX[Z'-8L
M[,=,U>#=+IFIPJ>);2YP%<8Y*';(G1U4U\KU_0>&Q-.M!5:4E*+V:V/]C,DS
MS!YEA:>.R^M&K2J*\91:<6O)K0****W/5"BBB@ HHHH **** "BBB@ HHHH
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MNI0RV]Q;RM#/!.I22.1#M9'1L%64@@@C(/!JO7ZRF?Z&QDFKH****!A1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.U[QE_>BT^]UH?Y*%]87^DW\^E:M!-:W5M*T%Q;7"-'+%+&2K(Z, RLI!!!
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M&OP*K]]?^#;_ /Y2%WG_ &3K6?\ TJL:^6XV_P"13BO\+/P;Z4/_ ";W/_\
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M4<+B_85W_P NJMHROVB[\L_+E;?>*/S>HI-PI:^R/Z8N%%%% !1110 4444
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M &)FD?\ I+'7T;7\L8[^/4]7^9_R3^(G_)09G_U^J_\ I<@HHHKE/C@HHHH
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M>,/'7A_2_"S6&L^*=6U:Q:76X4=K>\NY9HBRE,J=C#([&O+_ /B'E_X*2_\
M0)\)?^#V'_XBO[]**_3*?BOFD8J*4-/)_P"9_<V"_:#\>8>C3H4Z>'M%)+]W
M+9*R_P"7A_ 7_P 0\O\ P4E_Z!/A+_P>P_\ Q%'_ !#R_P#!27_H$^$O_![#
M_P#$5_?I15_\1;S7M#[G_F=7_%1/C[_GUA__  7/_P"6'\!?_$/+_P %)?\
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M ,%)?^@3X2_\'L/_ ,17]^E%'_$6\U[0^Y_YA_Q43X^_Y]8?_P %S_\ EA_
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M **** "DP,YI:* /SO\ VL/^"67[%/[8:RZG\4/"-K9Z]*I \4>'<:;J>XC
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M_P#0)\)?^#V'_P"(K^_2BOO?^(MYKVA]S_S/ZX_XJ)\??\^L/_X+G_\ +#^
MO_B'E_X*2_\ 0)\)?^#V'_XBC_B'E_X*2_\ 0)\)?^#V'_XBO[]**/\ B+>:
M]H?<_P#,/^*B?'W_ #ZP_P#X+G_\L/X"_P#B'E_X*2_] GPE_P"#V'_XBC_B
M'E_X*2_] GPE_P"#V'_XBO[]**/^(MYKVA]S_P P_P"*B?'W_/K#_P#@N?\
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ML_\ [ _[8O[4$\8^"GP^\0ZK:2.J'5I;<V>FH&[M>71B@X'. Y8CH#7^@/\
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M2?\ R[I_NZ=NSC&W-_V^Y/S$Q2T45\N?@X4444 %%%% !1110 4444 %%%%
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ME/\ XW1_PY8_;L_Z!OAC_P '*?\ QNO[(**/^(C8_P#EC]S_ ,P_XJ:^(O\
MSXPO_@J?_P M/XW_ /ARQ^W9_P! WPQ_X.4_^-T?\.6/V[/^@;X8_P#!RG_Q
MNO[(**/^(C8_^6/W/_,/^*FOB+_SXPO_ (*G_P#+3^-__ARQ^W9_T#?#'_@Y
M3_XW1_PY8_;L_P"@;X8_\'*?_&Z_L@HH_P"(C8_^6/W/_,/^*FOB+_SXPO\
MX*G_ /+3^-__ (<L?MV?] WPQ_X.4_\ C='_  Y8_;L_Z!OAC_P<I_\ &Z_L
M@HH_XB-C_P"6/W/_ ##_ (J:^(O_ #XPO_@J?_RT_C?_ .'+'[=G_0-\,?\
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M (<L?MV?] WPQ_X.4_\ C=(W_!%C]NTJ0--\,=/^@RG_ ,;K^R&BC_B(V/\
MY8_<_P#,/^*FOB+_ ,^<+_X*G_\ +3QS]GKP9KOPY^!7@_P!XG6)-1T;PWI^
MF7RPOYD8GMH%CD"N,!AN!P<<U['117PM6HYR<WUU/X!SC,ZF-Q=?&UK<U64I
M.VUY-MV\KL****S/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY2XMO#>F1!B"N,[;<9Q7[*^//]8_TD_E7YZ?M%_\?^E_]<IOYK7[9DOP1/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pacb-20250331_g1.jpg
<TEXT>
begin 644 pacb-20250331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ 08# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[Z_:#_:0\
M/_LXZ/I>I>(-/U._@U"X-O$NF1QNX8*6R0\B#& >A->(?\/1_AG_ -"WXL]_
M]%MO_DBL;_@JA_R3SP5_V%9/_1+5^=GAOPWJ7B[7;'1M(MFO=4OI1#;V\; &
M1ST R0*]_"8.E6HJ<S]<X>X;R[,<N6+Q2=];V=EH?I7_ ,/2/AES_P 4WXL_
M\!K;_P"2*='_ ,%1OABS8;P[XL0?WOLUK_\ )%?%(_8O^-6/^1!OO_ B#_XY
M535OV1/C'HMC)=W/@#5FBC&6%J$G?_OB-BQ_ ?TSM]4P>U_Q/47#O#3T577_
M !GZ@_"C]KOX8_&.\CL-#\0QV^K2<)IFI*;>=SC.$#<.1@YV%L8KV17W#-?@
M$LD^GW2NK26MU;R JRDH\;J>,$<A@1]<BOU!_8(_:BO/B]X?NO"'BBZ-UXJT
M>(2Q7C_?O;7(7<WJZ$JI/<,I.3DGBQ6!]DN>F[H^6XAX466TOK6#ES4^O=>?
MH?7NXTN330WX4I8CMFO'/S<,GVI>:;NSTQ2;CF@8[=0#3-WIS3U.10 ;N?:C
M-(1R.*/I0(=GUHJ,OT[TY6].:!BLV*Y+XH_$BP^$_@J^\3:I;W%U9VAC#Q6:
MJTA+R*@P&91U8=ZZO=FO#OVT5'_#//B0]]]J/_)J*M\/%5*L82ZL]++:$,5C
M:-"I\,I)/YLY#_AX3X$P/^)%XB/OY$&/P_?4O_#PGP%C_D!>(\_]<+?_ ./5
M^?Y^[N_.O4(_V8OBA-"DL?@^\DC<;E99(N0>G\5?5RRW!T_CT^9_06(X*X:P
M=GB9N-]KSL?5Y_X*$>!.,:#XB/K^X@_^/5T7A;]N#X:>)+I8+BYOM!=CM5M4
MM]J9/3+H75<\\L1T-?%S?LP_%%>O@R^_!HC_ .S5PWBCPCK7@K4CI^NZ7=:3
M>!=PCN863<">"N?O D8XST/I6?\ 9^#J/E@]?4YH\%\-8S]WAJSYO*2;^X_8
M'3]4MM5LXKJRN(;NVF4/'-"X='4C(((X(J628QJ6., 9K\[/V/?CM?\ @3QQ
M8^%;^X,WAW69Q;I'(Q/V:X8X1D]G<@$>^[CG/Z'74(NK:2(Y =2O!QV_2OG\
M5A7A:G)+8_&\_P BJY#C?JU5WB]4^Z/C/XA_\% -2TWQ5=6/A71-.N-*M96B
M^UZAYC//M."ZA& 53V)R<$$@=!]%? 7XW67QP\&C5X+4Z??02_9[RS9MWE2
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MHYSJ\(_4U]'@9<F&YNUS]KX6K/#Y![=*[CS/[CD?^%5^-?\ H3_$'_@KG_\
MB*?'\*/&\KK''X,\0/*YPJKI<Y8_0;:_=98UQ\J@#Z4[RQZ#\JX?[4E_*?,?
M\1 Q%M*$?O9^0GPC_84^*'Q*O(&U#2)/"&C,5,E]JZ%) O&0D!^<MCH"%!QC
M(K]0?@W\(- ^"/@:R\,^'X62WAS)-/)@RW$S8WR.1U8X_   <"NYVX]J.%&.
MU<&(Q=3$:/1'QN<<0XO.+1K/E@NB/Q)_:;UB;6_VA/B+<3%G=-<NK?+==D4A
MB4?]\H!^%?=G_!,3PG86'P;UK7TC5M2U'57ADFQ\WE1(FQ/IEG/_  *OC?\
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CJKDI:(^!XBX\K9G2>%P,>2#W;W?^2!!A<44H&**\ _)3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pacb-20250331_g2.jpg
<TEXT>
begin 644 pacb-20250331_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"S^TA^UU\7
M?!/QT\:Z%HGC.XL-)L-1>&VMEM+=A&@ P,M&2?Q->;?\-R?''_H?KG_P"M?_
M (U6/^UU_P G+?$7_L+2?R%?1?[%/[(OP\^.GPANO$7BFVU"74H]6FLU:UO&
MB7RUCB8< =<N>:^M:H4:,:DX+IT1_0\XY1EF5T<7BL/%IQCM"+=VO,\,_P"&
MY/CC_P!#]<_^ 5K_ /&JZGP7_P %%OC'X:U".75-4L?%-F&^>UU"QBBRO?#P
MJC ^A.?H1Q7V/_P[?^#/_/EK'_@R;_"OF']K_P#83M?@GX5;QGX-U"]U#P_!
M(D=_9:@5>:U#L%6174+N3<54@C(R#D@G&$*V"K2Y.5*_D>;A<TX9S.JL*L/&
M+EHKPBM>UUL_N/N+]G+]IKPQ^T?X;EO-(#Z;K-F%%_HUPX:6W)Z,K #?&3G#
M #IR >*]?K\._P!G[XL7OP5^+?A[Q3:S.EO;W"Q7T2GB>U<A9D([_+DC/1E4
M]0*_<,$, 0<BO*QN&6'FN79GY[Q1D<<FQ4?8_P .>J\K;KY77WBT5S7CCXE>
M%?AGIJW_ (J\0:?H-JV=C7TZQF0@9(13RY]E!->'WW_!0_X(V=XD$?B&^O8V
M.#<0:7.$7Z[E5OR!Z5R0HU*BO"+9\[A\MQN,CS8>C*2[I-K[SZ5HKS_P7\?O
MAY\1-#OM6\.^+=.U.SL+=KN[6-RLUO"HRTDD+ 2*H'<J*YH?MC?!=B /B%I1
M)_ZZ?_$TO95&VE%_<3'+\9*4H1HR;6ZY7IZZ:'LM%%(2%!).!61P"T5XI\0?
MVROA#\-;Z2QU3Q?;W6H1DJ]KI<;W;(PX*L8P54Y[$@UR_A__ (*%?!77;Q;>
M77[S2&8X634-/E5"<X^\@8#ZG KH6'K27,H.WH>Q#)\QJ4_:PP\W'ORO_(^D
MZ*S]!\0:7XJTFWU31M1M=6TVX7=#=V4RRQ2#V920:T*PVT9Y$HN+<9*S1^;/
MC[]J?XIZ/X[\1V%GXMGAM+74KF"&,6L!V(LK*HR8\G  ZU@_\-<?%S_H<I__
M  $M_P#XW7#_ !1_Y*9XN_["]Y_Z.>OJ?]FO]E?P)\4OA#IGB'7(+]M2N)9T
M=K>Z*+A)648&/0"OMZOU7#4HU*D%TZ(_JK'1R+)<OI8O&86#3Y5I3BW=J_EV
M/$/^&N/BY_T.4_\ X"6__P ;K<\-?MN?%/0[Q)+W5;77K<$9M[ZRB4$=_FB"
M-GZDU]0M^PE\+VZ1:NOTOO\ [&O"OVH?V1]+^%'A0>*_"U[>3:=#,D-Y9WS*
MYB#G:LB. .-VU2I!.6SG'%<M/$8"O)4U!:^2/#P><<(YM7C@HX:*E/17IQ6O
M176J;Z'U'\!?VBM!^.VFSBTB;3-<M$#W>ES.&*J3C?&W&],X&< @D @9&>Y^
M(/B"?PGX#\1ZW;1>=<Z;IUQ=Q1XR&:.-F (],BORZ^ OC"Z\#?&#PIJEM,T2
M_;XK>X )P\$C!)%([_*Q_$ ]J_6&>".ZADAFC66&12CQR*&5E(P00>H(KQ\?
MA8X6LN7X7_5C\TXMR*AP_F--T5>C/WDGTL]8W[=GOK\S\@;[XA>)]2\1-KT^
MOZBVLE_,%Z+EUE5LY&U@?E (& .F!7Z>_L]>,]3^('P9\+Z]K&#J5U;LLS@8
M\PQR/&)"/5@@8XXRU?+&K?"+]G&[\3O>Q?$:2PT]I=[Z7&^57GE%<IN"_7)]
MZ^U?"-OI%IX6TB+0$BCT-;2(V0@&$\DJ"A'U!!YYYKKS*M3J4X*,&GYJWR/H
M>.,TP>.P>'IT,/*$D]Y0<;*WPJ^_1Z::&O67XB\4:/X1TYK_ %O5+32;)3@S
MWDRQ)GTRQY/M7G7[0WQ^TWX%^%EG*1WVOWF5L-/9\;B.LCXY"+^IP!CJ/S9\
M>?$;Q%\3-<EU;Q'J<VHW+$[%=CY<*D_=C3HB^P_G7+@\OGBESR=H_F?/\-<&
MXG/H_6:LO9T>]KN7HNWG^>I^A^J_MH?"?2[AH5\037K*<%K6QF9?^^BH!_#-
M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
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M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
M7 P,\9KZ2^&/PK\,_!WPNOA[PGI[:9I0E:?R6GDF)D8 ,VYV8\[1QTKGQM:A
M72E#XCQ>*,SRG-8PK81/VVEW:RM;9]VNZOZ['Y8?%'_DIGB[_L+WG_HYZ^H_
MV;?VK/ WPL^$NF>'=;;41J-O+.[_ &>UWIAY688.X=B*^7/BC_R4SQ=_V%[S
M_P!'/72>"?V;_B+\1O#L&N^'O#O]H:5.SI'<?;K:+<58JWRO(K<$'M7T]>G1
MJT(QKNRTZVZ'[SFV!RW,,KHTLTJ<E/W7=R4=>5V5WY7T/L__ (;P^&'][6/_
M  !'_P 57A7[4/[6^F?%CPJOA7PO97<.FRS+->7E\JHTFPY5$0$\9PQ).> ,
M5P?_  QM\8?^A0_\J=G_ /'JY;QW\ _B!\--/^W^(_#-S86(8*UTDD<\2$]-
MS1LP7)XYQS7'0PN!A44H33?35'S659!PKA<93K87$1G43]U>TB]>FBW?8WOV
M6?AG>_$CXOZ((HF_LW2KB/4+V?!VJD;!E7/JS *![D]J_46OS/\ V8/VC;GX
M+>(%T[4 DWA/4)P;U1$#+ Q&T3(1R<<94YR <#-?I;%*D\221NLD;@,KJ<A@
M>00>XKR\W]I[9<R]WH?!>(WUQYE!UXVI<MH-=?YK^=^G:Q^,U]_Q^W'_ %T;
M^9K];OA!_P DE\$_]@2Q_P#1"5^2-]_Q^W'_ %T;^9K]6O!<TMO^S[H,L"EI
MT\+P-&H[L+12!^==V<*\*:\SZSQ)CSX;"1[R?Y(_.;]H3XES_%3XK:WK#2^9
M8Q2M:6"]EMXV(3'^]RQ]V->;T45[]."IQ4([(_7L+AJ>#H0PU%6C!)+Y!111
M5G4%?<7_  3[^),^H:3KG@F[E\P6&+^Q#')6-VVRJ/\ 9#E&^LC5\.U]$_L(
M231_'=%C!*/IEPLOLN4/_H06O.S"FJF&G?IJ?&<8X2GB\CQ"FOA7,O)QU_*Z
M^9\W?M=?\G+?$7_L+2?R%?5'[!W[-?PV^+GP5N];\6^%X=9U2/6)[9;B2XFC
M(C6.%@N$=1P6;MGFOE?]KK_DY;XB_P#86D_D*^]/^"8__)NM_P#]C!<_^B8*
M\O%2E#"1<7;8_/L^Q%;#<.T:E";C*T-4VGMY'H/_  PW\#O^A!MO_ VZ_P#C
MM=3X+_9G^%OP]OX[[0? ^DV=]$08[J2$SRQD=U>0L5/N#7IM%?.NM5DK.3^\
M_&*F9XZK%PJ5YM/HY-_J%?EQ_P %/O#LVF_';1]6*'[+J6BQ!9,<&2.6177\
M%,9_X%7ZCU\[?MN?L[S_ !\^%J-HT*R>*]"=[O3E/!N$*XEMP3P"X5",_P 4
M:C(!)KHP554:R<MMCV>%\PIY=FE.K5=HN\6^U^OWVOY'SC_P2S^(VGZ=KGB_
MP5=RK#?:DL.H6 ;CS?*#K,F<\L%9&  Z*Y[5^B]?@397VK^"_$27%K->:)K>
MFW'RR(6@N+:9#@CLRL"",=17U/X;_P""FOQ4T714LK[3_#^N7,:!5O[NUD25
MB!U<1R*I/3HJUZF,P,ZM3VE/J?>\2<)XG,,6\;@FGSVNF[:I6NNEK'W5^U[\
M1M,^&_[/OC&XU">-)]3L)M*LH6/S33SQM& !WP"S'V4U^,%M_P ?$7^^/YUW
M7Q@^.GC/XYZXNI>+=7DO?*+?9K*,>7;6H/41QC@=!DG+' R3BN%MO^/B+_?'
M\Z[\'AGAH6;U9];PWDLLEPDJ=25YR=W;;R2/VB_; \+7'C+]FGQ_IMK&9IQI
M_P!K6-026\B1)R !U.(C@>M?CQ\/?%'_  @_C[PUXC\HS_V/J=MJ'E#J_E2K
M)CJ.NVOWFFB2XB>*5%DC=2K(XR&!X(([BOR"_;#_ &5]2_9_\93:CI\#W/@?
M5+AFT^[4$BV9LM]FD]&49VD_>49ZA@/,RVK&TJ,NI\+P/F%'DJY96=N=W7G=
M6:];)?B?K9X7\3:;XR\-Z9KNCW*WFEZE;I=6TZ\;XW4$''8X/(/(.0:U*_%K
MX'?M9?$/X 0R6GAW4(;S1Y&+G2-5C::U#GJR@,K(3GG8PSWS@5WWQ$_X*+?%
M?QYH4^DVS:5X6@N%*2W&C02+<,I!!4222/LSGJH##L:REEE7GM%JQY]?@7'Q
MQ#A1E%T[Z-OIYJV_H?H#??MA?"32?'>K>$=2\76VFZOILWV>9KJ-UMS)@;E$
MV"@*D[6W$8(/H:]8T77M-\2:=%J&D:C:ZK82C,=U93K-$_T920:_"GX?_#[Q
M#\5O%UGX>\.6$NIZM>-PJ@X1<_-([?PJ,Y+&OV@^ /P=L?@3\+-'\)6;K<2V
MZF6\NU7'VBX<YD?Z=%&?X54=JSQF%I8=+EEJ<?$F0X'):=-4JK=1[IVVZORU
MV6OX'YC_ !1_Y*9XN_["]Y_Z.>OT&_8F_P"3>="_Z^+K_P!'O7Y\_%'_ )*9
MXN_["]Y_Z.>NN\!?M.?$#X:>&;?0- U2"UTRW9WCCDLXI""S%F^9E)ZDU]'B
M\//%8>,(;Z?D?MG$62XG/LFHX7"M*2<9>\VE91:Z)]S]3JQ/'$.E7'@W7(]=
M\O\ L9K*87GFXVB'8=Y.?;-?G;_PVS\6?^@[:_\ @N@_^)KEO'W[27Q$^)>D
M-I6N>('DTUR#):VT,<"28[/L4%A[$XX''%>-#**_,G*22_KR/S/"^'&:QK0E
M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
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5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pacb-20250331_g3.jpg
<TEXT>
begin 644 pacb-20250331_g3.jpg
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MGY<G[2>HV'C/XD6^FR?/I>FV:O%=Q'KN6*:/5&_W]+'-;?\ P962:?-^S/\
M'J;2;=8K5_BG;FVB0G"1FR&U1GL!@5;_ ." O_!!G]IW]@;]N+XJ_'#]J3P\
MYT7P=HU]X5^ ^H7&OVEY_:%A<WUQ+)?Q1P3.UEF-0?+E6)LZC-\F=Q'JW_!K
M/_P3E_;+_P""<?[.OQ0\"?MF_!S_ (0W5?$7C6UO]&M?^$AT[4?M%NEH(V?=
M8W$RIAQC#$'OC% 'ZE4444 %%%% !1110 4444 %%%% !7Y%_P#!7S_@B?\
M'_P1\5/'W_!5K_@D?\>/'G@OXS:S901^(O '@ZW5U\5/-<6\,[12>;'Y!V 7
M,B.LR.\&\!&.ZOUTHH _/[_@GG_P;[?L_P#['?PA^,'A'X\?%76_C1XM^/>G
MW%A\4O&7B" VLE_:S>:9(X4\V62-WDF>5YFE>1I C978 /FF/_@U=_:7\*^
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M$GGH) \$K,+>,!EPI3X]_;$_X-E?CU^U#_P4(\0_\%#?"?\ P5GU[P7XGO\
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M\/\ ^ 5/_EI^V?\ P]T_X)Y_]'!_^6GJW_R)1_P]T_X)Y_\ 1P?_ ):>K?\
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MX)Y_]'!_^6GJW_R)7XF44?ZG99_//[X__(A_Q,'QG_T#X?\ \ J?_+3]L_\
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M117Z^?Y_!1110 4444 %%%% !1110 4444 %%%% !1110!ZO^PI_R>;\+O\
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M "BBB@ HHHH ]>_X)_\ _)[_ ,)_^Q_TO_TI2OZ%J_GI_P""?_\ R>_\)_\
ML?\ 2_\ TI2OZ%J_/>,O][I?X?U/XS^DU_R4>!_Z]/\ ]+84445\:?S.%%%%
M '\]/_!0#_D]_P"+'_8_ZI_Z4O7D->O?\% /^3W_ (L?]C_JG_I2]>0U^UX+
M_<Z?^%?DC_4GAG_DG,%_UZI_^D1"BBBND]L**** "BBB@ HHHH **** "BBB
M@ HHHH *_9G_ ((%?\F0:A_V/]__ .DUI7XS5^S/_! K_DR#4/\ L?[_ /\
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M_P#Z36E?C-7[,_\ ! K_ ),@U#_L?[__ -)K2OFN+/\ D4O_ !+]3\,^D/\
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M **** "BBB@ HHHH ]>_X)__ /)[_P )_P#L?]+_ /2E*_H6K^>G_@G_ /\
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M?O\ Y++_ "#_ (CEX6_]##_RE7_^5'QS17V-_P .=OC9_P! ?QW_ .$-;?\
MRRH_X<[?&S_H#^.__"&MO_EE1_K+DG_/W_R67^0?\1R\+?\ H8?^4J__ ,J/
MCFBOL;_ASM\;/^@/X[_\(:V_^65'_#G;XV?] ?QW_P"$-;?_ "RH_P!9<D_Y
M^_\ DLO\@_XCEX6_]##_ ,I5_P#Y4?'-%?8W_#G;XV?] ?QW_P"$-;?_ "RH
M_P"'.WQL_P"@/X[_ /"&MO\ Y94?ZRY)_P _?_)9?Y!_Q'+PM_Z&'_E*O_\
M*CXYHK[&_P"'.WQL_P"@/X[_ /"&MO\ Y94?\.=OC9_T!_'?_A#6W_RRH_UE
MR3_G[_Y++_(/^(Y>%O\ T,/_ "E7_P#E1\<T5]C?\.=OC9_T!_'?_A#6W_RR
MH_X<[?&S_H#^._\ PAK;_P"65'^LN2?\_?\ R67^0?\ $<O"W_H8?^4J_P#\
MJ/CFOV9_X(%?\F0:A_V/]_\ ^DUI7Q9_PYV^-G_0'\=_^$-;?_+*OLS]@72/
MC9^PY\$+CX-?\,R^._%'GZ_<:G_:7V*VLMOFQPIY?E^?+G'E9W;N=W08Y\/B
M'.<MQV7>RH5+RNG:TE^:1^4>,OB;P/Q7P8\!E6+]I5]I"7+[.K'17N[SA%=>
M]S[BHKPO_AK#XV?]&/\ CO\ \"K;_P"*H_X:P^-G_1C_ ([_ / JV_\ BJ^$
M/Y+/=*^)/^"^O_)D&G_]C_8?^DUW7L__  UA\;/^C'_'?_@5;?\ Q5>(_M]:
M1\;/VX_@A;_!K_AF7QWX7\C7[?4_[2^Q6U[N\J.9/+\OSXL9\W.[=QMZ'/'?
ME=:EALPI5:CM%--_TCZ_@'-,#DO&>!QV-GR4J=2,I2LW9+=VBFW\DV?C;17V
M-_PYV^-G_0'\=_\ A#6W_P LJ/\ ASM\;/\ H#^._P#PAK;_ .65?I'^LN2?
M\_?_ "67^1_;G_$<O"W_ *&'_E*O_P#*CXYHK[&_X<[?&S_H#^.__"&MO_EE
M1_PYV^-G_0'\=_\ A#6W_P LJ/\ 67)/^?O_ )++_(/^(Y>%O_0P_P#*5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?E%^RU\.?C?_P %[_%WQ&_:Y^,'[8_Q8^'?P/T7Q[J'A?X-?#SX0^+GT'^T
M+6Q81R:OJ%Q$K/<O*Y.U"?W;*X!V@!OU=K\T?^#93Q+HOPH_9;\??\$Z_&NH
MQ6'Q+^!OQ8U_3O$OARZ<)=/9S79GM]01#R]O+YCJL@R#LSG#*2 :G[%7Q'_:
M0_8%_P""HUQ_P2:^/?[1'B?XM> /''P[E\8_!/QIX\NQ=Z_I[6TS1WFCWET
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M,\X#,^3%YO)7) /UTHJEX<GUBZ\/6%SXAM4@OY+*)KZ",Y6.8H"ZCV#9%7:
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M[^P;^P7K_P (]$TKP5\(=-\4^+=>^)7AC4=1<:C>7T\4=I']CO(0@-NL4@W
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MFG]O/]C#]LB^U;2_V6/VG/!GCR[T+:=7L_#>N17$UJC'"R-&IW>63P) -A/
M)- 'K=%>->$?^"AW[#?C_P",NE_L\>!/VJ_!&M>.=:NM0MM-\*Z3KT5S>RRV
M(E-VICC)*>5Y$^2V!F%P,E2![+0 4444 %%%% 'YB_\ !QS_ ,T;_P"YA_\
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M/'[97_!.W_@FA\-2;O0?AI%XJ\<^);ATQ)=WEAI@CBU&49/[R?4;V>5CV9V
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M?_!Q1X=\*OX5T^XTKX/_ +*<VHMYUFCXU34]82TB#Y'S,+.U)#')&0!7/?\
M!,;P3\$/B3\=OVW_ /@I%\7/A]HFKW,_QPUSPK9ZYJNFQ7,B^'O#VGV]JRQ-
M(#MAD*2!@N _DKNR%7'V1XQ_80_9>\=?M;>'/VYM>^'LZ_$_POHS:5IOB.QU
MZ]M1+9GS2L-S;PS+!=JIFE*^<C[2P(Y5=MKX=_L2?LQ_"?\ 9Z\1_LK?#_X;
M/IW@7Q:=8/B+1UUV^DDO&U5I6OW-U).UPK2F:3YED!3(V%-JX /Q9\,^#?C7
MJ?\ P1K_ ."?O[(_AC3?"J:5\9_C+?ZOK>B^.;VYMO#NH1_;M1UC3=$O&MT>
M0VMPSQ8B529'A0< G'VM9?L_?MG?#_\ ;M\(_MX?M//^S3X.L/@M\(/%(\2>
M'O@]JVIC5=;T.:V5K=)XKJUC'V6WN+3=&<A59I,9. /L'X@?\$^_V//BG^RA
MHO[$/C[X(6&I?#+PWI=A8>'O#L]Y<[],CLHUBM7@NA*+F.>-% $ZRB4Y;+G<
MV>7^$G_!)S]@WX*^ O'GP^\'?!BYFB^)_AR?0/'NM:WXLU34=8UC3)HFA>T?
M4KFY>[BB\MR D4J!3AAA@#0!XI_P;M?LK?#GX6_\$ROAC\<M4^&6AI\1/B18
MW?C#Q3XN.E1_VAJ$VI7,\\3-.1YFT6LL4:J#MV@\99B?O>L/X8_#;P3\&OAK
MX>^$'PTT)-+\.>%-#M-'\/Z9',\BVEE;0I#!"&D9G8)&BKEF+'&22>:W* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pacb-20250331_g4.jpg
<TEXT>
begin 644 pacb-20250331_g4.jpg
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MG5%?F+_Q$<_]6;_^9#_^]]'_ !$<_P#5F_\ YD/_ .]]'^K6=_\ /K_R:/\
MF'_$#?%+_H7_ /E6A_\ +3].J*_,7_B(Y_ZLW_\ ,A__ 'OH_P"(CG_JS?\
M\R'_ />^C_5K._\ GU_Y-'_,/^(&^*7_ $+_ /RK0_\ EI^G5%?F+_Q$<_\
M5F__ )D/_P"]]'_$1S_U9O\ ^9#_ /O?1_JUG?\ SZ_\FC_F'_$#?%+_ *%_
M_E6A_P#+3].J*_,7_B(Y_P"K-_\ S(?_ -[Z/^(CG_JS?_S(?_WOH_U:SO\
MY]?^31_S#_B!OBE_T+__ "K0_P#EI^G5%?F+_P 1'/\ U9O_ .9#_P#O?1_Q
M$<_]6;_^9#_^]]'^K6=_\^O_ ":/^8?\0-\4O^A?_P"5:'_RT_3JBOS%_P"(
MCG_JS?\ \R'_ />^C_B(Y_ZLW_\ ,A__ 'OH_P!6L[_Y]?\ DT?\P_X@;XI?
M]"__ ,JT/_EI^G5%?GI^S_\ \%X_^%Z?&_PG\&O^&5?[+_X2C7[73/[2_P"$
MY\_[-YTBIYGE_84WXSG;N7/J*_0NO.QN7XO+YJ.(CRMZK5/\FSXSB?@[B/@[
M$TZ&<4/93FN:*YH2NKVO>$I):]]0HHHKC/F0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OB3_@OK_R9!I__8_V'_I-=U]M
MU\2?\%]?^3(-/_['^P_])KNO4R3_ )&U'_$C[[PM_P"3B99_U]B?C-1117[
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MF88; QA*J]).R^?Z'5Q)QCD?"E'#ULPFU"O-4XM*ZO)73;Z1LKMGYV45[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$G_!?7_DR#3_\
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MI,%%%% !1110 4444 %%%% !1110 4444 %%%% 'KW_!/_\ Y/?^$_\ V/\
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M]O$ 9'9E5CD \#'/<CK7T!^W'_P31^&W['_[*/AOXV>'?C@_C;5->\5PZ?\
M;M,2%-,\AK:ZD8Q;6D:1@\*KO\S& WR@GCX[#, 0"1D8/O7Z$_ML?\H2_@%_
MV,5I_P"DFI5Z&85,51QM#EG:$I6<;+LWOO\ (^QXOQN?Y=Q1E+H8KEP]:LJ<
MJ2A'7W)R;<W>71+E7*N]^GYZU]G_ +.O[!W[+7A?]DBP_;._;N^)/B+2=#\1
MZF;+POHGAB-?/F^:10[DQN6+>3*X4!0$C#%CN"CXPK]"/V\"EU_P1N_9XN[$
M;H$O[2.1T^Z)/L5V"#[Y5_R-7FE2JI4:,).//*S:WM9O3M>QT\>XW,(5LLR[
M"UI45BJZA.<+*:@H3FU%M/E<G%*]KVO;<\6_X*%?L*^!?V9]$\&_&[X!>/+W
MQ)\./']EY^B7FI*HN;9S&LJQR%40,'1MR_(K HZL,KD\]_P35_9?^'?[7O[3
M]K\&_BA?ZK;:5-HUY=O+HUS'%/OB4%0&DC<8YY^6OHK]N<I;?\$8OV>[.[&V
MXDU:TDB1_O&/['>G(]L,GYBO//\ @A=_R?OI_P#V*^I?^@+7%#%XEY'6J.3Y
MH<Z3Z^ZVD_4^8P_$.=R\*,RQ<Z\G7P_UF$:NBD_92E&$G9)<UDKM+5J^YQ__
M  5"_8C\/?L1?'+3O"OP_OM3O/"VO:''?:1>:M,DLWF*QCGB9T1%8JP5^%&%
ME4<]:]__ &6?^"0?P:^)/["Z?M(_&#7O%-IXDO\ 0-0UC3;#3;^"*W6VC5S;
M%D>!V;>$60D,/ED4<&O0?CG\']6_X*,? 34OA?H;^;XR^#W[0&H^')I<;I(]
M'N-3:'S,=HXX7A8G^[8/Q7MWAKXF:+XL\=_M"_!WP.%B\,_"7X7:7X:TJVB;
M,:3&SU%Y]OH5"0PGWMZ\G$9KC?J$*<9M5(/WWULFDO\ P+F3^3/SW./$#B=\
M(X;!4<1*.,P\[XB:^)TU4ITZ;_[C*O3EY\LO,_#RBBBON3^K K]F?^"!7_)D
M&H?]C_?_ /I-:5^,U?LS_P $"O\ DR#4/^Q_O_\ TFM*^:XL_P"12_\ $OU/
MPSZ0_P#R;M_]?:?_ +<?;=%%%?F!_!P5\2?\%]?^3(-/_P"Q_L/_ $FNZ^VZ
M^)/^"^O_ "9!I_\ V/\ 8?\ I-=UZF2?\C:C_B1]]X6_\G$RS_K[$_&:BBBO
MV _TF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#U[_@G_P#\GO\ PG_[
M'_2__2E*_H6K^>G_ ()__P#)[_PG_P"Q_P!+_P#2E*_H6K\]XR_WNE_A_4_C
M/Z37_)1X'_KT_P#TMA1117QI_,X4444 ?ST_\% /^3W_ (L?]C_JG_I2]>0U
MZ]_P4 _Y/?\ BQ_V/^J?^E+UY#7[7@O]SI_X5^2/]2>&?^2<P7_7JG_Z1$*^
MY?V%?^"A7PQ\1>"_#/[%7[<7PU\->(/ %A<2-I7B?7I2IT58XI9(E==C>9\Q
M,*,I1E67:2R\5\-45.,P=''4N2IZIK1I]T^YEQ+PSEG%.7?5<6FFGS0G%N,Z
M<[-*<))IJ2OZ/9IK0^A?VZ?^"@?B7]LU?#GA'3?ASIW@OP9X0MS%X>\+Z9-Y
MJQ914#.X1%.U$5454547(&<DT?LB?MY?\,J_ _XI?!K_ (55_;W_  LK1VL?
M[2_MS[+_ &=FVN(-_E^1)YW^OW8W)]S&><CYZHI?V?@_JJP_+[F]KOH[[WOO
MKN8K@[AM9#')50MAHM24.:7Q1FJB;ES<S?.N9MR=WO=!7T+\;/V\?^%Q?L2^
M ?V.?^%5?V=_P@VHPW7_  D?]N>=]MV0W,>W[/Y"^7G[1G/F-]S&.<CYZHK:
MKAZ->4935W%W7D]CT\PR?+<TKX>MBH<TJ$^>F[M<L[.-]&D]&U9W7D>U?#7]
MJSP+X#_9#\8?LT:I^SCX?UC6?$^I"YL_'-VZ_:].7$0"J#$68KY;%"LB &5L
M@\AO0?V6_P#@I9I7PG^ ;?LL_M$_L]:5\3_ T%ZUWH]CJ%Z+>73Y&<R$*QCD
M#+O9V& K*9'&XJ=H^5**PJY?A*T91G'=\V[WVNG?3Y6/+Q_!O#N94*M+$4FU
M4J*JWSU$U4245.$E)2@TE;W'%;Z:N_OG[<W[>GBG]L_4_#^D6_@2P\'^#_"-
MD;;PSX4TR;S([52J*69PB!CMC1%"HJHJX Y8G%_87_:R_P"&+/CY;_'#_A /
M^$E\C2[FS_LO^U?L>[S5 W^9Y4N,8Z;>?45X[15K!86.$^K*/N6M;7KOKO\
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M*7KR&OVO!?[G3_PK\D?ZD\,_\DY@O^O5/_TB(4445TGMA1110 4444 %%%%
M!1110 4444 %%%% !7[,_P#! K_DR#4/^Q_O_P#TFM*_&:OV9_X(%?\ )D&H
M?]C_ '__ *36E?-<6?\ (I?^)?J?AGTA_P#DW;_Z^T__ &X^VZ***_,#^#@K
MXD_X+Z_\F0:?_P!C_8?^DUW7VW7Q)_P7U_Y,@T__ +'^P_\ 2:[KU,D_Y&U'
M_$C[[PM_Y.)EG_7V)^,U%%%?L!_I,%%%% !1110 4444 %%%% !1110 4444
M %%%% 'KW_!/_P#Y/?\ A/\ ]C_I?_I2E?T+5_/3_P $_P#_ )/?^$__ &/^
ME_\ I2E?T+5^>\9?[W2_P_J?QG])K_DH\#_UZ?\ Z6PHHHKXT_F<**** /YZ
M?^"@'_)[_P 6/^Q_U3_TI>O(:]>_X* ?\GO_ !8_['_5/_2EZ\AK]KP7^YT_
M\*_)'^I/#/\ R3F"_P"O5/\ ](B%%%%=)[84444 %%%% !1110 4444 %%%%
M !1110 5^S/_  0*_P"3(-0_['^__P#2:TK\9J_9G_@@5_R9!J'_ &/]_P#^
MDUI7S7%G_(I?^)?J?AGTA_\ DW;_ .OM/_VX^VZ***_,#^#@KXD_X+Z_\F0:
M?_V/]A_Z37=?;=?$G_!?7_DR#3_^Q_L/_2:[KU,D_P"1M1_Q(^^\+?\ DXF6
M?]?8GXS4445^P'^DP4444 %%%% !1110 4444 %%%% !1110 4444 >O?\$_
M_P#D]_X3_P#8_P"E_P#I2E?T+5_/3_P3_P#^3W_A/_V/^E_^E*5_0M7Y[QE_
MO=+_  _J?QG])K_DH\#_ ->G_P"EL****^-/YG"BBB@#^>G_ (* ?\GO_%C_
M +'_ %3_ -*7KR&O7O\ @H!_R>_\6/\ L?\ 5/\ TI>O(:_:\%_N=/\ PK\D
M?ZD\,_\ ).8+_KU3_P#2(A11172>V%%%% !1110 4444 %%%% !1110 4444
M %?LS_P0*_Y,@U#_ +'^_P#_ $FM*_&:OV9_X(%?\F0:A_V/]_\ ^DUI7S7%
MG_(I?^)?J?AGTA_^3=O_ *^T_P#VX^VZ***_,#^#@KXD_P""^O\ R9!I_P#V
M/]A_Z37=?;=?$G_!?7_DR#3_ /L?[#_TFNZ]3)/^1M1_Q(^^\+?^3B99_P!?
M8GXS4445^P'^DP4444 %%%% !1110 4444 %%%% !1110 4444 >O?\ !/\
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MRS\=^(-/EO\ 0_!MSK,*:G?VL8<R3PVQ;S)(U$4F7"E1Y;<\&N!^)W_!2/\
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M& 0R2Y8&3YBF%)!+@ ]H_8_\/)_P6A_X(U_!37OVD?B?XYTI_$6BVESXSNO
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M1,[,NQPPY?\ X-6+*VT[_@CWX8T^SCV0P>.?$T<29)VJNJ3@#)Y/ J+X7_\
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M])U7X=Z3-IR^,["]TBYU&VM_LKO,8+K-L8FV$J3*H56V[G]"\4?LP_'+4?\
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M;0_:DG-J-ZSQ'=YNU=WS$8. #U2P_P""B?Q)\:_M[_LT_!3P=HVF6O@3XV?
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M#2PB$RR2!F!7?@?K9I&FV6C:3:Z/ING6]G;VEND-O:6<02&!%4*J(H "J
M    * +%%%% !1110 4444 %%%% !1110 4444 %%%% !7S%_P %D_\ E&[\
M1_\ N#_^GBRHHKORO_D9T/\ ''_TI'UO /\ R765?]A-#_T[$_"BBBBOV4_T
MW/TZ_P"#<;_FLG_<O?\ N3K].J**_*.)?^1W5_[=_P#24?YZ>.7_ "=+,/\
MN%_Z8I!1117A'Y,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pacb-20250331_g5.jpg
<TEXT>
begin 644 pacb-20250331_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **_/3]H#_@O'_PHOXW^+/@U_P ,J_VI_P (OK]UIG]I?\)SY'VG
MR9&3S/+^POLSC.W<V/4UR'_$1S_U9O\ ^9#_ /O?7MPX=SFI!3C2T>OQ1_S/
MU+#>"WB9C,-#$4<!>$TI)^UHJZ:NG9U+[=]3].J*_,7_ (B.?^K-_P#S(?\
M][Z/^(CG_JS?_P R'_\ >^J_U:SO_GU_Y-'_ #-_^(&^*7_0O_\ *M#_ .6G
MZ=45^8O_ !$<_P#5F_\ YD/_ .]]'_$1S_U9O_YD/_[WT?ZM9W_SZ_\ )H_Y
MA_Q WQ2_Z%__ )5H?_+3].J*_,7_ (B.?^K-_P#S(?\ ][Z/^(CG_JS?_P R
M'_\ >^C_ %:SO_GU_P"31_S#_B!OBE_T+_\ RK0_^6GZ=45^8O\ Q$<_]6;_
M /F0_P#[WT?\1'/_ %9O_P"9#_\ O?1_JUG?_/K_ ,FC_F'_ ! WQ2_Z%_\
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M(?\ Y-V_^OM/_P!N/MNBBBOS _@X**** "BBB@ HHHH **** "BBB@ HHHH
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MW?';7OVD/V_?B[\:/&BQ1:MXE\-?:Q:QMD00+=6\:1*3R5CC$*9/4*,UQO\
MP;[6UY:_M1>/GNXG18/!+I<%^ C_ &V#AO0_*WY&O"K'_@H-;_#/]KNP_:C_
M &8O@%HGP^LK;25T^^\%VEV)K.^A.?.#M'%#@O\ (P(7*M&A^;&*].^(?_!7
MWPC;?#_Q;H/[+_[(.A?#?Q%X]B=?%/BBUU-9YG+APYC5((OG_>.58G"L[,%R
M<UGBLOQLU5A2I6C5C!;KW.72SUUT[7.3/>#^)L3#'87 8#EI9A1PM-7J4[8;
MV-XN,US/F2@[IT^>[5CXJUJ6WFUF[FM"/*>YD:+'3:6./TKZ"_X)-,Q_X*&_
M#($DXU*[ ]O]!N:Y[X:_M6>!? ?[(?C#]FC5/V<?#^L:SXGU(7-GXYNW7[7I
MRXB 508BS%?+8H5D0 RMD'D-S7[)GQ]_X9=_:'\,_'K_ (1/^W/^$=NI9O[*
M^W_9?M&^"2+'F^7)LQYF<[3TQWS7NXB->OA*U+DL[24=5[VFC\M=-3]7SJEF
MN;\.9G@8X=QFZ=6G2O*+]KS4K1DM?=O)\MIV:M=Z,[O_ (*F_P#*0+XG_P#8
M>3_TFAKT7_@A=_R?OI__ &*^I?\ H"U\]?M3_'3_ (:7_:!\3_'7_A%O[$_X
M22_6Y_LK[=]I^SXC1-OF[$W_ ',YVCK71?L+_M9?\,6?'RW^.'_" ?\ "2^1
MI=S9_P!E_P!J_8]WFJ!O\SRI<8QTV\^HKGK86O/(WATO?Y$K:;VM:^QY&9Y#
MFN(\*Y9/3IWQ+PJI\EX_&J:CR\U^7?2][>=C[S^.?P?U;_@HQ\!-2^%^AOYO
MC+X/?M :CX<FEQNDCT>XU-H?,QVCCA>%B?[M@_%>W>&OB9HOBSQW^T+\'? X
M6+PS\)?A=I?AK2K:)LQI,;/47GV^A4)#"?>WK\Z_V8O^"I?B3]FK]ICXH?'R
MP^%0U73OB;J5W?W7AA]?,(L[B2\DN(7\\0-YOEK--'_JUW!\_+C%9?[)_P#P
M4EUS]G#2OB['XG^&A\6:E\6UW:AJ3:[]C-I.5O-\NWR)?-W-=EL93&S&3G(\
M*MDV/E2E!1O&-G!76\G%SZ]+.WKH?DN9^&7%U; XC"PI*5*E[.>'CS05JE:K
M1GB=Y))4^2IRWLFJCY;['S)1117VA_3X5^S/_! K_DR#4/\ L?[_ /\ 2:TK
M\9J_9G_@@5_R9!J'_8_W_P#Z36E?-<6?\BE_XE^I^&?2'_Y-V_\ K[3_ /;C
M[;HHHK\P/X."BBOEK_@KO^T;\9?V7_V6+/XC_ OQC_8>M2^+[2RDO?[.M[G,
M#PW#,FRXCD3DQH<XSQUY-=&%P\\7B(T86O)V5]CU\@R7%<19S0RS#2BJE:2C
M%R;44WW:3=O1,^I:*_"C_A\E_P %(O\ HXW_ ,M#1_\ Y$H_X?)?\%(O^CC?
M_+0T?_Y$KZ3_ %.S/^>'WR_^1/V__B6KCK_H)PW_ ('5_P#E)^Z]%?A1_P /
MDO\ @I%_T<;_ .6AH_\ \B4?\/DO^"D7_1QO_EH:/_\ (E'^IV9_SP^^7_R(
M?\2U<=?]!.&_\#J__*3]UZ*_"C_A\E_P4B_Z.-_\M#1__D2C_A\E_P %(O\
MHXW_ ,M#1_\ Y$H_U.S/^>'WR_\ D0_XEJXZ_P"@G#?^!U?_ )2?NO17X4?\
M/DO^"D7_ $<;_P"6AH__ ,B4?\/DO^"D7_1QO_EH:/\ _(E'^IV9_P \/OE_
M\B'_ !+5QU_T$X;_ ,#J_P#RD_=>BOPH_P"'R7_!2+_HXW_RT-'_ /D2C_A\
ME_P4B_Z.-_\ +0T?_P"1*/\ 4[,_YX??+_Y$/^):N.O^@G#?^!U?_E)^Z]%?
MA1_P^2_X*1?]'&_^6AH__P B4?\ #Y+_ (*1?]'&_P#EH:/_ /(E'^IV9_SP
M^^7_ ,B'_$M7'7_03AO_  .K_P#*3]UZ*_"C_A\E_P %(O\ HXW_ ,M#1_\
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MZ4O7D-?M>"_W.G_A7Y(_U)X9_P"2<P7_ %ZI_P#I$0HHHKI/;"BBB@ HHHH
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M "BBB@ HHHH ]>_X)_\ _)[_ ,)_^Q_TO_TI2OZ%J_GI_P""?_\ R>_\)_\
ML?\ 2_\ TI2OZ%J_/>,O][I?X?U/XS^DU_R4>!_Z]/\ ]+84445\:?S.%%%%
M '\]/_!0#_D]_P"+'_8_ZI_Z4O7D->O?\% /^3W_ (L?]C_JG_I2]>0U^UX+
M_<Z?^%?DC_4GAG_DG,%_UZI_^D1"BBBND]L**** "BBB@ HHHH **** "BBB
M@ HHHH *_9G_ ((%?\F0:A_V/]__ .DUI7XS5^S/_! K_DR#4/\ L?[_ /\
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M%B\7W*J&9BQ  / R>!VJ#_AWO\$_^AM\=_\ A97/^->Z44 >%_\ #O?X)_\
M0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XU[I10!X7_P[W^"?_0V^._\
MPLKG_&C_ (=[_!/_ *&WQW_X65S_ (U[I10!X7_P[W^"?_0V^.__  LKG_&C
M_AWO\$_^AM\=_P#A97/^->Z44 >%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z
M&WQW_P"%E<_XU[I10!X7_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\ !/\ Z&WQ
MW_X65S_C7NE% 'A?_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\
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M9V?]X\:Q+A3\\JYXR:^</^"M^H:W_P $DOVU?#?_  7 ^&/@J^U?P9K^C_\
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MWQ*^*FK^9IG@>>'X_>$[73/ GA_G;IVFP27,A61]S&:Z)#R[B $#R>9^PU%
M'R/\3O\ AY+^VI^P!XSL?"WPVO\ ]E?XW1:HK>![>]\<:=KJ3"V:WG5I[G3Q
M)&D%S^_MF3!=,>85(V@_-'[9>A?\%?\ _@K9^SY;_P#!/'XG?\$Z;;X':%XJ
MU?2Q\7?BCJGQ-TO5;*"PM+N&[D72K:U9IYI)9($*;P H'EN1N,B_J?10!6T?
M2;'0=(M=#TN'R[:RMD@MX\YVQHH51D^@ JS110 4444 %%%% !1110 4444
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MXIT"W_M:TN_M6DW@M!;W.ZUED5-_E/\ NW*R+M^91D9^UZ* "OBC]C7]D?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%?F+_Q$<_]6;_^9#_^]]'_ !$<_P#5F_\ YD/_ .]]>[_JUG?_
M #Z_\FC_ )GZS_Q WQ2_Z%__ )5H?_+3].J*^%/V-O\ @M7_ ,-;?M(^'/V?
M/^&:?^$?_P"$@^V?\3?_ (3+[7]G\BSGN?\ 5?8X]^[R=OWQC=GG&#]UUYN,
MP.*R^JJ=>/*VK[IZ;=&^Q\/Q+PIG_!^/C@\WH^RJ2BII<T)>ZVXIWA*2WBU:
M]]-M@HKQ'XU_\%*O^"??[.'Q'C^$/QZ_;/\ AKX1\3OL\S0M>\86EO<VX< H
M9D9P8 P((,FT$<CBO9=&UG2/$6D6OB#P_JMM?V%];I<65[9SK+#<1.H9)$=2
M5=64@A@2"""*Y#YXLT444 %%%% !1110 4444 %%%<%X-_:>^!OQ ^/WC/\
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M\0/AI\2_AU\;/&UOX*B\2>!O"-SH=[X4\2WD<CV$!CDN9TO+.9HWB\P^7(I
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M10!\Q?\ #FW_ ()N_P#1N7_EWZQ_\ET?\.;?^";O_1N7_EWZQ_\ )=%%=_\
M:F9_\_Y_^!2_S/K?]?N.O^AKB?\ P?5_^2.G^#7_  31_8E_9^^).F_%WX1?
M!7^R/$6D>=_9^H?\)'J5QY7FPO#)^[FN71LQR.OS*<;LC! (]VHHKEK8BOB)
M<U6;D]KMM_F>'F>;YMG5=5\PQ$ZTTN52J3E-I)MV3DV[7;=MKM]PHHHK(\X*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacific Biosciences of California, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1590339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1305 O&#8217;Brien Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-8000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PACB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,084,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001299130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 58,507<span></span>
</td>
<td class="nump">$ 55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">284,603<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">31,645<span></span>
</td>
<td class="nump">27,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">54,007<span></span>
</td>
<td class="nump">58,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">15,471<span></span>
</td>
<td class="nump">18,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">444,923<span></span>
</td>
<td class="nump">495,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">24,794<span></span>
</td>
<td class="nump">30,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">44,408<span></span>
</td>
<td class="nump">16,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">18,182<span></span>
</td>
<td class="nump">389,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">317,761<span></span>
</td>
<td class="nump">317,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">9,189<span></span>
</td>
<td class="nump">9,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">860,789<span></span>
</td>
<td class="nump">1,260,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,037<span></span>
</td>
<td class="nump">16,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,337<span></span>
</td>
<td class="nump">22,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">15,241<span></span>
</td>
<td class="nump">13,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">10,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">5,570<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">66,602<span></span>
</td>
<td class="nump">66,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">50,480<span></span>
</td>
<td class="nump">14,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="nump">646,214<span></span>
</td>
<td class="nump">647,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">769,151<span></span>
</td>
<td class="nump">753,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,665,958<span></span>
</td>
<td class="nump">2,654,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,575,001)<span></span>
</td>
<td class="num">(2,148,926)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">91,638<span></span>
</td>
<td class="nump">506,594<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 860,789<span></span>
</td>
<td class="nump">$ 1,260,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">300,041,000<span></span>
</td>
<td class="nump">294,418,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">300,041,000<span></span>
</td>
<td class="nump">294,418,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 37,153<span></span>
</td>
<td class="nump">$ 38,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">4,345<span></span>
</td>
<td class="nump">1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LossOnPurchaseCommitment', window );">Loss on purchase commitment</a></td>
<td class="nump">4,068<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">38,524<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross (loss) profit</a></td>
<td class="num">(1,371)<span></span>
</td>
<td class="nump">11,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,053<span></span>
</td>
<td class="nump">43,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">40,168<span></span>
</td>
<td class="nump">43,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AmortizationOfAcquiredIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">362,042<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(18,700)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">427,563<span></span>
</td>
<td class="nump">92,644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(428,934)<span></span>
</td>
<td class="num">(81,362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,737)<span></span>
</td>
<td class="num">(3,575)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,294<span></span>
</td>
<td class="nump">6,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(426,377)<span></span>
</td>
<td class="num">(78,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(302)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(426,075)<span></span>
</td>
<td class="num">(78,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on investments</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (426,116)<span></span>
</td>
<td class="num">$ (78,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeLossPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding used in calculating net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">296,858<span></span>
</td>
<td class="nump">269,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">296,858<span></span>
</td>
<td class="nump">269,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 31,113<span></span>
</td>
<td class="nump">$ 35,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">26,333<span></span>
</td>
<td class="nump">22,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,040<span></span>
</td>
<td class="nump">3,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">$ 3,778<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AmortizationOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AmortizationOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LossOnPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Purchase Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LossOnPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 701,304<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 2,539,892<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="num">$ (1,839,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(78,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">6,891<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">6,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">19,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 649,017<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">2,566,304<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(1,917,253)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">294,418<span></span>
</td>
<td class="nump">294,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 506,594<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">2,654,804<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="num">(2,148,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(426,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(426,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">1,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 9,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">300,041<span></span>
</td>
<td class="nump">300,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 91,638<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,665,958<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
<td class="num">$ (2,575,001)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (426,075)<span></span>
</td>
<td class="num">$ (78,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">5,131<span></span>
</td>
<td class="nump">3,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">366,390<span></span>
</td>
<td class="nump">6,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="nump">1,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">9,201<span></span>
</td>
<td class="nump">19,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accretion of discount and amortization of premium on marketable securities, net</a></td>
<td class="num">(1,706)<span></span>
</td>
<td class="num">(4,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="num">(18,700)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">7,659<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(546)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(4,121)<span></span>
</td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(2,538)<span></span>
</td>
<td class="num">(11,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,525)<span></span>
</td>
<td class="nump">6,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">311<span></span>
</td>
<td class="num">(23,753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">1,332<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,618)<span></span>
</td>
<td class="num">(2,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">2,346<span></span>
</td>
<td class="num">(5,152)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(44,056)<span></span>
</td>
<td class="num">(75,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,389)<span></span>
</td>
<td class="num">(3,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(61,820)<span></span>
</td>
<td class="num">(191,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">113,443<span></span>
</td>
<td class="nump">161,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">45,234<span></span>
</td>
<td class="num">(34,136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock from equity plans</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">6,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Notes payable principal payoff</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">6,553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="num">(103,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">57,592<span></span>
</td>
<td class="nump">182,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">60,729<span></span>
</td>
<td class="nump">79,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">58,507<span></span>
</td>
<td class="nump">76,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash at end of period</a></td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">60,729<span></span>
</td>
<td class="nump">79,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability recognized due to lease extension</a></td>
<td class="nump">$ 29,575<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 ("2024 Annual Report").</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2025. Actual results could differ materially from these estimates.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentration and Other Risks</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025 and 2024, no customer accounted for 10% or more of total revenue during the period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, 36% of our accounts receivable were from domestic customers, compared to 36% as of December&#160;31, 2024. As of March&#160;31, 2025, one customer exceeded 10% of our net accounts receivable, while no customer represented 10% or more of our net accounts receivable as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 2.  FINANCIAL INSTRUMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42,952&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,555&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58,507&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,790&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,790&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">245,813&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">245,813&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">284,603&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">284,603&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45,174&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300,158&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">345,332&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,592&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">392,153&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the August 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apton Biosystems, Inc. (&#8220;Apton&#8221;)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the <span style="-sec-ix-hidden:f-368">twenty</span> trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our condensed consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability was calculated using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the five-year anniversary of the closing date of the acquisition. The key input used in the determination of the fair value included projected revenues of the high-throughput short-read products and services leveraging Apton's technology. As of March&#160;31, 2025, primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the five-year anniversary of the closing date of the acquisition, the estimated fair value of the contingent consideration liability was $0. An acceleration in the timing of projected revenues or an increase in the projected revenues may result in an increase in the fair value of the liability. A decrease in the discount rates, which include the risk-free rate and estimated subordinated credit spread for CCC credit rating, may result in an increase in the fair value of the liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of March 31, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,507&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,507&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,635&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,790&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">245,587&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">245,813&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284,222&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">452&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(71)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284,603&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,729&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(72)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">343,110&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,139&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,509&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">227,680&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72,478&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300,158&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated statements of operations and comprehensive loss </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $3.9 million for the three months ended March&#160;31, 2025 and $7.2 million for the three months ended March&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 3.  BALANCE SHEET COMPONENTS </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory, Net</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,479&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,270&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,914&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,429&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,822&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,523&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28,815)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22,768)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,007&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,755&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2024, as of the beginning of April 2024, noting no impairment. We recognized a $93.2&#160;million and $51.3&#160;million impairment charge in the second and fourth quarter of 2024, respectively, as a result of quantitative interim impairment tests.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based primarily on the decline in our stock price and overall market capitalization during the first quarter of 2025, driven in part by macroeconomic uncertainties, as well as our updated strategic plans and restructuring initiatives that prioritize accelerating adoption of HiFi sequencing and ceasing development of our high-throughput short-read platform, we concluded that changes to the timing and amount of expected future cash flows, among other factors, indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount, requiring an interim goodwill impairment assessment. As a result of the quantitative interim impairment test performed as of March 31, 2025, we concluded that there was no impairment, as the estimated fair value of the entity-level reporting unit exceeded the carrying value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value of the entity-level reporting unit as of March 31, 2025, we performed our impairment test using a combination of an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 12.0%. The discount rate was based on the weighted average cost of capital, determined using market, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our assessment would have resulted in a change in the fair value of the reporting unit of approximately $75&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation and a supportable control premium.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairment tests could affect the implied fair value of goodwill and may result in additional impairment charges in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technology, customer relationships, and acquired in-process research and development ("IPR&amp;D"). In connection with the Apton acquisition in August 2023, we allocated $55.0 million of the purchase price to IPR&amp;D. This asset is considered indefinite-lived until the associated research and development activities are either completed or abandoned, and is tested for impairment annually and more </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a $40.0&#160;million impairment charge in the fourth quarter of 2024 as a result of a quantitative interim impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our decision to cease development of the high-throughput short-read sequencing platform, which would utilize the IPR&amp;D, and the resulting changes to the expected future cash flows, among other factors, we concluded  that it was more likely than not that the fair value of the IPR&amp;D was less than its carrying amount, requiring an interim impairment assessment. Using a discounted cash flow model under the income approach, we determined the fair value was below carrying value and recorded a $15.0&#160;million impairment charge. The decline in the fair value of the IPR&amp;D below its carrying amount as of March 31, 2025 resulted primarily from changes in the timing of expected future cash flows as compared to the fair value as of December 31, 2024, driven by the restructuring initiatives that prioritize accelerating adoption of HiFi sequencing and resulted in ceasing development of our high-throughput short-read sequencing platform. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions used in the income approach include timing of future cash flows, revenue growth assumptions, a selected discount rate of 14.0%, and a selected obsolescence factor of 11 years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. A decrease of 200 basis points to the discount rate used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $3&#160;million, and an increase of one year to the obsolescence factor used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $3&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-462">Impairment charge</span></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of March&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5</a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. </a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 &#8212; 15</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,179&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(402,997)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,182&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,179&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,607)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,539&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(403,357)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,182&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,539&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,967)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,059&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,921&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,182&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review finite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, we revised the estimated useful life of the developed technology acquired in the 2021 Omniome, Inc. ("Omniome") acquisition. This change reflects updated strategic plans and restructuring initiatives focused on accelerating HiFi sequencing adoption, leading to ceased development of our high-throughput short-read platform and revised expectations for the timing and amount of future cash flows from short-read sequencing products and services. As a result of the change in estimate, during the three months ended March 31, 2025 we recognized accelerated amortization of $359.3&#160;million within amortization of acquired intangible assets in operating expenses, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. This expense reduced basic and diluted net loss per share by $1.21.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2025, the Company entered into an agreement to acquire certain developed technology and related intellectual property from The Chinese University of Hong Kong for total consideration of $9.7&#160;million. In addition, the Company entered into a license agreement for complementary developed technology during the three months ended March 31, 2025. Both the acquired technology and license are classified as intangible assets and are being amortized over an estimated useful life of three years. As of March 31, 2025, $5.0&#160;million of intangible assets acquired during the first quarter of 2025 remained unpaid, is included in accrued liabilities on the condensed consolidated balance sheets, and is expected to be paid in 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, as part of our interim goodwill impairment test, we also performed a recoverability test for the definite-lived asset group noting no impairment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5</a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Deferred Revenue</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had a total of $21.1&#160;million of deferred revenue, $15.2&#160;million of which was recorded as deferred revenue, current, and $5.9&#160;million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next five years. Revenue recorded in the three months ended March&#160;31, 2025 includes $4.6&#160;million that was included in deferred revenue as of December&#160;31, 2024. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of March&#160;31, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $58.7&#160;million, of which approximately 70% is expected to be converted to revenue over the next twelve months, approximately 23% in the following twelve months, and the remainder thereafter.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Warranties</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on the condensed consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,681&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,311&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,552)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,859&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,120&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE SENIOR NOTES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 4.  CONVERTIBLE SENIOR NOTES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2029 Convertible Senior Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#8220;SBN&#8221;), a subsidiary of SoftBank Group Corp., pursuant to which we agreed to exchange the remaining approximately $459.0&#160;million in aggregate principal amount of our previously held 1.50% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) outstanding for (i) $200.0&#160;million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;), (ii) 20,451,570 shares of common stock (the &#8220;Exchange Shares&#8221;) and (iii) $50.0&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The Exchange Shares were issued on November 21, 2024 (the &#8220;Closing Date&#8221;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes are subject to certain lock-up restrictions for a six-month period (the &#8220;Lock-Up Period&#8221;) beginning on the Closing Date of the 2024 Exchange Transaction; the lock-up restrictions will terminate immediately prior to the consummation of any change in control of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#8217;s common stock which would cause SBN's beneficial ownership of common stock to exceed either 9.9% of the total number of issued and outstanding shares of common stock or 9.9% of the combined voting power of all of the securities of the Company, in each case, following such conversion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are governed by an indenture (the &#8220;2029 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of 1.50% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15, commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $4.89 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2029 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the 181</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the 360</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange qualified as a troubled debt restructuring under ASC 470-60 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings by Debtors</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $154.4&#160;million, which resulted in a decrease of basic net loss per share of $0.56, during the year ended December 31, 2024 on our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2029 Notes of approximately $3.1&#160;million, including $0.2&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring on our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $1.8&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $50.0&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, no amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the liability for the 2029 Notes as of March&#160;31, 2025 is $213.5&#160;million, of which $210.5&#160;million is included as convertible senior notes, net, non-current, and $3.0&#160;million is included as accrued expenses on our consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the 2029 Notes during the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of December 31, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of March 31, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">213,500&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the estimated fair value (Level 2) of the 2029 Notes was $154.0&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2030 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 2028 Notes, pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;) in exchange for $441.0&#160;million principal amount of the 2028 Notes (the &#8220;2023 Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the 360</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0&#160;million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5&#160;million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $7.3&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our condensed consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5&#160;million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the 2023 Exchange Transaction, $459.0&#160;million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">434&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,720)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,959)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">435,714&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">435,494&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,516&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,533&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,755&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,772&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the estimated fair value (Level 2) of the 2030 Notes was $276.6 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2028 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $900.0&#160;million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February 16, 2021 and bore interest at a rate of 1.50% per annum. As discussed above, in June 2023 we completed an exchange of $441.0&#160;million in aggregate principal amount of our 2028 Notes for $441.0&#160;million aggregate principal amount of the 2030 Notes, leaving approximately $459.0&#160;million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $459.0&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $50.0&#160;million of cash. As of December 31, 2024 no amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $4.5&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $1.1&#160;million were extinguished by offsetting the carrying amount of the convertible senior notes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,721&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,802&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 5.  RESTRUCTURING</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we implemented an expense reduction initiative aimed at lowering our annualized run-rate operating expenses. These actions, which included workforce reductions and other cost-saving measures, were part of a broader strategic shift to prioritize the adoption of HiFi sequencing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-628">Total restructuring charges</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $2.5&#160;million was recorded in sales, general and administrative expense and $2.1&#160;million in research and development expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges included employee separation costs comprised of approximately $2.4&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $2.2&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the restructuring and strategic shift, we incurred an additional $388.2&#160;million in costs. These include $359.3&#160;million of accelerated amortization of certain intangible assets, $15.0&#160;million of IPR&amp;D impairment charges, $7.7&#160;million related to excess inventory due to decreased external demand and $3.8&#160;million for estimated losses on purchase commitments tied to anticipated future excess inventory included in cost of revenue, and $2.4&#160;million of accelerated depreciation of fixed assets. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the IPR&amp;D impairment assessment and the change in estimated useful life of the intangible asset and accelerated amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, excluding non-cash activities)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recorded in Q1 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid in Q1 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities</span></div><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,008&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-654"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,197&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For the three months ended March&#160;31, 2025, $1.0 million was recorded in sales, general and administrative expense.</span></div><div style="margin-top:3pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include $15.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include employee separation costs comprised of approximately $5.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $4.5&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs in the three months ended March&#160;31, 2025 are primarily related to a lease termination fee and other costs related to our exit of the San Diego office. Other costs in cumulative charges incurred to date are primarily related to accelerated amortization and depreciation of $8.1&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $3.6&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the three months ended June 30, 2024 resulting in a reduction in the operating lease liability balance of $4.4&#160;million, which was offset against the right-of-use asset on the condensed consolidated balance sheets. We fully exited our San Diego office in September 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional expense recorded</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(581)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(581)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of March&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability as of March&#160;31, 2025 is $1.8&#160;million, and is included in operating lease liabilities, current on the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 6.  COMMITMENTS AND CONTINGENCIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2025, we amended our existing lease covering our corporate headquarters, as well as our research and development, manufacturing, and distribution facilities in Menlo Park, California. The lease amendment extends the term to April 30, 2034. We will pay approximately $97.7&#160;million in base rent over the life of the amended lease and receive base rent abatement of approximately $11.6&#160;million for the period beginning on March 1, 2025 and ending on July 31, 2026. We are also entitled to a tenant improvement allowance of $7.2&#160;million. The lease amendment increased our operating lease right-of-use assets and operating lease liabilities by $29.6&#160;million on our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,327&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,941&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,165&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,389&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,761&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,897&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,480&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47,583)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of operating lease liabilities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,897&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,417&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,480&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,897&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was 10.1%. The weighted-average remaining lease term for our operating leases as of March&#160;31, 2025 was 9.0 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $2.4&#160;million and $3.0&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively, and were included in operating cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $2.0&#160;million and $2.6&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contingencies</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_100" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings, in Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnification</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of March&#160;31, 2025 and December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY PLANS AND SHARE-BASED COMPENSATION</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 7.  EQUITY PLANS AND SHARE-BASED COMPENSATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Equity Plans</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had 11.3&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of our 2024 Annual Report for more information on the Company's equity plans</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Options</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,509</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.09&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,562</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.24&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,287)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.20&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(236)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.91&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,548</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.80&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We issue PSUs for which the number of shares issuable is based on performance relative to specified revenue targets and continued employment through the vesting period. The PSUs are issuable following the third year of the performance period. Maximum achievement of the revenue goal under the PSUs will result in up to 200% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under the PSUs will result in no shares subject to the PSUs becoming eligible to vest. The following table summarizes the time-based RSUs and PSUs activity: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,211&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.41&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,618&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.25&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,870)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.51&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(552)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.79&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,407&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.73&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan ("ESPP")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under our ESPP wer</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e 1,752,417 and 1,194,436</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> durin</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g the three months ended March&#160;31, 2025 and 2024, respectively. In the first quarter of 2025, an additional 4.0&#160;million shares were reserved under the ESPP. As of March&#160;31, 2025, 16.5&#160;million shares of our common stock remain avai</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lable for issuance under our ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,165&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,106&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,607&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,429&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,201&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,525&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Determining Fair Value</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;95% &#8212; 96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;3.92% &#8212; 4.29%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.32%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.91</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2.45</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.96% &#8212; 4.31%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.54% &#8212; 5.27%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.93</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2.78</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 8.  NET LOSS PER SHARE</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the Notes, using the if-converted method, and outstanding equity awards using the treasury stock method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426,075)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(78,178)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,858</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269,578</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.44)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.29)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,858</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269,578</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.44)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.29)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,415</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,063</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,133</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,924</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7</a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. </a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Equity Plans and Sha</a><a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">re-Based Compensation</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on equity awards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND GEOGRAPHIC INFORMATION</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker (CODM) is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a regular basis, our CODM reviews:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total revenues by category</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">net loss per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,153&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,810&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,524&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,053&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,076&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,092&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">362,042&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,557&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(302)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426,075)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(78,178)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,303&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,678&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,240&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,610&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,153&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,810&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows: </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,016&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,025&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,097&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,113&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,009&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,040&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,153&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,810&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (426,075)<span></span>
</td>
<td class="num">$ (78,178)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2025. Actual results could differ materially from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, Restricted Cash and Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">42,952&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,555&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58,507&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,790&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,790&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">245,813&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">245,813&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">284,603&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">284,603&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45,174&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300,158&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">345,332&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,592&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">392,153&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of March 31, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents, Restricted Cash and Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,507&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,507&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,635&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,790&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">245,587&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">245,813&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284,222&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">452&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(71)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">284,603&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342,729&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(72)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">343,110&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,139&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,509&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">227,680&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72,478&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300,158&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,479&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,270&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,914&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,429&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,822&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,523&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28,815)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22,768)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,007&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,755&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of Impaired Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-462">Impairment charge</span></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of March&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets From Business Acquisitions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 &#8212; 15</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,179&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(402,997)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,182&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,179&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,607)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,539&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(403,357)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,182&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,539&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,967)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,059&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,921&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,182&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of Changes in Reserve for Product Warranties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,681&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,311&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,552)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,859&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,120&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the 2029 Notes during the three months ended March&#160;31, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of December 31, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of March 31, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">213,500&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,516&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,533&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">239&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,755&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,772&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,721&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,802&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Net Carrying Amount</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">434&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,720)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,959)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">435,714&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">435,494&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Interest Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Pre-Tax Restructuring Charges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-628">Total restructuring charges</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $2.5&#160;million was recorded in sales, general and administrative expense and $2.1&#160;million in research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,008&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-654"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,197&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> For the three months ended March&#160;31, 2025, $1.0 million was recorded in sales, general and administrative expense.</span></div><div style="margin-top:3pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include $15.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, excluding non-cash activities)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense recorded in Q1 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid in Q1 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities</span></div><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of March 31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,649&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional expense recorded</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">975&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(581)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(581)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of March&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock', window );">Schedule of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the maturities of our operating lease liabilities were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,327&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,941&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,165&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,389&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,761&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,897&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100,480&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47,583)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of operating lease liabilities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,897&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,417&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,480&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,897&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LesseeOperatingLeaseDescriptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Description [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LesseeOperatingLeaseDescriptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,509</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.09&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,562</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.24&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,287)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.20&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(236)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.91&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,548</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.80&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Time-Based RSUs and PSUs Activity</a></td>
<td class="text">The following table summarizes the time-based RSUs and PSUs activity: <div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,211&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.41&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,618&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.25&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,870)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.51&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(552)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.79&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,407&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.73&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,165&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,106&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,607&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,429&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,201&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,525&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;95% &#8212; 96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;3.92% &#8212; 4.29%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.32%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.91</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2.45</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.96% &#8212; 4.31%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.54% &#8212; 5.27%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.93</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$2.78</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426,075)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(78,178)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,858</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269,578</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.44)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.29)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">296,858</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">269,578</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.44)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.29)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,415</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,063</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity Awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,133</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,924</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Profit or Loss</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,153&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,810&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,524&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,528&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,053&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,076&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,092&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">362,042&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,557&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(302)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(426,075)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(78,178)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Location</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,303&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,678&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,240&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,610&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,153&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,810&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue by Category</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows: </span></div><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,016&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,025&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,097&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,113&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,009&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,040&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37,153&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,810&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) - Accounts Receivable - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Domestic Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_DomesticCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_DomesticCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pacb_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pacb_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 58,507<span></span>
</td>
<td class="nump">$ 55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">345,332<span></span>
</td>
<td class="nump">392,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">284,603<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">38,790<span></span>
</td>
<td class="nump">46,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">245,813<span></span>
</td>
<td class="nump">287,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">42,952<span></span>
</td>
<td class="nump">55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">45,174<span></span>
</td>
<td class="nump">57,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">15,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">300,158<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">284,603<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">38,790<span></span>
</td>
<td class="nump">46,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">245,813<span></span>
</td>
<td class="nump">287,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LongTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LongTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShortTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShortTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone', window );">Milestone revenue</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod', window );">Business acquisition, anniversary</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition', window );">Average trading period</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger', window );">Percentage of outstanding shares of common to be issued in merger</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Liability, Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common to be issued in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Average Trading Period, Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(18,700)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(18,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 342,729<span></span>
</td>
<td class="nump">$ 389,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">343,110<span></span>
</td>
<td class="nump">389,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">58,507<span></span>
</td>
<td class="nump">55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">58,507<span></span>
</td>
<td class="nump">55,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">284,222<span></span>
</td>
<td class="nump">334,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">284,603<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">38,635<span></span>
</td>
<td class="nump">46,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">38,790<span></span>
</td>
<td class="nump">46,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">245,587<span></span>
</td>
<td class="nump">287,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 245,813<span></span>
</td>
<td class="nump">$ 287,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 227,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Due after one year through five years</a></td>
<td class="nump">72,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 300,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Purchased materials</a></td>
<td class="nump">$ 44,479<span></span>
</td>
<td class="nump">$ 45,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">24,914<span></span>
</td>
<td class="nump">22,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">13,429<span></span>
</td>
<td class="nump">14,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">82,822<span></span>
</td>
<td class="nump">81,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="num">(28,815)<span></span>
</td>
<td class="num">(22,768)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 54,007<span></span>
</td>
<td class="nump">$ 58,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 51,300<span></span>
</td>
<td class="nump">$ 93,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate', window );">Goodwill impairment, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate', window );">Increase in basis point discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate', window );">Additional goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate', window );">Intangible asset impairment, discounted cash flow model, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm', window );">Intangible asset impairment, discounted cash flow model, term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate', window );">Intangible asset impairment, increase in basis point discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate', window );">Additional intangible asset impairment, change in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm', window );">Intangible asset impairment, increase in term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm', window );">Additional intangible asset impairment, change in term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,241<span></span>
</td>
<td class="nump">13,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StandardProductWarrantyPeriod', window );">Standard product warranty, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=pacb_DevelopedTechnologyAndIntellectualPropertyMember', window );">Developed Technology and Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Asset acquisition amount unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization', window );">Restructuring and related cost, accelerated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ChangeInEarningsPerShare', window );">Reduction in net loss, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod', window );">Contract with customer, liability, noncurrent, recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Allocation of purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalGoodwillImpairmentChangeInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Goodwill Impairment, Change In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalGoodwillImpairmentChangeInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Intangible Asset Impairment, Change In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Intangible Asset Impairment, Change In Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalIntangibleAssetImpairmentChangeInTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ChangeInEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ChangeInEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Impairment, Discounted Cash Flow Model, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill Impairment, Increase In Basis Point Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Discounted Cash Flow Model, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Increase In Basis Point Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Increase In Obsolescence Factor, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Accelerated Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringAndRelatedCostAcceleratedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfBalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Balance Sheet Components [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfBalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StandardProductWarrantyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StandardProductWarrantyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pacb_DevelopedTechnologyAndIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pacb_DevelopedTechnologyAndIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-Lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 389,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 18,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Impairment charges<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-Lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment charge</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 421,539<span></span>
</td>
<td class="nump">$ 411,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(403,357)<span></span>
</td>
<td class="num">(36,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">18,182<span></span>
</td>
<td class="nump">374,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">421,179<span></span>
</td>
<td class="nump">411,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(402,997)<span></span>
</td>
<td class="num">(36,607)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 18,182<span></span>
</td>
<td class="nump">374,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 3,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">4,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">4,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">2030 and thereafter</a></td>
<td class="nump">4,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 18,182<span></span>
</td>
<td class="nump">$ 374,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward', window );"><strong>Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Beginning balance</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 4,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Additions charged to cost of product revenue</a></td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Repairs and replacements</a></td>
<td class="num">(1,552)<span></span>
</td>
<td class="num">(2,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Ending balance</a></td>
<td class="nump">$ 2,859<span></span>
</td>
<td class="nump">$ 4,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 21, 2024 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares', window );">Lock-up period restriction (in months)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on debt restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringOfDebtPricePerShare', window );">Restructuring of debt (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 647,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 459,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PaymentsInConjunctionWithNotesExchange', window );">Payments made in conjunction with convertible notes exchange</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0229885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">459,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,714,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,000<span></span>
</td>
<td class="nump">$ 239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0465116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice', window );">Debt redemption, percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceTradingDays', window );">Debt redemption, trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays', window );">Debt redemption, consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtIssuanceCostLenderFees', window );">Debt issuance cost, lender fees</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, shares issued (in shares) | shares</a></td>
<td class="nump">20,451,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.02045157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Paid accrued but unpaid interest</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentAdditionalInterestInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentDebtDefaultCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Calendar Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentDebtDefaultCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentInterestInTheEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentInterestInTheEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtIssuanceCostLenderFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Cost, Lender Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtIssuanceCostLenderFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Holding Period For Transfer, Assignment Or Sale Of Founder Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PaymentsInConjunctionWithNotesExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments In Conjunction With Notes Exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PaymentsInConjunctionWithNotesExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringOfDebtPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Of Debt Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringOfDebtPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details) - 2029 Convertible Senior Notes<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Beginning balance</a></td>
<td class="nump">$ 214,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Ending balance</a></td>
<td class="nump">$ 213,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details) - 2030 Convertible Senior Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 441,000<span></span>
</td>
<td class="nump">$ 441,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized debt premium</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(5,720)<span></span>
</td>
<td class="num">(5,959)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 435,714<span></span>
</td>
<td class="nump">$ 435,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 1,516<span></span>
</td>
<td class="nump">$ 1,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of revenue<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">$ 4,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">4,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember', window );">2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">26,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesExcludingAdjustments', window );">Restructuring charges, excluding adjustments</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">15,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">4,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">4,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">10,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | Sales, general and administrative | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | Research and development | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">$ 16,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringChargesExcludingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Excluding Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringChargesExcludingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">$ 7,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">52,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits', window );">WARN act and other employee benefits</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesAdditionalCostsIncurred', window );">Additional costs incurred</a></td>
<td class="nump">388,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization', window );">Restructuring and related cost, accelerated amortization</a></td>
<td class="nump">359,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_GainLossOnPurchaseCommitments', window );">Loss on purchase commitments</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring | In Process Research And Development Indefinite Lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember', window );">2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits', window );">WARN act and other employee benefits</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember', window );">San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_GainLossOnPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_GainLossOnPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Accelerated Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringAndRelatedCostAcceleratedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringChargesAdditionalCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Additional Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringChargesAdditionalCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">$ 4,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember', window );">2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">4,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">4,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_OperatingLeaseExpectedBaseRentExpense', window );">Operating lease, base rent expense</a></td>
<td class="nump">$ 97,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount', window );">Lease base rent abatement</a></td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability recognized due to lease extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,575,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations', window );">Additional liability associated with indemnification obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Liability Associated With Indemnification Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Base Rent Abatement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_OperatingLeaseExpectedBaseRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Expected Base Rent, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_OperatingLeaseExpectedBaseRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Maturities of our Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">3,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">9,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">12,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">12,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">59,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">100,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(47,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">52,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BalanceSheetClassificationAbstract', window );"><strong>Balance Sheet Classification</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">$ 10,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">50,480<span></span>
</td>
<td class="nump">$ 14,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 52,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Classification [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock purchased under plan (in shares)</a></td>
<td class="nump">1,752,417<span></span>
</td>
<td class="nump">1,194,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember', window );">Time Based Restricted Stock Units PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal', window );">Amount eligible to vest upon achievement of goal</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember', window );">2020 Plan, Inducement Plan, And The Omniome Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="nump">16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Additional common stock purchased under plan (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - Time-based stock option<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">10,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">7,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(1,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">16,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">9.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">6.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">14,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">11,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(3,870)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">21,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">9.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">5.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 1,165<span></span>
</td>
<td class="nump">$ 2,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="nump">5,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">5,429<span></span>
</td>
<td class="nump">11,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 9,201<span></span>
</td>
<td class="nump">$ 19,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">113.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.96%<span></span>
</td>
<td class="nump">4.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.31%<span></span>
</td>
<td class="nump">5.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in shares)</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (426,075)<span></span>
</td>
<td class="num">$ (78,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per share (in shares)</a></td>
<td class="nump">296,858<span></span>
</td>
<td class="nump">269,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per share (in shares)</a></td>
<td class="nump">296,858<span></span>
</td>
<td class="nump">269,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.44)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share (in shares)</a></td>
<td class="nump">61,415<span></span>
</td>
<td class="nump">31,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Equity Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share (in shares)</a></td>
<td class="nump">47,133<span></span>
</td>
<td class="nump">36,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>customer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 37,153<span></span>
</td>
<td class="nump">$ 38,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">38,524<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,053<span></span>
</td>
<td class="nump">43,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(18,700)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">366,390<span></span>
</td>
<td class="nump">6,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">4,294<span></span>
</td>
<td class="nump">6,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(302)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(426,075)<span></span>
</td>
<td class="num">(78,178)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">37,153<span></span>
</td>
<td class="nump">38,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">38,524<span></span>
</td>
<td class="nump">27,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,053<span></span>
</td>
<td class="nump">43,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">20,076<span></span>
</td>
<td class="nump">22,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,092<span></span>
</td>
<td class="nump">21,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(18,700)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">362,042<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,557<span></span>
</td>
<td class="nump">3,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(302)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (426,075)<span></span>
</td>
<td class="num">$ (78,178)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 37,153<span></span>
</td>
<td class="nump">$ 38,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">16,303<span></span>
</td>
<td class="nump">17,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">9,240<span></span>
</td>
<td class="nump">8,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia-Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 11,610<span></span>
</td>
<td class="nump">$ 12,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 37,153<span></span>
</td>
<td class="nump">$ 38,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">31,113<span></span>
</td>
<td class="nump">35,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_InstrumentMember', window );">Instrument revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">11,016<span></span>
</td>
<td class="nump">19,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ConsumableMember', window );">Consumable revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">20,097<span></span>
</td>
<td class="nump">15,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 6,040<span></span>
</td>
<td class="nump">$ 3,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_InstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_InstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ConsumableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ConsumableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !>!K%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !>!K%J[ G0X\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZS2B@J.L%Q DD)":!N$6)
MMT4T3908M7M[VK!U('@ CK'_?/XLN=%!:A_Q*?J D2RFB]%U?9(ZK-F>*$B
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( !>!K%I'K+Z1W 4  .(>   8
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M>@8CGMH<J&YNM$R+,\F9U%K&Q>52\$ H\P&\GTNI=S?F!\IC[=&_4$L#!!0
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M]Z6 ;F9WH5ZW]:]79_\#4$L#!!0    ( !>!K%HC!G-A%0,  '(*   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK59K;]HP%/TK5C9-K=21!^'5020*
M5*W4M:BTVX=I']SD0JPZ<68[T.W7ST[2C)3PVL8'\..>XW-NKLGMKQA_%B&
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M,R4 WR^$D+\NU _L_J(Q^1=02P,$%     @ %X&L6H/X%B3E!0  WR0  !@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6S%6EUOVS84_2N$5VP-4,<B]9TY
M!EI;0H.U218G&X9A#ZQ$QUHET97H./WW(V55MBA:M5>N>[%%^]YSR7O(2QY)
MXPTM/I9+0AAXSM*\O!PL&5M=C$9EM"09+L_IBN3\GP4M,LQXLW@<E:N"X+AR
MRM(1,@QGE.$D'TS&U6^WQ61,URQ-<G);@'*=9;CX_(:D=',Y@(,O/]PECTLF
M?AA-QBO\2.:$/:QN"]X:-2AQDI&\3&@."K*X'+R&%R&J'"J+WQ*R*?>N@1C*
M!TH_BL95?#DP1(](2B(F(##_>B)3DJ8"B??C4PTZ:&(*Q_WK+^AA-7@^F ^X
M)%.:_I[$;'DY\ 8@)@N\3MD=W;PE]8!L@1?1M*P^P::V-08@6I>,9K4S[T&6
MY-MO_%PG8L\!F@<<4.V CG4P:P=3<D#N 0>K=K D!\LYX&#7#K8<X="@G=K!
MJ7*_35:5Z1EF>#(NZ 84PIJCB8N*KLJ;)SC)Q<R:LX+_FW _-IG>7,^"ZWDP
M _QJ?O/N:O;ZGC?F]_SK?7!]/P<W(6_=3']Y>_-N%MS-?P+!KP]7]W^ EP\Y
M7L<)(_$9&(*'^0R\?'$&RB4N2 F2'-POZ;K$>5R^ B]:[?&(\8Z+\*.H[N2;
M;2?1@4[>4X93A=NTWVU*LXQ/WCFCT4>%]ZS?^W7,!\<G/T[!+4[B(1_"%*\2
M=4^"KV!%T3I;IY@G"]RP)2D [QNO!$NQ1)\(N,HCFA'P\ATMRS,%?'@\_(PL
MDBAA;9 1GQ7-U$#-U$ 5JG4 ]0UY3/(\R1_YTDUQ'O'^\1QL"3X#F/%0T3DP
MX2N #&2J6.W%%S7SHESAB%P.>"I*4CR1P>3''Z!C_*SB>@MF5V"B7CY-D..Z
MEC4>/>V3JC-FH!,LU 36XM)LN#1/Y/(8_K:8SE[*70.:AI3R:=<,.9Y$B\+&
M-GW/1VV[0&$'_;9-V+490L_T#==N#%M)LIHD696G>2!)?!7RS;GD\YQGIKHZ
M$X6KJA]+FL:D*'GU^[1.V&?PYQU-4\ WMPTNXK]4R;-T3GZ=8#.=8(%.L% 3
M6(M]NV'?[ETBU_P8E_+ZJ^+2[M2>H>M!5YKDT]X I[*D$RS0"19^-1NM_#M-
M_IW>_&_WQ:BU+Q[BP^GVP$:VQ$9ON%/9T D6'-/]4%/$%A=NPX7;R\556:ZK
M78(N!"/B%%6**BC*843SO]?Y5A=L$K8$9%L15WQ?*?>/""KB>L.>6A3=3AHM
MVW2DC4=GQ$ G6*@)K$6PUQ#L_3<$JTCU.CPXG@^EU>AU-FWYY*:"\5SI?- [
MK%,9T 368L!O&/![&9B+13(4HCBNBAZO>+A*.7D6UT25:+^3(>AWZUYOW%/K
MWE$A YTA0TU@+5:@L=/#1B\O01[W2)[WN&B.S)92R/:BGUKA:K26Z'$1\@QI
MZ6B-&FA%"W6AM?G<N[\!3^'S* YAIU8YEF] J19-%7:<'9D:V*70=IR.B@H4
MAD/3D+:S4&4%?>AR-:4^?L&=W(<:];XZ<0J-[EL6E,_)1]K-^CM\\K36JN9U
MH;7)VNEY^(V"7DU05SK;AF/[LJ)7V"'9:%8;M>_(V);7G=E=0PLA>6)WC88(
M6IZ/G ,3>R?KX??4]5"KL->*-M.*%FA%"W6AM2?!3MW#?R_OH4+16LC9OZ%4
MLZ55X6M%"[2BA4>DI$W$3N9#?3H?*I2R)2N+_G@GDZ)5Z1\S@%!7R#8A.ZT/
M_R>QWQ_WY$K9E?NV@TQY4]*J][6BA;K0VCSO)#_\CIH?=M4Z%X:^O#2[JE^^
M/Z,&,N4CA%;=KPNM3<1.^4/]TK^&W,^DCXQ.*=2J_6%7_'=C!EICAKK0VD\\
M=^H?Z5+_MO*!9U>OFX9A=+:L(^UF_;T]^6FF5EVO"ZW-U$[7HV_1]6IVNGK=
MAXXIJU.%&2='9D:A_1VNI&P)+5"A>?()0&$T1+9K&WNK;9NGT=ZK'N+5'SYH
M+@1+D)(%=S7.73ZGBNW;--L&HZOJ[8\/E#&:59=+@KGF$0;\_P6E[$M#O%#2
MO-,T^0=02P,$%     @ %X&L6NM_N8CP!P  (R,  !@   !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6RMFFUSVK@6Q[^*AKMSIYTIQ9+\ +D),VG23CNS>9C2
M[KYV; &^M2U6DDFRGWZ/;&*#)2MDA[YH#!R)_WG0^4G&YX]<_))KQA1Z*O)2
M7HS62FW.)A.9K%D1RX]\PTKX9,E%$2MX*583N1$L3NM!13XAGA=.BC@K1_/S
M^KU[,3_GE<JSDMT+)*NBB,7S)Y;SQXL1'KV\\3U;K95^8S(_W\0KMF#JY^9>
MP*M).TN:%:R4&2^18,N+T24^N_*I'E!;_)&Q1[EWC;0K#YS_TB^^I1<C3RMB
M.4N4GB*&/UMVQ?)<SP0Z_MI-.FJ_4P_<OWZ9_4OM/#CS$$MVQ?,_LU2M+T;3
M$4K9,JYR]9T_?F4[AP(]7\)S6?^/'G>VW@@EE52\V T&!456-G_CIUT@]@;
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MB"9)R7!,G2'*%!+I@(8.ZZW05>WL-8PJE':B05(['["!!",[\%BLE;&58BD
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M$2(O>!;SNPATEB:<)Y?-,G!*'3V?[LTXJTS>T&5_OR]>UPY&.A9^8@"633S
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M,'CE: '>TU= [0=2T/VBZLU_ %!+ P04    "  7@:Q:N><^7IH-  "<*
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MXOFD%_[EK<->UP^0KEJ_&,M5N>3?Q1G[]=;^>*QYVOST;F9_<;9=;G^WA],
M7:C)6&!KOS<9G5F#^9M*K_GW9W-=53KGRQ5PGBII =XOM*[\#1W0_"#QQ?\
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M;$A/8MU &)\S  WH8H]'9V\_?/Q1%MN?7I\])LI(;F7H(^PT AD1?KNMN*V
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M[N?)\ NTAC04LC\\.>X=/]P:$AKHU]D: IZZZV- U8<-SDAG@^C'@"3,=Y>
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M]RCX>H=!/9*PKUX)"]<((H13WUHLH>3J2>2 U-O@]6HI[Y1\KL_7J0BEG*;
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M1\/YP2 >B+L?P2[YBT)N0[ U7]+;$^5H 9Y7UH;N!RG8?&(Z^Q]02P,$%
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M%A( -P0#IJ>W/_0 1F*;^MNQ#*KKU*1WIG$);_= ]ED1[23T/+4#W--FY4_
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M<FMS:&5E=',O<VAE970Q-"YX;6R=5MMNXS80_96!6A0;P/%%OB:U#219%[M
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M$5=G[\_/WIW-9^<?Q6P^O_AT_O'L_+VXO/CY;'[V]DH\N32%SK1R/[PZ\!"
MR!QDD=EI8#9]A-FA^,54?NW$VRI7^7#_ 01/TD];Z4^G.PG^(NU8'#X=B>ED
M^FP'O<.DC4.F=_B8-NQ*5OJ+)(<9B;FI' Z;R^ _52XNK7*J\N&!68IWNI)5
MIF4AKO!0P5F]$_^:+9RW<+=_/Z2A(,#1PP)0"+YTM<S4Z[V:>-D;M7?R_7=/
MGT]^VG&\HW2\HUW43TZETX[D'IR##C8XZD-B_RV$Q45C15/))M=>Y2(S<(/*
MA4]Q%;XLDU)=I]2UO%%BH50EH)=:6JS3%>TC7-)^B[#Q:\1X9IK*ZVJ%91I$
MZD(YL5*5LK(HMO1>U3[L]6LE/E4L"!O/C82QXM/X:BS>SV:7(R&=<$!%, #E
MN*$S^*QCA>U5+FWNQ*G!/Z;S;G9U.GIXT=SD>JFSZ&18.[N:C\5'4/]SJL$Y
MBR97+%]40+"%S(B/.-7&(6"K#*H@DQ@88;,VI ^SJ4#5-0NG<RTMHGHLYLIZ
M@#G(!LAO+;DTQE?&*Y%KEQ7&-3"U\-L:)R%240I6+7%H3_(5:W8'A2(,+(D]
M01ETE+*6U9:T][<Y#1V&=VKGL880'9[+SD/Z>Z,R52Z4;4'E2/3X?H4;*:FU
M!50B9/X;\)O?C5J6=!:8QE306$7J+9#9LL9:>C'84$$2YY GA3=B*;7%#F;&
MVNT$J(W3P9-@#Z0B-CURMF7+,><2IU]3'H4V8#@\(U$SZ=9BB:3LR,7Y]-BE
M#?QWT7@!;4%"G^30;..<_19TP(1VM#PAXT()=5LCV9)^(D$<18/.5DE+]H4Q
MQ;+Q\)S("NXV@Z9TY96-UA: SLI)SME!IPM92';>SIRJT,B%9(KQ#EA\EF#Q
MV4[T^N3X/&]AGI* X"'\^V,4V(&#SZ5<\4CLWL.PA$!0[N^-IBAK6,&EO(9&
M$PM2C70HINJ@*K^6L-IR"0L$*"@#$D *(%B'>8_Z[B#@*-*9ZV-;QN*"< &N
MO#*T@0-I)#80\4863>NH3J\J1CO$6I)]%..$]OFU<>1'A>3@B!P#B:@Y7=V
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MGS=D.S*'@AQ7M-7]-*6:+IM/AJ:C166?Z?="4Y*SS8R^LE":!32_$D)O.^:
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MD.N1%WJ;C1E?I<9N^.-AP5;X@.:QN%>T\AN4A&>8:RYS4+@<>9/PZJ9OY9W
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M1$Z'M^(V*XGVU,9#=*K5_F/UP!;4DDN372^P].(,1G.)N'<N[$3L^&:/"&4
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MB(Y^C+<$R53,1D%@%.@:!T]CT_3/B8M0@X ,PA#N*3:UM<$"/#++ON\2-X[
M]TD8Q'#-:B8Q%6-#,Q0?-ZUAIH@U//?!]XCO13"K&LJEC9$65.:(ZX7$=5WX
M^"'Q/?\33 M:YPS+""NTA#4M6TMDBK7!P-93X*3+F F TZKG)21VW5/HQ7B9
M5*8]?VP_H1M-O[=<8CEYK1&8HSZQ\(II!4'D$W?@0TA"-X([)%4:]D3%"-0X
MY'%K80P!\9(!S.Q[T/3)$+[F=M+V M<_?4D<LQ(ESZC&:,;?] /T!GZ$E0I-
M>@GQXN3T2(.'78.'/]W@BQVSRV=D0>22-@5/L<E36X)#C7X4^[ TWW2_:&77
M3Q@U?XE:[J+^FNZ>5$RB>A2<@!>1P W,(B91G,!5*_%G2^"&9QF6X8IBEYO>
MFZR,!YP3?^!"0H(P@HGB]+<Y38T2P?-(A-KP?!)C\V[E<[(7SLE>.D<8BCJ&
MHO_#T!2;(Q?R^1 M1P'_.RWI+M2OX6)6HZ!;J]M]C!-331<UC0L<%VAI%-!6
MYA?8&5GUQT;CYZ@B',)9F[Y 8$C/PXEE)L YCFJYYBFS1 JKQKT=*@CY#$CB
M>O^:>3]'7O_57Q^;*K=G&X5SI*WU]@#0O>V.3Y/MJ>'%?'OVPEKEO%90LA6Z
MNF<QJDENSS/;!RT:>X98"HTG$KLL\ C(I#' [RLA]/[!!.@.E>-_ %!+ P04
M    "  7@:Q:'6)^Q.@"  #E"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6R]5FUOVC 8_"M6)DV;U)&0\+8.(J6A[2*U@*#=I$W[8,(#6$WLU#;0
M_?O93LB@"IDJH7T!V_&=[\ZO_1WC3V(-(-%+FE QL-929I>V+>(UI%@T6 94
M?5DRGF*IJGQEBXP#7AA0FMBNXW3L%!-J^7W3-N%^GVUD0BA,.!*;-,7\]Q4D
M;#>PFM:^84I6:ZD;;+^?X17,0#YF$ZYJ=LFR("E001A%')8#*VA>ACW=WW3X
M1F G#LI(.YDS]J0KT6)@.5H0)!!+S8#5WQ9"2!)-I&0\%YQ6.:0&'I;W[#?&
MN_(RQP)"EGPG"[D>6#T++6")-XF<LMU7*/RT-5_,$F%^T:[HZU@HW@C)T@*L
M%*2$YO_XI<CA *!XJ@%N 7!? SHG %X!\(S17)FQ-<02^WW.=HCKWHI-%TPV
M!JW<$*IG<2:Y^DH43OKCZ6TPBGX$#]%XA(+1$,VBVU%T$X7!Z $%83A^'#U$
MHULT&=]%870]0Q^&(#%)Q$?T"05QS#94"C2%&,@6SQ-0K:%1#1R%C,9 )<=F
MPJ9$//5MJ33KD>VXT'>5ZW-/Z//0/:-R+= U7<"B A_6XYMN#8&MPBH3<_>)
M7;FUC/>8-Y#7O$"NX[:K!-7#AQ"7\%:-'*^<0,_PM4[QJ:B%)'$9NZ@*N99#
MGQ27(L,Q#"QU% C@6[#\]^^:'>=+E<$SD1W9;95V6X;=.V%WEI\V:+Q$,[*B
M9$EB3.5^)1*Z0A.6D)B 0#_O%!9%$E+QJRJ3UCDS.1/942;M,I-V[1(XWF=<
M[;,+E '7;>H@KK*>\WTV?/J<W_I.P^OT[>VAI7]T.I+:*:5VZJ7NSX8QK116
MBW[KG)R)[,AHMS3:_5_KM'O.3,Y$=I1)K\RD=^9UVJM8@LU7R[1VS+<ZL@]N
M4K5,5^:!(9"9M/Q2+5O+-TQ@KF[[;_?\ :3NB16A B6P5%"GT57[B>>/BKPB
M66;NY3F3:D^8XEJ]PX#K#NK[DC&YK^@!RI>=_P=02P,$%     @ %X&L6JC\
M6:JG!P  Z3L  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULM5MM;YM(
M$/XK*U]5]:1K# N[V&EB*4VNNDA)5,5)[S.Q-S$J+RY@IY7NQ]^"J8<U>/#B
M33\T?IE]_ P,/,\,</::I-^SA1 Y^1F%<78^6.3Y\G0XS&8+$?G92;(4L?SF
M.4DC/Y=OTY=AMDR%/R\71>&06A8?1GX0#R9GY6=?T\E9LLK#(!9?4Y*MHLA/
M?WT68?)Z/K 'OS^X#UX6>?'!<'*V]%_$5.2/RZ^I?#?<HLR#2,19D,0D%<_G
M@PO[]-*CQ8(RXEL@7K/::U*D\I0DWXLWU_/S@54P$J&8Y06$+_^LQ:4(PP))
M\OA1@0ZVOUDLK+_^C?ZE3%XF\^1GXC()_PWF^>)\,!J0N7CV5V%^G[S^(ZJ$
M6($W2\*L_)^\5K'6@,Q669Y$U6+)( KBS5__9[4A:@ML=\\"6BV@ARYPJ@5.
MF>B&69G6E9_[D[,T>25I$2W1BA?EMBE7RVR"N-B-TSR5WP9R73[Y<GUW<7=Y
M?7%#KN^F#_>/MW_?/4S)1S*5]3)?A8(DS^0BRT2>$3^>DYO ?PK"( ]$1FZ%
MGZU2,2=^3K[X04J^^>%*+I#[AMR+V2I-@_B%?/:S(",?KD3N!V'VIX1^G%Z1
M#^_^).]($).'1;+*)')V-LQE.@6IX:RB_GE#G>ZA?NNG)\2Q_R+4HJQE^26^
M_$K,MLM==?E0;L3MEJ3;+4E+/&</WF8KM:6Q6>>VKRN.T]-LZ<_$^4 >B)E(
MUV(P>?^'S:U/;4D9 E-2=+8I.ACZY-+/%F49S(H7XL<J6/NAB-NSWD#Q$JHX
MF:PG;,0L[VRXKJ?3$L4<S]I&*3S=+4\7Y3E=)&G^,1=I),\T69X&LUQL2+<1
MW6"Q&@4^MG9HXC$*2;8ER5"2-TG\<C!'UOA]FSETAV1'D,*2;UERE.5#DOLA
M\3=G@*AVQ#\71_RZ..+;^/(&%<=E3H-Q2]B82M+MG+TM9P\]$FLGJ39NGLG#
MT1"8DN=HF^<(/QR3.)>G6'D DEDBA74N4K_0QK:D1XTMO5OBS0A[Y%E[BGR\
MI3@^H'S"FFH<7D/C3LK-"(2R;8$D6BCIZW@MC\BH.+&=MLH2NERW@DRAJ<G6
M]-_N*5O50E-I&D)3TP1QME%A[-ZGM%%+=.1RR]DIN98X1Y[:N+VGZ$!:[0YM
M3=)E(H]?(4WH4TZRPD#M/87A6-J[QA":FCF(M>WVK4!4YK73-(2FI@ER;^-Z
MWUF!3?EV1E[#B;2$N=*+L#WU!SIOXT+_>#(](2_)6J1QP9&\]Z/E)R([N7CV
MJZL:463MW60(3=T.X!ULW#P@U6C4.)A"4],$ZV#CWJ&S&IMV@+IL9#?.ARUQ
M(X\SOJ<>P3C8N'.X$6L1$KN5&[I2>T<80E.;1C ;U.K;-AJU&:;0U#3!9E!4
MW_5:QPI+.<?1,=OM'EK"D.:1UAIYW"OHM8^TZ0B:_6-'D$H4/ /%/8-6"UEA
M=?2075$J4]!XBG?D/=M(VNR[769[[B[I9ACSV'@?:Y!LRHYI)"DJ^-H'J"$T
M-5?0?XKKOTXS29M]>Z/@L1"5(D@S137QJ&:R@D8I8R$J99!9BLMLI6+D/](E
MN#B0=C$90E/3!O&FX[ZB9E2[3:&ITU#0;N>X04&U'"LZ-$2E!5KKX%H+1:?5
M5.*HNKO&%)JZ#4##G;[3>,?H.-X4FIIF;2"/.X#."FS*>:,"L1"5%LB]@\L]
M5. 1;27^&]H[ZBVZ?P>LA(-;":0>C;H(4VAJFN B'-Q%=-9CMW- 0U1:X!P<
MW#ELZI&V,C+:U9M"4_,$N^&,^E:947MA"DU-$^R%@\\&]*Y#MEPE8/+?;MEA
MEQO4JY#@#US<'VA>A^QV"VB(2A+<@MOA%G2:2+?9<C<X8B$J1U!S%^_(>[:/
M;LNPWK)L-MJEK#?4=T&>7>>8!M(U.L8WA:;F6KOFCFN^3@/I-AOV1AEA(2I%
M$&$7'\$?TT"ZS;E[@S(6HE(&075Q0:V4ZX &$@?2+J:WF,*[(-ANWRF\:U2O
M3:&I:8)>N\=-X=VVZ7K+5<F6./0$!DKK'C*%I[JM)(ZJO9/>HLMGH.*L[X2>
M&9W0FT)3TP0?P' ?T%6+K*GK;=<G6\*0ZY,,+ ##+0!4XA$M)?X;VCOL+7I_
M!N:"X>8"J4NCOL(4FIHF^ J&^XK.NFP:A=8KE6UQR)5*5KN/K^-&OK(RG59N
M1GM[4VAJGF!%&.];;T:MARDT-4VP'@R?%6@UEZS[L@(:HG($W\!PWZ#76++N
MF__0$)4D> ?6X1VT;G#MOML/#5%O;@5MYWB'WO?VUNY6'0U1V8)$<_Q>O8YV
MDAL=X)M"4W,%O>>XWNNTD[S9OS=V1S,$N5>4@PAS? !_3$O)NX?S+2$8;1!5
M?LB WCF@K<2!M(OJ+:;P'*2:]YW"<Z-*;0I-3;-VS_YQ4WC>/85'0U1:H*S\
MD"F\H]M,XJC:N^8M.GX.RLW[3NBYT0F]*30U3=!^CFM_9P5VRST:HCX7 G+O
MX7(/%7A$$XG_AO8#)&_1]7M@*;R^M_][1MV$*30U37 3WG&W_U?+.5*/:,B&
MUK#V'&;Q$.RMG[X$<49"\2S76">>+.9T\USIYDV>+,M',Y^2/$^B\N5"^-+J
M% 'R^^<DR7^_*9[VW#[=._D?4$L#!!0    ( !>!K%HLH1%.B00  $$;   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;+6976_B.!2&_XJ5':UFI&[S
M >&C"TB49+1( ZI*NWNQV@LW,6!-8C.V ZVT/W[M!!)"4[=9>6Y:8O(^QWY/
M./C@T8&R[WR+D #/:4+XV-H*L;NQ;1YM40KY-=TA(M]94Y9"(2_9QN8[AF"<
MB]+$]ARG9Z<0$VLRRL?NV&1$,Y%@@NX8X%F:0O9RBQ)Z&%NN=1JXQYNM4 /V
M9+2#&[1"XG%WQ^2575)BG"+",26 H?78FKHWH=M7@OR./S$Z\+/70"WEB=+O
MZF(>CRU'S0@E*!(* >6_/9JA)%$D.8\?1ZA5QE3"\]<G^M=\\7(Q3Y"C&4W^
MPK'8CJV!!6*TAEDB[NGA#W1<D*]X$4UX_A<<BGM[0PM$&1<T/8KE#%),BO_P
M^6C$F<#MOB'PC@+O4N"_(>@<!9V/1N@>!=V/"ORC(%^Z7:P]-RZ  DY&C!X
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M",HTJAOD^VM*Q>E"!2A/S2;_ 5!+ P04    "  7@:Q:0)-/"68#  "1#
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6S55UUOTS 4_2M60 BD;4F_
MN]%&6KM-5-JFJ=W@ ?'@)K>-A6,7VVGAWW/MI%F[90'&>."EM1W?<\\Y-[9N
M!ANIONH$P)#O*1=ZZ"7&K$Y\7T<)I%0?R14(?+*0*J4&IVKIZY4"&KN@E/O-
M(.CZ*67""P=N[4:% YD9S@3<***S-*7JQPBXW R]AK==F+)E8NR"'PY6= DS
M,'>K&X4SOT2)60I",RF(@L70.VV<C!LNP.WXR&"C=\;$2IE+^=5.)O'0"RPC
MX! 9"T'Q;PUCX-PB(8]O!:A7YK2!N^,M^H43CV+F5,-8\D\L-LG0ZWLDA@7-
MN)G*S0<H!'4L7B2Y=K]D4^P-/!)EVLBT"$8&*1/Y/_U>&+$3@#C5 <TBH/DP
MH/U$0*L(:#FA.3,GZXP:&@Z4W!!E=R.:'3AO7#2J8<*6<684/F489\*+R?7I
M]7AR>DDFU[/;Z=W5^?7MC!R2&;XO<<:!R 49)U0L01,FR+DV#+V#F%Q0ILA'
MRK-\BQ2&X29A[%"S&!1U97I[!H8RKM\AYMWLC+Q]_8Z\MDBWB<PT%;$>^ 9U
M6#9^5' >Y9R;3W!ND2M,EVAR+F*(]^-]U%^:T-R:,&K6 EY1=41:C0/2#)J=
M"C[CWP]OU]!IE35I.;S64S4IK3T@EXS.&6>&H?]70'6FT'OT=0I1IA1:3D94
M,WU [H2<:U!K.L>B3<0J,W:/%!%&NU(<D#'E4<;SNGR>2LX)GH0-5?&7JAKD
M'-O5'.WM<J)7-(*AA]>'30Q>^.95HQN\KS+PA<#V[&R7=K;KT,,1+)D0UJHY
MY51$4*4VA^@Z"'OUK<-&OQ<$ W^]*Z,VT3-E=$H9G5H9^2FT1V=AWX_U]NA%
M]T<OVCUZ52KS#)T=E8=5,CN/S#CLW>_98]\MV7=KV>-1_44%NH^X/:15F^&9
M[O=*_KU:_I>P!DY:5<1K __TH+P0V)[&?JFQ_Q_<._V7M/.%P/;L/"[M//[[
M>^?XT5M?=2!K$SU31B.X;Q&"?W[S%"E^>?744WFNU)UNJ/&7UU0!T*VYI^IS
M_*D&?Z>Y2T$M7<^KT?%,F+S%*5?SOGID^VK;'#Y8QW[[U'69_CU,WJQC X.O
MJB8<%@@9'/6P3"KO?_.)D2O70LZEP8;4#1/\9@!E-^#SA91F.[$)RJ^0\"=0
M2P,$%     @ %X&L6LE?6[<J!0  Y!H  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&ULO5E1;^(X$/XK5FZUVI66$MM)"%U ZM+M'E);5:7=>SC=@PLN
M1)O$K&U@]W[].2%-2.*XC9KK"\3PS?CSV)YO1AGM&?\AUI1*\"L*8S&VUE)N
M3OM]L5C3B(@3MJ&Q^N>1\8A(->2KOMAP2I:I413VD6U[_8@$L349I;_=\,F(
M;648Q/2& [&-(L)_?Z$AVX\M:#W]<!NLUC+YH3\9;<B*SJF\W]QP->KG7I9!
M1&,1L!AP^CBVSN#I%*/$($5\#^A>'#V#9"D/C/U(!K/EV+(31C2D"YFX(.IK
M1Z<T#!-/BL?/S*F5SYD8'C\_>;](%Z\6\T $G;+PKV IUV/+M\"2/I)M*&_9
M_D^:+<A-_"U8*-)/L,^PM@466R%9E!DK!E$0'[[)KRP01P;0:3! F0%ZJ0'.
M#'"ZT .S=%GG1)+)B+,]X E:>4L>TMBDUFHU09QLXUQR]6^@[.3D8G9]=CV=
MG5V"V?7\[O;^ZNOUW1STP%R=E^4VI( ]@BD1ZT_I)_CZ<QOL2$AC*0")EV 6
M[ZB043K^<$XE"4+Q49G?S\_!AW<?P3L0Q.!NS;9"H<6H+Q7E9.+^(J/WY4 /
M-="[(OP$8/@)(!NY&O.IV?R<+G)SIVS>5X'*HX7R:*'4'V[P=QR5LYU:+'D(
M:4]=IIY000%SNMCR0 94@+\OE2F821J)?W3+/LSCZ.=)[NZIV) %'5OJ<@K*
M=]2:O/\#>O9G71 Z<E8*"<Y#@DW>)V<1XS+XER[!E FI6^K!WDOMDZRRFV '
M#=!PU-\=+T(#\X>N7<!*])R<GF.D]XTS(< V5BDN3%FN5&K3'L2#'_=H?L?%
M%8YUC&<C/4$W)^BV(QBJ,=4R=&NS]P:HPE"#@;ZMI^CE%#TCQ0L2</"=A%NJ
M8^759L0.AM"N$-/ _.$00SVU04YM8*0V7ZO3UY.41TI3A.3!0JH0+E2JTE$=
MU+=O6.5IQI1(^CE)WTCRDL6K%W/T:_-#%U=W^1E0B>4P9SDTLDSS>Y+3$V:
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M:W-H965T<R]S:&5E=#,S+GAM;*V674_;,!2&_XJ5H0DD((F3-(&UD4H+ FE
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M5*IJO^0B7G7OD YU'* T'TH+H#0*I3$HC:-HNO@:Q\%]@3=%N%"W 4KSH;0
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M")Z1T()K*4RB82IBC'^T=\F=RJ=@[],H: 2\9NH,6OX)!%[0A@_S"1P?O6K
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M69=<5F4?+B=&YD7O6TA#G;08)O3M@LH>H/VEE&8_L035UU#X'5!+ P04
M"  7@:Q:ZM&7%SP$   ^%0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6RU6%UOXC@4_2M6=K1JI6T3)R1 %R)1H#N5VDXUM+L/JWUP@P%KDIBQ'6A7
M^^/7^6A"P+@%A1=(R#V'<V_NC4_<6U/V@R\P%N U"F/>-Q9"+*],DP<+'"%^
M29<XEE=FE$5(R%,V-_F2833-0%%HVI;EF1$BL>'WLM\>F=^CB0A)C!\9X$D4
M(?9VC4.Z[AO0>/_A.YDO1/J#Z?>6:(XG6#PO'YD\,TN6*8EPS F- <.SOC&
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M4=_=&#E?X5]X/XI[".]@HK=(H5J":@+5)*HI5-.49H?\8*5 >*E =JU =K%
M=K5 =KE =KU =L% =L7 OZ(!ZYL&K._9@%UZH;_;]4YV6UCUCPJK_OCHDJ<8
M'3=!-8%J$M44JFE*LU-K"K"^NP#SNB' ;7DGM>.^K#,W!* #)Z@F4$VBFD(U
M36EV5$WQU?>\D\K[8E7W -[Y;6^5.KJ\=# :AL>7!\3HR FJ"523J*9035.:
M'6#3<_4O62UP%]']30&/RUP>K'U9^BQ^Z1[0.]![[7 IQRA\?C)M0!LN5!.H
M)E%-H9JF-#O*IN'JNQNN]]D\6]]7CU%^=G#K2V=0T:*KU::'E[@<IQ1MKU!-
MH)I$-85JFM+LE)H.K'])!W8P8]B=U6V?$%-/&=)5MIFG13!/_^@^O*+EV!,[
MVQ_USNU(C.Y(@FH"U22J*533E&8_D\#490//F[4>SRS4DX?J+@NRK]G^!5R;
M\."GM S2AR-S]_,*T$:MU8XOENU%QW,(=-@$U02J2513J*8IS<ZSJ=P&3U1N
M\_FRF4&D*R3):!/7:B=)/@DRVK&AFD UB6H*U32EV4$V?=W W=?YWZOC!KW#
MBK9SJ)8,3F_*BL:C4==U7^C $M44JFE*L_-JJK>!^]ZR>/]@F(=7<,^.EBV8
M'9VFZ PPVL:UFO5Z[N2\ SID@FH"U22J*533E&9']^#!7!>4;(?1K8IT=]78
MN9=P;L\[J.Z]B\Z_@D/W(T$U@6H2U12J:4JSTVO*MH&[;#M);WVH+;/9=G>;
MY)-)1LNW)_:T[T@RVL6AFD UB6H*U32EV4DV7=S LXOSN-W737L'^<R"A<<-
M'#IJ@FH"U22J*533E&;'UC1P W<#YWME9?VNWY:;Y7J[[@PRVKZA6HQJ":H)
M5).HIE!-4YH==]/2#?;]"G6-Y0!MZ5 M1K4$U02J2513J*8IS0ZT*?0&?VVA
MY^:] ^[>V7 2GI]$HX4>J@E4DZBF4$U3FOV89E/H#=V%WI^9C:3?S\U&W(/Y
M9AO58E1+4$V@FD0UA6J:TNRXF[YO&**SD2':Z*%:C&H)J@E4DZBF4$U3FAUH
MT_L-W;W?C\Y&W+QWP-T[Z[J\"-V1!-4$JDE44ZBF*<U.LVD%AT\]!<U[-K+[
MX^"JYH]9L2Z#WS>=I_W<PWNG';V!#]425!.H)E%-H9JF-/L;P'2+PP$[/T&K
M152+42U!-8%J$M44JFE*LP-MZL;A!77CC\Q/T,;QB9T-)X[Y"5HYHII -8EJ
M"M4TI=EI-I7C\ ?6O?29GWS\UGESH'MX[[2CRV2B6H)J M4DJBE4TY1F?P.8
M\G+(+I,Y1.M)5(M1+4$U@6H2U12J:4JS VWJR:'[)L(?GI^@=>43.]L?G6]S
MT!U)4$V@FD0UA6J:TNPTFVYRZ*[[HEXT]5J7V^UYQQ=].ARJ):@F4$VBFD(U
M36E6HD>FGQSUT G'"&T@42U&M035!*I)5%.HIBG-#K1I($?(T^)&ITM=]KN>
MH''K'LX[HFBGB&H"U22J*533E&9'U'2*HTLZQ<.(/@N::7!6!)^S[GG$Z/0Q
M9%%G6M';!%$M036!:A+5%*II2K/3:CK#D;LSO#UY2/=]^D=:O]694[0 1+48
MU9+1Z0/JHK#?]5!/@0XL6\TZ%(2#KJ.!0@?6E&;GT%1W(V>38N6PW+_LVL7Q
M6;#)Z@/H)M_\,ML613V)[0PF6N2A6HQJ2:O9P>QU!Q-MZ5!-H9JF-#N[IJ4;
M/?$(NMFLV&;S(/M^GVW*,S_BT28.U6)42T:GBX+V.Y\2@PXK44VAFJ8T.Y^F
M=QL]U;LYSFM=N!J]>PCO_*+=&JHEJ"903:*:0C5-:7;(3;<V8KNU$=JMH5J,
M:@FJ"523J*9035.:'6C3K8T\N[5+5Z-OW9/[J8?'9Q/0N_M0+4$U@6H2U12J
M:4JS,VL:M)&[0?-:BWYT^JBY_>O<CA-?:#6&:@FJ"523J*9035_TY;=R.#:]
MU_B"A3;-*EC/V@6X=Z=EZT-HLU;W_CW- MWG%^<>GSY*+>H-AN%P?!Q0]_[X
M!A35$E03J"913:&:IC0[PZ;J&KNKKH]WM7J7K^9'B[N553[[TBX_7Q7+Q2(K
M.K.[UYTKLMVZ=\$[MFC]A6H"U22J*533E&;'UM1?8\];ZKR?\=$.$ [L^6M[
MY#U.,%J)H5J":@+5)*HI5-.49B?85&+C2RHQ\B$?[8"'C^48/)],CZ.,]F&H
MEJ":0#6):@K5-*7943:MVMC=JIDYQ.':A'5>YYTQ[>B63B:Z:#>&:@FJ"523
MJ*9035.:'5)3GXW=]9D)Z;G%-,\&=GAZF==)8-&J#-425!.H)E%-H9JF-#NP
MID\;N_LTWT<GM9SC84>W[A&]4XH68J@F4$VBFD(U36EV2DTA-G:OE/FC]^8\
MP3M6([EU;^J=9K0-0S6!:A+5%*II2K/3;-JPL;L-\[V&P7=M$_?POG4PJL6H
MEJ":0#6):@K5-*79WP"F6AM/T>L;QNB]::@6HUJ":@+5)*HI5-.49@5Z8CJZ
MB>?#\#SG)T_PCM5(;MV;^J89U1)4$Z@F44VAFJ8T.\VFK9M<<F,:^VC'R9E'
MV!T_C/'6O6_>>49K/%03J"913:&:IC0[SZ;&F[AK/&R^?6:M'O?POM,35(M1
M+4$U@6H2U12J:4JSOP%,"SCIH_/M"7IO'*K%J):@FD UB6H*U32EV8$V7>#$
MW07^\'S;S3M6U[EU;^J=9K0T1#6!:A+5%*II2K/3;$K#R1/WW*&/GFX'>^IA
MT;?NG?(.,EHFHII -8EJ"M4TI=E!-F7BA+TYSS71=C_LS+TCWC,4M+%$M035
M!*I)5%.HIBG-_E8PC>6$O85O@M["AVHQJB6H)E!-HII"-4UI=J!-:3GY:Y?'
M?()W/)[LUKVI=YK1!A+5!*I)5%.HIBG-3K-I("<_L#SFGYBIG'\0FGM'O _L
M:'>):@FJ"523J*9035.:]:TP-=WEE%U7<XJNJXEJ,:HEJ"903:*:0C5-:7:@
M37TY]:PO/6<J3_"NBP7=FWJG&2TO44V@FD0UA6J:TNPTF_)RZBXOD^^SNW2S
MR(*/1;HITUESHK SM6@)B6HQJB6H)E!-HII"-4UI=I!-"3EE2\@I6D*B6HQJ
M":H)5).HIE!-4YH=:%-"3MTMX9N\+(/ZA6#VO5IN%MME>;=^+&NZ%YYS@]Z1
M1IM(5$M03:":1#75:AU+O]A]FZ:&M=-J2L:INV3LFD=<N%ZB6_:.+=H[HEJ"
M:@+5)*HI5-.49F?;]([3$3NU0-M#5(M1+4$U@6H2U12J:4JS VW:PZG[AL1W
MZ7(>I.U2S)^V5;#=W#?O>K@\I#/4XY,?1.&D:P&ZC@^,NA;=CMT[Z1U%M/=#
M-8EJ"M4TI>VC>%W>95D5IU5Z\W*=%8OL-ENMRF#6K'#8'& /WAL4V>?Z_R9\
MH<*KZY/W)^$+T?7^7\,7OT;-^Z\-?_/R/EUDOZ7%8KDI@U7VN1ZJ][RY\[U8
M+NX>WZCR^U=7X57P*:^J?+W[ZUV6SK.B^8#ZWS_G>?7P1C/ M[SXLOMT;OX?
M4$L#!!0    ( !>!K%K4/H5_G (  .T%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;(54VV[:0!#]E9$;58G4Q& N:5.P%"Y5D1(209(^5'U8[ &O
M8N_2W3'0O^^L[;A4!?IB[V7.F7/LF>EMM7FU"2+!+DN5[7L)T?K&]VV48";L
ME5ZCXINE-ID@WIJ5;]<&15R LM0/&HVNGPFIO+!7G#V:L*=S2J7"1P,VSS)A
M?@TPU=N^U_3>#F9RE9 [\,/>6JQPCO2\?C2\\VN66&:HK-0*#"[[WFWS9M!U
M\47 B\2MW5N#<[+0^M5M)G'?:SA!F&)$CD'P:X-#3%-'Q#)^5IQ>G=(!]]=O
M[%\*[^QE(2P.=?I-QI3TO8\>Q+@4>4HSO?V*E9^.XXMT:HLG;*O8A@=1;DEG
M%9@59%*5;[&KOL,>( B. ((*$!2ZRT2%RI$@$?:,WH)QT<SF%H75 LWBI'(_
M94Z&;R7C*!P^3%_&LZ?)X&X,\_%T\C"#Z</3> Z7,.<"B/,402]AF BU0@ND
M@1*$H!%\@JDF/CD?(0F9V@M&%,=#K39H2"X8.4<EM:DBST J>$IT;H6*;<\G
MEN]$^%$E=5!*#8Y(;<&]5I18&*L8X[_Q/MNNO0=OW@?!2<)[8:Z@U?S@='?@
M>3Z"\[.+$[RM^INV"M[6$=X1+@@FRI+)N7P)OM]Q $P(,_OCD.V2K7V8S77E
MC5V+"/L>MYU%LT$O?/^NV6U\/J&U76MMGV(/![B22DFUXMI.A8KPD,"2HEM0
MN"[?A$&SS6W?\S<'4G?JU)V3J;E0R'!7YB+ERB!D<P2XXW%C#ZHHV3I[*BZO
MCVGHUAJZ)S5P*?W'>_> ]U;GG[S^7@MF:%;%H+$0Z5Q1V8WU:3W+;LL6_A->
M#D(N2_XG%E)<,K1Q=<V633E<R@WI=='0"TT\'HIEPO,8C0O@^Z7F?JLV+D$]
MX</?4$L#!!0    ( !>!K%K7G^= QP(  #D'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;*U576_:,!3]*U963:VT-B%?73N(U +3D#J*H.T>ICV8
MY )6$SNS'6CWZW>=I!&E@6W27A)_W'-\SK5]W=T(^:A6 )H\92E7/6NE=7YI
MVRI>04;5F<B!X\Q"R(QJ[,JEK7()-"E!66J[CA/:&67<BKKEV$1&75'HE'&8
M2***+*/R^1I2L>E9'>ME8,J6*VT&[*B;TR7,0-_G$XD]NV%)6 9<,<&)A$7/
MNNI<]D,37P8\,-BHK38Q3N9"/)K.*.E9CA$$*<3:,%#\K:$/:6J(4,;/FM-J
MEC3 [?8+^^?2.WJ94P5]D7YCB5[UK(\626!!BU1/Q>8+U'X"PQ>+5)5?LJEC
M'8O$A=(BJ\&H(&.\^M.G.@];@(Z_!^#6 /=O 5X-\$JCE;+2UH!J&G6EV!!I
MHI'--,K<E&ATP[C9Q9F6.,L0IZ/^[?AA.+T;7=\,R6PX'MU.R?CV;C@CIV2&
M)R8I4B!B0<9XGOI4RF?&E^0J$P77Y'@ FK)4G6"LZW@.Z0N^!JG9'#$SX$Q(
M,A8:%,[?SP;D^.B$'!'&R=U*%(KR1'5MC1:,$#NNY5Y7<MT]<K]2>4:\S@=<
MT U:X/W#\ '$#=Q_#;<Q<4WVW"9[;LGG[>6;:S+B2LL"3[8FWV\P@(PT9.I'
MF[F*S6]G,Q?V4N4TAIZ%-U*!7(,5O7_7"9U/;5;_$]DKXUYCW#O$'DTDXS'+
M:4IH>1C:S%8,8<E@BLDZ\OV.XSA=>[UMXX]AKP3ZC4#_H,![CL+P+/Z"!&\U
M[A(F(6-%UB:T8@JV%7C^CLJ6F,!KEQ@T$H-_D\B4*BB/@<1"Z=;+$;Q1<1J<
MN[L9;8NZ""[:U8:-VO"@6E,!XI<*L'_3P[>[Z07GG=UTMH;Y%_Z.1GNKL)E'
M!:__DG%%4E@@T#D[1Y.R*M151XN\K'5SH;%RELT5OFT@30#.+P06I+ICRF?S
M6D:_ 5!+ P04    "  7@:Q:D),00TT#   )#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6RU5FUOVC 0_BM65DVMM#5OO': 5"C3D/JF0KL/TSX8
M<D#4Q&:V ]U^_<Y.F@(-62ME7Q+;N7O\/.<[YSH;+A[E$D"1ISABLFLME5J=
MV;:<+2&F\I2O@.&7.1<Q53@5"UNN!-# .,61[3E.PXYIR*Q>QZS=BEZ')RH*
M&=P*(I,XIN)W'R*^Z5JN];QP%RZ62B_8O<Z*+F ,ZGYU*W!FYRA!& .3(6=$
MP+QKG;MG ]?3#L;B(82-W!H3+67*^:.>C(*NY6A&$,%,:0B*KS4,((HT$O+X
ME8%:^9[:<7O\C/[5B$<Q4RIAP*/O8:"67:MED0#F-(G4'=]\@TQ07>/->"3-
MDVPR6\<BLT0J'F?.R" .6?JF3UD@MAP0I]C!RQR\?8?: 0<_<_"-T)29D75!
M%>UU!-\0H:T130],;(PWJ@F9/L:Q$O@U1#_5&]Q</PSO)J/^Y9",A]>CFSMR
M?3,9CLEG,L:4"9((")^3$5,@0"HR?,($DD".+T#1,)(G:'@_OB#'1R?DB(2,
M3)8\D90%LF,KY*=WL6<9EW[*Q3O Q2=7G*FE)$,60+#K;Z.N7)SW+*[OE0)>
M47%*?/<3\1RO7L!G\';W6@D=/X^U;_!J!_ \QW?(@+,U"!5.,;!C8"$7Y)HK
M* Q7*9PN\#.YHC/H6EC!$L0:K-['#V[#^5*DM2*P'>6U7'G-H/L'E%_ 5&$.
M2242O (4^7&)!F2D()8_BX37JA1>$=B.\'HNO%YZY'C:2N!5E= (BR.K(4AK
MJ$AXBM8P:/H&7O?<NMOHV.MM045&OI\;[1!MY$0;I43/8XY)^8>:NQ4+/M G
M%DJ94#8#,N-2%69H"EK?HN+Y[3VZY38[;)LYVV8IVPE7;PQH\]7F;K->WV-8
M9-3TBBFV<HJM?Q2[UWI7L9?"O3?G*P+;4=[.E;<K+?9VE<(K ML1[CHO/U.G
MTG+/X+8SS]G+S0(3M^FYQ<GI;OWVW?]1[QEJ*>'7)JU#=+T7NEY%!9\!-<H8
MOC9Q6\Y^O=M;354,8F%Z38FA29A*6Y!\->UG^[J?U4W9WCKVN>>FN[-?8-(F
M&1N,1<@DB6".D,YI$X,FTKXSG2B^,JW;E"ML!,UPB;TZ"&V W^<<;Y-LHC?(
MN__>7U!+ P04    "  7@:Q:]\+)N/,$  #1'   &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6RUF6]OJS84QK^*Q:ZF>Z5["]@D3;HD4O]MJ[1N5=)N
M+Z[VPH73P"[@S#9-KK0//QLH3IO@IJB\:8'@PW..'_MG\&3-^#<1 TBTR=)<
M3)U8RM6)ZXHPAHR*([:"7/WRP'A&I3KE2U>L.-"H;)2E+O:\H9O1)'=FD_+:
M#9]-6"'3)(<;CD21991_/X.4K:>.[SQ=F"?+6.H+[FRRHDM8@+Q;W7!UYC91
MHB2#7"0L1QP>ILZI?W(6>+I!><>?":S%UC'2J=PS]DV?7$53Q].*((50ZA!4
M_7N$<TA3'4GI^+<.ZC3/U VWCY^B_UPFKY*YIP+.6?I7$LEXZHP<%,$#+5(Y
M9^M?H4YHH..%+!7E7[2N[_4<%!9"LJQNK!1D25[]IYNZ$%L-,&YI@.L&N-1=
M/:A4>4$EG4TX6R.N[U;1]$&9:ME:B4MRW2L+R=6OB6HG9_/+Q>W\[OSV;G[U
M^R_H"UJH;H^*%!![0#<<OMS2#9J#D+P(9<&3?(G.8\J7(-#'"Y T2<4G] $E
M.;J-62%H'HF)*Y4N'=T-:PUGE0;<HH&@:Y;+6*#+/(+H>7M7Y=,DA9^2.L/6
M@->4'R'B?T;8PP-TM[A 'S]\LL0E3;%(&9>T%>MY(9B02&6LZP/\$=#7W]3]
MZ$I")O[>5X4J>+ _N!Y^)V)%0Y@Z:GR5$9W9CS_X0^\GB_2@D1[8HK^47O7A
M9[205,F%7.K^OLI#EJF>YRJU3&F(]>!3>=77OUYNI+YRK]QQF1<9<*H'UMY4
M[6+*RJD'<GB$O !+>H,FO8$U8MG1SW+<I\H:HV,'#!N%PSZ],^Q!^G$C_=A:
MW-,H2G1/TQ3!1N% @.JYD/&=P5I)K8(-RV :"H^S8!B,)^[C'@FC1L+([I@B
M*U*J)W!$,U8HOR9Y6' .$9(,1<K$^Y14,0<'*1DW2L:O.2UXW6G6&!V[R_?,
MG.[UZ;4Z^CNKWR*2_YYVJZ-M]_+X>+"_DWUL1. >#%<'W=:"A_[XN$6-X8YO
M9<.+#@V?9F_8A&D1Z4LT^D>M%?1$OI^_9$>7[WE>BRS#%-\^CR]HJF4L(5<L
M2$N/T4@M4A*EMJK=?^BP\6)_4%?+&7KX@UX'3!]@\0U9?.OLW]6KPUU/#,:M
MIC"P\.VTT$6C/(S+"D:*\"E;E2N,@[U@C=^UFH8T_JA7+UA!UE6]H9-OQU-'
M+XQWO-!N!6PXA*VD>+G..]@!]K =:X@-@+#?IP.P%6]=U1MRX3[(A7?)%02M
M#C#@PG9P76:KE'T'0 )6M'I?0*$JJ*B\<,":W?Z KM4TB,-!KU[H@VO8< W;
M7XO>N)2JHQVV8,:&3[@//N%=/EG$&#QA.YY><>0ALU,??,*&3[A7/N$^^(0-
MG["=3V]UY"Z86N8D8JA$7J%2)SO605\NH4<M:@QLB/UMQ^;' ]?7!\RB=A$=
M>YT8)A'<ZX<S*_&ZJM_ZZF>'6$?#[+YSX4$;48D!$K&_<]G\8E]Z'V*3/G!%
M#*Y(KZ]AI(_7,&(P1_K '-G%'/9;;6(P1^R8^T/&P-\(-GO(KO4S8".]@HWT
M 39BP$;>%6QD%VRM7ZT"@[:@#[350;>_V/I#?_1RJ>5N[3)EP)?E7II0'E//
MJ3:<FJO-?MUIM4ME;J\V^ZXI7R:Y0"D\J*;>T;&J Z_VSZH3R5;EGM4]DY)E
MY6$,- *N;U"_/S FGT[T YI=S-G_4$L#!!0    ( !>!K%J]9D6F%@8  ",M
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+6:76_;-A2&_PKA%4,'
M=)5%6_[(' ..Q6T9^A$DS7HQ[(*1:9NH)'H4[33#?OQ(29%,2V&CXJ07C47K
M/*3>8QWQI3B[%_)+MF5,H:])G&;GO:U2NS//RZ(M2VCV5NQ8JK]9"YE0I0_E
MQLMVDM%5'I3$'N[W1UY">=J;S_*V*SF?B;V*><JN),KV24+EPP6+Q?UYS^\]
M-ESSS5:9!F\^V]$-NV'J=G<E]9%7458\86G&18HD6Y_W%OX9P5,3D)_Q)V?W
MV=%G9"[E3H@OYN!R==[KFQ&QF$7*(*C^<V!+%L>&I,?Q3PGM57V:P.//C_1?
M\XO7%W-',[84\6>^4MOSWJ2'5FQ-][&Z%O>_L_*" L.+1)SE_Z/[XMSQL(>B
M?:9$4@;K$20\+?[2KZ401P&:TQZ RP!\&O!4#X,R8/#<@&$9,'QN0% &Y)?N
M%=>>"Q=21><S*>Z1-&=KFOF0JY]':[UX:GXH-TKJ;[F.4_-K<O/I^G;YZ?;Z
M\L-OZ&?T@4I)3>[0ZY IRN/L)]UZ>Q.BUZ]^0J\03]&GK=AG-%UE,T_I$1B.
M%Y6]712]X2=Z&Z#W(E7;#)%TQ59VO*='7@T?/P[_ CN![ZE\BP;^&X3[.&@9
MS](='K*H"A^VA(?N\#_VJ0[O/QE.GC_XH4.,097+0<X;/)5+EBFYC]1>\G2#
MEB)32*<)Z68F=4+_>J?/1Y>*)=G?;:DKX,-VN"E89]F.1NR\IRM23NS-?_S!
M'_5_:=,=$A9"P@@0S,K0L,K0T$6?7R8[RJ6NLPJ)M;Z7%$TW_"YFB&894ZTW
ME!/8-2L%;)3#S"/D,!_V];^9=SB6&[)+ @2SY XJN0.WW.E!2RWD ]I)<>#F
MX=8F<=!093P*IK8H2V=/77_0D##2'/Z@&KLEVZB2;>2435=%/>?(F"GV>D9B
MG@>ZGL1Y4\SI'8^Y>F@3LL &1R/Q1_[D1$AGWUV%A(2144-(/!B/VK4<5UJ.
MG5I^M/5[XQ9PW! PP)/I^$1!9X]=%82$$2"8I?2D4GKB5-K, )#U"&Q3V,GH
M6DXA82$DC #!K$1,JT1,7W(:,H7,$"0LA(01()B5(;]?S_K[SIOE\^+Z@S%I
M>6:$VC*)6+*+Q0-CZ(ZE;,W;9R,E]KA"X>'I!&+I[KRK[* T D6SA3^R6[Y3
M^!MVT ^$-&(HTC=&N\9^4V/<U-C93V>-(6D$BF9KC&N-L5/CQ6K%S2H$C0N1
M]3PFVDMY:CA+M7%#[<%DTJ*WL\_.>D/2"!3-UKNVG;[3,YT4?%-1)(NI8JM<
M_C>ZSD0L-M,@W4(3(17_EZHGYN)E5U8Z@NF@F0Y0@PE*(U T.QVUQ_2_83*?
MYWI*RK'2XW%39T@S&(+2"!3-UKDVE[[;7;X3689$BG9[&6V--XI$DG!EW'U[
M70]:*DU3<%"C"4HC4#1;\-J6^FY?NCBJ(RNFNXCXTW6DZ47;)BJ@9A241J!H
MMMBU;_7=QK5II]!_Z#)%5U)$3/_PS72>ZA\^6NAZ'^I932QV^<+69;K2T\>4
M*X;>\<,3#UU(U[D$I86@- )%L[-8>V)_\I)>S >URZ"T$)1&H&AVGFK+[#O]
MWO<L#)=$:[4M:"SF+MT==Q8=U -#T>Q71[4)QFX3;%Z[?'O%R WI>@^ TD)0
M&H&BV>FHK3'V7[)684@+NP2EA: T D6S\U3;:^RVU]^[=H2;3CL(&O7*W7EG
MX4%]-A3-%K[VV=CMLY^Q=H2;]GG8HC&H>0:E$2B:K7%MGK';/-_0%(6<;03Z
MN%[SB+6*#/I.%I06@M((%,U.1NVP<?"B3P1(\[L$I86@- )%L_-4&W/L-N;/
M7''"34\^&#6+$Z@G!Z41*)JM<^W)L=N3=UD P<UWR1._*3:H=0:E$2B:+79M
MG;'[??)W[X)P<SN7'5#37-*L'4"-93$"U:>M?&V&L=L,=]LS4<*.+\EO+JNZ
MN^PL(Z@-AJ(5<GM'FT$3)C?Y+MQ,3QGWJ2HV5E:MQ4[?"_^,Y!MB3]H7_MDB
MW_?JU9AB^_![*C<\S71ZUAK9?SO65486.W*+ R5V^9;3.Z&42/*/6T973)H3
M]/=K(=3C@>F@VA<]_Q]02P,$%     @ %X&L6MG9NG?^ P  "1,  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&ULO5AM;]LV$/XKA%84+;!&(OV>V09B
M)VL#K%M@)]N'81]HZ6P)E42-I.(8V(\?22F2 UNTX\;]$HL2[^[A'>]Y& [7
MC'\3(8!$3TF<BI$32IE=NJ[P0TBHN& 9I.K+DO&$2C7D*U=D'&A@C)+8)9[7
M=1,:I<YX:-[=\?&0Y3*.4KCC2.1)0OEF C%;CQSL/+^81:M0ZA?N>)C1%<Q!
M/F1W7(W<RDL0)9"*B*6(PW+D7.'+">EK S/CSPC68NL9Z:4L&/NF![?!R/$T
M(HC!E]H%53^/,(4XUIX4CG]+ITX54QMN/S][_]4L7BUF005,6?Q7%,APY/0=
M%,"2YK&<L?47*!?4T?Y\%@OS%ZW+N9Z#_%Q(EI3&"D$2I<4O?2H3L65 2(,!
M*0V(P5T$,BBOJ:3C(6=KQ/5LY4T_F*4::P4N2G55YI*KKY&RD^/9S?Q^]C"]
M?YC=_OX9?4)S5?8@CP&Q)9J!D#SW9<ZC=*5'P!\!+3;H?I.9"5,F)/IP#9)&
ML?B(WJ$H1?<ARP5- S%TI<*GH[A^B6528"$-6%KH*TME*-!-&D#PTMY5ZZH6
M1YX7-R%6AU\IOT M_#,B'NF@A_DU^O#NH\5OJTI:R_AM-_@U[EYD9]]BK3YT
MMUV*C/HP<E0[F=0ZX_<_X:[WBP5ANT+8-MY;365]43I3)U63JH9__Z;FHUL)
MB?AG'_3V&:!W*N@=:W*O@B#2#4MC!$^*? 2H[O<9W]D2!=3"6=<XTQ3T.&YW
MVX.A^[@'0K>"T#U4W_;A^EI]G)BD7H6P=\[Z]LX O5]![UN3.X%5E*8:]H3&
M-/5A'\#"16>KJKCG[2_JH(H[>,M]-=A!,.AU]B/ 7DVVGA7#E(H0972C9$WN
M)TAO)^RG3A\WQ-TB>6R-JPCU0,)+!]N!.]UV0UQ2QR7VN$)&2CDA0)))E7C^
M8MOZ:ML*]06I67&,%J#TP\\YWU^0,M0VPH8=@6L>QW8BOTFRF&T D(",<FK.
M"06J_]!Q)&\/<&(KX9KF\5EY'I^#Z''-]/A-J;[TUCF*ZW%-]MC.]H>;LGOT
MSJOY&ULY]IB.[+UFM37[8CO]OFE+[M)T4V)JEL9VFC[0DD?HLCW B9N:U!Q/
MO'.V)+$JR*GH:Z4@=J5X94N27=EHV &D%@UB%XT_9 C\E36WNSPU:[6.D-99
M:WX.$2&UB! KS1]W(BM]''4D([4"D#=5 +*K (VG,E(+ /E. 2"[ M!\*B.U
M!I#OU0"RJP&-IS)22P#Y<1)0ANI:",#=NIU(@*_,'8Q0<?)4%A<5U=OJGN>J
MN-VHIQ>71.H?>K55!8IAJ4R]BY[*#"_N78J!9)FYZU@P*5EB'D.@ 7 ]07U?
M,B:?!SI =?LU_A]02P,$%     @ %X&L6L_4&*!+!   /1,  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&ULK9A;;]LV%,>_"J$-0PLTT<6WV+,-.):V
M!:B=H$[7AV$/M'1L$Y5$EZ3M9)^^)*4H4DQK$: \Q!3%\S^'/U*'E_&)LN]\
M!R#04Q*G?&+MA-B/;)N'.T@POZ9[2.6;#64)%O*1;6V^9X C;93$MN<X?3O!
M)+6F8UWWP*9C>A Q2>&!(7Y($LR>;R&FIXGE6B\57\AV)U2%/1WO\196(+[N
M'YA\L@N5B"20<D)3Q& SL6;N*' ]9:!;_$W@Q$MEI+JRIO2[>KB+)I:C(H(8
M0J$DL/PYPASB6"G).'[DHE;A4QF6RR_J?^C.R\ZL,8<YC;^12.PFUHV%(MC@
M0RR^T--?D'>HI_1"&G/]'YVRMH..A<(#%S3)C64$"4FS7_R4@R@9N-T+!EYN
MX+TUZ%TPZ.0&G?=ZZ.8&W?<:]'(#W74[Z[L&YV.!IV-&3XBIUE)-%31];2UY
MD51-E)5@\BV1=F(ZOU\L[AX7P?)QA69+'\WOEX]WRS^#Y?PN6*$KM,2,8366
MZ(,/ I.8?Y2U7U<^^O#KQ[$M9 A*R YS=_/,G7?!70<M:"IV' 5I!%'5WI:A
M%_%[+_'?>K6""\RND3/XA#S'ZYGB>8=YQ[UH[K_?O&LP#^K-?0@OF5=@=(K!
M[&B]SJ7!I$E"A/R,!4<XC=!<LB;I%M*0 $<^X6%,^8$!^F>VYH+)C_1?0]"W
MF9.NV8G*7".^QR%,+)F:.+ C6-/??G'[SN\F_FV*^6V*!2V)54:J6XQ4MTY]
M>K\']5FE6Q2#3'.?=+*3B3<5")[D(L#!-#"99E]KJA7@.!T.!H[Z&]O',O1:
MYTVAMRD6M"16@=XKH/=JH7]6J$ND\1H+4%^+B74FU2NQ=F48!M:U/INR;E,L
M:$FLPKI?L.[7LGZ$%$O$)-DS>M20$8[EK@2GH7%J]\^F]L ST:[UVI1VFV)!
M2V(5VH."]J"6MM[?7='-U4'.;<RYW&"J_*]S"XH)7I.8B&<YZT.Z3<E_$*'H
M $C0O 4\B6SK9QJ96L]-5X/!V3![P]Z@=S;._GG#-RV"EN*J\+XI>-_4\OZF
M]Y\2(S[*/+X%%,FUE1[D))=9W3B_:_6:4LS$7*=,Y]IUW#<,V_09M"16P3TL
M< ^;X6:@SD#%\HD$L,1$O5:V*?7Z&(?H&3#CIC339A1!2V*5<7"=U]."4Y]H
M5"+?XV>]QS01K[=OBCQ7J^2+KF%9\/.&Y>6ZXQ@:!FW%5^57.FVY3?9]**3<
MN/NHEVF,T3VCXYGH^'G#"F_3IB=H*[XJ1N\5HU>+<19%1-TSX+BTNLEUCX8$
MJSQQ(F*'B#QB)BG9D!#K.PFZCLE6%\TSM]9E8^3>_RU@?JL.@UJ'&6:[=$V0
M -OJ^QF.],*5G;B+VNP.:.Z.?'U5\J9^YHYF^D;$?I7)+I;D@7A+4BYG]T9*
M.M<#.>=8=E>3/0BZUY<1:RH$371Q!S@"IAK(]QM*Q<N#<E#<F$U_ E!+ P04
M    "  7@:Q:F((#0*\#  #E#@  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6RMEVMOHS@4AO^*Q8Y6,]*TW ET$Z1ITMVMU*35)+/[V04GL<9@UC;)
M]-^O#91<(.X,ZI<$@\_+\QYC'WN\I^P[WR(DP(^,Y'QB;(4H;DR3)UN407Y-
M"Y3+)VO*,BADDVU,7C $TRHH(Z9C68&909P;\;BZ]\3B,2T%P3EZ8H"760;9
MRRTB=#\Q;./UQE>\V0IUPXS'!=R@)1+?BB<F6V:KDN(,Y1S3'#"TGAA?[)NI
M[:N JL<_&.WYT3505IXI_:X:]^G$L!01(B@12@+*OQV:(D*4DN3XKQ$UVG>J
MP./K5_4_*_/2S#/D:$K)OS@5VXD1&B!%:U@2\97N_T:-H0HPH817OV#?]+4,
MD)1<T*P)E@09SNM_^*-)Q%& [5T(<)H YV<#W"; K8S69)6M&10P'C.Z!TSU
MEFKJHLI-%2W=X%P-XU(P^13+.!%/'^?S^]7\;K%:@B^+&9@^+E;WB[_N%M/[
MNR6X DOYW:0E08"NP1R*DF&!$5<M6C+P6" &!<XWX ')7(('#)\QJ;M\G"$!
M,>&?I,JWY0Q\_/ )?  X!ZLM+3G,4SXVA72@.,RDH;VM:9T+M'/(KH%K?P:.
MY?@]X5-]^ PE;;AW&F[*O+7)<]KD.96>>Q&G2LB+2D<G 7WN:CFO7T[-V!M>
MP 1-##DE.6([9,2__V8'UA]]7M])[,2YVSIW=>KQA?S?UE%!%:56D%WLN,YH
M;.Z.P;72 \&]%MQ["SSH Z^C_"-P-_+L,W"M]$!POP7WWP(?]8'['?#(#OPS
M<*WT0/"@!0_> @_[P(,.N.VX871&KM4>2#YJR4=OD4=]Y*,>\E%P_K%HM0>2
MARUYJ"5?;9&LZ6N!6!]_V.'WHS ZGZ7:-PSDCUK^2,]/!22@S%/,$UKF J6
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MD9SMDX'B:WL\ON=*'[;MY0II@,(8Z/L+SM73P"R0OF'I_0M02P,$%     @
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M BO+4:M<:)';:>5):)A][&<*XRF11@'V-T+HP\(<4 ^\\5]02P,$%     @
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M[WEKZNX]GPU_LER] E!+ 0(4 Q0    ( !>!K%I&QTU(E0   ,T    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ %X&L
M6KL"=#CR    *P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ %X&L6IE<G",0!@  G"<  !,              ( !
MY $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  7@:Q:1ZR^D=P%
M  #B'@  &               @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ %X&L6HEG9#2-!@  :AT  !@              ("!
M-PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !>!K%HC
M!G-A%0,  '(*   8              " @?H4  !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"% ,4    "  7@:Q:29,KP T'  "N(0  &
M    @(%%&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M%X&L6H/X%B3E!0  WR0  !@              ("!B!\  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !>!K%KK?[F(\ <  ",C   8
M          " @:,E  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    "  7@:Q:3-K@ =@-  !=)0  &               @(')+0  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ %X&L6KGG/EZ:#0  G"@
M !@              ("!USL  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( !>!K%IW54^!)!$  )0T   8              " @:=)  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  7@:Q:%N@)JB$3
M  #B4P  &0              @($!6P  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( !>!K%IFF[R/2P@  #,9   9              "
M@5EN  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ %X&L
M6M:S(SAT"@  ;AH  !D              ("!VW8  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    "  7@:Q:Y>AA]0P*   7&P  &0
M        @(&&@0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( !>!K%KQ-OA^/@0  &$*   9              " @<F+  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ %X&L6A:5BP?(!0  R0P
M !D              ("!/I   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    "  7@:Q:*E\4)D0"  ";!0  &0              @($]E@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( !>!K%H3K8?K
M1 (  (H&   9              " @;B8  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ %X&L6GR8;#TH#0  ,R4  !D
M ("!,YL  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  7
M@:Q:&]]+H\0%  ":$0  &0              @(&2J   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !>!K%I_@.;9;@4  ,,-   9
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M970R-"YX;6Q02P$"% ,4    "  7@:Q:N4?:%M$#  !%"0  &0
M    @(%&Q0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M !>!K%IW_YO<>@0  & *   9              " @4[)  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ %X&L6AUB?L3H @  Y0D  !D
M             ("!_\T  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    "  7@:Q:J/Q9JJ<'  #I.P  &0              @($>T0  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !>!K%HLH1%.B00
M $$;   9              " @?S8  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ %X&L6D"33PEF P  D0P  !D              ("!
MO-T  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  7@:Q:
MR5];MRH%  #D&@  &0              @(%9X0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !>!K%JZP(NRB (  (H%   9
M      " @;KF  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ %X&L6EO/^'_J @  .P@  !D              ("!>>D  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  7@:Q:E^# I1T,  !QBP
M&0              @(&:[   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( !>!K%J3W=CN$@,  !D)   9              " @>[X  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ %X&L6NK1EQ<\
M!   /A4  !D              ("!-_P  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    "  7@:Q:Q>';6!@#  #?"0  &0
M@(&J  $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !>!
MK%H#;QS)* ,  !@(   9              " @?D# 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ %X&L6O>3ABJ_$@  I@P! !D
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M=#0S+GAM;%!+ 0(4 Q0    ( !>!K%J]9D6F%@8  ",M   9
M  " @<TH 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M%X&L6MG9NG?^ P  "1,  !D              ("!&B\! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    "  7@:Q:S]08H$L$   ]$P  &0
M            @(%/,P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( !>!K%J8@@- KP,  .4.   9              " @=$W 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ %X&L6DSYB:K] P
MTQ   !D              ("!MSL! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    "  7@:Q:.8KFUV #  #I"@  &0              @('K
M/P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !>!K%I2
MS9&XE 0   H4   9              " @8)# 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ %X&L6BA*MZZW P  ^0\  !D
M     ("!34@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
M"  7@:Q:&(=G 0L$  "4#P  &0              @($[3 $ >&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !>!K%H;&.H?&00  &T1   9
M              " @7U0 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L!
M A0#%     @ %X&L6@(0X Q- P  _ H  !D              ("!S50! 'AL
M+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  7@:Q:5"$2/R\#
M  "4"@  &0              @(%16 $ >&PO=V]R:W-H965T<R]S:&5E=#4U
M+GAM;%!+ 0(4 Q0    ( !>!K%H='M?8/@(  +@$   9              "
M@;=; 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ %X&L
M6HR*+ATM!0  +A8  !D              ("!+%X! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    "  7@:Q:(HY..'P#  #S#0  &0
M        @(&08P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( !>!K%KE3H[2L@,  *$0   9              " @4-G 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ %X&L6A2BU>9A P  C!8
M  T              ( !+&L! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  7
M@:Q:EXJ[',     3 @  "P              @ &X;@$ 7W)E;',O+G)E;'-0
M2P$"% ,4    "  7@:Q:V0Z"E(P$  "A)P  #P              @ &A;P$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %X&L6EEV ?CU 0  .",  !H
M             ( !6G0! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ %X&L6A?(S!O; 0  T2(  !,              ( !AW8! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $, 0P!,$@  DW@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>206</ContextCount>
  <ElementCount>329</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - CONVERTIBLE SENIOR NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - RESTRUCTURING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURING</Role>
      <ShortName>RESTRUCTURING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - RESTRUCTURING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGTables</Role>
      <ShortName>RESTRUCTURING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/RESTRUCTURING</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - SEQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SEQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails</Role>
      <ShortName>RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - RESTRUCTURING - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails</Role>
      <ShortName>RESTRUCTURING - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails</Role>
      <ShortName>RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities of our Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Maturities of our Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pacb-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="pacb-20250331.htm">pacb-20250331.htm</File>
    <File>pacb-20250331.xsd</File>
    <File>pacb-20250331_cal.xml</File>
    <File>pacb-20250331_def.xml</File>
    <File>pacb-20250331_lab.xml</File>
    <File>pacb-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pacb-20250331_g1.jpg</File>
    <File>pacb-20250331_g2.jpg</File>
    <File>pacb-20250331_g3.jpg</File>
    <File>pacb-20250331_g4.jpg</File>
    <File>pacb-20250331_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="733">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pacb-20250331.htm": {
   "nsprefix": "pacb",
   "nsuri": "http://www.pacificbiosciences.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "pacb-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "pacb-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pacb-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pacb-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pacb-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pacb-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 287,
   "keyCustom": 42,
   "axisStandard": 26,
   "axisCustom": 1,
   "memberStandard": 34,
   "memberCustom": 27,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://www.pacificbiosciences.com/20250331": 1
   },
   "contextCount": 206,
   "entityCount": 1,
   "segmentCount": 64,
   "elementCount": 618,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 733,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.pacificbiosciences.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS",
     "longName": "9952157 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS",
     "longName": "9952158 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES",
     "longName": "9952159 - Disclosure - CONVERTIBLE SENIOR NOTES",
     "shortName": "CONVERTIBLE SENIOR NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURING",
     "longName": "9952160 - Disclosure - RESTRUCTURING",
     "shortName": "RESTRUCTURING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952161 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION",
     "longName": "9952162 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE",
     "longName": "9952163 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION",
     "longName": "9952164 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables",
     "longName": "9955512 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables",
     "longName": "9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables",
     "longName": "9955514 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)",
     "shortName": "CONVERTIBLE SENIOR NOTES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ScheduleOfInterestExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ScheduleOfInterestExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables",
     "longName": "9955515 - Disclosure - RESTRUCTURING (Tables)",
     "shortName": "RESTRUCTURING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "longName": "9955516 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables",
     "longName": "9955517 - Disclosure - SEQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)",
     "shortName": "SEQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables",
     "longName": "9955518 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables",
     "longName": "9955519 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "longName": "9955520 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-36",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955521 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "longName": "9955522 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentIncomeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails",
     "longName": "9955523 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails",
     "longName": "9955524 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails",
     "longName": "9955525 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails",
     "longName": "9955526 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
     "longName": "9955527 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
     "longName": "9955528 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
     "longName": "9955529 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails",
     "longName": "9955530 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails",
     "longName": "9955531 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
     "longName": "9955532 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-107",
      "name": "pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-107",
      "name": "pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
     "longName": "9955533 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
     "longName": "9955534 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "us-gaap:DebtInstrumentUnamortizedPremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
     "longName": "9955535 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
     "longName": "9955536 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)",
     "shortName": "RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
     "longName": "9955537 - Disclosure - RESTRUCTURING - Narrative (Details)",
     "shortName": "RESTRUCTURING - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails",
     "longName": "9955538 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "shortName": "RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-156",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "longName": "9955539 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-160",
      "name": "pacb:OperatingLeaseExpectedBaseRentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-160",
      "name": "pacb:OperatingLeaseExpectedBaseRentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails",
     "longName": "9955540 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Maturities of our Operating Lease Liabilities (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Maturities of our Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:LesseeOperatingLeaseDescriptionTableTextBlock",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9955541 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
     "longName": "9955542 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-163",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails",
     "longName": "9955543 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-167",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-167",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955544 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
     "longName": "9955545 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
     "longName": "9955546 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955547 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails",
     "longName": "9955548 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-191",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-191",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails",
     "longName": "9955549 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails",
     "longName": "9955550 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-195",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
     "longName": "9955551 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-197",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
     "longName": "9955552 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "pacb_A2020PlanInducementPlanAndTheOmniomePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "A2020PlanInducementPlanAndTheOmniomePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan, Inducement Plan, And The Omniome Plan",
        "label": "2020 Plan, Inducement Plan, And The Omniome Plan [Member]",
        "documentation": "2020 Plan, Inducement Plan, And The Omniome Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2024RestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "A2024RestructuringMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Restructuring",
        "label": "2024 Restructuring [Member]",
        "documentation": "2024 Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2025RestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "A2025RestructuringMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Restructuring",
        "label": "2025 Restructuring [Member]",
        "documentation": "2025 Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2028ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "A2028ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 Convertible Senior Notes",
        "label": "2028 Convertible Senior Notes [Member]",
        "documentation": "Convertible Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2029NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "A2029NotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 Convertible Senior Notes",
        "label": "2029 Notes [Member]",
        "documentation": "2029 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2030ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "A2030ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 Convertible Senior Notes",
        "label": "2030 Convertible Senior Notes [Member]",
        "documentation": "2030 Convertible Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r774"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r79",
      "r151",
      "r592",
      "r630",
      "r631"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10",
      "r19",
      "r469",
      "r472",
      "r515",
      "r626",
      "r627",
      "r912",
      "r913",
      "r914",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "pacb_AchievementOfMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "AchievementOfMilestoneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of milestone",
        "label": "Achievement Of Milestone [Member]",
        "documentation": "Upon achievement of a milestone."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "pacb_AdditionalGoodwillImpairmentChangeInDiscountRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "AdditionalGoodwillImpairmentChangeInDiscountRate",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional goodwill impairment",
        "label": "Additional Goodwill Impairment, Change In Discount Rate",
        "documentation": "Additional Goodwill Impairment, Change In Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "AdditionalIntangibleAssetImpairmentChangeInDiscountRate",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional intangible asset impairment, change in discount rate",
        "label": "Additional Intangible Asset Impairment, Change In Discount Rate",
        "documentation": "Additional Intangible Asset Impairment, Change In Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalIntangibleAssetImpairmentChangeInTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "AdditionalIntangibleAssetImpairmentChangeInTerm",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional intangible asset impairment, change in term",
        "label": "Additional Intangible Asset Impairment, Change In Term",
        "documentation": "Additional Intangible Asset Impairment, Change In Term"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "AdditionalLiabilityAssociatedWithIndemnificationObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional liability associated with indemnification obligations",
        "label": "Additional Liability Associated With Indemnification Obligations",
        "documentation": "Additional Liability Associated With Indemnification Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r774",
      "r1070"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r924",
      "r925",
      "r926",
      "r927",
      "r1009",
      "r1071"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r417"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r822",
      "r832",
      "r864"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r860",
      "r868",
      "r872",
      "r880"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AmericasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AmericasMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Americas",
        "label": "Americas [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "pacb_AmortizationOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "AmortizationOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Amortization Of Acquired Intangible Assets",
        "documentation": "Amortization Of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r378",
      "r919",
      "r1022"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r293",
      "r300",
      "r739"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "pacb_AptonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "AptonMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apton",
        "label": "Apton [Member]",
        "documentation": "Apton"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaPacificMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AsiaPacificMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia-Pacific",
        "label": "Asia Pacific [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r1005"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, consideration transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r1006",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition amount unpaid",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r1005"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r131",
      "r150",
      "r170",
      "r200",
      "r206",
      "r224",
      "r228",
      "r267",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r464",
      "r466",
      "r496",
      "r587",
      "r665",
      "r731",
      "r732",
      "r774",
      "r803",
      "r972",
      "r973",
      "r1024"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r153",
      "r170",
      "r267",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r464",
      "r466",
      "r496",
      "r774",
      "r972",
      "r973",
      "r1024"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r761"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r1034"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "pacb_BalanceSheetClassificationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "BalanceSheetClassificationAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Classification",
        "label": "Balance Sheet Classification [Abstract]",
        "documentation": "Balance Sheet Classification [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r459",
      "r756",
      "r757"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r459",
      "r756",
      "r757"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "BusinessCombinationConsiderationTransferredRevenueAchievementMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue",
        "label": "Business Combination, Consideration Transferred, Revenue Achievement Milestone",
        "documentation": "Milestone Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in the estimated fair value of contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r918"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r113",
      "r460",
      "r482",
      "r483",
      "r484"
     ]
    },
    "pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, anniversary",
        "label": "Business Combination, Contingent Consideration Liability, Measurement Period",
        "documentation": "Business Combination, Contingent Consideration Liability, Measurement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability, non-current",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r113"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of purchase price",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r146",
      "r722"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Investments",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r92",
      "r167"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r92"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ChangeInEarningsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ChangeInEarningsPerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in net loss, basic (in dollars per share)",
        "label": "Change in Earnings Per Share",
        "documentation": "Change in Earnings Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r121",
      "r588",
      "r652"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r795",
      "r796",
      "r798",
      "r799",
      "r800",
      "r801",
      "r924",
      "r925",
      "r927",
      "r1009",
      "r1069",
      "r1071"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r653"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r653",
      "r671",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r591",
      "r774"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r155",
      "r157",
      "r161",
      "r583",
      "r600",
      "r601"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r235",
      "r707"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r235",
      "r633",
      "r707"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r235",
      "r707",
      "r893"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r235"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r235",
      "r707"
     ]
    },
    "pacb_ConsumableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ConsumableMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumable revenue",
        "label": "Consumable [Member]",
        "documentation": "Consumable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type [Axis]",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type [Domain]",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r406"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r406"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r406"
     ]
    },
    "pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ContractWithCustomerLiabilityNoncurrentRecognitionPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, noncurrent, recognition (in years)",
        "label": "Contract with Customer, Liability, Noncurrent, Recognition Period",
        "documentation": "Contract with Customer, Liability, Noncurrent, Recognition Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of convertible debt",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r357",
      "r358",
      "r368",
      "r369",
      "r370",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon conversion of convertible senior notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes, net, non-current",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120",
      "r1037"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r755",
      "r761",
      "r775",
      "r792",
      "r1066"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Cost, Amortization",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost of revenue",
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r170",
      "r267",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r496",
      "r731",
      "r972"
     ]
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue:",
        "label": "Cost of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r235"
     ]
    },
    "pacb_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One",
        "label": "Customer One [Member]",
        "documentation": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion, shares issued (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "pacb_DebtConversionTermsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtConversionTermsOneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms One",
        "label": "Debt Conversion Terms One [Member]",
        "documentation": "Debt Conversion Terms One"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtConversionTermsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtConversionTermsTwoMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms Two",
        "label": "Debt Conversion Terms Two [Member]",
        "documentation": "Debt Conversion Terms Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE SENIOR NOTES",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r168",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r345",
      "r346",
      "r356",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r372",
      "r379",
      "r380",
      "r382",
      "r503"
     ]
    },
    "pacb_DebtInstrumentAdditionalInterestInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentAdditionalInterestInEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional interest in the event of default (as a percent)",
        "label": "Debt Instrument, Additional Interest in the Event of Default",
        "documentation": "Debt Instrument, Additional Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r118",
      "r120",
      "r171",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r772",
      "r921",
      "r965",
      "r966",
      "r967",
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "verboseLabel": "Principal amount",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120",
      "r383"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r359"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r64",
      "r107",
      "r108",
      "r359"
     ]
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentConvertibleTermsOfConversionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentConvertibleTermsOfConversionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage of stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentDebtDefaultCalendarDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentDebtDefaultCalendarDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, debt default, calendar days",
        "label": "Debt Instrument, Debt Default, Calendar Days",
        "documentation": "Debt Instrument, Debt Default, Calendar Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of notes",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r503",
      "r504",
      "r745",
      "r746",
      "r772"
     ]
    },
    "pacb_DebtInstrumentInterestInTheEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentInterestInTheEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest in the event of default (as a percent)",
        "label": "Debt Instrument, Interest in the Event of Default",
        "documentation": "Debt Instrument, Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r385",
      "r503",
      "r504",
      "r772"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r358"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r772",
      "r921",
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r171",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r772",
      "r921",
      "r965",
      "r966",
      "r967",
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid accrued but unpaid interest",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentRedemptionPriceConsecutiveTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, consecutive trading days",
        "label": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentRedemptionPricePercentageOfConversionPrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, percentage of conversion price",
        "label": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "documentation": "Debt Instrument, Redemption Price, Percentage of Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentRedemptionPriceTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtInstrumentRedemptionPriceTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, trading days",
        "label": "Debt Instrument, Redemption Price, Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r42",
      "r43",
      "r57",
      "r106",
      "r108",
      "r171",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r772",
      "r921",
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt premium",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1020",
      "r1021",
      "r1023"
     ]
    },
    "pacb_DebtIssuanceCostLenderFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DebtIssuanceCostLenderFees",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance cost, lender fees",
        "label": "Debt Issuance Cost, Lender Fees",
        "documentation": "Debt Issuance Cost, Lender Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1023"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36"
     ]
    },
    "pacb_DevelopedTechnologyAndIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DevelopedTechnologyAndIntellectualPropertyMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed Technology and Intellectual Property",
        "label": "Developed Technology and Intellectual Property [Member]",
        "documentation": "Developed Technology and Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958",
      "r961",
      "r962"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DomesticCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "DomesticCustomersMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Customers",
        "label": "Domestic Customers [Member]",
        "documentation": "Domestic Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_EMEAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EMEAMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe, Middle East and Africa",
        "label": "EMEA [Member]",
        "documentation": "Regions of Europe, Middle East and Africa."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r190",
      "r193",
      "r194",
      "r195",
      "r199",
      "r457",
      "r463",
      "r477",
      "r478",
      "r584",
      "r602",
      "r724"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding used in calculating net loss per share:",
        "verboseLabel": "Denominator:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r190",
      "r193",
      "r194",
      "r195",
      "r199",
      "r457",
      "r463",
      "r477",
      "r478",
      "r584",
      "r602",
      "r724"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r196",
      "r197",
      "r198"
     ]
    },
    "pacb_EmployeeSeparationCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "EmployeeSeparationCostsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee separation costs",
        "label": "Employee Separation Costs [Member]",
        "documentation": "Employee Separation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r141",
      "r158",
      "r159",
      "r160",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r201",
      "r268",
      "r269",
      "r308",
      "r401",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r458",
      "r462",
      "r463",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r515",
      "r598",
      "r626",
      "r627",
      "r628",
      "r638",
      "r691"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r822",
      "r832",
      "r864"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r819",
      "r829",
      "r861"
     ]
    },
    "pacb_ExchangeTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ExchangeTransactionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Transaction",
        "label": "Exchange Transaction [Member]",
        "documentation": "Exchange Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r492",
      "r761"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r492",
      "r761"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r1011",
      "r1012",
      "r1017"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r763"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r763"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r491",
      "r492",
      "r494",
      "r519",
      "r520",
      "r521",
      "r745",
      "r746",
      "r753",
      "r754",
      "r755",
      "r761",
      "r765"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r409",
      "r414",
      "r481",
      "r492",
      "r519",
      "r753",
      "r754",
      "r755",
      "r761"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r409",
      "r414",
      "r481",
      "r482",
      "r492",
      "r520",
      "r745",
      "r746",
      "r753",
      "r754",
      "r755",
      "r761"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r481",
      "r482",
      "r483",
      "r484",
      "r492",
      "r521",
      "r745",
      "r746",
      "r753",
      "r754",
      "r755",
      "r761",
      "r765"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r490",
      "r493"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r491",
      "r492",
      "r494",
      "r519",
      "r520",
      "r521",
      "r745",
      "r746",
      "r753",
      "r754",
      "r755",
      "r761",
      "r765"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r381",
      "r399",
      "r474",
      "r495",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r599",
      "r737",
      "r761",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r775",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r942",
      "r943",
      "r944",
      "r945",
      "r1010",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r279",
      "r299",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r719",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r719",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r719",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r719",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r303",
      "r304",
      "r550",
      "r551",
      "r719"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r299",
      "r551",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r299",
      "r303",
      "r304",
      "r307",
      "r550",
      "r719",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r303",
      "r304",
      "r719"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r958"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Roll Forward]",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "pacb_GainLossOnPurchaseCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "GainLossOnPurchaseCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitments",
        "label": "Gain Loss On Purchase Commitments",
        "documentation": "Gain Loss On Purchase Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r40",
      "r41"
     ]
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnRestructuringOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on debt restructuring",
        "label": "Gains (Losses) on Restructuring of Debt",
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r675"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r280",
      "r582",
      "r732",
      "r738",
      "r762",
      "r774",
      "r949",
      "r950"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_GoodwillImpairmentDiscountedCashFlowModelDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "GoodwillImpairmentDiscountedCashFlowModelDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment, discount rate",
        "label": "Goodwill Impairment, Discounted Cash Flow Model, Discount Rate",
        "documentation": "Goodwill Impairment, Discounted Cash Flow Model, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_GoodwillImpairmentIncreaseInBasisPointDiscountRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "GoodwillImpairmentIncreaseInBasisPointDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in basis point discount rate",
        "label": "Goodwill Impairment, Increase In Basis Point Discount Rate",
        "documentation": "Goodwill Impairment, Increase In Basis Point Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r281",
      "r287",
      "r291",
      "r738",
      "r762"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross (loss) profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r82",
      "r130",
      "r170",
      "r267",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r496",
      "r726",
      "r731",
      "r930",
      "r932",
      "r933",
      "r934",
      "r935",
      "r972"
     ]
    },
    "pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up period restriction (in months)",
        "label": "Holding Period For Transfer, Assignment Or Sale Of Founder Shares",
        "documentation": "Holding Period For Transfer, Assignment Or Sale Of Founder Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge",
        "negatedTerseLabel": "Impairment charge",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r293",
      "r305"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r919",
      "r960",
      "r964"
     ]
    },
    "pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "InProcessResearchAndDevelopmentIndefiniteLivedMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research And Development Indefinite Lived",
        "label": "In Process Research And Development Indefinite Lived [Member]",
        "documentation": "In-process research and development indefinite lived"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research and Development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r960",
      "r961",
      "r962"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before benefit from income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r125",
      "r130",
      "r585",
      "r596",
      "r726",
      "r731",
      "r930",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "pacb_IncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "IncomeLossPerShareAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Income Loss per Share Abstrct",
        "documentation": "Income Loss per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r316",
      "r321",
      "r486",
      "r490",
      "r493",
      "r623",
      "r625",
      "r676",
      "r719",
      "r764",
      "r1039"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r321",
      "r486",
      "r490",
      "r493",
      "r623",
      "r625",
      "r676",
      "r719",
      "r764",
      "r1039"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r140",
      "r184",
      "r185",
      "r200",
      "r214",
      "r228",
      "r449",
      "r450",
      "r453",
      "r603",
      "r759"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r918"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedTerseLabel": "Decrease in operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r918"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r297",
      "r302",
      "r739"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r302",
      "r307",
      "r739"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r297",
      "r302",
      "r739"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r860",
      "r868",
      "r872",
      "r880"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r884"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r884"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r884"
     ]
    },
    "pacb_InstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "InstrumentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instrument revenue",
        "label": "Instrument [Member]",
        "documentation": "Instrument [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, discounted cash flow model, discount rate",
        "label": "Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate",
        "documentation": "Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "IntangibleAssetImpairmentDiscountedCashFlowModelTerm",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, discounted cash flow model, term (in years)",
        "label": "Intangible Asset Impairment, Discounted Cash Flow Model, Term",
        "documentation": "Intangible Asset Impairment, Discounted Cash Flow Model, Term"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, increase in basis point discount rate",
        "label": "Intangible Asset Impairment, Increase In Basis Point Discount Rate",
        "documentation": "Intangible Asset Impairment, Increase In Basis Point Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, increase in term (in years)",
        "label": "Intangible Asset Impairment, Increase In Obsolescence Factor, Term",
        "documentation": "Intangible Asset Impairment, Increase In Obsolescence Factor, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r958",
      "r960"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r376",
      "r386",
      "r747",
      "r748"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Contractual interest expense",
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r377",
      "r747",
      "r748"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r916"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, gross",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory, net",
        "totalLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r723",
      "r774"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory reserve",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r909"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory provision",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount and amortization of premium on marketable securities, net",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, All Other Investments [Abstract]",
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012",
      "r1016"
     ]
    },
    "us-gaap_InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "verboseLabel": "Total investments",
        "label": "Investments [Member]",
        "documentation": "Assets held for their financial return, rather than for the entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_LesseeOperatingLeaseDescriptionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "LesseeOperatingLeaseDescriptionTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Description [Table Text Block]",
        "documentation": "Lessee, Operating Lease, Description [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_LesseeOperatingLeaseLiabilityBaseRentAbatementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityBaseRentAbatementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease base rent abatement",
        "label": "Lessee, Operating Lease, Liability, Base Rent Abatement, Amount",
        "documentation": "Lessee, Operating Lease, Liability, Base Rent Abatement, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r62",
      "r65",
      "r66",
      "r67",
      "r68",
      "r170",
      "r267",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r465",
      "r466",
      "r467",
      "r496",
      "r651",
      "r725",
      "r803",
      "r972",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r122",
      "r594",
      "r774",
      "r922",
      "r946",
      "r1019"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r145",
      "r170",
      "r267",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r465",
      "r466",
      "r467",
      "r496",
      "r774",
      "r972",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities measured at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r1011"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate outstanding balance",
        "totalLabel": "Net carrying amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120",
      "r369",
      "r384",
      "r745",
      "r746",
      "r772",
      "r1037"
     ]
    },
    "pacb_LongTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "LongTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Long Term Restricted Cash Fair Value Disclosure",
        "documentation": "Long-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r447"
     ]
    },
    "pacb_LossOnPurchaseCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "LossOnPurchaseCommitment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitment",
        "label": "Loss On Purchase Commitment",
        "documentation": "Loss On Purchase Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r752",
      "r785",
      "r790",
      "r976",
      "r1038",
      "r1040",
      "r1041",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r415",
      "r447",
      "r484",
      "r547",
      "r622",
      "r624",
      "r632",
      "r643",
      "r644",
      "r696",
      "r698",
      "r700",
      "r701",
      "r703",
      "r717",
      "r718",
      "r736",
      "r749",
      "r758",
      "r765",
      "r766",
      "r770",
      "r771",
      "r786",
      "r974",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r415",
      "r447",
      "r484",
      "r547",
      "r622",
      "r624",
      "r632",
      "r643",
      "r644",
      "r696",
      "r698",
      "r700",
      "r701",
      "r703",
      "r717",
      "r718",
      "r736",
      "r749",
      "r758",
      "r765",
      "r766",
      "r770",
      "r786",
      "r974",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r752",
      "r785",
      "r790",
      "r976",
      "r1038",
      "r1040",
      "r1041",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Consolidated net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r126",
      "r143",
      "r154",
      "r156",
      "r160",
      "r170",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r191",
      "r267",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r457",
      "r463",
      "r478",
      "r496",
      "r597",
      "r673",
      "r689",
      "r690",
      "r802",
      "r972"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r177",
      "r178",
      "r179",
      "r180",
      "r187",
      "r188",
      "r192",
      "r195",
      "r463"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r860",
      "r868"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Reportable Segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r735",
      "r931"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expense",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r726",
      "r930",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r773"
     ]
    },
    "pacb_OperatingLeaseExpectedBaseRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "OperatingLeaseExpectedBaseRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, base rent expense",
        "label": "Operating Lease, Expected Base Rent, Expense",
        "documentation": "Operating Lease, Expected Base Rent, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, liability",
        "verboseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESScheduleofMaturitiesofourOperatingLeaseLiabilitiesDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r773"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r773"
     ]
    },
    "pacb_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock",
        "label": "Options To Purchase Common Stock [Member]",
        "documentation": "Options to purchase common stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r114",
      "r634",
      "r635"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss on investments",
        "verboseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r115"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, current",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r774"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, non-current",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "verboseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_OtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other costs",
        "label": "Other Restructuring [Member]",
        "documentation": "Restructuring and related activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r824",
      "r834",
      "r866"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r827",
      "r837",
      "r869"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r827",
      "r837",
      "r869"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent payments",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r917"
     ]
    },
    "pacb_PaymentsInConjunctionWithNotesExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "PaymentsInConjunctionWithNotesExchange",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments made in conjunction with convertible notes exchange",
        "label": "Payments In Conjunction With Notes Exchange",
        "documentation": "Payments In Conjunction With Notes Exchange"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares of common to be issued in merger",
        "label": "Percentage Of Outstanding Shares Of Common To Be Issued In Merger",
        "documentation": "Percentage of outstanding shares of common to be issued in merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Units (PSU)",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r388"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r653"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in share)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r388"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r653",
      "r671",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r590",
      "r774"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from equity plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r937"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r549",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r720",
      "r750",
      "r784",
      "r786",
      "r787",
      "r791",
      "r793",
      "r970",
      "r971",
      "r976",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r339",
      "r341",
      "r344"
     ]
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repairs and replacements",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions charged to cost of product revenue",
        "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued",
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r549",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r720",
      "r750",
      "r784",
      "r786",
      "r787",
      "r791",
      "r793",
      "r970",
      "r971",
      "r976",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r514",
      "r586",
      "r595",
      "r774"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r408",
      "r415",
      "r441",
      "r442",
      "r443",
      "r447",
      "r484",
      "r522",
      "r531",
      "r547",
      "r622",
      "r624",
      "r632",
      "r643",
      "r644",
      "r696",
      "r698",
      "r700",
      "r701",
      "r703",
      "r717",
      "r718",
      "r736",
      "r749",
      "r758",
      "r765",
      "r766",
      "r770",
      "r771",
      "r786",
      "r796",
      "r968",
      "r974",
      "r1014",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r335",
      "r336",
      "r408",
      "r415",
      "r441",
      "r442",
      "r443",
      "r447",
      "r484",
      "r522",
      "r531",
      "r547",
      "r622",
      "r624",
      "r632",
      "r643",
      "r644",
      "r696",
      "r698",
      "r700",
      "r701",
      "r703",
      "r717",
      "r718",
      "r736",
      "r749",
      "r758",
      "r765",
      "r766",
      "r770",
      "r771",
      "r786",
      "r796",
      "r968",
      "r974",
      "r1014",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r819",
      "r829",
      "r861"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes payable principal payoff",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "pacb_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r719",
      "r731",
      "r1032"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r820",
      "r830",
      "r862"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r821",
      "r831",
      "r863"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r828",
      "r838",
      "r870"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash at end of period",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r116",
      "r146",
      "r167",
      "r589"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r133",
      "r167"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r920"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r320",
      "r323",
      "r328"
     ]
    },
    "pacb_RestructuringAndRelatedCostAcceleratedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "RestructuringAndRelatedCostAcceleratedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, accelerated amortization",
        "label": "Restructuring and Related Cost, Accelerated Amortization",
        "documentation": "Restructuring and Related Cost, Accelerated Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated total restructuring costs to still be incurred",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative amount incurred to date",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r322",
      "r325",
      "r327"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional expense recorded",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r324",
      "r325",
      "r969"
     ]
    },
    "pacb_RestructuringChargesAdditionalCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "RestructuringChargesAdditionalCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional costs incurred",
        "label": "Restructuring Charges, Additional Costs Incurred",
        "documentation": "Restructuring Charges, Additional Costs Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_RestructuringChargesExcludingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "RestructuringChargesExcludingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges, excluding adjustments",
        "label": "Restructuring Charges, Excluding Adjustments",
        "documentation": "Restructuring Charges, Excluding Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WARN act and other employee benefits",
        "label": "Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits",
        "documentation": "Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r325",
      "r326"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891"
     ]
    },
    "pacb_RestructuringOfDebtPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "RestructuringOfDebtPricePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring of debt (in dollar per share)",
        "label": "Restructuring Of Debt Price Per Share",
        "documentation": "Restructuring Of Debt Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r326"
     ]
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated depreciation",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r109",
      "r593",
      "r629",
      "r631",
      "r637",
      "r654",
      "r774"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r268",
      "r269",
      "r308",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r458",
      "r462",
      "r463",
      "r468",
      "r470",
      "r471",
      "r473",
      "r476",
      "r505",
      "r506",
      "r626",
      "r628",
      "r638",
      "r1071"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r200",
      "r207",
      "r208",
      "r222",
      "r228",
      "r231",
      "r233",
      "r235",
      "r404",
      "r405",
      "r549"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r200",
      "r207",
      "r208",
      "r222",
      "r228",
      "r231",
      "r233",
      "r235",
      "r404",
      "r405",
      "r549"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Geographic Location",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, percentage",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset and lease liability recognized due to lease extension",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r773"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "pacb_SanDiegoOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "SanDiegoOfficeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego Office",
        "label": "San Diego Office [Member]",
        "documentation": "San Diego Office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248"
     ]
    },
    "pacb_ScheduleOfBalanceSheetComponentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ScheduleOfBalanceSheetComponentsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Components [Line Items]",
        "label": "Schedule of Balance Sheet Components [Line Items]",
        "documentation": "Schedule of Balance Sheet Components [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ScheduleOfBalanceSheetComponentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ScheduleOfBalanceSheetComponentsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Components [Table]",
        "label": "Schedule of Balance Sheet Components [Table]",
        "documentation": "Schedule of Balance Sheet Components [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r459"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents, Restricted Cash and Investments",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Carrying Amount",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r42",
      "r43",
      "r57",
      "r106",
      "r108",
      "r745",
      "r747",
      "r923",
      "r1021"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Category",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impaired Intangible Assets",
        "label": "Schedule of Impaired Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Indefinite-Lived [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r302",
      "r307",
      "r739"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets From Business Acquisitions",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r948",
      "r951"
     ]
    },
    "pacb_ScheduleOfInterestExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "documentation": "Schedule of Interest Expense [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r76",
      "r77",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Reserve for Product Warranties",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Pre-Tax Restructuring Charges",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r99",
      "r100"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Profit or Loss",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Time-Based RSUs and PSUs Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r110"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Purchase Plan",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r959"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r200",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r235",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r307",
      "r322",
      "r327",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r728",
      "r731",
      "r732",
      "r738",
      "r789",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r640",
      "r641",
      "r642",
      "r697",
      "r699",
      "r702",
      "r704",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r721",
      "r751",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r788",
      "r796",
      "r976",
      "r1038",
      "r1040",
      "r1041",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r218",
      "r220",
      "r221",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r727",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ServiceAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ServiceAndOtherMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service and other revenue",
        "label": "Service And Other [Member]",
        "documentation": "Service and Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount eligible to vest upon achievement of goal",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value per share (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "verboseLabel": "Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock remain available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value per share (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r910"
     ]
    },
    "pacb_ShortTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "ShortTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Short-Term Restricted Cash Fair Value Disclosure",
        "documentation": "Short-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StandardProductWarrantyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "StandardProductWarrantyPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard product warranty, period",
        "label": "Standard Product Warranty, Period",
        "documentation": "Standard Product Warranty, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r142",
      "r200",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r235",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r307",
      "r310",
      "r322",
      "r327",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r728",
      "r731",
      "r732",
      "r738",
      "r789",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r73",
      "r74",
      "r141",
      "r158",
      "r159",
      "r160",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r183",
      "r185",
      "r201",
      "r268",
      "r269",
      "r308",
      "r401",
      "r451",
      "r452",
      "r454",
      "r455",
      "r456",
      "r458",
      "r462",
      "r463",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r515",
      "r598",
      "r626",
      "r627",
      "r628",
      "r638",
      "r691"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r640",
      "r641",
      "r642",
      "r697",
      "r699",
      "r702",
      "r704",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r721",
      "r751",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r788",
      "r796",
      "r976",
      "r1038",
      "r1040",
      "r1041",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r201",
      "r506",
      "r549",
      "r636",
      "r639",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r797"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r201",
      "r236",
      "r506",
      "r549",
      "r636",
      "r639",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r691",
      "r797"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r823",
      "r833",
      "r865"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "StockIssuedDuringPeriodAverageTradingPeriodAcquisition",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average trading period",
        "label": "Stock Issued During Period, Average Trading Period, Acquisition",
        "documentation": "Stock Issued During Period, Average Trading Period, Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchased under plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r49",
      "r69",
      "r70",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional common stock purchased under plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r69",
      "r70",
      "r109"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r97",
      "r655",
      "r671",
      "r692",
      "r693",
      "r774",
      "r803",
      "r922",
      "r946",
      "r1019",
      "r1071"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY PLANS AND SHARE-BASED COMPENSATION",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r169",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r475",
      "r694",
      "r695",
      "r705"
     ]
    },
    "pacb_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_SupplementalBalanceSheetComponentsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "SupplementalBalanceSheetComponentsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components [Abstract]",
        "label": "Balance Sheet Components [Abstract]",
        "documentation": "Supplemental Balance Sheet Components Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology-Based Intangible Assets",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958",
      "r961",
      "r962"
     ]
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant improvement allowance",
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r1035",
      "r1036"
     ]
    },
    "pacb_TimeBasedRestrictedStockUnitsPSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "TimeBasedRestrictedStockUnitsPSUMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time Based Restricted Stock Units PSU",
        "label": "Time Based Restricted Stock Units PSU [Member]",
        "documentation": "Time Based Restricted Stock Units PSU"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedRestrictedStockUnitsRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "TimeBasedRestrictedStockUnitsRsusMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSU)",
        "label": "Time Based Restricted Stock Units Rsus [Member]",
        "documentation": "Time-Based Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250331",
     "localname": "TimeBasedStockOptionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-based stock option",
        "label": "Time Based Stock Option [Member]",
        "documentation": "Time-based stock option"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Option, Eligible Item or Group [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r381",
      "r399",
      "r474",
      "r495",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r599",
      "r761",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r775",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r942",
      "r943",
      "r944",
      "r945",
      "r1010",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r325",
      "r326"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government &amp; agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r134",
      "r135",
      "r136",
      "r137"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted average shares used in computing diluted net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average shares used in computing basic net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageRateOfTimeDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageRateOfTimeDepositsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share:",
        "label": "Weighted Average Rate of Time Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "60",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481408/470-60-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480637/718-40-25-10"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001299130-25-000102-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001299130-25-000102-xbrl.zip
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MGRT1A9/+HM_PJ@DA[;VI19U-_%.AY]\95P YP!4"Y@"G!83)*(7U#HR[PJC
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M^8,;=]B$M+,F<+@>K"-+X1ORT>K-JEP9^X6LYPZ+)V+MKM4R%C8'-)==N(^
ME,5ZE\]<SZI^NIMB1_:&VF]02P,$%     @ %X&L6K/P<8XK"   ["8  !D
M  !P86-B+3$P<7AE>'@S,3)X<3%X,C4N:'1M[5IM<]LV$OY^OP)G3U-[1I+U
M&MFRXQE%EAO=Y.R<K$Q[GSH0"5H8DP0+@)+57W_/ M2++3N1V[2U.I</CD@L
M%KO8!\\N )Y-;!*?GTT$#\__<?;/<IE=J"!/1&I9H 6W(F2YD>DM^S$4YHZ5
MRX543V5S+6\GEM6K]1;[4>D[.>6^W4H;B_.%GK,C_WQVY 8Y&ZMP?GX6RBF3
MX;L]B=[B.&H*_E8TFU$4G33JX_;;=BL0]7;0YL'/M3UTA;CO8^P\%N_V$IF6
M)X+&[S1;F3V=R=!..K5J];L])W=^%JG48C"-SOZGU[&AR8I[6^:QO$T[SI\]
MWW71'*A8Z<Y^U?T[I99RQ!,9SSO?CV0B#+L2,S94"4^_+QF>FK(16D9>T,A?
M1:=6AWGN<>;M;4-/+%.QL+]6)Z/[]Q,YEI8U:I4Z>VCRNMM<W\)SJ[+.6ZA=
MLSW 3 O]S8VO;F5\KS\<#2X'O>YH<'W%KB]9[\.@?\DN!U?=J]Z@^Q&OT-H?
MLD^?AS>?NU<C-KI^WLE7X%6M!:]N^KW/P\%HT+]A_9]Z'[I7/_19MS=BP\\?
M\:K6X.5:\X ?LN[5!:NU0O]48MT;UKVX_C3J7ZS<?<V^N@@B'G#7A:]1K5,(
M1Q_Z[*8[?-^]ZM^4KW_ZV/^O<QXM]6IU.XC2V'^X/\TG_1F4V+]DPGZ08Z/2
M$@N$MC*:,SOA]LU^Z_CT94M,IB&"TZG7*ZV_S*-:96'RGS_Z:<;#$$F@'(O(
MTK1@@MF$3P738BK%#$G"3J1AO^1< \/Q'.\SI2U3*;M4.F&U:OD_3$7L$P]D
M) /V7BH32)$&L!"O>U@!D=*IY"4V2(,*0G2R@R&JOZX0O><&@4$(DCF[2]4L
M%N&M*/E(%?$)%<9/%7(]U'.9,I[.69Y:G0N8C^SO"@%$B+,$3UKRF$4\P"O-
M5()T9967VQ!(!6)KN)Z32,+O!,9=TVGP+H0Q&#)V503&((% :E0-$'/0R!%4
MS683&4R8R>G/JO],:%$H(0<2:6*4%U2IS*2=P$&3B< 92'HSF*9"N#E%MY"-
MY^O3L*-P:^P(W 2+9(J $C96 2P!:Q!'LUYKEREX $B2T"/3(,Y#Z 1(UJ)5
M L D<4R&&!,\";9QO,)?$7KS:&A /)2DN$02>6P=]2@@PPUGG#T!-Q,6Q6IF
M%HC4XE8:JSD&XO32VPTK2VO ,@MC-JS=46PU7Q>V1@\"\6;_N%YKGYH"/45R
MIZ6O(F07H0_,H8O2@'$M'!X07SF.!<6-"8!P'$LSH1XDEH#YB/WH.90FB)7)
MT8\X4:O8 R/3*A A7AMV !R$ L#RP>[?!Q.>W@K6!=T,\Q@2KC9L'0AOA:L-
MZ<D_2BKS4@](TL^(D]9PZG%#MFP]4/1@H @#D9^/T0L)RMD[6O_PP]>"R%:E
MW:1IN! &=3MBXU+3UX%3HJP9\-QLWX72UU@ !,5(/B&J7$,!F&<JC>,S2(G4
MZ:$"=\6$ZVRJ1<P=JHJ,N$)&J6!::I1@1=AB5"Q#M_DW^=C(4'(MR0'I\[;C
M]Y0TY89RJ5N'QB5>QW[*"!B$;;_KE*$HE$$><R)MN.6,6.5D]/ 9?KTPP:^Q
M($'P*OJ+<$=Y=/R*4%MK;Z)V:S+: ._V-+8UAH'[J0P)FAR[-DY\S0U@3<4@
MX97K<($=H%GRL8REG5.B?FI86DD.9@Y!?A$\$%TK)EU:N"\<RG*= <'&%19!
MH'3H#'!EY:U(42_$ #):1$8KA$10,GNP8B7)#,R\HW -7A%</<GVISS.'1-1
M+$44H;*34T3!/%&A+0N#+9C5/SY=M#ETHB-8T?C2<*QR^[P%VW _7TH+JGNC
MKV]+V'A14;L%)_Q,P!X/+AI@YP 6OB* %7SH8[>) =H*%P67:WD2:"]@0<K,
M*@AR39%>2X-/:$V4L7A/)X+090(H*HY6V,$S72) %OST2+HP'+L:X7;QM,%/
M\Z5=A]ZJ"3?+FH&8S4%<A([RW7P4=#S'7OU.Q,66_I%\Z7=/T0[#NO4WV2ZY
M,[UPL2)**P8B0EQ'Y8J,"%<OJ"(VJL^E=1P5J%7:+!.W>P&522*M%>(+=#]6
M* VH/92PSRDY ';!KH;8&_]3';Q8<.*77,)\M[CR-'";_\/_[XJ^4<+NQJBL
M4.G1.2]M.VD#ZXYZ99%TE[N3F>!WE$5]I>7RJ*L1W>'BXECF1? J-A)^T_\$
M:?$0'8U8<M:S4"PJ2W0!GE  EGPJ-\CC)D\ !DR2<Z;(%4\>8.TPG[V^;4L7
MV3C2H(02@BP<D0$F[N2WP%/))S.93E4\%9314GY;'&#K@OM$DL5J+M ZFRC/
M=OP!6H&N;Y+N*]O&?._9F^KM8-*LKL'D]VNQ;M=5=!@#^4*7$?:89T9T%C].
MD2&RF,\[,G7!<YU."_5C9:U*.G0I/Z5,@W*DN.!T _KFXK[^Y+C2:#3HRM["
M;ALN!BYN\RON-O_(AIMMS4:E5J\]VURM/-_V);6-RG'C^=;?JK5Y FX\V4KM
MD9L(/QF8;I/Q]-U>8V_1H5@:G7IVSVH//P"@U?)XQOUDKW\1\2<N9?<MQ@46
MIT^M_^;S-_NUM]736KWDOAEY]%U&,3,O<]K?F3_K]E_A\?NY\W?IW=_%KS?[
M33"@^^NNUH>5XG;]@:=;XK=*#N]M-3M;B!8\Y3XYR# Q='C):$9.=V:*7=9]
M.*V@\MY$BHA=+M/+M:_7&;4=?/*'37B](7"X&9,C1])?S@HGL/)!\FW7'Q<E
MS:VSS?K769DR[N:MXP^AIV+C>ZU5*%WVJ*ZZ<$Q&G-O-+E_YQ*OXZ[\V.W)?
MN?T/4$L#!!0    ( !>!K%H1%1; P00  &T2   9    <&%C8BTQ,'%X97AX
M,S(Q>'$Q>#(U+FAT;=U86V_;-A1^WZ_@'"Q- $F6Y)LL.P92-\7ZL"5M4O1Q
MH$4J(B*1*DDET7[]#BG9<>PX<(=VR6K AJ5S>*[?N4C33!?Y;)I13&:_3']U
M7?1.)%5!N4:)I%A3@BK%^#7Z0JBZ0:[;<LU%64MVG6D4^N$ ?1'RAMWBAJZ9
MSNEL*6?:;:ZG7:MDNA"DGDT)NT6,G'18. K":$!3VB-^?]$;+<81QD-,TV01
MX4$4_!5TX"BP-V>4KG-ZTBD8=S-J],?]0:DG=XSH+ Y\_[>.Y9M-4P$NM-R)
MR(6,#WS[F1B*F^*"Y77\YHH55*$_Z1WZ) K,WS@*<^4J*EG:,"KV-P7!H,->
MWK5*04[..%T:$00#T(RF7<.TM'?+:DWOM8MS=LUC&[O.]S8SW#!SM&EF: )T
M=I^Q!=.H%WK!ALGK(<;R&J*L11D/0>R:[0EDE<KO;OQFC)\V?DZE9BE+L&:"
M(Y&B^=DY>E])SE0&8+VHI*HPF*4%"B+TV;OTYAZZI(EE#WH#W]GM\FOQ\52A
M4R)*O>[/E7C]=B_#//:')C-7&4676"XPI\H]O\]IC4X3;2BA[X=[(<\H_N'.
M;!6S=>8#1XG@O'7ICND,:7#H8X4E1#BOT2=:"FG=N<")@21ZRX1*&.4)6&&0
M"2E)!2 3.^@#3SQT9 0<'D1AZ$_FHB@QK^U5,#E&H..]D 4*?/<C@E-660FF
M"X(H)P"%/[!,LL.#8.A/>H%C^ZZ#L$(IRX&Z,A"24$FF&=B .4%G]TF&^36%
MCET43"E;-=QR$FCO**.2BA0,=- \DTQIACGZG7)9FQN,IB !)&IV2]%Y"EY2
M:7PSYUL7')38FJP?S*YD*503!+56>N8:K %@2S3L63%F-)A";45^YLR@_E*#
M:0H4$&I=Q&TUE&O5O0$V_2S8'*!C[9ASAG%!E245-;KAX@[B=TV?Z0L;@)R4
MF!"8B6Y.4QWW5MV109JXCMT@>C'0'K'CI1?_O?K'<8F\P<C$85?1K"'HWX'_
M43DU<I?5Y*"TRD%; O)S4PFKZI#T:\4D-8O)!CR/,!2A1,'@B!RO /502ZLZ
M:E$5C'M]QU;83P&;UX.;@1<M8<,X8*%H)CWT8HWA((&[-C<MDE+,#*Y*297)
MJ6/(.,\1' -;< X95R4D63GV5,HXYHFY#P()LZ)-$H&KRAM(" ">U:DV8.I]
M8XA.C?Y]5[6G$[,7N,)F2&J\@%[:DA="$BI=L"['I:+Q\L^$,%7FN(X9M]KL
MH4DK;"&T%D5L%NI;T](3G+=KA05J0VYW[7'DC:*16;>UA"]9*FXW<<]NXEU-
MMFG]T!L'T4ZR[P4[:<^*]<+A#Y Z]@9!?R^Q71N()A@0;@60.>GT.LL#+<CC
ML+Q'P>.%VN!^,^)-L%_H:<8^1[V#"CH\&$03:+YUTWJ#L&F]&\\Y;62^S>EF
M4]WI]DMX_+:V_JZ\^UG\.CSHCR;*_JXM>>=>L^<]<G=/$/O&Z\Y>(=J#M6U6
M=E"6$!V1,X),6";_FS@WSZ;;L5W(65,Z%S!AF!GT=MSLV*P-^]&%9#"A2AA1
M6_3C[5QU;0=_8D"LOQZ!;=R.NEC2'!N!6R],'E)A1X#_< 0O(!^5WC[2Q'AF
M;'[JO4?[V[SNZ=K73/\ 4$L#!!0    ( !>!K%J,(YR/L@0  #,3   9
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MEGJ1V]5C\+%=VU-=S];-\:.A+*T=HT NW7"1P6TKMSF*7#'G/(>\M7*;>:"
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M8>X80B&!4$CE9IUUE<ID1T@D 3,'/X9]AVP&.53 <==;61:8;U=0T,M6&FH
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M;J24_+;2#"HS6ZQA7F+F*S;[B[<,C@!?EILLK5E0,,Q<(FJT/K8EY"O#F7/
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M% 3O.8ZW.IF8--E"AYLGH7/J8;52#VL?:O4]UW'!IP5]3#ZV%G\2DNTW-H@
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MW+VYM@+DU$W%?N^Y9.J 3N/;;8N6L(<^55J%KO&8)*N7I48&KC1;R\BG^UT
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M#(C]HJO$MP9/1+7&)GT*-0RI38!8:K?*(K^^A,!D,$\RR("!,84QY<0>>.[
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MN^(&7<*O$GVS!%_;4@G1G'O;FBZH2O<*^;H(<5Y7,0RG/^J\*+J!Y?/WECT
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M;>BJ9=UM1/?,5DE #LWR<)GU<M-5"<P,+5=?THJ.VU5L^QV(\6_%\%*?&=#
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M_5[G# NP&^*V)69$?P<*:J,X+QBDJ+8%7RC<T+;H[UPDLC*;&4! _Q8];&O
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MM &G!1@[AD^3,BA&(_A!PLGX*_,!-LXW<_H+AA3=?(\9,31HEO2"72>7T2G
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M>C[*2 N48+I&U3==EUSHD86J6<+)CW<X>7G Q\*A/)R%Z+9E&5=5#C\C]W;
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M<M"U9>S5+>4/^".S4$MBO:MKB34H&O"/;=/R\"M/_C:"9>M&R@*Q9A9KS3R
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MUJK+@*&%:[1PS]OP;CGHV++9LP'+>()[\ P6"<Z)Q>TE&I!G?6US$ZK-\ )
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M:4SNXJ$DG])E ?)O@Y2Z+."=T;8^\?)#PB$QZV:*V='!>,Y<]**F,\4G/HR
M2308B0:S@\D?E&WR4YJ90VJHUP"S/NJHG0\UAX@I'^GBF D1QK;-K]ZQ+*?0
MW>Q8M4)E+2I_]1!V GTU':2R=@9;Z9_'-EIG<AS?PVGK<%':$54(Y8G#S39!
MURFEGDR;]W;@:#Z>"(^U6U"BF@_NH]!W+!D?5/RWRHG2Q@S9M3'W[%?&W,!!
MOT;1VKN@\RD2L:7:%TRL1><&^JTSD9X,/=Z<<VY#!=5Q:SPH9ZC@J-4?%PO-
M'C[(.VZU^Y6;<PA_Z%1M4>412FVI@\U3'.7A'>#P-C^I4"O);NC .3^F]BLR
MI7$4LR+I;:77*55[^\ZIK"4)$I6#!QQ56=%,69.09M;<.=LA;U;E0[[U:A]H
M%.GO-ENX2^6+OF#T[W?@K<8VO7>:,'<@HI+THBD'1)L;4>=+_[BF6M\<1-J^
M^[,FW_5LYJ[<I<]P0#=8$H=.D-3;1CT<(+\[ZUT$B:1\2OFLO'P>R&LZ7BG%
MIQ2$DCSLL?>DIR(>I/?6- B)HZ>@TJ-THV$\3/<Y$ZJ$^V;HFFTO]1\,0B6?
M?@6M2#=MKO<=C0ZT))Q^V$]DADZ9 +[ %._9)W''FY.XV;QL[S2_;#!J3'H=
MM:G6=MB\%*R+%:QB-5N[2U;(J0S[DX5E;8Q]^IWF>)P<JE.X<DN*F12S\[)?
M.\S4&;;!)QLUU=$Y36PM=).L8Z']A<R2&K>/Z\H-53 OZBZNG&1ZR?1EN5E[
M<'U);M:PTYAT!\U!RNC"3"]+2H"4@-.K_5T\H"XP^[#7[ ^+ND 5&4!>00:^
M206JWB<\7&KL_Q1QWG&B'+.<H.JPUYAT,F.JLE^M))6D[NN))O5.'XULP4;/
M(\^$ETQ2S'/;G4LR/;<DWPS2^>;HG8N294ZJ5Q*NSL9>L^&P[%ZSX_GU*5Q2
M/C-4P>_ME&]D1CL8&7FRY5N&W8^V@&48%[,,\IPK),'%U/FHO:,Z/^[5E![?
M&57RCOIH.MKR8!<EB5L@<0N.IG:ZQTV3C%1>\=+OEESQ<G3< BFQ4F)/XQ#N
M+K(EY7A&-/*BV^SVRRNED?(KY;>^\GL<\=TA0S7J'J9&IR+BNCV5>WKA.TVB
M]X0R5H'+]!:$P-*]VAXO_BGNU4IIDM)4_1#D[N)4EL=)"<_F>%"XJDB*UJDY
M[>)$ZSB2M8LS.-BO7.GHLI0#&_+OL9FA<LZXG#-^!+K).>/G/V>\)^>,7^2<
M\;1Y''+.^&7,&>^DSAGO;BG0S81+-1<;/+C/-/DR?"VZ_;EFALTR<%01[B$7
MCJK:J0"0ZF-T-!J?\JF%-DM#:0T^0RX!F,JA;3FHJK*D2;*Z773\5;<^@*JC
M/G@!(SFAJAH3JFK?1/&=K32=QGCS>?()\,F]*V;KFH*2J20>ETM:'9]G[A?<
M4?Q?ZA4I&&+ HM%FNU]6=<?%MT.!\ XR*\TNM?2]5+[_"L]]?&7+%_:;B3,X
M"[,\ HLTV\.19/G26'XH6?Z0+(^:_?'5+,KIX[;D]+(Y?20Y_>"<C@.6"_,Z
MCM-L=MNJY/72>'TL>?W0O/[9=*TT;NXT)L->7_)R6;S<;2N:0<. +$9Q7LG:
M^5@;4S@;^!I9>18K%KE&^@;,75"/=]%G&7?JJ<<Y,XPK*02I35"R)%J61%>\
M)'K<.Y.2Z)TGIU9ASEY8P6.0VA^DETP%Z33_<.G.X:^8%M(-/O/0M!W\IL5>
MF.$R15_0;#X^,!&-L\@OV1Q)"-'F3?I$\@T:IJ8<Q]*G+L\6P2>]QSXQ@V%:
M,CI*4;E.RV3A*,?DTYUGS:%7&":P!FQRYBS?PHNR@4/M]!?QI?%W\0^;:^]3
MWOY:F,P' 4J"ZF]:C.OH2WHFD!..\WGSAHF@\$F+V8RF6N&_Q2MQTGKHHS0I
M45LNS1GLCPB>FO6;,N>5,2-QC/C@M#UB/G'SD,48K5P;'X#OMQU+0]:[0C94
M5LQY-N$=(%?X5]T*I2E=/L&($HZM/"G&*HC2'PR)I[/7;?0A]ERM-=VB(WM]
M!O+KQAR4BR>%:Q/SYCJ.(0T^QW[J(%)-Q7;QW(',B@U[U1?P/?@KR*S+-3S.
M)M7L9V6!"5I\ISG3B:J4RR5&H'7D(FP5ICM_XA-4<>4.QA"4%06(%6:@*HI.
M=R.NQV.P&9\1FL)4"\IUXQ]3A36D NE#\%A5N5\9NKEB3>7.F+64=PWQ[\8O
M_..\0!&E [3D[!D.'%>Q6(*.L15W/:<%(/\[[$F?*>LED(-$+#HD%OE&IZI(
MY)*9BYN $]5F,[;T1/&?^F==L=E?+C-FI!SFYAI?WE263)L3H4QEQC3\;E@S
MP)9173\#8:^ C*;[]+QVP1 ^@Z!>P>UICJMRT(:+A7$:,KH)< 0XXEPZ!GU%
MKX;/:308!9\N:@M"O+>PS%7X!:%5KRT3^943 ?CB19^1.D>V!IJX2\<[(T%-
M. SO*)O*O !'<(:8F2 JJ(Y\6K)Y5"'"Z_ZC$%!$U%OJ1VY6D8G&U\;\.[<R
M-Z!DKX,%%"_%'P3N$Y;B]\>M;H;W!.*W]&83 ^WB6]UDYXT4Q=_TV!E_B7SD
M\X<X%&[1?.VBX"!BL+3*TH33LSQK!O((5#17( -3^,U"=^!_WTPC?FA"DCPC
M1<H-7C;5;/@FV3P="X'GB@&O6IJVK<"*@=70]$S?-A_D-V8]X <3!QHI N]$
MSO.&F/#.N-4L RA@!\\0!],.#F8 ?FTKY:);&T-V;_#3X(PT]!0KGNV-"?;(
M>%.HN)ISCPGGH6A/((6D9O#?G+= "5F.!MR4KF5)QW#?"Y["ELA<+E@\T QP
MELX;UQ[H;MP  X._H_QN@&*T0-6^(0?_$QA+^?_P/Z25\!:,!VKK<V;M*-']
M=(GV[C]TU;D.U/U-^&V/%E!\P7 Z>&%1'C8FXU:RI28BR"TE-!)[TV& @9N1
MT 1G@@2:P8>7]$_->DL_DB):M:5\-#UOPE,EL=/UUX&LL 2M *X**ET[S65$
M2X*RR\BN^,XC>8>:D6W%-P-V#DH#['R%ZZ/-C.#,1MO 0LL;"I5X][@QX0=$
M4SU3>S%"_R:KFAB#VRPH&Z/"LH&F M@M(B5?=&T*]QWG[:MIS%P0%B-GW,"7
MEGZ[W9CT6UEX:)[92RUF]#DUQ.D+W8*+SU^N9CE!F19H)BS"078SP/^>-R.7
M7YT\,LMER.-\/W@U,PUQ\05Q,= THC;", /Q[50#GV\&EZ!GQM"+IXN<+=PK
M?J6<,@5?AL_'<I/:V(L[(YN2393W-?S*\S]1UUOZ2GDRS3GY"*$;C@-B+JZM
MMHD6'3D#508Y<* *!//0!WUG=,XB]RWN?F"$:(TW?3SG(HRN;N;S7\6R[_Q5
M?TDT*J? ?K4#]E4;$\-,<&^(#+6YESV !O+66FZ=?*%ZTV-5SI>UJ/RU]#U0
M]%]-!ZFLG<%6^N>QC982N=V%FQN.*'RD_CQ_$ -%!E=!9/P,$7[5N9$EDP)J
MSF!<_U$@B&*WW 23'Q$+182"K'OIHUJ4_>=OO\S?:PE>#-KU>+-E"3FSXAU7
M:J[!MY\8O[\ ?U,,.#GM-IKEJ*Y'$G)XN5L8"0\^:^A2\!MCX3OB>+-_@'XO
M/N</$#%OA(+O]!9V=3N-24=M9>7,0[[NW#LZ$;XOZMWOLZN;'?UXA$3JM[*R
M?Z'-O3[K<'%YU6QR ZTYOT0FMRRT&?>MC[?_/:XR/;S*9-7H[T !>,B53P7^
MI34XVYJE^YDN&V\:_C=%Y)7(@6_W'F5[]Q-;=-!Y%Y10)%6$QPT@X^9K."CE
M:# M'S6_\U<A1;[!4\UYGLMQO]UO3!9P$4B_&[<\W1804FPC*^(1U1_>)= N
MQE]$@9T93"SYNT_ZPGPV:$QZK<$6/J, [JL6O>C&>0SY#ACR$YNQU919$>KT
M6DJLUTN"0DA0" D*(4$AR@>%Z$M0B(L$A>A+4(B+!87H9B(M%(F&[L&:F?&F
M]/OT-Q[ IK#__116QJLHZA+6IWJF)W>I64N18^091N^N(, A5N[2T==PMNO0
M=LU@NU0R9K/0UWBB;ZFS%_]:L="Q[,3V:CXBR1(%$R@MY9_F*WS!HAO\2GNC
MTK97N/-Q9YFN-2OM!_,J2Q3;G0+1')=7KF &5*2C5^:<BJ;X'\#GQ4@8N"PS
MBWE%/'Z%"ZP'YQYB6![O6VNX&%"BQ\:E@+I>P(9,RVX*GYD"9YAVG2ON&C\&
MWUWC+[UKE.U=RW '=)8^^43B!.CU&Y;B95"3B,>+*99P+#;\UJ:TJE?GP6-Y
M7NV,=ZUC/]F,*"&(N2% 0BG=)]C$$Y9K!.4]=$G")+>X[\#%<A84&,YYK29F
MS:B\)V/U>+TH='/**++Q[DW^U4B\."1R@<05OBZ!NNJ/MB7DF\'%7%L#T_VD
M!#6<2>;VX,UP94K>#=74NI-"6X1?XMT&[)N_'\30\38T:DR&R8SIWU(2D+ V
M= *\\^1W/J]&,]==/P'"DVL#7L/)(\G=_>*!&)LOE-_^U7S7?\R-4Q>YN,O'
M(P#-?4^K<^C34MN-22=9UO4W+U+!H7="><VLD]AM<66=A*IN/PG>NB7TQIPS
MF6CDDEF'"\DZ?!/V^@_- NN"":?ZYAW^"-MFT#(O^AQ,Y!8YC<1&'QP0"LV:
M"ZH(HKP5"("JG<;$A(6A'Q 7.;"__'D*U8ECOH]<FUAQV2L++7X)>H"JQT-?
MQ<H6=X5G@C6[CE<3S((F$#L4*6Y2A2!6S&">TL9B+OBJ#L[=G+*807&7_PZ>
MOIQJH@#Z60<OST)&)7MEZ0P="_ E0+\LJ18>&&>FK^DAG@,8\D%:RA_DGP(-
M\2$4#*=*?5RX_U)LJK!>F,BL,G#(9KR239LC-T4_+/;3Q'X7@\V8;6O66S-8
MLL:K&</+->:AK?(=<J/KI6E;(2$@1R\<[?>*:+S2([^MIDC=$2W"WX-77JM'
M\PH:%0L"#W''S^L,\>CJG_'&]\(9.XS[S5CYLQ8%8'P%^'R+/</7,%*/];OD
M=<..7QDUZ"A() L;('CYMQVN_P[JT/F1 FWPZ S:+@/;&(]#[X09>+^(R: ?
MCT_'!>RKW9RX@%705#<!6;D%#EC?.^?7@!?I5 +4OP3]1?<*F^?" QS4!P]P
MJ+;&W<TFNA >X.:H;?[?]]KE!+AI4=UMCTKQ/+QS ;EBI_E4H1!W[*GC/!%1
MGBPZ:H=WNH=$P"D*1\52;J/%V#FF7QZ4O)>"3;FMZWA[7_%^K+5W=W@Z:Z5A
M4F;?,S9L<ML$U>-0Z4 "B+GM@PE:#83V>& 6'X6WJF%?&-AX0P1AN:.Q(R+
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MBWHKQY"1 VF)3!DY@B@<:$O%1$$]HBB,=Q6%PPX J+.5^SV>UA?ED1<Q+>>
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MI-LCAGK%K#!(\5XX7(,,T$+"3(N&A;VDQD?X^3NL\Y8KOL)!8FKM:&4!KX:
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M6O"RMO1KH*[]I?\!2XM9M/N '%LGS;6# )*Z1_'621;<:4R^FHF 5^(7OBX
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M==<9YLQ9'*=C%D:*&HH8U\"H2S% P;[+?/3.(Z&$\O5U#VI]8,KB=R4 #[-
M%JA^@V*HM%ESAK=WAJ_]^/OI)ZP%O,0P =RE%FZL%.H1?CO ;WWU;83?KB?8
M=5G.IUI:9*#ZNPJS (7#[Y4;,$(BX<9I-"6=($%[ 1@LC?S$SS%D'OQD"/8
M:3VHBL);T<"#6V'N ICEGB<6<I>?$\8^D1TQU,JU,T,.H/GJ[6;]T*JW"W:\
M4#A&167L 6PW9;CH9GU>^NWFE%FIJ'OA\@_"Q=5J5[K=I77>>QGG7#DJTZA4
MFWM7?XZ3>KS^_#EUWIO<@6?4C,/YV,^"\7VA[7:>,C7;IF9[;5[?WV2MBX(#
M"32ZJ7"C^"#JTH_T?#Z:8[9 ;>V4(XOWEEM^O74L/W0\.@63#U;C_=P'91VX
M)M=N&XC!UIW/C%K*5$<F1)ZTE8V]VLKF\JT\'AFH^1F/40(^ U[GL;3"EQ."
M,E5U31]@I[X=Y.K'CE?N'4=GRA<_\,?IN-0IUCKYT)U/ROW)DNV UO9X[L%J
MW1\+5XMPW/,U_C_M..7K&9S^TBGEBW:]L>M=+]WNSLF'SGQ]1]EV'_PE<KW
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M9M&T8<N-$#Y8(;PV7PS\'Z)_^E\1A64L4>.Z,*?VWDCAXY+"YT/@#BR"MP;
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M0@)4BMDW!52&!T8B8W2N\L.3PAZF]1@<F+>4=5EX9FXQTESDC8F: -_"B.[
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M,]M'[^.O\SE5JCPOJ=C+-\NO*_#5/^8_[W8JW6KY5]6*\Y-F+,S0E%NVE9_
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M8!\V!(P;,F;\?+4KG2.0$6CT">D31BMHK ^"GMTXQC\KED;)!!W7,'A?C,.
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M*6'I$"R1)ISASL(3"0_AM1?V1BCEV+Z;P(U)51NLW@LN_: W_ _\F29QXK(
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MAZ* _H&^7^KQ(_H27R)?3YBO!R%WRB$>R14-/Z2_SQC7CL$2%>H/^>,"!*#
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MN[%LB88P9(PLR! X*/2X26,J4739R6@78QH* B>#&\4P S='Q""K*Y$\/72
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MLK1I@:%AI/@-SR&"9=\HM,;.NU^P5?7KS:8E1HWZ5*RJ'3:\;%ONK5<9/J'
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M)7O@?EW@&@92],.XFD^.Q_3WUU-RF'<AG7 '#V57TM-J<E]DD&D>9Q[7OX;
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M'&SA/VC2_R'C%E[X9+J$FUJ$"^66(2RK8RACT96GD1O;#.[CJQ3<8FJRU7+
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M2G!-3ML]2D%-W=>ZD<R4N#B+'X+?S_7JC6$U0:1A:8O_5P#IK!M"U3!%$23
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M9,[*5=<R&3C1@SXB/+72X/\4T <@N%6B''51HN)NB!2@V0NK@I-O>QVZJ'Z
M*\@$GL;5-+ECSE9_X?.;I;[967"_2A=2O&Z<QSTQM!CJ6M]X'9D?XN>&V3.%
MX^IPTQ6K;^#0@PO05$@/A;2J#&>NPWG5U^X L6HZG401 .F1](:G8B>["2<?
MVXK LA"'/E^C! !8_6_9#)B*9)K63SVQ??I/GY^MF+C GSS3+RBI\89?C4=
MV[B\2MCOV6B@%HE[#W-:7'JGHWNXGQ.MU^/=RY%Q+73TXE[^Z*A<5D1USX?J
MX=YEW[CJ)D\P&YT*M9<"-7P)Q59W0$(I=2SEP\KI0^E/1YE\;6<3?6?"<7@P
MM]A/ELXEIQ$[A ^PD7Z&6*/?:N\N69:THV5VTN3N(P*I7=@&4C/G;4\*4:WR
M2S=M\X@^Y;BED!:.GULD#^4.,Z^5 ;L6VT@V5LWN\T%/>!Q>=5Y-#FN[=/2_
M*-H&RTWH>SA6J')SQX#Z)8FY_!T"W1];B%%FUN;+6RW-ZAW0Q8S/4+82&&,,
M>'EA4!(_G)XJV@5V]4QODP2-(%37HBD.9^E0&SN7[\]LMF,W/B/H4N@O#*_L
M49^HO7J]/L(%@KQ D!<(\@)!?CT(\N,%@OQ!0I"_6"#('R0$^?T,B3"]MRLW
M&-FI]D4,GDE"%-QQ#)X;ZNDN(<+^]X"Y;<I:]ZJX!_.RX;S!1A+B_K.Q6.K!
M/W#'PG_@WY(7QT1KVW)?GAN)D!L9 1K_/50')MGR1!,I*=&&N>:PR1VSD?5=
M*2'>AYCKMZW*ZM>V"3$FNQQJS&])]"\33#P0\8L]Y97PTY20F/^*I'9/!^[Q
MTS5,,CB["O/VX%>W6V1$(+5%3!<65%<:&D.42P5%:0*8780Q852LPHJ'[9*K
MP(QLM-%&JG8:HJ:A]S'?15?*&8P+TPY]S646GW-214&JV$$\#R^SS81PA$AL
MB$([CK# [V8?3Y(>GV7++.MYZ-KSKMQ+ AWF!TEYRMH_D8.:5R'528Z"A%CA
MP;0A+5!I,T8E.B2=&#J*5RD;!&%82;6?F!;:PO$I68^7GX/CD_0N1T2TJ/AP
M6^YXI&VR$X[(L]777I9^QAQD%F"6,,987]V"8R(%,4Q6?OI-::D'$17</IJZ
M?>BTA3^"'?F/QT^^>++Y[*L[NE?\H#_\)E.*FNGG'03WVT=B57?T_[Z2_Y*1
MW<'&/KX5'N)'XE_[$<-U)K="H_O,XW;^(;B=VSELO_TV>7NW_E^D=$W,,ALJ
MFI='#TJ: 3#!'XZ<>A]Q3S!48X^B ,+9+G>X?8#Y TU)-Z&T$K.$!C_B/T3E
MUC>A4.X-B5A79JFD7"$4\28V'''V#^K63_45<++9\\'LODS<]-)0*$-*T\;+
M)A6U Z%KVD9NME^P?B 95FK'AS__>T"M9;+;V2!,7YKJ2K9.=U\EUVTD>==M
M1>G:"U*,SB38([<<J1(C87[XI<3A+PPS]X?)N@K:' 9F)#0]+19^B7P%JC*N
M5>H%G+S^:$@7PO@WEXQD[=F/8 (AQKD(31;L1,K@LK'!LE?L+NP8AKR5?UW@
MR._;0N]0MW)JZ43+LO=;8%F]>V1CG\ 1-J*0>=,Q:P14=NU1W&5;@]"'L9*_
MG-.WV3;0;^"&UZ*I+)?SPZ:.LF"<79#7#T*W@[".==<R">B!,()'=OE$1TBJ
MIMITX-&XA<)SB%B0+W2JQRGYX390P(M(:G+H>3?2D-'%]L!>%F@EWX0'Y1ZM
MF0#")D264?_]9=/=,V!>%L_VE"";YJYNL07QZF""RVF<Y3H4ONA.B0,!8" /
M;-3&ZFPKC$K[[2:$+1>9TU1@5(; KMO)ZPJ"'\)6M6S)$!(EXR^2KR'JAWL2
M267DLL0JH]A/=RK'7^@3BFJ.>;;+EKW?+2LA$O?6[&Q%!(=[Z*I 7:,:)RE*
ME6 %'9HD"4O@PW"K$NTTM\T)M2TE>Y8UO$^?= *LIE=4JMX]=5.Y\ ,CU+IV
M2]L.QQ[Y:D?R=I3]I:?U@1&7>#&1+(R_VF!D6ZPOS/P6-:D(]WZJGF?YE 1Y
MM&RCMQ'::'^$;2O-=->6R&(7A]C@>VQL6;S9MW3"Q=OSH&!OI!-7D:5++4=)
M=AC6>%FH>PT[]/[$8)## U))8'4"+*IUX("AOFFLO?%5R_9Z$",=*UK5KZ.8
MXJ3(OF[+%2I"6N+1K<L'5*U].5'^/L5<)A<T78-6U<U5+Q5B*HW".&'4[28<
M[[D3$]>&]"+2F;?,K=QJFKRE\.P.Z=H%_[C@'Q?\XX)_?-/XQT\6_.,'B7_\
M<L$_+OC']P8)\2]L3Q='3+I4QK5UZD^A;KU,Q^V:>KQZ-P_&BWTV^^K2S,ZI
MU,E>'>P1-.:&PA409WJK+MVL2^'J>-&UP_E%GNFECG]I=[R,/:?4';ZYX-$0
MJ\%DXQ"I\2;-?3\/VXKP=6D_DN@&46&->36P8(&!)_V,'R\5PU!/J&J&"$C,
MF2:NV4CYY/$(L5;.":O3V>I?"6F"*_S,=4I--UC=L&3C=)63CTO2H@K5H*]0
M[W-D@9UZ3\W[:YMVP@!(J;Q'S)0Q_76(>(8<0AC5Z%1J;*8X)@D#R>:>(Q<:
MX[L&D=,TU<)":%1HDN #1E]'2^R2D!Y]8WEE(7Q*$Y-2'<B?F7Y(AI8_';Y8
MC9\_/&3RB!?48KP3>,C44C,)3B\YUY(G+0'QPC]BOSB!271OHG2G51'A38]#
M[ +EDI4N.1]L9S:(P9##9^V<MV^D)GZBF??!&/.?[*TX&9!NP/ZW+XN0"87L
MR5<7K?WPS)/I(&(-+D'^W3"4?*DH;U]CY4W6DE:6^)0FGE'<N.K$+D1E.GQP
MP#174Q)5C!@%2M[8WZ_69=>Q#J\<4Y\T(9*$EZ&CSVH+.:6"Y#?ERA)>;O^+
M\NE8>H4!R;@9/JGE3?P$O(;4,9MPWAZ1 Y(8M.CA."I"MMIODO$C^IQ=>=D*
MNA]&R4403D_I?2VM%,QM!P.Z'9\=J>SAF1%Z(QCG%&7>?#&7US OY4K_07F%
MW%^>:8\++S\/C31TNV^;>JJFPZR^XR"I&:Q?CX6;_7[J^' 2E+%17!J.5P?J
MZ"&2D8B;S!)9PI,P^1TQ1!0.P4^] N3/C+]"SI7A6J6$GA2T+4'NRUSV)!XC
MO!;\B%%"T'ZGKIGM>/^D.R:#EI!2NL(#9&LR<T7")J+/H+X2N;CA1Q69JH<Z
MOVD%N>+GPOUF/ RMLES$74QP$=2EK6E9Z1JFA&BI2K]3[S/15>(@<3!3?0BO
MN,DB3A)K;'?[/M\M1135)8O3GLH:L;GD7.D['\J$B%"4N&5:6F<EBM%.0T2$
M]WCB)]'Q$(N3K#\<ERX$H4Y(=GNT@WMR :,A95>>]+?,_>Q:!(J;_&Y6;/?>
MEXL5QKLT-[YTC5R%>!^$( QQCKR6MU=J0>F-F:1$:,ITD5,I:ENF=+KX8>FQ
M9L,Q.8L9RN3UK61"Z.*=VOQL\ #]G":3J>=&UP4YB^*R;)F8: ^/#JR+#J<2
M%X0. +[7.O1\5\)(CK:-X^5N5#HI,AMV\J'"&>,R1PH"%V=?+J<H#Z%EO\"V
MID/?JF55UZ3.)S5!OH+-?*U/Z3*Q0S<-%I C98:#>A/]3X@Q'Z\]&PZZHL:6
MA1NIT@I/4MJYCBPO2*(@)<N;%K8V>KZ%@F(IP2PEF*4$<\\EF"=+">9#+,%\
M]O%2@EE*,.]-DA"=JSVX7,0$H%$"Q="Q!Y)RO<QOS;3-M^J)]#RD(_#,1 O\
M/)8\LC!S\V3:"&LL&%U8SR3+A>_TIG'RV!Y,FM$%E!PX"HK^2G@DR-=G!!."
M+)%JO"]2P"620AQ._-X\CT.S0XB4RZ9I%0K#=?#2RWXBNDUJ%YR&DCF^K'JF
M9';[Z?7VS-GJV] ?*HX-^[AK"P5\W=B>NU'^"0B6:I0SQQ2CM!9POG%3=9MA
M?TDM,Q3D[JL>0C\:"WYB',67QV/8'XZW?SW_8E5#7.DTR^N3)(4T3V92)$).
MT>"!**6WFZ( QCVC]%*UY0Q5)3]2]ECPTP2! TS')>/EQAY1?!3^Z/33XAI;
M L?7D!QG<)&*C!?,-5X(RV?/Y,/XJHH-+BAC'8E8-Y03*R(^M=G^B9N;#<48
MDJ:DV/GLX>($QX.-1]N\NR022DF@>V2=[VLN5C^VFPNF\;7^;=9TE&\FQV9F
MG_KE/ Q=/TCJ'BR"32/G3+8\ZT&@ZS2S-(*D-X=%(-/UB$>*31XL[T?&_+T3
M$^H^!$?DDOJW)!V39L7CN/[XU>JBO8*)[W0NJMZWA>4D+3SGK*^P\=,O25;*
MQ:Z1IQ,WHY"@F 2!W3@4N,MJ;9GGLZYM^8P=98+ZX,XG3$43W(Z69"PGS)6:
MWF4W.*V@@^C@6R3 NA,= ;I4^,N987B='6.-^?T&:RN4KF& :6'9>Q[R>;8]
M._O2Z_SPV>H[NLL%FHKY-$EJNS0-?*.FRQ?31Y3HD:074AY89T;ZRU+-;WJ"
MN;)49F!#MC<%)F*O&H[$($[T":[A)R_KNRF8;%^<G5I+157(M1!3]FFK&%I?
MN N"U=O>6NZI>(WDTWOO63Z?/:1CZE^[D&>@$=@GU';P]"9C$79%I]\S/.AY
M;"POM ,<-[4"+(BHF3A%9)9NJ@>\3JNH6R1P&Y[__>7J;\?M6;%Z_@O\ZG;U
M][)I#TB^_C+I6G[6;,Y6'_T!/XY__ ,+%/P0P!W87*#WC@\Q)0/[>Z7DAP^C
M[W@>R(311:F_3 _2YQ;*\ ]_85((5>HA1X&9BJ7[@C::5:UK*S.L@RKXH']8
M,3(&L4CMT*^8,XEJ&8R<2IIB55UAJJ7D)L:E^]I"OM&W?P?4U<A3C=Z6."!R
MJ<5^8S>!9/?!'/921^J#WWOBD$V?;%0<D&V-;C!<TCO32] 'L&=2D%:SL)V1
M>XJU<_!@2RX6F9H$>OB-72,P+/CU3<C]1RPM=N&2:>VP$(E7QC;!W7'P:M*1
MI.M ]7D^?WTX'NL@W2$U%B6I_,DZ39<50@M0,4E.LU].U(4B=R]A=_^'''MX
M]$N-_U;/D8E@=+'B(7*CQS@D] ;"N\T3#0D4[HD6??;RN6:WTU%_)YM=5HPN
M<_7.$X"<54[)"*$U%V"%VC,S;F3I4BR'QVSLK/\_*W7^=(&,,0V)DO"N6!;&
M+4S<XW*7$1;!=K&4/F_>^(6W+*H1(O24(D:"CY$GO&0/$9[S]>$0X(]_;DNX
M.O7V^\?+K__L+R]W%X]@.<%%<WV,K*QS\'HF&KSTP=>VGD[%ZV%D0_-@21%N
MPY=TG^C]8-Q>!X&^XEI*BF+,!TO6+C6#+!>VX^O3)=_4L/K-3G0.F!.T.<ZY
M+<79%M&#E<)7_!$9Z10(MC"!L%[C+-Y N^? 0G$69MDTG6_JM-N$:&,?L(Q?
M]7L^U_K6"J<P1\0E8!48[>\&P@'A5*3>(.HX43)$AMD=>W/\TG0K'))V4ZI,
M ]PP=5U:G$*B6)I:HALV\SG1MK4XX^V5;)&XCR6BDH!OU]9U>T6()6;%8Y=,
M -3.\^+,9/;*>;BHLF\5;>*(9#-\E Y0'LPLMR@[!1\I*373&>T!<1<CCB,;
MV7A@?TH/"(V-_ &1;L2P'.6. @KBX6&1<8;NHCSTB'PHY@F&VKB?);OR@GQ+
MRXA/<!+1S]Y1/G#!."P8AP7CL& <WC#&X=,%X_!!8AP>+QB'!>/PWF2B7[C6
M @_M3U19)03;HR[ HZK1_*.4CGTT& 7Q'DS^V,_ F!+RM+HJ/0*8LJQ>(="]
M,@5N8)PPP1"F-..[Z43#NTI[VEN]BV1#G,CQ!');E/M[+JOUEB^*7'D89$4M
M",-Y1,V/DO(\O\!_4JW-\!G#\:+MF/HG^S%I>TF8HRGF1-E')X1Q&#IPX4.O
MQ5,'WSE@_N$X\>"D&.GKUTE-CNK;"0J\V7+& '\:OGW]@9078 55"#339^F_
M3F]W#D+=H#$C;+];T?OQC]HB[$C^0W(N6D+D-#]'79CU"5B1)0:M=O51]4?X
MIPM2"A:N/(S"8@XFR=7&L3S"[9&,MH!GX</J.EQ2 \Q% $^.*.'[<A>.#.[O
MZ6/P.6KBD"3,7DFD]!R['F2*Y3^J+O^X.N<^L*#99!@]#4J;"++:]LR '<AD
M#U_C)B?L7^1*=K9-*.&-TS<^&/;U6 F?.0-)2LO:)O;4WN4:I#0GY&$PJ5JJ
M&X2>'?FNKZDEZ!8<#):JY+=?CE>2:A%>W;JIPE;SCGVRU2>V7,%*P PK8C"$
M%?P]%J.N=N%1S[V("$^0V7!HCFIRGUFRX]I]KRH2/-UI-P<O^_3%6#A&@OJD
M'.6PJ$W8590XDKPTBV7O<G!.$=O([U9>?\#U<I& @EW:UI>\Z0WN&%LTVUNK
M43P8YV0>*& 'F*;$)#1$.*-8]42JC8EESJGQ?#D]C50^N6S,IF%N%:TRC/A7
MWL4^13W#'V$5F+/5=W0X+ZCT:UV=$[KP)2=M+0/;4)96CT9BY?/V>OH^]TPA
M;@9M*/UO^4K+F^.*/?YC(5=2K#3IR"ZKME:9+AF00BOS6B99AZ2@>=VNM+(\
MCNK[LKO$HL8_FPI/JG"[]&B,X&MCRHOO!IS@,D-VT-K1%!@'1X_WVB94.(P\
M[^_ZDFDP8)T/8MS5M'!)U9KPTH$@_TK'Q108)!5Y( 3:[ZN^M\1_X_ _2;7Z
M;YPBUEF?HJS0K>QQ%X@UR^E,L"YMH*FXREN<RF.R1V.EFO=%5IS^6B8H(^WE
M!=6D]L:#00C'<#14E@/C]E/8$(9X2OMEVA;^I^L@>C!=L9)983^F?ZNV.6_Q
M*I,J>4'R:O#/O_+6$T2IW*I3NN/V15IH[ <W01ZI.O ;ID"!:>R+NW7DL=(U
MSD(]O@VW=*KFQOI/%_9NJ(63!_TLO%D97,]+,#E_HV*?[XV_UE(R [KYJ5O>
M4IX^'0?GBGF9UX1(5=DX28$1O_GSL)7]QL.K ^L8X'>0'( 4"8DLP+]/H:PL
MB%HJHT!E9 [P+Y_7UQ).@91A4RD%T#&TS^](^$!?VF@\Y_DM(I=GV41XT&FI
MARSUD*4>LM1#WG0]Y.E2#_D@ZR&?+/60I1[R/F4:,ORWR'BR6K#ZG]>"P6>"
MP#$A&3$1QJ:2Q+U3Q.*XTT[X^'XW^8V(&,.I+#&I&35!"V9V276X?+*-@F'?
M,GM5<MI,6@&$@%YB=90*O(8%: V_P,1E6<Z<,VZTV-25EBK-J2^.)/44CY0<
M86M5R77?\=H-?<@RQTIGH\R821RHR9U14U"#[634YF.A'*=W*:VQF]A6VY8F
MZGTJ0^E.?Q=5*-^NZ80EC#6-&D!X1W6NL#'U-8<-S3%YM7&;382?8(8AD,\)
MF-+]1R:)+(5VXHVC<OKGPA);9C\\>Z=/W7,.#<_#W!-)5Q,[G(>*-V]HSDLA
M4M*N.3-Q+E*=H0Z=3:C=G-K=<2TKG,?#FU#\<8*'!;/WV)30S31+D2'^!_PS
MY;+^&IIV7VUHR5^6U579:$^.@H[_^DPQQP5\XE7X).O@X2X?/9??7&"B/?CT
M'CSY>S0I_V^+=>'DR">].A.905R@PJ?X"C%?X\2(?.A[F&"XC8>.3,]WS7G-
MG1[;U4^8'+)Q?EMQ?29^]H>R 5N"^^>OL#\%N3HUU?RR,"^4);IA/%3YR'Y,
MZQWVU_#KW\+276FOE7SWI^$"S, _0@N[Q/I-^!'P"9SIDDR_.Z$[E0A/C?-<
MGY>1MT[8^M@.#Y\\=H,RA)5;K:I$<<ET\^&UW% RA^MX!ZSS6;,UG/(ZIL;%
M&"?9\?S"L#9M.]"X.FQFTA?EJKDW3?B&7>\RLW.L;3/6Y/;&)#45CB(XW?)$
ME" -^@B/P&8!HEK(E;@C]GW,4'RCQW2S?\3*BKSUR\CH2YG2<$Y%Z@H&L^4T
M=<Q6XM"I?Y8\!*SCRQMDN<(X7.I1&A^0C&E9^.$T\<?M^XK]QYM<"4"XLL=0
M?=FC=;MYE<OV['@PUOP[8@J8W&%3Z55JA-<4INL)GDAG6B^(<U[6X7B%=.M^
M;3,>/G%P]E@Z2ENOM%!D26I'O4@4O9';8@./ H](=@Z>NII8<$G%<QOV#7BV
MW,U&B'9\K;T-799GVA+,.G#I@9SA"]>3ESR8#@4/1+K#^P!W7YS+1*6)1Q=G
MP]=\M)=N/C2A3Q##B+QY_#5)*-O4%<GZ8@=@'Z^VV.DG,^YJ++&%'/,=![I=
MFU!'(\HE&J0(N?^^0'(3' XB[?RBVJ1GY_3T$\+3S-L%-\ 0EX1;;7A..&4N
MNXI_RK5N#XTU#1VHUZ,B>I7(_.*V\=GJ9;LJ+UNN/\C;^.I'@=@:>7#$T""K
M0>BK3EN.?)5S3#;)&7@.:ZA0US&TP.]J_QD)>*FQ7!Z:^#R>BLAU#KGN'8@B
M>@),P$*, [34YATS_NG&62KJMTPI+PO/IOM3&$_ZOMWB64^.;=]:M^9)+UU_
M6]Q8 !D?7PKSP$T;%#'$O4%&4Y#22_/*:F.0V!ON+?(=81LBZ!5'MS:"5BKE
MH-6O)',0YW^N\L-5L8ZY0],H]($0-[P/V8G$=Y%SMB$#FA/3&IGL&)3 4\D
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M 3PM@*<%\+0 GMXXX.GS!?#T00*>/ET 3PO@Z;VIT"1T*]J>20'P-..SJQ^
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MPV]Q!A/B8"=05_'&0#6I4(VHT!BR%4)GM1(>:6QQ5'B+%!O>%;979Q1JW*>
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M3X^Y07+-45XX7,=-0SJ.89;!.]"EU\6Q=Y>IH\K$0 LT20NU=?DM[3;BO%-
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M(TIC1&E\IUO!1[R29R%Q?EF0E)X# S>,NH>()A=VJ)I#<YK5N>,ODH19YPY
MB:QUQ)$P\=8PPMR3WR2<,TH,8((=/P5Y:R@T 'D$]\XSH_-TX')#FJBLX08
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MO:&.>C=RI,Q=PG)24H"^*:9VY1ZH+)AGZB6_4;+F/*JN2!/<1.<75\9N6)%
M8,<!$W1;<UWY'-B>+$+>J\&J W<V[A42(7AM#KE(W-*51\)L!/QM MTIB!V]
M?>B4Y#5X.2RP/"_(S6:VSISRZ-CQ_"Q *[#WM1&L!]W$5(-"[<6;87N#) .P
MO\_ (/31>R$X$<JD&G-*U-SN=L8>N=?#I/T?:P, MQFXFPTS]ROO4.C?VM Y
MB .I6-;W]8*_*IN*2^)/^U.=9I[6PSD67.=/X[F!"5#)4U[RICKLM'6/2NL-
MU$27ZXYV+"XC]CH\!JFDR>>.M ?%HQ_J*AB8J!GK)CAU79BR//L$S@M>+6'V
ME3BD5,=!&5IM##Z=Z3+8C1@TMR[[:.^4]KB4N $V$:"-<B^&NY!<=SF3;OUS
M/>C0*OTS;QGDW;8FG4BWO>_NZMHVO!EF,%G7/E?\N2FUSTRBV1U&E IC#FW,
MH8TYM#&'=M,YM(,QAW8?<VC/]L8<VKW,H=VABU9 FAX[S[Q_(W?><0!)"FC#
M'54U^*+X]"/4^K&^X6OG<;UGT*1URF3 =*^GR>S3*<;1=G@ YOB_%[<\'#];
M;SAIAUITRR]V52>O><@_(K/2$93'X&TM%DFG<M5P*!I#,"!68[]!<C3V;W@!
MW*!\ATKP&V^S#F@LUQG/1J2B,7P=H)Q'@W%D"FU/JS))$508U3/K.E.D%W7L
M3C$Z3<C-LRR%:QP%CN,^1>50RS"=PFLQ%G((CJ3YHB37QIAS#Q)D@2;3-87N
M)%0;!%^*D2DM(/JA6 W2NJBP#4=D.KD(7-MV\]J_%5GBE_E[OAL>VCX)Q=S1
MT?M#(9F3L*;'&\IMDN/I<%53#[;CHWBN,/X%.88P_.6([AUDG2#^E  ;1*K/
M0/\4TV3^BO3WI&@A1C&)X=S>VXT.%:\39,-.:^ZX[9#7O&*=#MT*KW0$]UY?
M8X!_4KV;\;"Y6Q9^!Z?/_PD?0?=N9SCHXWK@NDD5K:BX:G:PFLSSRSN%TN&X
MX$?I)#>)IF5F5W#N)?OP=V=.CS((6R0N78:M0U0"M1P?Q*W 7GG*,I@[CSY
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M/@3X/H-:-IFM,#]&WO1 7:G+JP6%I1U6$D7#3$?2EU ]8/DH<3SP^XAQ(=Y
MR>#K_Z]#RN O%[[B'&N?,+. C.D!(\, _X J_!QD(+@.Z\!&>@%[\F:K-B>5
MRZNX!N#CJ?$EO+G"&'7H!V#%@J\L$ZMJEK%[OE.QFW'J<MPI$8Z)T,&7H@^0
M.83XIN""<KV"X-K5 W]>.3 ,>;?F5T[34E\HOZ (6.MNX3$0AZ>*G^2/?A_
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M_E"%.O2_0GL;SZIJ#U6(_1^ON(GMJHI#%=.SZUB]K#Z%]XA:GT\Z#";5([P
M\>3SQW&_S,Q&21!5#>F''"*3_'*F_FFC5C0C;R%5$\FJOYUN5]@BY;G$&CI?
MU-_;/3VH'!0IJ+C55J7K);M69K7@8=BF12T]''1[@TFO"W],AO?]KC'M=6^,
M>V/0Z4V^]GK3R:.#/8L*.=NLC$4%X@5H75]?G;>O)%H3:&82PA421W'J*""/
M?/KHUPV'/Q]1S6KX$>:@YY(("I+O%>(D)RW>Y[OBC7Y-<#QX_"=3^.]#;S"=
M#&^'H][8F/;AK3& 0@^C<>\K5.C_WKL?3EZ]R]?AK+6/BW+V$?%&PUL4<4?
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M>A4GM=;Y9B)OF2ER\[3QZJ0Q6QDH=%-06$ZU_6BH>VR<%FZ)JOJ%TK7>RWP
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MB-'D@/^#I,[U[84&N Z%*=5U4/&@F;DL]]W.\WP2_NNZ/TZ/L4YZ2F6?:&;
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M5-,<@I"U6^.OPK*+,3@UM?8T@VASD5>\]"_#9W]S_QR-%T,@Y]FSU@3IB&-
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M7WN<^/IH#Y)A6U+>$MYMG 9?H([1;_M'?WJYZ"9TB[,GN!4DH*V2!2G%Q"&
M5;:,^U*!6.%3$M4GU3\'Z"#94T\%2PBR=D2X$;K%'#!)N1.")$BV%(=D[L":
M7(K.#6&4F.Q-_5GC+^/Z\>BRCD*6L&;M&' CD/>V/YO1_R]=AFSP&43R:.ZK
MR"'+&%/)QF.Q=C)U0V@_'G?65,N2/,C-8L -0=YD-!6=H/?8'\6>)\*0( E2
M71D0S"-^)]":LVC929FX;A@"7A?!07%F>[I8PJ#-.U0^!_RV>\4B)ZYG,A6.
ME)&&1N026-+@-:' 6=0I:$]%]1'>[1 >%+6VH*0EG-IX@$:CIB<]+:A,'@':
M4'*(M)3@O;.@J=8L*:)9]?'&C8 =)(/JJV0)<2J,+6Z $K\84##N2^JA52\D
MYP%HZ?<E/!<HD0*?&<X4,49+L0L*W4'\<<FTIIJ6T*K"^.,-FS#-SVK:<Y)I
MPTB E)W"(SI2,#P8( SW6$5+J4/] =IUL/^X1*RMV"4,73L6/I?5U VC&\>;
MKG?_*-.%A]/O-P9B="8E/+DA"'R#A+,*'"5H)4I31GQ((B)K9*P_^YB#HD=E
MJ2Y1N-J#&=J]1W'VFE.T>W07<[0?K^@X2?LX27LW>\=QDO9QDO9QDO9QDO9P
M6;^7XR3MXR3M)GVACI.TCY.TCY.TCY.TCY.TCY.TZUH@^S[3^#A)^U72[CA)
M>S.V'2=I'R=I'R=I'[8%=IRD?9RDO6<SCH^3M%\5S8Z3M(^3M%_O!-SC).WC
M).WC).WC).WC).TFNC].TCY.TMZ?F<K'2=K'2=K'2=K'2=J'-DG[.)3X((82
MUQ]/?1Q*7%MIQZ'$KX$(QZ'$QZ'$QZ'$QZ'$^SJ4N'H7L.-0XKH:.PXEWGL2
M'(<2'X<2'X<2K]P4CD.)CT.)CT.)]X ;QZ'$QZ'$QZ'$QZ'$QZ'$CVL*]VWJ
M['$H\5X84?M*C^-0XN-0XN-0XN-0XCVAUW$H\7$H\7$H\7$H\9Z0YSB4^#B4
M>.O:. XE/E3^'(<2'X<2'X<2'X<2[^F><QQ*?!Q*?!Q*?!Q*?!Q*O'9NV'$H
M\7$H<8W.)<>AQ,>AQ,>AQ,>AQ,>AQ/LWFN\XE'@=GAR'$A^'$J]%G ,_J(Y#
MB9OYX<>AQ,>AQ,>AQ,>AQ(]+I(]#B?>,0<>AQ,>AQ,>AQ,>AQ#\@$8]#B8]#
MB0]A*/%"9J,G^=DW,WT?XMUD1O'+C]K"R.*6Z]UP@O%M'GSSR3MW)/6,F&1=
MZ>A7TC.DLGBV906E'Y!+R<G(:D=GUL&Y<7?'V[?VA:?/.^%P%BP5%J62+ .A
M;+DJ,@XB;J=2X#?8XU3%S=L_MD+8]0SEK7'J2=/([A2U+].5VT[(2C93;@T'
M2DJ<Q6L'QH@ GH@<A+94V>HE;/L]1W$;9-EPIF(;I>W)4+LFD(\S%3ND087I
M=NOH<$_H9Z5R3!,!2052TC,X&!D5^C5<&^(3HV;+ELC>3/O9=]:U4=W.9BH&
M$H5C*@)WI:V9<Z7I%/ZCO;1,4BDHJ]W.]9!F*K91\5HS%=OH9[LS%3^-!H-?
M1N,_T"7O.>EPQ=*#3\&5J@<!1G &-"1FHR4B59_,V0S9WM&HOF_0@8HZ&9/^
M$-J'-'U:A8ZFIA;9,] E(B1",& 2,>!<]L+JK%2H'?YO@FNOI@FMK=,GVT]E
MA71QA+7K8:"%]](9T+PDC 4VJR!&;T9G;V@*7-4WE?:SS<0V:=29BBJV&6O%
M>4%PN_6X^7K%/8C2H-LZ9B![GB-:D%EV$/MKNPEM\BX]>MK%U$W30H%A=)7.
MQR5N/TZ7Q0[_EN9?/"W1V$GYI=/A]=5-7F_/H,:(XAQ(Z7PD2,QH4J.LO$M6
M<V8]B=6MQP[6<>!OYHX4OK+IU8YN69Z1^2^HH$7OL'OI[%U>Q&R 9JMW-;6D
M5NDZYQDX=^:T]=Q:IQ+HH"D([3(XP1Q0?&,4\5Y%XK?GCG1P7;-,ZF^^W_ML
M'MJUEF?%60"5<\3C-I>L1"- 4*.H<8QR7MN>;HMQ6U<VU7FS^HJF ^7LRR5-
MFP';,B7" F&0I9@EPJ)%)24'[C7-A+BL(M_>2[A_ES-=T*1Y:& C=77@ZK6=
MG]L$;D?7,BVA[N9*IC/5-Z=8-;WM =U(-I'Z4$8W604B6@$^" %.!<FM,]J$
MVD[A7M#LA2N8?659&W5UP*XE S\^];]<WLYJ1]^)%21@6&FB380&ZX@%2XS6
MQ.1@16TVO0!IKSS@S54ZZDX?'<3&%Q4@LSXPQ0RX[']=0%.6.F=MAJA*Z8=(
M#!S1'B*>_UI85X)FM>MS5L,Y;)K4TD/EH=N?2L>8^9C)C,Z)= (2*3UB',W@
M>5+@@D$S,,F@?:,$O!>&;-\^\*"-Y/5%6S$R?0MB0;,&,-J8M4TT7?_5?ME,
MW4#XC]6W@>2Z>%$7]_:<$4*$!"\B[A<F.G"4.J#.!B,S2SXVNA'?M0)7&(#U
M]==&8)7U]AM*ZNKZZ@:($]8D&2W(TD9 !"G >LH@DJ2$\Y*YG"MH[L%#MSO8
M?FVQCVK(K*(!-0/B_KP')*"YYG60X!*/I5(6/T(' \]J$T,V0DC;*/+[DO+N
M/_05*F]MF6W5%;_7I4I+8I/G 9SEH@S8=F!4U)"#5"1G3DFLW8]GO]J&;2V.
M75T=V\U*^W5<IB9RYR3AC(.6AB ^=.V\2PG02)<V273GS/;H,L?T0U%E#35L
M-\AW$L+UU?7@29_5:)0SR1I@+KG2E8R@$1,E!,:%%309(;<8YUN!\L>B4@U5
M=9!+] SB#VG:BUD$FW#U4>/F*"3#\]0( L2D)'/!K6H/CWL>T8]%FK8J6#FJ
ML*-<E;?G'_Y^^NGSV9OWIQ>G'\[./WTX_WQZ\:'4-$]Q/1ODG33\RU5S2-99
M3:5\D'?)3\^&I9_V;&3R+:^42%J$Z&>#DD'X4'BE!7"F@\CHEW!;._5A!93-
M+Q/N_]EYO"L'FAP*#]#I+J/(+2WYX@:LC?@&&:F":^2CKKVZK>9NU-#QTRN!
MS:2Z+QD9#]<QB\9$910M[5B"$:4%8D*QQ,"!I4#Q4.0:=]E.R;'+T/'&>GV6
M)ZWEV\GEXGU$]ZX^FN#J*"5B%:;=Y#YLJK-G*;"AP+=)"!*(D3DZ2%2@E^Z,
M!I.U!4]DSIX&1E*WI\2.LQ.VQ8,V<JZH__G@&52!>3L:?DOH&>%F=Y&&_='X
MPVB:%C>77GD=:>3@<FG6A4C!V6!G8[N-3H3KW&Q"YHN/VKZ+44<EH\[D63'V
MM4#'R;/HN,@N48_ZD[R@4Z4%DHB@@A)$,LI3;C:HY\5''8BV*\JSBW?;W@=C
MC$F<H#,K,RN7V]2#I;A[169P Q-!RX9]?A__Y0/1Y?K2JA@@FH$Y_3/,!OW,
MYK/,6]/=H&)*ZTP3!4J+,<J$!N<=@9P2$\031BUII,.5CS@$9=:1W\JHSOK&
MUOO1\,LTC:_*DC_C[\RL"J.SEKC[ S64E=E-$@S:$Y"8UYSDH+6IW41Y&8Y#
M\;DVEG$'X=['F&X(W@151S[7<D2[\;@VU]@+%-A W!UX7"O0T:"R]SR6ZW@.
MHO0%,8PJ<"SQR'FVV8=73((7O*UM<:"-E#O0_3UKL0!;),#$R'(.#KCVI6@\
M)W!4.'!*44THIX[7CKDM!;+]L[^&EIYVQ]]0Q+7]KH<GW#U\99CKY#S/OU)>
MDQGKT3/ __4*M \:A"HV2D(_D?),I(V"!LD;V7CMGOO:S_^N15W1'&P)]>:E
M: )VN;6P,3]V81UTKL_U>+.!,FI[^*U!<Q=X%+*,A?4.1!:XP2J'/JV*E ;+
MI&XXAWD_F+/"I-AOXK3101>$N0,T1SA<I(,B*JT,FEA<!C2V-//@J2T-XW2R
M5*$!\;CB^AERK'K*EAO+=ZN=QSRH(MHNC(]'P#[_,;H!1HVA7J-AE9DN22Y$
M@O5H;R=<:A3&,X2]KLYOG_(CZ7P]T796\F6323I8!TPZ!,%2 $N3AD2E=R0&
MHT.CT-*^EWS5LB'7E][*=D6;%P,U@7%X55VMA+^B*F@=R758U264XOCF:]!(
M/4"3(^-&(]#(" 3]T6R(U8TB/+M68*.JKAKZ:R.P3JNZ!-'!)#S I?%E9%6I
M6,AE:V%<J!2BB:Q&/=Z>5'6U$OO*JJXV,NNTJBL+FZC6''*Q743F&FR,%FPP
M)MA(,VT66'T=55UK*V]MF76>E/36C<??^\,O)U>CZS+[W97*,D7 132JA/(2
M''$)*48R N-)LFX3DQ[BV?6%Z?L.,EHWD'@'!5L/L9T-IVF<)M-/;IIFS2CC
MO=F".A#/*9>0C?-ETT$G2T<)7@;'2!DOJ&*GW'@.W2$RI9HV.M]%?G$A+?A,
ME562X7IE%" 2QSTR)0;))R]8#B3HVFU15F$Y1$ZL*>D.[MT?>N@WL8!2[[.
M>G'ID+UGD\EUBK0G7?9.4@%!X5DG/'J+Z#8*H&K6?HHG6[V#?#N$A\.6CK12
M^Y+FH_M> $W."LQ_7@]GN41E[O8L56R19]1S7*)-B]Z-I!9I;HD"SS*!+,K8
M&.H(>>P?K(BC-7O>ZZ9!5X*M&(*90?S;:!#G4V3[H_C+:#S+)LMI?#*9]+\,
M9RVPQQ>N]!GZ!?<Z?."<MCV)YC;WE(*2$AT?'1-89000X[(C5FKNFHUH71/
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M+5%*R@7-(AAJ))J:9228UAGW*YM3H)D&6_O>= 64PU!Z#3DOT7_-]AP+7C[
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M,K-."^G!9^'(S:&@R45ZP[AL?>0LH6&[+9'8\8$#3.MTKMJ=1Q8^4B]=K)?
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MC.!R#A!TCA2R8!%J)_=DBYI_?FJ_RU,:J6'21(8=E(F]_O/UV?5@>&+'*(G
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M(B5!"(&0Y.;]K5O6NNO[X[MWSE[GC[WG[#W/S-GSS- 6:&L G[FQF3' P,
MW*8_ &T9, *8&!G_'71AI@\6=A869F863C8V5G9N3FYN+DXN+AY> 3X>7GY>
M+BZ^4WS\@D+"PL+<(!'14T*B D+"0O]NPL!$_X:9A8.%A4.(AXM'Z/]9:!\!
M?G8 PL#*Q" #,/(S,/$ST 8!,  PL##\1X#_*0R,=!M9V=@Y.+GH"JU\ ",#
M$Q,C,]._5M-7X^GK #,_B\ 9-4-6P1L>;#(A0NJ)S\O89:^^[Q>V_8*7T_ ,
M?<3!>4I$5$S\[#EYA?.*ES2UM'4N7S'ZYYJQB:F9N9V]@Z.3\TT7KSO>=WU\
M_?S#PB,BHZ)C8I.24U+3'C])S\E]D9=?\/)5X=ORBLJJZIK:N@_-+:UM[1V=
M79\&!H>&1T;'/L_,?IV;1R\L+F&PN/4?/S=^_=XD[/W=/R >DHZ._\7% # Q
M_"_Y+W'QTW$Q,C,S,;/]BXN!,>I?!7YFEC-JK *&-]@\0@1EU!/9A:X^+WO?
MSR&K88L7]@S]PGE*[A+F+.%?:/]!]M\#]NC_"]G_!O9_<"T!W$P,]. Q\0-0
M@/R'F$2IT(.2=7X=NU=B>:!VR"2;#BW"A5>2]S&/\L= ,MRWI9/1C^$#7ZAB
M-&"Z'8N"[[L&44T;@DB*:2>Y*!;X@J,U16#N:!&#Y-ETOX"^%QXHLXB(L/C]
MCQ:1\([51!\88^P].<>;YZ\8!KV%V9$8;Y;L]"28K;HN+OHFY-& @1F(6!@-
M$%K-@.+%EVE SODO-*#_1I]HLT>/+G80O$+61-  .:<A6:(J:2[[B"\(B9<!
M42\[: 8M"N*D,[S.?D<]U+R;KI9_JDP>3L9J*<,9*!KM<Q<?P CZUP9Z+NT[
M1-  L>,D?#FQF^1%R-K3Y0$-JBUOS@07WJVH6HG2F>+3YC7FC3PUK+0H?,B-
M7A,8@Y2&-S6>;9SK>5A_7H'057+1Y$PB^%8ZQ9#R".JOA,I8 7?AT](O/$6G
MMT0GOW>'KO:VCKI-;OXRK]4?.'_YLGR&<"+1HJ2H"^+Z./J&=TM?:U*!)J07
M75IVL(.SR+7D(=GFR[8%C$"UN4O]W?VZFV>%BK)\1;>_,EW__GM2W^H:(-%)
M++^4'*I3_ML@S6<^/1-IM?\CR,I7M&&AR0*;/9@!2J9R]A&T:H-"(GQ\O4#"
MA?6F%J,U%\5>1'BL=/4N(G@I+?;P 3W2L\-5?^B>O^(J2-BVP>-"P_Z');XA
M+]_I6OQG,VC191 IVCKQ(A1[#2N[NVZ8/7#X%8G'ES)X40W<95&4X'8:@)L[
MHB;L[$[U7H4N9F"3IRO>DR![IM_N.]Z469<N'8(Y*;>S6>-F?\(-/7644M]%
M1K_J6 V8&IG;H'+RKUFIO2$]/J9B051]-Y$4Y'U0:HE<E_.%"T$M(EZMKO;M
M2Z_TU7^Y.>GM#89K$L(2)J!"3H@D523K8QJP-3<07?[I"OI1JVSUGRZW^=QH
MD>"LGZ<L/Y9P;NPR&NN@C'[?I $^:YL09_UX*U\\C,<+&I7:<-13443.7I""
MVK?-W<-V?>A(W5GR!DE.=X1'R)Y^I"-3F>,EGJ_S40PQA5HXQ+72@$2]$"^,
M*SE).RWBU5"7B:P@,2!5Q]C:)Y1!FMRQ 2U#VV34^\E<9OB*8)-"FA^=. IC
M_$,MO @]-$"F_ADNH=%A1=6>7(Z#/H;C;7@L+ D.<]DIX997<.:M>6_)[F4_
M-5 M:UW)MX6M/4.##4^'@Z_%L9"^>Q,&^LN='GW]?3AM07PPKA6X8O^0J7^G
M@L_P.&ON:(, (L83JA_&W0BKU$JL]=?Z9-O6WI:/4 ZK2G!D8>@?5N\-#<G*
M(P9M>>#3;I*\UN*O[L+: GA,'#MNIA25EBCD);CAF@6<<6T&>NM.M9EE*:E2
MYJ6#\8<"WC&\(F<K79G1K3.3NIU179!T[@<S]Z%/M2._12% I%VR8W34VK+4
M%?;A3NPI2>=^!8>T+&[$U.H;9AQ;&6N/8OB&H[F:2^F+M7<ZQ<,?!C"W?\A_
MD?[Q$VRN+1WP%SP,;=T81(G<TKC02<D(RLV(OZ#&)[T\Y4R-&+MY$DW*\ KV
MR1Y>^G-Y\VQ?SC4:T.?\#,K@/A$:.^,4:DK1*DCM+,9,VE9XDOU1\VXCSU?R
MG \1*'@J#6AWRM2[K&<37:?08U8='I-WBBOOD,7 :%^1 ^5"#L",#(% )_;X
MK2LC:;N.FZQ89]<GM^/N5&3,.2?T&AM.QI RI6YI#[= -'0P/2.R?EB/'61+
M*PP/\8%=DPE_VV&=#P'3@$<U8?C#?B_J6WJN>>O2IT9Y@5S'4:4C:<"3'MD#
M1#-RK0Z\9QTG\IM21P..S]9CLA\F*,_VL!&*^JDR\^>TCAU?UXR$A"B6A=:
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M)G-_IP&_YA$=2 _8T1FZ^L)5W%%ZSP!E"BI;G8F@-F!HP#:*(G<$(GYXGS-
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M;;*)+5;^//(36:?1DX/T%SXZ?,>F7QOOT/#16CG*LGZ\3J!BY>8]AMA"FA1
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MXD6^N"*G&%;&(8<ZFI'VYUB^;BVE?&+$$=H,PKG9"?QT9]R2XQ7/4CL!H!F
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M0.23^4LS(0E'\TQD#*:F]C@!*]J%KWF:L>\B6"GV-#I1#H$[!E6@6 _\AFR
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M9^M;(Z+N49\KS;G5CH(.SS-5/UFVC#?P;>#:2:F0@OF+&"*XG:PPO QTMH;
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M-7-S''T^$C.<!0*P!$X[!V(Q-/%?[3:UX95Q!B%GH^OS#.]-F+PI]WIMM$>
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M7/6N/O[AX.^4R_>4S)./*Q$-#T12"'D97RDO+I4HQQ686-/41F^_XOYV>^A
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MDJBG9H3FNP]Y?=_VI;W+LMHB>B=6\=EYV\@L50[]=(0@5XN4:XV8!P[IT=A
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MU D=U2XYH:4E=45YD:!P.I1+XRS59PZ#,(6WI:S2<BMD]@^=^GN8PJ4TY>@
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M ?N#+&#?3F!B4$/7)MH9B.9>_QIZQ4%D\AC"NQ^EMXWM3#EYV#".E^_CR7Z
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M4@H-*^Z<8.=K$G9S]MJ]IL;U5CNNCD<^DPFYIO.;4"J), 5(4V>^;18KR?6
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M&E<C8&"0G><,"[L\/'M,S++MM,0<S*L;7F&Z##HM2;9RY?3N."-<T9T;K4?
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M#R&D%TH]6VZ+S7@CIZ(WPE"X08&<=2 ^1&/B]L(#8N[W#AZZV+[E@$IZG?$
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M1"*1CYAG%&.F_@,*\/KCU7=TN$<XV%(.?M>T#;V1,=Z885SY8[P'8%#:[A7
M(]+^P7$5SO;(Z;BQ</^0'P321R!I:=!;_Z]^H&_Z+F_=ACRF@C-2QHCR@B%<
MYNHGS 5B45@P%F4)B4'S-X^3\6U&.Z+!2TL5:#B/(V-H\RZ6%VBNUJ)V!#VT
M:!\6R961.4YD7/LP*.B!:@]_VB+:M>>UP<:.D)SBG)<)PLII0CC-2\1HJ$Y9
M2G%CS.., @8F7L*)9]V^V[LP/SHZIYO+$)1Z2,ES.Z3$=JS.16_%($8V%M8P
MN[)_MO,^;.<BF '!M+'@MHNL>88=%FAS =5@U.TB N.%X%S@L!./<[*@G=O7
MR^R\9G5S^3M)BB(B84Q0P8H<89D2Q CF*$D$H4*R,&&@.M C-#QO"N!\U2$X
MS!R]"X6$6>,>,740[<@Y/(P."./(OSM&853G;D#$?<]NZ*.V0[%>Y7S5^XY1
M0L.LP 42'!.$J?+;B"@2E*9IS!(A,E&4L'E8NP0\ZUM'[J_0P5=[*)AIVB6R
MP=1L3<F+CIT2P]F0J[WE1YYO=5RXP]%6)S[GJ5*V/E5\=;^9;S]M&P?5ZPX-
M?Y?3IY]J![Y^E15]DK=_RHI/:_E03;F<<,:)C%*,>(C5*2NG(2J2A"-**<LQ
ME22/W1;..A; =U*4YJ9KU",6LQFMZN!%5FW3'M<]>UR_6S-K])'?&,S:F13;
MUF>J;3=M>GI2;7OU7 5KR8).M& M6] (-V+UK:?7,E8QKFOV/U9MKJ>7 R[5
M]<7'Q;,@CC+U8[G@_UIW&3K,QJOWRL8BF94EI@+%:<;4,8]PQ,*0HDB6G"9I
MQ L,RJQWRY[O]+E^[YAMBP#=_F<S3U[SN[9HUG,D7+PIPYWHW? '[C/]J1.G
MMY(=^*^.9@G78\VB<(BG^Q$5+IA[K\D5#H$=&&CAD@I\W&YW$_1E6G,Z^X>D
MU>U<?&ZZ[O \(9(6B,D<(\Q(B&BF_I-@CG&1J'\MC/)<AHAX-J,=V:"E&VC"
M@:(<?#8.]@\B-&SX7,D-,U]6(H.&]YZ3R6J0[\E%1QOJ>TZL_H#?LY^UC'8?
MJ6+>U#?]-M]>%][^R=5'KY_U;Q,L*,U#3E%(PTCGHV6H($2@0H@BBN(BXVD&
M:\1KQ8?15_J2KKJ:J[_J^]-5VV&U;3D##*!;(6P88O>&FMLV$+U&Y'VN@I:M
MH.7+8;#^$EA<A?.M>!@WX'\)3 =7 A<M9IFA]4JG,^V4?%E4/^BLE_ZE9T!\
MI<ONMV_*9_F^F*F5GA[_D+-7^74Q7_ZL-^VE)NIDQ[),,!13G5^;:K\CB@EB
M>8HQS<J"F:6&N&;,LZ_R>:7;^06+N0S>]*:]J(*9A$X(=/82S$S>>T +LX+-
M4-$M6U?!AF54+BJDF;X*.D:50;R>-09-64.J?*8?BE]U?%O_<^-#706=($UM
MN'IA]^J%:1>@W\O/83:;8X1=Y;^Y8FO<C#G'8![DV+E>W_:::5$M]9C7N_FK
M[,9_3W@2)R4I4T12SO1I+E<_A01A+F)&RRS#):@MS3$BWG/I-I2@=S-' #&]
M/[E,3.@=AZ*&-+G 1%B+:X?3TCB[&CA"8N3P_6DA#T/L Y^%-[#\KB/S3<E)
M&&8I)F&A ,*E[L/'$2N3 J5Y*3E-BBA.C9*4=E;U'736V7_U<JKC!E^5R[BJ
MV@ZVD'*>712&=<Q:-J!2V8D%ZFIY(,8%'2VW:XW6S?* _7XGR\-_A'=8>9"+
M;_39R&WO?=SS]_WA]C[09,Q[G:S%&/Y>6TH ^U:?91[4:&2/7:L.(NLU1FL-
MLL=TO^?'_C_!O['?%O/OJYF,0I9&UU7U6#W/E^++C#Z9?H=/+N#Y6_U-C_O0
M]U>:,HIV>I'KG4X/)).GYQ(!@#BO!4XP@.F%F?C![YH+1UUZSDIII4ZG5QU-
MP<X*UE>Y\Q^V'<3,%\_RUT5=M_6'N@G$2IV<NNC68EY_DNHH+]O//=(_=<'B
MLJ**AGK7U5O3(T*/U]/-P]I#U[I=^21.)(F*/%9'(:J\-.6;*2^M("@2"98E
M3\LT%9#F#AYY!5D->&<(S7/ &N;4_\QE.5T&^LL03!M6@Z7F%3J?V-^+,SN\
M?9#7 3-@+3/!7S3;_]&^@RWGP9;U]=OJ/M]PWXX6W7*[&1[A<EBR=TR=S5?V
MQ^G((YF]0WXXQ=D_22N?3#MV<G']^M2TLM%Y<=?/2X!+=O3Y$3RRQEU7_[].
M+&W([^6Q#E^\F:-AY)==# 3<+;L< ZA;-BBDK5=V?-$QG;)!L?9\LN'/CEW'
MT/SG45&]GHL']071A[3/BV<ZG4\(X5&>L1B5!==AZ;!$+.$E"AG/0Y+R4C)8
MOJ<')CT;BJ[C:$,_^+TE"6RCX^75F(;*WQ=PF$%J0=9$SR,]8GK_>2C>/85_
M@,5_DS3]\R"[2\4WH.6R]X9RR"J=[7$WOV>U K/F37];RM475H<_)JP0K" E
M1H)E'.&B8(@55""6BR1*&,VE,+H'O(P-[S>% UTWIAUO.MMBJ:_:=/F73KDP
M'=-^X1L8MJ;CX0H]E@ZT>EBSI7X(^HP%+6=73>1M%'!=M-9P";*'OAJ7@>VH
MIX8I1G8--<ZN_@&Z:9@B8-9*PW@U^*GY?K6L%55U,'_Z+OE"';[>[N8"<AUW
M>@7?)V?0[=R H.>/Q&YDA-G4'LU@353KMYB^3L5*G8W=7?"=%\_J.#RP[&@'
MXO.B]8_$!I^V\,>NA9AJ"T]GFS1;I> +/M6737I<B:(AG]MFUDWO1#:;/K6!
M-.61E06C"4684CVRL2@0B0N"",=<%DF<"V%T\+V4$<^ZO.5L.U!(>V<=;^VH
MG>DN=\%BRQ[ ?;CD;1AX9R-A##S/;N'=<!5LV0HT7\$>8\']Z/ "_+.18+;S
MT+S!#?//'& TZ*%=LOYX/IH#%':\-!?K6496==7G75VOI/B\JO2T@Z9JOPDM
MU,>#$!,J8US$<80P"4N$I6ZE&><285:&'.=4O= "%#B%\^#[.*^8H?J$LR@#
MOGA^5JI4-^77ZN"NOA__7,UYHU_-%B+;(.J+6J%NCO9--Q?3L_TE+\(P3.H7
M7MBNT5(-6G:NVGKW^NIXW?LVV'45T%*]QN#+HBKE=+FJ7'9&L8?'5634@H-Q
M Y_V$!W$-2]8RL["_;)8B#^FL]GVZ*MOF2>"A)P4*4,R)!G"<280(S%':9&D
M4A)1Q 348>XX&=]V:D,LX J[)VC&S ELS.S*Y1+#3,>:WE4O.!5HDNYLP;!(
MCM3]!)%1-7I8T'VE/?/I2[OW7#@$8-L7)I12'69UR"#-$X23(D*L3#E2;DE8
MI&%!RU1.U &<+> ]?%PQ"=&//JOF.VROG<SNL(YVZUVS''QI,[TV3.L'/NL/
MJW_[)EO5:KK3-0_:-OQQ]G(-G9UW?6% 7^CDF]J.5=F\K?+(VUKSK-O)M6]I
MI 9 KK%UW@3(&8/OU C(-<"GFP$YIP2_+VARA/AR16>SMP<Z%7^K;Q8_Y$QR
M98FZ^BGP+&3(FIZ=M-U\LXZG0#,5O-;_I]%I.G\+UMRM2\;,KR% ^)V_F/ %
M'<PX6J+F82:R#1Y6=QL@0J/==MB(W[__L'K^4I=R?\#?]5RLG=B]7H))6D8)
MSCF2<9$B+(1$C&<Y2G%"8BD8"0EHN)X%#Y[MSTYKQ\'YE*U+^&E53^=-8Q[^
M7ZMI/;VHWZ/YBX#Z=U[@M7?@#L'4#3W6'(WDEX$Q<>YXF7/P3IX5&*+3KA-\
MJ0LJ$+[*9R8K<.%!^YCOK(EMKKU%-4$GV7G'Y *A8'K=KQWXO27FKG+SF B7
M509T:XU?$+ KQ-$Z@+V/N)Z8_5LMR]7LUVDI)[D@1<1BCL),<(3S2*)")!DJ
M,!68%&&81S%D(S<AZEFO;NOE]+FYW6U)!IHF.'L4A*+9+NP:&YAZ#CHQ5WVL
MQIBU?2BQ]XG;/9(?9.[V(0CFT[>//&M;N+UIJ;/I;*5'@\T6^I QH23CB<A"
ME)=EB' :IX@V13\EXX(5DH@$Y.D/D_-]\[,E#IPR= 8E,P/@3G:8ZO?H]MO?
M!5O:+@N/361T5CL\2&SD\E\3P0\K>(V>LNSUN4F0T2&$N_D-?9DNZ:QS'4.E
MP"(M*<(,JZV?,8)(1B,]X+40>8EI"6S@.41MO*Q%31RIS;XC#VS,.8B8F98[
MPP&FY*<A<.B-@V1TU<1RD-:XG2E-Q#YH-VGTD$4VL^Y6>3>OEU63&'FS4*:D
M6DZ;(W3U7-^7[5]J70&GN[QE991&$>6(\) AK%N1DU*GHC&2IJ&0.0F-IHQ9
MT/:L_4WWV"TW5T&/GZ;,I@[NRV#+$JA5G@W4PX;",X PL_'AL .D'OO#T"[;
M&(JEH^QB.Q@&$XJ!2XZ70VPGZT[:L.42\"AD6U/\_/102;&LGN>@OG1''_;M
M1;7%]M-G7>FD"<METXH-TH?NN-#GPY07RPOTEDZ*ZK3GW*!45O'+XRN.%L4<
M%*@?RQS^H-UYYK,L956=+.[O4OZ[JKR#.O_ZTYLN\+\OCRZCMQZ2%B1)J/*+
M>%8@G,4,$2D3E"0)(S*2*2.@WB:>^?4=1VTR]+OT\GX/A9W:1]UT2L_<57]M
MNG3H=+B.W]V>01"_8:P7;G:@^T"O$6;DQGV#X$/D2+@Z.H;ZYG;4@^Q(T.\?
MA<<B:SG7:U'7;0^])SGG;]LP7#TI118+7&0HXD(B3%.,",8%B@L9TS)-U;_F
MD)WA-"G?:77W7[_>/7Z]_?;X([C^]CFXN?_V>/?ME]MO-W>W/X!#ND[#9697
MW8  ,XE;>CI/>$O2<0:<N8BN1F>=)C3N?*RS A\,P3K_A*VWV#_G?5<N?CN3
MLQFB_"#5]T.=[Y_DA)6$%*GR^M)$!\-U<*R(PQPE(8XBK>58&,V  -+UK.A;
MNL&+)GREBQ(ZTE GS Q'4V?*.3H7!KQZ2#VT2#V<1\K"V0')[<QI,:,ZLO,!
M@N+0B8 ];F<];E;U<O$LJ^]RUI:,_YR^U-T]4,EQ*,)(Y\OHF[."E8CAG*$H
M)%BY)FG(20JQ& .T?+L#'>6@ZI.&V8<AI,QL@B/Y@9[ 6O0=JA[NR@RD<Z3M
M0Y1&U7 #D?>UVN01.TW^)O^XYLT@35TX72WFZD?>GH,?%K,I?VO_N\VI)CR5
M+)4")33)D=K]<Z7>(D4I4?X S7A",E#*"Y0![YX!;QH%;%@*=GF":3\873.3
MX!,SF)U0G)S&2OD*#1_![]W_>CE%V(+AR*R R8]J:VS!V3= UNO86:7]DL"N
MAGA2)EDF1,B1B#)U&LD904562%2DO.0,1YF$=5@X0<?WC7Q7$:VS;L5B-J-5
M6Q3=-'D!9N">0BJ+"&&)P HIPA F<8@**4L4)XE,:)H7:49A=>L.L+(J/E^C
M-9?+8+:N'V^@\@J@F25V  HP:GU0GWVUKK!W9U+/2.7(<IZB,JJ!/"/JOAT\
M]W'7Q0CUI[>O])^+ZF9&Z[JYE>&\P"DI*,J9'LH9Q0DB$0U1R)(D5G\J<UA
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M&'=7=>/N=$SA*J!;K@+:8\OVT&R&.334X!S)2R(._9F!-PV(/8:"Z]% M U
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M0Y+P&#[+WC6"[L;3>X"0%12'7+GP,9&I^OJ1&-%4$A3'.8O3/(Y(3*!3YOT
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M VPYX/\;8>9R?*CW#+-V'^@5@QV=T6!WY!_YYW=4MVHT^/>]L?$(V_=>ZXV
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M%Y@%Z='=:3*_I>W.=)C)Z,A2G"$VJF$P$WS?#A@^91GJED\Z9OY=OBPJ';D
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MB\6VVHD!$H/WXT&)'.V]QVF,NL\.BKF_IPY_V$4_R =:W5?-,+ZV3_"#K)J
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MMKB7RP@SC"#Q+)I@'I/B@@Z8.\N-W/[RF"B'O2^/?LI6C=11=E&]+%KU;+)
M;K0&5V\W"R$G*<F+J&0816$4(RPBY:3E$4&4\[ 428@S;%3S:TAO'$7;8>&J
M35H*FH-\PTB@.8'JWS",I@KI#!PK#;T(%PO%-9+V DT>7G]DU382]E#7S1Z#
M7^D^5D)MWW=S\3A=SJ3I_>WN4YZUM:%A?BN[)]'Y*UA[86#:]5A1H5,H]B*(
M8OHZ%2LZ"X;E!-VU'A?)ZF)U;ZG1;E&/B]"_,CWQ"=N20Z52^I6TTU-YDA4L
MI 3Q.,\1SDN&:,(I*M1/69$G,L]A391VEO=]E[ F9CEJ=A<*LV.[O8 P)3*7
MS:+8[Y@(SBKZ=A8?N6SOF&"'M7E'/V4[N*N]A>QF4.L;RPGG/"=A$J.4A QA
M+@4B,0F1Q)13F8:")P5D3,X1&B#%LIV-LTX<L+N:.X:,F8I=*"],S];$UI/?
MKP)-S^6(K)/".!N#=4AAY%%7)T4\'&=U^J/P ]V-\A>O*TF;(T>1%)%,2H[*
M)M>>JT,;XSS6OT:4)H+CT*A&9W]AWQ<<^B"B:0%/83NRGS]NV4H$4R9#84!'
MIV.<6YV1=A8:[3!TC/W^J>?HOU\\O:UK^+\9Y!26!99E*I$,=:%IG'-$TABC
MO,@I3K$05)00-^\T*=_JTDVCZ,UMLQ[0M@^2V>[D1G287NT,9ML,Y/ P\NJ\
M<.XGLNT3>J]I;"<$'IC$=NH)6U?R579Y$%_E,Y/5),[3(LU)@<HH375*0(:*
M,HQ1F,H0TSB249;"IKSN4?"LK#UZ?X4ZC_M8Y 4M<LFQPJ+0W7X+C%BBMO>L
ME#)+N"B+!,.NT"]"P^JR>^U6;^A>"HJI/WV!H%!O>D,J^+TEYG3<[ E!G'G2
M^^N/[$>?$._0BS[U0>O*U5,#9K\O9K,OBTJWQIA$-*<R9\J)2'06"PD)(DSH
M&=2X3$7$<$9!_5#-R'JV48/MW=276',2=*S *UU-8#538O=@P33;#4XVE;$
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MYC$W#5SDB]1%&#."2!I[R"51$@C.W<QU(26P!Z.#G-NT^)6V53:DE@QDI3G
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M/:2-2WZG(*4-R>6PHS^$R8D58[D*5F1]M#WV^>F9Y*6:7YL[N9^+!UX^K5C
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MY*JY_SP*FO&<K6^_Y>E<0_"[S/3Z@%Q* @ CF$69.I_OG6CO.7E7,8XCX<N
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M=\'_]X64\E>^?FM_833T!>4D0"*@,O].O1@EGD^1SRCQA""$^5JUM ,REG+
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M)<VSK'<"W>R 2VF":E6.FDGN]76R-Z?_7*NS4RNM&M+6:E\Y/<55 +2U+ED
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M *P[NAE/+,J,VX 7P03<&C8&="6EY53:8+5]K6)Y&_!L!)".@Z\J -E*F V
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M2L/<3J=?W'C94[8TNYR,AO%F@RW:RMXQ>)J7D'>C.SM^;[UC<CIQH\$IA+=
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MGU398JU#[XXVJ[ V.+OZBCP7$+C1.S<JZ75G%RG-2P+=9/P8&W?P(\%(F?!
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M?>S]E,&%5^)42))EA9AP&',)GV&1O9^](8FG$+RN[OB]3$HC$7"_@4H%+34
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MC5[F[T&,L"QT0[*6P]8?>/QW_OZ ,4N9#A)0EA2$-0P]!,87W5Z2=$CVTXK
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M ACG77:9\*AK]R7OG*E&[/[^ ;MJZS2!G@:VTS:Y#M98[V*(0'+.Z >6:O9
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MR1W793T<)@\ET0; >W\;_TYEYRF>E-8JGU-A:]'I'U'#?TB+@*R?\$B<ML(
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M+=JIL!F&!4?JAXT<^&L CC^!<W9'I3U@T^G?:1&FR_1A,0UI8@/)+#@%SJL
M(E *-D0&D;(0/77*LX:OR.>V=J2AQ!;@/]SU6@V+QQ.&?/)%\M%(TK,,2@PY
MX$J_,U'ZJGFM4(B.@564!.(]D[YZT][#;>](K\MC/+ C8?(8[M676/-(W.I9
M_@C4:"0D"BF$#()$ X8Q Z7RP7N-[*L^J?'0>SS2<.G/>'"'1.?/<'H?B98]
MRQ]?&KAERB%YRT&@I@-GM(>L?;)>!^9E:NWT]MSCD09I?\;3.R0ZC^'T5O(C
M-"T9J;R$[%"SB60E&(%^!+5$>*_*GU8OWF_(IVTO&'R,9W4$+%8-)#=28WK;
MA.W3GTODUP?\GX,7FW8A8M2JT]Y<:J/\5$4:C%L?.X2T\#PBN)T&*4U,W$0K
MJJ>R_RSEI\ZA;TP2<LW*,CQ->?#2<="4<F4-I4I5?^#_I_RT)V:'*S_M(_X&
M++?[56E2<Y^2P'M7,R0^$(\LE!9]2$:3CCPQ6;OW_$]9?MH+!,^6G_:12 -P
M&J0ZC03-28P<*,,S+103R .;@&H3T!MB4>1_RD_[E9_V@M4ARD_[R+B9\M/'
MV@]_7%XMMQ60D6@C&;=@(S,@2KZC\:@*3-364Q*2(MVF"W5<L/%WT<%AT;E%
M](XR:D"_?DB+/%]<;H8"(R^OMY&HM29X!;3DI@M7SG,T ?"0*X76#_>FMM'Y
M!"F-O_4="H0U!=8 [JJD' F1)<OE^=^5!XD,EJ1U>;C0-"3GR<%O\5^F.GH?
M@_3 LC]FM/?.C46/->0L(L3UV#NJ$WA--23C2!E>P!67K1R*7[ ZN@=J1ZN.
M[@.AG<_6M[3P\[%/5_?'AFVNMP\V<JLUQ-*&3+BHP3!)(1BI5 J&"E)[WM7!
M-G>DIVM8>!\^4WD'I!U/@N/.[+F?93;1A!L6=09"2BL@F='ZX(Z!MR@_4;2I
M/7BN1:6]->[N_.3'< ^<';.9^2)?_K763;?5MSE&Y8T'ZZ($H=&+=2)I",&F
MZ ASEC<S%JKGWHXT0_$G.7][X&S?ZM3&3^ V7?,.<Y(A7)>(C[>\^.%"@K%"
M )&*1B=LDNG@*?[UMG>DN88_R3G<#VT_^5%\:*MS8ASW:!LPHV)IYF+ .&N
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MT^SIN5-K3)QEZ"XD4%J+,GJ+K).>("3T8YCE/)-\D"/02E5^,^#I!.H=)=D
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M@$5;0^/V",/$H.\4C%40+S<>(J'USX_=PUG<IR+)(E?1V^L#*+1&^$!1#@A
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MT9O_,'\\)R7[^X__ %!+ 0(4 Q0    ( !>!K%J=OYN)M0\  "Y3   >
M          "  0    !A,3 R:F%M97-G:6)S;VYO9F9E<FQE='1E<BYH=&U0
M2P$"% ,4    "  7@:Q:>0W3/AD6  "#D@  '@              @ 'Q#P
M83$P,W!A8V)I;V]U='-I9&5D:7)E8W1O<F,N:'1M4$L! A0#%     @ %X&L
M6A_5LU(I"   J"8  !D              ( !1B8  '!A8V(M,3!Q>&5X>#,Q
M,7AQ,7@R-2YH=&U02P$"% ,4    "  7@:Q:L_!QCBL(  #L)@  &0
M        @ &F+@  <&%C8BTQ,'%X97AX,S$R>'$Q>#(U+FAT;5!+ 0(4 Q0
M   ( !>!K%H1%1; P00  &T2   9              "  0@W  !P86-B+3$P
M<7AE>'@S,C%X<3%X,C4N:'1M4$L! A0#%     @ %X&L6HPCG(^R!   ,Q,
M !D              ( ! #P  '!A8V(M,3!Q>&5X>#,R,GAQ,7@R-2YH=&U0
M2P$"% ,4    "  7@:Q:P\IO&,XR @"/$!< $0              @ 'I0
M<&%C8BTR,#(U,#,S,2YH=&U02P$"% ,4    "  7@:Q:D++Z9AH3   &RP
M$0              @ 'F<P( <&%C8BTR,#(U,#,S,2YX<V102P$"% ,4
M"  7@:Q:;9CB7ADA  ![1 $ %0              @ $OAP( <&%C8BTR,#(U
M,#,S,5]C86PN>&UL4$L! A0#%     @ %X&L6J=.Y',]9P  VP\% !4
M         ( !>Z@" '!A8V(M,C R-3 S,S%?9&5F+GAM;%!+ 0(4 Q0    (
M !>!K%KU9*.V?1L  $,<   4              "  >L/ P!P86-B+3(P,C4P
M,S,Q7V<Q+FIP9U!+ 0(4 Q0    ( !>!K%H/$G<6TAD  * :   4
M      "  9HK P!P86-B+3(P,C4P,S,Q7V<R+FIP9U!+ 0(4 Q0    ( !>!
MK%HJ@FH!=$(  "M0   4              "  9Y% P!P86-B+3(P,C4P,S,Q
M7V<S+FIP9U!+ 0(4 Q0    ( !>!K%IS;I109SL  'A*   4
M  "  42( P!P86-B+3(P,C4P,S,Q7V<T+FIP9U!+ 0(4 Q0    ( !>!K%K+
MB'=[-#P  !9*   4              "  =W# P!P86-B+3(P,C4P,S,Q7V<U
M+FIP9U!+ 0(4 Q0    ( !>!K%IREQJRIA$! *+ "@ 5              "
M 4, ! !P86-B+3(P,C4P,S,Q7VQA8BYX;6Q02P$"% ,4    "  7@:Q:$_-&
ML+2F  #,[ < %0              @ $<$@4 <&%C8BTR,#(U,#,S,5]P<F4N
9>&UL4$L%!@     1 !$ B 0   .Y!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>pacb-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pacb="http://www.pacificbiosciences.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pacb-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:DomesticCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pacb:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:A2020PlanInducementPlanAndTheOmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="customer">
        <measure>pacb:customer</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001299130</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition contextRef="c-70" id="f-368">P20D</pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition>
    <us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-462">http://fasb.org/us-gaap/2024#GoodwillAndIntangibleAssetImpairment</us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-105" decimals="8" id="f-621" unitRef="number">0.02045157</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-139" decimals="7" id="f-622" unitRef="number">0.0229885</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-120" decimals="7" id="f-623" unitRef="number">0.0465116</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-628">http://fasb.org/us-gaap/2024#CostOfRevenue</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-654">http://fasb.org/us-gaap/2024#CostOfRevenue</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-34899</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Pacific Biosciences of California, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">16-1590339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">1305 O&#x2019;Brien Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">521-8000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">PACB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">300084685</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">58507000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">284603000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">334561000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">31645000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">27524000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">54007000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">58755000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">15471000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">18781000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">444923000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">495681000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">24794000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">30505000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">44408000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">16091000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">18182000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">389572000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">317761000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">317761000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">9189000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">9305000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">860789000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">1260447000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">14037000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">16590000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">29337000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">22595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">15241000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">13864000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">2417000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">10026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">5570000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">3224000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">66602000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">66299000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">5855000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">5900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">50480000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">14914000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">646214000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">647494000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">546000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">769151000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">753853000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-82" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-83" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-84"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-85"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-86" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-87" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-88" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-89" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-90" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-91" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-95"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-96" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-97" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-98" unitRef="shares">300041000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-99" unitRef="shares">300041000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-100" unitRef="shares">294418000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-101" unitRef="shares">294418000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-102" unitRef="usd">300000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">294000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-104" unitRef="usd">2665958000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">2654804000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-106" unitRef="usd">381000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">422000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-108" unitRef="usd">-2575001000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">-2148926000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-110" unitRef="usd">91638000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">506594000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-112" unitRef="usd">860789000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">1260447000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">31113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">35009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">6040000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-117" unitRef="usd">3801000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">37153000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-119" unitRef="usd">38810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">26333000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">22447000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-122" unitRef="usd">3778000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-8" decimals="-3" id="f-123" unitRef="usd">3738000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">4345000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-9" decimals="-3" id="f-125" unitRef="usd">1343000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <pacb:LossOnPurchaseCommitment contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">4068000</pacb:LossOnPurchaseCommitment>
    <pacb:LossOnPurchaseCommitment contextRef="c-9" decimals="-3" id="f-127" unitRef="usd">0</pacb:LossOnPurchaseCommitment>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">38524000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-9" decimals="-3" id="f-129" unitRef="usd">27528000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">-1371000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-9" decimals="-3" id="f-131" unitRef="usd">11282000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">29053000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-3" id="f-133" unitRef="usd">43455000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">40168000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-135" unitRef="usd">43753000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">15000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-9" decimals="-3" id="f-137" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">362042000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-9" decimals="-3" id="f-139" unitRef="usd">5506000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-9" decimals="-3" id="f-141" unitRef="usd">-70000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">427563000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-9" decimals="-3" id="f-143" unitRef="usd">92644000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-428934000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="-3" id="f-145" unitRef="usd">-81362000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">1737000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-9" decimals="-3" id="f-147" unitRef="usd">3575000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">4294000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-149" unitRef="usd">6759000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-426377000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-151" unitRef="usd">-78178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-302000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-9" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-426075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-155" unitRef="usd">-78178000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-9" decimals="-3" id="f-157" unitRef="usd">-525000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">-426116000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="-3" id="f-159" unitRef="usd">-78703000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">-1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-163"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-164" unitRef="shares">296858000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="-3" id="f-165" unitRef="shares">269578000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-166" unitRef="shares">296858000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="-3" id="f-167" unitRef="shares">269578000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-10" decimals="-3" id="f-168" unitRef="shares">294418000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-169" unitRef="usd">294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-170" unitRef="usd">2654804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-171" unitRef="usd">422000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-172" unitRef="usd">-2148926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-173" unitRef="usd">506594000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-174" unitRef="usd">-426075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">-426075000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-176" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-16" decimals="-3" id="f-178" unitRef="shares">5623000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-16" decimals="-3" id="f-179" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-17" decimals="-3" id="f-180" unitRef="usd">1953000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">1959000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-182" unitRef="usd">9201000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">9201000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="-3" id="f-184" unitRef="shares">300041000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-185" unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-186" unitRef="usd">2665958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-187" unitRef="usd">381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-188" unitRef="usd">-2575001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-189" unitRef="usd">91638000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-22" decimals="-3" id="f-190" unitRef="shares">267744000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-191" unitRef="usd">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-192" unitRef="usd">2539892000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-193" unitRef="usd">219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-194" unitRef="usd">-1839075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-195" unitRef="usd">701304000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-196" unitRef="usd">-78178000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-197" unitRef="usd">-78178000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-3" id="f-198" unitRef="usd">-525000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-9" decimals="-3" id="f-199" unitRef="usd">-525000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-29" decimals="-3" id="f-200" unitRef="shares">4536000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-29" decimals="-3" id="f-201" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-30" decimals="-3" id="f-202" unitRef="usd">6887000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-9" decimals="-3" id="f-203" unitRef="usd">6891000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-204" unitRef="usd">19525000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-9" decimals="-3" id="f-205" unitRef="usd">19525000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-206" unitRef="shares">272280000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-207" unitRef="usd">272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-208" unitRef="usd">2566304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-209" unitRef="usd">-306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-210" unitRef="usd">-1917253000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-211" unitRef="usd">649017000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">-426075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-213" unitRef="usd">-78178000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">5131000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-9" decimals="-3" id="f-215" unitRef="usd">3240000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">366390000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-9" decimals="-3" id="f-217" unitRef="usd">6853000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">1258000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-9" decimals="-3" id="f-219" unitRef="usd">1921000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">9201000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-9" decimals="-3" id="f-221" unitRef="usd">19525000</us-gaap:ShareBasedCompensation>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">15000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-9" decimals="-3" id="f-223" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">1706000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-9" decimals="-3" id="f-225" unitRef="usd">4031000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-9" decimals="-3" id="f-227" unitRef="usd">-70000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">7659000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-9" decimals="-3" id="f-229" unitRef="usd">3000</us-gaap:InventoryWriteDown>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">-546000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-9" decimals="-3" id="f-231" unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">-719000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-9" decimals="-3" id="f-233" unitRef="usd">-403000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">4121000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-9" decimals="-3" id="f-235" unitRef="usd">-6292000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">2538000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-9" decimals="-3" id="f-237" unitRef="usd">11655000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">-3426000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-9" decimals="-3" id="f-239" unitRef="usd">-3051000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">-1525000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-9" decimals="-3" id="f-241" unitRef="usd">6644000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">311000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-9" decimals="-3" id="f-243" unitRef="usd">-23753000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">1332000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-9" decimals="-3" id="f-245" unitRef="usd">1601000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">-1618000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-9" decimals="-3" id="f-247" unitRef="usd">-2376000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">2346000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-9" decimals="-3" id="f-249" unitRef="usd">-5152000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">-44056000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-9" decimals="-3" id="f-251" unitRef="usd">-75682000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">1389000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-253" unitRef="usd">3879000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">5000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-9" decimals="-3" id="f-255" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">61820000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-9" decimals="-3" id="f-257" unitRef="usd">191907000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">113443000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-9" decimals="-3" id="f-259" unitRef="usd">161650000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">45234000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-9" decimals="-3" id="f-261" unitRef="usd">-34136000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">1959000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-9" decimals="-3" id="f-263" unitRef="usd">6891000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-9" decimals="-3" id="f-265" unitRef="usd">338000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">1959000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-9" decimals="-3" id="f-267" unitRef="usd">6553000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">3137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-9" decimals="-3" id="f-269" unitRef="usd">-103265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-270" unitRef="usd">57592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-271" unitRef="usd">182633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-272" unitRef="usd">60729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-35" decimals="-3" id="f-273" unitRef="usd">79368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-274" unitRef="usd">58507000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-35" decimals="-3" id="f-275" unitRef="usd">76646000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-276" unitRef="usd">2222000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-35" decimals="-3" id="f-277" unitRef="usd">2722000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-278" unitRef="usd">60729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-35" decimals="-3" id="f-279" unitRef="usd">79368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">29575000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-9" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-282">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in this report to &#x201c;PacBio,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; and &#x201c;our&#x201d; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 ("2024 Annual Report").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2025. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Concentration and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2025 and 2024, no customer accounted for 10% or more of total revenue during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, 36% of our accounts receivable were from domestic customers, compared to 36% as of December&#160;31, 2024. As of March&#160;31, 2025, one customer exceeded 10% of our net accounts receivable, while no customer represented 10% or more of our net accounts receivable as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-283">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-284">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of March&#160;31, 2025. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-285">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive loss in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are also reported in other income (expense), net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income (expense), net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-36" decimals="2" id="f-286" unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-37" decimals="2" id="f-287" unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-38" decimals="2" id="f-288" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-289">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2023-09 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-04 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-290">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 2.  FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;42,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;245,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;245,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;284,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;284,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;45,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;345,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the August 2023 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apton Biosystems, Inc. (&#x201c;Apton&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition. At this time, the number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the &lt;span style="-sec-ix-hidden:f-368"&gt;twenty&lt;/span&gt; trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our condensed consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability was calculated using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify contingent consideration within Level 3 as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the five-year anniversary of the closing date of the acquisition. The key input used in the determination of the fair value included projected revenues of the high-throughput short-read products and services leveraging Apton's technology. As of March&#160;31, 2025, primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the five-year anniversary of the closing date of the acquisition, the estimated fair value of the contingent consideration liability was $0. An acceleration in the timing of projected revenues or an increase in the projected revenues may result in an increase in the fair value of the liability. A decrease in the discount rates, which include the risk-free rate and estimated subordinated credit spread for CCC credit rating, may result in an increase in the fair value of the liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending balance as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;245,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;245,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;284,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;284,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;343,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;227,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;72,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment income included in other income, net &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated statements of operations and comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was $3.9 million for the three months ended March&#160;31, 2025 and $7.2 million for the three months ended March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-291">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-292">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;42,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;245,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;245,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;284,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;284,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;45,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;345,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-39" decimals="-3" id="f-293" unitRef="usd">42952000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-40" decimals="-3" id="f-294" unitRef="usd">15555000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-41" decimals="-3" id="f-295" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-296" unitRef="usd">58507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-42" decimals="-3" id="f-297" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-43" decimals="-3" id="f-298" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-44" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-300" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-45" decimals="-3" id="f-301" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-46" decimals="-3" id="f-302" unitRef="usd">38790000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-47" decimals="-3" id="f-303" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-48" decimals="-3" id="f-304" unitRef="usd">38790000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-49" decimals="-3" id="f-305" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-50" decimals="-3" id="f-306" unitRef="usd">46905000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-51" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-52" decimals="-3" id="f-308" unitRef="usd">46905000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-53" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-54" decimals="-3" id="f-310" unitRef="usd">245813000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-311" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-312" unitRef="usd">245813000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-314" unitRef="usd">287656000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-315" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-316" unitRef="usd">287656000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-317" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-318" unitRef="usd">284603000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-319" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-320" unitRef="usd">284603000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-322" unitRef="usd">334561000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-323" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-324" unitRef="usd">334561000</us-gaap:InvestmentsFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-39" decimals="-3" id="f-325" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-40" decimals="-3" id="f-326" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-41" decimals="-3" id="f-327" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-3" decimals="-3" id="f-328" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-42" decimals="-3" id="f-329" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-43" decimals="-3" id="f-330" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-44" decimals="-3" id="f-331" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-332" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-39" decimals="-3" id="f-333" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-40" decimals="-3" id="f-334" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-41" decimals="-3" id="f-335" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-3" decimals="-3" id="f-336" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-42" decimals="-3" id="f-337" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-43" decimals="-3" id="f-338" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-44" decimals="-3" id="f-339" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-340" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-39" decimals="-3" id="f-341" unitRef="usd">45174000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-40" decimals="-3" id="f-342" unitRef="usd">300158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-41" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-344" unitRef="usd">345332000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-42" decimals="-3" id="f-345" unitRef="usd">57592000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-43" decimals="-3" id="f-346" unitRef="usd">334561000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-44" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-348" unitRef="usd">392153000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-39" decimals="-3" id="f-349" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-40" decimals="-3" id="f-350" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-41" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-3" decimals="-3" id="f-352" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-42" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-43" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-44" decimals="-3" id="f-355" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-4" decimals="-3" id="f-356" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-39" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-40" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-41" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-360" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-42" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-43" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-44" decimals="-3" id="f-363" unitRef="usd">18700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-364" unitRef="usd">18700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-69" decimals="-5" id="f-365" unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone contextRef="c-70" decimals="-5" id="f-366" unitRef="usd">50000000</pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-71" id="f-367">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger contextRef="c-72" decimals="3" id="f-369" unitRef="number">0.199</pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-73" id="f-370">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-73" id="f-371">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-73" decimals="-6" id="f-372" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-373">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability for the three months ended March&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending balance as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-44" decimals="-3" id="f-374" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-74" decimals="-3" id="f-375" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-41" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;245,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;245,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;284,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;284,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;343,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;227,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;72,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-75" decimals="-3" id="f-378" unitRef="usd">58507000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-75" decimals="-3" id="f-379" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-75" decimals="-3" id="f-380" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-75" decimals="-3" id="f-381" unitRef="usd">58507000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-76" decimals="-3" id="f-382" unitRef="usd">38635000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-76" decimals="-3" id="f-383" unitRef="usd">169000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-76" decimals="-3" id="f-384" unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-76" decimals="-3" id="f-385" unitRef="usd">38790000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-77" decimals="-3" id="f-386" unitRef="usd">245587000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-77" decimals="-3" id="f-387" unitRef="usd">283000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-77" decimals="-3" id="f-388" unitRef="usd">57000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-77" decimals="-3" id="f-389" unitRef="usd">245813000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-64" decimals="-3" id="f-390" unitRef="usd">284222000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-64" decimals="-3" id="f-391" unitRef="usd">452000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-64" decimals="-3" id="f-392" unitRef="usd">71000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-64" decimals="-3" id="f-393" unitRef="usd">284603000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-394" unitRef="usd">342729000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-395" unitRef="usd">453000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-396" unitRef="usd">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-397" unitRef="usd">343110000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-398" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-399" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-400" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-401" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-78" decimals="-3" id="f-402" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-78" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-78" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-78" decimals="-3" id="f-405" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-79" decimals="-3" id="f-406" unitRef="usd">46746000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-79" decimals="-3" id="f-407" unitRef="usd">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-79" decimals="-3" id="f-408" unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-79" decimals="-3" id="f-409" unitRef="usd">46905000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-80" decimals="-3" id="f-410" unitRef="usd">287393000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-80" decimals="-3" id="f-411" unitRef="usd">418000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-80" decimals="-3" id="f-412" unitRef="usd">155000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-80" decimals="-3" id="f-413" unitRef="usd">287656000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-68" decimals="-3" id="f-414" unitRef="usd">334139000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-68" decimals="-3" id="f-415" unitRef="usd">602000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-68" decimals="-3" id="f-416" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-68" decimals="-3" id="f-417" unitRef="usd">334561000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-418" unitRef="usd">389509000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-419" unitRef="usd">602000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-420" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-421" unitRef="usd">389931000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-422" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-423" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-424" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-425" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue contextRef="c-3" decimals="-3" id="f-426" unitRef="usd">227680000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue contextRef="c-3" decimals="-3" id="f-427" unitRef="usd">72478000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-3" decimals="-3" id="f-428" unitRef="usd">300158000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-5" id="f-429" unitRef="usd">3900000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-9" decimals="-5" id="f-430" unitRef="usd">7200000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-431">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 3.  BALANCE SHEET COMPONENTS &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inventory, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. We performed our annual assessment for goodwill impairment in the second quarter of 2024, as of the beginning of April 2024, noting no impairment. We recognized a $93.2&#160;million and $51.3&#160;million impairment charge in the second and fourth quarter of 2024, respectively, as a result of quantitative interim impairment tests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based primarily on the decline in our stock price and overall market capitalization during the first quarter of 2025, driven in part by macroeconomic uncertainties, as well as our updated strategic plans and restructuring initiatives that prioritize accelerating adoption of HiFi sequencing and ceasing development of our high-throughput short-read platform, we concluded that changes to the timing and amount of expected future cash flows, among other factors, indicated that it was more likely than not that the fair value of the reporting unit was less than its carrying amount, requiring an interim goodwill impairment assessment. As a result of the quantitative interim impairment test performed as of March 31, 2025, we concluded that there was no impairment, as the estimated fair value of the entity-level reporting unit exceeded the carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the fair value of the entity-level reporting unit as of March 31, 2025, we performed our impairment test using a combination of an income approach and a market approach to determine the fair value of the reporting unit. The income approach utilized estimated discounted cash flows, while the market approach utilized comparable company information. Significant assumptions used in the income approach included revenue growth expectations and a selected discount rate of 12.0%. The discount rate was based on the weighted average cost of capital, determined using market, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. An increase of 100 basis points to the discount rate used in our assessment would have resulted in a change in the fair value of the reporting unit of approximately $75&#160;million. The assessed fair value was deemed reasonable based on a market capitalization reconciliation and a supportable control premium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairment tests could affect the implied fair value of goodwill and may result in additional impairment charges in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include developed technology, customer relationships, and acquired in-process research and development ("IPR&amp;amp;D"). In connection with the Apton acquisition in August 2023, we allocated $55.0 million of the purchase price to IPR&amp;amp;D. This asset is considered indefinite-lived until the associated research and development activities are either completed or abandoned, and is tested for impairment annually and more &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized a $40.0&#160;million impairment charge in the fourth quarter of 2024 as a result of a quantitative interim impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our decision to cease development of the high-throughput short-read sequencing platform, which would utilize the IPR&amp;amp;D, and the resulting changes to the expected future cash flows, among other factors, we concluded  that it was more likely than not that the fair value of the IPR&amp;amp;D was less than its carrying amount, requiring an interim impairment assessment. Using a discounted cash flow model under the income approach, we determined the fair value was below carrying value and recorded a $15.0&#160;million impairment charge. The decline in the fair value of the IPR&amp;amp;D below its carrying amount as of March 31, 2025 resulted primarily from changes in the timing of expected future cash flows as compared to the fair value as of December 31, 2024, driven by the restructuring initiatives that prioritize accelerating adoption of HiFi sequencing and resulted in ceasing development of our high-throughput short-read sequencing platform. The impairment charge is included on our consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions used in the income approach include timing of future cash flows, revenue growth assumptions, a selected discount rate of 14.0%, and a selected obsolescence factor of 11 years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. A decrease of 200 basis points to the discount rate used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;amp;D of approximately $3&#160;million, and an increase of one year to the obsolescence factor used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;amp;D of approximately $3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to IPR&amp;amp;D during the three months ended March&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-462"&gt;Impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of March&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5&lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;. &lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restructuring&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on costs incurred in connection with our current year restructuring activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3 &#x2014; 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(402,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(403,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of intangible assets with finite lives is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review finite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2025, we revised the estimated useful life of the developed technology acquired in the 2021 Omniome, Inc. ("Omniome") acquisition. This change reflects updated strategic plans and restructuring initiatives focused on accelerating HiFi sequencing adoption, leading to ceased development of our high-throughput short-read platform and revised expectations for the timing and amount of future cash flows from short-read sequencing products and services. As a result of the change in estimate, during the three months ended March 31, 2025 we recognized accelerated amortization of $359.3&#160;million within amortization of acquired intangible assets in operating expenses, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. This expense reduced basic and diluted net loss per share by $1.21.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;7, 2025, the Company entered into an agreement to acquire certain developed technology and related intellectual property from The Chinese University of Hong Kong for total consideration of $9.7&#160;million. In addition, the Company entered into a license agreement for complementary developed technology during the three months ended March 31, 2025. Both the acquired technology and license are classified as intangible assets and are being amortized over an estimated useful life of three years. As of March 31, 2025, $5.0&#160;million of intangible assets acquired during the first quarter of 2025 remained unpaid, is included in accrued liabilities on the condensed consolidated balance sheets, and is expected to be paid in 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2025, as part of our interim goodwill impairment test, we also performed a recoverability test for the definite-lived asset group noting no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5&lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_49" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;. Restructuring&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on costs incurred in connection with our current year restructuring activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, we had a total of $21.1&#160;million of deferred revenue, $15.2&#160;million of which was recorded as deferred revenue, current, and $5.9&#160;million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next five years. Revenue recorded in the three months ended March&#160;31, 2025 includes $4.6&#160;million that was included in deferred revenue as of December&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of March&#160;31, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $58.7&#160;million, of which approximately 70% is expected to be converted to revenue over the next twelve months, approximately 23% in the following twelve months, and the remainder thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Product Warranties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on the condensed consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-3" decimals="-3" id="f-433" unitRef="usd">44479000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-3" id="f-434" unitRef="usd">45270000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-3" decimals="-3" id="f-435" unitRef="usd">24914000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-4" decimals="-3" id="f-436" unitRef="usd">22172000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-3" decimals="-3" id="f-437" unitRef="usd">13429000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-438" unitRef="usd">14081000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="c-3" decimals="-3" id="f-439" unitRef="usd">82822000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-4" decimals="-3" id="f-440" unitRef="usd">81523000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="c-3" decimals="-3" id="f-441" unitRef="usd">28815000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-4" decimals="-3" id="f-442" unitRef="usd">22768000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-443" unitRef="usd">54007000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-444" unitRef="usd">58755000</us-gaap:InventoryNet>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-81" decimals="-5" id="f-445" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-82" decimals="-5" id="f-446" unitRef="usd">93200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-83" decimals="-5" id="f-447" unitRef="usd">51300000</us-gaap:GoodwillImpairmentLoss>
    <pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-3" decimals="3" id="f-448" unitRef="number">0.120</pacb:GoodwillImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:GoodwillImpairmentIncreaseInBasisPointDiscountRate contextRef="c-3" decimals="4" id="f-449" unitRef="number">0.0100</pacb:GoodwillImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalGoodwillImpairmentChangeInDiscountRate contextRef="c-1" decimals="-6" id="f-450" unitRef="usd">75000000</pacb:AdditionalGoodwillImpairmentChangeInDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-71" decimals="-5" id="f-451" unitRef="usd">55000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-83" decimals="-5" id="f-452" unitRef="usd">40000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-84" decimals="-5" id="f-453" unitRef="usd">15000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-3" decimals="3" id="f-454" unitRef="number">0.140</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm contextRef="c-3" id="f-455">P11Y</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm>
    <pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate contextRef="c-3" decimals="4" id="f-456" unitRef="number">200</pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate contextRef="c-1" decimals="-6" id="f-457" unitRef="usd">3000000</pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate>
    <pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm contextRef="c-3" id="f-458">P1Y</pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInTerm contextRef="c-1" decimals="-6" id="f-459" unitRef="usd">3000000</pacb:AdditionalIntangibleAssetImpairmentChangeInTerm>
    <us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to IPR&amp;amp;D during the three months ended March&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-462"&gt;Impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of March&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-85" decimals="-3" id="f-461" unitRef="usd">15000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-84" decimals="-3" id="f-463" unitRef="usd">15000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-86" decimals="-3" id="f-464" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3 &#x2014; 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(402,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(403,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-87" id="f-466">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-88" id="f-467">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-89" decimals="-3" id="f-468" unitRef="usd">421179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-89" decimals="-3" id="f-469" unitRef="usd">402997000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-89" decimals="-3" id="f-470" unitRef="usd">18182000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-90" decimals="-3" id="f-471" unitRef="usd">411179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-90" decimals="-3" id="f-472" unitRef="usd">36607000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-90" decimals="-3" id="f-473" unitRef="usd">374572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-91" id="f-474">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-91" decimals="-3" id="f-475" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-91" decimals="-3" id="f-476" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-91" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-92" decimals="-3" id="f-478" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-92" decimals="-3" id="f-479" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-92" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-3" decimals="-3" id="f-481" unitRef="usd">421539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-482" unitRef="usd">403357000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-483" unitRef="usd">18182000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-484" unitRef="usd">411539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-485" unitRef="usd">36967000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-486" unitRef="usd">374572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-487">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of intangible assets with finite lives is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-488" unitRef="usd">3059000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-489" unitRef="usd">4078000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-490" unitRef="usd">4078000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-491" unitRef="usd">1301000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-492" unitRef="usd">745000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-3" decimals="-3" id="f-493" unitRef="usd">4921000</pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">18182000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pacb:RestructuringAndRelatedCostAcceleratedAmortization contextRef="c-93" decimals="-5" id="f-495" unitRef="usd">359300000</pacb:RestructuringAndRelatedCostAcceleratedAmortization>
    <pacb:ChangeInEarningsPerShare
      contextRef="c-94"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">1.21</pacb:ChangeInEarningsPerShare>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-95" decimals="-5" id="f-497" unitRef="usd">9700000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-96" id="f-498">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-97" id="f-499">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-98" decimals="-5" id="f-500" unitRef="usd">5000000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-501" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ContractWithCustomerLiability contextRef="c-99" decimals="-5" id="f-502" unitRef="usd">21100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-99" decimals="-5" id="f-503" unitRef="usd">15200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-99" decimals="-5" id="f-504" unitRef="usd">5900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod contextRef="c-100" id="f-505">P5Y</pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-100" decimals="-5" id="f-506" unitRef="usd">4600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-3" decimals="-5" id="f-507" unitRef="usd">58700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c-101" decimals="2" id="f-508" unitRef="number">0.70</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-101" id="f-509">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c-102" decimals="2" id="f-510" unitRef="number">0.23</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-102" id="f-511">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <pacb:StandardProductWarrantyPeriod contextRef="c-1" id="f-512">P1Y</pacb:StandardProductWarrantyPeriod>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="c-4" decimals="-3" id="f-514" unitRef="usd">3100000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-26" decimals="-3" id="f-515" unitRef="usd">4681000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-1" decimals="-3" id="f-516" unitRef="usd">1311000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-9" decimals="-3" id="f-517" unitRef="usd">1600000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-1" decimals="-3" id="f-518" unitRef="usd">1552000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-9" decimals="-3" id="f-519" unitRef="usd">2161000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrual contextRef="c-3" decimals="-3" id="f-520" unitRef="usd">2859000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-35" decimals="-3" id="f-521" unitRef="usd">4120000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 4.  CONVERTIBLE SENIOR NOTES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2029 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#x201c;SBN&#x201d;), a subsidiary of SoftBank Group Corp., pursuant to which we agreed to exchange the remaining approximately $459.0&#160;million in aggregate principal amount of our previously held 1.50% Convertible Senior Notes due 2028 (the &#x201c;2028 Notes&#x201d;) outstanding for (i) $200.0&#160;million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the &#x201c;2029 Notes&#x201d;), (ii) 20,451,570 shares of common stock (the &#x201c;Exchange Shares&#x201d;) and (iii) $50.0&#160;million of cash (the &#x201c;2024 Exchange Transaction&#x201d;). The Exchange Shares were issued on November 21, 2024 (the &#x201c;Closing Date&#x201d;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes are subject to certain lock-up restrictions for a six-month period (the &#x201c;Lock-Up Period&#x201d;) beginning on the Closing Date of the 2024 Exchange Transaction; the lock-up restrictions will terminate immediately prior to the consummation of any change in control of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#x2019;s common stock which would cause SBN's beneficial ownership of common stock to exceed either 9.9% of the total number of issued and outstanding shares of common stock or 9.9% of the combined voting power of all of the securities of the Company, in each case, following such conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are governed by an indenture (the &#x201c;2029 Indenture&#x201d;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of 1.50% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15, commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $4.89 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2029 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the 181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day to, and including, the 360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange qualified as a troubled debt restructuring under ASC 470-60 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Troubled Debt Restructurings by Debtors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $154.4&#160;million, which resulted in a decrease of basic net loss per share of $0.56, during the year ended December 31, 2024 on our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2029 Notes of approximately $3.1&#160;million, including $0.2&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring on our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $1.8&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $50.0&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, no amounts were outstanding on the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the liability for the 2029 Notes as of March&#160;31, 2025 is $213.5&#160;million, of which $210.5&#160;million is included as convertible senior notes, net, non-current, and $3.0&#160;million is included as accrued expenses on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the 2029 Notes during the three months ended March&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the estimated fair value (Level 2) of the 2029 Notes was $154.0&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2030 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 2028 Notes, pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#x201c;2030 Notes&#x201d; and together with the 2029 Notes, the &#x201c;Notes&#x201d;) in exchange for $441.0&#160;million principal amount of the 2028 Notes (the &#x201c;2023 Exchange Transaction&#x201d;), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The 2030 Notes were issued on June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are governed by an indenture (the &#x201c;2030 Indenture&#x201d;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day to, and including, the 360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0&#160;million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5&#160;million related to the respective portion of the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2030 Notes of approximately $7.3&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our condensed consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5&#160;million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the closing of the 2023 Exchange Transaction, $459.0&#160;million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;435,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;435,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the estimated fair value (Level 2) of the 2030 Notes was $276.6 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2028 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $900.0&#160;million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February 16, 2021 and bore interest at a rate of 1.50% per annum. As discussed above, in June 2023 we completed an exchange of $441.0&#160;million in aggregate principal amount of our 2028 Notes for $441.0&#160;million aggregate principal amount of the 2030 Notes, leaving approximately $459.0&#160;million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $459.0&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $50.0&#160;million of cash. As of December 31, 2024 no amounts were outstanding on the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2028 Notes of approximately $4.5&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $1.1&#160;million were extinguished by offsetting the carrying amount of the convertible senior notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-103" decimals="-5" id="f-523" unitRef="usd">459000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-103" decimals="4" id="f-524" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-104" decimals="-5" id="f-525" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-104" decimals="4" id="f-526" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c-105" decimals="0" id="f-527" unitRef="shares">20451570</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-106" decimals="-5" id="f-528" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares contextRef="c-107" id="f-529">P6M</pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-106" decimals="4" id="f-530" unitRef="number">0.099</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-106" decimals="4" id="f-531" unitRef="number">0.099</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-104" decimals="4" id="f-532" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-104"
      decimals="2"
      id="f-533"
      unitRef="usdPerShare">4.89</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-105" decimals="2" id="f-534" unitRef="number">1.50</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-105" decimals="INF" id="f-535" unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-105" decimals="INF" id="f-536" unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-105" decimals="2" id="f-537" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-105" id="f-538">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-108" decimals="4" id="f-539" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-108" id="f-540">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-105" id="f-541">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-109" decimals="4" id="f-542" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-110" id="f-543">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-111" id="f-544">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-109" id="f-545">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-109" id="f-546">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-112" decimals="-5" id="f-547" unitRef="usd">154400000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <pacb:RestructuringOfDebtPricePerShare
      contextRef="c-112"
      decimals="2"
      id="f-548"
      unitRef="usdPerShare">0.56</pacb:RestructuringOfDebtPricePerShare>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-113" decimals="-5" id="f-549" unitRef="usd">3100000</us-gaap:DeferredFinanceCostsGross>
    <pacb:DebtIssuanceCostLenderFees contextRef="c-113" decimals="-5" id="f-550" unitRef="usd">200000</pacb:DebtIssuanceCostLenderFees>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-114" decimals="-5" id="f-551" unitRef="usd">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-106" decimals="-5" id="f-552" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <us-gaap:LongTermDebt contextRef="c-103" decimals="0" id="f-553" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:ConvertibleNotesPayable contextRef="c-115" decimals="-5" id="f-554" unitRef="usd">213500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-115" decimals="-5" id="f-555" unitRef="usd">210500000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-115" decimals="-5" id="f-556" unitRef="usd">3000000</us-gaap:AccruedLiabilitiesCurrent>
    <pacb:ScheduleOfInterestExpenseTableTextBlock contextRef="c-1" id="f-557">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the 2029 Notes during the three months ended March&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:ConvertibleNotesPayable contextRef="c-116" decimals="-3" id="f-558" unitRef="usd">214200000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-117" decimals="-3" id="f-559" unitRef="usd">700000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:ConvertibleNotesPayable contextRef="c-115" decimals="-3" id="f-560" unitRef="usd">213500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-118" decimals="-5" id="f-561" unitRef="usd">154000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-119" decimals="-5" id="f-562" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-119" decimals="5" id="f-563" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-119" decimals="-5" id="f-564" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-119" decimals="5" id="f-565" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-119"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">21.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice contextRef="c-120" decimals="2" id="f-567" unitRef="number">1.50</pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice>
    <pacb:DebtInstrumentRedemptionPriceTradingDays contextRef="c-120" id="f-568">P20D</pacb:DebtInstrumentRedemptionPriceTradingDays>
    <pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays contextRef="c-120" id="f-569">P30D</pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-120" decimals="2" id="f-570" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-120" decimals="2" id="f-571" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-120" id="f-572">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-120" decimals="4" id="f-573" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-121" id="f-574">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-120" id="f-575">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-120" decimals="4" id="f-576" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-122" id="f-577">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-123" id="f-578">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-124" id="f-579">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-124" id="f-580">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-125" decimals="-5" id="f-581" unitRef="usd">-2000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-126" decimals="-5" id="f-582" unitRef="usd">1500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-127" decimals="-5" id="f-583" unitRef="usd">7300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-119" decimals="3" id="f-584" unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-128" decimals="-5" id="f-585" unitRef="usd">2500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:LongTermDebt contextRef="c-129" decimals="-5" id="f-586" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-587">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;435,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;435,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-130" decimals="-3" id="f-588" unitRef="usd">441000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-131" decimals="-3" id="f-589" unitRef="usd">441000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-130" decimals="-3" id="f-590" unitRef="usd">434000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-131" decimals="-3" id="f-591" unitRef="usd">453000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-130" decimals="-3" id="f-592" unitRef="usd">5720000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-131" decimals="-3" id="f-593" unitRef="usd">5959000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt contextRef="c-130" decimals="-3" id="f-594" unitRef="usd">435714000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-131" decimals="-3" id="f-595" unitRef="usd">435494000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-132" decimals="-3" id="f-596" unitRef="usd">1516000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-133" decimals="-3" id="f-597" unitRef="usd">1533000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-132" decimals="-3" id="f-598" unitRef="usd">239000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-133" decimals="-3" id="f-599" unitRef="usd">239000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-132" decimals="-3" id="f-600" unitRef="usd">1755000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-133" decimals="-3" id="f-601" unitRef="usd">1772000</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-134" decimals="-5" id="f-602" unitRef="usd">276600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-135" decimals="-5" id="f-603" unitRef="usd">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-135" decimals="4" id="f-604" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-129" decimals="-5" id="f-605" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-119" decimals="-5" id="f-606" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt contextRef="c-129" decimals="-5" id="f-607" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-136" decimals="-5" id="f-608" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-137" decimals="-5" id="f-609" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-106" decimals="-5" id="f-610" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <us-gaap:LongTermDebt contextRef="c-138" decimals="-3" id="f-611" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-135" decimals="-5" id="f-612" unitRef="usd">4500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-135" decimals="3" id="f-613" unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-139" decimals="-5" id="f-614" unitRef="usd">1100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-140" decimals="-3" id="f-615" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-141" decimals="-3" id="f-616" unitRef="usd">1721000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-140" decimals="-3" id="f-617" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-141" decimals="-3" id="f-618" unitRef="usd">81000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-140" decimals="-3" id="f-619" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-141" decimals="-3" id="f-620" unitRef="usd">1802000</us-gaap:InterestExpenseDebt>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-624">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 5.  RESTRUCTURING&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2025 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2025, we implemented an expense reduction initiative aimed at lowering our annualized run-rate operating expenses. These actions, which included workforce reductions and other cost-saving measures, were part of a broader strategic shift to prioritize the adoption of HiFi sequencing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-628"&gt;Total restructuring charges&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; $2.5&#160;million was recorded in sales, general and administrative expense and $2.1&#160;million in research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges included employee separation costs comprised of approximately $2.4&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $2.2&#160;million of severance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the restructuring and strategic shift, we incurred an additional $388.2&#160;million in costs. These include $359.3&#160;million of accelerated amortization of certain intangible assets, $15.0&#160;million of IPR&amp;amp;D impairment charges, $7.7&#160;million related to excess inventory due to decreased external demand and $3.8&#160;million for estimated losses on purchase commitments tied to anticipated future excess inventory included in cost of revenue, and $2.4&#160;million of accelerated depreciation of fixed assets. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_40" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 3. Balance Sheet Components&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on the IPR&amp;amp;D impairment assessment and the change in estimated useful life of the intangible asset and accelerated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, excluding non-cash activities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recorded in Q1 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid in Q1 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2024 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-654"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total restructuring charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For the three months ended March&#160;31, 2025, $1.0 million was recorded in sales, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:31.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cumulative charges incurred to date include $15.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative charges incurred to date include employee separation costs comprised of approximately $5.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $4.5&#160;million of severance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other costs in the three months ended March&#160;31, 2025 are primarily related to a lease termination fee and other costs related to our exit of the San Diego office. Other costs in cumulative charges incurred to date are primarily related to accelerated amortization and depreciation of $8.1&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $3.6&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the three months ended June 30, 2024 resulting in a reduction in the operating lease liability balance of $4.4&#160;million, which was offset against the right-of-use asset on the condensed consolidated balance sheets. We fully exited our San Diego office in September 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional expense recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of March&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability as of March&#160;31, 2025 is $1.8&#160;million, and is included in operating lease liabilities, current on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-628"&gt;Total restructuring charges&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; $2.5&#160;million was recorded in sales, general and administrative expense and $2.1&#160;million in research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-654"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total restructuring charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; For the three months ended March&#160;31, 2025, $1.0 million was recorded in sales, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:31.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cumulative charges incurred to date include $15.9 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-142" decimals="-3" id="f-626" unitRef="usd">4649000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-142" decimals="-3" id="f-627" unitRef="usd">4649000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-93" decimals="-3" id="f-629" unitRef="usd">4649000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-93" decimals="-3" id="f-630" unitRef="usd">4649000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-143" decimals="-5" id="f-631" unitRef="usd">2500000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-144" decimals="-5" id="f-632" unitRef="usd">2100000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits contextRef="c-93" decimals="-5" id="f-633" unitRef="usd">2400000</pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits>
    <us-gaap:SeveranceCosts1 contextRef="c-93" decimals="-5" id="f-634" unitRef="usd">2200000</us-gaap:SeveranceCosts1>
    <pacb:RestructuringChargesAdditionalCostsIncurred contextRef="c-93" decimals="-5" id="f-635" unitRef="usd">388200000</pacb:RestructuringChargesAdditionalCostsIncurred>
    <pacb:RestructuringAndRelatedCostAcceleratedAmortization contextRef="c-93" decimals="-5" id="f-636" unitRef="usd">359300000</pacb:RestructuringAndRelatedCostAcceleratedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-145" decimals="-5" id="f-637" unitRef="usd">15000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown contextRef="c-93" decimals="-5" id="f-638" unitRef="usd">7700000</us-gaap:InventoryWriteDown>
    <pacb:GainLossOnPurchaseCommitments contextRef="c-93" decimals="-5" id="f-639" unitRef="usd">3800000</pacb:GainLossOnPurchaseCommitments>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-93" decimals="-5" id="f-640" unitRef="usd">2400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-641">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, excluding non-cash activities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense recorded in Q1 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid in Q1 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of March 31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional expense recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of March&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-142" decimals="-3" id="f-642" unitRef="usd">4649000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-142" decimals="-3" id="f-643" unitRef="usd">4649000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-142" decimals="-3" id="f-644" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-142" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-146" decimals="-3" id="f-646" unitRef="usd">4649000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-146" decimals="-3" id="f-647" unitRef="usd">4649000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-146" decimals="-3" id="f-648" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-146" decimals="-3" id="f-649" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringCharges contextRef="c-147" decimals="-3" id="f-650" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-147" decimals="-3" id="f-651" unitRef="usd">10008000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-148" decimals="-3" id="f-652" unitRef="usd">975000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-148" decimals="-3" id="f-653" unitRef="usd">16189000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-149" decimals="-3" id="f-655" unitRef="usd">975000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-149" decimals="-3" id="f-656" unitRef="usd">26197000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <pacb:RestructuringChargesExcludingAdjustments contextRef="c-149" decimals="-5" id="f-657" unitRef="usd">1000000.0</pacb:RestructuringChargesExcludingAdjustments>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-150" decimals="-5" id="f-658" unitRef="usd">15900000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-151" decimals="-5" id="f-659" unitRef="usd">5900000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-152" decimals="-5" id="f-660" unitRef="usd">4400000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits contextRef="c-149" decimals="-5" id="f-661" unitRef="usd">5500000</pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits>
    <us-gaap:SeveranceCosts1 contextRef="c-149" decimals="-5" id="f-662" unitRef="usd">4500000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-153" decimals="-5" id="f-663" unitRef="usd">8100000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:InventoryWriteDown contextRef="c-153" decimals="-5" id="f-664" unitRef="usd">3600000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-154" decimals="-5" id="f-665" unitRef="usd">-4400000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:RestructuringReserve contextRef="c-155" decimals="-3" id="f-666" unitRef="usd">170000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-156" decimals="-3" id="f-667" unitRef="usd">170000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-148" decimals="-3" id="f-668" unitRef="usd">975000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-149" decimals="-3" id="f-669" unitRef="usd">975000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-148" decimals="-3" id="f-670" unitRef="usd">581000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-149" decimals="-3" id="f-671" unitRef="usd">581000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-157" decimals="-3" id="f-672" unitRef="usd">564000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-158" decimals="-3" id="f-673" unitRef="usd">564000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-157" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-158" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:OperatingLeaseLiability contextRef="c-159" decimals="-5" id="f-676" unitRef="usd">1800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-677">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 6.  COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record operating lease right-of-use assets and liabilities on our consolidated balance sheets for all leases with a term of more than 12 months. The operating lease right-of-use assets and liabilities are calculated as the present value of remaining minimum lease payments over the remaining lease term using our estimated secured incremental borrowing rates at the commencement date. Lease payments included in the measurement of the lease liability comprise the fixed rent per the term of the Lease. All of our leases are operating leases. Lease payments comprise the base rent per the term of the lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We often have options to renew lease terms for buildings. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 7, 2025, we amended our existing lease covering our corporate headquarters, as well as our research and development, manufacturing, and distribution facilities in Menlo Park, California. The lease amendment extends the term to April 30, 2034. We will pay approximately $97.7&#160;million in base rent over the life of the amended lease and receive base rent abatement of approximately $11.6&#160;million for the period beginning on March 1, 2025 and ending on July 31, 2026. We are also entitled to a tenant improvement allowance of $7.2&#160;million. The lease amendment increased our operating lease right-of-use assets and operating lease liabilities by $29.6&#160;million on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the maturities of our operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;59,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(47,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Present value of operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use our incremental borrowing rate to determine the present value of lease payments, as the implicit rates in our leases are not readily determinable. The weighted-average discount rate used to measure our operating lease liabilities was 10.1%. The weighted-average remaining lease term for our operating leases as of March&#160;31, 2025 was 9.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the present value of operating lease liabilities was $2.4&#160;million and $3.0&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively, and were included in operating cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $2.0&#160;million and $2.6&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see subsection titled &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_100" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Legal Proceedings, in Part II, Item 1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of March&#160;31, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <pacb:OperatingLeaseExpectedBaseRentExpense contextRef="c-160" decimals="-5" id="f-678" unitRef="usd">97700000</pacb:OperatingLeaseExpectedBaseRentExpense>
    <pacb:LesseeOperatingLeaseLiabilityBaseRentAbatementAmount contextRef="c-161" decimals="-5" id="f-679" unitRef="usd">11600000</pacb:LesseeOperatingLeaseLiabilityBaseRentAbatementAmount>
    <us-gaap:TenantImprovements contextRef="c-161" decimals="-5" id="f-680" unitRef="usd">7200000</us-gaap:TenantImprovements>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-681" unitRef="usd">29600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <pacb:LesseeOperatingLeaseDescriptionTableTextBlock contextRef="c-1" id="f-682">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the maturities of our operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;59,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(47,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Present value of operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:LesseeOperatingLeaseDescriptionTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-683" unitRef="usd">2327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-684" unitRef="usd">3941000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-685" unitRef="usd">9165000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-686" unitRef="usd">12389000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-3" decimals="-3" id="f-687" unitRef="usd">12761000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-3" decimals="-3" id="f-688" unitRef="usd">59897000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-689" unitRef="usd">100480000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-690" unitRef="usd">47583000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-691" unitRef="usd">52897000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-692" unitRef="usd">2417000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-693" unitRef="usd">50480000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-694" unitRef="usd">52897000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-695" unitRef="number">0.101</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-696">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:PaymentsForRent contextRef="c-1" decimals="-5" id="f-697" unitRef="usd">2400000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c-9" decimals="-5" id="f-698" unitRef="usd">3000000</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-699" unitRef="usd">2000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-9" decimals="-5" id="f-700" unitRef="usd">2600000</us-gaap:OperatingLeaseCost>
    <pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations contextRef="c-4" decimals="0" id="f-701" unitRef="usd">0</pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations>
    <pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations contextRef="c-3" decimals="0" id="f-702" unitRef="usd">0</pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-703">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 7.  EQUITY PLANS AND SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), the 2020 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, we had 11.3&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9 &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Part II, Item 8 of our 2024 Annual Report for more information on the Company's equity plans&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,287)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We issue PSUs for which the number of shares issuable is based on performance relative to specified revenue targets and continued employment through the vesting period. The PSUs are issuable following the third year of the performance period. Maximum achievement of the revenue goal under the PSUs will result in up to 200% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under the PSUs will result in no shares subject to the PSUs becoming eligible to vest. The following table summarizes the time-based RSUs and PSUs activity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units (RSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Performance Stock Units (PSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan ("ESPP")&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued under our ESPP wer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e 1,752,417 and 1,194,436&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; durin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g the three months ended March&#160;31, 2025 and 2024, respectively. In the first quarter of 2025, an additional 4.0&#160;million shares were reserved under the ESPP. As of March&#160;31, 2025, 16.5&#160;million shares of our common stock remain avai&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lable for issuance under our ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Determining Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;95% &#x2014; 96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;3.92% &#x2014; 4.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;113%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.96% &#x2014; 4.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.54% &#x2014; 5.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-162"
      decimals="-5"
      id="f-704"
      unitRef="shares">11300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-705">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,562&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,287)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-163"
      decimals="-3"
      id="f-706"
      unitRef="shares">10509000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-163"
      decimals="2"
      id="f-707"
      unitRef="usdPerShare">11.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-164"
      decimals="-3"
      id="f-708"
      unitRef="shares">7562000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-164"
      decimals="2"
      id="f-709"
      unitRef="usdPerShare">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-164"
      decimals="-3"
      id="f-710"
      unitRef="shares">1287000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-164"
      decimals="2"
      id="f-711"
      unitRef="usdPerShare">9.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-164"
      decimals="-3"
      id="f-712"
      unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-164"
      decimals="2"
      id="f-713"
      unitRef="usdPerShare">6.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-165"
      decimals="-3"
      id="f-714"
      unitRef="shares">16548000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-165"
      decimals="2"
      id="f-715"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal contextRef="c-166" decimals="2" id="f-716" unitRef="number">2</pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-717">The following table summarizes the time-based RSUs and PSUs activity: &lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units (RSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Performance Stock Units (PSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-167"
      decimals="-3"
      id="f-718"
      unitRef="shares">14211000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-168"
      decimals="-3"
      id="f-719"
      unitRef="shares">392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-167"
      decimals="2"
      id="f-720"
      unitRef="usdPerShare">7.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-168"
      decimals="2"
      id="f-721"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-169"
      decimals="-3"
      id="f-722"
      unitRef="shares">11618000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-170"
      decimals="-3"
      id="f-723"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-724"
      unitRef="usdPerShare">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-170"
      decimals="2"
      id="f-725"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-169"
      decimals="-3"
      id="f-726"
      unitRef="shares">3870000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-170"
      decimals="-3"
      id="f-727"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-728"
      unitRef="usdPerShare">9.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-170"
      decimals="2"
      id="f-729"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-169"
      decimals="-3"
      id="f-730"
      unitRef="shares">552000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-170"
      decimals="-3"
      id="f-731"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-732"
      unitRef="usdPerShare">5.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-170"
      decimals="2"
      id="f-733"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-171"
      decimals="-3"
      id="f-734"
      unitRef="shares">21407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-172"
      decimals="-3"
      id="f-735"
      unitRef="shares">392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-171"
      decimals="2"
      id="f-736"
      unitRef="usdPerShare">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-172"
      decimals="2"
      id="f-737"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c-1" decimals="0" id="f-738" unitRef="shares">1752417</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c-9" decimals="0" id="f-739" unitRef="shares">1194436</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-173"
      decimals="-5"
      id="f-740"
      unitRef="shares">4000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-174"
      decimals="-5"
      id="f-741"
      unitRef="shares">16500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-742">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-3" id="f-743" unitRef="usd">1165000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-3" id="f-744" unitRef="usd">2106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-3" id="f-745" unitRef="usd">2607000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-178" decimals="-3" id="f-746" unitRef="usd">5788000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-179" decimals="-3" id="f-747" unitRef="usd">5429000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-180" decimals="-3" id="f-748" unitRef="usd">11631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-181" decimals="-3" id="f-749" unitRef="usd">9201000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-182" decimals="-3" id="f-750" unitRef="usd">19525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-751" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-9" decimals="INF" id="f-752" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-753">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;95% &#x2014; 96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;3.92% &#x2014; 4.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-183" id="f-754">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-184" id="f-755">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-183" decimals="2" id="f-756" unitRef="number">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-183" decimals="2" id="f-757" unitRef="number">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-184" decimals="2" id="f-758" unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-183" decimals="4" id="f-759" unitRef="number">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-183" decimals="4" id="f-760" unitRef="number">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-184" decimals="4" id="f-761" unitRef="number">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-183" decimals="0" id="f-762" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-184" decimals="0" id="f-763" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-183"
      decimals="2"
      id="f-764"
      unitRef="usdPerShare">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-184"
      decimals="2"
      id="f-765"
      unitRef="usdPerShare">2.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c-1" id="f-766">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;113%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.96% &#x2014; 4.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.54% &#x2014; 5.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$2.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-185" id="f-767">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-186" id="f-768">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-187" id="f-769">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-188" id="f-770">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-189" decimals="2" id="f-771" unitRef="number">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-190" decimals="2" id="f-772" unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-189" decimals="4" id="f-773" unitRef="number">0.0396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-189" decimals="4" id="f-774" unitRef="number">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-190" decimals="4" id="f-775" unitRef="number">0.0454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-190" decimals="4" id="f-776" unitRef="number">0.0527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-189" decimals="0" id="f-777" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-190" decimals="0" id="f-778" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-189"
      decimals="2"
      id="f-779"
      unitRef="usdPerShare">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-190"
      decimals="2"
      id="f-780"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-781">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 8.  NET LOSS PER SHARE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the Notes, using the if-converted method, and outstanding equity awards using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(426,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(78,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;269,578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;269,578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47,133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,924&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note &lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;. &lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity Plans and Sha&lt;/a&gt;&lt;a href="#i8ceeb5c9aa84416fb9d34124a1b6c447_55" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;re-Based Compensation&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for detailed information on equity awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-782">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(426,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(78,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;269,578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;296,858&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;269,578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-783" unitRef="usd">-426075000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-9" decimals="-3" id="f-784" unitRef="usd">-78178000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-785" unitRef="shares">296858000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="-3" id="f-786" unitRef="shares">269578000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-787"
      unitRef="usdPerShare">-1.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-788"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-789" unitRef="shares">296858000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="-3" id="f-790" unitRef="shares">269578000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-791"
      unitRef="usdPerShare">-1.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-792"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-793">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares issuable upon conversion of convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47,133&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,924&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-191"
      decimals="-3"
      id="f-794"
      unitRef="shares">61415000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-192"
      decimals="-3"
      id="f-795"
      unitRef="shares">31063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-193"
      decimals="-3"
      id="f-796"
      unitRef="shares">47133000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-194"
      decimals="-3"
      id="f-797"
      unitRef="shares">36924000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-798">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker (CODM) is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a regular basis, our CODM reviews:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;total revenues by category&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the segment profit or loss, including significant segment expenses is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;362,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(426,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(78,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-799"
      unitRef="customer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-800">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the segment profit or loss, including significant segment expenses is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;27,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;362,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(426,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(78,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-195" decimals="-3" id="f-801" unitRef="usd">37153000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-196" decimals="-3" id="f-802" unitRef="usd">38810000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c-195" decimals="-3" id="f-803" unitRef="usd">38524000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-196" decimals="-3" id="f-804" unitRef="usd">27528000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-195" decimals="-3" id="f-805" unitRef="usd">29053000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-196" decimals="-3" id="f-806" unitRef="usd">43455000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-195" decimals="-3" id="f-807" unitRef="usd">20076000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-196" decimals="-3" id="f-808" unitRef="usd">22537000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-195" decimals="-3" id="f-809" unitRef="usd">20092000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-196" decimals="-3" id="f-810" unitRef="usd">21216000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-195" decimals="-3" id="f-811" unitRef="usd">15000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-196" decimals="-3" id="f-812" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-195" decimals="-3" id="f-813" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-196" decimals="-3" id="f-814" unitRef="usd">-70000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-195" decimals="-3" id="f-815" unitRef="usd">362042000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-196" decimals="-3" id="f-816" unitRef="usd">5506000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-195" decimals="-3" id="f-817" unitRef="usd">2557000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-196" decimals="-3" id="f-818" unitRef="usd">3184000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-195" decimals="-3" id="f-819" unitRef="usd">-302000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-196" decimals="-3" id="f-820" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-195" decimals="-3" id="f-821" unitRef="usd">-426075000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-196" decimals="-3" id="f-822" unitRef="usd">-78178000</us-gaap:NetIncomeLoss>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-823">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-197" decimals="-3" id="f-824" unitRef="usd">16303000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-198" decimals="-3" id="f-825" unitRef="usd">17678000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-199" decimals="-3" id="f-826" unitRef="usd">9240000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-200" decimals="-3" id="f-827" unitRef="usd">8356000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-201" decimals="-3" id="f-828" unitRef="usd">11610000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-202" decimals="-3" id="f-829" unitRef="usd">12776000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-830" unitRef="usd">37153000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-831" unitRef="usd">38810000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-832">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-203" decimals="-3" id="f-833" unitRef="usd">11016000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-204" decimals="-3" id="f-834" unitRef="usd">19025000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-205" decimals="-3" id="f-835" unitRef="usd">20097000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-206" decimals="-3" id="f-836" unitRef="usd">15984000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-5" decimals="-3" id="f-837" unitRef="usd">31113000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-838" unitRef="usd">35009000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-839" unitRef="usd">6040000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-840" unitRef="usd">3801000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-841" unitRef="usd">37153000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-842" unitRef="usd">38810000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-843">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-844">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-845">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-846">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
